Exhibit 2

Appendix of exhibits to Intervenors’ proposed complaint in intervention
### TABLE OF CONTENTS

Exhibit 1 FDA-Approved Label for Misoprostol (Cytotec) (Jan. 2017) ................. App. 0001

Exhibit 2 Maarit Niinimaki et al., *Comparison of rates of adverse events in adolescent and adult women undergoing medical abortion: population register based study*, BJM, April 20, 2011 ........................................................................................................ App. 00016


Exhibit 4 James Studnicki et al., *A Longitudinal Cohort Study of Emergency Room Utilization Following Mifepristone Chemical and Surgical Abortions, 1999-2015*, Health Serv. Rsch. & Managerial Epidemiology, Nov. 9, 2021 ....................... App. 0031

Exhibit 5 James Studnicki et al., *A Post Hoc Exploratory Analysis: Induced Abortion Complications Mistaken for Miscarriage in the Emergency Room are a Risk Factor for Hospitalization*, Health Servs. Rsch. & Managerial Epidemiology, May 20, 2022 ................................................................................................. App. 0043

Exhibit 6 Katherine A. Rafferty & Tessa Longbons, #AbortionChangesYou: A Case Study to Understand the Communicative Tensions in Women’s Medication Abortion Narratives, 36 Health Commc’n 1485 (2021) ........................................ App. 0048

Exhibit 7 Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drugs and Biological Products in Pediatric Patients, 63 Fed. Reg. 66,632 (Dec. 2, 1998) ........................................................................................................ App. 0060

Exhibit 8 New Drug, Antibiotic, and Biological Drug Product Regulations; Accelerated Approval, 57 Fed. Reg. 58,942 (Dec. 11, 1992) .......................................................... App. 0102

Exhibit 9 2002 Citizen Petition ................................................................................ App. 0136

Exhibit 10 FDA Letter to Population Council re: NDA (Feb. 18, 2000) ................. App. 0232

Exhibit 11 FDA Approval Memo. to Population Council re: NDA 20-687 Mifeprex (mifepristone) (Sept. 28, 2000) ................................................................................................. App. 0240

Exhibit 12 2000 FDA Approval Letter for Mifeprex (mifepristone) Tablets at 1 (Sept. 28, 2000) ......................................................................................................................... App. 0249

Exhibit 14 AAPLOG Statement on FDA removing Mifepristone safety protocols (REMS).................................................................................................................. App. 0284


Exhibit 17 2011 FDA Supplemental Approval Letter to Danco Laboratories, LLC (June 6, 2011) (2011 Approval Letter)................................................................. App. 0325

Exhibit 18 2011 REMS for NDA 20-687 Mifeprex (mifepristone) Tablets, 200mg (June 8, 2011) (2011 REMS) ................................................................................... App. 0330

Exhibit 19 2016 FDA Letter to Danco Laboratories re: NDA 020687, Supp 20 (Mar. 29, 2016) .............................................................................................................. App. 0342

Exhibit 20 FDA, Center for Drug Evaluation and Research, Summary Review of Application Number: 020687Orig1s020 (Mar. 29, 2016) (2016 Summary Review) .................................................................................................................. App. 0351

Exhibit 21 Beverly Winikoff et al., Extending Outpatient Medical Abortion Services Through 70 Days of Gestational Age, 120 Obstetrics & Gynecology 1070 (2012) .................................................................................................................. App. 0380

Exhibit 22 Mary Gatter et al., Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days, 91 Contraception 269 (2015) .................................................................................................................. App. 0388

Exhibit 23 2019 Citizen Petition of AAPLOG to FDA (Mar. 29, 2019)...................... App. 0394

Exhibit 24 2019 FDA ANDA Approval Letter to GenBioPro, Inc. (Apr. 11, 2019) ... App. 0421

Exhibit 25 FDA Supplemental Approval Letter to Danco Laboratories, LLC (Apr. 11, 2019) .............................................................................................................. App. 0428


Exhibit 28 FDA Supplemental Approval Letter to Danco Laboratories, LLC (May 14, 2021) .............................................................................................................. App. 0443
Exhibit 29 2021 FDA Center for Drug Evaluation & Research Director Patrizia Cavazzoni Letter to Dr. Graham Chelius (Dec. 16, 2021) ........................................ App. 0450


Exhibit 31 Questions and Answers on FDA’s Adverse Event Reporting System (FAERS) ............................................................................................................. App. 0493

Exhibit 32 Kathi A. Aultman et al., Deaths and Severe Adverse Events after the use of Mifepristone as an Abortifacient from September 2000 to February 2019, 26 Law & Medicine 3, 25–26 (2021) ........................................................................ App. 0498

Exhibit 33 Christiana A. Cirucci et al., Mifepristone Adverse Events Identified by Planned Parenthood in 2009 and 2010 Compared to Those in the FDA Adverse Event Reporting System and Those Obtained Through the Freedom of Information Act, 8 Health Servs. Rsch & managerial Epidemiology 1 (2021) ... App. 0524

Exhibit 34 FDA Adverse Event Reporting System (FAERS) Electronic Submissions App. 0530

Exhibit 35 Specifications for Preparing and Submitting Electronic ICSRs and ICSR Attachments (April 2021), https://www.fda.gov/media/132096/download ........ App. 0536

Exhibit 36 Declaration of James Studnicki................................................................. App. 0585

Exhibit 37 Declaration of Priscilla K. Coleman, Ph.D. ............................................. App. 0594

Exhibit 38 Declaration of Tumulesh K.S. Solanky..................................................... App. 0647

Exhibit 39 DHSS Abortion Data Affidavit .................................................................. App. 0665

Exhibit 40 Declaration of Juliet Charron .................................................................... App. 0675

Exhibit 41 Declaration of Lora Brown........................................................................ App. 0679
Exhibit 1

FDA-Approved Label for Misoprostol (Cytotec) (Jan. 2017)
WARNINGS

CYTOTECE (MISOPROSTOL) ADMINISTRATION TO WOMEN WHO ARE PREGNANT CAN CAUSE BIRTH DEFECTS, ABORTION, PREMATURE BIRTH OR UTERINE RUPTURE.

UTERINE RUPTURE HAS BEEN REPORTED WHEN CYTOTEC WAS ADMINISTERED IN PREGNANT WOMEN TO INDUCE LABOR OR TO INDUCE ABORTION. THE RISK OF UTERINE RUPTURE INCREASES WITH ADVANCING GESTATIONAL AGES AND WITH PRIOR UTERINE SURGERY, INCLUDING CESAREAN DELIVERY (see also PRECAUTIONS and LABOR AND DELIVERY).

CYTOTEC SHOULD NOT BE TAKEN BY PREGNANT WOMEN TO REDUCE THE RISK OF ULCERS INDUCED BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS).

PATIENTS MUST BE ADVISED OF THE ABORTIFACIENT PROPERTY AND WARNED NOT TO GIVE THE DRUG TO OTHERS.

Cytotec should not be used for reducing the risk of NSAID-induced ulcers in women of childbearing potential unless the patient is at high risk of complications from gastric ulcers associated with use of the NSAID, or is at high risk of developing gastric ulceration. In such patients, Cytotec may be prescribed if the patient
• has had a negative serum pregnancy test within 2 weeks prior to beginning therapy.
• is capable of complying with effective contraceptive measures.
• has received both oral and written warnings of the hazards of misoprostol, the risk of possible contraception failure, and the danger to other women of childbearing potential should the drug be taken by mistake.
• will begin Cytotec only on the second or third day of the next normal menstrual period.

DESCRIPTION

Cytotec oral tablets contain either 100 mcg or 200 mcg of misoprostol, a synthetic prostaglandin E1 analog.
Misoprostol contains approximately equal amounts of the two diastereomers presented below with their enantiomers indicated by (±):

\[
\begin{align*}
\text{C}_{22}\text{H}_{38}\text{O}_5 & \quad \text{M.W.} = 382.5 \\
(\pm) \text{ methyl 11\ensuremath{\alpha},16-dihydroxy-16-methyl-9-oxoprost-13E-en-1-oate}
\end{align*}
\]

Misoprostol is a water-soluble, viscous liquid.

Inactive ingredients of tablets are hydrogenated castor oil, hypromellose, microcrystalline cellulose, and sodium starch glycolate.

**CLINICAL PHARMACOLOGY**

**Pharmacokinetics:** Misoprostol is extensively absorbed, and undergoes rapid de-esterification to its free acid, which is responsible for its clinical activity and, unlike the parent compound, is detectable in plasma. The alpha side chain undergoes beta oxidation and the beta side chain undergoes omega oxidation followed by reduction of the ketone to give prostaglandin F analogs.

In normal volunteers, Cytotec (misoprostol) is rapidly absorbed after oral administration with a \( T_{\text{max}} \) of misoprostol acid of 12 ± 3 minutes and a terminal half-life of 20–40 minutes.

There is high variability of plasma levels of misoprostol acid between and within studies but mean values after single doses show a linear relationship with dose over the range of 200–400 mcg. No accumulation of misoprostol acid was noted in multiple dose studies; plasma steady state was achieved within two days.

Maximum plasma concentrations of misoprostol acid are diminished when the dose is taken with food and total availability of misoprostol acid is reduced by use of concomitant antacid. Clinical trials were conducted with concomitant antacid, however, so this effect does not appear to be clinically important.
After oral administration of radiolabeled misoprostol, about 80% of detected radioactivity appears in urine. Pharmacokinetic studies in patients with varying degrees of renal impairment showed an approximate doubling of $T_{1/2}$, $C_{\text{max}}$, and AUC compared to normals, but no clear correlation between the degree of impairment and AUC. In subjects over 64 years of age, the AUC for misoprostol acid is increased. No routine dosage adjustment is recommended in older patients or patients with renal impairment, but dosage may need to be reduced if the usual dose is not tolerated.

Drug interaction studies between misoprostol and several nonsteroidal anti-inflammatory drugs showed no effect on the kinetics of ibuprofen or diclofenac, and a 20% decrease in aspirin AUC, not thought to be clinically significant.

Pharmacokinetic studies also showed a lack of drug interaction with antipyrine and propranolol when these drugs were given with misoprostol. Misoprostol given for 1 week had no effect on the steady state pharmacokinetics of diazepam when the two drugs were administered 2 hours apart.

The serum protein binding of misoprostol acid is less than 90% and is concentration-independent in the therapeutic range.

After a single oral dose of misoprostol to nursing mothers, misoprostol acid was excreted in breast milk. The maximum concentration of misoprostol acid in expressed breast milk was achieved within 1 hour after dosing and was 7.6 pg/ml (CV 37%) and 20.9 pg/ml (CV 62%) after single 200 µg and 600 µg misoprostol administration, respectively. The misoprostol acid concentrations in breast milk declined to < 1 pg/ml at 5 hours post-dose.

**Pharmacodynamics:** Misoprostol has both antisecretory (inhibiting gastric acid secretion) and (in animals) mucosal protective properties. NSAIDs inhibit prostaglandin synthesis, and a deficiency of prostaglandins within the gastric mucosa may lead to diminishing bicarbonate and mucus secretion and may contribute to the mucosal damage caused by these agents. Misoprostol can increase bicarbonate and mucus production, but in man this has been shown at doses 200 mcg and above that are also antisecretory. It is therefore not possible to tell whether the ability of misoprostol to reduce the risk of gastric ulcer is the result of its antisecretory effect, its mucosal protective effect, or both.
In vitro studies on canine parietal cells using tritiated misoprostol acid as the ligand have led to the identification and characterization of specific prostaglandin receptors. Receptor binding is saturable, reversible, and stereospecific. The sites have a high affinity for misoprostol, for its acid metabolite, and for other E type prostaglandins, but not for F or I prostaglandins and other unrelated compounds, such as histamine or cimetidine. Receptor-site affinity for misoprostol correlates well with an indirect index of antisecretory activity. It is likely that these specific receptors allow misoprostol taken with food to be effective topically, despite the lower serum concentrations attained.

Misoprostol produces a moderate decrease in pepsin concentration during basal conditions, but not during histamine stimulation. It has no significant effect on fasting or postprandial gastrin nor on intrinsic factor output.

Effects on gastric acid secretion: Misoprostol, over the range of 50–200 mcg, inhibits basal and nocturnal gastric acid secretion, and acid secretion in response to a variety of stimuli, including meals, histamine, pentagastrin, and coffee. Activity is apparent 30 minutes after oral administration and persists for at least 3 hours. In general, the effects of 50 mcg were modest and shorter lived, and only the 200-mcg dose had substantial effects on nocturnal secretion or on histamine and meal-stimulated secretion.

Uterine effects: Cytotec has been shown to produce uterine contractions that may endanger pregnancy. (See boxed WARNINGS.)

Other pharmacologic effects: Cytotec does not produce clinically significant effects on serum levels of prolactin, gonadotropins, thyroid-stimulating hormone, growth hormone, thyroxine, cortisol, gastrointestinal hormones (somatostatin, gastrin, vasoactive intestinal polypeptide, and motilin), creatinine, or uric acid. Gastric emptying, immunologic competence, platelet aggregation, pulmonary function, or the cardiovascular system are not modified by recommended doses of Cytotec.

Clinical studies: In a series of small short-term (about 1 week) placebo-controlled studies in healthy human volunteers, doses of misoprostol were evaluated for their ability to reduce the risk of NSAID-induced mucosal injury. Studies of 200 mcg q.i.d. of misoprostol with tolmelin and naproxen, and of 100 and 200 mcg q.i.d. with ibuprofen, all showed reduction of the rate of significant endoscopic injury from about 70–75% on placebo to 10–30% on misoprostol. Doses of 25–200 mcg q.i.d. reduced aspirin-induced mucosal injury and bleeding.

Reducing the risk of gastric ulcers caused by nonsteroidal anti-inflammatory drugs (NSAIDs): Two 12-week, randomized, double-blind trials in osteoarthritic patients who had gastrointestinal symptoms but no ulcer on endoscopy while taking an NSAID compared the ability of 200 mcg of Cytotec, 100 mcg of Cytotec, and placebo to reduce the risk of gastric ulcer (GU) formation. Patients were approximately equally divided between ibuprofen, piroxicam, and naproxen, and continued this treatment throughout the 12 weeks. The 200-mcg dose caused a marked,
statistically significant reduction in gastric ulcers in both studies. The lower dose was somewhat less effective, with a significant result in only one of the studies.

**Reduction of Risk of Gastric Ulcers Induced by Ibuprofen, Piroxicam, or Naproxen**

<table>
<thead>
<tr>
<th>Therapy Duration</th>
<th>Therapy</th>
<th>Study No. 1</th>
<th>Study No. 2</th>
<th>Studies No. 1 &amp; No. 2**</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Cytotec 200 mcg q.i.d. (n=74)</td>
<td>Cytotec 100 mcg q.i.d. (n=77)</td>
<td>Placebo (n=76)</td>
</tr>
<tr>
<td>4 weeks</td>
<td>1 (1.4)</td>
<td>3 (3.9)</td>
<td>11 (14.5)</td>
<td>6 (9.7)</td>
</tr>
<tr>
<td>8 weeks</td>
<td>0</td>
<td>1 (1.3)</td>
<td>4 (5.3)</td>
<td>2 (3.2)</td>
</tr>
<tr>
<td>12 weeks</td>
<td>0</td>
<td>1 (1.3)</td>
<td>4 (5.3)</td>
<td>3 (4.8)</td>
</tr>
<tr>
<td>therapy 4 weeks</td>
<td>1 (1.4)*</td>
<td>5 (6.5)*</td>
<td>19 (25.0)</td>
<td>11 (17.7)</td>
</tr>
<tr>
<td>therapy 8 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>therapy 12 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Statistically significantly different from placebo at the 5% level.
** Combined data from Study No. 1 and Study No. 2.

In these trials there were no significant differences between Cytotec and placebo in relief of day or night abdominal pain. No effect of Cytotec in reducing the risk of duodenal ulcers was demonstrated, but relatively few duodenal lesions were seen.

In another clinical trial, 239 patients receiving aspirin 650–1300 mg q.i.d. for rheumatoid arthritis who had endoscopic evidence of duodenal and/or gastric inflammation were randomized to misoprostol 200 mcg q.i.d. or placebo for 8 weeks while continuing to receive aspirin. The study evaluated the possible interference of Cytotec on the efficacy of aspirin in these patients with rheumatoid arthritis by analyzing joint tenderness, joint swelling, physician’s clinical assessment, patient’s assessment, change in ARA classification, change in hand grip strength, change in duration of morning stiffness, patient’s assessment of pain at rest, movement, interference with daily activity, and ESR. Cytotec did not interfere with the efficacy of aspirin in these patients with rheumatoid arthritis.

**INDICATIONS AND USAGE**

Cytotec (misoprostol) is indicated for reducing the risk of NSAID (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of
complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. Cytotec has not been shown to reduce the risk of duodenal ulcers in patients taking NSAIDs. Cytotec should be taken for the duration of NSAID therapy. Cytotec has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months’ duration. It had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with NSAID use.

CONTRAINDICATIONS
See boxed WARNINGS.

Cytotec should not be taken by pregnant women to reduce the risk of ulcers induced by nonsteroidal anti-inflammatory drugs (NSAIDs).

Cytotec should not be taken by anyone with a history of allergy to prostaglandins.

WARNINGS
See boxed WARNINGS.

For hospital use only if misoprostol were to be used for cervical ripening, induction of labor, or for the treatment of serious post-partum hemorrhage, which are outside of the approved indication.

PRECAUTIONS
Caution should be employed when administering Cytotec (misoprostol) to patients with pre-existing cardiovascular disease.

Information for patients: Women of childbearing potential using Cytotec to decrease the risk of NSAID-induced ulcers should be told that they must not be pregnant when Cytotec therapy is initiated, and that they must use an effective contraception method while taking Cytotec.

See boxed WARNINGS.

Cytotec is intended for administration along with nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, to decrease the chance of developing an NSAID-induced gastric ulcer.

Cytotec should be taken only according to the directions given by a physician.

If the patient has questions about or problems with Cytotec, the physician should be contacted promptly.

THE PATIENT SHOULD NOT GIVE CYTOTEC TO ANYONE ELSE. Cytotec has been prescribed for the patient’s specific condition, may not be the correct treatment for
another person, and may be dangerous to the other person if she were to become pregnant.

The Cytotec package the patient receives from the pharmacist will include a leaflet containing patient information. The patient should read the leaflet before taking Cytotec and each time the prescription is renewed because the leaflet may have been revised.

Keep Cytotec out of the reach of children.

**SPECIAL NOTE FOR WOMEN:** Cytotec may cause birth defects, abortion (sometimes incomplete), premature labor or rupture of the uterus if given to pregnant women.

Cytotec is available only as a unit-of-use package that includes a leaflet containing patient information. See *Patient Information* at the end of this labeling.

**Drug interactions:** See *Clinical Pharmacology*. Cytotec has not been shown to interfere with the beneficial effects of aspirin on signs and symptoms of rheumatoid arthritis. Cytotec does not exert clinically significant effects on the absorption, blood levels, and antiplatelet effects of therapeutic doses of aspirin. Cytotec has no clinically significant effect on the kinetics of diclofenac or ibuprofen.

Prostaglandins such as Cytotec may augment the activity of oxytocic agents, especially when given less than 4 hours prior to initiating oxytocin treatment. Concomitant use is not recommended.

**Animal toxicology:** A reversible increase in the number of normal surface gastric epithelial cells occurred in the dog, rat, and mouse. No such increase has been observed in humans administered Cytotec for up to 1 year.

An apparent response of the female mouse to Cytotec in long-term studies at 100 to 1000 times the human dose was hyperostosis, mainly of the medulla of sternebrae. Hyperostosis did not occur in long-term studies in the dog and rat and has not been seen in humans treated with Cytotec.

**Carcinogenesis, mutagenesis, impairment of fertility:** There was no evidence of an effect of Cytotec on tumor occurrence or incidence in rats receiving daily doses up to 150 times the human dose for 24 months. Similarly, there was no effect of Cytotec on tumor occurrence or incidence in mice receiving daily doses up to 1000 times the human dose for 21 months. The mutagenic potential of Cytotec was tested in several *in vitro* assays, all of which were negative.

Misoprostol, when administered to breeding male and female rats at doses 6.25 times to 625 times the maximum recommended human therapeutic dose, produced dose-related pre- and post-implantation losses and a significant decrease in the number of live pups.
born at the highest dose. These findings suggest the possibility of a general adverse effect on fertility in males and females.

**Pregnancy:**

**Teratogenic effects:** See boxed **WARNINGS.** Congenital anomalies sometimes associated with fetal death have been reported subsequent to the unsuccessful use of misoprostol as an abortifacient, but the drug's teratogenic mechanism has not been demonstrated. Several reports in the literature associate the use of misoprostol during the first trimester of pregnancy with skull defects, cranial nerve palsies, facial malformations, and limb defects.

Cytotec is not fetotoxic or teratogenic in rats and rabbits at doses 625 and 63 times the human dose, respectively.

**Nonteratogenic effects:** See boxed **WARNINGS.** Cytotec may endanger pregnancy (may cause abortion) and thereby cause harm to the fetus when administered to a pregnant woman. Cytotec may produce uterine contractions, uterine bleeding, and expulsion of the products of conception. Abortions caused by Cytotec may be incomplete. If a woman is or becomes pregnant while taking this drug to reduce the risk of NSAID-induced ulcers, the drug should be discontinued and the patient apprised of the potential hazard to the fetus.

**Labor and delivery:** Cytotec can induce or augment uterine contractions. Vaginal administration of Cytotec, outside of its approved indication, has been used as a cervical ripening agent, for the induction of labor and for treatment of serious postpartum hemorrhage in the presence of uterine atony. A major adverse effect of the obstetrical use of Cytotec is uterine tachysystole which may progress to uterine tetany with marked impairment of uteroplacental blood flow, uterine rupture (requiring surgical repair, hysterectomy, and/or salpingo-oophorectomy), or amniotic fluid embolism and lead to adverse fetal heart changes. Uterine activity and fetal status should be monitored by trained obstetrical personnel in a hospital setting.

The risk of uterine rupture associated with misoprostol use in pregnancy increases with advancing gestational ages and prior uterine surgery, including Cesarean delivery. Grand multiparity also appears to be a risk factor for uterine rupture.

The use of Cytotec outside of its approved indication may also be associated with meconium passage, meconium staining of amniotic fluid, and Cesarean delivery. Maternal shock, maternal death, fetal bradycardia, and fetal death have also been reported with the use of misoprostol.

Cytotec should not be used in the third trimester in women with a history of Cesarean section or major uterine surgery because of an increased risk of uterine rupture. Cytotec should not be used in cases where uterotonic drugs are generally contraindicated or where hyperstimulation of the uterus is considered inappropriate, such as cephalopelvic disproportion, grand multiparity, hypertonic or hyperactive uterine patterns, or fetal
distress where delivery is not imminent, or when surgical intervention is more appropriate.

The effect of Cytotec on later growth, development, and functional maturation of the child when Cytotec is used for cervical ripening or induction of labor has not been established. Information on Cytotec's effect on the need for forceps delivery or other intervention is unknown.

The use of Cytotec (misoprostol) for the management of postpartum hemorrhage has been associated with reports of high fevers (greater than 40 degrees Celsius or 104 degrees Fahrenheit), accompanied by autonomic and central nervous system effects, such as tachycardia, disorientation, agitation, and convulsions. These fevers were transient in nature. Supportive therapy should be dictated by the patient’s clinical presentation.

Nursing mothers: Misoprostol is rapidly metabolized in the mother to misoprostol acid, which is biologically active and is excreted in breast milk. There are no published reports of adverse effects of misoprostol in breast-feeding infants of mothers taking misoprostol. Caution should be exercised when misoprostol is administered to a nursing woman.

Pediatric use: Safety and effectiveness of Cytotec in pediatric patients have not been established.

ADVERSE REACTIONS
The following have been reported as adverse events in subjects receiving Cytotec:

Gastrointestinal: In subjects receiving Cytotec 400 or 800 mcg daily in clinical trials, the most frequent gastrointestinal adverse events were diarrhea and abdominal pain. The incidence of diarrhea at 800 mcg in controlled trials in patients on NSAIDs ranged from 14–40% and in all studies (over 5,000 patients) averaged 13%. Abdominal pain occurred in 13–20% of patients in NSAID trials and about 7% in all studies, but there was no consistent difference from placebo.

Diarrhea was dose related and usually developed early in the course of therapy (after 13 days), usually was self-limiting (often resolving after 8 days), but sometimes required discontinuation of Cytotec (2% of the patients). Rare instances of profound diarrhea leading to severe dehydration have been reported. Patients with an underlying condition such as inflammatory bowel disease, or those in whom dehydration, were it to occur, would be dangerous, should be monitored carefully if Cytotec is prescribed. The incidence of diarrhea can be minimized by administering after meals and at bedtime, and by avoiding coadministration of Cytotec with magnesium-containing antacids.

Gynecological: Women who received Cytotec during clinical trials reported the following gynecological disorders: spotting (0.7%), cramps (0.6%), hypermenorrhea (0.5%), menstrual disorder (0.3%) and dysmenorrhea (0.1%). Postmenopausal vaginal
bleeding may be related to Cytotec administration. If it occurs, diagnostic workup should be undertaken to rule out gynecological pathology. (See boxed **WARNINGS**.)

**Elderly:** There were no significant differences in the safety profile of Cytotec in approximately 500 ulcer patients who were 65 years of age or older compared with younger patients.

Additional adverse events which were reported are categorized as follows:

**Incidence greater than 1%:** In clinical trials, the following adverse reactions were reported by more than 1% of the subjects receiving Cytotec and may be causally related to the drug: nausea (3.2%), flatulence (2.9%), headache (2.4%), dyspepsia (2.0%), vomiting (1.3%), and constipation (1.1%). However, there were no significant differences between the incidences of these events for Cytotec and placebo.

**Causal relationship unknown:** The following adverse events were infrequently reported. Causal relationships between Cytotec and these events have not been established but cannot be excluded:

*Body as a whole:* aches/pains, asthenia, fatigue, fever, chills, rigors, weight changes.

*Skin:* rash, dermatitis, alopecia, pallor, breast pain.

*Special senses:* abnormal taste, abnormal vision, conjunctivitis, deafness, tinnitus, earache.

*Respiratory:* upper respiratory tract infection, bronchitis, bronchospasm, dyspnea, pneumonia, epistaxis.

*Cardiovascular:* chest pain, edema, diaphoresis, hypotension, hypertension, arrhythmia, phlebitis, increased cardiac enzymes, syncope, myocardial infarction (some fatal), thromboembolic events (e.g., pulmonary embolism, arterial thrombosis, and CVA).

*Gastrointestinal:* GI bleeding, GI inflammation/infection, rectal disorder, abnormal hepatobiliary function, gingivitis, reflux, dysphagia, amylase increase.

*Hypersensitivity:* anaphylactic reaction

*Metabolic:* glycosuria, gout, increased nitrogen, increased alkaline phosphatase.

*Genitourinary:* polyuria, dysuria, hematuria, urinary tract infection.

*Nervous system/Psychiatric:* anxiety, change in appetite, depression, drowsiness, dizziness, thirst, impotence, loss of libido, sweating increase, neuropathy, neurosis, confusion.
**Musculoskeletal:** arthralgia, myalgia, muscle cramps, stiffness, back pain.

**Blood/Coagulation:** anemia, abnormal differential, thrombocytopenia, purpura, ESR increased.

**OVERDOSAGE**
The toxic dose of Cytotec in humans has not been determined. Cumulative total daily doses of 1600 mcg have been tolerated, with only symptoms of gastrointestinal discomfort being reported. In animals, the acute toxic effects are diarrhea, gastrointestinal lesions, focal cardiac necrosis, hepatic necrosis, renal tubular necrosis, testicular atrophy, respiratory difficulties, and depression of the central nervous system. Clinical signs that may indicate an overdose are sedation, tremor, convulsions, dyspnea, abdominal pain, diarrhea, fever, palpitations, hypotension, or bradycardia. Symptoms should be treated with supportive therapy.

It is not known if misoprostol acid is dialyzable. However, because misoprostol is metabolized like a fatty acid, it is unlikely that dialysis would be appropriate treatment for overdosage.

**DOSAGE AND ADMINISTRATION**
The recommended adult oral dose of Cytotec for reducing the risk of NSAID-induced gastric ulcers is 200 mcg four times daily with food. If this dose cannot be tolerated, a dose of 100 mcg can be used. (See Clinical Pharmacology: Clinical studies.) Cytotec should be taken for the duration of NSAID therapy as prescribed by the physician. Cytotec should be taken with a meal, and the last dose of the day should be at bedtime.

**Renal impairment:** Adjustment of the dosing schedule in renally impaired patients is not routinely needed, but dosage can be reduced if the 200-mcg dose is not tolerated. (See Clinical Pharmacology.)

**HOW SUPPLIED**
Cytotec 100-mcg tablets are white, round, with SEARLE debossed on one side and 1451 on the other side; supplied as:

<table>
<thead>
<tr>
<th>NDC Number</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>0025-1451-60</td>
<td>unit-of-use bottle of 60</td>
</tr>
<tr>
<td>0025-1451-20</td>
<td>unit-of-use bottle of 120</td>
</tr>
<tr>
<td>0025-1451-34</td>
<td>carton of 100 unit dose</td>
</tr>
</tbody>
</table>

Cytotec 200-mcg tablets are white, hexagonal, with SEARLE debossed above and 1461 debossed below the line on one side and a double stomach debossed on the other side; supplied as:

<table>
<thead>
<tr>
<th>NDC Number</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>0025-1461-60</td>
<td>unit-of-use bottle of 60</td>
</tr>
<tr>
<td>0025-1461-31</td>
<td>unit-of-use bottle of 100</td>
</tr>
</tbody>
</table>
0025-1461-34 carton of 100 unit dose

Store at or below 25°C (77°F), in a dry area.

This product’s label may have been updated. For current full prescribing information, please visit www.pfizer.com.

Distributed by
Pfizer

G.D. Searle LLC
Division of Pfizer Inc, NY, NY 10017

LAB-0170-7.0
Revised February 2018
PATIENT INFORMATION

Read this leaflet before taking Cytotec® (misoprostol) and each time your prescription is renewed, because the leaflet may be changed.

Cytotec (misoprostol) is being prescribed by your doctor to decrease the chance of getting stomach ulcers related to the arthritis/pain medication that you take.

Do not take Cytotec to reduce the risk of NSAID-induced ulcers if you are pregnant. (See boxed WARNINGS.) Cytotec can cause abortion (sometimes incomplete which could lead to dangerous bleeding and require hospitalization and surgery), premature birth, or birth defects. It is also important to avoid pregnancy while taking this medication and for at least one month or through one menstrual cycle after you stop taking it. Cytotec may cause the uterus to tear (uterine rupture) during pregnancy. The risk of uterine rupture increases as your pregnancy advances and if you have had surgery on the uterus, such as a Cesarean delivery. Rupture (tearing) of the uterus can result in severe bleeding, hysterectomy, and/or maternal or fetal death.

If you become pregnant during Cytotec therapy, stop taking Cytotec and contact your physician immediately. Remember that even if you are on a means of birth control it is still possible to become pregnant. Should this occur, stop taking Cytotec and contact your physician immediately.

Cytotec may cause diarrhea, abdominal cramping, and/or nausea in some people. In most cases these problems develop during the first few weeks of therapy and stop after about a week. You can minimize possible diarrhea by making sure you take Cytotec with food.

Because these side effects are usually mild to moderate and usually go away in a matter of days, most patients can continue to take Cytotec. If you have prolonged difficulty (more than 8 days), or if you have severe diarrhea, cramping and/or nausea, call your doctor.

Take Cytotec only according to the directions given by your physician.

Do not give Cytotec to anyone else. It has been prescribed for your specific condition, may not be the correct treatment for another person, and would be dangerous if the other person were pregnant.

This information sheet does not cover all possible side effects of Cytotec. This patient information leaflet does not address the side effects of your arthritis/pain medication. See your doctor if you have questions.

Keep out of reach of children.

This product’s label may have been updated. For current full prescribing information, please visit www.pfizer.com.
Exhibit 2

Maarit Niinimaki et al., *Comparison of rates of adverse events in adolescent and adult women undergoing medical abortion: population register based study*, BJM, April 20, 2011
Comparison of rates of adverse events in adolescent and adult women undergoing medical abortion: population register based study

Maarit Niinimäki, consultant gynaecologist, Satu Suhonen, chief physician, Maarit Mentula, consultant gynaecologist, Elina Hemminki, research professor, Oskari Heikinheimo, chief physician, Mika Gissler, research professor

ABSTRACT
Objective To determine the risks of short term adverse events in adolescent and older women undergoing medical abortion.

Design Population based retrospective cohort study.


Participants All women (n=27 030) undergoing medical abortion during 2000-6, with only the first induced abortion analysed for each woman.

Main outcome measures Incidence of adverse events (haemorrhage, infection, incomplete abortion, surgical evacuation, psychiatric morbidity, injury, thromboembolic disease, and death) among adolescent (<18 years) and older (≥18 years) women through record linkage of Finnish registries and genital Chlamydia trachomatis infections detected concomitantly with abortion and linked with data from the abortion register for 2000-6.

Results During 2000-6, 3024 adolescents and 24 006 adults underwent at least one medical abortion. The rate of chlamydia infections was higher in the adolescent cohort (5.7% v 3.7%, P=0.001). The incidence of adverse events among adolescents was similar or lower than that among the adults. The risks of haemorrhage (adjusted odds ratio 0.87, 95% confidence interval 0.77 to 0.99), incomplete abortion (0.69, 0.59 to 0.82), and surgical evacuation (0.78, 0.67 to 0.90) were lower in the adolescent cohort. In subgroup analysis of primigravid women, the risks of incomplete abortion (0.68, 0.56 to 0.81) and surgical evacuation (0.75, 0.64 to 0.88) were lower in the adolescent cohort. In logistic regression, duration of gestation was the most important risk factor for infection, incomplete abortion, and surgical evacuation.

Conclusions The incidence of adverse events after medical abortion was similar or lower among adolescents than among older women. Thus, medical abortion seems to be at least as safe in adolescents as it is in adults.

INTRODUCTION
Pregnancies among teenagers are mostly unplanned and offer a special challenge to family planning services. Most of all such pregnancies (up to 82% in the United States) are unintended. The decision to continue or terminate a pregnancy is strongly associated with age. Besides age, being a student or being single are important factors in young women’s decisions on abortion. In the United States, 6% of all abortions are carried out in under 18s. In the United Kingdom, 9.5% of abortions in 2009 were in adolescents. Thus abortions among teenagers are common and are an important public health problem.

The medical termination of pregnancy using the antiprogestin mifepristone and a prostaglandin analogue has been widely established in several countries during the past decade. In 2009, 40% of abortions were medical in the United Kingdom. In Sweden and Finland the corresponding figures were 72% and 76%, respectively.

Increasing use of medical termination of pregnancy points to a need for appropriate studies to confirm its safety in various target groups. Using nationwide register based data we showed that both medical and surgical abortions are generally safe, with few serious complications when gestation is less than 63 days. The most common adverse events were haemorrhage and incomplete abortion. However, in that study we did not assess the safety of medical abortion among adolescents.

Data on the safety of medical abortion among adolescents are limited. In a small prospective study, medical abortion was found to be highly effective and well tolerated in adolescents aged 14 to 17 when gestation was less than 56 days. Initially, half of the participants experienced stress and fear, but these emotions improved significantly within the month after abortion.

In the present nationwide study we compared the safety of medical abortion between adolescents and adults. To eliminate the possible influence of previous pregnancies on the outcome of termination of pregnancy, we carried out a subgroup analysis among primigravid women. In addition we assessed the impact of a positive Chlamydia trachomatis test result at the time of abortion.
abortion on the incidence of infections after abortion—a situation of great clinical relevance to adolescents.

METHODS

From the national abortion register compiled by the National Institute for Health and Welfare we identified all women who had undergone induced abortion in Finland during 2000-6. The study population consisted of women who had had a medical abortion (mifepristone alone or in combination with misoprostol or other prostaglandins) at 20 weeks or less of gestation. We divided the women into two cohorts based on age at the time of abortion: adolescents (<18 years) and adults (≥18 years). To keep the observations independent, we included only the first abortion for women who had more than one during the study period. To assess the potential learning curve in the introduction of medical abortion, we analysed the results in part separately for the first years (2000-3) of its use compared with established use (2004-6). We linked the data with the care register for health institutions (later called the hospital register) and the national infectious diseases register, both compiled by the National Institute for Health and Welfare, and the cause of death register of Statistics Finland. We followed the women for 42 days after the induced abortion and linked all events recorded in the hospital register and cause of death register with the abortion register.

The Finnish national register on induced abortions and sterilisations has been maintained since 1977. In accordance with the current legislation, doctors performing induced abortions are obliged to report cases to the register within one month, using a specific data collection form. In Finland, data on induced abortions are collected from all hospitals and clinics that carry out induced abortions. The register contains data on women having termination of pregnancy. These data include information on pregnancy history, occupation, type of residence, municipality, and marital status. Data on current pregnancy include information on duration of gestation at the time of abortion, indication for abortion, and method of termination.

We have previously described Finnish legislation on induced abortion. Briefly, current legislation permits termination of pregnancy of up to 20 weeks’ gestation (24 weeks in cases of a medical condition of the fetus) for social, medical, or ethical reasons. A national guideline on the care of women seeking abortion was published in 2001 and updated in 2007. Based on this guideline all women should be screened for C trachomatis and treated if it is present and screened for bacterial vaginosis at the first visit before the termination of pregnancy. Prophylactic antibiotics are not routinely used.

Data collection

All hospitals in Finland are required by law to provide the hospital register with information on inpatient treatment (all hospitals) and outpatient visits (public hospitals). This register contains information on diagnosis (international statistical classification of diseases and related health problems, ICD-10) and treatment (Nordic classification of surgical procedures), as well as the dates of the treatment episodes. To analyse adverse events related to induced abortion, we linked information on the study participants in the hospital register for all hospital inpatient episodes and outpatient visits within 42 days after termination of pregnancy with data in the abortion register. We selected diagnoses and codes for surgical procedures in the cohorts for those considered to be of clinical importance.

We divided the complications into eight categories (see box): haemorrhage, infection, incomplete abortion, surgical evacuation, psychiatric morbidity, injury or other reason for surgical operation, thromboembolic disease, and death. The classification was based on that reported in the joint study of the Royal College of General Practitioners and the Royal College of Obstetricians and Gynaecologists and modified for this and our previous study.

The cause of death register contains data from death certificates and covers all deaths of Finnish citizens and permanent residents in Finland, classified according to ICD-10 codes. All the early deaths (within 42 days of termination of pregnancy) were classified as direct, indirect, or accidental.

The National Department of Infectious Disease Epidemiology and Control at the National Institute for Health and Welfare collects information on cases of detected C trachomatis infections. Since 1997 it has been mandatory for laboratories to report all positive cases to the national infectious diseases register based on the Communicable Diseases Act and Decree of 1987. Since 2004, laboratory notifications have included personal identification numbers, enabling linkage of the data with that in other registries. Since 2004 genital C trachomatis has been detected by DNA or RNA testing.

Statistical analysis

To assess differences between the groups we used the Mann-Whitney test for age and the χ² test for categorical variables. The χ² test was also used to calculate the difference in the incidence of adverse events, except for rare ones (psychiatric morbidity, injury, thromboembolic disease, and death) when we used Fisher’s
Table 1 | Characteristics of the two study cohorts. Values are numbers (percentages) unless stated otherwise

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Adolescent cohort (≥18 years, n=3024)</th>
<th>Adult cohort (≥18 years, n=27 030)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (median) age (years), range</td>
<td>16.1 (16.0), 13-17</td>
<td>27.6 (26.0), 18-50</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Previous pregnancies:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>2913 (96.3)</td>
<td>10 474 (43.6)</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>111 (3.7)</td>
<td>13 532 (56.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Previous deliveries:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>2972 (98.3)</td>
<td>12 059 (50.2)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Yes</td>
<td>52 (1.7)</td>
<td>11 947 (49.8)</td>
<td></td>
</tr>
<tr>
<td>Previous induced abortions:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>3004 (99.3)</td>
<td>19 432 (80.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Yes</td>
<td>20 (0.7)</td>
<td>4574 (19.3)</td>
<td></td>
</tr>
<tr>
<td>Marital status:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Married</td>
<td>12 (0.4)</td>
<td>5634 (23.5)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cohabiting</td>
<td>126 (4.2)</td>
<td>4546 (18.9)</td>
<td></td>
</tr>
<tr>
<td>Single</td>
<td>2882 (95.3)</td>
<td>13 785 (57.4)</td>
<td></td>
</tr>
<tr>
<td>Data missing</td>
<td>4 (0.1)</td>
<td>41 (0.2)</td>
<td></td>
</tr>
<tr>
<td>Type of residence:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban</td>
<td>1979 (65.4)</td>
<td>17 977 (74.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Densely populated</td>
<td>486 (16.1)</td>
<td>2986 (12.4)</td>
<td></td>
</tr>
<tr>
<td>Rural</td>
<td>559 (18.5)</td>
<td>3043 (12.7)</td>
<td></td>
</tr>
<tr>
<td>Duration of gestation (weeks):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;9</td>
<td>2424 (80.2)</td>
<td>20 143 (83.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>9-12</td>
<td>139 (4.6)</td>
<td>660 (2.7)</td>
<td></td>
</tr>
<tr>
<td>13-16</td>
<td>283 (9.4)</td>
<td>1761 (7.3)</td>
<td></td>
</tr>
<tr>
<td>17-20</td>
<td>171 (5.7)</td>
<td>1151 (4.8)</td>
<td></td>
</tr>
<tr>
<td>Data missing</td>
<td>7 (0.2)</td>
<td>311 (1.3)</td>
<td></td>
</tr>
<tr>
<td>Chlamydia trachomatis positive test result*</td>
<td>99/1749 (5.7)</td>
<td>496/13 547 (3.7)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

*Data available for 2004-6.

RESULTS

During 2000-6, 27 030 women underwent medical abortion between five and 20 weeks of gestation. Of these women, 3024 were younger than 18 (adolescent cohort) and the remaining 24 006 were older (adult cohort). Including only the first induced abortion for each woman during 2000-3, medical abortion was carried out in 1275 (29.3%) adolescents and in 10 459 (31.7%) adults. In 2004-6 the corresponding numbers were 1749 (61.9%) and 13 547 (63.3%).

The two cohorts differed significantly for various characteristics (table 1). The adolescents had fewer previous deliveries and induced abortions and were more often single and living in a non-urban setting. In both groups, most of the medical abortions (over 80%) were performed before nine weeks of gestation, but the mean duration of gestation was more advanced among adolescents. The incidence of *C trachomatis* infections, diagnosed four weeks before to six weeks after abortion, was higher in the adolescent cohort, as calculated for 2004-6.

Table 2 describes the incidence of adverse events among the two cohorts, as well as among the primigravid women. The adolescent cohort had a significantly higher incidence of haemorrhage (2004-6: 11.9% of 3024; 12.8% of 10 459; P<0.001), incomplete abortion (2450 (10.2%) v 212 (7.0%), P<0.001), and surgical evacuation of retained products of conception (3121 (13.0% v 333 (11.0%), P=0.002). Odds ratios were calculated for main adverse events [haemorrhage, infection, incomplete abortion, and surgical evacuation], after adjustment for parity, previous abortions, marital status, type of residence, duration of gestation, and year of abortion. In the adolescent cohort the adjusted odds ratios were significantly lower for haemorrhage, incomplete abortion, and surgical evacuation than in the adult cohort. In addition, the adult cohort had more participants with adverse events (5535 (23.1%) v 575 (19.0%), P<0.001).

In the subgroup analysis carried out among the primigravid women, the proportion of women with haemorrhage (1505 (14.4%) v 374 (12.8%), P=0.035), incomplete abortions (887 (8.5%) v 201 (6.9%), P=0.006) and a higher overall number of adverse events (2224 (21.1%) v 552 (18.9%), P=0.031) was significantly higher in the adult cohort. After adjustment for marital status, type of residence, duration of gestation, and year of abortion, the risks for incomplete abortion and surgical evacuation were lower in the primigravid adolescents than in the primigravid adults (table 2).

The incidence of a psychiatric diagnosis was higher among the adolescents in both the cohort and the primigravid cohort, even though the overall numbers were low. Two deaths were reported during the follow-up period. Both of these occurred in adults and were unrelated to the pregnancy (intracranial trauma and melanoma).

The figure shows the results of logistic regression among the primigravid women for risk of main adverse events [haemorrhage, infection, incomplete abortion, and surgical evacuation]. An increased risk of haemorrhage was associated with living in a densely populated area. The risk of bleeding after medical abortion was higher during 2004-6 than during 2000-3. Gestations of 9-12 or 13-16 weeks were associated with a lower risk of haemorrhage than gestations of less than nine weeks. The risk of haemorrhage was also significantly lower in the adolescent cohort.

Advanced duration of gestation (9-12, 13-16, and 17-20 weeks) was associated with an increased risk of infections after abortion (figure). Additionally, being married or cohabiting compared with being single was associated with an increased risk of infection.
Also, the risk was higher in the later period (2004-6) than in 2000-3. The risk of infection was similar between the two cohorts.

Advanced duration of gestation was strongly related to the risk of incomplete abortion and surgical evacuation. The risk of incomplete abortion was lower in adolescents (odds ratio 0.69, 95% confidence interval 0.58 to 0.82) than in adults. The risk of surgical evacuation was increased in women living in rural areas and in those who were married or cohabiting. When abortion was carried out in the later period (2004-6) the risk of surgical evacuation was diminished (figure).

The risk of infections after abortion as a result of concurrent chlamydia infection was assessed among women who underwent abortion during 2004-6. In logistic regression analysis of the whole cohort, the risk of infection after abortion was not associated with concurrent chlamydia infection (1.02, 0.58 to 1.78). Moreover, no significant difference in the rate of infections after abortion emerged between adolescents and those with a positive test result for *C trachomatis* (data not shown).

### DISCUSSION

In the present study the rate of adverse events and complications after medical abortion in adolescents was similar to or lower than that in adults. Various characteristics of the two cohorts differed significantly (table 1), but the risk of adverse events was calculated after adjustment for these factors. This study covered almost all abortions carried out in Finland in all regions and hospitals during a seven year period and thus shows reliable national trends. Earlier studies assessing the completeness of the Finnish abortion register found that 99% of abortions were reported to the register and at least 95% of information matched the medical records.16 17

<table>
<thead>
<tr>
<th>Adverse events</th>
<th>Adolescent cohort (&lt;18 years) % (95% CI)</th>
<th>Adult cohort (≥18 years) % (95% CI)</th>
<th>P value</th>
<th>Adjusted odds ratio (95%CI)*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All women</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemorrhage</td>
<td>12.8 (11.6 to 14.0)</td>
<td>15.4 (15.0 to 16.0)</td>
<td>&lt;0.001†</td>
<td>0.87 (0.77 to 0.99)†</td>
</tr>
<tr>
<td>Infection</td>
<td>2.0 (1.5 to 2.6)</td>
<td>2.1 (1.9 to 2.2)</td>
<td>0.742</td>
<td>0.97 (0.73 to 1.30)</td>
</tr>
<tr>
<td>Incomplete abortion</td>
<td>7.0 (6.1 to 8.0)</td>
<td>10.2 (9.8 to 10.6)</td>
<td>&lt;0.001†</td>
<td>0.69 (0.59 to 0.82)†</td>
</tr>
<tr>
<td>Surgical evacuation</td>
<td>11.0 (9.9 to 12.1)</td>
<td>13.0 (12.6 to 13.4)</td>
<td>0.002‡</td>
<td>0.78 (0.67 to 0.90)‡</td>
</tr>
<tr>
<td>Psychiatric morbidity</td>
<td>0.10 (0.02 to 0.29)</td>
<td>2 NA</td>
<td>0.012†</td>
<td>—</td>
</tr>
<tr>
<td>Injury</td>
<td>0.13 (0.04 to 0.34)</td>
<td>0.15 (0.10 to 0.19)</td>
<td>1.000</td>
<td>—</td>
</tr>
<tr>
<td>Thromboembolic disease</td>
<td>0.07 (0.01 to 0.24)</td>
<td>0.11 (0.07 to 0.15)</td>
<td>0.764</td>
<td>—</td>
</tr>
<tr>
<td>Death</td>
<td>0 NA</td>
<td>2 NA</td>
<td>0.392</td>
<td>—</td>
</tr>
<tr>
<td><strong>No of adverse events per woman</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>2449</td>
<td>18471</td>
<td></td>
<td>—</td>
</tr>
<tr>
<td>1</td>
<td>488</td>
<td>4456</td>
<td></td>
<td>—</td>
</tr>
<tr>
<td>2</td>
<td>82</td>
<td>994</td>
<td>&lt;0.001†</td>
<td>—</td>
</tr>
<tr>
<td>3</td>
<td>5</td>
<td>83</td>
<td>0.35 (0.27 to 0.42)</td>
<td>—</td>
</tr>
<tr>
<td>4</td>
<td>0 NA</td>
<td>2 NA</td>
<td>0.392</td>
<td>—</td>
</tr>
<tr>
<td><strong>Primigravid women</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemorrhage</td>
<td>12.8 (11.6 to 14.1)</td>
<td>1505</td>
<td>0.035†</td>
<td>0.88 (0.78 to 1.00)</td>
</tr>
<tr>
<td>Infection</td>
<td>2.0 (1.5 to 2.5)</td>
<td>2.2 (1.9 to 2.5)</td>
<td>0.486</td>
<td>1.01 (0.75 to 1.37)</td>
</tr>
<tr>
<td>Incomplete abortion</td>
<td>6.9 (6.0 to 7.9)</td>
<td>8.5 (7.9 to 9.0)</td>
<td>0.006‡</td>
<td>0.68 (0.56 to 0.81)‡</td>
</tr>
<tr>
<td>Surgical evacuation</td>
<td>10.7 (9.6 to 11.8)</td>
<td>1136</td>
<td>0.794</td>
<td>0.75 (0.64 to 0.88)‡</td>
</tr>
<tr>
<td>Psychiatric morbidity</td>
<td>0.10 (0.02 to 0.30)</td>
<td>1 NA</td>
<td>0.034†</td>
<td>—</td>
</tr>
<tr>
<td>Injury</td>
<td>0.14 (0.04 to 0.35)</td>
<td>0.10 (0.04 to 0.16)</td>
<td>0.521</td>
<td>—</td>
</tr>
<tr>
<td>Thromboembolic disease</td>
<td>0.07 (0.01 to 0.25)</td>
<td>0.10 (0.04 to 0.16)</td>
<td>1.00</td>
<td>—</td>
</tr>
<tr>
<td>Death</td>
<td>0 NA</td>
<td>1 NA</td>
<td>0.391</td>
<td>—</td>
</tr>
<tr>
<td><strong>No of adverse events per woman:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>2361</td>
<td>8250</td>
<td>0.031†</td>
<td>—</td>
</tr>
<tr>
<td>1</td>
<td>468</td>
<td>1838</td>
<td></td>
<td>—</td>
</tr>
<tr>
<td>2</td>
<td>79</td>
<td>356</td>
<td></td>
<td>—</td>
</tr>
<tr>
<td>3</td>
<td>5</td>
<td>30</td>
<td>0.29 (0.18 to 0.39)</td>
<td>—</td>
</tr>
<tr>
<td>4</td>
<td>0 NA</td>
<td>0 NA</td>
<td>0 NA</td>
<td>—</td>
</tr>
</tbody>
</table>

*Not applicable owing to small number of women.

*Adult cohort as reference for all women adjusted for parity, previous abortions, marital status, type of residence, duration of gestation, and year of abortion; adult cohort as reference for primigravid women adjusted for marital status, type of residence, duration of gestation, and year of abortion.

†Statistically significant.
events may vary substantially. Another drawback is that no conclusions can be made on the effects of abortion beyond the 42 days of follow-up. A further limitation is that data on \textit{C. trachomatis} could only be linked with registry data from 2004, when identification numbers were first archived.

More women sought help for bleeding after abortion when gestation was less than nine weeks. This finding parallels that reported in our previous study.\textsuperscript{6} This might be explained partly by the fact that medical abortions at nine weeks or more of gestation are carried out by hospitals, and not on an outpatient basis.\textsuperscript{9} Moreover, an increasing number of these early abortions are carried out at home using self administered misoprostol.

The risk of surgical evacuation of retained products after medical abortion decreased during 2004-6 compared with 2000-3, whereas the number of incomplete abortions remained the same. These findings probably reflect a learning curve in providing medical abortion. However, the lower number of surgical evacuations occurred at the expense of an increased rate of consultations as a result of uterine bleeding. We took into account the possible bias caused by the differences between the study periods (2000-3 and 2004-6) by adjusting the odds ratios of adverse events by study period.

The rate of infections after abortion was higher (2.0\%) than that reported in an earlier review in which medical abortion was assessed (0.9\%).\textsuperscript{18} The higher figure may in part be a result of the register based nature of the present study—that is, the diagnostic criteria lacked uniformity. In recent reviews, however, the incidence of infections after medical abortion in the second trimester has been estimated to be about 3\%.\textsuperscript{19,20} Thus in the present study, concerning pregnancies of up to 20 weeks’ duration, the incidence of infections was comparable with that reported in the recent
Experience of pain or satisfaction with care could not be studied in the present setting, as these outcomes are not registered in the Finnish abortion register. In a randomised study, women with higher gestational age and first pregnancy seemed to be less satisfied with medical abortion as a result of more pain during the termination.\textsuperscript{23} The effective treatment of pain must be taken into account when adolescents, predominantly nulliparous women, undergo induced abortion.

Conclusion

The present population based national study provides evidence that medical abortion is not associated with additional risks of adverse events among adolescents in the short term compared with adult women. The data were derived from one country with a homogenous population but can be generalised to populations with high quality healthcare and easy access to specialist treatment.

The preliminary results of this study were presented at the International Federation of Obstetrics and Gynecology (FIGO) meeting in Cape Town, South Africa October 2009, and in the International Federation of Professional Abortion and Contraception Associations (FAPAC) meeting in Seville Spain, October 2010 (MN). We thank AniBiigo (National institute for Health and Welfare, Oulu, Finland) for her professional help with the statistics.


case 2:22-cv-00223-z   document 176-1   filed 01/12/24   page 26 of 684   pageid 5784  

bmj.com | online first | bmj.com on 10 October 2023 at Missouri State Library. Protected by copyright. http://www.bmj.com/ 

bmj.com first published as 10.1136/bmj.d2111 on 20 April 2011. Downloaded from http://www.bmj.com/ on 10 October 2023 at Missouri State Library. Protected by copyright.
17 Heikinheimo O, Gissler M, Suhonen S. Age, parity, history of abortion and contraceptive choices affect the risk of repeat abortion. Contraception 2008;78:149-54.

Accepted: 20 February 2011
Exhibit 3

Maarit J. Mentula et al., Immediate adverse events after second trimester medical termination of pregnancy: results of a nationwide registry study, 26 Hum. Reprod. 927, 931 (2011)
Immediate adverse events after second trimester medical termination of pregnancy: results of a nationwide registry study

Maarit J. Mentula1, Maarit Niinimäki2, Satu Suhonen3, Elina Hemminki4, Mika Gissler4,5, and Oskari Heikinheimo1,*

1Department of Obstetrics and Gynecology, Helsinki University Central Hospital, P.O. Box 610, 00029-HUS Helsinki, Finland 2Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu, Finland 3The City of Helsinki Health Care Centre, Unit for Maternity and Child Health Care and Health Promotion, Helsinki, Finland 4The National Institute for Health and Welfare, Helsinki, Finland 5The Nordic School of Public Health, Gothenburg, Sweden

*Correspondence address. Tel: +358-50-4271533; E-mail: oskari.heikinheimo@helsinki.fi

Submitted on August 25, 2010; resubmitted on January 3, 2011; accepted on January 11, 2011

Background: Increasing gestational age is associated with an increased risk of complications in studies assessing surgical termination of pregnancy (TOP). Medical TOP is widely used during the second trimester and little is known about the frequency of complications. This epidemiological study was undertaken to assess the frequency of adverse events following the second trimester medical TOP and to compare it with that after first trimester medical TOP.

Methods: This register-based cohort study covered 18 248 women who underwent medical TOP in Finland between 1 January 2003 and 31 December 2006. The women were identified from the Abortion Registry. Adverse events related to medical TOP within 6 weeks were obtained from the Hospital Discharge Registry.

Results: When compared with first trimester medical TOP, second trimester medical TOP increased the risk of surgical evacuation [Adj. odds ratio (OR) 7.8; 95% confidence interval (CI) 6.8–8.9], especially immediately after fetal expulsion (Adj. OR 15.2; 95% CI 12.8–18.0). The risk of infection was also elevated (Adj. OR 2.1; 95% CI 1.5–2.9). Within the second trimester, increased length of gestation did not influence the risk of surgical evacuation or infection after medical TOP.

Conclusions: Medical TOP during the second trimester is generally safe. Surgical evacuation of the uterus is avoided in about two-thirds of cases, though it is much more common than after first trimester medical TOP. The risks of surgical evacuation and infection do not increase with gestational weeks in the second trimester TOP.

Key words: complication / adverse event / second trimester / termination of pregnancy / medical

Introduction

With an estimated 29 induced abortions per 1000 women aged 15–44 years globally per annum (Sedgh et al., 2007), termination of an unwanted pregnancy is one of the most common gynaecological procedures. In developed countries, legal termination of pregnancy (TOP) is safe (Sedgh et al., 2007), the overall death rate being 10 per 100 000 procedures (Guttmacher Institute, 2009).

While the overall risks are low, increasing gestational age is, nevertheless, associated with an increased risk of complications. For example, from 1988 to 1997 in USA the risk of death increased by 38% for each additional week of gestation (Bartlett et al., 2004).

However, these data are mostly derived from surgical abortion (Guttmacher Institute, 2009). In large studies medical TOP using the combination of mifepristone and misoprostol seems to be more effective in earlier gestation (Ashok et al., 2002, 2004). Up to 9 weeks of gestation the overall rate of complete abortion can be up to 98% with only 2% needing a surgical intervention (Ashok et al., 2002). At 13–21 weeks of gestation the rate of successful abortion has been reported to be as high as 97%, with only 8% needing a surgical intervention (Ashok et al., 2004).

The method of second trimester TOP is still controversial, especially regarding adverse events and complications. Yet studies comparing surgical and medical second trimester TOP are rare and...
randomized comparison has proven difficult to carry out (Grimes, 2008; Lohr et al., 2008). In Northern Europe second trimester TOP is largely performed medically, i.e. using a combination of mifepristone and misoprostol (Lohr et al., 2008). Therefore there is a need for an epidemiological study evaluating the effects following the second trimester medical TOP.

The purpose of the present study was to assess the rate of adverse events and complications following the second trimester medical TOP and to compare it with those following the first trimester medical TOP. We focused in particular on haemorrhage, infection and surgical evacuation in cases of incomplete abortion.

Materials and Methods

We performed a register-based cohort study which included women who underwent medical TOP in Finland between 1 January 2003 and 31 December 2006. We linked three national registries: the study cohort was identified from the Abortion Registry (THL, 2010a) and data on adverse events were obtained from the Hospital Discharge Registry (THL, 2010b) (official name: Care Registry for Health Care Institutions) and the Cause-of-Death Registry of Statistics Finland (Statistic Finland, 2010).

The flow chart (Fig. 1) shows the formation of the cohorts. When a woman had more than one induced abortion during the study period, only the first TOP was included. Altogether, 695 (3.5%) women who underwent medical TOP were excluded from the study. The exclusion criteria were:

(i) Any other concomitant surgical procedure (laparoscopic sterilization, n = 20) performed at the same time.
(ii) Data could not be linked to hospital registry (n = 668), i.e. TOP performed at a private clinic as outpatient care.
(iii) Other reasons (n = 7): one woman with a kidney transplant and immunosuppressive medication, five women with twin pregnancies and one woman with previously diagnosed uterus bicornis.

Data concerning the method of induced abortion was derived from linkage of the Abortion Registry (THL, 2010a) and the Hospital Discharge Registry (THL, 2010b). During 2003–2006 medical TOP was defined in the Abortion Registry as: use of mifepristone alone or in combination with misoprostol or other prostaglandins, or prostaglandins alone. Details of the medical methods used were not available. However, mifepristone became available in Finland in 2000. Finnish national guidelines on TOP were published 25 September 2001 (Finnish Medical Society Duodecim, 2007). Data on background characteristics (age, previous pregnancies, socioeconomic and marital status, duration of gestation, year, indication for TOP, place of residence) were identified from the Abortion Registry (THL, 2010a). Women undergoing TOP for fetal indications, i.e. suspected or confirmed fetal anomalies or abnormalities (12 women, i.e. 0.07% during the first trimester and 844 women, i.e. 42% during the second trimester) were excluded. The final diagnosis of the fetal indication was not available and as the effect of fetal abnormalities on the adverse events or complications could not be assessed these pregnancies were excluded from the study analysis.

TOP is allowed in Finland up to 20 weeks of gestation (140 days of amenorrhea) or up to 24 weeks of gestation (168 days of amenorrhea) in cases of a confirmed medical condition of the fetus (FINLEX, 1970). Approval with a legal indication for TOP is needed, though the legislation is interpreted liberally. The indications can be grouped as medical (women’s or fetal health), ethical (e.g. rape) and social reasons. Social reasons include pregnancy and childbirth being an unbearable burden to a woman, age under 17 or over 40 years, and 4 or more deliveries. The approval for TOP has to be applied for from The National Supervisory Authority for Welfare and Health (Valvira, 2010) for all terminations because of congenital anomalies or if gestational weeks are over 12.

The follow-up time after TOP was 6 weeks (42 days). From the registries described above, we retrieved information on the diagnoses, based on ICD-10, the International Statistical Classification of Disease (2010) and operation codes based on the Nordic Classification of Surgical Procedures (2010) concerning all hospital-inpatient episodes (all hospitals) and outpatient visits (all public hospitals) during the follow-up period. Diagnoses and codes were evaluated to select those considered to be of clinical importance and related to TOP.

Complications were divided into following outcomes:

(i) Haemorrhage (any reported haemorrhages).
(ii) Infection (pelvic inflammatory disease, endometritis, cervicitis, wound infections, pyrexia of unknown origin, urinary tract infections and septicaemia).
(iii) Incomplete abortion (surgical evacuations or any reported incomplete abortion). Surgical evacuation was divided into three outcomes: total (all patients undergoing evacuation), evacuation at the time of TOP (i.e. following fetal expulsion and during the first stay at the hospital) and evacuation during follow-up (i.e. after the first hospital stay).

Some rare complications were considered as severe complications. They were:

(i) Injuries or other reasons for surgical procedures (all injuries, cervical laceration, uterine perforation, all surgical interventions during the time of follow-up).
(ii) Thromboembolic disease (pulmonary embolism, deep vein thrombosis).
(iii) Death (death from any cause, pregnancy-related death according to the World Health Organization definition).

This classification was based on that reported in the Joint Study of the Royal College of General Practitioners and the Royal College of Obstetricians and Gynaecologists (Davies et al., 2004) and further modified for our study.

This study was approved by the Ministry of Social Affairs and Health as required for registry-based studies in Finland. Statistics Finland also gave their permission to use confidential personal-level data from the death registry. The Data Protection Ombudsman was notified regarding data linkage before the analyses, as required by the national data-protection legislation.
All personal-level data that could be used to identify individuals was removed before the actual analysis was started.

**Statistical analysis**

Statistical analyses were performed using Predictive Analysis Software (PASW) 18.0 for Mac (SPSS Inc., Chicago, IL, USA). Differences in continuous variables were analysed with Mann-Whitney U-test for skewed data and data were presented as median and interquartile range (IQR). The χ² test or Fisher’s exact test were used as appropriate for independent nominal data. The level of statistical significance was P < 0.05. In the analysis of surgical evacuation percentages during the observed time, 95% confidence interval (CI) for percentage was presented. Binary logistic regression models were used to adjust for differences in the background characteristics in comparison of the first and second trimester TOP. The background characteristics that differed statistically significantly between the groups were entered in the analysis. Estimated risks are presented as odds ratios (OR) with 95% CIs.

**Results**

The observed cohort consisted of 18,248 women who underwent medical TOP between 2003 and 2006, 94% during the first trimester and 6% during the second trimester. During that period 57 and 95% of all terminations of pregnancy were performed medically in the first and second trimester, respectively.

The duration of gestation [median (IQR)] was 7 weeks (7–8) during the first trimester and 15 weeks (14–17) during the second trimester. Table I shows the demographics of the study groups. Compared with the first trimester cohort, women undergoing medical TOP during the second trimester were younger, more often single or cohabiting and less often married. They were also more often of lower socioeconomic status and had had fewer previous deliveries. In the second trimester, the indication for medical TOP was more often age under 17 years, unknown or due to woman’s health issues and less often social (i.e. continuation of pregnancy, and subsequent childbirth forming an unbearable burden to the woman) than for the first trimester medical TOP.

The main adverse events and complications (haemorrhage, infection, incomplete abortion, i.e. of the requirement for surgical evacuation) are shown in Table II. Medical second trimester TOP increased the risk of surgical evacuation, especially immediately after expulsion of the fetus when compared with the first trimester medical TOP. Second trimester medical TOP was also associated with a higher risk of infection. The risk of haemorrhage was lower during and after second trimester TOP, except in cases when surgical evacuation of residual tissue was needed.

Medical TOP was followed by 23 (0.13%) surgical procedures other than evacuation, i.e. severe complications. Of these, 20 (0.12%) occurred after first trimester medical TOP and 3 (0.26%) after second trimester medical TOP (P < 0.2). First trimester medical TOP was followed by a laparoscopic saturation of the uterus in three cases and 17 other repairing operations and second trimester medical TOP was followed by one abdominal hysterectomy, one saturation of the cervix and one other repair operation. There were no thromboembolic diseases during follow-up. There were no deaths as a result of TOP during the study period.

The effect of increasing gestation on the surgical evacuation, infection and haemorrhage was evaluated. The overall incidence of surgical evacuation following medical TOP was 9.9% (95% CI 9.5–10.3). The percentages of surgical evacuation compared with increasing gestation are shown in Fig. 2. The need for surgical evacuation increased as gestational weeks increased beyond 11. The overall incidence of infection following medical TOP was 2.1% (95% CI 0.8–3.9). The percentages of infection compared with increasing gestation are shown in Fig. 3. The risk of infection increased with increasing gestation. The
Overall incidence of haemorrhage following medical TOP was 16.9% (95% CI 15.6–18.2). The risk of haemorrhage varied according to gestation.

### Discussion

We found that in comparison with the first trimester medical TOP, second trimester medical TOP was associated with an increased risk of surgical evacuation and infection. However, serious complications that need surgical repair after medical TOP and medical second trimester TOP were rare 0.1 and 0.3%, i.e. 1 and 3 per 1000 procedures, respectively. The present results also confirm that in Finland second trimester TOP (i.e. during gestational Weeks 13–24) is mostly (95%) performed medically.

This nationwide retrospective cohort study gives information about the contemporary use of medical abortion in non-selected material. It was derived from a registry, the coverage of which is almost 100% (Gissler et al., 1996). In addition, the hospital registry data for in-patient care, the provision of which is mandatory, was available from all hospitals and out-patient care data were available from all public hospitals, adding to the information value of the study. There were, however, differences in coding treatments (Nordic Centre for Classifications in Health Care, 2010) and diagnoses (International Statistical Classification of Diseases, 2010) among Finnish hospitals. Thus, the severity of reported adverse events may vary considerably. Moreover, while the registry differentiates between medical and surgical TOP, the database does not provide precise information on the medication used to perform TOP. We therefore restricted our analysis to years 2003–2006, during

---

### Table I Demographics of the women undergoing medical TOP in 2003–2006.

<table>
<thead>
<tr>
<th></th>
<th>First trimester (n = 17087)</th>
<th>Second trimester (n = 1161)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>25 (20–32)</td>
<td>22 (18–30)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Marital status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Married</td>
<td>3235 (18.9)</td>
<td>119 (10.2)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cohabiting</td>
<td>2843 (16.6)</td>
<td>222 (19.1)</td>
<td>0.03</td>
</tr>
<tr>
<td>Single</td>
<td>11009 (64.4)</td>
<td>820 (70.6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Residence</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban</td>
<td>12379 (72.4)</td>
<td>853 (73.5)</td>
<td>0.5</td>
</tr>
<tr>
<td>Densely populated</td>
<td>2494 (14.6)</td>
<td>155 (13.4)</td>
<td>0.2</td>
</tr>
<tr>
<td>Rural</td>
<td>2214 (13.0)</td>
<td>153 (13.2)</td>
<td>0.8</td>
</tr>
<tr>
<td>Socioeconomic status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper white-collar workers</td>
<td>1010 (5.9)</td>
<td>27 (2.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Lower white-collar workers</td>
<td>3299 (19.3)</td>
<td>159 (13.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Blue-collar workers</td>
<td>2214 (13.0)</td>
<td>148 (12.7)</td>
<td>0.8</td>
</tr>
<tr>
<td>Students</td>
<td>5895 (34.5)</td>
<td>400 (34.5)</td>
<td>0.97</td>
</tr>
<tr>
<td>Others</td>
<td>1086 (6.4)</td>
<td>80 (6.9)</td>
<td>0.5</td>
</tr>
<tr>
<td>Unknown</td>
<td>3583 (21.0)</td>
<td>347 (29.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Previous deliveries</td>
<td>7478 (43.8)</td>
<td>416 (35.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Previous miscarriage</td>
<td>2164 (12.7)</td>
<td>152 (13.1)</td>
<td>0.7</td>
</tr>
<tr>
<td>Previous TOP</td>
<td>2664 (15.6)</td>
<td>184 (15.8)</td>
<td>0.8</td>
</tr>
<tr>
<td>Current TOP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year of TOP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2003</td>
<td>3691 (21.6)</td>
<td>265 (22.8)</td>
<td>0.3</td>
</tr>
<tr>
<td>2004</td>
<td>4270 (25.0)</td>
<td>314 (27.0)</td>
<td>0.1</td>
</tr>
<tr>
<td>2005</td>
<td>4533 (26.6)</td>
<td>295 (25.4)</td>
<td>0.4</td>
</tr>
<tr>
<td>2006</td>
<td>4573 (26.8)</td>
<td>287 (24.7)</td>
<td>0.1</td>
</tr>
<tr>
<td>Indication for TOP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Woman’s health</td>
<td>46 (0.3)</td>
<td>13 (1.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Social</td>
<td>15317 (89.6)</td>
<td>914 (78.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Ethical</td>
<td>6 (&lt;0.1)</td>
<td>0</td>
<td>0.7</td>
</tr>
<tr>
<td>Age &lt; 17</td>
<td>1035 (6.1)</td>
<td>160 (13.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age ≥ 40</td>
<td>417 (2.4)</td>
<td>27 (2.3)</td>
<td>0.8</td>
</tr>
<tr>
<td>≥ 4 deliveries</td>
<td>219 (1.3)</td>
<td>18 (1.6)</td>
<td>0.4</td>
</tr>
<tr>
<td>Unknown</td>
<td>47 (0.3)</td>
<td>29 (2.5)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Data shown as numbers (percentages) or median (IQR, interquartile range).
which medical TOP using mifepristone and misoprostol was widespread throughout the country (THL, 2010a).

The rate of surgical evacuation associated with second trimester medical TOP was high (39%) in the present study. A potential explanation is that these data are derived from hospitals treating 200 second trimester terminations of pregnancy per year with all doctors performing the treatments. This may lead to unnecessary surgical treatments. Further, surgical evacuation of the uterus quickly after expulsion of the fetus was more or less routine until year 2000. For example, we published surgical evacuation percentages of 45–64% associated with second trimester medical TOP performed with mifepristone and misoprostol in 2001 (Heikinheimo et al., 2004). Nevertheless, it will be interesting to see if the low rates in surgical evacuation (8%: Ashok et al., 2004) following medical second trimester TOP, reported from centres with extensive experience with medical methods, can also be reached at a national level.

Reassuringly, the incidence of infection leading to a hospital visit (4%) following medical second trimester TOP in this nationwide study was similar to that 3% reported earlier (Ashok et al., 2004; Lohr et al., 2008). Moreover, the risk of infection was largely associated with evacuation of residual tissue.

It is interesting to note that the incidence of reported haemorrhage was lower during the second trimester TOP when compared with that of the first trimester. However, if haemorrhage occurred, it resulted in surgical intervention in more than half of the cases during the second trimester and in less than one-fifth of the cases during the first trimester.

### Table II: Adverse events and complications among women undergoing TOP between 2003 and 2006.

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>First trimester (n = 17,087)</th>
<th>Second trimester (n = 1161)</th>
<th>OR (95% CI)</th>
<th>P-value</th>
<th>Adj. OR*</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Surgical evacuation (total)</td>
<td>1,357 (7.9)</td>
<td>447 (38.5)</td>
<td>7.3 (6.4–8.3)</td>
<td>&lt;0.001</td>
<td>7.8 (6.8–8.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>At the time of TOP</td>
<td>396 (2.3)</td>
<td>306 (26.4)</td>
<td>15.1 (12.8–17.8)</td>
<td>&lt;0.001</td>
<td>15.2 (12.8–18.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>During follow-up</td>
<td>961 (5.6)</td>
<td>141 (12.1)</td>
<td>2.3 (1.9–2.8)</td>
<td>&lt;0.001</td>
<td>2.5 (2.1–3.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>2. Haemorrhage (total)</td>
<td>2,937 (17.2)</td>
<td>167 (14.4)</td>
<td>0.8 (0.7–0.96)</td>
<td>0.01</td>
<td>0.8 (0.7–0.98)</td>
<td>0.03</td>
</tr>
<tr>
<td>Haemorrhage with surgical evacuation</td>
<td>541 (3.2)</td>
<td>96 (8.3)</td>
<td>2.8 (2.2–3.5)</td>
<td>&lt;0.001</td>
<td>3.1 (2.4–3.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>3. Infection (total)</td>
<td>330 (1.9)</td>
<td>46 (4.0)</td>
<td>2.1 (1.5–2.9)</td>
<td>&lt;0.001</td>
<td>2.1 (1.5–2.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Infection with surgical evacuation</td>
<td>138 (0.8)</td>
<td>28 (2.4)</td>
<td>3.0 (2.0–4.6)</td>
<td>&lt;0.001</td>
<td>3.3 (2.2–5.0)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Data are shown as n (%).

*First trimester cohort was used as a reference adjusted for age, marital status, socio-economic status, previous deliveries and indication for TOP.

### Figure 2
Percentage of surgical evacuation in relation to duration of gestation following medical TOP in 2003–2006. Bars represent 95% CI for percentage.

### Figure 3
Percentage of infection in relation to duration of gestation following medical TOP in 2003–2006. Bars represent 95% CI for percentage.
Also the need of surgical evacuation of residual tissue seemed to occur earlier following second than first trimester TOP. It may be speculated that the lower rate of haemorrhage seen after the second trimester TOP is due to the fact that these women are managed at the hospital and undergo surgical evacuation more often. Thus, the lower incidence of reported haemorrhage following the second trimester TOP may be more due to different management than to a biological difference(s) between the first and second trimester TOP.

The optimal method for second trimester TOP continues to be debated, as medical second trimester TOP with mifepristone and misoprostol is associated with higher overall rate of adverse events and complications when compared with dilatation and evacuation (Grimes, 2008; Lohr et al., 2008). However, TOP performed with mifepristone and misoprostol during gestational Weeks 13–24 has been shown to be effective and acceptable (Ashok et al., 2004; Lohr et al., 2008). The safety of surgical TOP at more than 15 weeks of gestation depends on the skills of the practitioners (Grimes, 2008; Lohr et al., 2008). As the medical method for TOP is less dependent on the skills of doctors, it might be the preferred method in some health care settings.

We conclude that in comparison with medical TOP performed during the first trimester, medical second trimester TOP was associated with increased frequency of adverse events, most of which are minor. However, the risks of surgical evacuation or infection did not increase with increasing gestation duration in the second trimester. These data encourage further development and use of medical methods for second trimester TOP.

Authors’ roles

All authors have equally participated in the planning of the study, analysis of the data and preparing of the manuscript.

Funding

This study was supported by Helsinki University Central Hospital Research funds.

References

Heikinheimo O, Suonen S, Haukkamaa M. One- and 2-day mifepristone-misoprostol intervals are both effective in medical termination of second-trimester pregnancy. Reprod Biomed Online 2004; 8:236 – 239.
Exhibit 4

James Studnicki et al., A Longitudinal Cohort Study of Emergency Room Utilization Following Mifepristone Chemical and Surgical Abortions, 1999-2015, Health Serv. Rsch. & Managerial Epidemiology, Nov. 9, 2021
A Longitudinal Cohort Study of Emergency Room Utilization Following Mifepristone Chemical and Surgical Abortions, 1999–2015

James Studnicki¹, Donna J. Harrison², Tessa Longbons¹, Ingrid Skop¹, David C. Reardon³, John W. Fisher¹, Maka Tsulukidze⁴, and Christopher Craver¹

Abstract

Introduction: Existing research on postabortion emergency room visits is sparse and limited by methods which underestimate the incidence of adverse events following abortion. Postabortion emergency room (ER) use since Food and Drug Administration approval of chemical abortion in 2000 can identify trends in the relative morbidity burden of chemical versus surgical procedures.

Objective: To complete the first longitudinal cohort study of postabortion emergency room use following chemical and surgical abortions.

Methods: A population-based longitudinal cohort study of 423,000 confirmed induced abortions and 121,283 subsequent ER visits occurring within 30 days of the procedure, in the years 1999-2015, to Medicaid-eligible women over 13 years of age with at least one pregnancy outcome, in the 17 states which provided public funding for abortion.

Results: ER visits are at greater risk to occur following a chemical rather than a surgical abortion: all ER visits (OR 1.22, CL 1.19-1.24); miscoded spontaneous (OR 1.88, CL 1.81-1.96); and abortion-related (OR 1.53, CL 1.49-1.58). ER visit rates per 1000 abortions grew faster for chemical abortions, and by 2015, chemical versus surgical rates were 354.8 versus 357.9 for all ER visits; 31.5 versus 8.6 for miscoded spontaneous abortion visits; and 51.7 versus 22.0 for abortion-related visits. Abortion-related visits as a percent of total visits are twice as high for chemical abortions, reaching 14.6% by 2015. Miscoded spontaneous abortion visits as a percent of total visits are nearly 4 times as high for chemical abortions, reaching 8.9% of total visits and 60.9% of abortion-related visits by 2015.

Conclusion: The incidence and per-abortion rate of ER visits following any induced abortion are growing, but chemical abortion is consistently and progressively associated with more postabortion ER visit morbidity than surgical abortion. There is also a distinct trend of a growing number of women miscoded as receiving treatment for spontaneous abortion in the ER following a chemical abortion.

Keywords
induced abortion, mifepristone, medical abortion, emergency room, Medicaid

Introduction

Since its fast-track approval by the USA Food and Drug Administration (FDA) in September 2000, induced abortion by the administration of mifepristone and misoprostol (ie, chemical abortion) has grown to over 50% of all induced abortions in the United States and may, in fact, be responsible for ending a long-term decline in the number of induced abortions in the United States¹

Research on the safety of induced abortion, and particularly those that are chemically induced, continues to be handicapped

¹ Charlotte Lozier Institute, Arlington, VA, USA
² American Association of Pro-Life Obstetricians and Gynecologists, Eau Claire, MI, USA
³ Elliot Institute, Springfield, IL, USA
⁴ Florida Gulf Coast University, Fort Myers, FL, USA

Corresponding Author:
James Studnicki, Charlotte Lozier Institute, Arlington, VA, USA.
Email: jstudnicki@lozierinstitute.org

Creative Commons Non Commercial CC BY-NC. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
in the United States by the absence of a comprehensive national reporting system of pregnancy outcomes. The Centers for Disease Control and Prevention (CDC) Abortion Surveillance Reports are derived from a profoundly flawed system in which reporting by the states is voluntary, with many states reporting intermittently and some not at all. The reporting of specific data elements is similarly piecemeal and, most disappointing, no event-level data is actually available for any rigorous analytical purposes. Adverse events which may be related to an induced abortion such as a death, incomplete abortion, severe bleeding, or infection are often underreported because there is no certain way to link the adverse event to the precipitating abortion. Further, the FDA’s adverse event reporting requirements for mifepristone extend only to deaths. Large population-based record-linkage studies from nations with comprehensive reproductive history data linked to adverse events provide the best opportunity to overcome many of these data limitations and find a much higher overall incidence of adverse events in the chemical compared with the surgical cohort. By contrast, USA studies of chemical abortion safety are frequently conducted on opportunity samples of women who have recently undergone an induced abortion. Already limited by the nonrandom nature of patient selection, these studies are frequently subject to design limitations such as the exclusion of an incomplete abortion as a complication, or an unacceptably high percentage of women lost to follow-up.

The emergency room (ER) visit is a particularly insightful event by which to assess and compare the relative safety of chemical and surgical abortions for 2 reasons. First, adverse events following a mifepristone abortion are more likely to be experienced at home in the absence of a physician, increasing the likelihood of an ER visit. Second, the ER visit can be for any number of complications and is, therefore, a broad proxy indicator for abortion-related morbidity. One major concern is that ER secondary data describes treatment for a condition (eg, hemorrhage) which may be attributed to a prior event (eg, abortion), but, as we have seen, the prior event is often missed. For example, a study of abortion-related emergency room visits in the United States, using the Nationwide Emergency Department Sample, categorized whether visits were abortion related based only on information taken from the ER visit record. There was no independent confirmation from a different source that an abortion had occurred. Therefore, a woman who was experiencing excessive bleeding following a chemical abortion but did not reveal the abortion to the ER physician would not be identified as an abortion-related visit. Not surprisingly, the study found an extraordinarily low percentage (0.01%) of abortion-related visits among all ER visits to women age 15 to 49. For all the reasons related to data availability and quality, as well as methodological inadequacies, evidence suggests that postabortion complications are substantially underreported.

As we have described, research on adverse events following induced abortion varies by procedure, protocols to detect complication, length of follow-up and the sources and quality of data. The emergency room visit as a comprehensive marker for post-abortion complications has been infrequently and inadequately utilized in existing research. Therefore, the objective of this research was to complete the first population based longitudinal cohort study of the trajectory of postabortion emergency room utilization following both chemical and surgical abortions in order to test the hypothesis that chemical abortion results in higher emergency room utilization. We selected a longitudinal cohort design because of its superiority to cross-sectional approaches in suggesting causation. Uniquely, our methodology includes first a confirmation of the actual provision of either a chemical or surgical abortion and, only after confirmation, identifies broadly all emergency room utilization before disaggregating abortion-related ER use. In the absence of a national abortion registry, this analysis is intended to provide the most comprehensive view of postabortion-related morbidity in the years following the FDA approval of mifepristone abortion, as well as a glimpse of what we might expect in the future.

Methods

Data were obtained from the enrollee-level Medicaid Analytic eXtract files licensed through the Centers for Medicare and Medicaid Services (CMS) Chronic Condition Data Warehouse’s Medicaid data. The analytic dataset is comprised of enrollees from the 17 states whose official policies applied state funds to most abortions not covered by federal Medicaid during the period 1999 through 2015. Not all states funded abortion consistently or to the same extent during the study period. Despite their official policies, Arizona and Illinois funded relatively few abortions during this period, and Alaska experienced a short interruption to its abortion coverage. Not all states had provided claims data through 2015 due to differing reporting timeframes. The latest year of data relative to each state was 2013 for Arkansas, Illinois, Maryland, Montana, and New Mexico; 2014 for Arizona, Hawaii, Massachusetts, and Washington; and 2015 for California, Connecticut, Minnesota, New Jersey, New York, Oregon, Vermont, and West Virginia.

The study population was made up of enrollees over 13 years of age with at least one identifiable pregnancy outcome from 1999 through the latest year of data available for each state. For each beneficiary, all unique pregnancy outcomes were identified using International Classification of Diseases, Ninth Revision (ICD-9) codes. Additionally, Current Procedural Terminology, fourth Edition (CPT4) and Healthcare Common Procedure Coding System (HCPCS) codes were used to confirm pregnancy outcomes.

These codes were used to allocate all pregnancy outcomes into 4 categories: live birth (ICD-9V27.0, V27.2, and V27.5), natural fetal loss (ICD-9V271.1, V27.4, V27.7, 630, 631, 633, 634), induced abortion (ICD-9 635.xx, CPT4 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, and HCPCS: S0199, S2260, S2265, S2266, S2267, X7724, X7726, S0190, S0191), and undetermined (ICD-9 636.xx, 637.xx, 638.xx). In order to identify each unique pregnancy, multiple diagnostic or treatment codes within 30 days of a pregnancy loss (natural, induced, or undetermined) or within 180 days of a live birth were counted as a single pregnancy outcome using the first
date associated with that series of Medicaid claims. Twins and higher order gestations that resulted in a combination of live birth and fetal loss were excluded from the analysis.

The analytic strategy was composed of 3 phases. First, we identified every confirmed surgical induced abortion (ICD/ CPT codes—CPT4 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857) and every confirmed chemical induced abortion (HCPCS codes S0190, S0191) in each specific year 1999 to 2015 (index abortion). Codes S0190 and S0191 were added by CMS on January 1, 2001, so chemical abortions prior to that date could have been missed; however, because mifepristone did not receive approval from the FDA until September 28, 2000, the number of mifepristone abortions not captured here is likely minimal. Additionally, as an explanatory variable, we determined whether there was a prior induced abortion or live birth in the 12 months preceding the index abortion procedure. Second, we identified every emergency room visit occurring within thirty days of the index abortion procedure (Place of Service code 23 [emergency room]), including multiple visits for each patient. We further disaggregated ER visits into 3 categories: all-cause, abortion-related codes (ICD-9, 630-639) and spontaneous abortion code (ICD-9, 634). We mapped and adjusted the appropriate codes during the last two quarters of calendar year 2015 to reflect the transition from ICD-9 to ICD-10. The following descriptive metrics were calculated: chemical abortions as a percent of total induced abortions; ER visits following chemical abortions as a percent of total ER visits following total induced abortions; coded abortion-related visits as a percent of total ER visits following an induced abortion; miscoded spontaneous abortion ER visits as a percent of total ER visits following an induced abortion; miscoded spontaneous abortion ER visits as a percent of abortion-related ER visits following an induced abortion; and abortion ER visit rates per 1000 specified induced abortions for all-cause, coded abortion-related, and miscoded spontaneous abortion visit categories. Comparisons of the 1999 to 2015 longitudinal trajectory of these descriptive metrics are displayed in a series of 9 figures.

Third, we performed logistic regression models to identify the association of selected predictor variables with the likelihood of experiencing each of the 3 defined categories of ER visits following an induced abortion. The outcome variable in each equation was the dichotomous indication (yes/no) of the following abortion or live birth in the 12 months preceding the index abortion procedure. The odds ratios were calculated for the 1999 to 2015 longitudinal trajectory of these descriptive metrics are displayed in a series of 9 figures.

Summary analytic tables were created using (SAS/STAT) software, version (10) of the SAS system for (Unix).
As a percent of abortion-related visits (ICD-9, 630-639), visits miscoded for spontaneous abortion treatments (ICD-9, 634) following a confirmed mifepristone abortion averaged approximately 30% between 2003 and 2012 and increased between 2013 and 2015, reaching 60.9%. ER visits miscoded as treatment for spontaneous abortion as a percent of abortion-related visits following a confirmed surgical abortion are consistently lower percentage than for those following a chemical abortion, peaking at 39% in 2015 (Figure 6). Treatment in the ER miscoded as for spontaneous abortion is consistently and progressively more likely following a chemical abortion than following a surgical abortion.

All-cause ER visit rates within 30 days of an abortion have increased consistently throughout the study period for all types of induced abortion. There were 78.4 all-cause visits per 1000 surgical abortions in 1999 and 357.9 in 2015, an increase of 356% in the rate. Using 2002 as the initial year with sufficient abortion and ER visit counts to calculate a rate, the chemical

### Table 1. Chemical and Surgical Induced Abortions and ER Visits Within 30 Days, 1999-2015.

<table>
<thead>
<tr>
<th>Year</th>
<th>Chemical Abortions</th>
<th>Chemical All ER Visits</th>
<th>Chemical 630 to 639</th>
<th>Chemical 634</th>
<th>Surgical Abortions</th>
<th>Surgical All ER Visits</th>
<th>Surgical 630 to 639</th>
<th>Surgical 634</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999</td>
<td>0</td>
<td>4479</td>
<td>351</td>
<td>15</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2000</td>
<td>0</td>
<td>7248</td>
<td>598</td>
<td>31</td>
<td>11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2001</td>
<td>15</td>
<td>9986</td>
<td>732</td>
<td>20</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2002</td>
<td>352</td>
<td>7729</td>
<td>977</td>
<td>41</td>
<td>10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2003</td>
<td>803</td>
<td>13 012</td>
<td>1792</td>
<td>70</td>
<td>12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td>1319</td>
<td>18 463</td>
<td>2871</td>
<td>99</td>
<td>14</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2005</td>
<td>1360</td>
<td>19 226</td>
<td>4178</td>
<td>170</td>
<td>42</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td>1192</td>
<td>20 558</td>
<td>5042</td>
<td>218</td>
<td>51</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td>1521</td>
<td>21 244</td>
<td>6060</td>
<td>263</td>
<td>53</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2008</td>
<td>1988</td>
<td>22 125</td>
<td>6954</td>
<td>313</td>
<td>66</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td>3032</td>
<td>25 764</td>
<td>7879</td>
<td>358</td>
<td>91</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td>4848</td>
<td>30 019</td>
<td>8820</td>
<td>386</td>
<td>114</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>6834</td>
<td>32 394</td>
<td>10 044</td>
<td>465</td>
<td>104</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td>8768</td>
<td>36 204</td>
<td>11 401</td>
<td>536</td>
<td>150</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>6856</td>
<td>35 814</td>
<td>11 681</td>
<td>558</td>
<td>142</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>6909</td>
<td>28 101</td>
<td>9970</td>
<td>466</td>
<td>120</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>15 279</td>
<td>29 558</td>
<td>10 578</td>
<td>651</td>
<td>254</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

As a percent of abortion-related visits (ICD-9, 630-639), visits miscoded for spontaneous abortion treatments (ICD-9, 634) following a confirmed mifepristone abortion averaged approximately 30% between 2003 and 2012 and increased between 2013 and 2015, reaching 60.9%. ER visits miscoded as treatment for spontaneous abortion as a percent of abortion-related visits following a confirmed surgical abortion are consistently lower percentage than for those following a chemical abortion, peaking at 39% in 2015 (Figure 6). Treatment in the ER miscoded as for spontaneous abortion is consistently and progressively more likely following a chemical abortion than following a surgical abortion.

All-cause ER visit rates within 30 days of an abortion have increased consistently throughout the study period for all types of induced abortion. There were 78.4 all-cause visits per 1000 surgical abortions in 1999 and 357.9 in 2015, an increase of 356% in the rate. Using 2002 as the initial year with sufficient abortion and ER visit counts to calculate a rate, the chemical

**Figure 1.** Medicaid abortions (surgical and chemical), 1999–2015, and chemical abortion % total.
abortion rate increased from 102.3 in 2002 to 354.8, a rate increase of 247%. When the surgical rate increase is calculated from 2002 (126.4) and 2015 (357.9), the rate increase is 183%. Both the consistent increase in the rate of ER visits per abortion procedure and the higher chemical rate relative to the surgical rate after 2004 are apparent in Figure 7.

Abortion-related ER visits (ICD-9 630-639) per abortion exhibit a similar upward trend in rates for both surgical and chemical abortions, but, beginning in 2002, a growing divergence by type of abortion is evident. The surgical abortion to abortion-related visit rate increases from 5.3 in 2002 to 22.0 in 2015, an increase of 315%. Chemical abortion visit rates during the same period went from 8.5 to 51.7, an increase of 507% (Figure 9).

ER visit rates miscoded as for spontaneous abortion (ICD-9 634) within 30 days of a surgical abortion show a declining pattern from a peak of 1.5 in 2000 to a low point of 0.8 in 2004, a gradual increase between 2.2 and 4.3 from 2005 to 2014, and a doubling to 8.6 in 2015. By contrast, ER visit rates miscoded as for spontaneous abortion treatment following a chemical abortion show a consistent increase from 8.55 in 2007, the first year ER visits in this category reached double digits, to 31.5 in 2015. Between 2007 and 2015, the ER visit rate miscoded for spontaneous abortion increased 244% following surgical abortion and 268% following chemical abortion (Figure 8). Caution previously noted regarding the coding and classification of these visits is similarly warranted here.

A summary of the logistic regression analyses is in Table 2. All 3 types of ER visits during the study observation period are more likely to occur following a chemical abortion than following a surgical abortion: all-cause (OR 1.22, CL 1.19-1.24); abortion-related (OR 1.53, CL 1.49-1.58); and spontaneous abortion (OR 1.88, CL 1.81-1.96). Prior pregnancy outcomes increase the likelihood of any type of subsequent ER visit. However, an ER visit is significantly more likely to occur following a prior chemical abortion than following a prior surgical abortion: all-cause (OR 2.54, CL 2.38-2.70 vs OR 1.78, CL 1.73-1.82); abortion-related (OR 1.80, CL 1.65-1.97 vs OR 1.35, CL 1.29-1.41); and spontaneous abortion (OR 1.74, CL 1.54-1.96 vs OR 1.43, CL 1.35-1.52). A prior live birth is a lower risk factor for post abortion ER visits than is either a chemical or surgical induced abortion: all-cause (OR 1.52, CL 1.48-1.56); abortion-related (OR 1.09, CL 1.04-1.15); and spontaneous abortion (OR 1.12, CL 1.04-1.20).

Hispanics are slightly more likely than whites to experience any type of post abortion ER visit: all-cause (OR 1.07, CL 1.05-1.10); abortion-related (OR 1.03, CL 1.00-1.07); and spontaneous abortion (OR 1.03, CL 0.98-1.09). Blacks, by contrast, are consistently less likely than whites to experience any type of post abortion ER visit: all-cause (OR 0.59, CL 0.58-0.61); abortion-related (OR 0.68, CL 0.66-0.71); and spontaneous abortion (OR 0.72, CL 0.68-0.76). Age at time of the abortion and years of Medicaid eligibility are not important risk factors in predicting post abortion emergency room use.

Figure 2. Emergency room (ER) use following surgical abortion, 1999-2015.
Discussion

Regression analysis definitively supports the hypothesis that chemical abortion is associated with more frequent emergency room visits of all kinds for the entire study period. In addition, we found that ER visit rates per 1000 abortion procedures increased consistently throughout the study period following both types of induced abortion, but the rates for mifepristone abortion visits grew faster, especially for abortion-related visits. By 2015, mifepristone versus surgical ER rates were: all visits (354.8 vs 357.9); miscoded spontaneous abortion

Figure 3. Emergency room (ER) use following chemical abortion, 1999–2015.

Figure 4. Abortion-related visits as a percent of all emergency room (ER) visits.
The reasons for the increasing rate of ER visits following mifepristone abortions are not readily apparent but may be influenced by mifepristone abortion providers who are unable or unskilled to handle complications after chemical abortions. This finding would be consistent with an analysis of FDA Adverse Event Reports which showed that abortion providers only managed slightly over half of the dilation and curettage procedures (D&Cs) required for hemorrhage and retained tissue, and the remainder were handled by the emergency room. Further research is needed to delineate whether there is a difference between ER visit utilization after abortions performed by those abortion providers untrained in surgical procedures (ie, midwives, advance practice clinicians, Family Medicine providers and other types of providers). This finding is also of significance when considering the implications of removing a requirement for in-person medical supervision of mifepristone abortion as is currently under consideration by the FDA.

These findings are especially consequential because they are derived directly from all paid medical claims records, unlike most other studies of abortion complications which involve voluntary survey reporting and/or a more limited query of a select set of treatment codes. The more comprehensive examination of all ER codes associated with confirmed abortion events undertaken in this research requires reconsideration of previous findings which now appear to have understated the full range of risks associated with abortion. For example, previous research on only fee-for-service California Medicaid beneficiaries and using only a single code (ICD-9 635.xx) in 2009 to 2010 concluded that 6.4% of all abortions were followed by any ER visit within 6 weeks and 0.87% were followed by an abortion-related visit. Results of our research summarized for the same 2 years found 4.8 times (30.7%) the number of total ER visits and 1.8 times (1.56%) the number of abortion-related visits within our shorter 30-day postabortion observation period. We were able to detect this more accurate number of complications because the women were included in our study based on a CPT code payment for mifepristone abortion, thus eliminating the need for the treating physician to recognize a complication from a chemical abortion.

The finding that many ER visits following known induced abortions are misclassified as postmiscarriage complications is particularly noteworthy. Abortion studies in the United States consistently report lower postabortion complication rates than are documented in the international scientific literature. There are likely multiple reasons for this discrepancy, but among them are the miscoding of abortion-related complications by the provider and the nondisclosure of prior abortion history by the patient. Women obtaining chemical abortions must sign a patient agreement indicating they will bring with them the mifepristone medication guide if seeking emergency care, but some abortion advocates encourage women to withhold information if seeking treatment for an adverse event. Our study demonstrated ER visits misclassified or miscoded as spontaneous abortion grew for both types of induced abortion, reaching 39% of abortion-related visits following surgical abortion and 60.9% of visits following chemical abortion in 2015. These mifepristone abortion complications would have been invisible to previous researchers, resulting in a large underestimation of actual mifepristone abortion complications. Our more accurate estimation has significant implications for the evaluation of risks communicated
to women in the process of informed consent prior to abortion, as well as in policy making regarding mifepristone abortion.

Consistent with CDC reports, we found the percentage of abortions performed by means of mifepristone and misoprostol increased from 4.4% of total abortions in 2002 to 34.1% in 2015. Similarly, ER visits following mifepristone abortion grew from 3.6% of all postabortion visits in 2002 to 33.9% of all postabortion visits in 2015. The trend toward increasing use of mifepristone abortion requires all concerned with health care utilization to carefully follow the ramifications of ER utilization.

There are limitations related to the use of Medicaid claims data. Medicaid-eligible beneficiaries are by definition financially disadvantaged and are not representative of all women experiencing abortion. Conversely, a data set composed entirely of low-income women may also be considered an advantage since results are unlikely to be explained by differences in income or other factors strongly associated with income. The lower risk of any ER visit following induced abortion among

![Figure 6. Miscoded spontaneous abortion visits as a percent of abortion-related emergency room (ER) visits.](image)

![Figure 7. Total emergency room (ER) visits per 1000 abortions.](image)
Black women suggests that a more granular analysis of the influence of race is warranted. Services received by eligible women but paid by another source (e.g., out of pocket) are not included in the claims data. Services received when the women were not eligible are similarly not included. Administrative data are also subject to limitations regarding coding errors, inconsistent coding, and the exclusion of codes considered nonessential for billing.16,17 There are inconsistencies in coding which may vary state by state. Our data extraction protocol required both an ICD code and CPT code to

Figure 8. Miscoded spontaneous abortion emergency room (ER) visits per 1000 abortions.

Figure 9. Abortion-related emergency room (ER) visits per 1000 abortions.
identify beneficiaries who had an induced abortion. To the extent that some states or individual providers do not code an abortion with an ICD code, our study population may undercount the number of abortions. This undercount would likely be due to a random variation in coding protocols and is unlikely to affect the trends related in our findings.

In summary, mifepristone abortion is consistently and progressively associated with increased morbidity in the form of postabortion emergency room utilization among the population of women with publicly funded abortions. The determination of the causes and potential means of prevention for this burden of illness should have the highest priority of our health agencies and elected officials. Additional research is necessary to investigate the prevalence and type of effects beyond 30 days.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Table 2. Logistic Regression Odds Ratio Estimates (OR) and (Wald) Confidence Limits (CLs).**

<table>
<thead>
<tr>
<th></th>
<th>Any ER Visit</th>
<th>Abortion-Related Visit</th>
<th>Spontaneous Abortion Visit</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR 95% CLs</td>
<td>OR 95% CLs</td>
<td>OR 95% CLs</td>
</tr>
<tr>
<td>Chemical versus Surgical Abortion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black versus White</td>
<td>0.59 0.58 to</td>
<td>1.07 1.05 to</td>
<td>0.72 0.68 to</td>
</tr>
<tr>
<td>Hispanic versus White</td>
<td>1.10 1.10 to</td>
<td>0.91 0.89 to</td>
<td>1.09 1.07 to</td>
</tr>
<tr>
<td>Other versus White</td>
<td>0.93 0.93 to</td>
<td>0.91 0.91 to</td>
<td>0.89 0.89 to</td>
</tr>
<tr>
<td>Pregnancy 365 d prior versus no surgical abortion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prior</td>
<td>1.78 1.73 to</td>
<td>1.50 1.48 to</td>
<td>1.35 1.30 to</td>
</tr>
<tr>
<td>chemical abortion</td>
<td>2.54 2.38 to</td>
<td>1.56 1.50 to</td>
<td>1.43 1.38 to</td>
</tr>
<tr>
<td>Prior live birth</td>
<td>1.52 1.48 to</td>
<td>1.09 1.04 to</td>
<td>1.42 1.37 to</td>
</tr>
<tr>
<td>Age</td>
<td>0.993 0.992 to 1.000 1.000</td>
<td>0.997 to 1.000 to 1.000</td>
<td>0.997 to 1.000 to 1.000</td>
</tr>
<tr>
<td>Months</td>
<td>1.008 1.007 to 1.006 1.005</td>
<td>1.006 1.006 to 1.006</td>
<td>1.006 1.006 to 1.006</td>
</tr>
</tbody>
</table>

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Charlotte Lozier Institute.

**ORCID iDs**

James Studnicki [https://orcid.org/0000-0003-2958-7493](https://orcid.org/0000-0003-2958-7493)

Tessa Longbons [https://orcid.org/0000-0003-0479-9166](https://orcid.org/0000-0003-0479-9166)

**References**


Gynecol. 2015;125(1):175-183. doi: 10.1097/AOG.0000000000000603


**Author Biographies**

**James Studnicki** is currently Vice President and Director of Data Analytics at the Charlotte Lozier Institute in Arlington, Virginia. Over a span of four decades, he held academic appointments at the Johns Hopkins University School of Hygiene and Public Health, the University of South Florida College of Public Health, and the University of North Carolina, Charlotte, where for ten years he served as the Irwin Belk Endowed Chair in Health Services Research. He holds Doctor of Science (ScD) and Master of Public Health (MPH) degrees from Johns Hopkins and a Master of Business Administration (MBA) from the George Washington University.

**Donna J. Harrison**, M.D. dip ABOG received her M.D. from the University of Michigan and completed ObGyn residency at a University of Michigan Affiliate hospital (St. Joseph Mercy Hospital). She is currently CEO of the American Association of Pro-Life Obstetricians and Gynecologists.

**Tessa Longbons** is a research associate with the Charlotte Lozier Institute. Her research focuses on abortion statistics at the state and national levels and the changing landscape of abortion policy, provision, and access in the United States. She received her B.A. from Thomas Edison State University.

**Ingrid Skop**, M.D., F.A.C.O.G. has been practicing obstetrician-gynecologist in San Antonio, Texas for 24 years. She received her Bachelor of Science in physiology from Oklahoma State University and her medical doctorate from Washington University School of Medicine. She completed her residency in obstetrics and gynecology at the University of Texas Health Science Center at San Antonio. She is a Fellow of the American College of Obstetrics and Gynecology, a Charlotte Lozier Institute Associate Scholar and Chairman of the American Association of Pro-Life Obstetricians and Gynecologist's Maternal Mortality Committee. She is the Board Chairman of Any Woman Can Pregnancy Resource Center—which specializes in free mental health counseling and is a board member of The Source for Women—a consortium of holistic women's health care centers in Texas. She is married to a physician and is the proud mother of two sons and a daughter.

**David C. Reardon** is the director of Elliot Institute, a biomedical ethicist, and a lead author on numerous studies and books examining the risk factors and effects of pregnancy loss on women and families.

**John W. Fisher** is currently an Associate Scholar at the Charlotte Lozier Institute. Following a 22 year career as a nuclear submarine officer, he served as the Director of Life Support and engineering at the Florida Aquarium, Chief Financial Officer of Technology Transfer Services, and 10 years as an Assistant Professor at the University of North Carolina at Charlotte College of Health and Human Services. He holds a PhD in Information Systems and Decision Sciences from the University of South Florida, a JD from Massachusetts School of Law, and Master's degrees from the Massachusetts Institute of Technology (Ocean Engineering), University of Notre Dame (Administration), Indiana University (Business Administration), and the United States Naval War College (National Security Policy). He is currently a member of the bar in New Hampshire and Massachusetts.

**Maka Tslulkidze**, MD, PhD, MPH is an Assistant Professor at the Florida Gulf Coast University, Marieb College of Health & Human Services. Before joining FGCU, she was a Postdoctoral Fellow at the Dartmouth Center for Health Care Delivery Science. She has earned a PhD degree from the University of North Carolina at Charlotte and MD from Tbilisi Medical Academy. Previously she was a UNICEF National Consultant to the Parliament of Georgia, Short-Term Consultant at PAHO/WHO and Senior Expert at the Parliament of Georgia, Committee on Health and Social Issues. She has also worked as a Deputy Chair/Project Manager for the Task Force for Prevention of Micronutrient Malnutrition and Food Fortification Initiatives established under the Parliament of Georgia, Committee on Health and Social Issues.

**Christopher Craver** is an independent health services researcher affiliated with the Charlotte Lozier Institute focused on the use of secondary healthcare data sources in population based scientific research. He is widely published in many healthcare topics including cancer treatment, rare disease populations, and the efficacy of surgical services.
Exhibit 5

James Studnicki et al., A Post Hoc Exploratory Analysis: Induced Abortion Complications Mistaken for Miscarriage in the Emergency Room are a Risk Factor for Hospitalization, Health Servs. Rsch. & Managerial Epidemiology, May 20, 2022
A Post Hoc Exploratory Analysis: Induced Abortion Complications Mistaken for Miscarriage in the Emergency Room are a Risk Factor for Hospitalization

J. Studnicki¹, T. Longbons¹, D. J. Harrison², I. Skop¹, C. Cirucci¹, D. C. Reardon³, C. Craver¹, J. W. Fisher¹, and M. Tsulukidze⁴

Abstract

Introduction: Previous research indicates that an increasing number of women who go to an emergency room for complications following an induced abortion are treated for a miscarriage, meaning their abortion is miscoded or concealed.

Objective: To determine if the failure to identify a prior induced abortion during an ER visit is a risk factor for higher rates of subsequent hospitalization.

Methods: Post hoc analysis of hospital admissions following an induced abortion and ER visit within 30 days: 4273 following surgical abortion and 408 following chemical abortion; abortion not miscoded versus miscoded or concealed at prior ER visit.

Results: Chemical abortion patients whose abortions are misclassified as miscarriages during an ER visit subsequently experience on average 3.2 hospital admissions within 30 days. 86% of the patients ultimately have surgical removal of retained products of conception (RPOC). Chemical abortions are more likely than surgical abortions (OR 1.80, CL 1.38-2.35) to result in an RPOC admission, and chemical abortions concealed are more likely to result (OR 2.18, CL 1.65-2.88) in a subsequent RPOC admission than abortions without miscoding. Surgical abortions miscoded/concealed are similarly twice as likely to result in hospital admission than those without miscoding.

Conclusion: Patient concealment and/or physician failure to identify a prior abortion during an ER visit is a significant risk factor for a subsequent hospital admission. Patients and ER personnel should be made aware of this risk.

Keywords
induced abortion, medical abortion, emergency room, inpatient admission, retained products of conception, medicaid

Introduction

In a previous study, we found abortion-related emergency room (ER) treatment rates from 2002–2015 increased 315% and 507% following surgical and chemical abortions respectively.¹ During this same period, we also found an increasing number of abortion patients misclassified/miscoded as having post miscarriage complications. A contributory factor to these miscodings may be the advice given to women by some abortion providers to conceal their abortion when seeking care in the ER for adverse events.²³ Since 60.9% of abortion-related ER visits following a chemical abortion were being miscoded as miscarriage by 2015, there is concern that this misinformation (ie, miscarriage rather than induced abortion) might result in sub-optimal care and, subsequently, an increased likelihood of hospital admission.¹ We use the risk of hospitalization following one
or more ER treatments as a proxy for misinformed and suboptimal post abortion care.

**Methods**

Data were obtained from the enrollee-level Medicaid Analytic eXtract files licensed through the Centers for Medicare and Medicaid Services (CMS) Chronic Conditions Data Warehouse. The analytic dataset is comprised of enrollees from the 17 states whose official policies applied state funds to abortions not covered by federal Medicaid during the period 1999–2015. The study population was made up of enrollees over 13 years of age with at least one identifiable pregnancy outcome. For each beneficiary, all unique pregnancy outcomes were identified using International Classification of Diseases, Ninth Revision (ICD-9) codes. Additionally, Current Procedure Terminology, Fourth Edition (CPT4) and Healthcare Common Procedure Coding System (HCPCS) codes were used to confirm pregnancy outcomes. Every emergency room visit occurring within 30 days of the index abortion was identified (Place of Service code 23—emergency room). Emergency room visits within 30 days of a surgical or chemical induced abortion but treated for spontaneous abortion or miscarriage (ICD-9, primary diagnosis 634) are considered miscoded and possible concealment by the patient. Hospital admissions considered for the purpose of surgical removal of retained products of conception (RPOC) comprise ICD-9 procedure codes 690, 694, and 695.

In the original study, between 1999–2015, there were 423,000 confirmed induced abortion Medicaid procedures (361,924 surgical and 61,076 chemical), followed by 121,283 ER visits (99,928 surgical and 21,355 chemical). The exploratory post hoc analysis identified 4,273 hospital admissions within 30 days of a surgical abortion and following an ER visit and 408 hospital admissions within 30 days of a chemical abortion and following an ER visit.

Summary analytic tables were created using (SAS/STAT) software, version 10 of the SAS system for (Unix). Copyright (2019) SAS Institute Inc.


**Results**

Women experiencing chemical abortion and a subsequent emergency room (ER) visit within 30 days were less likely (OR 0.81, CL 0.70-0.95) to be hospitalized for any reason in that same time period than women who had experienced surgical abortion. This is true both for women whose prior abortion was concealed by miscoding during the ER visit and those for whom no mistaken miscarriage coding occurred (Table 1). Abortions miscoded in the ER were more likely to result in hospitalization for any reason (OR 1.06, CL 0.87-1.28) than those not miscoded. However, the subset of chemical abortion patients whose abortion was miscoded as miscarriage did exhibit a striking pattern of multiple admissions (3.2 per patient) for those women who were subsequently admitted compared to 1.8 admissions per woman whose abortion was not miscoded. Thus, the number of admissions per patient was 78% higher in women whose chemical abortion was concealed.

Further analysis determined that admissions for surgical RPOC were experienced by 86.3% of the women whose chemical abortion was subsequently miscoded in the ER, 2.5 times the rate of surgical abortion patients (34.2%) whose abortion was similarly miscoded. A very strong contrarian pattern emerges for hospital admissions involving surgical RPOC by aspiration and curettage or dilation and curettage. Chemical abortions are significantly more likely (OR 1.80, CL 1.38-2.35) than surgical abortions to result in an RPOC admission and chemical abortions miscoded in the ER are more likely (OR 2.18, CL 1.65-2.88) than abortions without miscoding to have a subsequent RPOC admission.

Chemical abortion patients whose subsequent ER visit is mistakenly coded as an adverse event related to miscarriage experience multiple hospital admissions within 30 days of the abortion.

| Table 1. | Hospital Admissions (for any Reason and RPOC) Following an Abortion and an Emergency Room Visit: by Type of Abortion with and without Miscoding as a Miscarriage. |
|----------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Abortion miscoded as miscarriage (ICD 634) | Surgical abortion | Chemical abortion |
| No. patients with ER visits | 567 (3.3) | 16,671 (96.7) | 17,238 | 366 (11.2) | 2912 (88.8) | 3278 |
| No. ER patients admitted for any reason | 114 (5.9) | 1823 (94.1) | 1937 | 22 (10.4) | 190 (89.6) | 212 |
| % ER patients admitted for any reason | 20.1% | 10.9% | 11.2% | 6.0% | 6.5% | 6.4% |
| Total no. admissions for any reason | 232 (5.4) | 4041 (94.6) | 4273 | 71 (17.4) | 337 (82.6) | 408 |
| Admissions per patient for any reason | 2.0 | 2.2 | 2.2 | 3.2 | 1.8 | 1.9 |
| No. patients admitted for surgical RPOC | 39 (13.0) | 262 (87.0) | 301 | 19 (21.6) | 69 (78.4) | 88 |
| % admitted patients requiring surgical RPOC | 34.2% | 14.4% | 15.5% | 86.4% | 36.3% | 41.5% |
| No. surgical RPOC admissions | 42 (13.3) | 274 (86.7) | 316 | 22 (23.7) | 71 (76.3) | 93 |
| % surgical RPOC admissions of total admissions | 18.1% | 6.8% | 7.4% | 31.0% | 21.1% | 22.8% |
| Surgical RPOC admissions per patient | 1.1 | 1.0 | 1.0 | 1.2 | 1.0 | 1.1 |
abortion and are particularly at risk to experience a hospitalization that involves RPOC.

Discussion

Our research indicates that an ER physician’s misclassification of a failed induced abortion as a miscarriage correlated with higher rates of hospitalization and surgical intervention for RPOC. A patient’s concealment of a chemical abortion, and/or the ER staffs’ failure to identify the failed abortion attempt, are risk factors for multiple hospital admissions and delayed provision of necessary surgical treatment, compared with care for those whose abortion is not miscoded.

One possible explanation is that ER physicians may tolerate a higher level of pain, tenderness, or bleeding if they know they are dealing with an induced abortion patient rather than a spontaneous abortion patient experiencing the same symptoms. It may be that these women were considered sick enough to be admitted, yet surgical care was delayed while alternative treatment options were explored. The percent of admitted women who underwent surgical intervention for RPOC is strikingly higher for women whose induced abortions were miscategorized as miscarriages.

It is important for emergency room personnel to obtain an accurate history when faced with an incomplete induced abortion. Additionally, it is advisable for abortion providers to tell women that if they present to an ER after the abortion, they can simply say they are having a miscarriage.2,3 Abortion providers should advise women that they may be at increased risk of multiple hospitalizations and surgical intervention if they do not inform medical personnel that they are experiencing an abortion complication. As required by the mifepristone Risk Evaluation and Mitigation Strategy, patients should be strongly reminded to bring the Medication Guide when seeking medical care in an emergency room.4 Further research on adverse events associated with miscoding of induced abortion is warranted.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Charlotte Lozier Institute.

ORCID iDs

J. Studnicki https://orcid.org/0000-0003-2958-7493
T. Longbons https://orcid.org/0000-0003-0479-9166
C. Cirucci https://orcid.org/0000-0002-4681-6529

References


Author Biographies

J. Studnicki is currently Vice President and Director of Data Analytics at the Charlotte Lozier Institute in Arlington, Virginia. Over a span of four decades, he held academic appointments at the Johns Hopkins University School of Hygiene and Public Health, the University of South Florida College of Public Health, and the University of North Carolina, Charlotte, where for ten years he served as the Irwin Belk Endowed Chair in Health Services Research. Dr. Studnicki holds Doctor of Science (ScD) and Master of Public Health (MPH) degrees from Johns Hopkins and a Master of Business Administration (MBA) from the George Washington University.

T. Longbons is a research associate with the Charlotte Lozier Institute. Her research focuses on abortion statistics at the state and national levels and the changing landscape of abortion policy, provision, and access in the United States. She received her B.A. from Thomas Edison State University.

D. J. Harrison, MD received her MD from the University of Michigan and completed her OB/GYN residency at a University of Michigan affiliate hospital (St. Joseph Mercy Hospital). She is a diplomat of the American Board of Obstetrics and Gynecology. She is currently CEO of the American Association of Pro-Life Obstetricians and Gynecologists.

I. Skop, M.D., F.A.C.O.G. is Senior Fellow and Director of Medical Affairs for the Charlotte Lozier Institute. Prior to joining CLI, she served for over 25 years in private practice as an obstetrician-gynecologist in San Antonio. Dr. Skop received her Bachelor of Science in physiology from Oklahoma State University and her medical doctorate from Washington University School of Medicine. She completed her residency in obstetrics and gynecology at the University of Texas Health Science Center at San Antonio. Dr. Skop is a Fellow of the American College of Obstetricians and Gynecologists and is a lifetime member of the American Association of Pro-Life Obstetricians and Gynecologists.

C. Cirucci, MD received her Bachelor of Science in Mechanical Engineering from Virginia Tech in Blacksburg, VA and her MD from Thomas Jefferson University, Philadelphia, PA. She completed her residency in obstetrics and gynecology at the Medical College of Virginia in Richmond, VA. She is a diplomate of the American Board of Obstetrics and Gynecology and a life Fellow of the American College of Obstetricians and Gynecologists. She is a member of the Christian Medical and Dental Associations, the North American...
Menopause Society, the Pennsylvania Medical Society, and the Allegheny County Medical Society. She is a board member of the American Association of Pro-Life Obstetricians and Gynecologists. She worked in private practice for twenty years in Pittsburgh, PA.

D. C. Reardon is the director of Elliot Institute, a biomedical ethicist, and a lead author on numerous studies and books examining the risk factors and effects of pregnancy loss on women and families.

C. Craver is an independent health services researcher affiliated with the Charlotte Lozier Institute focused on the use of secondary health-care data sources in population based scientific research. He is widely published in many healthcare topics including cancer treatment, rare disease populations, and the efficacy of surgical services.

J. W. Fisher is currently an Associate Scholar at the Charlotte Lozier Institute. Following a 22-year career as a nuclear submarine officer, he served as the Director of Life Support and engineering at the Florida Aquarium, Chief Financial Officer of Technology Transfer Services, and 10 years as an Assistant Professor at the University of North Carolina at Charlotte College of Health and Human Services. Dr. Fisher holds a PhD in Information Systems and Decision Sciences from the University of South Florida, a JD from Massachusetts School of Law, and master's degrees from the Massachusetts Institute of Technology (Ocean Engineering), University of Notre Dame (Administration), Indiana University (Business Administration), and the United States Naval War College (National Security Policy). He is currently a member of the bar in New Hampshire and Massachusetts.

M. Tsulukidze, MD, PhD, MPH is an Assistant Professor at the Florida Gulf Coast University, Marieb College of Health & Human Services. Before joining FGCU, Dr. Tsulukidze was a Postdoctoral Fellow at the Dartmouth Center for Health Care Delivery Science. She has earned a Ph.D. degree from the University of North Carolina at Charlotte and MD from Tbilisi Medical Academy. Previously Dr. Tsulukidze was a UNICEF National Consultant to the Parliament of Georgia, Short-Term Consultant at PAHO/WHO and Senior Expert at the Parliament of Georgia, Committee on Health and Social Issues. She has also worked as a Deputy Chair/Project Manager for the Task Force for Prevention of Micronutrient Malnutrition and Food Fortification Initiatives established under the Parliament of Georgia, Committee on.
Exhibit 6

Katherine A. Rafferty & Tessa Longbons,

#AbortionChangesYou: A Case Study to Understand the Communicative Tensions in Women’s Medication Abortion Narratives, 36 Health Commc’n 1485 (2021)
#AbortionChangesYou: A Case Study to Understand the Communicative Tensions in Women’s Medication Abortion Narratives

Katherine A. Rafferty & Tessa Longbons

To cite this article: Katherine A. Rafferty & Tessa Longbons (2021) #AbortionChangesYou: A Case Study to Understand the Communicative Tensions in Women’s Medication Abortion Narratives, Health Communication, 36:12, 1485-1494, DOI: 10.1080/10410236.2020.1770507

To link to this article: https://doi.org/10.1080/10410236.2020.1770507
#AbortionChangesYou: A Case Study to Understand the Communicative Tensions in Women’s Medication Abortion Narratives

Katherine A. Rafferty and Tessa Longbons

* Iowa State University; + Charlotte Lozier Institute

ABSTRACT

One out of four women in the United States will have an abortion by age 45. While abortion rates are steadily declining in the United States, the rate of medication abortions continues to increase, with 39% of all abortions being medication abortions. Our study is one of the first to analyze women’s narratives after having had a medication abortion. Using relational dialectics theory, we conducted a case study of the nonpartisan website, Abortion Changes You. Our contrapuntal analysis rendered four sites of dialectical tension found across women’s blog posts: only choice vs. other alternatives, unprepared vs. knowledgeable, relief vs. regret, and silence vs. openness. Each site of struggle characterized a different noteworthy moment within a woman’s medication abortion experience: the decision, the medication abortion process, identity after abortion, and managing the stigmatizing silence before and after the abortion. We discuss theoretical and practical implications about how the larger politicized discourses prevalent within the abortion debate impact the liminality of women who are contemplating a medication abortion and affect their own narrative construction about the medication abortion experience.

One out of four women will undergo an abortion procedure in the United States by age 45 (R. K. Jones & Jerman, 2017), and 862,320 reported abortions occur each year (Jones et al., 2019). Despite its frequency, abortion remains a highly contested and stigmatized biopolitical public health issue in the United States (Altshuler et al., 2017). The historic Roe v. Wade case has resulted in two nationalized political movements – Right to Life and Right to Choice – that have juxta- posed stances on the legality of abortion. However, the stigma and shame associated with abortion precede and transcend this historic case. Stormer (2010) concluded that a collective memory of secrets and shame has characterized the topic of abortion since Planned Parenthood’s 1955 conference, “Abortion in the United States”.

While abortion rates are steadily declining in the U.S. (Jones et al., 2019), the rate of medication abortions continues to increase. In 2000, the U.S. Food and Drug Administration (FDA) approved mifepristone to be used in combination with misoprostol as a form of medication abortion. Since then, the annual number of medication abortions has risen steadily: less than 6% of all abortions in 2001 to 39% of all abortions in 2017 (Jones et al., 2019, 2008). Between 2014–2017, the number of medication abortions provided at facilities other than hospitals increased by 25% (Jones et al., 2019). Presently, over one-third of all reported abortions in the U.S. are medication abortions (Jones et al., 2019). In 2016, the FDA protocol expanded provider eligibility for dispensing mifepristone to women. Thus, abortion provision is transitioning from formalized medical procedures conducted in health care settings to a protocol where most of the abortion occurs individually at home with limited clinician assistance (Biggs et al., 2019). Given the privatization of abortion provision, research is needed to examine the distinct experiences of women who have undergone this type of abortion. After all, researchers have found that women often elect to have a medication abortion over a surgical abortion because of more privacy, convenience, and the perception of having more control (Newton et al., 2016). However, medication abortion has been found to have a higher complication rate that results in more emergency department visits post-medication abortion compared to post-surgical abortion (Upadhyay et al., 2015).

Medication abortion practices in the U.S. adhere to the following evidence-based guidelines: using mifepristone in combination with a prostaglandin to carry success rates up to 99% for early pregnancy termination with rare occurrence of serious adverse events. However, the focus of this research is on successful terminations, increases in abortion access, and reductions of in-person clinic visits (H. E. Jones et al., 2017). There remains a dearth of research, particularly in the U.S., that examines women’s personal experiences with having this type of abortion procedure (e.g., acknowledging their emotions, understanding their self-efficacy with completing the abortion at home, being aware of whether they are adequately informed about the process). To our knowledge, the only study is from Sweden; researchers used semi-structured telephone interviews with 119 women who had a medication abortion (Hedqvist et al., 2016). They found that almost half (43%) experienced more bleeding than expected, and one-
fourth (26%) bled for more than four weeks. In addition, one-third (34%) stated that they received insufficient information about what to expect. Women who had never had an abortion nor had gone through childbirth were more likely to feel misinformed.

Scholars know that the medication abortion process is distinct from surgical abortions, with the features of medication abortion (e.g., lack of medical presence, time required for abortion completion, personal experiences with pain and bleeding) influencing women’s perception and satisfaction (Newton et al., 2016). Yet, this research on women’s satisfaction with medication abortion is often conflicting (Kimport et al., 2012) and limited (Hedqvist et al., 2016). Given that women increasingly prefer medication abortion over surgical abortion (Newton et al., 2016), the need for studying women’s experiences post-medication abortion becomes imperative.

**Importance of analyzing unsolicited blogging narratives about one’s abortion**

To understand women’s medication abortion experiences, it is important to study platforms where women engage in unsolicited talk. Unsolicited talk is ideal for collecting formative research that can be studied to explore individual and cultural experiences (Baxter, 2011). First, the audience of these texts is a “generalized other” (Mead, 1982), or culture, rather than a specific individual with whom the author has a relationship (Langellier & Peterson, 2004). The absence of a specific audience encourages narrators to provide an unadulterated account of their experience, rather than tailor their story to specific individuals (e.g., a friend who has had a certain stance on the abortion). Similarly, anonymity allows for potentially muted or stigmatized groups to post information without fear of sanctioning. In a culture where abortion remains highly contested and talk about having had an abortion is often muted or stigmatized (Altshuler et al., 2017), it is likely that women may prefer to self-disclose their medication abortion experiences online rather than via face-to-face channels. Furthermore, because women traditionally constitute a co-meditative other (i.e., Mead, 1982), or culture, rather than a specific individual with whom the author has a relationship (Langellier & Peterson, 2004). The absence of a specific audience encourages narrators to provide an unadulterated account of their experience, rather than tailor their story to specific individuals (e.g., a friend who has had a certain stance on the abortion). Similarly, anonymity allows for potentially muted or stigmatized groups to post information without fear of sanctioning. In a culture where abortion remains highly contested and talk about having had an abortion is often muted or stigmatized (Altshuler et al., 2017), it is likely that women may prefer to self-disclose their medication abortion experiences online rather than via face-to-face channels. Furthermore, because women traditionally constitute a co-meditative other (i.e., Mead, 1982), or culture, rather than a specific individual with whom the author has a relationship (Langellier & Peterson, 2004). The absence of a specific audience encourages narrators to provide an unadulterated account of their experience, rather than tailor their story to specific individuals (e.g., a friend who has had a certain stance on the abortion). Similarly, anonymity allows for potentially muted or stigmatized groups to post information without fear of sanctioning. In a culture where abortion remains highly contested and talk about having had an abortion is often muted or stigmatized (Altshuler et al., 2017), it is likely that women may prefer to self-disclose their medication abortion experiences online rather than via face-to-face channels. Furthermore, because women traditionally constitute a co-meditative other (i.e., Mead, 1982), or culture, rather than a specific individual with whom the author has a relationship (Langellier & Peterson, 2004). The absence of a specific audience encourages narrators to provide an unadulterated account of their experience, rather than tailor their story to specific individuals (e.g., a friend who has had a certain stance on the abortion). Similarly, anonymity allows for potentially muted or stigmatized groups to post information without fear of sanctioning. In a culture where abortion remains highly contested and talk about having had an abortion is often muted or stigmatized (Altshuler et al., 2017), it is likely that women may prefer to self-disclose their medication abortion experiences online rather than via face-to-face channels. Furthermore, because women traditionally constitute a co-meditative other (i.e., Mead, 1982), or culture, rather than a specific individual with whom the author has a relationship (Langellier & Peterson, 2004). The absence of a specific audience encourages narrators to provide an unadulterated account of their experience, rather than tailor their story to specific individuals (e.g., a friend who has had a certain stance on the abortion). Similarly, anonymity allows for potentially muted or stigmatized groups to post information without fear of sanctioning. In a culture where abortion remains highly contested and talk about having had an abortion is often muted or stigmatized (Altshuler et al., 2017), it is likely that women may prefer to self-disclose their medication abortion experiences online rather than via face-to-face channels. Furthermore, because women traditionally constitute a co-meditative other (i.e., Mead, 1982), or culture, rather than a specific individual with whom the author has a relationship (Langellier & Peterson, 2004). The absence of a specific audience encourages narrators to provide an unadulterated account of their experience, rather than tailor their story to specific individuals (e.g., a friend who has had a certain stance on the abortion). Similarly, anonymity allows for potentially muted or stigmatized groups to post information without fear of sanctioning. In a culture where abortion remains highly contested and talk about having had an abortion is often muted or stigmatized (Altshuler et al., 2017), it is likely that women may prefer to self-disclose their medication abortion experiences online rather than via face-to-face channels. Furthermore, because women traditionally constitute a co-meditative other (i.e., Mead, 1982), or culture, rather than a specific individual with whom the author has a relationship (Langellier & Peterson, 2004). The absence of a specific audience encourages narrators to provide an unadulterated account of their experience, rather than tailor their story to specific individuals (e.g., a friend who has had a certain stance on the abortion).

**Online blogs as a platform for unsolicited talk**

One backchannel platform of unsolicited talk is online blogs. Blogs provide a computer-mediated platform where people can self-disclose their personal thoughts, feelings, and experiences to others online. The proliferation of blogs in the last decade has transformed the way that we, as a society, “share, create, and curate information with individuals and communities” (Becker & Freburg, 2014, p. 415). Blogs often resemble online personal journal entries that enable writers to freely express themselves in ways that may be less face-threatening or stigmatizing (M. Jones & Alony, 2008). One of the many applications and uses of blogs is to share experiences and events through storytelling.

**Relational Dialectics Theory (RDT)**

Because talking about one’s abortion experience remains stigmatized and muted (Cockrill & Nack, 2013), examining women’s stories after having had a medication abortion may illuminate the competing discourses surrounding this debated moral and social issue (e.g., largely evident in the two polarized movements: Right to Choice v. Right to Life), as well as some of the larger dominant discourses from the polarized political movements that influence how women tell their own medication abortion story. Given this goal, RDT (Baxter, 2011) is a relevant framework to assess the competing cultural norms and expectations, which are also referred to as discourses. At any given moment, discourses may be dominant/centripetal or marginalized/centrifugal (i.e., anything that deviates from the dominant discourse). Scholars use RDT as a framework to examine the interplay between certain discourses that then construct social meaning and reality for individuals. Within the theory, there are four types of utterances (i.e., speaking chains) from which dialectical tensions (i.e., centripetal vs. centrifugal) may stem: distal already-spoken – utterances reflecting the cultural meaning and discourses that cultural members give voice to in their talk; proximal already-spoken – utterances conveying past meanings and discourses within a given relationship; proximal not-yet-spoken – immediate response from the hearer in the interaction; and distal not-yet-spoken – anticipated responses of a generalized other within the culture. The purpose of this paper is to examine how, if at all, these four types of utterance chains are present within women’s medication abortion narratives.

A second aspect of RDT (Baxter, 2011) is to understand how social reality is created discursively through power. Power is located in the struggle between marginalized/centrifugal and dominant/centripetal discourses. There are three ways that power can be located within discourses: diachronic separation, synchronic interplay, and discursive transformation. Diachronic separation occurs when discourses emerge in different texts or locations. Synchronic interplay is when discourses negate (total rejection of a competing discourse), counter (offer limited legitimacy to a discourse), and/or entertain (consider multiple worldviews/discourses or general ambivalence toward discourses) one another. Finally, discursive transformations occur when the interplay of competing discourses creates new meanings rather than remaining in opposition to one another (Baxter, 2011). This current study will focus on examining the synchronic interplay among the centripetal and centrifugal discourses.

**A case study of women who have experienced medication abortion**

To analyze women’s personal narratives and the larger discourses influencing their talk about their own medication abortion, we conducted a case study of the website www.abortionchangesyou.com. We selected this website for several reasons: it is not openly politicized, bloggers do not interact with others, bloggers post anonymously, bloggers do not need to create an account in order to post, and the platform is a space for unsolicited stories with no reward or
compensation to those who post. Furthermore, from a strategic storytelling standpoint (Tyler, 2007), it is important to study women’s blogs from an organization that recognizes and respects each woman’s individual narrative, as opposed to propagating narratives that openly align with the agenda of only one political movement. The woman who created this website has had an abortion herself and openly shares this information on the “About Us” page. The naming of her own abortion experience grounds co-cultural theorizing (M. Orbe, 2005; M. P. Orbe, 1998) such that other women who feel muted may be empowered and capable of finding similar language strategies.

In this case study, we explore the complexity and consequentiality of women’s language choices with anonymously telling their own medication abortion story, as well as offer the potential to capture the interplay of individual, organizational, and social discourses surrounding the abortion debate. The current divisiveness surrounding the socio-political climate in the U.S. about abortion provides further exigency and credence for this research. Our critical analysis is rooted in the interpretive paradigm with the purpose of explaining, describing, and illustrating the stories that women share on this website (Tracy, 2013). The following research questions guide our iterative analysis:

RQ1: What topics are women disclosing to the “generalized other” in their blog?

RQ2: What (if any) sites of struggle characterize women’s abortion narrative?

**Methods**

We conducted a case study approach (Arden Ford et al., 2014) of one website, [www.abortionchangesyou.com](http://www.abortionchangesyou.com). Case studies are a contextual examination used to understand a phenomenon within a particular context “and with respect to multiple perspectives within that context” (Arden Ford et al., 2014, p. 118). By employing a case study approach, we were able to draw on multiple perspectives (e.g., 98 different blog stories) that were rooted in a specific context. This methodological choice is common in other communication research, where the unit of analysis is an organization and the goals are to provide an in-depth understanding of the unique particulars and complexities of the case within a larger social context (Norander & Brandhorst, 2017).

Our case study included 98 blogs from women who have had a medication abortion and shared their story on the website. We included all blogs posted between October 2007 – February 2018. This date range reflects the time period between the submission of the first medication abortion blog on the website in 2007, and the point at which we extracted our data for analysis in 2018. Women’s blogs ranged in length from one paragraph to three pages of text, single-spaced (the average number of words for the 98 blogs was 655 words). All 98 blogs included content about one’s own medication abortion; the vast majority (91 women; 93%) also discussed the events and emotions experienced before and after their medication abortion.

**Data analysis and synthesis**

The case study approach allows for different data analysis strategies (Norander & Brandhorst, 2017). Because the purpose of our case study is to develop a thick description of the case, using an interpretive analytic strategy is most prudent. We selected Baxter’s (2011) contrapuntal analysis to study the meanings circulating around individual and relational identities evidenced within the language choices of the women blogging about their own medication abortion. Given the larger competing discourses about the legality of abortion in the U.S., we felt that the struggle of competing and contradictory discourses would likely be apparent in women’s personal blogging narratives. Further, contrapuntal analysis (Baxter, 2011) offered a critical perspective to our analysis as we studied the voices of marginalized women (e.g., women who have had a medication abortion) whose perspectives are often muted and stigmatized in society.

To understand the competing discourses and how meaning was constructed through their interplay, we conducted the first stages of thematic analysis to identify the discourses evident within each blog post (Braun & Clarke, 2006). This process required the three coders to independently familiarize themselves with the entire data set: reading the blogs several times and conducting line-by-line coding that captured the essence of the story in each line. Many of the inductive analytic codes applied to the text were descriptive (e.g., uncertainty; not ready), process (e.g., discovering pregnancy, taking the pills), or in vivo codes (e.g., wanted baby; alone; Saldana, 2013). The coders met regularly for five months to discuss the codes independently applied to each blog post. During this time, codes emerged into themes as processes were identified in the data and repetitively noticed by all three coders (e.g., changing self perception, silence, responsibility, good parenting). Discrepancies in coding were discussed during coding meetings and resolved through group consensus (Strauss & Corbin, 1990).

During the third and fourth months of data analysis, we went back to the data set to identify where discourses competed (e.g., culpability; justification). Here, we paid particular attention to where the bloggers used instances of negating (e.g., claiming another discourse as irrelevant or rejecting it), countering (e.g., offering a particular discursive position in replacement of another), and entertaining (e.g., not completely rejecting a discourse, but instead noting the potential possibilities with different discourses; Baxter, 2011). Women used negating when saying, “can’t,” “not,” “couldn’t,” and “never.” Examples of countering were most apparent when women used the word “but.” Entertaining often occurred when women used the words “possibility” and “could have.” Finally, we identified where and how competing discourses interpenetrated (Baxter, 2011). Dialogically contractive discursive practices are silenced discourses. Examples of these discursive practices included negating talk, such as: “can’t talk about the abortion,” or “there was no other choice.” In contrast, dialogically expansive discursive practices are discourses that are encouraged and amplified. Women used these discourses when saying things like: “I don’t want the procedure, but I don’t want the baby” or “hoping for a brighter future now that it is over.”
Data were analyzed until the point of theoretical saturation (i.e., no new thematic categories were present in the blog posts; Strauss & Corbin, 1990), which occurred after the 54th blog post. However, we continued to analyze the remaining blog posts in an effort to verify that our analysis of the discourses evident in the 54 posts accurately reflected all of the posts within the entire data set. Further, we wanted to extract the best exemplars from the entire case study and desired that quotations within all posts be considered for representation. Clear and concise exemplars of competing discourses within women’s narratives were then selected and agreed upon by all coders.

Trustworthiness and rigor

Evaluation of the quality of case study research should be determined by criteria associated within the naturalistic paradigm (Arden Ford et al., 2014). Trustworthiness is the criterion that assesses the credibility, transferability, dependability, and confirmability of the data collection and analysis processes (Lincoln & Guba, 1985). We upheld these principles when conducting this study by beginning with a careful design that clearly defined its purpose, research questions, and notion of “boundedness” (i.e., establishing the limits and context of the case; Arden Ford et al., 2014). Second, we spent sufficient time developing and analyzing the case: our analysis transpired over five months. Third, we upheld the principles of reflexivity by using inductive coding for all blog posts and writing individual and group memos throughout the entire coding process as a way to remain transparent and keep a data audit. Fourth, we had a team of three female coders, which allowed for the presence of multiple feminine perspectives.

Findings

Our research questions focused on the topics that women discussed in their personal online blogging narrative posted to www.abortionchangesyou.com (RQ1), and what (if any) sites of struggle were evident in these narratives (RQ2). Our contrapuntal analysis (Baxter, 2011) rendered four sites of dialectical tension: only choice vs. other alternatives, unprepared vs. knowledgeable, relief vs. regret, and silence vs. openness. Each site of struggle characterized a different noteworthy moment within a woman’s medication abortion experience: the decision, the medication abortion process, identity after the abortion, and managing the stigmatizing silence before and after the abortion. When recounting their decision to have an abortion, women referenced the struggle of only choice vs. other alternatives. As women discussed the medication abortion process, the competing discourse of unprepared vs. knowledgeable was evidenced. Women’s narratives about their identity after the abortion indicated the dialectical struggle of relief vs. regret. Finally, the challenges with managing the tension between silence vs. openness pervaded women’s narratives. Below we discuss each site of struggle using exemplar quotes from women’s blogs. Quotes were not edited from their original post.

The decision: Only choice vs. other alternatives

Part of women’s narratives included a detailed account of their decision to have a medication abortion. This decision was described as being rife with contradiction, and not a flippant choice. Women enumerated various reasons that were influential in their decision-making process: bad timing, financial instability, relationship problems, lack of family support, not married, too young, too many other children, not prepared to be a parent yet, and/or best decision given the circumstances. After stating one of the aforementioned reasons, 92 women (94%) also explained that abortion was the only or best option given the circumstances. For example, one woman said: “I felt the child growing inside of me. I was rubbing my stomach without me even knowing. I felt the doubt in my heart, but kept telling myself this is the best decision I needed to make” (6-18-17). A different woman recounted:

“I always leaned more towards keeping the baby and my boyfriend more towards abortion. I knew I could have the baby but it would be difficult. We both work jobs that barely pay over minimum wage and we both were scared to grow up and care for a child” (10-24-17).

Collectively, these exemplars illustrate how any possibility of keeping the baby was negated by one of the reasons that warranted the need for having a medication abortion. Many of the reasons women cited for choosing abortion align with the discourses from the Right to Choice movement: “A pregnancy to a woman is perhaps one of the most determinative aspects of her life. It disrupts her body. It disrupts her education. It disrupts her employment. And it often disrupts her entire family life” (Roe v. Wade).

However, the decision to have a medication abortion was not always independently made by the woman. In fact, 52 women (53%) reported that the father to their child or other family members (e.g., parents) negated women’s own desires to keep the baby. For example, one woman said:

“I remember my husband telling me, ‘well, don’t expect me to be too happy with the idea of having it if you decide to keep it. I won’t be too loving.’ That was a knife through my heart and I made the tough decision to go through with the abortion” (7-6-12).

Other family members also influenced women’s medication abortion decision, albeit her own desires to keep her baby:

“But my father on the other hand was a different story. He is an old school Puerto Rican who told me that I had to leave if I kept the baby. I had 2 weeks to get an abortion or else he would disown me forever” (3-8-2018).

In both accounts, women communicated their personal choice to have their baby; yet, their choice was negated by family and friends who advocated that abortion was necessary. Centrifugal discourses about others influencing or pressuring women to have an abortion are marginalized discourses.

Finally, when making their decision, 48 women (49%) reported vacillating between keeping their baby and having a medication abortion. Ultimately, outside circumstances or other people influenced their decision to abort. As mentioned earlier, 92 women (94%) shared that abortion was the best or
only option available given the circumstances. In many of these narratives, women did not believe nor realize that other alternatives, besides abortion, were tenable options until after having the abortion. For instance, one woman said:

“They all tell you ‘it’s your choice’ in the moment, but you don’t feel that it is. Being unable to afford it, unable to tell your loved ones, not having the help or feeling unable to support a child. When your partner doesn’t want it like you do. All these things push you, blind you to a decision that you don’t realize will destroy you” (8-23-17).

Similarly, another woman recounted: “I was kind of excited but I was so scared to tell my family …. I told my mom and her first response was I hope you’re getting an abortion. You’re going to be a terrible mom” (11-5-17). Both exemplars illustrate the distal and proximal already-spoken discourses that influenced each woman’s decision to have a medication abortion. Ultimately, these centripetal discourses (coming from society, the pro-choice movement, other people in their lives, or their own fears) negated the centrifugal discourse that other alternatives (adoption or keeping their baby) were justifiable options available to them.

**The medication abortion process: Unprepared vs. knowledgeable**

Medication abortions where women underwent most of the process individually at home with limited assistance from a medical provider are becoming more commonplace (Biggs et al., 2019; H. E. Jones et al., 2017). While this process is generally reported to be safe and adhere to evidence-based guidelines (H. E. Jones et al., 2017), little is known about women’s personal experiences with having this type of abortion. All women in this case study reported having had a medication abortion. Forty-eight women (49%) provided detailed accounts of their actual medication abortion experience at home. Women said things like: “I felt her come out” (1-8-16). Some women detailed the hardships of this process by saying: “I was in so much pain on the bathroom floor” (3-15-18); “the pills made me vomit, lose control of my bowels, sweat, faint, pass out, and go into full labor” (10-9-09); and “I lay on my bed in the fetal position, holding my stomach” (9-5-15). Other women did not self-report such negative experiences: “The actual process of taking the pill was frightening but not as bad as I imagined” (9-8-15) and “I just popped some pills and got a period” (7-1-15).

In analyzing women’s talk about the medication abortion process, a second site of struggle was identified: **knowledgeable vs. unprepared.** In this struggle, women discussed how they were told certain information about the medication abortion process (e.g., when to take the pills, what the pills do, the need to contact a provider if complications arise), but ultimately this information was insufficient, limited, or misleading. Fourteen women (14%) reported being inadequately prepared about what to expect during the medication abortion process. For example, one woman said:

“They lied to me and said they would give me some pills that would make it just like a late period with a little cramping … The pain of the contractions was so intense I felt like my intestines were pulled out slowly. I collapsed screaming on my bathroom floor, sweat, tears, blood, vomit, and shit all over me” (10-9-09).

Similarly, a different woman recounted:

“They told me, if you by chance are in pain you can take these pain relievers. If by chance I’m in pain? That sounded like the process would be easy and not so painful. Well NO that was not the case, within 30 minutes I felt really bad cramping. It just kept getting worse and worse. I was crying and moaning from the pain. I literally thought I was dying” (9-2-17).

In both instances, women’s personal abortion experiences did not align with the proximal-already-spoken messages (e.g., “it’s just a pill”) that they were told by their medical providers.

When women’s personal experiences contradicted what they were originally told by health care providers, family, or friends women felt deceived. One woman communicated her frustration by saying: “They told me it wouldn’t hurt and I wouldn’t feel a thing. THAT WAS SUCH A LIE. I felt everything, I heard everything, I seen everything. I ended up blacking out from the pain and puking all over myself” (11-5-17). Similarly, another woman said:

“We were told we would go back to normal and it won’t affect us but they were wrong!!! All I feel is emptiness and hatred. I used to be the happiest most positive girl. All I want is to take it back” (12-15-14).

Even if women did not explicitly report feeling deceived, many women stated that they were inadequately prepared about what to expect. For instance, one woman said: “I knew to expect blood clotting, but nothing could’ve prepared me for seeing her body. It was the color of my own skin, and was actually starting to look like a person” (1-8-16). Within women’s narratives, they expressed a desire for more detailed information about things such as: potential side effects, the intensity of cramping and bleeding, what to do after passing the baby, and potential negative emotions (e.g., fear, uncertainty, sadness, pain) felt after the abortion. When this comprehensive information was not communicated to them prior to taking the pills at home, women reported feeling misled, misinformed, and even deceived. These types of experiences and feelings after having had a medication abortion remain centrifugal discourses that are muted within the abortion debate.

**Identity after medication abortion: Relief vs. regret**

A third site of dialectical struggle was found in women’s talk about their identity after the medication abortion. Most women (N = 81; 83%) reported that their medication abortion changed them, which is not surprising given the name of the website: **Abortion Changes You.** Of noteworthy significance is understanding how women talked about these changes and the tension evident in this part of their narrative. Of the 81 women (83%) who stated feeling changed after their medication abortion, 75 women (77%) reported being changed in a negative way. Here, women said things like: “I really thought that I could somehow go back to the way things were before finding out I was pregnant. But I cannot. I am not the same person, and my husband is certainly not the same either” (7-11-11). Negative changes often occurred when women’s...
actual abortion experience did not align with their preconceived ideas about what to expect. These ideas were informed by larger discourses from society, as well as messages from others (e.g., health care providers). Three women indicated a positive change after their abortion by noting something like:

"Abortion did change my life … As soon as the stomach cramps (only slightly worse than regular menstrual pains) went away, I felt like a whole new person. I couldn’t believe how much energy I had again. It was like waking out of a deep depression" (7-1-15).

Positive changes were denoted by experiencing an initial sense of relief with no longer being pregnant. Finally, three women were ambivalent or didn’t report their change as positive or negative. One woman said: "I truly believe there is no right and wrong with this situation, it is a life changer but it’s your choice" (9-7-10).

Women discussed various issues when talking about change: impact on their emotional health as a result of the abortion, differences in their relationship with their partner/spouse, and new perspectives on their general views of abortion. However, conflicting emotions were evident across all women’s blog posts. For instance, one woman said:

"I went home and confessed to my mother … She helped pull the gigantic blood clots from my body … No one told me it would be like this; the clinic simply gave me what I asked for without telling me what it entailed" (7-20-16).

Similarly, another woman recounted: "I thought maybe after the due date I would feel better, but it doesn’t end there. It NEVER ends! The pain and emptiness stays there forever" (4-30-17). In these different accounts, the women alluded to their initial expectations of what the medication abortion would entail or what others told them would happen after their abortion. When a woman’s actual medication abortion experience did not align with these messages, women felt disempowered, vulnerable, lost, upset, and sometimes deceived.

When discussing the changes experienced after the abortion, many women talked about emotional changes. One woman said:

"At first it all seemed like a weight had been lifted and everything was okay then I started to feel really sad and low and now all I do is think about how many weeks pregnant I would have been and what my baby would look like and I miss so much" (4-26-10).

As mentioned, processing one’s abortion experience was emotional and took time. Some women wrestled with experiencing negative and difficult emotions after having their abortion. In fact, 37 women (38%) explicitly stated problems with anxiety, depression, drug abuse, and suicidal thoughts as a result of the abortion. For example, one woman said: "I am haunted by the image of my tiny baby. I always will be. I cut myself and even wanted to die" (3–22-13). Another woman recounted: "Looking at my kids thinking of another beautiful child. Couldn’t live with myself. Wishing God would take my life" (12–16-11). Collectively, these exemplars illustrate women’s emotional changes about processing of their medication abortion.

Finally, 75 women (77%) explicitly stated that they regretted their decision to have an abortion. However, the term regret was rife with contradiction and also included talk about initial relief. For instance, one woman said: "I know I did the right thing for myself and it would be a lot harder for me right now. But I still would give anything to go back in time and keep my baby" (11–19-12). Regret was regarded as a process that was realized over time and through one’s life experience. One woman stated: "Had I known how badly I would feel now, I would have kept the baby, even if I had to go through it alone" (10–21-15). Another woman elaborated upon this process by saying:

"Knowing what I know now at almost a year later I would not have the abortion. That was my child and I should have done what I needed to do to give them a great life. I thought I had no options but I did. I should have put my child first. No matter how early the abortion is its still a growing life and I wish I had done things differently" (4-30-17).

In both accounts, women defined regret as the emotional pain, suffering, remorse, and guilt felt after the medication abortion. Yet, these emotions were often coupled with initial feelings of relief from no longer being pregnant. In sum, the decision to have a medication abortion was significant, transformative, and lifechanging for these women. One woman noted this change by saying: "From the outside, our life looks exactly the same as it would have. But on the inside, everything has changed for me" (10–21-15). Collectively, these accounts expose how the different emotional changes resulted in a lived, dialectical tension between their life before the abortion and their life after the abortion.

Managing the comprehensive stigmatizing silence: Silence vs. openness

Across women’s narratives, there existed an overarching dialectical tension of silence vs. openness, which was difficult for many women to manage when interacting with others. In this struggle, women shared how their medication abortion was often a solo, private experience that was not openly shared with others. Many women decided not to inform certain family members about their pregnancy and abortion. Women noted feelings of shame, embarrassment, worry, or fear as some of the reasons for not telling others. Along with stating these emotions, women said things like: "I never told the father and I don’t intend to" (8-4-17); "I don’t know if I will ever tell my husband and children about what I did" (2–11-12); or "I couldn’t talk to my family" (3–16-17). The initial decision to remain silent made it difficult to talk openly with others about their feelings and experiences after their medication abortion. Silence was also experienced in other ways: one woman was glad she was home alone during her abortion so no one could hear her, while a different woman left the abortion clinic and began crying and said, “why is there so much silence here?” as she was taking her pill alone in her bathroom at home.

Even if women did allow certain family members to become privy to their abortion decision, openly discussing their feelings after the abortion remained difficult. When talking with others, one woman said: "I love my husband but it is beyond difficult for me to talk to him about this,"
because I know he wants nothing more than to just move on from this” (4–28–18). A different woman recounted: “My close friends know here but I don’t really feel I can talk to them about it. I don’t feel like i can talk to anyone about it” (2-9-13). Despite these women’s desires to talk about their abortion, others (e.g., the baby’s father, their husband, family members) refused to engage in conversation with them. As a result, women said things like: “I feel like I have no one to speak to about it since he doesn’t think about it the way I do” (9-8-15), and “I try to talk about it with my family and the baby’s dad but they all tell me it’s in the past” (10–28–17).

Oftentimes, certain dates (such as their child’s due date) or friends with other babies who are of similar age to their “would-have-been child” led to triggering events where women desired to express their feelings with others, but felt like they couldn’t talk openly. For instance, one woman said: “But I haven’t really been able to share the true regret and near constant jealousy of my loved ones engagements or pregnancies” (11–21–16). Another woman stated: “I knew I had to have an abortion, but these feelings I have right now I never imagined I’d have. I don’t want to go out, I don’t want to tell anyone, all I feel like doing is crying” (7–8–18). Thus, the isolation and silence leading up to her own medication abortion continued to pervade after the abortion, creating additional communication challenges with freely expressing her emotions with family and friends.

Silence was often described as being frustrating and challenging. In fact, 59 women (60%) reported feelings of isolation and alienation. As a result, some women personally attacked themselves. For example, one woman said: “I feel like I’m living a lie I get up get ready for work get my family up like normal the days go on like normal but I’m not normal I killed my baby I’m a monster!!” (3–14–17). Similarly, a different woman wrote: “As a mom I feel like a monster and I have to act like nothing happened” (4–18–17). These demeaning language choices (e.g., monster, killer) are present in the distal-already-spoken societal discourses about abortion. Women’s awareness of these larger discourses led some women to write about their intentional use of selective language choices when talking about their abortion with others. One woman shared: “I tried to find an OB/GYN that could see me ASAP. I went in and told them I had a miscarriage because I was ashamed of the truth of what I did” (3–21-18). Finally, some women reported struggling in silence by saying things like: “I am in desperate need of assistance and I am too embarrassed to attend an in person support group” (11–21–16), and “And when I got home, I had to hold it all in. I was so ashamed of my choice. I couldn’t let anyone know” (2–11–11). Even though these women were able to anonymously write about their abortion on this website, they felt muted by their loved ones because of the centripetal discourses of shame and embarrassment associated with abortion.

Discussion

A national study that assessed women’s support for and interest in alternative models of abortion provision found that about half of U.S. women are supportive of and nearly one-third are interested in medication abortion (Biggs et al., 2019). The growing interest and practice in this type of abortion provision warrant scholars to understand women’s experiences. Our study is the first in the U.S. to conduct a case analysis of women’s online blogging narratives about having had a medication abortion. We focused on understanding the discursive dynamics and contradictions that influenced and shaped women’s talk about their own experiences. Our analysis rendered four sites of dialectical tension: only choice vs. other alternatives, unprepared vs. knowledgeable, relief vs. regret, and silence vs. openness. Each site of struggle characterized a different stage of women’s medication abortion narrative: the decision, the medication abortion process, after-abortion identity, and the general stigmatizing silence associated with abortion.

As other scholars have noted (Kimport & Doty, 2019), we found that women relied upon language choices that aligned with the existing ideological frameworks from both the Right to Life and Right to Choice movements. For instance, some women used the words “fetal tissue,” while other women used the word “baby” when referencing their pregnancy. Women also explicitly mentioned distal already-spoken messages from both movements about how they were told “it’s just a pill” or “I’ve killed my baby.” Such language choices are not idle linguistic distinctions, but rather indicate a woman’s awareness of the different semantics and terminology surrounding the larger cultural narratives about abortion. This awareness was particularly evident when women discussed the overarching silence stigmatizing one’s abilities to openly talk with family and friends about their medication abortion experience. Thus, women’s talk about their own personal experiences, their justification for having an abortion, and their own sense-making after the medication abortion were shaped by the available heuristics and frames from larger cultural discourses and political movements (Kimport & Doty, 2019).

Cultural narratives of abortion are powerful and construct meaning and truth (Ludlow, 2008). While a woman’s personal story about her medication abortion is individual and now occurs in a more private setting (e.g., at home), this experience remains social and political, defined, and reified by larger cultural narratives and semantics (Beynon-Jones, 2017; Cockrill & Nack, 2013). The sexual liberalism script that reflects positive attitudes toward nontraditional sexual behaviors influences individual’s attitudes about abortion (Tokunaga et al., 2015), as well as their own narratives about medication abortion. We found evidence of these larger discourses within women’s talk about their own medication abortion, and in particular, their rationale for their decision, their description of the medication abortion process, their reflections on their identity after the abortion, and the overall stigmatizing silence resulting in a muted voice and the public illegitimacy of their own narrative. For instance, many of the justifiable reasons recounted by women in this case study for having an abortion align with the centripetal discourses of the Right to Choice movement regarding bodily rights and a woman’s freedom of choice. Among women having abortions in the U.S., finances and lack of readiness are the most commonly cited reasons for choosing abortion (Finer et al., 2005).

The presence of larger cultural narratives can result in dialectical tensions as one seeks to construct her own abortion narrative and considers disclosing that narrative to others. In
particular, many women described experiencing both relief and regret after their abortion. Historically, these two emotions have been juxtaposed and positioned as binary emotions that are socially and politically aligned (Ehrlich & Doan, 2019). The Right to Choice movement discourse aligns with the notion that abortion proffers emotional relief, whereas the Right to Life movement discourse positions itself with abortion resulting in regret. This polarized alignment and framing results in both movements speaking different languages and never fully listening nor engaging with the other (Wiederhold, 2014). One proposed origin of this framing dates back to the legal reasoning of the 2007 U.S. Supreme Court case Gonzales v. Carhart, where the federal partial-birth abortion ban was upheld. However, our analysis of women’s narratives post-medication abortion exposes the complex duality of these two emotions often being experienced in tandem, as opposed to being simplistic binaries. The either-or, unidimensional script from both the Right to Choice and Right to Life movements – abortion provides either relief or results in regret – fueled a sense of tension for many of the women as they processed their identity after the abortion and considered openly disclosing those private experiences with others. Thus, these women’s narratives illustrate that one’s individual experiences with having had a medication abortion may result in a both/and: initial relief coupled with later regret. A reliance upon political movement discourses to construct one’s own narrative may continue to marginalize or invalidate one’s own private medication abortion experience when the larger scripts remain politically charged and polarized (LaRoche & Foster, 2018).

The stigma and risk that characterize the topic of abortion are influenced and shaped by the larger centrifugal discourses from both the Right to Choice and Right to Life movements (Beynon-Jones, 2017; Cockrill & Nack, 2013). For example, Cockrill and Nack (2013) found that women seeking an abortion often attempt to manage the stigma of abortion through non-disclosure, stating their reasons for having an abortion as “exceptional” and necessary, or condemning the Right to Life perspectives about abortion. In a different study on Southside Chicago African-American adolescent females, the majority of sexually active teens never talked with their parents about the topic of abortion, and almost 20% expressed fears of harm or eviction if their parent were to learn of an abortion in their past (Sisco et al., 2014). In our case study, we found that women also experienced stigma, silence, and fear that led them to remain private and/or secretive with certain individuals throughout their medication abortion experience. Silence before or during the medication abortion process resulted in women experiencing additional challenges later on with talking openly about one’s experiences. Altogether, these findings align with communication scholars who have found that when private health information disclosures are deemed as being threatening or stigmatizing, one’s private health information remains concealed (Baxter & Akkoor, 2011; Ebersole & Hernandez, 2016). This is important because secrecy of one’s abortion is associated with poorer coping (Major & Gramzow, 1999; Major et al., 1997), and may result in further isolation and lack of social support from others (Cockrill & Biggs, 2017).

Recent movements such as Shout Your Abortion and #YouKnowMe have tried to dispel the stigma and silence surrounding abortion. However, these movements remain politically aligned and purport the “American Dream” abortion narrative: I was able to go to college/graduate/get a good job due to my abortion. These more recent public narratives frame abortion as a restitution or quest experience (Frank, 1995), where women are portrayed as being able to return to normalcy and good health, or regard their abortion story as one part of their personal journey that they were able to overcome. While such discourses were evident in some women’s blogs and have been shown to reduce abortion stigma when openly disclosed (Cockrill & Biggs, 2017), many women’s narratives within this case study characterized chaos narratives (Frank, 1995) where the abortion experience interrupted their daily lives and left them feeling out of control. Most notably, over 50% of the sample reported that the father to their child or other family members used negating language as a means to justify a woman’s need for an abortion, albeit her own desires to keep her baby. In addition, 75 women (77%) regretted their decision, and 37 women (38%) reported struggling with mental illness and suicidal thoughts after the abortion. While previous scholarship has also found evidence of some women experiencing negative outcomes after an abortion due to a lack of decision-making power and limited social support (Kimport et al., 2011), as well as possible significant relationships between abortion and mental health problems (see Fergusson et al., 2013; Reardon, 2018), these centrifugal discourses remain muted and marginalized in the U.S. abortion debate.

Limitations and directions for future research

As with all scholarship there are limitations. Most notably, there is a lack of generalizability due to the limited scope: we only analyzed women’s medication abortion narratives anonymously posted to one website. However, it is important to note that the purpose of this project was to make analytic generalizations based on gathering an in-depth descriptive understanding of these women’s medication abortion narratives. Second, all qualitative case studies are limited by the sensitivity and integrity of the investigators. We attempted to surmount this obstacle by having three qualitatively trained female researchers who completed independent coding and collectively participated in the contrapuntal analysis process. Third, case study research is criticized for not having a clear set of systematic procedures (Yin, 2014). To address this concern, we sought to clarify and provide transparency with the methodological techniques used. Fourth, the anonymity of women’s blog submissions to the website did not allow us to gather and report the social demographics of the women who anonymously shared their abortion narratives, which again hinders the generalizability of our findings. Finally, the population of women who write an anonymous post about their abortion experience may be different from those who do not.

All of these limitations provide avenues for future research. Most importantly, this single case study demonstrates the need for a broader, pluralistic, mixed-method research strategy that "EX. 6 pg. 009"
App. 0057
assesses women’s medication abortion narratives, particularly given its increased popularity amongst women seeking this type of abortion provision. Such research could interview women who have had a medication abortion, as well as use surveys to assess different variables such as demographic factors, health literacy, and privacy management strategies employed when talking about one’s medication abortion.

**Conclusion**

In sum, our findings show that the medication abortion experience is rife with tension and contradiction. This complexity and duality are not evident in much of the larger cultural discourses and political debates about abortion. Many women in this case study noted that their decision to have a medication abortion was not a flippant decision or an easy choice where women remained unscathed. Women’s narratives about their medication abortion experience were complex, and no singular narrative fully encapsulated or defined what women experienced during and after their medication abortion. Therefore, it is critical to transcend the silence in order to expose both sides of the debate and understand how these larger discourses influenced women’s personal language choices when constructing their own abortion narrative and anonymously sharing it with others online. The tensions and dialectical struggles experienced after having a medication abortion and attempting to share it with others remain silent from public discourse and debate (Hallgarten, 2018). Presently, this silence positions one’s abortion story as an either-or, binary experience that is politically aligned with one movement or another. The larger discourses prevalent within both the Right to Life and Right to Choice movements impact the liminality of women who are contemplating a medication abortion and affect their own narrative reconstruction and sense-making after their private medication abortion.

**Acknowledgments**

We would like to thank Chuck Donovan, Michaelaene Fredenburg, and Genevieve Plaster for their support and assistance throughout the entire research process. We also want to thank Caroline Funk for her assistance with data analysis. In addition, we would like to recognize the women, who through their own accord and as separate from this research study, chose to publicly share their story online.

**References**


Orbe, M. P. (1998). From the standpoint(s) of traditionally muted groups: Explicating a co-cultural communication theoretical model.


Exhibit 7

Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drugs and Biological Products in Pediatric Patients, 63 Fed. Reg. 66,632 (Dec. 2, 1998)
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 201, 312, 314, and 601
[Docket No. 97N–0165]
RIN 0910–AB20
Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drugs and Biological Products in Pediatric Patients
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is issuing new regulations requiring pediatric studies of certain new and marketed drug and biological products. Most drugs and biological products have not been adequately tested in the pediatric subpopulation. As a result, product labeling frequently fails to provide directions for safe and effective use in pediatric patients. This rule will partially address the lack of pediatric use information by requiring that manufacturers of certain products provide sufficient data and information to support directions for pediatric use for the claimed indications.

DATES: Effective date. The regulation is effective April 1, 1999. Compliance dates. Manufacturers must submit any required assessments of pediatric safety and effectiveness 20 months after the effective date of the rule, unless the assessments are waived or deferred by FDA.


SUPPLEMENTARY INFORMATION:

I. Introduction

In the Federal Register of August 15, 1997 (62 FR 43900) (hereinafter referred to as the proposal), FDA proposed to require that manufacturers of certain new and marketed drugs and biologicals conduct studies to provide adequate labeling for the use of these products in children. As described in the proposal, children are subject to many of the same diseases as adults, and are, by necessity, often treated with the same drugs and biological products as adults. However, many drugs and biological products marketed in the United States that are or could be used in children are inadequately labeled for use in pediatric patients or for use in specific pediatric subgroups (Refs. 1 and 2). Indeed, many of the drugs and biological products that are widely used in pediatric patients carry disclaimers stating that safety and effectiveness in pediatric patients have not been established (Refs. 2 and 3). Safety and effectiveness information for some pediatric age groups is particularly difficult to find. For example, there is almost no information on use in patients under 2 years of age for most drug classes (Ref. 1).

As described in more detail in the proposal, the absence of pediatric labeling information poses significant risks for children. Inadequate dosing information exposes pediatric patients to the risk of adverse reactions that could be avoided with an appropriate pediatric dose. The lack of pediatric safety information in product labeling exposes pediatric patients to the risk of age-specific adverse reactions unexpected from adult experience. The proposal cited reports of injuries and deaths in children resulting from use of drugs that had not been adequately tested in the pediatric population. The absence of pediatric testing and labeling may also expose pediatric patients to ineffective treatment through underdosing, or may deny pediatric patients therapeutic advances because physicians choose to prescribe existing, less effective medications in the face of insufficient pediatric information about a new medication. Failure to develop a pediatric formulation of a drug or biological product where younger pediatric populations cannot take the adult formulation, may also deny pediatric patients access to important new therapies, or may require pediatric patients to take the drug in extemporaneous formulations that may be poorly or inconsistently bioavailable.

The proposed rule described previous steps taken by FDA in recent years to address the problem of inadequate pediatric testing and inadequate pediatric use information in drug and biological product labeling. FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have implemented a “Pediatric Plan” designed to focus attention on, and encourage voluntary development of, pediatric data both during the drug development process and after marketing. In addition, in the Federal Register of December 13, 1994 (59 FR 64240) (hereinafter referred to as the 1994 rule), FDA issued a regulation requiring manufacturers of marketed drugs to survey existing data and determine whether those data were sufficient to support additional pediatric use information in the drug’s labeling. Under the 1994 rule, if a manufacturer determines that existing data permit modification of the label’s pediatric use information, the manufacturer must submit a supplemental new drug application (NDA) to FDA seeking approval of the labeling change.

Although the preamble to the 1994 rule recognizes FDA’s authority to require drug and biological product manufacturers to conduct pediatric studies on a case-by-case basis, the rule does not impose a general requirement that manufacturers carry out studies when existing information is not sufficient to support pediatric use information. Instead, if there is insufficient information to support a pediatric indication or pediatric use statement, the rule requires the manufacturer to include the product’s labeling the statement: “Safety and effectiveness in pediatric patients have not been established.”

The response to the 1994 rule has not substantially addressed the lack of adequate pediatric use information for marketed drugs and biological products. Pediatric labeling supplements were submitted for approximately 430 drugs and biologicals, a small fraction of the thousands of prescription drug and biological products on the market. Of the supplements submitted, approximately 75 percent did not significantly improve pediatric use information. Over half of the total supplements submitted simply requested the addition of the statement “Safety and effectiveness in pediatric patients have not been established.” Others requested minor wording changes or submitted unorganized, unanalyzed collections of possibly relevant data. Approximately 15 percent (approximately 65) of the supplements provided adequate pediatric information for all relevant pediatric age groups, and another 8 percent (approximately 35) provided adequate pediatric information for some but not all relevant age groups. The absence of adequate pediatric use information remains a problem for new drugs and biologicals as well as for marketed products. The proposal presented data from 1988 through the 1990’s showing that the percentage of new products entering the marketplace with adequate pediatric safety and effectiveness information has not increased in the last decade.

After receiving comments, FDA considered the number of new molecular entities (NME’s) approved in 1991 and 1996.
with potential usefulness in pediatric patients and looked at the adequacy of pediatric labeling for those drugs. Fifty-six percent (9/17) of the NME's approved in 1991 with potential usefulness in pediatric patients had some pediatric labeling at the time of approval. In 1996, only 37 percent (15/40) of the NME's with potential usefulness in pediatric patients had some pediatric labeling at the time of approval. For both 1991 and 1996, those drugs counted as having pediatric labeling may not have been studied in all age groups in which the drug was potentially useful. The manufacturers of an additional 7 of the 1991 drugs and 17 of the 1996 drugs promised to conduct pediatric studies after approval. Since publication of the proposal, figures for 1997 NME's have become available. In 1997, 39 NME's were approved. Twenty-seven had potential usefulness in pediatric patients, and 33 percent of these (9/27) had some pediatric labeling at the time of approval. Postapproval studies were requested or promised for an additional six. It is uncertain how many of the commitments made for postapproval studies of the 1996 and 1997 drugs will result in pediatric labeling. Of the seven NME's approved in 1991 for which sponsors made commitments to conduct postapproval pediatric studies, pediatric labeling has been added to only one. This figure reflects both studies that resulted in positive labeling, i.e., safety and dosing information, and studies that resulted in warnings against pediatric use. It does not reflect studies that failed to provide any useful information about pediatric use or studies that were completed but the sponsor failed to seek a change in its pediatric use labeling.

Therefore, we believe that voluntary efforts have, thus far, not substantially increased the number of products entering the marketplace with adequate pediatric labeling. FDA has therefore concluded that additional steps are necessary to ensure the safety and effectiveness of drug and biological products for pediatric patients. This rule requires the manufacturers of new and marketed drugs and biological products to evaluate the safety and effectiveness of the products in pediatric patients, if the product is likely to be used in a substantial number of pediatric patients or would provide a meaningful therapeutic benefit to pediatric patients over existing treatments.

In addition to issuing this rule, FDA has initiated other actions that it hopes will expedite the development of adequate pediatric use information. FDA has issued a draft guidance document entitled “General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products” (November 30, 1998). FDA also plans to develop additional guidance on how to develop effectiveness, safety, and dosing information to support pediatric labeling. The agency also supported a provision in the reauthorized Prescription Drug User Fee Act (PDUFA) eliminating user fees for pediatric supplements to encourage the submission of these supplements.

Finally, FDA has issued a guidance document entitled “Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products,” describing the kinds of studies that can support effectiveness in supplemental or original applications. In that document, FDA provides guidance to manufacturers on the circumstances in which FDA may approve an initial or supplemental claim in which substantiation of the results of an adequate and well-controlled trial is provided by information other than a second adequate and well-controlled trial precisely replicating the first trial, or the circumstances in which such trials without the extensive documentation ordinarily required could be utilized. This guidance will often be relevant to the data needed to support claims in a pediatric population.

Since the issuance of the proposal, Congress has enacted a bill that has an impact on pediatric studies of certain drugs. The Food and Drug Administration Modernization Act of 1997 (FDAMA) (Pub. L. 105-115) contains provisions that establish economic incentives for conducting pediatric studies on drugs for which exclusivity or patent protection is available under the Drug Price Competition and Patent Term Restoration Act (Pub. L. 98-417) and the Orphan Drug Act (Pub. L. 97-414). These provisions extend by 6 months any existing exclusivity or patent protection on a drug for which FDA has requested pediatric studies and the manufacturer has conducted such studies in accordance with the requirements of FDAMA. FDAMA also specifically recognizes FDA’s intention to require pediatric studies by regulation and extends by 6 months any existing exclusivity or patent protection on a drug whose manufacturer submits pediatric studies in compliance with this rule, if the studies meet the completeness, timeliness, and other requirements of section 505A. Under FDAMA, a manufacturer who submits pediatric studies required under this rule may receive a 6-month extension of exclusivity or patent protection granted to the manufacturer for that drug.

Although FDA expects the exclusivity offered by FDAMA to provide a substantial incentive for sponsors to conduct some pediatric studies, the agency nonetheless believes that this final rule is necessary to significantly increase the number of drug and biological products that have adequate labeling. Certain limitations on the scope and effect of the exclusivity offered by FDAMA are likely to leave significant gaps in pediatric labeling. For example, because FDAMA exclusivity applies only to products that have exclusivity or patent protection under the Drug Price Competition and Patent Term Restoration Act and the Orphan Drug Act, it provides no incentive to conduct studies on certain categories of products, including most antibacterials, biologics, and off-patent products.

In addition, the voluntary nature of the incentive provided by FDAMA is likely to leave many drugs, age groups, and indications unstudied. Given limited resources to conduct pediatric studies, it is probable that manufacturers will elect to conduct pediatric studies preferentially on those drugs for which the incentives are most valuable, i.e., on drugs with the largest sales. This may leave unstudied drugs that are greatly needed to treat pediatric patients, but that have smaller markets. For similar reasons, manufacturers are less likely to seek FDAMA exclusivity by conducting studies on drugs that require studies in neonates, infants, or young children. The youngest pediatric populations are more difficult to study and may require pediatric formulations, making pediatric studies of these groups more expensive, thereby reducing the value of the incentives provided by FDAMA. Thus, where there is a great medical need for data on drugs with relatively small markets or for studies on neonates, infants, or young children, it may be necessary to require the collection of such data, rather than rely on incentives.

Finally, manufacturers are eligible for FDAMA exclusivity when they submit a study to FDA that is consistent with FDA’s written request for such a study. The study results are not required to provide useful information on pediatric use (e.g., the results may be inconclusive), and the sponsor is not required to obtain approval of a supplement adding the information gained in the study to the drug label. Thus, FDA provides no guarantee that the studies conducted under the statute will result in improved pediatric labeling.
For these reasons, FDA believes that there remains an important need for this rule. FDA has concluded, however, that with respect to already marketed drugs eligible for exclusivity under FDAMA, the publication of the list required by section 505A(b) and the availability of pediatric exclusivity may diminish the need to exercise the agency’s authority to require studies. Under the rule, FDA has discretion whether to require studies of marketed drugs (see §201.23 (21 CFR 201.23)). FDA believes that, in exercising its discretion under §201.23, it is appropriate to determine whether manufacturers will undertake the needed studies voluntarily. FDA will therefore allow an adequate opportunity for manufacturers voluntarily to submit studies for drugs listed by FDA as having a high priority. If, following such an opportunity, there remain marketed drugs for which studies are needed and the compelling circumstances described in the rule are met, the agency will consider exercising its authority to require studies. With respect to marketed drugs and biologics that are not eligible for exclusivity under FDAMA, FDA intends to exercise its authority to require studies as of the effective date of the rule in the circumstances described in the regulation. FDA emphasizes that the appearance of a drug or biologic on the list published under section 505A(b) carries no implication that FDA will require studies on that drug or biologic under this rule. FDA intends to reserve its authority to require studies of marketed drugs and biologics to situations in which the compelling circumstances described in the regulation are present.

FDA intends to issue further regulations and guidance implementing the pediatric exclusivity provisions of FDAMA, which will, among other things, provide guidance on the interaction of this rule and FDAMA exclusivity.

II. Highlights of the Final Rule

This final rule is designed to ensure that new drugs and biological products contain adequate pediatric labeling for the approved indications at the time of, or soon after, approval. The final rule establishes a presumption that all new drugs and biological products will be studied in pediatric patients, but allows manufacturers to obtain a waiver of the requirement if the product does not represent a meaningful therapeutic benefit over existing treatments for pediatric patients and is not likely to be used in a substantial number of pediatric patients. The rule also authorizes FDA to require pediatric studies of those marketed drugs and biological products that: (1) Are used in a substantial number of pediatric patients for the claimed indications, and where the absence of adequate labeling could pose significant risks; or (2) would provide a meaningful therapeutic benefit over existing treatments for pediatric patients, and the absence of adequate labeling could pose significant risks to pediatric patients.

A. Scope of Rule

The proposed rule would have required an application for a drug classified as a “new chemical entity” or a new (never-before-approved) biological product to contain safety and effectiveness data available, the need for the product, the amount of drug or biological product is indicated, will be necessary, will depend upon the particular cases, and whether deferral delay the availability of a product to pediatric patients for the indications claimed by the manufacturer. The specific pediatric information required for biological products that: (1) Are used in a substantial number of pediatric patients, but allows manufacturers to obtain a waiver of the requirement if the product is widely used in pediatric patients for those indications. In the proposed rule, the pediatric study requirement for drugs was contained in §314.50(g) (21 CFR 314.50(g)). In the final rule, the requirement is located in new §314.55, because §314.50 does not contain other specific study requirements. The location of the requirement for biological products (§601.27 (21 CFR 601.27)) remains unchanged in the final rule.

C. Age Groups

The final rule requires pediatric studies in each age group in which the drug or biological product will provide a meaningful therapeutic benefit or will be used in a substantial number of pediatric patients for the indications claimed by the manufacturer. The relevant age groups will, however, be defined flexibly, depending on the pharmacology of the drug or biological product, rather than following the fixed age categories defined in the 1994 rule and identified in the preamble to the proposed rule. For drugs and biological products that offer a meaningful therapeutic benefit, the rule requires manufacturers to develop pediatric formulations, if needed, for those age groups in which studies are required. Manufacturers may, however, avoid this requirement if they demonstrate that reasonable attempts to develop a pediatric formulation have failed.

D. Not-Yet-Approved Products

1. Deferral of Studies Until After Approval

The final rule permits the submission of pediatric information to be deferred until after approval if there is an adequate justification for deferral, e.g., because pediatric studies should not begin until some safety and/or effectiveness information on adults has been collected, or awaiting the completion of pediatric studies would delay the availability of a product to adults. When trials should begin in particular cases, and whether deferral will be necessary, will depend upon the seriousness of the disease for which the drug or biological product is indicated, the need for the product, the amount of safety and effectiveness data available, and what types of pediatric studies are needed.

In general, FDA expects that studies of drugs or biological products for diseases that are life threatening in pediatric patients and that lack adequate indications claimed by the manufacturer. It does not require a manufacturer to study its product for unapproved or unclaimed indications, even if the product is widely used in pediatric patients for those indications.

In the proposed rule, the pediatric study requirement for drugs was contained in §314.50(g) (21 CFR 314.50(g)). In the final rule, the requirement is located in new §314.55, because §314.50 does not contain other specific study requirements. The location of the requirement for biological products (§601.27 (21 CFR 601.27)) remains unchanged in the final rule.
therapy could begin earlier than studies of drugs that are less urgently needed, ordinarily as early as the availability of preliminary safety data in adults (frequently referred to as phase 1 data), even if data from well-controlled studies are not yet available for less critical drugs and biologics. Pediatric studies could ordinarily begin when additional safety and/or effectiveness data from the initial well-controlled trials in adults (frequently referred to as phase 2 data) became available. Of course, studies of products for exclusively pediatric diseases ordinarily need not await the development of adult data. The timing of individual pediatric studies will, however, necessarily depend on the specific information available about the product in question. For example, a study of a noncritical drug in adolescents might begin after the initial safety studies in adults, if all the parties involved agreed that initiation was appropriate in light of the results of the adult and animal safety studies.

In other cases, studies should not begin in pediatric patients until significantly more adult data are collected. For example, FDA does not believe that early study or use in pediatric patients is appropriate for some so-called “me-too” drugs that are expected to be widely used but are members of a drug class that already contains an adequate number of approved products with pediatric labeling. Such drugs may not have been shown to provide any benefit over other products in the same class, and may introduce new risks that are not apparent until the drug has been in wide use after marketing. Studies of such drugs will therefore usually be deferred until the safety profiles of the drugs are established through marketing experience. To encourage use of properly labeled drugs in pediatric patients, FDA may require the pediatric use section of the approved labeling of such a me-too drug to contain a statement recommending preferential use of other drugs that are adequately labeled for pediatric use.

2. Waiver of the Study Requirement

The pediatric study requirement applies to all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, and new routes of administration, unless FDA waives the requirement. Under criteria established in the rule, FDA may waive the study requirement for some or all pediatric age groups. The burden is on the sponsor to justify a waiver. A waiver will be granted if the waiver request demonstrates that the product meets both of the following conditions:

(1) The product does not represent a meaningful therapeutic benefit for pediatric patients over existing treatments, and (2) the product is not likely to be used in a substantial number of pediatric patients. There was some confusion in the comments on the proposed rule over these waiver criteria. FDA emphasizes that the study requirement applies to a product that offers a meaningful therapeutic benefit even if it is not used in a substantial number of pediatric patients, and vice versa.

In response to comments, FDA has refined its definitions of “meaningful therapeutic benefit” and “substantial number of pediatric patients.” To define meaningful therapeutic benefit for both drugs and biologics covered by this rule, FDA has relied, in part, on CDER’s current administrative definition of a “Priority” drug, applied to pediatric populations. The administrative definition of “Priority” products for biologics relies on different criteria (Ref. 2).

Use of CDER’s Priority drug definition to help define “meaningful therapeutic benefit” is not intended to affect the administrative definition of a Priority biologic. The Priority classification for drugs is determined based on CDER’s estimate, at the time of NDA submission, of a drug’s therapeutic, preventive, or diagnostic value. A Priority drug is defined as one that, if approved, would be a significant improvement in the treatment, diagnosis, or prevention of a disease, compared to marketed products approved for that use. In establishing meaningful therapeutic benefit for pediatric use, the comparison will be to other products adequately labeled for use in the relevant pediatric population.

If there are no such products, a new product would usually be considered to have a meaningful therapeutic benefit. Improvement over existing products labeled for pediatric use can be demonstrated by, for example: (1) Evidence of increased effectiveness in treatment, prevention, or diagnosis of disease; (2) elimination or substantial reduction of a treatment-limiting drug reaction; (3) documented enhancement of patient compliance or (4) evidence of safety and effectiveness in a new subpopulation. Evidence of improvement over existing therapies need not in all cases come from head-to-head trials.

To help ensure that pediatric patients have a sufficient range of treatments available, a product will also be considered to provide a meaningful therapeutic benefit if it is in a class of products or for an indication for which there is a need for additional therapeutic options, notwithstanding the fact that it might not be a priority drug. In contrast to the range of therapies for a given indication often available to adults, there are relatively few instances in which therapeutic alternatives are not adequately labeled for pediatric patients. For some diseases, however, it is therapeutically important to have a range of available treatment options, e.g., because there are frequent treatment failures. The Priority definition would cover the first product labeled for pediatric use, but might not cover the second or third product for a given indication or in a given class, if the subsequent product did not offer an advantage over existing therapies. The specific number of products needed will depend on such factors as the severity of the disease being treated and the adverse reaction profile of existing therapies. FDA will seek further guidance on applying this criterion from a panel of pediatric experts.

Thus, new products will meet the definition of a meaningful therapeutic benefit if: (1) They provide a significant improvement over existing adequately labeled therapies; or (2) if they are indicated for diseases or conditions, or are in product classes, in which there are currently few products labeled for pediatric use and more therapeutic options are needed. FDA expects that over time, as the number of products adequately labeled for pediatric patients grows, the number of new products meeting the second criterion will diminish. FDA emphasizes that the addition of the second criterion for defining meaningful therapeutic benefit under this final rule is not intended to alter the definition of a Priority drug, and that products meeting the second criterion will not thereby be eligible for Priority status. FDA also notes that the rule’s definition of meaningful therapeutic benefit is intended to apply only in the pediatric study context.

FDA has also revised the proposed definition of “a substantial number of pediatric patients.” Many comments argued that the number chosen by FDA in the proposal (100,000 prescriptions per year or 100,000 pediatric patients with the disease) was arbitrary.

Physician mention data from the IMS National Disease and Therapeutic Index (Ref. 38), which tracks the use of drugs by measuring the number of times physicians mention drugs during outpatient visits, shows that pediatric use of drugs is generally grouped in two distinct ranges. Physicians mention drugs for pediatric use generally fall either below 15,000 per year or above 100,000 per year. Few drugs fall within the two ranges. Thus, selecting a cut-off
for “substantial number of pediatric patients” in the middle of the two ranges will provide a reasonable discrimination between products that are widely used and those that are less commonly used, and the specific number chosen will not arbitrarily include or exclude a significant number of drugs. FDA has therefore chosen 50,000 as the cut-off for a substantial number of pediatric patients. Because the number of pediatric patients with the disease or condition is easier to determine than the number of prescriptions per year, a substantial number of pediatric patients will be defined as 50,000 pediatric patients with the disease or condition for which the drug or biological product is indicated. Although physician mentions per year does not correspond exactly to the number of patients with the disease or condition, they provide a rough approximation and the IMS data show that the number of products included or excluded is relatively insensitive to changes in the cut-off chosen. As proposed, a partial waiver for a particular pediatric age group would be available under this method if 15,000 patients in that age group were affected by the disease or condition. This definition of “a substantial number of pediatric patients” has not been codified, however, and FDA may modify it, after consulting with a panel of pediatric experts. Any modification will be issued in a guidance document with an opportunity for comment.

FDA will also waive the pediatric study requirement where: (1) The applicant shows that the required studies on the product are impossible or highly impractical because, for example, the population is too small or geographically dispersed; (2) the product is likely to be unsafe or ineffective in pediatric patients; or (3) reasonable efforts to develop a pediatric formulation (if one is needed) have failed.

To reduce the burden on manufacturers in applying for waivers and deferrals, FDA intends to issue a guidance document providing a format for a request for waiver or deferral.

E. Marketed Products

The final rule is also intended to improve pediatric use information for already marketed drugs and biological products. The rule codifies FDA’s authority, discussed in the 1994 rule, to require, in the compelling circumstances described by the regulation, that manufacturers of already marketed drugs and biological products conduct studies to support pediatric-use labeling for the claimed indications. The criteria for requiring studies of marketed products have been revised slightly in response to comments.

F. Early Discussions and Pre- and Postmarket Reports

The final rule contains provisions designed to encourage discussions of the need for pediatric studies early in the drug development process, as well as pre- and postmarketing reporting requirements designed to assist FDA in determining whether pediatric studies are needed for particular products and whether required studies are being carried out with due diligence.

G. Pediatric Committee

Many comments on the proposed rule urged FDA to form a committee of outside experts to assist in various aspects of the implementation of the rule. FDA has concluded that such a panel could provide useful advice and experience. FDA will convene a panel of pediatric experts, including at least one industry representative, and seek its advice on a range of issues related to implementation of the rule, including: (1) The agency’s implementation of all aspects of the final rule, including its waiver and deferral decisions; (2) which marketed drugs and biological products meet the criteria for requiring studies; (3) when additional therapeutic options are needed for a given disease or condition occurring in pediatric patients; (4) ethical issues raised by clinical trials in pediatric patients; (5) the design of trials and analysis of data for specific products or classes of products; and (6) issues related to the progress of individual studies.

H. Remedies for Violation of the Rule

For violations of this rule, FDA would ordinarily expect to file an enforcement action for an injunction, asking a Federal court to find that the product is misbranded under section 502 of the act (21 U.S.C. 352) or is an unapproved new drug under section 505(a) of the act (21 U.S.C. 355) or an unlicensed biologic under section 351 of the Public Health Service Act, and to require the company to submit an assessment of pediatric safety and effectiveness for the product. Violation of the injunction would result in a contempt proceeding or such other penalties as the court ordered, e.g., fines. FDA does not intend, except possibly in rare circumstances, to disapprove or withdraw approval of a drug or biological product whose manufacturer violates requirements imposed under this rule.

III. Comments on the Proposed Rule

FDA received 54 written comments on the proposed rule from pediatricians, professional societies, parents, members of the pharmaceutical industry, organizations devoted to specific diseases, and patient groups. A significant majority of the comments, primarily those from pediatricians, professional societies, parents, organizations devoted to specific diseases, and patient groups, supported regulations requiring that drugs and biologics be studied in children. Many of these comments described the problems faced by the pediatric community and parents resulting from inadequate pediatric labeling and the absence of pediatric formulations, and argued that a pediatric study requirement was long overdue. Some comments, primarily those from the pharmaceutical industry, opposed a pediatric study requirement, arguing that existing voluntary measures and incentives were sufficient to ensure adequate pediatric labeling. Finally, a number of comments addressed FDA’s legal authority to require pediatric testing of drugs and biologics.

FDA also held a day-long public hearing on October 27, 1997, in Washington, DC, at which recognized experts in the field, members of the pharmaceutical industry, and other interested parties were given an opportunity to discuss the issues raised by the proposed rule. There were three panels, each of which comprised representatives from industry, the pediatric community, organizations devoted to specific diseases, patient groups, and a bioethicist. The panels considered the following three issues: (1) When pediatric studies are needed, (2) what types of studies are needed, and (3) special challenges in testing pediatric patients. Those who spoke were nearly unanimous in their support for some kind of regulation requiring pediatric studies of some drugs and biologics. There was, however, a wide range of views on which drugs and biologics should be the subject of required studies and on how the requirement should be implemented.

Many written and oral comments raised specific issues for consideration by the agency. These comments are addressed below.

A. Purpose of Rule

1. FDA received many comments arguing that this rule is needed to ensure adequate medical care for children. Many comments from pediatricians stated that they regularly must prescribe to young children drugs
that are not labeled for children under 6 or even 12, and for which pediatric dosage forms do not exist. One comment stated that, without adequate testing and labeling, physicians must estimate appropriate pediatric doses, and that even at “appropriate” doses, it is not known whether use in children is as safe as use in adults. One comment argued that the absence of pediatric labeling puts children at greater risk for adverse drug reactions (ADR’s) and therapeutic failures than adults. According to another comment, most common and severe ADR’s in pediatric patients would be eliminated by adequate testing, and that perhaps 2 percent of all pediatric hospitalizations are due to ADR’s. One comment concluded that the failure to conduct pediatric studies results in a different standard of care for children and adults in this country.

A comment from a pharmaceutical trade association argued, however, that most of the toxicity problems identified by FDA as caused by inadequate pediatric labeling were from the 1950’s and that these “dated” examples are not relevant to current practice. As an example, the comment cited chloramphenicol, a drug referred to by FDA in the proposed rule because, when it was used in the 1950’s in neonates without adequate testing, it was responsible for many infant deaths (Ref. 4). According to the comment, it is now known that chloramphenicol can be used in neonates if the dose is correct. The comment also stated that practicing physicians have access to adequate dosing information from case reports in the medical literature.

FDA agrees that the absence of adequate pediatric labeling puts pediatric patients at risk for adverse drug reactions and ineffective dosing. FDA believes that the reference to new dosing information that permits use of chloramphenicol in infants illustrates the need for this final rule. Had adequate safety and dosing information been available earlier, many infant’s lives could have been saved. Instead, inadequately supported dosing information was not available until after the drug had been used in a large number of babies, with tragic consequences. FDA also disagrees with the comment that the remaining reports cited in the proposal of unexpected toxicity in pediatric patients from inadequately tested drugs are “dated.” Contrary to the assertion in the comment, a majority of these reports are from the 1950’s and 1990’s (Refs. 5 through 14).

FDA also does not believe that case reports scattered through the medical literature are an adequate substitute for organized and complete pediatric labeling information. To the extent that published experience is informative and credible, it should be used to improve labeling. The comments received from pediatricians reflect their view that there is often no adequately supported dosing and safety information for the drugs they use routinely in their patients. Even where case reports are available, they describe a limited number of pediatric patients and cannot provide sufficient information to establish the safety profile of a drug in pediatric patients.

Some comments argued that pediatric studies are needed because differences between children and adults can make extrapolation from adult data treacherous. One comment pointed out that research on antiarrhythmics in pediatric patients has revealed many surprises in dosing and side effects. For example, drugs that bind to milk may cause safety or effectiveness problems in pediatric patients not detected in adults. FDA agrees that pediatric dosing cannot necessarily be extrapolated from adult dosing information using an equivalence based either on weight milligram/kilogram (mg/kg) or body surface area (mg/m^2). There are potentially significant differences in pharmacokinetics, or unique drug-food interactions, that may alter a drug’s blood levels in pediatric patients. Moreover, there can be pharmacodynamic differences between adults and pediatric patients.

3. Several comments argued that voluntary measures have not resulted in a significant increase in pediatric labeling, and that new products continue to enter the market without adequate, or any, pediatric labeling. Pediatricians, professional societies, parents, organizations devoted to specific diseases, and patient groups provided many examples of diseases and drug classes for which pediatric labeling was long-delayed, inadequate, or nonexistent. Acquired immune deficiency syndrome (AIDS) drugs were frequently cited as an example of the industry’s failure to obtain adequate pediatric labeling at or near the time of approval. One comment pointed to protease inhibitors, which are theoretically most effective in newborns but have not been tested or approved for use in this group. Even for older children, the comment observed that it has taken over a year after adult approval to obtain pediatric labeling for these life-saving drugs. Another comment stated that the absence of drugs for human immunodeficiency virus (HIV) infection that are appropriately labeled and formulated for pediatric patients causes parents to give children inappropriate doses, sometimes giving up part of their own dose if the child’s physician will not prescribe it.

Other comments pointed out that epilepsy is considered a pediatric disease but claimed that many new epilepsy drugs are approved without information for use in pediatric patients. These comments urged that anti-epileptic drugs be added to the list of drug classes with inadequate labeling. A comment from a specialist in pulmonary medicine stated that although asthma is a common disease in pediatric patients, adult formulations are often released first, leaving pediatric patients without effective treatments. Other comments observed that not one of the standard immunosuppressive medications used in pediatric patients has been tested in pediatric patients. One comment contended that poor information about the pharmacokinetics of these drugs in pediatric patients has led to inadequate dosing to achieve effectiveness and possibly unnecessary toxicity.

The American Psychiatric Association commented that significant psychiatric diseases are increasingly diagnosed in pediatric patients, who may be treated with drugs despite the lack of pediatric labeling. According to this comment, most psychoactive medications are underutilized in pediatric patients due to the lack of pediatric labeling and to fear of overdosing. In the case of anti-hyperactivity drugs, however, the comment states that as many children are overtreated as undertreated, especially among pre-school age children. A comment from the National Institute of Mental Health (NIMH) stated that the rule was much needed to provide essential data on the safety and effectiveness of psychiatric medications in pediatric patients. This comment attached seven NIMH reviews of the existing data on psychotropic medications for pediatric patients, identifying many critical knowledge gaps that remain to be addressed by pediatric research.

One comment stated that pediatric nephrologists frequently prescribe drugs to pediatric patients for life-threatening conditions, including antihypertensive medications, diuretics, lipid-lowering agents, and immunosuppressive agents, even for pediatric patients less than 2 years of age, without benefit of formal studies. This comment further stated that drug therapy for chronic conditions like kidney failure is currently based on the experience gained from drug usage in children after approval for the indication in adults, and that
discovering "inadequate dosing or severe side effects by empiric use of these drugs is not desirable or safe."

Another comment provided the results of a survey of 4,898 pediatric patients with end-stage renal disease on the medications they receive. Ninety-seven percent received prednisolone or prednisone, 91 percent received cyclosporine, and 84 percent received azathioprine. According to the comment, none of these drugs was studied in pediatric patients and no information on the pharmacokinetics of these drugs in pediatric patients is available.

In contrast, several comments from the pharmaceutical industry argued that voluntary measures, the 1994 rule, and the incentives provided by FDAMA are adequate to assure adequate pediatric labeling and that FDA has not given these steps sufficient time to work. Several comments argued that to obtain pediatric studies, FDA should use encouragement and early discussion with sponsors, together with incentives, rather than imposing new requirements. These comments contended that sponsors should make "phase 4 commitments" (commitments to conduct pediatric studies after approval) and FDA should track these commitments. According to one comment, these methods have not been systematically used by FDA. According to another comment, FDA did not describe its present experience in getting manufacturers to conduct pediatric studies. Other comments argued that FDA has not allowed the 1994 rule sufficient time to produce results and that the agency should wait until it has reviewed and acted upon all supplements submitted under that rule before imposing new requirements. One comment contended that if the 1994 rule was successful in producing pediatric labeling for marketed drugs, the new rule should apply only to new drugs. One comment argued that incentives, including exclusivity, waiver of user fees, tax credits, and expedited reviews of pediatric supplements, and liability protection for research physicians, Institutional Review Boards (IRB's), universities, pharmaceutical firms, and parents, are the best means of obtaining pediatric labeling. A few comments argued that excessive litigation will follow imposition of this rule.

Two comments argued that the 53 NME's approved in 1996 demonstrate that pediatric labeling efforts by the industry are adequate, and that new requirements are not needed. Although the figures used in the 2 comments do not agree exactly, these comments stated that 20 or 21 of the 53 have potential for pediatric use. According to these comments, of these 4 have approved pediatric labeling, 14 have planned or ongoing studies, 1 is switching to over-the-counter (OTC) use, and 1 or 2 have no immediate plans for pediatric labeling activities. One comment contended that, between 1990 and 1997, a 28 percent increase occurred in the number of new drugs in development for pediatric uses, but provided no data to support this claim. FDA believes that the current state of pediatric labeling for drugs and biologics in the United States, as amply illustrated by comments from the pediatric community, is unsatisfactory. The agency's failure to obtain a significant increase in labeling for either new or marketed drugs or biologics through other measures implemented over the last several years demonstrates the need for a requirement that sponsors conduct pediatric studies of drugs and biologics that represent a meaningful therapeutic benefit to pediatric patients or that will be widely used in pediatric patients. As described in section I of this document, the response to the 1994 rule has not produced a significant improvement in pediatric labeling for marketed drugs. FDA received labeling supplements only for a small fraction of the drugs and biologics on the market. Of those supplements it did receive, over half of the submissions merely sought to add a statement to the product's labeling that "safety and effectiveness in pediatric patients have not been demonstrated," and less than a quarter provided adequate pediatric information for some or all relevant age groups.

The agency's experience in attempting to obtain pediatric labeling for new drugs entering the marketplace through voluntary measures has also been disappointing. As described in the proposal, the percentage of NME's with adequate pediatric labeling has not increased since 1991, when the agency began systematic efforts to obtain better pediatric labeling. Although the number of requests by the agency and commitments by sponsors to conduct phase 4 (postapproval) pediatric studies may have increased, these requests and commitments have so far infrequently resulted in pediatric labeling. Table 1 of this document displays the results of commitments or requests to conduct pediatric studies postapproval between 1991 and 1996. FDA notes that the table does not reflect any labeling supplements under review. There are a total of six pediatric labeling supplements currently under review for NME's approved between 1991 and 1996. These supplements may or may not add significant new labeling information; but, in any case, would not substantially increase the number of successfully conducted postapproval studies.

As Table 1 of this document reflects, FDA's figures disagree with those of the commitments for the number of 1996 NME's with potential for pediatric use, the number with some pediatric labeling at the time of approval and the number for which commitments or requests for postapproval studies have been made. The comments did not identify specific drugs, so it is not possible to determine why the two sets of figures conflict. Nevertheless, the historical experience reflected in the table suggests that most of the postapproval pediatric studies for which commitments were made for the

Table 1.—Pediatric Labeling

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>NME's approved</td>
<td>14</td>
<td>11</td>
<td>11</td>
<td>7</td>
<td>14</td>
<td>13</td>
<td>70</td>
</tr>
<tr>
<td>Pediatric studies not needed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Label includes some pediatric use information or pediatric studies complete at time of approval</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td></td>
<td></td>
<td>11</td>
</tr>
<tr>
<td>Postapproval pediatric studies promised or requested</td>
<td>9</td>
<td>4</td>
<td>15</td>
<td>16</td>
<td>5</td>
<td>15</td>
<td>44</td>
</tr>
<tr>
<td>Pediatric labeling added after approval</td>
<td>7</td>
<td>10</td>
<td>2.10</td>
<td>2.30</td>
<td>2.10</td>
<td>17</td>
<td>64</td>
</tr>
</tbody>
</table>

1 In one case, pediatric use information provided for one of two approved indications.
2 In one case, pediatric data requested for second of two approved indications.
3 In one case, pediatric data requested for additional age groups.
1996 NME’s will not result in pediatric labeling. Of the 17 commitments to conduct pediatric studies in 1996, there have thus far been only 2 additions of pediatric labeling. Although several additional studies supporting labeling changes may be submitted in the future, the experience reflected in Table 1 of this document suggests that this will not be a large number. For example, the 27 promised or requested studies for the 1991 through 1993 cohorts have resulted in just 3 additions of pediatric labeling 5 to 7 years after approval. Thus, FDA does not agree that the experience with 1996 NME’s demonstrates the adequacy of current efforts to obtain pediatric labeling.

None of the comments claiming that the rule will result in excessive litigation provided any evidence suggesting a relationship between pediatric testing and increased litigation or liability. As shown in the number of NME’s with pediatric labeling at the time of approval, a significant minority of drug and biologic manufacturers already conducts pediatric testing. FDA is aware of no evidence that excessive litigation has been associated with this testing.

With respect to the argument that the incentives provided by FDAMA will be insufficient to ensure adequate pediatric labeling, FDA believes that a mixture of incentives and requirements is most likely to result in real improvements in pediatric labeling. FDA is hopeful, e.g., that the FDAMA incentives will make more resources available for pediatric studies. As described earlier, FDA does not believe, however, that incentives alone will result in pediatric studies on some of the drugs and biologics where the need is greatest. The incentives provided by FDAMA are available only for drugs already covered by the exclusivity or patent protection provided by sections 505 and 526 of the act. Thus, the FDAMA incentives are not available for many already marketed drugs, or for many antibiotics or biologics. In addition, limited resources available to conduct pediatric studies and fiduciary obligations to shareholders may cause manufacturers to conduct pediatric studies preferentially on those drugs where the incentives are most valuable, rather than on those drugs or biological products where studies are most needed.

4. Two comments argued that the rule is inconsistent with a 1977 FDA document entitled “General Considerations for the Clinical Evaluation of Drugs in Infants and Children,” which recommended, among other things, that “reasonable evidence of efficacy generally * * * be known before infants and children are exposed to [a drug].” As described in more detail in section III.D of this document under “Deferral,” FDA expects that for drugs and biologics other than those for life-threatening diseases without adequate treatment, clinical trials in pediatric patients will ordinarily begin no earlier than when initial data from well-controlled trials in adults (frequently referred to as phase 2 data) become available to ensure that reasonable preliminary evidence of safety and/or effectiveness is available before pediatric patients are exposed to the drug or biological product. How much evidence of safety or effectiveness is “reasonable evidence” that should be available before pediatric trials may begin will be determined on a case-by-case basis. Thus, FDA believes that this rule is substantially consistent with the 1977 document.

FDA notes that the 1977 document was based upon a report prepared for FDA under contract with the American Academy of Pediatrics (AAP). The AAP is currently developing proposed revisions to this document concerning the types of data needed to support pediatric labeling. The 1977 document, which falls under the general category of guidance documents, does not bind FDA or the public, but represents the agency’s current thinking on a particular issue. Alternative approaches may be used if the alternative satisfies the requirements of the applicable statute and regulations (62 FR 8961, February 27, 1997) (Good Guidance Practices document). Until such time as an updated guidance on the clinical evaluation of drugs in infants and children is published, sponsors are encouraged to confer with the agency before initiating pediatric studies.

5. Several comments challenged FDA’s use of the 1994 IMS National Disease and Therapeutic Index (NDTI) data on the 10 drugs used most frequently in pediatric patients without adequate labeling, arguing that the data incorrectly imply that physicians have no labeling information, when in fact prescribing information is now, or will be, available for most of the 10 drugs listed.

These comments misunderstand the purpose for which FDA cited the 1994 data. Those data provided a snapshot of the labeling information available to physicians for 10 widely used drugs at a given point in time. Even if additional information had been added to the labels of these drugs in the 4 years since the survey was conducted, there was none available during a year in which the drugs, together, were prescribed to pediatric patients over 5 million times. FDA notes, moreover, that contrary to the suggestion in the comments, adequate labeling has been added for only 1 of the 10 drugs for the age group described in the proposal.

6. Two comments disputed the estimated number of times their products were prescribed to pediatric patients. One manufacturer argued that the total units sold of Auralgan were less than the listed number of prescriptions. Another manufacturer disputed the estimates of Ritalin use. This manufacturer also complained that it was not contacted by FDA about use of Ritalin despite the statement in the proposal that FDA had contacted the manufacturers of the top 10 drugs used without adequate labeling in pediatric patients.

Limitations on the data used to estimate number of prescriptions may have resulted in the discrepancy noted by the manufacturers of Auralgan or Ritalin. The number of prescriptions is estimated from data provided by IMS America, Ltd. IMS NDTI surveys a sample of physicians (more than 2,940 physicians representing 27 specialties) to determine the number of times that, during patient contacts, physicians mentioned specific drugs for particular age groups. Physician mentions may not correlate exactly with actual usage. In addition, the NDTI numbers taken from the sample of physicians are extrapolated to the nation as a whole, using a given formula. With respect to the claim that FDA has not contacted the manufacturer of Ritalin, FDA notes that it has scheduled meetings with the manufacturer to discuss use of the drug in children, which have been canceled at the manufacturer’s request.

7. One comment challenged FDA’s use of quinolones as an example of a class of drug that does not need to be studied in pediatric patients. The comment claimed quinolones do need to be studied in pediatric patients because of their important use in cystic fibrosis patients.

FDA agrees that fluoroquinolones may provide important therapeutic benefits to patients with cystic fibrosis. At present, all approved fluoroquinolones are labeled with the following statement: “Safety and effectiveness in children and adolescents less than 18 years of age have not been established.” In addition, the label includes a statement advising that the fluoroquinolones cause arthropathy in juvenile animals. Historically, the agency has recognized a potential therapeutic role for the fluoroquinolones in children with cystic fibrosis and hematology/oncology.
disorders. Indeed, FDA recently approved ciprofloxacin labeling containing a discussion of cystic fibrosis experience in the pediatric use subsection. These actions show that the agency recognizes that there may be a need to study quinolones in some pediatric patients.

8. One comment from a pharmaceutical company argued that serious ethical, legal, medical, and technical difficulties often prevent conducting pediatric studies. The comment cited difficulties in enrolling pediatric patients in sufficient numbers, unwillingness of parents to enroll children, and the absence of pediatric patients with the disease near convenient and qualified study centers. According to the comment, studies have been successfully conducted in pediatric patients in the past where there was a medical need for the drug in pediatric patients, but this rule would require pediatric studies of drugs intended for adults that may or may not be administered to pediatric patients. The comment also contended that the rule will necessitate a massive infusion of resources for industry, FDA, and medical specialty organizations, and that the agency should start with a small list of diseases with similar pathophysiology in adults and children, and a small list of drug classes known to have similar metabolism, and plan a graduated approach.

Contrary to the suggestion in the comment, this rule is designed to require studies only in those settings in which there is a significant medical need or where usage among pediatric patients is likely to be substantial. FDA acknowledges the difficulties encountered in some cases, but agrees that when the need for studies these difficulties have been overcome and that pediatric studies have been successfully conducted in many situations. FDA believes that the number of such studies already conducted each year, for example of antibiotics, vaccines, and roughly 25 percent of NMEs, support the view that such studies are not medically, ethically, or technically impossible. FDA also emphasizes that this rule will not require studies in settings where ethical or medical concerns militate against studies. As with all studies regulated by FDA, no pediatric study may go forward without the approval of an IRB, which is responsible for ensuring that the study is ethical and adequately protects the safety of the subjects. In addition, the deferral provisions of the rule are specifically designed to ensure that no pediatric study begins until there are sufficient safety and effectiveness data to conclude that the study is ethically and medically appropriate.

B. Scope

The proposal would have covered only original applications for those drugs classified as “new chemical entities,” including antibiotics, and new biological products that had never been approved for any indication. A “new chemical entity,” defined in 21 CFR 314.108(a), is a drug that contains no previously approved active moiety. Under the proposal, chemical modifications that did not change the active moiety, such as the formation of a different salt or ester of the moiety, would not have required further study. New indications or dosage forms of a previously approved moiety also would not have required further studies. FDA sought comment on whether the requirement should apply more broadly, e.g., to applications for minor chemical modifications of approved products, modifications of approved products, new indications, dosage forms or new routes of administration.

9. A majority of those who commented on the scope of the rule recommended that the final rule cover all new drugs and biologics, including new dosage forms and indications, because modifications in existing drugs may be as therapeutically significant to pediatric patients as the original drug or biologic. These comments included pediatricians, medical societies, one pharmaceutical company, and one disease-specific organization. Several comments, including two companies, an IRB, the AAP, a disease-specific organization, and a professional society recommended including new indications and dosage forms on a case-by-case basis, generally if their inclusion were recommended by an expert panel. Several comments supported the narrow scope of the proposal, including a pharmaceutical trade association, a professional society, and several companies. The pharmaceutical trade association suggested that the rule might also apply to new formulations uniquely suited to pediatric patients.

FDA has reconsidered the scope of the rule in light of the comments and has concluded that, in some cases, the need for pediatric studies is as great for modifications of existing products and new claims as for the original products. A new indication or dosage form for a previously approved drug, e.g., could be far more relevant to pediatric patients than the originally approved product. From a public health standpoint, FDA cannot justify the distinction in the proposal between new chemical entities and never-before-approved biologics, on one hand, and significant modifications of those products, on the other hand. Therefore, FDA has revised proposed §§ 314.55 (proposed 314.50(g)) and 601.27(a) to cover applications for new active ingredients, new indications, new dosage forms, new dosing regimens, and new routes of administration. The final rule exempts from its coverage any drug for an indication or indications for which orphan designation has been granted under the Orphan Drug Act (21 U.S.C. 360bb). FDA believes this exemption is appropriate because the purpose of the Orphan Drug Act is to encourage the development of drugs for patient populations that are so small as to make the manufacture and sale of the drug unprofitable if not for the incentives offered by the Orphan Drug Act. Imposition of a pediatric study requirement on an orphan drug could conflict with the balance struck by the Orphan Drug Act, by further raising the cost of marketing the drug. This exemption does not apply after marketing under § 201.23 of this final rule.

FDA’s decision to expand the scope of the rule does not mean, however, that pediatric studies would always be needed for a new product entering the marketplace, or for a new claim. The waiver criteria will apply equally to modifications of existing drugs and biologicals. Thus, FDA will require studies only of those new drugs and biologics that offer a meaningful therapeutic benefit to pediatric patients or that are expected to be used in a substantial number of pediatric patients. In many cases, moreover, new dosage forms might need relatively little pediatric data, such as pharmacokinetic data alone.

10. One comment sought clarification of the applicability of the rule to generic drugs. The comment argued that the collection of pediatric data was unwarranted where a generic manufacturer was copying a drug with an adult dose, and that FDA should require a pediatric bioequivalence study only where the innovator submits a supplement for a new dose or regimen in the pediatric population. Another comment from a generic drug trade association argued that bioequivalence studies in children should never be required to support approval of a generic drug.

This rule does not impose any requirements on studies submitted in support of applications for generic copies of approved drugs that meet the requirements of section 505(j) of the act. FDA also does not currently require bioequivalence studies to be conducted.
in children for generic drugs. FDA notes that petitions submitted under section 505(j)(2)(C) for a change in active ingredient, dosage form, or route of administration may be denied if investigations must be conducted to show the safety and effectiveness of the change. Thus, if a petition is submitted for a change that would require a pediatric study under this rule, the petition may be denied.

C. Required Studies

FDA proposed to amend its regulations related to the content of NDA and biologic license applications (BLA’s) to include required information on pediatric studies for certain applications. Under the proposal, an application for a new chemical entity or never before approved biologic would have been required to contain data adequate to assess the safety and effectiveness of the product for all pediatric age groups for the claimed indications. Unless FDA granted a deferral or partial waiver of the requirement. As described in section III.B of this document under “Scope”, FDA has revised § 314.55(a) (proposed § 314.55(g)(1)) and § 601.27(a)) to cover applications for new active ingredients, new indications, new dosage forms, new dosing regimens, and new routes of administration. Under the final rule, all covered applications will be required to contain data adequate to assess the safety and effectiveness of the product, unless FDA has granted a waiver or deferral of the requirement (see “Waiver” and “Deferred Submission” in section III.D and E of this document). Assessments required under this section for a product that represents a meaningful therapeutic benefit over existing drugs must be carried out using appropriate formulations for the age group(s) for which the assessment is required, unless reasonable efforts to produce a pediatric formulation had failed (see “Waiver” in section III.E of this document). Comments on issues related to formulation are addressed under “Pediatric Formulations” in section III.I of this document. The proposal did not mandate particular types of studies. The proposal recommended that the sponsor consult with FDA on the types of data that would be considered adequate to assess pediatric safety and effectiveness in particular cases.

FDA received several comments on the design and conduct of clinical trials in pediatric patients. One comment asked for clarification of what is meant by “adequate evidence” to demonstrate safety and effectiveness. The comment argued that FDA should not require two adequate and well-controlled trials for pediatric studies, and that the amount of evidence required should depend on the ability of the data to be extrapolated from adult to pediatric patients, the seriousness of the illness to be treated, the ability to assess meaningful measures of efficacy in pediatric patients, and the feasibility of conducting adequate trials in relatively uncommon pediatric disease states.

Another comment claimed that the ability to extrapolate from adult efficacy data is limited and argued that well-controlled trials in pediatric patients should be the norm. This comment also stated that safety cannot be extrapolated from adult data and recommended studying 300 pediatric patients for an adequate period to identify frequent ADR’s. Other comments questioned the appropriateness of extrapolating from adult effectiveness data in a variety of settings. One comment argued that in the area of blood products, in addition to extrapolating from pharmacokinetic data, it may be appropriate to extrapolate from adult data using relative blood volume replacement. Several comments urged reliance on a variety of other sources of data, including published studies and reports, and actual use information. One comment urged FDA to rely on advanced scientific and statistical methods that optimize safety, convenience, and informativeness, while minimizing unnecessary or uninformative clinical trials.

FDA agrees that “adequate evidence” of safety and effectiveness for pediatric patients does not always require two adequate and well-controlled trials. One of two central purposes of the 1994 rule was to make it clear that pediatric effectiveness may, in appropriate circumstances, be based on adequate and well-controlled studies in adults with supporting data in pediatric patients that permit extrapolation from the adult data. FDA agrees, however, that extrapolation from adult effectiveness data would not always be appropriate and that it may not be appropriate to extrapolate pediatric safety from adult safety data. FDA has specifically noted, in the FDA guidance document entitled “Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products,” that if further controlled trial data were needed in a population subset, it would usually be sufficient to conduct a single additional controlled trial. FDA also agrees that useful information can come from data other than adequate and well-controlled trials, and encourages the submission of valid and reliable data from a variety of sources. The type and amount of data required in any particular case will depend upon many factors, including those cited in the comments.

One comment urged FDA, in the final rule, to encourage sponsors to use Computer-Assisted Trial Design (CATD), allowing them to reduce number of actual trials in pediatric patients. FDA encourages the use of any validated scientific method for designing, conducting, or analyzing clinical trials.

One comment questioned whether there will be a sufficient pool of pediatric subjects to complete trials, in light of the increase in the number of trials occasioned by the rule. FDA believes that with appropriate organization, the pool of pediatric patients available for studies should be adequate. The Pediatric Pharmacology Research Units (PPRU’s), a network of groups instituted to conduct pediatric research, some of which are located outside of major population centers, have an established record of recruiting pediatric patients and completing valid studies. Even where the number of pediatric patients affected by a disease is small, valid studies have sometimes been successfully conducted. It should also be reemphasized that many of the studies contemplated under the rule are pharmacokinetic studies, dose-response studies with short-term endpoints (pharmacodynamic studies) and safety studies that are likely to impose relatively little burden on individual patients. Where, however, patient recruitment is so difficult as to make the study impossible or highly impractical, the rule permits a waiver of the study requirement (§§ 314.55(c) and 601.27(c)).

One comment urged that the final rule include a broader research requirement, and sought to have drug interactions and drug metabolism taken into consideration. Another comment sought to have the final rule codify minimal requirements for studies, such as toxic overdose and pharmacokinetic data. One comment urged FDA not to codify specific requirements for clinical trials, but to establish these requirements in consultation with an expert pediatric committee.

FDA declines to codify specific requirements for pediatric studies. Flexibility is necessary to assure that required studies are appropriate for each product. FDA will, however, consult with a pediatric committee on specific pediatric study issues.
15. One comment from a professional pharmacy organization urged that all protocols for pediatric studies be reviewed by pediatric experts, including a pharmacist knowledgeable about pharmacodynamic factors in each age group. FDA reviews protocols for pediatric studies submitted in investigational new drug applications (IND’s), and its reviewers include experts in pediatrics and pharmacology.

D. Deferred Submission

The proposal recognized that there would be circumstances in which it would be appropriate to permit the submission of pediatric data after approval. Two such circumstances were described in the preamble to the proposal: (1) Where adult safety or effectiveness data need to be collected before the product could be appropriately studied in pediatric patients. If such data were collected, the product was ready for approval in adults before studies in pediatric patients were completed. Although not included in the text of the proposal, these examples have been added to the final rule. Under the proposal, FDA would have the authority to defer the submission of some or all of the required pediatric data until after approval of the product for adult use, on its own initiative or at the request of the applicant. Under the proposed provisions, if the applicant requested deferral, the request would be required to contain an adequate justification for deferring pediatric studies. If FDA concluded that there were adequate justification for deferring the submission of pediatric use studies, the agency could approve the product for use in adults subject to a requirement that the applicant submit the required pediatric studies within a specified time after approval. It is important to appreciate that deferred submission of pediatric data refers to the date on which the data are submitted, not when the studies are initiated. Thus, deferred studies will generally be initiated before approval, unless it is concluded that the full adult database or marketing experience is needed before pediatric studies may appropriately begin.

FDA stated in the proposal that it would consult with the sponsor in determining a deadline for the deferred submission, but tentatively concluded that it would require the submission not more than 2 years after the date of the initial approval. To ensure that deferral would not unnecessarily delay the submission of pediatric use information, FDA proposed that a request for deferred submission include a description of the planned or ongoing pediatric studies, and evidence that the studies were being, or would be, conducted: (1) With due diligence, and (2) at the earliest possible time. FDA sought comment on the circumstances in which FDA should permit deferral, and on the factors that should be considered in determining whether a given product was one that should be studied in adults before pediatric patients. FDA received many comments on the deferral provisions in the proposal.

16. A few comments stated that the deferral provisions are an appropriate means of assuring that pediatric patients are not studied before adequate safety data have been gathered. A number of comments from the pharmaceutical industry asserted, however, that the proposal would require concurrent testing in adults and pediatric patients despite medical and ethical reasons for delaying testing pediatric testing. For example, a comment from a pharmaceutical trade association claimed that the rule:

* * * would require testing of new medical compounds in children before safety in adults has been studied adequately, before effectiveness in adults has been established, and in young children and neonates without adequate information about the effects of the drug in older pediatric patients.

These industry comments appear to have misunderstood the explicit deferral provisions of the rule and perceived them as rare exceptions to a usual requirement that adults and children be studied at the same time. Nothing in the rule requires concurrent testing in adults and pediatric patients, nor testing in infants and neonates before testing in older children. As stated previously and in the proposal, the deferral provisions were specifically included to, among other things, ensure that pediatric studies could be delayed when necessary to assure that appropriate safety and/or effectiveness data were available to support pediatric testing.

17. Most of the comments on deferral focused on whether the need for safety and/or effectiveness data in adults before initiating pediatric studies should be a basis for deferral. Comments from disease-specific organizations, medical societies, including the AAP, and pediatricians argued that deferral should be granted rarely if at all on this basis. One comment argued that deferring availability of life-saving drugs to children cannot be rationalized scientifically, legally, or ethically, and contended that deferral should not be permitted for serious and life-threatening diseases where there is no substantial difference between the disease or the anticipated effect of the drug in children or adults. Another comment argued that deferral should be used sparingly in all age groups, including infants and neonates, and that its use should be evaluated in the context of the seriousness of the condition to be treated, the therapeutic advance the drug represents, and the likelihood that the drug will be given to children as soon as it is approved.

According to this comment, the risks of research in pediatric patients may be outweighed by the risks that the drug will be given to them without data.

One comment argued that pediatric studies of important drugs should be conducted in parallel to adult studies, especially in children under 12. Several comments from the pediatric community, however, supported the development of some adult safety and/or effectiveness data before initiation of pediatric studies. One comment from an organization devoted to pediatric AIDS stated that while the general assumption should be that pediatric studies will be submitted at the same time as adult studies, it may be appropriate to have some testing in adults before children. The AAP stated that it is appropriate to begin studies in pediatric patients after phase 1 and phase 2 studies in adults have defined routes of clearance and metabolic pathways. Thus, the comment urged that pediatric studies be conducted during phases 2 and 3, not 4. A comment from a nephrology organization argued that drugs for organ-specific diseases should be studied in phase 3, as soon as phase 1 and 2 trials have shown safety in adults. This and another comment stated that testing studies until approval compromises clinical trial enrollment, citing the experience with recombinant erythropoietin. According to these comments, erythropoietin was not studied in pediatric patients until after its approval for adults, and enrollment was so difficult that pediatric studies were not completed for 5 years.

Several comments from the pediatric community also cited limited circumstances in which they believed deferral to be appropriate. A medical society argued that data should be collected after adult studies only for drugs with narrow therapeutic indices, unusual accumulation in the body, where the drug study requires extensive blood sampling, or where the study design places young patients at risk for limited information gain.

Many comments from the pharmaceutical industry argued, in contrast, that deferral should be
rule, rather than the exception. Most of these comments contended that it was unethical to begin studying drugs in pediatric patients, other than those that are intended primarily for pediatric patients, unless the drugs are shown to be reasonably safe and effective in adult patients. All argued that pediatric studies must not be initiated until substantial data in adults are available, but cited different initiation points, e.g., after phase 2, after safety and effectiveness is established in adults and an approvable letter is received, after approval, after 1 year of marketing. Although many of these industry comments argued that pediatric studies should be conducted exclusively as phase 4 (postapproval) commitments, a significant number of industry comments acknowledged that pediatric studies could begin before approval, generally after phase 2, and that there were circumstances in which deferral was not appropriate. One comment argued that since early pediatric studies often require pediatric formulations and because up to 50 percent of drugs are abandoned before phase 3, it is wasteful to require companies to manufacture a pediatric formulation and begin studies before the end of phase 2. Another comment argued that no pediatric studies should begin before the decision to proceed to phase 3, except where: (1) The disease affects only pediatric patients; (2) the disease mainly affects pediatric patients, or the natural history or severity of the disease is different in pediatric patients and adults; or (3) the disease affects both pediatric patients and adults and lacks adequate treatment options. One comment urged that the final rule state that “in most cases, pediatric testing should not be conducted with any drug or biological product until certain adult safety and/or effectiveness information has been collected.” According to this comment, there could be exceptions where no other therapy was available and there was a potential for the drug to be lifesaving. A pharmaceutical trade association argued for a presumption that pediatric studies not begin until the end of phase 2, and listed circumstances in which deferral should not occur: (1) Where the disease is life threatening and there is no alternative therapy, (2) where the drug is intended for a pediatric indication, (3) where the drug presents no major safety issues, (4) where the drug class is well studied in pediatric patients, or (5) where a large amount of “off-label” use in pediatric patients is anticipated.

In general, FDA expects that some data on adults will usually be required to initiate studies of drugs and biologics for life-threatening diseases without adequate treatment than for less serious diseases. Pediatric studies of drugs and biologics for life-threatening diseases may in some cases be appropriately begun as early as the initial safety data in adults become available, because the urgency of the need for such products may justify early trials despite the relative lack of safety and effectiveness information. In such cases, deferral of submission of pediatric studies until after approval will be unnecessary, unless drug development is unusually rapid and the product is ready for approval in adults before completion of the pediatric studies.

Pediatric studies on products for less serious diseases should generally not begin until more adult data have been collected, ordinarily no earlier than the availability of data from the initial well-controlled studies in adults. As noted earlier in this document, there may occasionally be exceptions to this principle where all parties agree that earlier initiation is appropriate. Whether deferral of submission of the data until after approval will be necessary for such products will depend upon when pediatric studies can scientifically and ethically begin in each case and how difficult the studies are to complete. In some cases, FDA expects that scientific and ethical considerations will dictate that studies not begin until after approval of the drug or biological product. For example, pediatric studies of “me-too” drugs that do not offer a meaningful therapeutic benefit and that are members of a drug class that already contains an adequate number of approved products with pediatric labeling may be deferred until well after approval. In cases where a drug has not been shown to have any benefit over other adequately labeled drugs in the class, the therapeutic need is likely to be low and the risks of exposing pediatric patients to the new product may not be justified until its safety profile is well established in adults through marketing experience. Because the basis for the deferral in such cases will be concern that the drug presents risks to pediatric patients that will not be known until there is widespread marketing experience, without offsetting benefit, FDA may require, in appropriate cases, that such drugs carry labeling that recommends the preferential use in pediatric patients of products that are already adequately labeled. Such a statement might read:

The safety and effectiveness of this product have not been established in children. There are alternative therapies that have been shown to be safe and effective for use in children with [indicated condition]. Ordinarily, products already labeled for use in children should be used in preference to [name of this product].

FDA labeling regulations at 21 CFR 201.57 express the agency’s authority to ensure that drugs are safe for use under the conditions prescribed, recommended, or suggested in their labeling, and to require labeling identifying safety considerations that limit the use of drugs to certain situations. Some drugs with no demonstrated advantage over available therapy can nonetheless be expected to have wide use in pediatric patients. Pediatric studies of such drugs should be initiated relatively early, even if they are not completed at the time of approval.

A comment from a pharmaceutical company listed several circumstances in which it argued FDA should permit deferral: (1) The pediatric population is so small that enrollment and completion of trials cannot be accomplished in parallel with adult trials, (2) the natural course of the disease is different in adults and children, (3) analytic tools and clinical methodologies cannot be easily adapted to the pediatric population, (4) the drug has complex pharmacokinetic properties in adults making it hard to extrapolate a pediatric dosage range, (5) the scope and nature of nonclinical studies support only adult clinical studies, (6) two or more attempts to develop a pediatric formulation have failed, or (7) unique drug-drug or drug-food interactions in children confound drug development. Another comment added to this list: (1) Where fewer than 200,000 pediatric patients are affected by the disease being treated, and (2) drugs with a low therapeutic index.

FDA agrees that some of these circumstances could make completion of studies prior to approval in adults difficult, but does not agree that they would make studies impossible or impractical in all cases. The need for deferral must be considered case-by-case. A small pediatric population, e.g., might make completion of controlled trials very slow, but might not prevent obtaining pharmacokinetic data. Simply citing a pediatric population under 200,000 will not be sufficient to justify deferral; a small fraction of this number participating in trials may be sufficient to support timely pediatric studies, depending on the nature of the studies. As an example, over 50 percent of the estimated 6,000 pediatric patients with cancer each year are enrolled in clinical trials (Ref. 15).
be any reason to conclude that deferral is warranted solely because the natural course of the disease is different in adults and children. FDA also disagrees that deferral is necessarily warranted where analytic tools and clinical methodologies cannot be easily adapted to pediatric patients. Deferral may be necessary in some cases where the infants and toddlers are unable to provide subjective outcome data, but it may also be possible to utilize alternative endpoints or to extrapolate effectiveness data from older pediatric age groups, obtaining pharmacokinetic data from the younger age groups to determine an appropriate dose. Drugs with a low therapeutic index that do not fulfill an urgent need should, in general, be studied in pediatric patients later in drug development.

With respect to complex pharmacokinetic properties that prevent extrapolation of adult data to pediatric patients, low-therapeutic index drugs, and unique drug-drug or drug-food interactions in pediatric patients, FDA believes that the need for pediatric studies before approval is even greater where these conditions are present; moreover, none of them represents a significant impediment to studies. Recognizing that drugs and biologics approved for adults are regularly prescribed to pediatric patients despite the absence of adequate dosing and safety data, information positively suggesting that dosing and safety cannot be extrapolated from adult data increases the importance of conducting pediatric studies before the product is widely used in pediatric patients. The absence of supporting nonclinical studies (e.g., studies in young animals) should not usually be a basis for deferral, if needed, are readily conducted. Moreover, a full adult data base provides pertinent safety information that might make further preclinical data unnecessary.

Difficulties in developing an adequate pediatric formulation may, in some cases, justify deferral of studies in young pediatric patients. In other cases, however, it may be appropriate to study a less-than-optimal formulation, e.g., an injectable, if one is available, in pediatric patients while awaiting the development of a more desirable pediatric formulation.

19. One comment argued that it was "unacceptable" to defer pediatric studies to avoid delaying approval for adult use. Instead, the comment urged FDA to provide a "limited approval" for adult use until pediatric data are available and impose a monetary penalty for failure to comply. Another comment argued that permitting deferral to avoid delay in adult marketing could be applied to most applications, creating a de facto situation in which pediatric data were understood to be not required until 2 years after approval. One comment stated that while pediatric dosing schedules are essential, pediatric studies should not delay approval of drugs for a major population, adults.

FDA continues to believe that deferral is appropriate where awaiting the completion of pediatric studies would delay the availability of a safe and effective drug or biological product for adults. Granting a deferral does not automatically mean, however, that pediatric studies need not be submitted for 2 years or that initiating them should be long delayed. The proposal suggested 2 years as the maximum period for a deferral. Where pediatric studies are supposed to be nearing completion at the time a product is ready for approval in adults, FDA expects that the period of deferral would be significantly shorter than 2 years. Where some useful pediatric information, e.g., safety information, is available at the time of approval, even if some required studies are not complete, FDA may require that the pediatric use section of the product's labeling include that information, to the extent consistent with 21 CFR 201.57(i)(9). FDA also notes that it has no authority to impose a monetary penalty for failure to submit a required study of a drug or biological product. FDA must ask a court to impose such a penalty in a contempt proceeding.

20. Several comments argued that pediatric trials should be conducted sequentially, beginning with the oldest pediatric age group, and ending with the youngest. One comment stated that IRB's would be tested in a drug in younger children before older children. The AAP argued that there is little defense for studying pediatric patients sequentially from oldest to youngest, and that such a policy will result in approvals without data in neonates. This comment argued that the timing of studies should give consideration to safety, but without consideration of sequence. Another comment argued that FDA should not routinely require that drugs for serious and life-threatening diseases be studied sequentially. In HIV, according to this comment, drug testing should be "as simultaneous as possible" because safety and dosing may be initiated in each age group in a dose escalating manner regardless of the results in previously tested groups. FDA agrees that age-dependent sequential studies are not necessarily appropriate. Particularly were there is urgent need for a product, there may be good reason to study older and younger children at the same time.

21. A few comments objected to FDA's tentative decision to require the submission of studies ordinarily no later than 2 years after the initial approval. One comment stated that deferral of up to 2 years was excessive, citing the "critical" need to ensure timely performance of pediatric studies in populations where the drug is likely to be used. Another comment stated that 2 years may be adequate for collecting pharmacokinetic data, but not necessarily for collecting safety data. According to this comment, the size of the clinical database will be the principal determinant of when data should be submitted. A comment from the American Red Cross stated that the extensive IRB review of studies of blood products involving pediatric patients, and the difficulty in enrolling such patients, makes the 2-year deferral deadline unrealistic for this category of product.

FDA agrees with the comments that the 2-year deadline suggested by the proposal may not be appropriate, and that the length of the deferral should be decided on a case-by-case basis. The timing of the deferred submission will depend upon such factors as the need for the drug or biologic in pediatric patients, when sufficient safety data become available to initiate pediatric trials, the nature and extent of pediatric data required to support pediatric labeling, and substantiated difficulties encountered in enrolling patients and in developing pediatric formulations. FDA may also extend the date for submission of studies at the time of approval, e.g., where other drugs in the class have been approved during the pendency of the NDA, and the new drug is no longer needed as a therapeutic option.

E. Waivers

FDA does not intend to require pediatric assessments unless the product represents a meaningful therapeutic benefit over existing treatments or is expected to be used in a substantial number of pediatric patients. FDA also does not intend to require pediatric assessments in other situations where the study or studies necessary to carry out the assessment are impossible or highly impractical or would pose undue risks to pediatric patients. Thus, FDA proposed to add § 314.50(g)(3) (now § 314.55(c)) and § 601.27(c) to authorize FDA to grant a waiver of the pediatric study requirement on its own initiative or at the request of the applicant unless the product represented a meaningful therapeutic benefit over existing...
treatments, or was likely to be used in a substantial number of pediatric patients. These provisions also require FDA to grant a waiver if necessary studies were impossible or highly impractical, because, e.g., the number of pediatric patients was very small or patients were geographically dispersed, or there was evidence strongly suggesting that the product would be ineffective or unsafe in some or all pediatric populations. If a waiver were granted because there was evidence that the product would be ineffective or unsafe in pediatric patients, this information would be included in the product's labeling.

An applicant could request a full waiver of all pediatric studies if one or more of the grounds for waiver applied to the pediatric population as a whole. A partial waiver permitting the applicant to avoid studies in particular pediatric age groups could be requested if one or more of the grounds for waiver applied to one or more pediatric age groups. In addition to the other grounds for waiver, the proposal would allow FDA to grant a partial waiver for those age groups for which a pediatric formulation was required (see "Pediatric Formulations" in section III.I of this document), if reasonable attempts to produce a pediatric formulation had failed.

The proposal would require the applicant to include in the request for a waiver an adequate justification for not providing pediatric use information for one or more pediatric populations. FDA would grant the waiver request if the agency found that there was a reasonable basis on which to conclude that any of the grounds for a waiver had been met. If a waiver were granted on the ground that it was not possible to develop a pediatric formulation, the waiver would cover only those pediatric age groups requiring a pediatric formulation.

The agency also proposed two possible methods of determining a "substantial number of patients." The first method would focus on the number of times the drug or biologic was expected to be used in pediatric patients, annually. Under this method, FDA tentatively concluded that 100,000 or more prescriptions or uses per year in all pediatric age groups would be considered a substantial number.

The second proposed method for establishing whether there was a substantial number of pediatric patients would focus on the number of pediatric patients affected by the disease or condition for which the product is intended. Under this method, FDA tentatively concluded that 100,000 pediatric patients affected by the disease or condition for which a product was indicated would be considered a "substantial number" of pediatric patients. FDA sought comment on the waiver criteria and on these methods of calculating a substantial number of pediatric patients. FDA also sought comment on whether cost to the manufacturer should justify a waiver.

FDA received many comments on the waiver provisions of the proposal, and has made certain changes in response to the comments, as described below.

22. As proposed, new drugs and biologics are presumptively required to be studied in pediatric patients, unless a waiver is granted. The presumption in the proposal was supported by comments from pediatricians, a pharmacy organization, disease specific organizations, and medical societies, including the AAP. Several industry comments argued, however, that new drugs and biologics should presumptively not be covered by the rule, unless they were specifically identified by FDA as needing to be studied. One of these comments stated that companies should not have to waste the effort of applying for waiver for drugs of no potential benefit to pediatric patients, which the comment estimated as a majority of those developed.

FDA continues to believe that it is appropriate to presume that drugs and biologics should be studied in pediatric patients, and that this presumption should be overcome only if there are clear grounds for concluding that such studies are unnecessary. Pediatric patients are a significant subgroup, affected by many of the same diseases as adults, and are forfeitable users of new drugs and biologics. The agency has stated, in the context of pediatric studies and other subpopulations, that an application for marketing approval should contain data on a reasonable sample of the patients likely to be given a drug or biological product once it is marketed (59 FR 64240 at 64243; 58 FR 39406 at 39407, July 22, 1993). FDA does not believe that the cost of drafting a waiver request will be great, particularly where the basis for the waiver is that the product has no potential use in pediatric patients. To assist sponsors in preparing such waivers, FDA has included in this document a partial list of diseases that are unlikely to occur in pediatric patients and for which waiver requests need include only reference to this document.

23. FDA received many comments on the proposed criteria for waiving pediatric studies. A few comments supported the proposed criteria. Many comments from pediatricians, medical societies, and disease-specific organizations argued that the proposed grounds for waiver were too broad. Several of these stated that the rule should apply to drugs for all conditions that affect pediatric patients unless there is a special reason not to do so. One comment argued that waivers should be available only for drugs known to be extremely toxic in pediatric patients or to have no anticipated use in pediatric patients.

Other comments from the pharmaceutical industry argued that the waiver provisions were too narrow. One comment from a generic trade association urged that pediatric studies be required only when there is a significant public health concern with respect to the safety of a drug product in pediatric patients or to the availability of adequate pharmacological intervention for pediatric patients for the indication. Another comment stated that the criteria in the proposal "do not begin to address the complexities associated with moving forward on a clinical development plan" and argued that additional criteria should include: (1) The lack of correlative safety evidence, (2) liability concerns, and (3) prohibitive cost (but the sponsor, not FDA, should be allowed to determine the importance of cost).

FDA believes that the criteria for waiver in the final rule strike a careful balance. On one hand, requiring studies for all new products would have potentially severe resource implications for manufacturers and the agency. On the other hand, obtaining studies only where the studies impose no burden on the sponsor would continue to expose millions of pediatric patients to unnecessary risks and ineffective treatment. Requiring pediatric studies only of those drugs or biologics that offer a meaningful therapeutic benefit or that are expected to be used in a substantial number of pediatric patients focuses limited resources on those products that are most critically needed for the care of pediatric patients.

24. Several comments addressed the definition of "meaningful therapeutic benefit." Some comments from the pharmaceutical industry stated that "meaningful therapeutic benefit" should be defined as it is used in 21 CFR 314.500. (That regulation applies to drugs "that provide meaningful therapeutic benefit to patients over existing treatments (e.g., ability to treat patients unresponsive to, or intolerant of, available therapy, or improved patient response over available therapy).") One of these comments.
suggested that analogous cases in the pediatric context would be: (1) Where the drug treats a pediatric disease for which no other treatments exist; (2) where the drug treats patients who are unresponsive to or intolerant of other drugs; or (3) where the drug produces a superior response over other treatments. One industry comment argued that the agency should consult with the sponsor, and the pediatric investigators involved to assess whether the drug will provide a “meaningful therapeutic benefit.” According to the comment, the assessment should include the likely use of the product in a specific pediatric population, the likely benefit without increased risk to patients versus existing treatments, a “definitive need” for a new therapy in very serious or life-threatening illnesses, and the cost and feasibility of developing the necessary formulations and of conducting studies. Another comment from a disease-specific organization argued that “meaningful therapeutic benefit” should be a relative term, depending on the severity of the illness, the potential risk posed by the drug, and the availability of alternative treatments. One comment from a medical society devoted to the treatment of psychiatric disorders contended that “meaningful therapeutic benefit” should mean that the product enables a child to function better, and participate in age-appropriate activities, such as playing and going to school, without undue pain and suffering from the disease or disorder. Another comment argued that “meaningful therapeutic benefit” should mean better response or ability to treat nonresponsive patients. Another comment maintained that the presumption should be that a product represents a meaningful therapeutic benefit in pediatric patients if it is expected to provide a meaningful therapeutic benefit in adults.

Several comments from the pharmaceutical industry contended that it is not possible to define meaningful therapeutic benefit before approval or that FDA should not be responsible for defining it. A pharmaceutical trade association argued that meaningful therapeutic benefit is the decision of the sponsor, not FDA, and that it is not possible to determine meaningful therapeutic benefit until a drug has been used for some period of time. Another comment maintained that FDA must first have adult data to reach the conclusion that a drug offers a meaningful therapeutic benefit. The same comment also argued that a rigorous determination of meaningful therapeutic benefit would require randomized, controlled trials in pediatric patients.

FDA disagrees that it is impossible or beyond FDA’s expertise to reach a conclusion before approval about whether a product has the potential to offer a meaningful therapeutic benefit. FDA routinely estimates the therapeutic benefit of new drugs and biologics at the time applications are first submitted, in order to determine whether to assign “Priority” (expedited) status to the review of the application. In assigning Priority status to new drug applications, CDER determines whether the product, if approved, “would be a significant improvement compared to” marketed (or approved, if such is required) products, including nondrug products or therapies. “Improvement can be demonstrated by, for example: (1) Evidence of increased effectiveness in treatment, prevention, or diagnosis of disease; (2) elimination or substantial reduction of a treatment-limiting drug reaction; (3) documented enhancement of patient compliance; or (4) evidence of safety and effectiveness in a new population” (Ref. 16). These criteria are similar to many of the criteria suggested in the comments. FDA notes that demonstration of an advantage over existing products may come from evidence other than head-to-head comparisons of the new product and existing products. For example, in some cases a new product could be shown to lack an adverse effect associated with an existing product, or to have an effect on a different outcome or on a different stage of disease than an existing product, without a direct comparison of the two products.

FDA has concluded that in determining whether a product offers a meaningful therapeutic benefit, it will use the Priority definition, with some modifications. First, in determining whether a product is expected to be an improvement over other products, the comparison will be made only to other products that are already adequately labeled for use in the relevant pediatric population. Second, it is often therapeutically necessary to have two or more therapeutic options available, because some patients will be unresponsive to a given therapy. Because the Priority definition would not cover more than the first or second product for a given indication or in a given class (unless the product offered an advantage over others for the indication or in the class), a drug or biologic will also be considered to provide a meaningful therapeutic benefit if it is in a class of drugs and for an indication for which there is a need for additional therapeutic options. The specific number of products needed will depend upon such factors as the severity of the disease being treated, and the adverse reaction profile of existing therapies. FDA has added this definition of meaningful therapeutic benefit to §§ 314.55(c)(5) and 601.27(c)(5). This rule’s definition of meaningful therapeutic benefit is intended to apply only in the pediatric study context and is not intended to alter the definition of a Priority drug.

25. Several comments addressed the definition of “a substantial number of pediatric patients.” A few comments argued that it would be difficult to estimate product use until after marketing. Several comments argued that FDA should not base waivers on the number of patients or prescriptions. Many other comments claimed that the proposed numerical cut-offs are arbitrary. These comments maintained that waivers should be decided on a case-by-case basis. Several comments urged that FDA consult with an expert panel in deciding whether pediatric use was substantial.

Comments from the pediatric community contended that the numerical cut-offs in the proposal were too high, and would preclude studies of many serious diseases affecting fewer than 100,000 pediatric patients. One comment, for example, voiced concern that pediatric patients with less common seizure types may not benefit from the regulations because the use is not sufficiently widespread. Another comment argued that numerical cut-offs should not apply to drugs for serious and life-threatening diseases, unless the number of pediatric patients was so low as to make clinical study impossible. Another comment suggested that studies be required not only for uses greater than 100,000 prescriptions, but for “drugs used chronically for a defined, though smaller group of pediatric patients, usually for organ-specific diseases, such as kidney failure or hypertension.”

Comments from the pharmaceutical industry argued that the numerical cut-offs proposed by FDA were too low. Some of these comments argued that 100,000 prescriptions per year translates to fewer than 100,000 patients, and that the resulting population could be so small that it would be difficult to study. Several of these comments urged that cut-off for substantial use be 200,000 patients with the disease, the threshold established by the Orphan Drug Act for identifying rare diseases.

FDA has decided to revise its proposed method of defining a substantial number of patients, in light of the comments. Physician mention
threatening diseases will be considered adequately labeled for pediatric patients until there are enough adequately labeled products available, many new drugs and biologics for serious and life-threatening diseases will be considered to offer a meaningful therapeutic benefit and thus will be required to be studied, even if the products are not also used in a substantial number of pediatric patients. This will be particularly true during the first few years after implementation of this rule when few drugs and biologics will yet be adequately labeled for use in pediatric patients, and a larger proportion of new entrants into the marketplace will be considered to be medically necessary therapeutic options.

In response to the comments arguing that FDA’s proposed numerical cut-off is too low and will result in too many pediatric studies, FDA expects to defer until after approval many of the studies of products that will be used in a substantial number of pediatric patients but that do not offer a meaningful therapeutic benefit. As described previously in response to comments on the deferral provisions, studies of new drugs and biologics that do not offer a meaningful therapeutic benefit and are adequately labeled for use in pediatric patients are likely to be deferred until well after approval of the product for adults.

A few comments addressed the provisions that would permit waiver if pediatric trials were impossible or impractical. One comment argued that the provision authorizing waiver if the proposed population was “too small or too widely dispersed” was too broad. This comment urged that tests should be waived only if “significant efforts to recruit patients fail.” The comment also argued that the unsupported suggestion that tests are “impractical” should not be accepted, and that evidence of due diligence should be required. Another comment argued that waivers should never be granted because the population is too small or dispersed. In response to this comment, many safety and pharmacokinetic studies are already required to support pediatric labeling, the size of the population or geographic dispersion would only rarely be a sufficient basis to consider trials impossible or highly impractical. Because of the speed and efficiency of modern communications tools, geographic dispersion will justify a waiver only in extraordinary circumstances and will generally have to be coupled with very small population size. FDA is not persuaded that inability to recruit patients because of parental fears associated with administration of the drug is an adequate basis to conclude that studies are impractical where there is also evidence that similar products are regularly prescribed to pediatric patients outside of clinical trials.

Several comments responded to the request for comment on whether cost should justify a waiver. Comments from the pediatric community argued that cost to the manufacturer should never or rarely justify a waiver. Two of these comments stated that the cost of failure to study is always higher than the cost of research. Another comment stated that cost may be a factor, but FDA must be careful not to allow studies to be waived automatically because they “cost too much.” Two comments from a pharmaceutical company and a pharmaceutical trade association argued that FDA should not have responsibility for assessing the costs of a study.

In light of the comments, FDA has concluded that it does not have an appropriate basis to evaluate and weigh cost in granting or declining to grant a waiver. Therefore, cost will not ordinarily be a factor in determining whether a waiver should be granted.

HIV/AIDS drugs should be a benchmark of when a waiver should not be granted: Any group as big or bigger than the pediatric AIDS population should be considered big enough to study. Another comment argued that because of special difficulties encountered in recruiting pediatric patients into studies of blood products, such as parental fear of disease transmission, the inability to obtain a sufficient number of test subjects should be added to the criteria for waiver or to the definition of “highly impractical.”

FDA agrees with those comments urging that this ground for waiver be interpreted narrowly and that unsupported assertions be rejected as a basis for waiver. Although the number of patients necessary to permit a study must be decided on a case-by-case basis, FDA agrees that there are methods available to conduct adequate studies in very small populations. Moreover, where only safety or pharmacokinetic studies are required to support pediatric labeling, the size of the population or geographic dispersion would only rarely be a sufficient basis to consider trials impossible or highly impractical. Because of the speed and efficiency of modern communications tools, geographic dispersion will justify a waiver only in extraordinary circumstances and will generally have to be coupled with very small population size. FDA is not persuaded that inability to recruit patients because of parental fears associated with administration of the drug is an adequate basis to conclude that studies are impractical where there is also evidence that similar products are regularly prescribed to pediatric patients outside of clinical trials.

Several comments responded to the request for comment on whether cost should justify a waiver. Comments from the pediatric community argued that cost to the manufacturer should never or rarely justify a waiver. Two of these comments stated that the cost of failure to study is always higher than the cost of research. Another comment stated that cost may be a factor, but FDA must be careful not to allow studies to be waived automatically because they “cost too much.” Two comments from a pharmaceutical company and a pharmaceutical trade association argued that FDA should not have responsibility for assessing the costs of a study.

In light of the comments, FDA has concluded that it does not have an appropriate basis to evaluate and weigh cost in granting or declining to grant a waiver. Therefore, cost will not ordinarily be a factor in determining whether a waiver should be granted.
28. One comment claimed that the proposal lacks adequate regulatory procedures for timely processing of waiver requests and will result in a new layer of bureaucracy. As described previously in response to comments on the deferral provisions, preliminary decisions on whether to grant waivers will be provided to the sponsor at the end of phase 1 for drugs and biologics for life-threatening diseases and at the end of phase 2 for other products. FDA does not agree that processing of waiver requests will result in a new layer of bureaucracy. The decisions will be made by the division responsible for reviewing the NDA or BLA. FDA intends to ensure that the process is timely and fair. To reduce the burden on manufacturers in applying for waivers and deferrals, FDA intends to issue a guidance document providing a format for a request for waiver or deferral.

One comment asked that the rule clarify that the onus is on the manufacturer to justify waivers. Another comment argued that the proposed standard for granting a waiver (“reasonable basis”) places an inadequate burden of proof on manufacturers. According to this comment, manufacturers should be required to present “persuasive proof,” and FDA should have to find that the grounds for waiver have “in fact” been met.

FDA agrees that the burden is on the manufacturer to justify waivers, but believes that the rule already adequately imposes that burden. The rule requires both a certification from the manufacturer that the grounds for waiver have been met and an adequate justification for the waiver request. FDA believes that it would be inappropriate to require “proof” that the grounds for waiver have “in fact” been met because each ground requires a degree of speculation about the safety and effectiveness of, or the ability to test, a product, in a population in which it has not yet been tested.

30. Many comments from pediatricians, disease-specific organizations, a pharmacists’ organization, a medical society, several companies, a pharmaceutical trade association, and the AAP urged the decision to require pediatric studies be reviewed by a panel of outside pediatric experts. Some of the comments recommended that the panel include industry representatives. The comments were divided on whether the panel would review only waiver requests or would be responsible for identifying, in the first instance, those drugs that need study. Some of these comments believed that the rule should include no criteria for granting waivers and that the decision should be made on a case-by-case basis in consultation with the expert panel.

As described later in this document, FDA intends to convene a panel of pediatric experts, which will include one or more industry representatives, to assist the agency in implementing this rule. FDA will bring before that panel some issues related to waivers. FDA does not believe, however, that it is reasonable to bring every product undergoing clinical studies before the panel for a decision on whether pediatric studies are required. Because many dozens of drugs and biologics reach the end of phase 1 and phase 2 each year, and the panel could not realistically meet more than once every few months, insisting that each product be brought before the panel would introduce substantial delay into the development and review of drugs and biologics. Moreover, many waiver decisions will be straightforward and noncontroversial.

FDA does, however, agree that it would be beneficial to have the advice of pediatric experts on its administration of the waiver provisions of the rule. FDA will therefore ask the panel, at least on an annual basis for the first several years, to review the agency’s waiver decisions and provide advice on whether it believes that the criteria used in making those decisions were appropriate. FDA will use the advice it receives to modify future waiver decisions. FDA also expects to consult with individual members of the panel on difficult waiver decisions in their fields of expertise.

31. One comment suggested that FDA identify diseases that are not likely to occur in pediatric patients, such as prostate cancer, and classes of drugs not likely to be used in pediatric patients, and grant blanket waivers. Another comment listed the following product classes as having no applicability to pediatric patients: Alcohol abuse agents, Alzheimer’s agents, Amyotrophic lateral sclerosis agents, antifibrosis therapy, antiparkinsonian agents, fertility agents, gout preparations, multiple sclerosis drugs, oral hypoglycemics, osteoporosis agents, oxytocics, tremor preparations, uterine relaxants, and vasoconstrictors (including cerebral vasodilators).

FDA agrees that there are some disease and drug classes that have extremely limited applicability to pediatric patients and that waiver is appropriate for these. The decision to grant a waiver in such cases would be based on a conclusion that a disease does not have sufficient significance in the pediatric population (either because of frequency or severity) to constitute a meaningful therapeutic benefit for pediatric patients or to be used in a substantial number of pediatric patients. FDA emphasizes that this decision would not be intended to prevent or impede studies of these diseases or drug classes in the pediatric population, should a sponsor wish to conduct them.

The agency has identified the diseases following for which waivers will be likely to be granted. Some of the diseases listed in the comment are included in FDA’s list. Others, such as osteoporosis, gout, multiple sclerosis, and tremors can develop in children, and are not included in FDA’s list. Waiver decisions on products for the listed diseases are expected to be straightforward and noncontroversial. FDA may add to or revise this list in the future by issuing guidance documents. An applicant who wishes to obtain a waiver because the product is indicated for a disease on the list may refer in the waiver request to this Federal Register notice, or to any guidance document modifying this notice. FDA’s list follows:

1. Alzheimer’s disease.
2. Age-related macular degeneration.
3. Prostate cancer.
5. Non-germ cell ovarian cancer.
6. Renal cell cancer.
8. Uterine cancer.
10. Squamous cell cancers of the oropharynx.
12. Colorectal cancer.
15. Osteoarthritis.
17. Amyotrophic lateral sclerosis.
18. Arteriosclerosis.
19. Infertility.
20. Symptoms of the menopause.

F. Pediatric Use Section of Application

FDA proposed to add § 314.50(d)(7), under which applicants would be required to include in their applications a section summarizing and analyzing the data supporting pediatric use information for the indications being sought. FDA received no comments on this provision. The new pediatric use section will be required to contain only brief summaries of the studies together with a reference to the full description of each provided elsewhere in the application.
G. Planning and Tracking Pediatric Studies

1. Sections 312.23(a)(3)(v), 312.47 (b)(1)(i), (b)(1)(iv) and (b)(2), and 312.82—Early Discussion of Plans for Pediatric Studies

In the proposal, FDA identified several critical points in the drug development process, before submission of an NDA or BLA, during which the sponsor and FDA should focus on the sponsor’s plans to assess pediatric safety and effectiveness. These time points include: Any pre-IND meeting or “end-of-phase 1” meeting for a drug designated under subpart E of part 312 (21 CFR part 312), the IND submission, the IND annual report, any “end-of-phase 2” meeting, the presentation of the IND to an FDA drug advisory committee, and any pre-NDA or pre-BLA meeting. Of these, the pre-IND meeting, the “end-of-phase 1” meeting, the IND submission, the IND annual report, the “end-of-phase 2” meeting, and the pre-NDA/pre-BLA meeting are codified in part 312, FDA’s regulations governing IND’s.

In a separate rulemaking, FDA has already amended the IND annual report requirement to include discussion of pediatric patients entered in trials (63 FR 6694, February 11, 1998). In the proposal, FDA proposed to amend §§ 312.23(a)(3)(v), 312.47 (b)(1)(i) and (b)(2), and 312.82 (a) and (b) to specify that these meetings and reports should include discussion of the assessment of pediatric safety and effectiveness. To assist manufacturers in planning for studies that may be required under this proposal, FDA also proposed to inform manufacturers, at the “end-of-phase 2” meeting, of the agency’s “best judgment” at that time, of whether pediatric studies would be required for the product and when any such studies should be submitted. The proposal also stated that, in addition to the discussions of pediatric testing codified in the proposal, FDA would assist manufacturers by providing early consultations on chemistry and formulation issues raised by manufacturers under this rule.

Because, as described previously, studies of drugs and biologics for life-threatening diseases may begin as early as the end of phase 1, FDA will, at the end-of-phase 1 meeting, provide the sponsor with such a product the agency’s best judgment, at that time, whether pediatric studies will be waived or deferred. Section 312.82(b) has been revised to include this requirement. Because studies of other products may begin as early as the end of phase 2, FDA will, at the end-of-phase 2 meeting, provide the agency’s best judgment, at that time, whether waiver or deferral is appropriate. Although a formal request for deferral or waiver is not required until submission of the NDA or BLA, FDA has revised § 312.47(b)(1)(iv) to state that if a manufacturer who plans to seek a waiver or deferral should provide information related to the waiver or deferral in the advance submission required before the end-of-phase 1 or end-of-phase 2 meeting, as appropriate.

As described earlier, a pediatric study required under this rule may be eligible for exclusivity under FDAMA, if such study “meets the completeness, timeliness, and other requirements of [section 505A].” (See 21 U.S.C. 355A(i).) Among other requirements, a pediatric study must, to be eligible for exclusivity, be responsive to a written request for the study from FDA. To obtain a written request, a manufacturer may submit a proposed written request to FDA that contains the information described in a guidance document issued by FDA entitled, “Qualifying for Pediatric Exclusivity Under Section 505A of the Federal Food, Drug, and Cosmetic Act.” A manufacturer who has been told in the end-of-phase 1 or end-of-phase 2 meeting that it is FDA’s best judgment at that time that it does not intend to waive the study requirement may submit a proposed written request at any time thereafter. FDA will issue a written request for a study required under this rule promptly after an adequate proposed written request is submitted.

FDA also sought comment on the types of evidence that FDA should examine to ensure that deferred pediatric studies are carried out in a timely fashion. In response to comments, FDA has revised § 312.47 (b)(1)(iv) and (b)(2) to require submission of information about planned and ongoing pediatric studies.

32. One comment supported the proposed provisions and the need for early consultation with sponsors, stating that discussions should take place as early as possible in drug development. The comment urged that proposed § 312.47(b)(1)(iv) be revised to acknowledge the possibility that studies could already be underway.

FDA agrees with this comment and has revised § 312.47(b)(1) as suggested in the comment.

33. Several comments provided suggestions on how to assure that deferred studies are carried out expeditiously. One comment urged that the criteria to ensure deferred studies are carried out in a timely fashion be modeled on the AIDS Clinical Trials Group (ACTG) system of National Institute of Allergy and Infectious Diseases (NIAID). Another comment recommended that evidence demonstrating that the required studies were underway be submitted to FDA within 6 months of approval. This comment suggested that the evidence should include: (1) a finalized protocol, (2) evidence of sufficient entry of patients to address the objective of the protocol, and (3) a timeline for data analysis and submission to FDA.

Another comment argued that the burden should be on manufacturers to provide evidence that studies are being conducted with due diligence through submission of protocols, progress reports, and certifications by researchers. To hold manufacturers accountable, this comment suggested that proprietary information related to deferrals be made available to the public, including deferral requests, FDA action, postmarketing status reports, and the timeline for deferred studies. One comment argued that FDA’s current procedures are adequate to track the timeliness of pediatric studies. A pharmaceutical trade association argued that FDA should institute an adequate tracking system and meet periodically with the sponsor to discuss the progress of the studies, but that no new rules are needed.

FDA agrees that an adequate system for ensuring that studies, both deferred and nondeferred, are carried out in a timely manner requires the submission of plans and progress reports from the sponsor at defined intervals. As described previously, FDA will provide sponsors with a preliminary decision on whether pediatric studies will be required and their timing at the end-of-phase 1 meeting, for drugs and biologics for life-threatening diseases, and at the end-of-phase 2 meeting, for other products. FDA has revised § 312.47(b)(1)(iv) to state that sponsors should submit, in the advance submission for the end-of-Phase 2 meeting, a proposed timeline for protocol finalization, enrollment, completion, data analysis, and submission of pediatric studies, or, in the alternative, information to support a planned request for waiver or deferral. For drugs and biologics for life-threatening diseases, the submission should be made in advance of the end-of-Phase 1 meeting. FDA has also revised § 312.47(b)(2)(iii) to state that sponsors should submit, in the submission in advance of the pre-NDA or pre-BLA meeting, information on the status of needed and ongoing pediatric studies. The proposed language of § 312.47 has been slightly modified to
seek information on “needed” and ongoing studies rather than “planned” and ongoing studies. This change has been made because not every sponsor elects to have an end-of-phase 1 or end-of-phase 2 meeting. In those cases, the need for a pediatric study may be discussed for the first time at the pre-NDA or pre-BLA meeting. FDA has also revised the title of § 312.47(b)(2) from NDA or pre-BLA meeting. FDA has also need for a pediatric study may be of-phase 2 meeting. In those cases, the elects to have an end-of-phase 1 or end-been made because not every sponsor seeks information on “needed” and pediatric studies. (Additional postmarketing data in each group to allow dosing adjustments. The proposal recognized studies in neonates and young infants present special problems, and sought comment on whether it is appropriate to require the assessment of safety and effectiveness in this age group.

36. Several comments addressed the requirement that all relevant age groups be studied. Some comments opposed studies in more than one age group. One comment contended that required studies in pediatrics may place an unnecessary burden on the sponsor, and that FDA should require only one group, presumably that with the highest potential use. Another comment claimed that requiring studies in all four age groups would almost never be justified. In most cases, according to this comment, it should be possible to study a single subgroup and extrapolate. Other comments argued that studies in more than one age group could be necessary depending on the pharmacokinetics of the drug, the disease, and expected use of the drug. Most of these comments stated that the type and extent of studies in different age groups must be decided on a case-by-case basis. Several comments contended that drugs should be studied in each age group in which they are expected to be used. One comment stated that studies in toddlers are especially needed. A comment from an organization devoted to pediatric AIDS argued that all age groups should be studied unless the manufacturer provides compelling evidence that it would be impossible or virtually impossible to study that group.

FDA continues to believe that studies in more than one age group may be necessary, depending on therapeutic benefit and use in each age group, and on whether data from one age group can be extrapolated to other age groups.
37. Many comments argued that the pediatric subgroups identified in the proposal were arbitrary and that FDA should be flexible in determining which age ranges or stages of development need to be studied. A comment from a pharmaceutical trade association contended that rigid age divisions for required studies were inappropriate, and that the method by which the compound is cleared from the body must be considered in light of what is known about physical development. The AAP stated that the groups identified in the proposal provide acceptable guidelines, but should not be adhered to rigidly. One comment argued that the definition of pediatric patients should include all subgroups of growth and development from 0 to 21 years.

FDA agrees that the age ranges identified in the proposal may be inappropriate in some instances and that it will be reasonable in some cases to define subgroups for study using other methods, such as stage of development. FDA has deleted the references in the rule to specific age ranges.

38. Several comments addressed inclusion of neonates in studies. One comment maintained that because neonates are a special challenge, they should not ordinarily be included in studies under this rule. Another comment described the difficulties in conducting studies in infants and neonates and recommended that before studies in this group there be an assessment of “the expected extent of use and potential benefit in this patient population” and an evaluation of safety data in adults and older pediatric patients. One comment contended that there are not many instances in which the net benefit will outweigh the risk of exposing neonates and young infants to drugs. This and another comment also argued that it is not always possible to extrapolate from data in older pediatric patients. A pharmaceutical trade association maintained that validated end-points and ability to assess these by age should determine which age groups to include, and that it may not be possible to study certain end-points in very young pediatric patients. One comment argued that early research on neonates raises special ethical issues. Citing the 1977 FDA guideline, this comment asserted that testing in neonates should occur only when substantial evidence of benefit or superiority over accepted agents has been demonstrated in older pediatric patients.

Other comments argued that neonates should not be excluded from studies. According to one comment, study designs will be appropriate and necessary ethical issues will be addressed if neonatologists are included in the review of studies. Another comment stated that neonates represent the greatest disparity in drug disposition compared to adults, and that, on a scientific and ethical basis, they must therefore be included in drug studies. The AAP stated that premature infants, newborns, and infants are more difficult to study, but that the difficulties do not outweigh the importance of studying them. According to this comment, inadequate study of neonates has led to frequent and severe toxicity. This comment agreed that it is inappropriate to extrapolate from older pediatric patients to the youngest age group.

FDA agrees that the benefits and risks to premature infants, neonates, and infants must be carefully weighed before these pediatric patients are included in pediatric studies. Although the agency believes that studies in these groups may be frequently required or desired until adequate safety data have been collected, there will be cases in which the drug or biologic is important and expected to be used in these groups. In such cases, it will be appropriate to require studies in these groups. To exclude them from study would be to subject the most vulnerable patients to the risks of the drugs in clinical use without adequate information about safety or dosing. FDA agrees that studies in neonates and young infants raise special ethical issues, but once these issues are addressed in each case, the studies should proceed.

1. Pediatric Formulations

As described in the proposal, testing of a product in pediatric patients could require the development of a pediatric formulation. Many young children are unable to swallow pills and may require a liquid, chewable or injectable form of the product. A standardized pediatric formulation also ensures bioavailability and consistency of dosing, compared to alternatives such as mixing ground-up tablets with food, and permits meaningful testing of safety and effectiveness. FDA proposed in §§ 201.23, 314.50(g)(1) (now 314.55(a)) and 601.27(a) to require a manufacturer to produce a pediatric formulation, if one were necessary, only in those cases where a new drug or new biological product provided a meaningful therapeutic benefit over existing treatments, and where the study requirement had not been waived in the age group requiring the pediatric formulation. The proposal recognized that the difficulty and cost of producing a pediatric formulation may vary greatly depending upon such factors as solubility of the compound and taste. FDA proposed to waive the requirement for pediatric studies (see “Waivers” in section III.E of this document) in age groups requiring a pediatric formulation, if the manufacturer provided evidence that reasonable attempts to produce a pediatric formulation had failed.

FDA sought comment on whether it is appropriate to require a manufacturer to develop a pediatric formulation, on whether the cost of developing a pediatric formulation should ever justify a waiver of the pediatric study requirement, and on how to define “reasonable attempts” to develop a pediatric formulation.

39. Many comments from the pediatric community argued that it is appropriate to require manufacturers to produce pediatric formulations. Several comments from pediatricians and parents described the difficulties and uncertainties in attempting to administer adult formulations to pediatric patients, and argued that pediatric formulations are essential to assure bioavailability, accurate dosing, and patient compliance, and to avoid wasting medications. The AAP argued that FDA should require development of an appropriate formulation for each age group for which the drug will be used, taking into account the formulation, administration and ability to dose accurately.

Comments from the pharmaceutical industry described technical problems in producing pediatric formulations, including stability, taste and palatability, and claimed that FDA underestimated these difficulties. Some of these comments maintained that requiring development of pediatric formulations during the investigational phase will necessitate diversion of resources, increase the cost of the adult formulation, and create a disincentive to produce drugs with pediatric uses. One comment argued that it would be wasteful to require development of a pediatric formulation before some evidence of effectiveness has been collected and dose selection has been achieved, because before that time the drug could be abandoned because of lack of safety or effectiveness. A pharmaceutical trade association opposed a pediatric formulation requirement, arguing that the government has no right to tell manufacturers what products to market. This comment stated that only if FDA successfully demonstrated that “all attempts to develop a voluntary solution have failed” might the industry consider other options. One comment stated that
a single drug could require more than one pediatric formulation for different pediatric age groups, such as a chewable tablet, a nonalcohol containing liquid, and sprays. Counting failed attempts, this comment claimed that producing a pediatric formulation may cost millions of dollars.

FDA believes that for drugs and biologics that offer a meaningful therapeutic benefit to pediatric patients, it is essential to provide pediatric formulations that ensure bioavailability and accurate dosing. FDA disagrees that it is inappropriate for the government to require manufacturers to produce pediatric formulations. As many comments demonstrated, adult formulations of these drugs are frequently used in pediatric patients because there is no other choice. Drug manufacturers profit from these uses, but do not take responsibility for them. Where a product is commonly being used in a subpopulation for an indication not recommended by the manufacturer, it is appropriate to require the manufacturer to take steps to ensure that the use is safe and effective.

FDA agrees that producing a pediatric formulation can be difficult or, rarely, impossible and has attempted to account for this problem by permitting waiver of the pediatric study requirement where reasonable efforts have failed. FDA notes that the pharmaceutical industry did not respond to FDA’s request to help define what should constitute such “reasonable attempts.”

To permit pediatric studies that may begin, for products for life-threatening diseases, at the end of phase 1, or, for other products, at the end of phase 2, it may be necessary to begin development of a pediatric formulation before initiation of clinical trials. FDA does not agree that it is wasteful to begin development of a pediatric formulation at this stage. This rule is premised on the view that for drugs and biologics that have important use in pediatric patients, it is the responsibility of the manufacturer to ensure that use is safe and effective. Although some such products may ultimately prove to be unsafe or ineffective, work on pediatric formulations of such products is not necessarily more wasteful than work on adult formulations. FDA does not agree that manufacturers will be required to develop several pediatric formulations for different age groups. Even for a drug that was to be used in all pediatric age groups, a liquid formulation, e.g., might be usable in all age groups.

FDA has no basis to conclude that producing pediatric formulations will increase the cost of adult formulations or create incentives for producing drugs and biologics with pediatric uses. No evidence was submitted to support either of these assertions.

FDA agrees that producing pediatric formulations may be usable in all age groups. A liquid formulation, e.g., might be used in all pediatric age groups, a liquid formulation, e.g., might be used in all pediatric age groups. Even for a drug that was to be used in all pediatric age groups, a liquid formulation, e.g., might be usable in all age groups.

FDA is concerned that the availability of this approach may undermine efforts to produce standardized pediatric formulations. There are, however, one or two examples in which approved labeling carries directions for producing pediatric formulations.
extend one pediatric formulations. FDA will consider, on a case-by-case basis whether such an approach is appropriate, e.g., where it has not been possible to develop a stable commercial formulation.

J. Marketed Drug and Biological Products

FDA proposed in § 201.23 to codify its authority to require, in certain circumstances, a manufacturer of a marketed drug or biological product to conduct pediatric studies, and, if so, on the circumstances in which the studies should be carried out. FDA notes that the response to the 1994 rule and other voluntary measures have not produced a significant improvement in pediatric labeling for many marketed drugs and biologics.

43. Many comments from the pediatric community agreed that FDA should codify its authority to require pediatric studies on marketed drugs. Several comments from the pharmaceutical industry argued that the absence of labeling for marketed drugs was not a compelling reason for studies. One comment contended that the phrase “very significant illness” was ill-defined. One comment stated that it was “so open-ended and subjective as to be impossible for use as a regulatory standard.” Another comment suggested that any definition of “very significant illness” would be arbitrary and overbroad.

44. FDA received many comments on the grounds for requiring studies of marketed drugs and biologics, as described in the preamble to the 1994 rule (59 FR 64240 at 64243) and in “Legal Authority” section IV of this document. FDA has also concluded, as described previously, that the response to the 1994 rule and other voluntary measures have not produced a significant improvement in pediatric labeling for many marketed drugs and biologics. In addition, as one pharmaceutical company conceded, manufacturers are unlikely to initiate clinical research on marketed drugs whose patents have expired, or are about to expire. FDA has therefore concluded that where pediatric information is critical to patient care, it is necessary to require that pediatric studies be carried out. FDA notes that new requirements are sometimes imposed on already marketed consumer products when such requirements are necessary to protect the public health. FDA emphasizes, however, that it will require studies of marketed products only in the compelling circumstances described in the regulation.
FDA has also revised the first criterion to conform more closely to the criteria for requiring studies in not-yet-approved drugs and biologics, replacing "widely used" with "used in a substantial number of pediatric patients." FDA will use the same definition of "substantial number" for both marketed and not-yet-approved drugs and biologics. The first criterion will, however, continue to include the requirement that "the absence of adequate labeling could pose significant risks to patients." FDA believes that the pediatric study requirement may impose greater burdens on the manufacturers of marketed drugs and biologics than the manufacturers of not-yet-approved products, and that it is appropriate to require studies only in the compelling circumstances described in the regulation. In determining which marketed products "could pose significant risks to patients," FDA will consider such factors as the severity of the illness and the consequences of inadequate treatment, the number of pediatric prescriptions, and any available information on adverse events associated with use of the product.

FDA emphasizes that it intends to exercise its authority under § 201.23 only in compelling circumstances. FDA has estimated that it will require studies of approximately two marketed drugs per year.

FDA agrees that an expert panel can provide useful experience and guidance in developing a prioritized list of marketed drugs and biologics that meet the criteria for required studies. FDA intends to seek advice on developing such a list from a pediatric panel, as described in section III.M of this document ("Pediatric Committee").

FDA also notes that FDAMA requires the agency to publish a list of marketed drugs for which "additional pediatric information may produce health benefits in the pediatric population." FDA published this list within 180 days of the enactment of FDAMA, as required by that statute. Although the products on the list designated as high priority may be appropriate candidates for required studies under this rule, the list of high priority products is not necessarily exhaustive. Other products that might be subject to a requirement under this rule might not appear on the list. FDA also emphasizes that there is no implication that the agency will require studies of any particular product on the list. As noted in the Introduction to this preamble, before imposing any requirements under § 201.23, FDA intends to allow manufacturers eligible for FDAMA incentives an adequate opportunity to voluntarily conduct studies of marketed drugs in response to those incentives. If, following such an opportunity, there remain marketed drugs for which studies are needed and the compelling circumstances described in the rule are met, the agency will consider exercising its authority to require studies.

45. One comment claimed that the proposal requires studies only from manufacturers of innovator drugs (sponsors of the original application for the drug), while the major market share for many of these drugs is now held by generic manufacturers. This comment argued that a waiver should be granted if ANDA holders fail to share the costs of required studies. Another comment argued that the pediatric study requirement should apply only to the sponsor of the original application. "Where the agency requires pediatric studies on a multi-source marketed drug, each manufacturer of that drug, whether innovator or generic, will be responsible for satisfying the study requirement. To avoid duplication of research, FDA will encourage all the manufacturers to jointly fund an appropriate study. If, however, a joint study is not agreed to, each manufacturer will be responsible for submitting adequate studies."

K. Ethical Issues

In the proposal, FDA noted that because pediatric patients represent a vulnerable population, special protections are needed to protect their rights and to shield them from undue risk. To address ethical concerns in research on pediatric patients, both the AAP (Ref. 17) and the Department of Health and Human Services (DHHS), 45 CFR part 46, subpart D, have developed guidelines for the ethical conduct of clinical studies in pediatric patients. FDA advised in the proposal that sponsors should adhere to these guidelines for pediatric studies conducted under this rule. The agency also sought comment on ethical issues raised by the proposal.

46. A few comments addressed appropriate ethical guidelines for pediatric studies. Several comments said that existing ethical guidelines provide an adequate framework for pediatric studies. A comment from the AAP stated that ethical conduct should be guided by the DHHS and AAP guidelines, and that IRB approval that explicitly ensures protection of vulnerable subjects should be obtained. This comment also stated that the AAP guidelines provide a means to ensure ethical conduct of studies without impeding pediatric research. One comment said that DHHS' ethics regulations may not provide sufficient protection for pediatric patients and suggested incorporating AAP guidelines for ethical conduct of pediatric studies into FDA's human subjects protections regulations. Another comment contended that pediatric studies should strictly adhere to regulations currently in effect for studies of human subjects who are unable to give consent, and urged FDA to further define requirements for investigation in vulnerable populations.

FDA believes that adherence to the DHHS and AAP guidelines will provide sufficient protection to pediatric patients from the risks of research. FDA will, however, seek advice from a panel of pediatric experts on whether additional protections are necessary.

47. Several comments addressed the ethics of requiring pediatric studies as described in the proposal. Two comments asserted that children are overmedicated and that administering drugs to children is unacceptable and "ungodly." Comments from the pharmaceutical industry claimed that the rule as drafted would result in unethical testing of pediatric patients. One comment maintained that the regulations do not adequately protect pediatric patients from the risks of research because they impose a "general rule that a deferral of testing in pediatrics will only be granted in narrow and limited circumstances."

In contrast, comments from the pediatric community maintained that far more serious ethical concerns are raised by using untested drugs in pediatric patients than by conducting pediatric research. A comment from the AAP stated that there is no greater ethical dilemma than whether to give a drug with insufficient safety and effectiveness data to a child, or to withhold treatment and let the disease progress untreated.

Some comments suggested specific points in drug development at which pediatric testing becomes ethical. One comment argued that testing in pediatric patients before efficacy is demonstrated in adults may unnecessarily expose pediatric patients to a product's risks before its benefits are established. Another comment contended that it is unethical to begin studying drugs in pediatric patients that are not intended primarily for pediatric patients until the drug is adequately characterized in...
adult patients, including choice of appropriate adult dose and establishment of reasonable evidence of safety and efficacy with an acceptable therapeutic margin. A pharmaceutical trade association argued that it is unethical to begin trials in pediatric patients until enough adult safety and effectiveness data have been gathered to conclude that the drug “is likely to be approved for use in adults.”

FDA believes that some of the comments from the pharmaceutical industry misstate the application of the rule. As described fully previously, deferral of pediatric studies is specifically permitted in those cases where data should be collected in adults before exposing pediatric patients to the agent. There is no suggestion in either the proposed or final rule that deferral will be granted only in “narrow and limited circumstances.” FDA believes that, as drafted, the deferral provisions of the rule permit ethical pediatric testing that does not expose pediatric patients to inappropriate risks.

48. A few comments urged that placebo-controlled trials in pediatric patients be used rarely if at all. The AAP stated that placebo controls should not be used where that design would impose a substantial increase in risk to the child or would impede the ability to perform useful clinical trials. This comment urged that alternatives to placebo controls be used wherever possible and that where placebo controls are used, the study design should incorporate safeguards to avoid undue risk.

The question of appropriate control group arises only when there is a need for controlled trials to establish efficacy in the pediatric population. FDA agrees that alternatives to placebo-controlled trials should be used wherever they can provide sufficient information to establish effectiveness. FDA often accepts data from active control studies for certain therapeutic classes, such as anti-infectives and oncologic drugs. (See 21 CFR 314.126.) In some cases, new treatments can also be studied against a placebo together with a background of existing therapy, i.e., studied in “add-on” trials.

49. One comment argued that parents should not be given money or equivalent compensation for participation in drug studies. This comment suggested that any compensation could be put in the child’s IRA.

The IRB overseeing a research study, rather than FDA, is responsible for determining whether compensation offered to the subjects of the study is ethically appropriate.

L. Remedies

If a manufacturer failed, in the time allowed, to submit adequate studies to evaluate pediatric safety and effectiveness required under proposed § 201.23(c) or § 314.55 (proposed § 314.50(g)), FDA proposed to consider the product misbranded under section 502 of the act or an unapproved new drug under section 505(a) of the act (see “Legal Authority,” in section IV of this document). Although proposed § 201.23 expressly covered both drugs and biologics, FDA inadvertently omitted in that section a reference to actions against biologics that have not obtained a license under section 351 of the Public Health Service Act. Such a reference has been added in the final rule. When a product is misbranded or an unapproved new drug, sections 302, 303, and 304 of the act (21 U.S.C. 332, 333, 334) authorize injunction, prosecution or seizure. FDA may also seek an injunction or bring a prosecution under the Public Health Service Act. In the proposal, FDA advised that it would bring an enforcement action for injunctive relief for failure to submit a required assessment of pediatric safety or effectiveness. Violation of the injunction would result in a contempt proceeding or such other penalties as the court ordered, e.g., fines. As noted in the proposal, FDA does not intend to deny or withdraw approval of a product for failure to conduct pediatric studies, except possibly in rare circumstances, because removal of a product from the marketplace could deprive other patients of the benefits of a useful medical product. Such circumstances might arise where the predominant use of the product was in pediatric patients rather than adults, and there were life-threatening risks associated with use of the product in pediatric patients when used without proper dosing and safety information in the labeling.

To assist FDA in determining whether pediatric assessments are needed or are being carried out with due diligence, FDA proposed to amend § 314.81(b)(2) (21 CFR 314.81(b)(2)) (annual postmarketing reports) to require that annual reports filed by the manufacturer contain information on labeling changes that have been initiated in response to new pediatric data, analysis of clinical data that have been gathered on pediatric use, assessment of data needed to ensure appropriate labeling for the pediatric population, and information on the status of ongoing pediatric studies. FDA also proposed to require that, where possible, the annual report contain an estimate of patient exposure to the drug product, with special reference to the pediatric population.

50. Several comments agreed with the agency that withdrawal or denial of approval is inflexible and supported the use of injunctive remedies. One comment argued that if FDA provides no incentives, disincentives to avoid pediatric trials must be strong, and that withdrawal and denial of approval must therefore be used as a remedy. FDA continues to believe that refusal to approve or removal from the market is generally an unsatisfactory remedy from a public health perspective because it denies adequately studied populations access to safe and effective medicines.

51. Several comments supported the imposition of monetary fines. One comment urged that fines be imposed in the amount of a percentage of the profits to ensure that large and small companies had an equal disincentive. Several comments argued that fines should be used by FDA to fund pediatric studies carried out by government or private agencies. One comment contended that monetary penalties, such as fines or shortening of exclusivity, are the only practical remedy because industry and government are economically driven, but that injunctions are too costly. Although FDA continues to believe that court-imposed fines are an appropriate remedy for failure to submit pediatric assessments, the agency has no authority itself to impose fines for violation of this rule, to set the amount of such fines, or to take the fines and direct them to specific activities.

52. Two comments opposed treating investigative products as “misbranded” because this could limit access to the drugs or could delay availability of the products for adult use. According to one comment, FDA should consider a misbranding charge only if the sponsor failed to meet a phase 4 commitment. Another comment argued that injunction or prosecution are appropriate only as a final response, and that other, unspecified means are more efficient to elicit compliance. This comment also argued that if FDA would serve only to deprive patients of safe and effective drugs.

The comments arguing that a misbranding charge could limit access or delay approval provided no basis for concluding that these results would occur, and FDA is aware of none. FDA agrees that injunction and prosecution are appropriate remedies only if the sponsor has been given an adequate opportunity to meet its obligations under the rule. FDA emphasizes, however, that providing adequate...
pediatric labeling cannot be long-delayed without putting the health of pediatric patients at risk and that the agency will not accept unwarranted delays in submitting required studies. FDA also notes that it does not intend ordinarily to use seizure as a remedy for failure to conduct required studies. 53. Some comments offered additional or alternative remedies for failure to conduct required studies. One comment urged that failure to provide information to support pediatric labeling result in highly visible warnings on prescription and OTC labels that the drug has not been approved by FDA for pediatric use. Two comments argued that the label should disclose the status of pediatric studies, whether waivers or deferrals had been requested or granted, and the timetable for full compliance. Another comment contended that incentives are more effective than penalties, and that FDA discussions with sponsors during drug development would achieve the results sought in the proposal. FDA agrees that publicity can sometimes be a useful tool for encouraging compliance. FDA does not believe, however, that it is feasible to include in labeling detailed information about the status of pediatric trials, because that information could change frequently. As described in section III.M of this document, FDA will, in appropriate cases, bring issues related to the progress of pediatric studies before a panel of pediatric experts, and may utilize other forms of publicity to provide the public with information about the status of required pediatric studies. FDA notes, e.g., that FDAMA contains provisions concerning disclosure of information on the status of pediatric studies. FDA may also consider the use of prominent warnings about the absence of data on pediatric use, if necessary in particular cases.

M. Pediatric Committee

A large number of comments recommended that FDA form a panel of pediatric experts to provide advice on a range of topics related to implementation of this rule. Two comments recommended that an expert panel give advice on all facets of the rule. Several comments suggested more specific roles for the panel. For example, the AAP recommended that the panel provide advice on waiver requests, which marketed drugs require study, whether a drug is "widely used," whether to accept a manufacturer's failure to develop a pediatric formulation, relevant age groups for study, the appropriateness of deferral, and appropriate timetables for completion of deferred studies. A disease-specific organization urged that a pediatric committee assist in establishing "pediatric guidelines and practice," including a list of drugs for which studies would be required, protocol design, formulations, and age ranges. Two industry comments recommended that the panel review which drugs require testing and labeling, at what phase of drug development pediatric patients should be exposed, when waivers should be granted, what methods should be used to evaluate safety and effectiveness, the economic burdens on industry, and liability issues. Several comments, including comments from a pharmaceutical trade association, a disease-specific organization, a medical society, and pediatricians, recommended that the panel give advice on which drugs should be studied in pediatric patients. One comment suggested that FDA appoint a pediatric pharmacology expert to each of the existing drug advisory committees, except possibly the Fertility and Maternal Health Advisory Committee.

FDA has concluded that a panel of pediatric experts could provide useful advice and experience on several aspects of the implementation of the rule. FDA will therefore convene a panel of pediatric experts, including at least one industry representative, and seek its advice on a range of issues. Such a panel may be composed of pediatric experts appointed to each of FDA's existing drug advisory committees. As described in section III.E of this document under "Waivers," FDA does not believe it would be practical to ask such a committee to review every waiver or deferral request. However, the agency will ask the panel to provide annual oversight of the agency's implementation of the final rule, including the agency's record of granting or refusing waivers and deferrals. FDA will also seek the advice of the panel in identifying specific marketed drugs and biological products that should be studied in pediatric patients, and the age groups in which they should be studied. FDA will also ask for advice on assessing when additional therapeutic options are needed in treating specific diseases and conditions occurring in pediatric patients. As described previously, FDA will seek the panel's advice on ethical issues raised by clinical trials in pediatric patients, and whether additional rules should be implemented in this area. Where a manufacturer is not carrying out required studies according to the agreed upon timetable, FDA may seek the advice of the panel on whether the manufacturer is acting with due diligence. In addition, FDA may bring before the panel other issues that arise in the implementation of the rule, including the design of trials and analysis of data for specific products and classes of products.

N. Other Comments

54. Several comments suggested various forms of oversight for the implementation of the rule. One comment suggested that FDA establish a plan to prospectively evaluate these regulations, including their effect on the cost of drug development and on the time to new drug approval, and the number and success of pediatric studies actually performed. Another comment urged FDA to appoint a "Children's Studies Ombudsman." One comment asked that the rule include an appeals mechanism to resolve disputes between sponsors and agency reviewers.

As described previously, FDA intends to convene a panel of pediatric experts, including at least one representative of the pharmaceutical industry, to, among other things, review the agency's implementation of the rule. FDA notes that it already has procedures for resolution of disputes between sponsors and FDA reviewing divisions, 21 CFR 312.48 and 314.103, and that these procedures will be available for disputes that arise under this rule.

55. Several comments contended that the rule is inconsistent with requirements in Canada, Europe, and Japan for pediatric studies. These comments argued that the rule was at odds with harmonization efforts and urged FDA to harmonize its requirements with those of other countries. One comment recommended that the United States, the European Union (EU), and Japan adopt pediatric drug development as a topic for global discussion and harmonization.

Although FDA is not required to harmonize its labeling regulations and enforcement with those of our International Conference on Harmonization (ICH) partners, harmonization is a goal that the agency strives to achieve. FDA intends to work through the ICH process to harmonize methods for conducting pediatric studies.

56. A few comments sought additional incentives for pediatric studies. One industry comment suggested that FDA should provide: (1) Priority reviews for applications containing pediatric data or ongoing studies; (2) waiver of user fees for pediatric effectiveness supplements; and (3) application of the subpart E
regulations (21 CFR part 312, subpart E) to pediatric development of new drugs and biological products, to address the issues associated with small sample size and therapeutic need.

Since the publication of the proposal, two significant new incentives have become available for pediatric research. First, as described elsewhere in this document, FDAMA provides 6 months of exclusive marketing to certain applicants who conduct pediatric studies. Second, as a result of changes made during the reauthorization of the PDUFA, user fees are no longer required for supplements that are solely for the purpose of adding a new indication for use in pediatric populations.

IV. Legal Authority

In the proposal, FDA cited as authority for the requirements in the rule sections 502(a), 502(f), 505(d)(7) of the act, and § 201.5 (21 CFR 201.5), which require directions for use and prohibit false or misleading labeling; section 201(n) of the act, which defines as misleading labeling that fails to reveal material facts related to consequences of the customary or usual use of a drug; sections 201(p), 301(a) and (d) (21 U.S.C. 331(a) and (d)), and 505(a) of the act, which subject a drug to enforcement action if it is not recognized as safe and effective or approved for the conditions prescribed, recommended, or suggested in the labeling; section 502(j) of the act, which prohibits drugs that are dangerous to health when used in the manner suggested in their labeling; sections 505(f) and 505(k) of the act, which authorize FDA to impose conditions on the investigation of new drugs, including conditions related to the ethics of an investigation, and to require postmarketing reports; section 701(a) of the act, which authorizes FDA to issue regulations for the efficient enforcement of the act; and section 351 of the Public Health Service Act, which formerly required biological products to meet standards designed to insure their "continued safety, purity, and potency." FDA notes that section 351 was amended by FDAMA, and now requires biological products to be "safe, pure, and potent."

FDA has authority under section 302 of the act and under the Public Health Service Act to seek an injunction requiring studies of certain marketed drugs on the grounds that the absence of pediatric safety and effectiveness information in the labeling renders the product misbranded or an unapproved new drug. The act also authorizes seizures of misbranded or unapproved drugs under section 304 of the act.

Misbranding drugs and introducing unapproved new drugs into interstate commerce are prohibited acts under sections 301(a), (d), and (k) of the act. The statutory definition of "drug" is set out at section 201(g) of the act.

57. Several comments agreed that FDA has authority to require pediatric testing of drugs and biological products. One comment argued that the act already gives FDA the authority to require that all drugs be tested in pediatric patients, and that the rule, which permits waivers and deferred testing in some cases, weakens the agency's existing statutory authority. One comment contended a provision of FDAMA granting exclusivity to "any pediatric study [that is] required pursuant to regulations promulgated by the Secretary [and that meets certain other requirements]" shows that Congress agrees that FDA has authority to require pediatric studies. This comment also argued that, to the extent that FDA's position on its authority to require pediatric studies has changed, the change in position is justified because the proposal articulates a reasoned basis for the change.

FDA agrees that it has the authority to require pediatric testing of drugs and biologics. For the reasons cited in the preamble to the proposed and final rules, FDA has concluded that the requirements in the rule appropriately balance the need for adequate pediatric labeling and the limitations on resources available for pediatric testing and agency review. FDA also agrees that the reference in FDAMA, which was enacted after the proposal was issued, to pediatric studies required by FDA, demonstrate that Congress is aware of FDA's position that it has the authority to issue this rule and that the agency has such authority. Finally, FDA agrees that it has articulated a reasoned basis for its position that the agency has authority to require pediatric studies, but notes that FDA previously stated its position that it has the authority to require pediatric studies in 1994 (59 FR 64240 at 64243; 58 FR 39406 at 39409). The agency has also previously asserted its authority to require studies in pediatric patients and in other subpopulations for both not-yet-approved products and marketed products. In the preamble to the 1994 rule, FDA made the following statement:

"If FDA concludes that a particular drug is widely used, represents a safety hazard, or is therapeutically important in the pediatric populations, and the drug sponsor has not submitted any pediatric use information, then the agency may require that the sponsor develop and/or submit pediatric use information.

If FDA has made a specific request for the submission of pediatric use information because of expected or identified pediatric use, and the sponsor fails to provide such information, the agency may consider the product to be a misbranded drug under section 502 of the act, or a falsely labeled biological product. (See 21 U.S.C. 355 and 42 U.S.C. 262.)"

58. Several comments argued that FDA lacks authority to require pediatric studies of drugs. A few comments cited remarks by former Commissioner David Kessler during a 1992 speech. In that speech, David Kessler stated his opinion that FDA does not have "the authority to require manufacturers to seek approval for indications which they have not studied." Other comments argued that FDA has no authority to require the study of any indications or populations other than those proposed by the manufacturer. One comment challenged FDA's reliance on section 201(n) of the act for not-yet-approved drugs, claiming that the agency cannot know what will be the "customary or usual uses" of an unmarketed drug. A few comments argued that the agency's legal theory would authorize the agency to require studies of all off-label indications.

FDA disagrees that any of these arguments show that FDA lacks authority to issue this rule. Under FDA's longstanding policy, statements made in speeches, even by Commissioners, are informal expressions of opinion and do not constitute a formal agency position on a matter. As such they are not binding on the agency. (See, e.g., 21 CFR 10.85(k).)"
FDA may also consider the actual uses of the drug of which the manufacturer has, or should have, notice, even if those uses are not promoted by the manufacturer, 21 CFR 201.128. Section 201(n) of the act defines labeling as misleading if it fails to include material facts about the consequences of "use of the [drug] * * * under such conditions of use as are customary or usual." Sections 201(p) and 505(d) of the act authorize FDA to require evidence establishing the safety and effectiveness of uses "suggested" by the manufacturer’s labeling as well as those expressly recommended in the labeling. Thus, the agency has authority to require a manufacturer to establish the safety and effectiveness of, and adequately label its product for, use of the product in a subpopulation for which the product is not labeled if that use is common or suggested in the labeling.

As described in the proposal, there is extensive evidence that drugs and biologics indicated for diseases that affect both adults and pediatric patients are routinely used in pediatric patients despite the absence of pediatric labeling, and even in the face of disclaimers stating that safety and effectiveness have not been established in pediatric patients. FDA may therefore consider pediatric use to be "customary or usual" or "commonly used" where the drug is indicated for a disease or condition that affects both adults and children, and the drug is not contraindicated in pediatric patients.

FDA may also consider pediatric use to be "suggested" in a drug’s labeling even where such use is not expressly recommended or is even disclaimed. The medical community generally expects that drugs and biological products will behave similarly in demographic subgroups, including age and gender subgroups, even though there may be variations among the subgroups, based on, e.g., differences in pharmacokinetics. Thus, where a drug or biological product is indicated for a disease suffered equally by men, women, and children, and is not contraindicated in women or pediatric patients, the product will be widely prescribed for all three subgroups even if it were studied only in, or labeled only for, men.

FDA disagrees that it can know nothing, in advance of marketing, about whether a drug or biological product will be used in pediatric patients. The evidence cited in the proposal and contained by comments from the pediatric community is overwhelming that products indicated for diseases that affect both adults and children are and will be commonly used in pediatric patients. Indeed, pediatricians often have no choice but to use these products in pediatric patients. A drug product that provides a meaningful therapeutic benefit either because it represents a significant improvement in therapy or because it is a necessary therapeutic option can be expected to be routinely used in the treatment of pediatric patients. Under the rule, the decision that a product will provide a meaningful therapeutic benefit or will be used in a substantial number of pediatric patients is made on a case-by-case basis, depending upon such factors as the number of pediatric patients affected by the disease for which the product is indicated, the availability and adequacy of other therapeutic options to treat pediatric patients for the disease, and whether similar products, e.g., products in the same drug class, have been widely used in pediatric patients.

Finally, FDA emphasizes that this rule applies only where a product is expected to have a clinically significant use in pediatric populations for the indications already claimed by the manufacturer. The record before the agency documents widespread evidence of actual use of products in the pediatric population for indications labeled for adults. This record supports FDA’s conclusion that it has authority to require pediatric studies of drugs and biologics that have or are expected to have a clinically significant use among pediatric patients for the claimed indications. The agency has not examined evidence concerning the use of approved products for diseases or conditions not in the label, and the rule does not apply in those situations.

60. Two comments addressed the agency’s reliance on section 701(a) of the act. One comment argued that 701(a) of the act, in combination with the substantive statutory provisions cited by FDA, authorizes this rule because the agency has demonstrated that the rule is reasonably related to the purposes of the act. Another comment argued that 701(a) of the act does not authorize the agency to enforce requirements beyond those imposed by the act.

Section 701(a) of the act gives the Secretary authority to issue regulations for the efficient enforcement of the act. Consonant with the Supreme Court’s determination that the language of the act should not be read restrictively, but in a manner consistent with the act’s purpose of protecting the public health, a regulation issued under section 701(a) of the act will be sustained so long as it is reasonably related to the purposes of the act. United States v. Nova Scotia Food Products Corp., 568 F.2d 240, 246 (2nd Cir. 1977).

V. Implementation Plan

FDA proposed that the rule would become effective 90 days after the date of its publication in the Federal Register. For new drug and biologic product applications submitted before the effective date of the final rule, the agency proposed a compliance date of 21 months after the effective date of the final rule (for a total of 2 years after issuance of the final rule). For new drug and biologic product applications submitted on or after the effective date of the final rule, the agency proposed a compliance date of 15 months after the effective date of the final rule (for a total of 18 months after issuance of the final rule). FDA has revised the final rule to become effective 120 days after publication in the Federal Register, to allow additional time for comment on the revised information collection requirements. FDA has also revised the compliance dates. All applications will have a compliance date of 20 months after the effective date of the rule (for a total of 2 years after publication of the final rule).

60. Two industry comments argued that the proposed effective dates were too short. One of these suggested that 15 and 21 months were too short to develop a pediatric program and formulation, conduct trials, analyze data, and submit an application. Two comments asked that FDA clarify what “compliance” means. According to one of these comments, 15 months would be adequate for initiation of discussions with a sponsor about plans, but inadequate for completion of studies. This comment also argued that it is not in children’s interest to rush through pediatric studies to meet an arbitrary deadline. Another comment offered the example of Ritonavir, a drug to treat HIV infection, for which pediatric studies reportedly took 21 months even after development of a pediatric formulation. According to the comment, it took 15 months to agree on a protocol, 3 months to recruit patients, and 3 months to the first interim analysis of data. One disease-specific organization argued that the effective dates were too long. This comment proposed 12 months from the effective date of final rule, which could be extended by 6 months if genuine difficulties occurred. The comment also urged that compliance with the early discussion requirements be immediate. One comment argued that pending applications should be granted a full
waiver and treated as marketed products.

“Compliance,” as referred to in the proposal, means the submission of an assessment of pediatric safety and effectiveness under §314.55(a) (proposed §314.50(g)(1) or 601.27(a)), unless a waiver or deferral for all relevant age groups has been granted. FDA has reconsidered the compliance dates and has concluded that applications submitted on or after the effective date of the final rule should be given 20 months from the effective date of the final rule to achieve compliance. Although FDA does not believe that development of, and agreement on, a protocol should take 15 months, protocol development, enrollment, and data analysis may together take up to 2 years. There is no reasonable basis on which to distinguish between an application submitted 1 day before the effective date of the final rule, and one submitted a day later.

All other provisions of the rule will become effective on the effective date of the rule. One hundred twenty days from the date of publication in the Federal Register is sufficient time to meet these new requirements.

VI. Paperwork Reduction Act of 1995

This final rule contains information collection requirements that are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (the PRA) (44 U.S.C. 3501–3520). The title, description, and respondent description of the information collection requirements are shown below with an estimate of the annual reporting burden. Included in the estimate is the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing each collection of information.

With respect to the following collection of information, FDA invited comment on: (1) Whether the proposed collection of information is necessary for proper performance of FDA’s functions, including whether the information will have practical utility; (2) the accuracy of FDA’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.

OMB filed a Notice of Action, not approving the proposed collection of information. OMB requested that, as part of the final rule, FDA address all comments received on the information collection requirements contained in the rule, particularly with respect to the reporting burden imposed by the rule. FDA received one comment concerning the proposed burden estimates of this rulemaking under the PRA. The comment contended that FDA underestimated the time required to comply with the annual reporting requirements of the proposed rulemaking.

The agency received several comments that questioned the accuracy of FDA’s estimate of the burden of the proposed collection of information as being too low and requested changes. For example, one comment requested changes in the burden estimate for manufacturers requesting deferrals of submission of pediatric data as well as the estimate that manufacturers submit pediatric information in their annual report. In addition, the estimate for manufacturers to submit in their annual reports the analysis of available safety and efficacy data conducted or obtained in the pediatric population as well as proposed labeling was questioned. Based on these comments, the agency increased the proposed burden estimates. These issues are discussed in more detail in the preamble to the final rule.

Concerning §314.50(d)(7), the comment stated that in order to comply with this requirement, “one company” estimated that, for one pediatric reporting project, medical staff had spent at least 118 hours, rather than the 8 hours that FDA had estimated, reviewing the medical literature and summarizing the findings. FDA does not believe that this comparison is fully appropriate because §314.50(d)(7) does not require an applicant to review the medical literature, or other studies, de novo. It simply requires an applicant to provide a brief summary of data that have already been fully reported and analyzed elsewhere in the same application. However, because the data to be summarized may be more extensive than originally estimated, FDA has, in response to the comment, increased its estimate of the reporting burden for this requirement from 8 hours to 50 hours.

Concerning §314.55(a), the comment contended that FDA’s estimate of 10 companies submitting NDA’s annually for NME’s is too low. The comment implied that, based on data for 1996, 50 companies would be a more realistic estimate. The comment also contended that FDA’s estimate of 16 hours for a manufacturer to prepare the report of the data supporting the safety and effectiveness of the drug for the indication for the pediatric population is too low. In response to this comment, FDA has revised its burden estimate from 16 to 48 hours. FDA has also made a corresponding change in the estimate for §601.27(a). FDA has revised the estimate of the number of companies affected from 10 to 51 to reflect the broader scope of the rule.

Concerning §314.55(b), the comment stated that FDA’s estimate of 9 manufacturers requesting deferrals of the submission of pediatric study data and the estimate that this would take 8 hours to complete are too low. In response to this comment, FDA has revised its burden estimate from 8 hours to 24 hours. FDA has also made a corresponding change in the estimate for §601.27(b). FDA has revised the estimate of the number of companies affected from 8 to 51 to respond to the comment and to reflect the broader scope of the rule.

Concerning §314.81(b)(2)(i), the comment contended that FDA’s estimate of 1.5 hours for manufacturers to submit pediatric information in their annual reports is too low. In response to this comment, FDA has revised its burden estimate from 1.5 hours to 8 hours and has made a corresponding change in its estimate for §601.27(c).

Concerning §314.81(b)(2)(vi)(c), the comment contended that FDA’s estimate of 1.5 hours for manufacturers to submit in their annual reports the analysis of available safety and efficacy data conducted or obtained in the pediatric population as well as proposed labeling changes is too low. The comment stated that even an estimate of 15 hours would be too low. Although the comment did not provide an estimate of the hours required to satisfy §314.81(b)(2)(i) and (b)(2)(vi)(c), FDA has increased its estimates to 8 and 24 hours, respectively.

Based upon these comments, FDA has decided to increase the agency’s proposed burden estimates. These revisions are reflected in the Table 2 of this document. In addition, the burden estimates for §§314.55(a), (b), and (c), and 601.27(a), (b), and (c), have increased because of the new requirements in the final rule to include, in addition to applications for new chemical entities and never-before-approved biological applications for new active ingredients, new indications, new dosage forms, new dosing regimens, and new routes of administration. These estimates are based upon FDA’s analysis of all marketing applications and efficacy
Title: Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drugs and Biological Products in Pediatric Patients

Description: This final rule includes the following reporting requirements:
1. Reports on planned pediatric studies in IND's (§ 312.23(a)(10)(iii));
2. Reports for end-of-phase 1 and end-of-phase 2 meetings under § 312.47(b)(1)(iv) and reports for pre-NDA meetings under § 312.47(b)(2).
3. Summaries of data on pediatric safety and effectiveness in NDA's (§ 314.50(j)(7));
4. Reports assessing the safety and effectiveness of certain drugs and biological products for pediatric use in NDA's and BLA's or in supplemental applications (§ 314.55(a) and 601.27(a));
5. Requests seeking deferral of required pediatric studies (§ 314.55(b) and 601.27(b));
6. Requests seeking waiver of required pediatric studies (§ 314.55(c) and 601.27(c));
7. Postmarketing reports of analyses of data on pediatric safety and effectiveness (§§ 314.81(b)(2)(vi)(c) and 601.37(a)(1));
8. Postmarketing reports on patient exposure to certain marketed drug products (§§ 314.81(b)(2)(i) and 601.37(a)(2));
9. Postmarketing reports on labeling changes initiated in response to new pediatric data (§§ 314.81(b)(2)(vi)(c) and 601.37(a)(3));
and
10. Postmarketing reports on the status of required postapproval studies in pediatric patients (§§ 314.81(b)(2)(vii) and 601.37).

The purpose of these reporting requirements is to address the lack of adequate pediatric labeling of drugs and biological products by requiring the submission of evidence on pediatric safety and effectiveness for products with clinically significant use in children.

Description of Respondents: Sponsors and manufacturers of drugs and biological products.

### TABLE 2—ESTIMATED ANNUAL REPORTING BURDEN

<table>
<thead>
<tr>
<th>21 CFR section</th>
<th>No. of respondents</th>
<th>Annual frequency per response</th>
<th>Total annual responses</th>
<th>Hours per response</th>
<th>Total hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>201.23</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>312.47(b)(1)(w)</td>
<td>27</td>
<td>1.2</td>
<td>32</td>
<td>16</td>
<td>512</td>
</tr>
<tr>
<td>312.47(b)(2)</td>
<td>36</td>
<td>1.3</td>
<td>46</td>
<td>16</td>
<td>736</td>
</tr>
<tr>
<td>314.50(d)(7)</td>
<td>213</td>
<td>1</td>
<td>213</td>
<td>50</td>
<td>10,650</td>
</tr>
<tr>
<td>314.55(a)</td>
<td>51</td>
<td>1</td>
<td>51</td>
<td>48</td>
<td>2,448</td>
</tr>
<tr>
<td>314.55(b)</td>
<td>51</td>
<td>1</td>
<td>51</td>
<td>24</td>
<td>1,224</td>
</tr>
<tr>
<td>314.55(c)</td>
<td>176</td>
<td>1</td>
<td>176</td>
<td>8</td>
<td>1,408</td>
</tr>
<tr>
<td>314.81(b)(2)(i)</td>
<td>625</td>
<td>1</td>
<td>625</td>
<td>8</td>
<td>5,000</td>
</tr>
<tr>
<td>314.81(b)(2)(vi)(c)</td>
<td>625</td>
<td>1</td>
<td>625</td>
<td>24</td>
<td>15,000</td>
</tr>
<tr>
<td>314.81(b)(2)(vii)</td>
<td>625</td>
<td>1</td>
<td>625</td>
<td>1.5</td>
<td>937.5</td>
</tr>
<tr>
<td>601.27(a)</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>48</td>
<td>144</td>
</tr>
<tr>
<td>601.27(b)</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>24</td>
<td>72</td>
</tr>
<tr>
<td>601.27(c)</td>
<td>3</td>
<td>1</td>
<td>4</td>
<td>8</td>
<td>32</td>
</tr>
<tr>
<td>601.37(a)</td>
<td>69</td>
<td>1</td>
<td>69</td>
<td>8</td>
<td>552</td>
</tr>
<tr>
<td>601.37(b)</td>
<td>69</td>
<td>1</td>
<td>69</td>
<td>24</td>
<td>1,656</td>
</tr>
<tr>
<td>601.37(c)</td>
<td>69</td>
<td>1</td>
<td>69</td>
<td>1.5</td>
<td>103.5</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td><strong>40,571</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1There are no capital or operating and maintenance costs associated with this collection of information.

The information collection provisions of this final rule have been submitted to OMB for review. Prior to the effective date of this final rule, FDA will publish a notice in the Federal Register announcing OMB's decision to approve, modify, or disapprove the information collection provisions in this final rule. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

**VII. Environmental Impact**

The agency has determined under 21 CFR 25.30(h) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

**VIII. Analysis of Impacts**

A. Introduction and Summary

FDA has examined the impacts of the final rule under Executive Order 12866, the Regulatory Flexibility Act (5 U.S.C. 601–612), and the Unfunded Mandates Reform Act (Pub. L. 104–4). Executive Order 12866 directs agencies to assess all costs and benefits of available regulatory alternatives and, when regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety, and other advantages; distributive impacts; and equity). Under the Regulatory Flexibility Act, unless an agency certifies that a rule will not have a significant economic impact on a substantial number of small entities, the agency must analyze regulatory options that would minimize the impact of the rule on small entities. The Unfunded Mandates Reform Act (Pub. L. 104–4) (in section 202) requires that agencies prepare an assessment of anticipated costs and benefits before proposing any rule that may result in an expenditure by State, local, and tribal governments,
in the aggregate, or by the private sector, of $100 million or more in any one year (adjusted annually for inflation).

The agency has reviewed this final rule and has determined that the rule is consistent with the regulatory philosophy and principles identified in Executive Order 12866, and in these two statutes. This rule is an economically significant regulatory action, because of its substantial benefits. It is also a significant regulatory action as defined by the Executive Order due to the novel policy issues it raises. With respect to the Regulatory Flexibility Act, the agency certifies that the rule will not have a significant economic impact on a substantial number of small entities. Since the rule does not impose any mandates on State, local, or tribal governments, or the private sector that will result in an expenditure of $100 million or more in any one year, FDA is not required to perform a cost-benefit analysis according to the Unfunded Mandates Reform Act.

FDA is requiring that a limited class of important new drugs and biologicals that are likely to be used in pediatric patients contain sufficient data and information to support directions for this use. As the approved labeling for many of these new products lacks adequate pediatric information, their use in children greatly increases the risk of inappropriate dosing, unexpected adverse effects, and suboptimal therapeutic outcomes. This rule is designed to ensure that new drugs, including biological drugs, that are therapeutically important and/or likely to be used in a substantial number of children contain adequate pediatric labeling at the time of, or soon after, approval.

The agency estimated the costs to industry of the required new pediatric studies by first determining what the annual costs would have been in 1993 to 1997, had the rule become effective in 1993. The methodology included: (1) Constructing a data base of all 583 NDA’s and efficacy supplements approved by the agency over that 5-year period for drugs and biologicals likely to produce health benefits in the pediatric population, (2) determining which of those applications would have been required to conduct additional pediatric studies, (3) calculating how many unapproved and already marketed drugs and biologicals would have needed additional pediatric studies, and (4) estimating the size and cost of the additional studies. The analysis indicated that, on average, this regulation would have required an estimated 378 additional pediatric studies on about 82 drugs and biologicals per year. These studies would have involved a total of 10,860 pediatric patients, 7,408 in efficacy studies, and 3,452 in PK studies. In addition, an estimated 33 of the 82 drugs and biologicals needing new pediatric data each year may have needed new pediatric dosage forms. FDA judges that the additional studies would have cost about $45 million and the new dosage formulations about $33 million annually, for a total annual cost of almost $80 million. The agency found, however, that roughly 42 percent of the costs of the studies would have been spent voluntarily had the extended pediatric exclusivity provisions of the recent FDAMA statute been in place. Adjusting for this effect lowers the agency’s final cost estimate for this rule to about $46.7 million per year.

FDA could not develop a quantifiable estimate of the benefits of this regulation, although numerous anecdotal examples illustrate the current health problem. To consider some of the potential benefits, the agency examined hospitalization rates for five serious illness (asthma, HIV/AIDS, cancer, pneumonia, and kidney infections) and found significantly higher rates for children than for middle-aged adults. Although FDA cannot estimate the extent to which these differences reflect the relative lack of pharmaceutical safety and efficacy information for pediatric compared to adult use, the agency calculated that a 25 percent reduction in these differentials would lead to direct medical cost savings of $228 million per year. FDA also estimates that about two-thirds of the approved applications needing pediatric studies will be addressed by the incentives established by FDAMA. If these medical cost savings were adjusted by a similar ratio, the analysis suggests that a 25 percent reduction in the pediatric/adult hospitalization rate differentials would yield annual savings of $76 million for these five illnesses.

B. Number of Affected Products and Required Studies

In the preamble to its proposal, FDA explained that neither the precise number of drugs that would require additional pediatric studies nor the cost of these studies could be predicted with certainty. To develop plausible estimates of the number of new drugs and biologicals that would be affected, the agency had examined the pediatric labeling status at time of approval for each NMEA, as important biological approved from 1991 to 1995, and used these estimates to project the number of drugs that would have required additional pediatric data had the proposal been in place over that period.

Several industry comments declared that FDA’s analysis of the proposal substantially underestimated the economic impact by misunderstanding both the number and size of the studies that would be required. Only two of the comments, however, included alternative estimates. One suggested that each new drug could require the testing of 300 or more pediatric patients for safety data alone. The other comment estimated that, “each new drug studied would probably require a minimum of six clinical trials (two each in Phases I, II, and III), for one indication and one formulation.” This comment explained that Phase I trials would include 20 patients, Phase II trials 50 patients, and Phase III trials 100 patients. Assuming two trials for each phase, the comment projected that 34,000 pediatric patients would need to be studied each year (170 patients x 2 trials x 100 drugs).

FDA agrees that some applications will require data from a substantial number of pediatric patients. The agency believes, however, that most studies will not include large numbers of pediatric patients. For example, FDA does not necessarily require two pediatric studies for each trial phase. Moreover, FDA’s 1994 final rule (59 FR 64240) explains that extrapolations from adult effectiveness data based on PK studies and other safety data can be sufficient to provide the necessary pediatric dosing information for drugs and biologicals that work by similar mechanisms in adults and children. The agency expects that the majority of the studies will rely, to some extent, on such extrapolations.

On the other hand, the proposal primarily addressed drugs and biologicals that contained no previously approved active moiety. The final rule requires pediatric data for new active ingredients, new indications, new dosage forms, new dosing regimens, and new routes of administration that represent a meaningful clinical benefit over existing treatments for children, or that are likely to be widely used in children. The rule also requires pediatric studies for marketed drugs and biologicals that are already widely used among children for the claimed indications, if the absence of adequate labeling could pose significant risks; or if the drug would provide a meaningful clinical benefit over existing treatments for pediatric patients, but additional dosing or safety information is needed to permit their safe and effective use in children.

To develop a revised estimate of the number of drugs and biologicals that...
would require additional pediatric data, FDA constructed a data base of all 583 applications and efficacy supplements approved over the 5-year period from 1993 to 1997 for drugs and biologicals for which pediatric labeling would be likely to provide a significant health benefit. The selected drugs and biologicals included all those for which the active moiety was listed in the priority section in the Federal Register of May 20, 1998 (63 FR 27733), document entitled “List of Drugs For Which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population” (“List”). Mandated by FDAMA, this publication includes the agency’s priority list of drugs and biologicals that would likely provide a significant benefit to the pediatric population. The selection criteria used to prepare this priority list were almost identical to those set forth in this final rule, i.e.,

- The drug product, if approved for use in the pediatric population, would be a significant improvement compared to marketed products labeled for use in the treatment, diagnosis, or prevention of a disease in the relevant pediatric population (i.e., a pediatric priority drug); or,
- The drug is widely used in the pediatric population, as measured by at least 50,000 prescription mentions per year; or,
- The drug is in a class or for an indication for which additional therapeutic options for the pediatric population are needed.

FDA then identified each of the 583 applications that would likely have needed additional pediatric studies had this rule been in effect. The number and type of studies needed were projected based on specific decision rules derived from agency experience in reviewing drug applications and developed strictly for the purpose of estimating the regulatory costs of this rule. Although in practice, these rules would have been subject to numerous exceptions, in the aggregate, FDA believes that they provide plausible estimates of the total number and type of pediatric studies that would have been required. The decision rules were as follows:

1. All New Chemical Entities (NCE’s) and biologicals were assumed to need both an efficacy study and a PK study for each age group identified in the priority section of the “List” as needing pediatric information, although FDA believes that this assumption overstates the true number of efficacy studies that will be needed.
2. For the following categories of applications, both an efficacy and a PK study were assumed for each designated age group. A gain, FDA believes that this assumption may overstate the true number of efficacy studies that will be needed: Neurological drugs; Oncology drugs; Nausea agents; Pulmonary agents; NSAIDs—arthritis/pain; AIDS/HIV agents; Asthma drugs; Anesthesia drugs; Hormones; Dermatological agents; Acne agents
3. A PK study alone was assumed sufficient for each relevant age group for the following types of non-NCE applications: Allergies; Infectious diseases; Cardiovascular diseases; Imaging agents; Hematology agents; GI disorders; Urologic drugs
4. If pediatric labeling was already adequate as the result of an approved application, additional applications for new dosage forms were assumed to be exempt.
5. If a second applicant sought approval for the same indication of the same drug as a previous applicant that had already satisfied the pediatric labeling requirements, the second applicant was considered exempt from the pediatric labeling requirement.
6. Because the regulation imposes requirements only on new NDA’s or efficacy supplements that specifically address an indication needing pediatric data, no pediatric requirements were assumed for an NDA supplement submitted for a new indication not identified as needing pediatric data.
7. Orphan drugs were excluded from additional research requirements.

The results of this analysis (see Table 3 of this document) show that about 44 percent, or an estimated 255, of the total 583 drug and biological applications for the products on the priority section of the “List” drugs approved over the 5-year period would have required additional pediatric studies, had the rule been in effect starting in 1993. Assuming separate studies for each pediatric age group specified in the “List,” indicates that an estimated 459 efficacy studies and 713 PK studies would have been required for these applications.

These estimates understate the required research effort, however, because they omit pediatric studies for drugs that fail to gain approval. It is difficult to judge how much additional pediatric research would be directed towards nonapprovable products. The agency notes, however, that because only about 63.5 percent of all NME’s that enter phase III trials are eventually approved (Ref. 18), the number of drugs entering phase III trials is about 58 percent greater than the number of actual approvals (100/63.5 = 1.58). Moreover, there are two additional complications. First, under the rule, FDA expects to defer for several years the conduct of pediatric studies of “me-too” drugs that do not offer a meaningful therapeutic benefit and that are members of a drug class that already contains an adequate number of approved products with pediatric labeling. No additional pediatric studies would be expected for this group of new approved drugs. On the other hand, applications for “lifesaving” drugs may need to begin pediatric trials by the start of Phase II. On the assumption that these two factors would roughly offset, FDA has retained the 58 percent figure as a reasonable adjustment factor to account for the number of studies conducted for drugs that fail to gain approval. Finally, each year, the agency expects to identify about two “already marketed” drugs that require additional pediatric efficacy data.

As shown in Table 4 of this document, adjusting for the “never approved” and the “already marketed” applications implies that, had this rule become effective in 1993, about 1,892 new pediatric studies would have been required over the 1993 to 1997 period. About 740 of the studies would have been efficacy studies and 1,151 PK studies. Thus, on average, each year, the rule would have required about 378 new pediatric studies for about 82 NDA’s and or NDA supplements—148 efficacy studies and 230 PK studies.
C. Number of Pediatric Patients

The number of pediatric patients needed varies with the particular type of drug studied. However, based on agency experience, FDA estimates that, for each pediatric age group studied, typical pediatric PK studies may involve about 15 patients and typical efficacy studies about 50 patients. For example, if 2 of the 4 age groups lack PK studies, FDA assumed that a total of 30 subjects would be needed for the studies. If 3 of the 4 age groups lack efficacy studies, a total of 150 subjects were assumed to be needed in all 3 age groups. These assumptions indicate that, had this rule become effective in 1993, each year, about 82 NDA’s would have required additional pediatric studies; 7,408 pediatric patients in efficacy studies and 3,452 pediatric patients in PK studies, for an annual total of about 10,860 pediatric patients.

D. Costs of Compliance

1. Cost of Pediatric Studies

FDA’s analysis of the proposal assumed that new studies would cost pharmaceutical firms from $5,000 to $9,000 per pediatric patient. Only one comment, that of a large U.S. pharmaceutical company, submitted actual estimates of the cost of conducting pediatric trials. This comment stated that a PK or bioavailability/bioequivalency study of 20 patients would cost at least $100,000, a Phase II trial of 50 patients would cost a minimum of $150,000, and a Phase III trial of 100 patients would cost $200,000. For its revised analysis, therefore, FDA assumes that a PK study of 15 patients will cost $100,000 per affected age group and that an efficacy study of 50 patients will cost $150,000 per affected age group. Although a few trials may need to be larger and, thus more expensive; others will require substantially fewer pediatric patients. Thus, FDA believes these figures reasonably project the average added costs.

As FDA estimates that the regulation would have required pharmaceutical companies to annually conduct an estimated 378 additional pediatric studies for 82 NDA’s, 148 efficacy studies, and 230 PK studies; the above unit cost estimates imply total industry costs of $45 million annually. Although the industry comment that included the cost data projected clinical trial costs totaling over $100 million per year, this estimate assumed the need for 34,000 additional pediatric patients. FDA found that had this rule been in place over the 1993 to 1997 period, it would have required additional data from about 10,860 patients per year.

2. Cost of New Formulations

In its earlier analysis of the proposal, FDA calculated that about 30 percent of all NME’s were available only in tablets or hard capsules at the time of approval. Acknowledging the potential difficulties of developing new formulations for certain drugs, FDA estimated that the overall costs could average $1 million for each new formulation developed. Several comments questioned the agency’s estimates. Based on an informal survey of its members, a major industry trade association reported that the development of a pediatric formulation could take from 5 months to 4 years and cost from $500,000 to $3.5 million. It also objected to the agency’s estimate of the number of drugs that would require reformulation. The association, however, apparently misunderstood FDA’s methodology. The agency had found that 10 of 14 drugs per year would not need reformulation because a potentially adequate dosage form (liquid, an injectable, a solution, a dermatological, etc.) was already available. The association believed that FDA has assumed that only tablets and/or capsules were available for the ten drugs. None of these comments,
however, offered an alternative methodology for projecting the aggregate value of these costs.  

To develop reasonable estimates of the number of new dosage forms that would be needed, FDA again reviewed all of the 255 approved drug applications that would likely have required new pediatric studies during the 1993 to 1997 period, had this rule been in place. The agency generally assumed that those drugs identified as having a meaningful clinical pediatric benefit for the youngest three age groups, but available only in tablets or hard capsules at the time of approval, would have needed to develop an alternative dosage form. The agency also assumed that a new pediatric formulation would not be counted if a more appropriate pediatric dosage form was subsequently approved for the same drug. FDA is aware that these estimates can not be considered precise. For example, not all liquids are adequate for pediatric populations. On the other hand, new formulations may not be needed if a drug is used primarily for children between the ages of 8 and 12 years. Nevertheless, as shown in Table 3 of this document, the results of this methodology show that about 35 percent of the approved applications needing studies, or about 18 per year, would have needed new dosage forms. Table 4 of this document raises this estimate by 83 percent, or to 33 per year, to account for the number of new dosage forms developed for drugs not subsequently approved. While FDA cannot confidently predict a typical initiation time for this effort, the 83 percent adjustment calculation assumes that work on about 25 percent of all new formulations would be initiated at the start of Phase 2 trials and 75 percent by the start of Phase 3 trials. (The probability of approval was assumed to be .635 for a drug entering phase 3 trials and .31 for a drug entering phase 2 trials (Ref. 18).)

The development of some pediatric formulations will be difficult, the development of others relatively straightforward and achieved without substantial problem. The rule requires only that sponsors take all reasonable steps to develop needed new formulations. Thus, while acknowledging that the cost for particularly difficult formulations may be higher, FDA has retained its average cost estimate of $1 million to develop each new dosage form and projects this total industry cost at nearly $33 million per year.

3. Cost of Added Paperwork Requirements

The rule also requires additional industry effort for new or expanded paperwork reporting. Section VI of this document describes these reporting tasks, discusses the industry comment that questioned the agency's estimate of the paperwork burden for the proposal, and presents the agencies revised estimate for this final rule. As shown in that section, FDA projects an annual burden of about 40,000 hours per year. On the assumption that 25 percent of these hours will be for upper management staff, 50 percent for middle management staff, and 25 percent for administrative and clerical support, at respective labor costs of $52, $34, and $17 per hour, FDA estimates these total paperwork costs at about $1.4 million per year.

4. Total Costs

Table 5 of this document summarizes the agency's estimates of costs for efficacy studies, PK studies, new dosage forms, and paperwork. Because the expense of pediatric trials and dosage form development will be spread over 2 or 3 years for any given drug, the total costs to industry in any given year are unlikely to vary as much as shown in Table 5. Most importantly, however, the average $80.1 million annual cost figure reflects only what the rule would have cost had the rule been in effect from 1993 to 1997. The incentives generated by the additional 6-month marketing exclusivity offered by FDAMA will reduce the future costs of the regulation.

### Table 5.—Estimated Industry Costs—Compliance With Pediatric Labeling

<table>
<thead>
<tr>
<th>Year</th>
<th>Efficacy studies</th>
<th>PK studies</th>
<th>New dosage form developed</th>
<th>Paperwork</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1993</td>
<td>$15.3</td>
<td>19.7</td>
<td>22.3</td>
<td>1.4</td>
<td>58.6</td>
</tr>
<tr>
<td>1994</td>
<td>17.9</td>
<td>19.0</td>
<td>31.6</td>
<td>1.4</td>
<td>69.9</td>
</tr>
<tr>
<td>1995</td>
<td>16.7</td>
<td>17.3</td>
<td>24.1</td>
<td>1.4</td>
<td>59.5</td>
</tr>
<tr>
<td>1996</td>
<td>35.6</td>
<td>34.4</td>
<td>53.9</td>
<td>1.4</td>
<td>125.2</td>
</tr>
<tr>
<td>1997</td>
<td>25.7</td>
<td>24.7</td>
<td>35.3</td>
<td>1.4</td>
<td>87.0</td>
</tr>
<tr>
<td>Average Per Year</td>
<td>$22.2</td>
<td>$23.0</td>
<td>$33.4</td>
<td>$1.4</td>
<td>$80.0</td>
</tr>
</tbody>
</table>

Where the estimated exclusivity gain exceeded the cost of all required studies, including the development of new dosage forms, FDA concluded that the studies for that drug would have been initiated voluntarily and their cost attributable to FDAMA rather than to this regulation.

The methodology assumed that a 6-month gain of marketing exclusivity would be worth about 25 percent of a drug's annual sales revenue during the year the exclusivity is needed, less 60 percent for production, administrative, and marketing costs (Ref. 19). Costs of conducting the required studies for each of the 85 drugs were based on the cost estimates described previously ($150,000 for each efficacy study, $100,000 for each PK study, and $1 million for each new dosage form. The present value of the additional revenues (at a 7 percent discount rate) were calculated from 1997 sales data published by IMS America (Ref. 20). Because 1997 sales revenues probably underestimated the sales revenues that will be realized at the time that the added exclusivity is used, this methodology likely underestimates the effects of FDAMA, hence overestimating the costs of the rule. In general,
however, this analysis was insensitive to the precise assumptions used. For example, using an 11 percent rather than 7 percent discount rate raises the cost totals by only $1.2 million per year. The agency had determined that the necessary studies would have been conducted voluntarily for 56 out of the 85 affected applications (66 percent). Adjusting estimates of only the approved applications by this percentage (FDAMA was not assumed to affect studies for applications not obtaining approval), FDA projects that the annual costs attributable to this rule will be approximately $46.7 million, or about 42 percent below the non-FDAMA adjusted figure of $80 million.

Further, although the agency has not yet evaluated the full economic impact of the FDAMA legislation, it believes that the present value of the net revenues expected from the 6 months of added exclusivity granted under the new FDAMA legislation will greatly exceed the additional costs imposed by this rule. One industry publication (MedAdNews, June 1998, p. 10) for example, reports that products currently valued at $41 billion in annual sales will come off patent between 1998 and 2008, or an average of $11 billion per year. Alternatively, FDA estimates that the annual revenues for NCE's coming off patent may average between $200 and $300 million each. If 25 NCE's lose exclusivity each year, these annual revenues would range from $5 billion to $7.5 billion. If only 60 percent of these NCE's become eligible for extended exclusivity, the methodology described above implies that industry net incomes will increase from $300 to $450 million per year. Thus, FDA and this rule, taken together, will provide critical pediatric information without diverting current resources from pharmaceutical innovation.

*COM041**COM041*E. Benefits

The rule addresses two major problems associated with the lack of adequate information on the effects of drugs on pediatric patients: (1) Adverse drug reactions in children due to inadvertent drug overdoses or other drug administration problems that could be avoided with better information on appropriate pediatric use; and (2) under use of safe and effective drugs for children due to the prescribing of an inadequate dosage or regimen, a less effective drug, or no drug at all because of uncertainty over the drug's effect on children or the unavailability of a pediatric formulation. By developing improved information on whether, and in what dosage, a drug is safe and effective for use in children, FDA believes that the regulation will result in fewer adverse drug reactions and fewer instances of less-than-optimal treatment of pediatric patients.

Despite numerous reports of children endangering themselves and the public because of inadequate drug labeling, FDA has found no systematic studies in the literature that evaluate the overall magnitude of the harm that results from the incomplete labeling of drugs for use in children. In the preamble to the proposal, the agency specifically requested, “information on any available studies or data related to the incidence and costs of either undertreatment or avoidable ADE’s in pediatric age groups due to the lack of information on the effects of pharmaceuticals.” The comments received cited case after case of children who have died or suffered because of the inadequate testing of drugs in children, but the information was largely anecdotal and related to particular instances of drug misuse or underuse.

For example, physicians who care for HIV-infected patients expressed frustration at their inability to treat children with drugs known to be effective in adults. Pulmonary specialists described the dearth of information on risks versus benefits of new antimicrobials for pediatric patients, citing the example of ciprofloxacin, a quinolone that may be valuable in treating cystic fibrosis, although the safety and effectiveness of the drug in children has not been established. Comments received from asthma specialists reaffirmed the difficulties of administering medications, treating drug side effects, or withholding treatment for children with asthma, due to the lack of research on drug safety and effectiveness.

In both written comments and in the public hearing in October 1997, concerns were raised about the costs of not implementing a requirement for pediatric labeling. A avoidable adverse outcomes, cited in relation to pediatric dosage problems, included opportunistic infections from too much immunosuppression, and loss of grafts in pediatric renal transplant patients with too little immunosuppression. Comments also cited added health care, including increased hospitalizations, required as a result of less effective treatment for pediatric patients. One comment estimated the cost of delayed access in terms of infant deaths, attributing an additional 2,000 unnecessary infant deaths over a 2-year period to the delay in access to AZT for HIV-exposed infants. Another suggested using the Vaccine Injury Compensation program figure of $250,000 per child as the value of an avoided death resulting from an ADR. Other comments confirmed that many adverse outcomes develop quickly and would be detected in early clinical studies (e.g., “gray syndrome” in babies treated with chloramphenicol).

While clearly demonstrating the critical need for improved pediatric information, these comments do not suggest a practical methodology for quantifying the aggregate benefits of this rule. FDA, also, has been unable to develop a precise assessment of the probable regulatory benefits. The agency's approach to estimating regulatory benefits therefore is framed in terms of the following two questions: (1) Are data available to assess current differences in the safety of drug therapy for adults versus children with the same condition? and (2) Are data available to assess current differences in the effectiveness of drug therapy for adults versus children with the same condition?

FDA first attempted to assess the safety of drug therapy by looking for differences in the frequency and severity of ADR’s for adult versus children treated for the same condition. The available clinical and health survey data, however, did not provide a reliable estimate of the contribution of ADR’s to pediatric as compared to adult rates of mortality and morbidity. ADR-related data are limited by the lack of a general requirement and a ready mechanism for the comprehensive reporting of incidents directly attributable to ADR’s (Ref. 21). Moreover, most available studies have not addressed ADR rates and associated death rates by age group within a treated condition (Refs. 22, 23, and 24). For example, one study of pediatric patients shows an ADR-related admission rate in the range of only 2.0 to 3.2 percent, well below the average for adult and pediatric studies combined. Pediatric cancer patients, however, experienced a 22 percent ADR-admission rate (Ref. 25), suggesting that pediatric risks may be significantly greater within condition-defined subpopulations. In addition, potential concerns about negative public attention (Ref. 26) or liability inhibit reporting of ADR’s. Finally, for many seriously ill patients, it is very difficult to attribute a specific medical outcome to a particular medication, as opposed to some other complication in the patient’s condition, or misadventure in the patient’s care. The agency found therefore that it could not rely on available ADR studies to derive an assessment of the potential benefits of this rule.
Data to assess the effectiveness of drug therapy would indicate differences in clinical outcomes, or in other health care utilization concomitant with drug therapy. If drug therapies for children were less effective than that for adults with the same condition, one might see longer recovery times, or lower recovery rates, together with increased health services use, assuming a similar prognosis and course of illness. A limitation to this approach is that the prognosis and course of illness may not be the same in children and adults with the same serious health condition, even if the same drugs were included in best-practice treatment. Moreover, differential patterns of health care utilization may reflect variations in physician practice patterns, insurance benefits, or patient and family behavior and preferences, rather than measures of drug effectiveness. Notwithstanding such limitations, comparisons of health care resource use for one therapeutic approach compared to another are commonly used in evaluations of therapy effectiveness in the field of pharmacoeconomics. In this instance, FDA finds that health care utilization data may provide at least an indirect indication of potential benefits. Hospitalization rates, in particular, are the most extensively studied measure of morbidity related to adverse drug reactions and of quality of care for a number of chronic (e.g., asthma) and acute conditions (e.g., pneumonia) (Refs. 27 and 28). While hospitalizations due to adverse drug reactions or drug therapy undertreatment are not always recognized, these admissions are routinely classified with a primary diagnosis of the underlying disease. FDA therefore has relied on diagnosis-related hospitalization rates to develop an order-of-magnitude assessment of the potential benefits of this rule.

For this assessment, the agency compared rates of hospitalization of pediatric patients to rates of hospitalization of adult patients for several important disease conditions. Next, the agency examined the potential direct and indirect cost savings that would be realized by diminishing any age-related disparities. The pediatric population was defined to be all persons under the age of 15 and the comparison group to be those adults between the ages of 15 and 44. (The exclusion of older adult patients minimizes the confounding effect of the age-related increased morbidity and mortality.) Comparisons were limited to asthma, HIV/AIDS, cancer, pneumonia, and kidney infection, as these conditions are life threatening, occur in both adults and children, and comparable data are available for adult and pediatric patients. Moreover, reports received in the FDA Spontaneous Reporting System (SRS) in 1993 indicated that the therapeutic areas for which the highest number of ADR's were reported for patients under age 15, relative to the number reported for patients 15 to 44, included those for anti-infectives, pulmonary drugs and oncology drugs. Direct costs were based on the estimated number of cases, hospitalization rates, and length of stay for each of the selected conditions. The number of cases reported were based on national health survey (Ref. 29) and public surveillance data (Refs. 30, 31, and 32). In 1994, the total number of cases for these 5 conditions, in patients under age 15, was approximately 66.5 million. The total number of cases for patients ages 15 to 44 was approximately 8.3 million. The number of hospitalizations per year for which the selected condition was the primary diagnosis was obtained from the National Hospital Discharge Survey (Ref. 33). As shown in Table 6 of this document, the pediatric hospitalization rate exceeded the adult rate for all five conditions.

**Table 6.—Hospitalization Rates per Patient per Year**

<table>
<thead>
<tr>
<th>Primary diagnosis</th>
<th>Rate under age 15</th>
<th>Rate for ages 15-44</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthma</td>
<td>.045</td>
<td>.024</td>
</tr>
<tr>
<td>HIV/AIDS</td>
<td>.533</td>
<td>.233</td>
</tr>
<tr>
<td>Cancer</td>
<td>4.247</td>
<td>3.903</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>.147</td>
<td>.129</td>
</tr>
<tr>
<td>Kidney infection</td>
<td>.191</td>
<td>.073</td>
</tr>
</tbody>
</table>

The average length of hospital stay (ALOS) for patients with the selected condition as the primary diagnosis (based on ICD-9 code) was obtained from recent hospital survey data (Ref. 34), the average cost per day of inpatient hospital care for each of the selected conditions was based on hospital charge data reported in the survey (Ref. 35), and the cost of physician services associated with each episode of hospitalization was based on physician charge data (Ref. 36). Each episode of care was assumed to include physical charges for emergency room service, daily inpatient visits, and a postdischarge office visit. For cancer hospitalizations, daily inpatient visits and a follow-up office visit were included. The calculation of indirect costs assumed 8 hours of parental time away from work for each episode of hospitalization and income and productivity losses based on average employee compensation, as reported in the 1997 U.S. Statistical Abstract. A detailed description of all assumptions, calculations, and data sources is included in the full agency report (Ref. 37).

The assumed hypothesis is that a substantial fraction of the difference between pediatric and adult hospitalization rates for like disease conditions are attributable to the greater range of drug therapies and better information on drug dosages for adults. FDA cannot estimate the precise magnitude of the relevant fraction. Nevertheless, if the differentials between pediatric and adult hospitalization rates were reduced by 25 percent, the resulting direct cost savings would be $228 million, with indirect cost savings of $5.3 million per year. If the differentials were reduced by as much as 50 percent, the direct cost savings would be $456 million per year, with indirect savings of $10.6 million. Even if the differentials were as low as 10 percent, the resulting reductions in hospitalization would lead to direct cost savings of $91.2 million, with indirect savings of $2.1 million per year.

The timing of the benefit after the rule's implementation is uncertain. The previous values represent the potential benefit over time as the safety and effectiveness of drugs are more extensively tested, new and already marketed drugs become labeled for use in children, and new formulations and dosage forms are developed to facilitate therapy for children. The figures may overestimate the impact for the selected conditions over the next few years, but may underestimate the potential benefits for these patients in the longer term if there is an increasing prevalence of asthma, cancer, and respiratory and other infectious diseases in the pediatric population. Thus, the lower reduction estimate may be more realistic in the near-term, with the higher reduction estimates offering a better indication of longer-term benefit.

As discussed previously, FDA believes that the new FDAMA statute will cause some of these pediatric studies to be conducted voluntarily. In its assessment of costs, the agency found that about two-thirds of the applications for approved drugs needing pediatric studies may be undertaken voluntarily due to the incentives established by FDAMA. Adjusting the previous medical cost savings by a similar ratio suggests that if all of the new pediatric studies achieved a 25 percent reduction in the pediatric/adult hospitalization differentials, the additional studies prompted by this rule would yield...
annual savings of $76 million for just those five diseases. This estimate may represent a lower bound on the benefits to pediatric patients, however, because a number of other disease conditions are also common to children and adults, including such life-threatening conditions as hypertensive disease and renal disease. These pediatric populations also would experience significant benefits from increased safety and access to drug treatments currently available only to adult patients. Moreover, the analysis omits any quantification of benefits for reduced pain and suffering and reduced pediatric mortality. Thus, the full benefits of the rule could easily exceed $100 million per year. Therefore, in accordance with the SBREFA, the Administrator of the Office of Information and Regulatory Affairs of the Office of Management and Budget (the Administrator) has determined that this rule is likely to result in an annual effect on the economy of $100 million or more and thus is a major rule for the purpose of congressional review.

F. Small Entities

The rule will impose a burden on relatively few small entities, because new drug development is typically an activity completed by large multinational firms. Only one industry comment questioned the agency’s determination that the rule would not have a significant effect on a substantial number of small entities. That comment indicated that about 1,500 small entities are conducting diagnostic and therapeutic R&D in the United States and that “[c]ontributions to new drug approvals by the ‘biotech’ and ‘small pharma’ sector are increasing year by year, and the pace of change will—almost certainly—continue.”

FDA agrees that small firms contribute substantially to the early development of many new drugs and biologicals. Nevertheless, because of the considerable resources needed for clinical testing and marketing, the agency finds that very few of these small firms retain ownership and control through the large-scale clinical testing and approval stages. Moreover, many of the products that are sponsored by small companies are eligible for orphan designation and therefore exempted from this rule. To approximate the number of small firms that might be significantly affected, FDA determined the sponsor company size for all of the approved applications that may have required additional pediatric studies. The analysis assumed that a firm that had this rule been in place over the years from 1993 to 1997. The agency found that, on average, based on the Small Business Administration’s definition of a small firm, only three approved applications per year were submitted by small companies. Multiplying by the previously described 1.58 factor to account for unapproved applications increases this estimate of the number of small entities that may have been significantly affected by this rule to just five small firms per year. Because the agency has certified that the rule will not impose a significant economic impact on a substantial number of small entities, the Regulatory Flexibility Act does not require the agency to prepare a Regulatory Flexibility Analysis. Moreover, the agency further points out that the required new studies will comprise a very small part of the total cost of developing new drugs or biologics, which is generally estimated in the hundreds of millions of dollars for each new drug.

G. Regulatory Alternatives

The agency carefully examined two major alternatives to the final rule. The first alternative considered was the initial proposal, which covered only NCE’s. The estimated cost of this alternative, excluding the FDAMA adjustment, would be about $40 million, or roughly 50 percent of the cost of the final rule. The agency rejected this alternative because of the predominant view of the medical community that additional pediatric data were needed for all of the drugs and biologicals that may be therapeutically significant in pediatric populations, not just for the new chemical entities. The other major alternative considered was to delay implementation of the rule until the effects of the new FDAMA statute have been reviewed. FDA fully expects the FDAMA exclusivity provisions to provide a substantial incentive to conduct large numbers of pediatric studies. Nevertheless, the agency finds that relying on these incentives, alone, would leave numerous gaps in many important areas of pediatric labeling. For example, as described earlier in this preamble, voluntary research may overlook studies for many important drugs, especially where such studies require the development of new pediatric dosage forms. Thus, notwithstanding FDAMA incentives, FDA has determined that this regulation is necessary to protect the pediatric population and that further delay is not warranted.

IX. References

The following references have been placed on display in the Dockets Management Branch (HFA - 305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, and may be seen by interested persons between 9 a.m. and 4 p.m., Monday through Friday.


20. IMS America, “1997 Retail Perspective and Provider Perspective.”


38. IMS, National Disease and Therapeutic Index, IMS America: Plymouth Meeting, PA.

List of Subjects

21 CFR Part 201

Drugs, Labeling, Reporting and recordkeeping requirements.

21 CFR Part 312

Drugs, Exports, Imports, Investigations, Labeling, Medical research, Reporting and recordkeeping requirements, Safety.

21 CFR Part 314

Administrative practice and procedure, Confidential business information, Drugs, Reporting and recordkeeping requirements.

21 CFR Part 601

Administrative practice and procedure, Biologics, Confidential business information.

Therefore, under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and under authority delegated to the Commissioner of Food and Drugs, 21 CFR parts 201, 312, 314, and 601 are amended as follows:

PART 201—LABELING

1. The authority citation for 21 CFR part 201 continues to read as follows:


2. Section 201.23 is added to subpart A to read as follows:

§ 201.23 Required pediatric studies.

(a) A manufacturer of a marketed drug product, including a biological drug product, that is used in a substantial number of pediatric patients, or that provides a meaningful therapeutic benefit over existing treatments for pediatric patients, as defined in §§ 314.55(c)(5) and 601.27(c)(5) of this chapter, but whose label does not provide adequate information to support its safe and effective use in pediatric populations for the approved indications may be required to submit an application containing data adequate to assess whether the drug product is safe and effective in pediatric populations. The application may be required to contain adequate evidence to support dosage and administration in some or all pediatric subpopulations, including neonates, infants, children, and adolescents, depending upon the known or appropriate use of the drug product in such subpopulations. The applicant may also be required to develop a pediatric formulation for a drug product that represents a meaningful therapeutic benefit over existing therapies for pediatric populations for whom a pediatric formulation is necessary, unless the manufacturer demonstrates that reasonable attempts to produce a pediatric formulation have failed.

(b) The Food and Drug Administration (FDA) may by order, in the form of a letter, after notifying the manufacturer of its intent to require an assessment of pediatric safety and effectiveness of a pediatric formulation, and after offering an opportunity for a written response and a meeting, which may include an advisory committee meeting, require a manufacturer to submit an application containing the information or request for approval of a pediatric formulation described in paragraph (a) of this section within a time specified in the order, if FDA finds that:

(1) The drug product is used in a substantial number of pediatric patients for the labeled indications and the absence of adequate labeling could pose significant risks to pediatric patients; or

(2) There is reason to believe that the drug product would represent a meaningful therapeutic benefit over
existing treatments for pediatric patients for one or more of the claimed indications, and the absence of adequate labeling could pose significant risks to pediatric patients.

(c)(1) An applicant may request a full waiver of the requirements of paragraph (a) of this section if the applicant certifies that:

(i) Necessary studies are impossible or highly impractical because, e.g., the number of such patients is so small or geographically dispersed, or

(ii) There is evidence strongly suggesting that the product would be ineffective or unsafe in all pediatric age groups.

(2) An applicant may request a partial waiver of the requirements of paragraph (a) of this section with respect to a specified pediatric age group, if the applicant certifies that:

(i) The product:

(A) Does not represent a meaningful therapeutic benefit over existing therapies for pediatric patients in that age group, and

(B) Is not likely to be used in a substantial number of patients in that age group, and

(C) The absence of adequate labeling could not pose significant risks to pediatric patients; or

(ii) Necessary studies are impossible or highly impractical because, e.g., the number of patients in that age group is so small or geographically dispersed, or

(iii) There is evidence strongly suggesting that the product would be ineffective or unsafe in that age group, or

(iv) The applicant can demonstrate that reasonable attempts to produce a pediatric formulation necessary for that age group have failed.

(3) FDA shall grant a full or partial waiver, as appropriate, if the agency finds that there is a reasonable basis on which to conclude that one or more of the grounds for waiver specified in paragraphs (c)(2) or (c)(3) of this section have been met. If a waiver is granted on the ground that it is not possible to develop a pediatric formulation, the waiver will cover only those pediatric age groups requiring that formulation. If a waiver is granted because there is evidence that the product would be ineffective or unsafe in pediatric populations, this information will be included in the product’s labeling.

(d) If a manufacturer fails to submit a supplemental application containing the information or request for approval of a pediatric formulation described in paragraph (a) of this section within the time specified by FDA, the drug product may be considered misbranded or an unapproved new drug or unlicensed biologic.

PART 312—INVESTIGATIONAL NEW DRUG APPLICATION

3. The authority citation for 21 CFR part 312 continues to read as follows:


4. Section 312.23 is amended by redesignating paragraph (a)(10)(iii) as paragraph (a)(10)(iv) and adding new paragraph (a)(10)(iii) to read as follows:

§ 312.23 IND content and format.

(a) * * *

(10) * * *

(iii) Pediatric studies. Plans for assessing pediatric safety and effectiveness.

* * * * *

5. Section 312.47 is amended by revising paragraph (b)(1)(i) and the first sentence of paragraph (b)(3)(iv), by removing the fifth sentence of paragraph (b)(1)(v) and adding two sentences in its place, by revising the heading of paragraph (b)(2) and the second and last sentences of the introductory text of paragraph (b)(2), and by redesignating paragraph (b)(2)(iii) as paragraph (b)(2)(iv) and by adding new paragraph (b)(2)(iii) to read as follows:

§ 312.47 Meetings.

* * * * *

(b) * * *

(i) End-of-Phase 2 meetings—(i) Purpose. The purpose of an end-of-phase 2 meeting is to determine the safety of proceeding to Phase 3, to evaluate the Phase 3 plan and protocols and the adequacy of current studies and plans to assess pediatric safety and effectiveness, and to identify any additional information necessary to support a marketing application for the uses under investigation.

* * * * *

(iv) Advance information. At least 1 month in advance of an end-of-Phase 2 meeting, the sponsor should submit background information on the sponsor’s plan for Phase 3, including summaries of the Phase 1 and 2 investigations, the specific protocols for Phase 3 clinical studies, plans for any additional nonclinical studies, plans for pediatric studies, including a time line for protocol finalization, enrollment, completion, and data analysis, or information to support any planned request for waiver or deferral of pediatric studies, and, if available, tentative labeling for the drug.

* * *

(v) Conduct of meeting. * * * The adequacy of the technical information to support Phase 3 studies and/or a marketing application may also be discussed. FDA will also provide its best judgment, at that time, of the pediatric studies that will be required for the drug product and whether their submission will be deferred until after approval.

* * *

2. "Pre-NDA" and "pre-BLA" meetings. * * * The primary purpose of this kind of exchange is to uncover any major unresolved problems, to identify those studies that the sponsor is relying on as adequate and well-controlled to establish the drug’s effectiveness, to identify the status of ongoing or needed studies adequate to assess pediatric safety and effectiveness, to acquaint FDA reviewers with the general information to be submitted in the marketing application (including technical information), to discuss appropriate methods for statistical analysis of the data, and to discuss the best approach to the presentation and formatting of data in the marketing application. * * *

To permit FDA to provide the sponsor with the most useful advice on preparing a marketing application, the sponsor should submit to FDA’s reviewing division at least 1 month in advance of the meeting the following information:

* * * * *

(iii) Information on the status of needed or ongoing pediatric studies.

* * * * *

6. Section 312.82 is amended by revising the last sentence of paragraph (a) and by removing the second sentence of paragraph (b) and adding two sentences in its place to read as follows:

§ 312.82 Early consultation.

* * * * *

(a) Pre-investigational new drug (IND) meetings. * * * The meeting may also provide an opportunity for discussing the scope and design of phase 1 testing, plans for studying the drug product in pediatric populations, and the best approach for presentation and formatting of data in the IND.

(b) End-of-phase 1 meetings. * * * The primary purpose of this meeting is to review and reach agreement on the design of phase 2 controlled clinical trials, with the goal that such testing will be adequate to provide sufficient data on the drug’s safety and effectiveness to support a decision on its approvability for marketing, and to discuss the need for, as well as the design and timing of, studies of the drug in pediatric patients. For drugs for life-threatening diseases, FDA will provide its best judgment, at that time, whether pediatric studies will be required and whether their submission will be deferred until after approval.

* * *
PART 314—APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG OR AN ANTIBIOTIC DRUG

7. The authority citation for 21 CFR part 314 continues to read as follows:


8. Section 314.50 is amended by adding paragraph (d)(7) to read as follows:

§ 314.50 Content and format of an application.

(d) * * * * * * *

(7) Pediatric use section. A section describing the investigation of the drug for use in pediatric populations, including an integrated summary of the information (the clinical pharmacology studies, controlled clinical studies, or uncontrolled clinical studies, or other data or information) that is relevant to the safety and effectiveness and benefits and risks of the drug in pediatric populations for the claimed indications, a reference to the full descriptions of such studies provided under paragraphs (d)(3) and (d)(5) of this section, and information required to be submitted under § 314.55.

§ 314.55 Pediatric use information.

(a) Required assessment. Except as provided in paragraphs (b), (c), and (d) of this section, each application for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration shall contain data that are adequate to assess the safety and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. Where the course of the disease and the effects of the drug are sufficiently similar in adults and pediatric patients, FDA may conclude that pediatric effectiveness can be extrapolated from adequate and well-controlled studies in adults usually supplemented with other information obtained in pediatric patients, such as pharmacokinetic studies. Studies may not be needed in each pediatric age group, if data from one age group can be extrapolated to another. Assessments of safety and effectiveness required under this section for a drug product that represents a meaningful therapeutic benefit over existing treatments for pediatric patients must be carried out using appropriate formulations for each age group(s) for which the assessment is required.

(b) Deferred submission. (1) FDA may, on its own initiative or at the request of an applicant, defer submission of some or all assessments of safety and effectiveness described in paragraph (a) of this section until after approval of the drug product for use in adults. Deferral may be granted if, among other reasons, the drug is ready for approval in adults before studies in pediatric patients are complete, or pediatric studies should be delayed until additional safety or effectiveness data have been collected. If an applicant requests deferred submission, the request must provide a certification from the applicant of the grounds for delaying pediatric studies, a description of the planned or ongoing studies, and evidence that the studies are being or will be conducted with due diligence and at the earliest possible time.

(2) If FDA determines that there is an adequate justification for temporarily delaying the submission of assessments of pediatric safety and effectiveness, the drug product may be approved for use in adults subject to the requirement that the applicant submit the required assessments within a specified time.

(c) Waivers—(1) General. FDA may grant a full or partial waiver of the requirements of paragraph (a) of this section on its own initiative or at the request of an applicant. A request for a waiver must provide an adequate justification.

(2) Full waiver. An applicant may request a waiver of the requirements of paragraph (a) of this section if the applicant certifies that:

(i) The drug product does not represent a meaningful therapeutic benefit over existing treatments for pediatric patients and is not likely to be used in a substantial number of pediatric patients;

(ii) Necessary studies are impossible or highly impractical because, e.g., the number of such patients is so small or geographically dispersed; or

(iii) There is evidence strongly suggesting that the drug product would be ineffective or unsafe in all pediatric age groups.

(3) Partial waiver. An applicant may request a waiver of the requirements of paragraph (a) of this section with respect to a specified pediatric age group, if the applicant certifies that:

(i) The drug product does not represent a meaningful therapeutic benefit over existing treatments for pediatric patients in that age group, and is not likely to be used in a substantial number of patients in that age group;

(ii) Necessary studies are impossible or highly impractical because, e.g., the number of patients in that age group is so small or geographically dispersed;

(iii) There is evidence strongly suggesting that the drug product would be ineffective or unsafe in that age group; or

(iv) The applicant can demonstrate that reasonable attempts to produce a pediatric formulation necessary for that age group have failed.

(4) FDA action on waiver. FDA shall grant a full or partial waiver, as appropriate, if the agency finds that there is a reasonable basis on which to conclude that one or more of the grounds for waiver specified in paragraphs (c)(2) or (c)(3) of this section have been met. If a waiver is granted on the ground that it is not possible to develop a pediatric formulation, the waiver will cover only those pediatric age groups requiring that formulation. If a waiver is granted because there is evidence that the product would be ineffective or unsafe in pediatric populations, this information will be included in the product’s labeling.

(5) Definition of "meaningful therapeutic benefit." For purposes of this section and § 201.23 of this chapter, a drug will be considered to offer a meaningful therapeutic benefit over existing therapies if FDA estimates that:

(i) If approved, the drug would represent a significant improvement in the treatment, diagnosis, or prevention of a disease, compared to marketed products adequately labeled for that use in the relevant pediatric population. Examples of how improvement must be demonstrated include, for example, evidence of increased effectiveness in treatment, prevention, or diagnosis of disease, elimination or substantial reduction of a treatment-limiting drug reaction, documented enhancement of treatment, prevention, or diagnosis of a disease, compared to marketed products adequately labeled for that use in the relevant pediatric population.

(ii) The drug is in a class of drugs or for an indication for which there is a need for additional therapeutic options.

(iii) The drug is in a class of drugs or for an indication for which there is a need for additional therapeutic options.

(iv) The drug is in a class of drugs or for an indication for which there is a need for additional therapeutic options.

(v) The drug is in a class of drugs or for an indication for which there is a need for additional therapeutic options.

(vi) The drug is in a class of drugs or for an indication for which there is a need for additional therapeutic options.

(vii) The drug is in a class of drugs or for an indication for which there is a need for additional therapeutic options.

(viii) The drug is in a class of drugs or for an indication for which there is a need for additional therapeutic options.

(ix) The drug is in a class of drugs or for an indication for which there is a need for additional therapeutic options.

(x) The drug is in a class of drugs or for an indication for which there is a need for additional therapeutic options.

(xi) The drug is in a class of drugs or for an indication for which there is a need for additional therapeutic options.

(xii) The drug is in a class of drugs or for an indication for which there is a need for additional therapeutic options.

(xiii) The drug is in a class of drugs or for an indication for which there is a need for additional therapeutic options.

(xiv) The drug is in a class of drugs or for an indication for which there is a need for additional therapeutic options.

(xv) The drug is in a class of drugs or for an indication for which there is a need for additional therapeutic options.

(xvi) The drug is in a class of drugs or for an indication for which there is a need for additional therapeutic options.

(xvii) The drug is in a class of drugs or for an indication for which there is a need for additional therapeutic options.

(xviii) The drug is in a class of drugs or for an indication for which there is a need for additional therapeutic options.

(xix) The drug is in a class of drugs or for an indication for which there is a need for additional therapeutic options.

(xx) The drug is in a class of drugs or for an indication for which there is a need for additional therapeutic options.

(2) * * *
PART 601—LICENSING

11. The authority citation for 21 CFR part 601 is revised to read as follows:


12. Section 601.27 is added to subpart C to read as follows:

§601.27 Pediatric studies.

(a) Required assessment. Except as provided in paragraphs (b), (c), and (d) of this section, each application for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration shall contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Where the course of the disease and the effects of the product are similar in adults and pediatric patients, FDA may conclude that pediatric effectiveness can be extrapolated from adequate and well-controlled effectiveness studies in adults, usually supplemented with other information in pediatric patients, such as pharmacokinetic studies. In addition, studies may not be needed in each pediatric age group, if data from one age group can be extrapolated to another. Assessments required under this section for a product that represents a meaningful therapeutic benefit over existing treatments must be carried out using appropriate formulations for the age group(s) for which the assessment is required.

(b) Deferred submission. (1) FDA may, on its own initiative or at the request of an applicant, defer submission of some or all assessments of safety and effectiveness described in paragraph (a) of this section until after licensing of the product for use in adults. Deferral may be granted if, among other reasons, the product is ready for approval in adults before studies in pediatric patients are complete, pediatric studies should be delayed until additional safety or effectiveness data have been collected. If an applicant requests deferred submission, the request must provide an adequate justification for delaying pediatric studies, a description of the planned or ongoing studies, and evidence that the studies are being or will be conducted with due diligence and at the earliest possible time.

(2) If FDA determines that there is an adequate justification for temporarily delaying the submission of assessments of pediatric effectiveness, the product may be licensed for use in adults subject to the requirement that the applicant submit the required assessments within a specified time.

(c) Waivers—(1) General. FDA may grant a full or partial waiver of the requirements of paragraph (a) of this section on its own initiative or at the request of an applicant. A request for a waiver must provide an adequate justification.

(2) Full waiver. An applicant may request a waiver of the requirements of paragraph (a) of this section if the applicant certifies that:

(i) The product does not represent a meaningful therapeutic benefit over existing therapies for pediatric patients and is not likely to be used in a substantial number of pediatric patients;

(ii) Necessary studies are impossible or highly impractical because, e.g., the number of such patients is so small or geographically dispersed; or

(iii) There is evidence strongly suggesting that the product would be ineffective or unsafe in all pediatric age groups.

(3) Partial waiver. An applicant may request a waiver of the requirements of paragraph (a) of this section with respect to a specified pediatric age group, if the applicant certifies that:

(i) The product does not represent a meaningful therapeutic benefit over existing therapies for pediatric patients in that age group, and is not likely to be used in a substantial number of patients in that age group;

(ii) Necessary studies are impossible or highly impractical because, e.g., the number of patients in that age group is so small or geographically dispersed; or

(iv) The applicant can demonstrate that reasonable attempts to produce a pediatric formulation necessary for that age group have failed.

(4) FDA action on waiver. FDA shall grant a full or partial waiver, as appropriate, if the agency finds that there is a reasonable basis on which to conclude that one or more of the grounds for waiver specified in paragraphs (c)(2) or (c)(3) of this section have been met. If a waiver is granted on the ground that it is not possible to develop a pediatric formulation, the waiver will cover only those pediatric age groups requiring that formulation. If a waiver is granted because there is evidence that the product would be ineffective or unsafe in pediatric populations, this information will be included in the product's labeling.

(5) Definition of "meaningful therapeutic benefit". For purposes of this section, a product will be considered to offer a meaningful therapeutic benefit over existing therapies if FDA estimates that:

(i) If approved, the product would represent a significant improvement in the treatment, diagnosis, or prevention of a disease, compared to marketed products adequately labeled for that use in the relevant pediatric population. Examples of how improvement might be demonstrated include, e.g., evidence of increased effectiveness in treatment, prevention, or diagnosis of disease.
elimination or substantial reduction of a
treatment-limiting drug reaction;
documented enhancement of
compliance; or evidence of safety and
effectiveness in a new subpopulation; or
(ii) The product is in a class of
products or for an indication for which
there is a need for additional
therapeutic options.
(d) Exemption for orphan drugs. This
section does not apply to any product
for an indication or indications for
which orphan designation has been
granted under part 316, subpart C, of
this chapter.
13. Section 601.37 is added to subpart
D to read as follows:
§ 601.37 Annual reports of postmarketing
pediatric studies.
Sponsors of licensed biological
products shall submit the following
information each year within 60 days of
the anniversary date of approval of the
license, to the Director, Center for
Biologics Evaluation and Research:
(a) Summary. A brief summary stating
whether labeling supplements for
pediatric use have been submitted and
whether new studies in the pediatric
population to support appropriate
labeling for the pediatric population
have been initiated. Where possible, an
estimate of patient exposure to the drug
product, with special reference to the
pediatric population (neonates, infants,
children, and adolescents) shall be
provided, including dosage form.
(b) Clinical data. Analysis of available
safety and efficacy data in the pediatric
population and changes proposed in the
labeling based on this information. An
assessment of data needed to ensure
appropriate labeling for the pediatric
population shall be included.
(c) Status reports. A statement on the
current status of any postmarketing
studies in the pediatric population
performed by, or on behalf of, the
applicant. The statement shall include
whether postmarketing clinical studies
in pediatric populations were required
or agreed to, and if so, the status of these
studies, e.g., to be initiated, ongoing
(with projected completion date),
completed (including date), completed
and results submitted to the BLA
(including date).
Michael A. Friedman,
Acting Commissioner of Food and Drugs.
Donna E. Shalala,
Secretary of Health and Human Services.
[FR Doc. 98–31902 Filed 11–27–98; 8:45 am]
Exhibit 8

*New Drug, Antibiotic, and Biological Drug Product Regulations; Accelerated Approval, 57 Fed. Reg. 58,942 (Dec. 11, 1992)*
### EXHIBIT J

**OFFER GUARANTEE CALCULATION WORKSHEET**

<table>
<thead>
<tr>
<th>COLUMN</th>
<th>(A) MAXQ (000/bbls)</th>
<th>(B) UNIT PRICE</th>
<th>(C) DLI (000/bbls)</th>
<th>(D) MINQ (000/bbls)</th>
<th>(E) TOTAL DLI PRICE</th>
<th>(F) BOND FACTOR (%)</th>
<th>(G) PRODUCT ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ROW</td>
<td>(000/$)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>$</td>
<td></td>
<td>$</td>
<td>x50</td>
<td>$</td>
<td></td>
<td>$</td>
</tr>
<tr>
<td>2</td>
<td>$</td>
<td></td>
<td>$</td>
<td>x50</td>
<td>$</td>
<td></td>
<td>$</td>
</tr>
<tr>
<td>3</td>
<td>$</td>
<td></td>
<td>$</td>
<td>x50</td>
<td>$</td>
<td></td>
<td>$</td>
</tr>
<tr>
<td>4</td>
<td>$</td>
<td></td>
<td>$</td>
<td>x50</td>
<td>$</td>
<td></td>
<td>$</td>
</tr>
<tr>
<td>5</td>
<td>$</td>
<td></td>
<td>$</td>
<td>x50</td>
<td>$</td>
<td></td>
<td>$</td>
</tr>
<tr>
<td>6</td>
<td>$</td>
<td></td>
<td>$</td>
<td>x50</td>
<td>$</td>
<td></td>
<td>$</td>
</tr>
<tr>
<td>7</td>
<td>$</td>
<td></td>
<td>$</td>
<td>x50</td>
<td>$</td>
<td></td>
<td>$</td>
</tr>
<tr>
<td>8</td>
<td>$</td>
<td></td>
<td>$</td>
<td>x50</td>
<td>$</td>
<td></td>
<td>$</td>
</tr>
<tr>
<td>9</td>
<td>$</td>
<td></td>
<td>$</td>
<td>x50</td>
<td>$</td>
<td></td>
<td>$</td>
</tr>
<tr>
<td>10</td>
<td>$</td>
<td></td>
<td>$</td>
<td>x50</td>
<td>$</td>
<td></td>
<td>$</td>
</tr>
<tr>
<td>11</td>
<td>$</td>
<td></td>
<td>$</td>
<td>x50</td>
<td>$</td>
<td></td>
<td>$</td>
</tr>
</tbody>
</table>

**Total**

1. Using a separate worksheet for each MLI offered against, from the SPR Sales Offer Form, enter the MLI maximum quantity offered on (expressed in thousands of barrels) in Column (A), Row 1.

2. Starting with the highest DLI unit price offered on the MLI from the SPR Sales Offer Form (and the highest preference if the unit prices of two or more DLIs are the same) enter the unit price in Row 1, Column (B); the DLI letter in Row 1, Column (C); the DLI desired quantity is Row 1, Column (D) (in thousands of barrels) and the minimum quantity in Row 1, Column (E). (The minimum quantity is either the Government’s minimum contract quantity, if the offer indicates the offeror will accept as little as that amount, or the desired quantity, if the offeror indicates he will accept no less than that amount. See instructions for the SPR Sales Offer Form.)

3. If either the desired quantity in Column (D), or the minimum quantity in Column (E) exceeds the maximum quantity in Column (A), you have made an error either on this form or the offer form and should recheck your figures.

4. Multiply the price in Row 1, Column (B) times the desired quantity in Column (D) (as expressed in thousands) and enter the total DLI price in Column (F).

5. Multiply the total DLI price in Column (F) times the factor in Column (G) and enter the product in Column (H). The factor is $2 of 1000.

6. Subtract the DLI desired quantity in Row 1, Column (D) from the maximum quantity in Row 1, Column (A). Enter the result in Row 2, Column (A). If the result is zero, go to step 11.

7. Enter the next highest unit price for the MLI from the offer form in Row 2, Column (B). Enter the DLI letter, desired quantity, and minimum quantity in their respective columns. If there is a maximum quantity remaining in Row 2, Column (A), but no more DLI offers, or the minimum quantity in Row 2, Column (E) exceeds the maximum quantity, you may have made an error and should recheck your figures.

8. Multiply the lesser of the remaining maximum quantity in Column (A) (even if this quantity is less than MINQ), or the desired quantity in Column (D) times the unit price and enter the resulting total DLI price in Column (F).

9. Multiply Column (F) times the factor in Column (G) and enter the product in Column (H).

10. Repeat steps 6-9 for the next higher unit price until the maximum quantity remaining is zero, then go to step 11.

11. Sum the amounts in Column (H) and enter the total in Row 8, Column (H). Sum this amount for all the worksheets. If the sum of all the worksheets is less than $10,000,000, enter the sum in the spaces marked offer bond on the SPR Sales Offer Form. If the sum exceeds $10,000,000, then enter $10,000,000 on the offer form. Send with the offer or wire concurrently to the U.S. Treasury (refer to instructions in the Notice of Sale) an offer guarantee in the amount indicated on the offer form. These worksheets need not be submitted with the offer and should be retained for your files.

[FR Doc. 92-18574 Filed 12-10-92; 8:45 am]

BILLING CODE 4820-01-C

EX. 8 pg. 001
Friday
December 11, 1992

Part VI

Department of the Interior

Fish and Wildlife Service
50 CFR Part 32
Refuge-Specific Hunting and Fishing Regulations; Proposed Rule

EX. 8 pg. 002
DEPARTMENT OF THE INTERIOR
Fish and Wildlife Service
50 CFR Part 32
FIN 1018-AA71
Refuge-Specific Hunting and Fishing Regulations

AGENCY: Fish and Wildlife Service, Interior.

ACTION: Proposed Rule.

SUMMARY: The Fish and Wildlife Service (Service) proposes to amend certain regulations that pertain to migratory game bird hunting, upland game hunting, big game hunting and sport fishing on individual national wildlife refuges. Refuge hunting and fishing programs are reviewed annually to determine whether the individual refuge regulations governing these programs should be modified, deleted or have additions made to them. Changing environmental conditions, State and Federal regulations, and other factors affecting wildlife populations and habitat may warrant modifications to ensure the continued compatibility of hunting and fishing with the purposes for which the individual refuges were established. Modifications are designed, to the extent practical, to make refuge hunting and fishing programs consistent with State regulations. In addition, these refuge-specific regulations are consistent with the proposed new format which reorganizes all hunting and fishing regulations under one part as proposed in another document published in the Federal Register on November 25, 1992.

DATES: Comments must be received on or before December 28, 1992. See SUPPLEMENTARY INFORMATION below for discussion of comment periods.

ADDRESSES: Address comments to: Assistant Director—Refuges and Wildlife, U.S. Fish and Wildlife Service, 1849 C Street, NW., MS 670 ARLSQ, Washington, DC 20240; Telephone (703) 358-2043.

FOR FURTHER INFORMATION CONTACT: Duncan L. Brown, Division of Refuges, U.S. Fish and Wildlife Service, 1849 C Street, NW., MS 670 ARLSQ, Washington, DC 20240; Telephone (703) 358-2043.

SUPPLEMENTARY INFORMATION: 50 CFR part 32 contains provisions governing hunting and fishing on national wildlife refuges. Hunting and fishing are regulated on refuges to (1) insure compatibility with refuge purposes, (2) properly manage the wildlife resource, (3) protect other refuge values and (4) insure refuge user safety. On many refuges, the Service policy of adopting State hunting regulations is adequate in meeting these objectives. On other refuges, it is necessary to supplement State regulations with more restrictive Federal regulations to insure that the Service meets its management responsibilities, as outlined under the section entitled “Conformance with Statutory and Regulatory Authorities.” Refuge-specific hunting and fishing regulations may be issued only after a wildlife refuge is opened to migratory game bird hunting, upland game hunting, big game hunting or sport fishing through publication in the Federal Register. These regulations may list the wildlife species that may be hunted or are subject to sport fishing, seasons, bag limits, methods of hunting or fishing, descriptions of open areas, and other provisions as appropriate. Previously issued refuge-specific regulations for hunting and fishing are contained in 50 CFR part 32. Many of the proposed amendments to these sections are being promulgated to standardize and clarify the existing language of these regulations.

The policy of the Department of the Interior is, whenever practicable, to afford the public an opportunity to participate in the rulemaking process. It is, therefore, the purpose of this proposed rulemaking to seek public input regarding these proposed amendments. Special circumstances in the reformatting of the hunting and fishing regulations as proposed to be revised at 57 FR 53686 on November 25, 1992, limit the amount of time that the Service can allow for public comment. Accordingly, interested persons may submit written comments to the Assistant Director, Refuges and Wildlife (ADDRESSES above) by the end of the comment period. All substantive comments regarding content or format will be considered by the Department prior to issuance of a final rule.

Conformance With Statutory and Regulatory Authorities

The National Wildlife Refuge System Administration Act (NWRSAA) of 1966, as amended (16 U.S.C. 668dd), and the Refuge Recreation Act of 1962 (16 U.S.C. 460k) govern the administration and public use of national wildlife refuges. Specifically, section 4(d)(1)(A) of the NWRSAA authorizes the Secretary of the Interior to permit the use of any area within the Refuge System for any purpose, including but not limited to, hunting, fishing and public recreation, accommodations and access, when he determines that such uses are compatible with the major purpose(s) for which the area was established.

The Refuge Recreation Act authorizes the Secretary to administer areas within the Refuge System for public recreation as an appropriate incidental or secondary use only to the extent that it is practicable and not inconsistent with the primary purpose(s) for which the areas were established. The Refuge Recreation Act also authorizes the Secretary to issue regulations to carry out the purposes of the Act. Hunting and sport fishing plans are developed for each refuge prior to opening it to hunting or fishing. In many cases, refuge-specific hunting and fishing regulations are included in the hunting and sport fishing plans to ensure the compatibility of the hunting and sport fishing programs with the purposes for which the refuge was established. Initial compliance with the NWRSAA and Refuge Recreation Act is assured when hunting and sport fishing plans are developed, and the determinations required by these acts are made prior to the addition of refuges to the lists of areas open to hunting and fishing in 50 CFR. Continued compliance is ensured by annual review of hunting and sport fishing programs and regulations.

Economic Effect

Executive Order 12291 requires the preparation of regulatory impact analyses for major rules. A major rule is one likely to result in an annual effect on the economy of $100 million or more; or a major increase in costs or prices for consumers, individual industries, government agencies or geographic regions. The Regulatory Flexibility Act of 1980 (5 U.S.C. 601 et seq.) further requires the preparation of flexibility analyses for rules that will have a significant effect on a substantial number of small entities, which include small businesses, organizations or governmental jurisdictions.

The proposed amendments to the codified refuge-specific hunting and fishing regulations would make relatively minor adjustments to existing hunting programs. The regulations are not expected to have any gross economic effect and will not cause an increase in costs or prices for consumers, individual industries, Federal, State, or local governments, agencies, or geographic regions. The benefits accruing to the public are expected to exceed by a large margin the costs of administering this rule. Accordingly, the Department of the Interior has determined that this proposed rule is not a “major rule” within the meaning of E.O. 12291 and Executive Order 12866.
would not have a significant economic effect on a substantial number of small entities within the meaning of the Regulatory Flexibility Act.

Paperwork Reduction Act

The information collection requirements for part 32 are found in 50 CFR part 25 and have been approved by the Office of Management and Budget under 44 U.S.C. 3501 et seq. and assigned clearance number 1018–0014. The information is being collected to assist the Service in administering these programs in accordance with statutory authorities which require that recreational uses be compatible with the primary purposes for which the areas were established. The information requested in the application form is required to obtain a benefit.

The public reporting burden for the application form is estimated to average six (6) minutes per response, including time for reviewing instructions, gathering and maintaining data, and completing the form. Direct comments on the burden estimate or any other aspect of this form to the Service Information Collection Clearance Officer, U.S. Fish and Wildlife Service, 1849 C Street NW, MS 224 ARLSQ, Washington, DC 20240; and the Office of Management and Budget, Paperwork Reduction Project (1018–0014), Washington, DC 20503.

Environmental Considerations

Compliance with the National Environmental Policy Act of 1969 (NEPA) (42 U.S.C. 4332(C)) and the Endangered Species Act of 1973 (16 U.S.C. 1531–1543) is assured when hunting and sport fishing plans are developed, and the determinations required by these acts are made prior to the addition of refuges to the lists of areas open to hunting and fishing in 50 CFR. Refuge-specific hunting and fishing regulations are subject to a categorical exclusion from the NEPA process if they do not significantly alter the existing use of a particular national wildlife refuge. The changes proposed in this rulemaking would not substantially alter the existing uses of the refuges involved. Information regarding hunting and fishing permits and the conditions that apply to individual refuge hunts, sport fishing activities and maps of the respective areas are available at refuge headquarters or can be obtained from the regional offices of the U.S. Fish and Wildlife Service at the addresses listed below:

Region 1—California, Hawaii, Idaho, Nevada, Oregon, and Washington.


Region 2—Arizona, New Mexico, Oklahoma, and Texas.

Assistant Regional Director—Refuges and Wildlife, U.S. Fish and Wildlife Service, Box 1306, Albuquerque, New Mexico 87103; Telephone (505) 798–1828.

Region 3—Illinois, Indiana, Iowa, Michigan, Minnesota, Missouri, Ohio and Wisconsin.


Region 4—Alaska, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, Tennessee, South Carolina, Puerto Rico and the Virgin Islands.

Assistant Regional Director—Refuges and Wildlife, U.S. Fish and Wildlife Service, Richard B. Russell Federal Building, 75 Spring Street, SW, Atlanta, Georgia 30303; Telephone (404) 381–0833.


Assistant Regional Director—Refuges and Wildlife, U.S. Fish and Wildlife Service, 300 W. Gate Center Drive, Hatfield, Massachusetts 01035; Telephone (413) 253–9200.

Region 6—Colorado, Kansas, Montana, Nebraska, North Dakota, South Dakota, Utah and Wyoming.

Assistant Regional Director—Refuges and Wildlife, U.S. Fish and Wildlife Service, Box 25486, Denver Federal Center, Denver, Colorado 80225; Telephone (303) 236–8145.

Region 7—Alaska (Hunting and fishing on Alaska refuge is in accordance with State regulations. There are no refuge-specific hunting and fishing regulations for these refuges).


Duncan L. Brown, Division of Refuges, U.S. Fish and Wildlife Service, Washington, DC 20240, is the primary author of this proposed rulemaking document.

List of Subjects in 50 CFR Part 32

Hunting, Fishing, Reporting and recordkeeping requirements, Wildlife, National wildlife refuges.

Accordingly, it is proposed to amend Part 32, as proposed to be revised at 57 FR 22866 on November 25, 1992, of chapter I of title 50 of the Code of Federal Regulations as set forth below:

PART 32—[AMENDED]

1. The authority citation for part 32 would continue to read as follows:


2. Section 32.20 Alabama is amended by revising paragraph C. of the Choctaw National Wildlife Refuge; by revising paragraphs A., B., and C. of Enfua National Wildlife Refuge to read as follows:

§ 32.20 Alabama.

* * * * *

Choctaw National Wildlife Refuge

C. Big Game Hunting. Hunting of white-tailed deer and feral hogs is permitted on designated areas of the refuge subject to the following condition: Permits are required.

* * * * *

Enfua National Wildlife Refuge

A. Hunting of Migratory Game Birds. Hunting of geese, ducks, coots, mourning doves, snipe and woodcock is permitted on designated areas of the refuge subject to the following condition: Permits are required.

B. Upland Game Hunting. Hunting of quail and rabbit is permitted on designated areas of the refuge subject to the following condition: Permits are required.

C. Big Game Hunting. Hunting of white-tailed deer is permitted on designated areas of the refuge subject to the following condition: Permits are required.

* * * * *

3. Section 32.22 Arizona is amended by revising paragraph C. of the Buenos Aires National Wildlife Refuge to read as follows:

§ 32.22 Arizona.

* * * * *

Buenos Aires National Wildlife Refuge

C. Big Game Hunting. Hunting of mule deer and white-tailed deer, javelina and feral hogs is permitted on designated areas of the refuge.

* * * * *

4. Section 32.23 Arkansas is amended by revising paragraph B. of the Big Lake National Wildlife Refuge to read as follows:
§32.23 Arkansas.

Big Lake National Wildlife Refuge

* * *

B. Upland Game Hunting. Hunting of squirrel, rabbit, raccoon, beaver and opossum is permitted on designated areas of the refuge subject to the following condition: Permits are required.

§32.24 California.

Delevan National Wildlife Refuge

A. Hunting of Migratory Game Birds. * * *

3. Hunters assigned to the spaced blind unit are restricted to within 100 feet of their assigned hunt site except for retrieving downed birds, placing decoys, or traveling to and from the parking area.

* * *

Lower Klamath National Wildlife Refuge

A. Hunting of Migratory Game Birds. * * *

3. Only unloaded firearms may be carried on hunter access routes open to motor vehicles or when taken through posted retrieving zones when traveling to and from the hunting areas.

* * *

Sacramento National Wildlife Refuge

A. Hunting of Migratory Game Birds. * * *

3. Hunters assigned to the spaced blind unit are restricted to within 100 feet of their assigned hunt site except for retrieving downed birds, placing decoys, or traveling to and from the parking area.

Tule Lake National Wildlife Refuge

* * *

§32.27 Delaware.

Prime Hook National Wildlife Refuge

C. Big Game Hunting. Hunting of deer and turkey is permitted on designated areas of the refuge subject to the following conditions:

2. Deer hunting on Area A must be from designated stands only, unless actively tracking or retrieving wounded deer.

3. Hunting Areas A and B and the North Hunting Area are open to shotgun and muzzleloader deer hunting.

4. Archery deer hunting is permitted on the North Hunting Area only.

* * *

§32.33 Indiana.

Muscatatuck National Wildlife Refuge

C. Big Game Hunting.

5. Non-hunters must stay in vehicles when entering the hunt area during the second state deer muzzleloader season.

9. Section 32.37 Louisiana is amended by revising paragraph B. for Atchafalaya National Wildlife Refuge by revising paragraph B.2. and adding a new paragraph B.5., by revising paragraph C. for Upper Ouachita National Wildlife Refuge to read as follows:

§32.37 Louisiana.

Atchafalaya National Wildlife Refuge

B. Upland Game Hunting. Hunting of squirrel, rabbit, raccoon, opossum, nutria, muskrat, mink, fox, bobcat, beaver and opossum is permitted on designated areas of the refuge.
subject to the following condition: Hunting shall be in accordance with Sherburne Wildlife Management Area regulations.

D’Arbonne National Wildlife Refuge

B. Upland Game Hunting. * * *

2. Feral hogs, coyotes, and beaver may be taken during all refuge hunts.

3. Dogs are allowed for hunting squirrels, rabbits and raccoon only from the end of the last refuge gun deer hunt to the end of small game season.

C. Big Game Hunting. Hunting of white-tailed deer is permitted on designated areas of the refuge subject to the following conditions:

1. Either-sex deer hunting with firearms is permitted during the second consecutive Saturday and Sunday and fourth consecutive Friday and Saturday in November only.

2. Feral hogs, coyotes, and beaver may be taken during all refuge hunts.

3. Only still hunting is permitted.

4. Deer stands may not be left unattended.

5. All deer must be checked at a designated check station.

Delta National Wildlife Refuge

A. Hunting of Migratory Game Birds. Hunting of migratory game birds is permitted on designated areas of the refuge subject to the following condition: Permits are required.

B. Upland Game Hunting. Hunting of rabbit is permitted on designated areas of the refuge subject to the following condition: Permits are required.

C. Big Game Hunting. Hunting of white-tailed deer is permitted on designated areas of the refuge subject to the following condition: Permits are required.

Upper Ouachita National Wildlife Refuge

B. Upland Game Hunting. * * *

2. Feral hogs, coyotes and beaver may be taken during all refuge hunts.

4. Nontoxic shot is required while hunting upland game species.

5. Dogs are allowed for hunting squirrels, rabbits and raccoon only from the end of the last refuge gun deer hunt to the end of small game season.

C. Big Game Hunting. Hunting of white-tailed deer is permitted on designated areas of the refuge subject to the following conditions:

1. Either-sex deer hunting with firearms is permitted during the second consecutive Saturday and Sunday and fourth consecutive Friday and Saturday in November only.

2. Feral hogs, coyotes, and beaver may be taken during all refuge hunts.

3. Firearms must be unloaded while being transported in a vehicle or boat.

4. Only still hunting is permitted.

5. Deer stands may not be left unattended.

10. Section 32.38 Maine is amended by revising paragraph C.2. for Moosehorn National Wildlife Refuge; by adding new paragraph B.1. and by adding a new paragraph C.1. to Rachel Carson National Wildlife Refuge; and by revising paragraph C.1. of Sunkhaze Meadows National Wildlife Refuge to read as follows:

§ 32.38 Maine.

Moosehorn National Wildlife Refuge

C. Big Game Hunting. * * *

2. Hunters during firearms big game season must wear in a conspicuous manner on head, chest and back a minimum of 400 square inches of solid-colored hunter orange clothing or material.

Rachel Carson National Wildlife Refuge

B. Upland Game Hunting. * * *

1. Hunters during firearms big game season must wear in a conspicuous manner on head, chest and back a minimum of 400 square inches of solid-colored hunter orange clothing or material.

Sunkhaze Meadows National Wildlife Refuge

C. Big Game Hunting. * * *

1. Hunters during firearms big game season must wear in a conspicuous manner on head, chest and back a minimum of 400 square inches of solid-colored hunter orange clothing or material.

11. Section 32.39 Maryland is amended by revising paragraph C.4. for Blackwater National Wildlife Refuge; and by revising paragraph C.5. for Eastern Neck National Wildlife Refuge to read as follows:

§ 32.39 Maryland.

Blackwater National Wildlife Refuge

C. Big Game Hunting. * * *

4. Hunters during firearms big game season must wear in a conspicuous manner on head, chest and back a minimum of 400 square inches of solid-colored hunter orange clothing or material.
B. Upland Game Hunting. Hunting of upland game birds is permitted on designated areas of the refuge subject to the following conditions:

1. Hunters shall possess and use only non-toxic shot while in the field.
2. Hunting is permitted beginning on the opening day of Montana waterfowl hunting season and is closed at the end of the hunting day of November 30.


§ 32.49 New Jersey.

Edwin B. Forsythe National Wildlife Refuge

A. Hunting of Migratory Game Birds.

1. Hunters may not use or possess more than 25 shells per day in Hunting Areas A, B, and C in the Barnegat Division and in Hunting Unit 1 in the Brigantine Division.
2. In Hunting Area B of the Barnegat Division, hunting is restricted to designated sites, with each site limited to one party of hunters. A minimum of six decoys per site is required.
3. No sites or areas may be occupied before 4:00 a.m. Access is by boat only.
4. Hunters during firearms big game season must wear in a conspicuous manner on head, chest and back a minimum of 400 square inches of solid-colored hunter orange clothing or material.

Great Swamp National Wildlife Refuge

C. Big Game Hunting.

1. Hunters during firearms big game season must wear in a conspicuous manner on head, chest and back a minimum of 400 square inches of solid-colored hunter orange clothing or material.

Supawna Meadows National Wildlife Refuge

C. Big Game Hunting.

1. Hunters during firearms big game season must wear in a conspicuous manner on head, chest and back a minimum of 400 square inches of solid-colored hunter orange clothing or material.

Supawna Meadows National Wildlife Refuge

C. Big Game Hunting.

1. Hunters during firearms big game season must wear in a conspicuous manner on head, chest and back a minimum of 400 square inches of solid-colored hunter orange clothing or material.

16. Section 32.51 New York is amended by removing paragraph A.4. and redesignating paragraphs A.5. through A.7. by adding a new paragraph B.3., and by revising paragraph C.1. for Iroquois National Wildlife Refuge; and by revising paragraph B., by removing paragraph C.1. and redesignating paragraphs C.2. and C.3. as paragraphs C.1. and C.2., and revising the newly designated C.2. of Montezuma National Wildlife Refuge to read as follows:

§ 32.51 New York.

Iroquois National Wildlife Refuge

B. Upland Game Hunting.

1. Hunters during firearms big game season must wear in a conspicuous manner on head, chest and back a minimum of 400 square inches of solid-colored hunter orange clothing or material.

Montezuma National Wildlife Refuge

C. Big Game Hunting.

1. Hunters during firearms big game season must wear in a conspicuous manner on head, chest and back a minimum of 400 square inches of solid-colored hunter orange clothing or material.

Cape Romain National Wildlife Refuge

A. Hunting of Migratory Game Birds.

1. Only unloaded firearms may be carried on hunter access routes open to motor vehicles or when taken through posted retrieving zones when traveling to and from the hunting areas.

B. Upland Game Hunting. Hunting of phasian is permitted on designated areas of the refuge subject to the following condition: Only unloaded firearms may be carried on hunter access routes open to motor vehicles or when taken through posted retrieving zones when traveling to and from the hunting areas.

19. Section 32.57 Pennsylvania is amended by removing paragraph A.2. and redesignating paragraph A.3 as A.2., and by revising paragraphs C. introductory text and C.1. for Erie National Wildlife Refuge to read as follows:

§ 32.57 Pennsylvania.

C. Big Game Hunting.

1. Hunting of deer and turkey is permitted on designated areas of the refuge subject to the following conditions:
   a. The refuge is open to turkey hunting during the State spring turkey season.

20. Section 32.60 South Carolina is amended by revising paragraph A. for Cape Romain National Wildlife Refuge to read as follows:

§ 32.60 South Carolina.

Cape Romain National Wildlife Refuge

A. Hunting of Migratory Game Birds.

Hunting of rails is permitted on designated areas of the refuge subject to the following condition: Permits are required.

B. Upland Game Hunting. Hunting of squirrel, rabbit, quail, raccoon and opossum is permitted on designated areas of the refuge subject to the following condition: Permits are required.

and A.4 as A.2 and A.3 of San Bernard National Wildlife Refuge to read as follows:

§ 32.63 Texas.

Aransas National Wildlife Refuge
C. Big Game Hunting.

4. Archery hunting is permitted in October on specified days listed in the refuge hunt.

5. Firearms hunting is permitted in November on specified days listed in the refuge hunt.

Brazoria National Wildlife Refuge
A. Hunting of Migratory Game Birds.

2. Hunters during firearms big game season must wear in a conspicuous manner on head, chest and back a minimum of 400 square inches of solid-colored hunter orange clothing or material.

C. Big Game Hunting.

Great Dismal Swamp National Wildlife Refuge
C. Big Game Hunting.

4. Hunters during firearms big game season must wear in a conspicuous manner on head,

chest and back a minimum of 400 square inches of solid-colored hunter orange clothing or material.

24. Section 32.67 Washington is amended by revising paragraph A. for Conboy Lake National Wildlife Refuge to read as follows:

§ 32.67 Washington

Conboy Lake National Wildlife Refuge
A. Hunting of Migratory Game Birds.

Hunting of doves, geese, coots, and common snipe is permitted on designated areas of the refuge.

25. Section 32.69 Wisconsin is amended by revising paragraph A.2 for Horicon National Wildlife Refuge; and by revising paragraph C of the Trempealeau National Wildlife Refuge to read as follows:

§ 32.69 Wisconsin.

Horicon National Wildlife Refuge
A. Hunting of Migratory Game Birds.

2. Only participants in the Young Wildlife and Special Programs are permitted to hunt.

Trempealeau National Wildlife Refuge
C. Big Game Hunting.


Richard N. Smith,
Acting Director, U.S. Fish and Wildlife Service.

[FR Doc. 92–29030 Filed 12–10–92; 8:45 am]

BILLING CODE 4310–08–M
Friday
December 11, 1992

Part VII

Department of the Interior

Bureau of Indian Affairs

Stockbridge-Munsee Alcohol Beverage
Control Law; Notice
DEPARTMENT OF THE INTERIOR

Bureau of Indian Affairs

Stockbridge-Munsee Alcohol Beverage Control Law


AGENCY: Bureau of Indian Affairs, Interior.

ACTION: Notice.

SUMMARY: This Notice is published in accordance with authority delegated by the Assistant Secretary—Indian Affairs by 209 DM 8, and in accordance with the Act of August 15, 1953, 67 Stat. 586, 18 U.S.C. 1151. This Notice certifies that Resolution No. 1317, the Stockbridge-Munsee Liquor Ordinance was duly adopted by the Stockbridge-Munsee Council on May 22, 1992. The ordinance provides for the regulation of the activities of the manufacture, distribution, sale, and consumption of liquor in the area of Indian Country under the jurisdiction of the Stockbridge-Munsee Tribe, Wisconsin.

DATES: This Ordinance is effective as of December 11, 1992.

FOR FURTHER INFORMATION CONTACT:
Chief, Branch of Judicial Services, Division of Tribal Government Services, 1849 C Street, NW., MS 2611-MIB, Washington, DC 20240; telephone (202) 208-4400.

SUPPLEMENTARY INFORMATION: The Stockbridge-Munsee Liquor Ordinance (No. 1317) is to read as follows:

Liquor Control Ordinance—
Stockbridge-Munsee Community of Wisconsin

Whereas, The Tribal Council of the Stockbridge-Munsee Community of Wisconsin has the authority to adopt ordinances regulating liquor in the Indian Country that lies within the jurisdiction of the Community, by virtue of the provisions of Article VII, sections 1(a), (e), and (h) of the Constitution of the Stockbridge-Munsee Community of Wisconsin, adopted October 30, 1937; and

Now therefore be it resolved, That the Tribal Council of the Stockbridge-Munsee Community of Wisconsin authorizes the issuance of licenses for on-premises sale of alcohol beverages within the Indian Country that lies within the jurisdiction of the Community, provided:

1. Licenses

A. Licenses for the sale of alcohol beverages shall only be for the sale of such beverages within buildings used for casinos and restaurant-bar operations owned and regulated by the Stockbridge-Munsee Community.

B. Any restaurant-bar operation must produce more than 50% of its gross sales from food service in order to be licensed after the first year of operation.

C. Licenses issued to businesses owned by the Stockbridge-Munsee Community for the sale of alcohol beverages shall be subject to the same procedures that apply to the initial issuance of a license.

D. Licenses issued to businesses owned by the Stockbridge-Munsee Community for the sale of alcohol beverages shall be effective for a period of three years, renewable upon the compliance of its holder with all the provisions of this Ordinance and other applicable law.

2. Licenses for the sale of alcohol beverages shall be issued by the Tribe to a Tribal casino or restaurant-bar of the Community if the Tribal Council finds, in its sound discretion, on the basis of the facts disclosed by the application and by such additional information as the Tribal Council deems relevant, that such issuance is in the interest of the Community.

3. Licenses for the sale of alcohol beverages issued by the Tribal Council shall contain the following requirements:

(1) Each license shall require its holder to conform its operations to the laws of the Community, the State of Wisconsin and the United States of America;

(2) No license shall be effective for a term of more than one year from the date of its issuance, and each renewal thereof shall be subject to the same procedures that apply to the initial issuance of a license;

(3) Each license shall explicitly state that its continued validity is dependent upon the compliance of its holder with all the provisions of this Ordinance and other applicable law.

4. No license may give away or sell alcohol beverages at a loss.

F. The Tribal Council of the Community shall have the authority to suspend or revoke any license issued under this Ordinance, under the following procedures:

(1) Upon receiving information suggesting that the holder of a license under this Ordinance may have violated the terms of the license or applicable law, the Tribal Council shall give the license holder written notice that the Tribal Council intends to suspend or revoke the holder’s license. Such notice shall be sent by certified mail, return receipt requested, to the agent of the license holder and shall specify the grounds for the proposed suspension or revocation.

(2) Any license holder who receives a notice of a proposed suspension or revocation may request a hearing by the Tribal Council, by sending a written request therefor, certified mail, return receipt requested, to the Chairman of the Stockbridge-Munsee Community, at the Community’s Tribal Center, within seven (7) days of the license holder’s receipt of the notice.

(3) Upon receipt of the request for a hearing under this Ordinance, the Tribal Council shall set a date for a hearing, which shall be no later than thirty days from the receipt of the hearing request.

(4) At a hearing held under this Ordinance, the holder of a license under this Ordinance shall be permitted to present evidence with respect to the holder’s compliance with the terms of its license and applicable law. In reaching its decision, the Tribal Council may consider such evidence, together with all other evidence it deems relevant. Following a hearing, if in the judgment of the Tribal Council the license holder has not complied with

EX. 8 pg. 011
the terms of its license and applicable law, the Tribal Council shall suspend or revoke its license; and if in the judgment of the Tribal Council the terms of the license and applicable law have been complied with, the proceedings shall be dismissed. In either case, the decision of the Tribal Council shall be final.

G. The Tribal Council of the Stockbridge-Munsee Community may reject any application for a license, or for a renewal of a license, under this Ordinance, if the applicant previously has committed acts which have resulted in the suspension or revocation of a license under this Ordinance.

2. Agent

Any Tribally owned entity licensed under this Ordinance shall appoint, subject to the approval and confirmation of the Tribal Council, an agent who shall have full authority and control of the premises and of the conduct of all business on the premises relative to alcohol beverages. This person shall also be the person designated by Wis. Stats. § 125.04(6) requiring the appointment of agents.

3. Authority of the Tribal Council

A. The Tribal Council, or any individual member thereof or any person acting with prior written authorization of the Tribal Council may enter any premises licensed under this ordinance at any time to observe the activities taking place.

B. Written authorization may be enacted at a closed session of the Tribal Council and remain confidential until any report made by such person is before the Tribal Council for action or until such person seeks to gain access to the premises of any Tribally licensed facility during normal closed hours in which case it shall be presented to the manager on duty at the time, and said manager shall immediately admit the person to the premises.

C. Tribal Council members do not need such written authorization and may enter any Tribally licensed facility at any time upon identifying themselves if such admission is sought during normal closed hours.

4. Separate Licenses for Each Facility

Each Tribally owned entity licensed under this Ordinance shall be required to file a separate application and hold a separate license for each facility it operates.

5. Transfer of Licenses Prohibited

No license issued under this Ordinance may be transferred to any other entity or person.

6. State Law Applicable

The Stockbridge-Munsee Community recognizes the applicability of general State Law governing the sale of alcohol beverages.

7. State Law Adopted

The Stockbridge-Munsee Community hereby adopts for purposes of Tribal enforcement against any entity licensed by the Tribe under this ordinance the following provisions, as modified, of chapter 125 of the Wisconsin Statutes:

125.02 Definitions. Except as otherwise provided, in this ordinance.

125.02(1) Alcohol beverages means fermented malt beverages, malt or wine, wine and intoxicating liquor as defined below.

125.02(2) Fermented malt beverage means any beverage made by the alcohol fermentation of an infusion in pasturage, malt and hops, with or without unmalted grains or decorticated and degraded grains or sugar containing 0.5% or more by alcohol volume.

125.02(3) Interchangeable liquor means all ardent, spirituous, distilled or vinous liquors, liquids or compounds, whether medicated, proprietary, patented or not, and by whatever name called, containing 0.5% or more of alcohol by volume, which are beverages, but does not include "fermented malt beverages".

125.02(22) Wine means products obtained from the normal alcohol fermentation of the juice or must of sound, ripe grapes, other fruits or other agricultural products, imitation wine, compounds, vegetable juices, vinegar, cider, perry, mead and sake, if such products contain 0.5% or more of alcohol by volume.

125.02(24) Legal drinking age means 21 years of age.

125.02(14) Person means natural person, sole proprietorship, partnership, corporation or association.

125.02(14m) Premises means the area described in a license issued by the Tribal Council.

125.02(17) Regulation means any rule or ordinance adopted by the Tribal Council.

125.02(20) Sell, sold, sale or selling means any transfer of alcohol beverages with consideration or any transfer without consideration if knowingly made for purposes of evading the law relating to the sale of alcohol beverages or any device, scheme or transaction for obtaining alcohol beverages, including the solicitation of orders for, or the sale of future delivery of, alcohol beverages.

125.02(20) Underage person means a person who has not attained the legal drinking age.

125.04 General licensing requirement. No person may sell, manufacture, rectify, or brew any alcoholic beverage, or engage in any other activity for which this ordinance provides a license without holding the appropriate license.

125.04(2) No license may be issued in violation of this ordinance. No license may be issued to any person except as provided in this ordinance. Any license issued in violation of this ordinance is void.

125.04(10) License to be framed and posted.

(a) Frame. Licenses for the sale of alcohol beverages shall be enclosed in clear plastic or other transparent front which allows the license to be clearly read.

(b) Display. Licenses shall be conspicuously displayed for public inspection at all times in the room or place where the sale of alcohol beverages is carried on.

125.07 Underage and intoxicated persons; presence on licensed premises; possession; penalties.

(a) Alcohol beverages. Restrictions relating to underage persons.

1. No person may procure for, sell, dispense or give away any alcohol beverages to any underage person not accompanied by his or her parent, guardian or spouse who has attained the legal drinking age.

2. No licensee may sell, vend, deal or traffic in alcohol beverages to any underage person not accompanied by his or her parent, guardian or spouse who has attained the legal drinking age.

3. No adult may knowingly permit or fail to take action to prevent the illegal consumption of alcohol beverages by an underage person on premises under the adult's control.

4. No adult may intentionally encourage or contribute to a violation of this section.

(b) Sales of alcohol to intoxicated persons.

1. No person may procure for, sell, dispense or give away alcohol beverages to a person who is intoxicated.

2. No licensee may sell, vend, deal or traffic in alcohol beverages to any person who is intoxicated.

EX. 8 pg. 012

App. 0114
Any tribal entity selling alcohol beverages shall require the proof of age specified by this section.

(a) Definition. In this section, "official identification card" means a valid operator's license issued under chapter 343 of the Wisconsin Statutes that contains the photograph of the holder, an identification card issued under section 342.50 of the Wisconsin Statutes or an identification card issued under section 125.08 of the Wisconsin Statutes.

(b) Use. No card other than the identification card authorized under this section may be recognized as an official identification card by the Tribe for purposes of obtaining alcohol beverages at any Tribally licensed entity.

8. Closing Hours

Every entity licensed by the Stockbridge-Munsee Community shall observe the closing hours established by Wisconsin Statutes governing Class B Retail State licenses. Failure to do so shall be the basis for the revocation of licenses issued by the Tribal Council.

David J. Matheson,
Acting Assistant Secretary—Indian Affairs.

[FR Doc. 92-30132 Filed 12-10-92; 8:45 am]
BILLING CODE 4310-03-M
Part VIII

Department of Health and Human Services
Food and Drug Administration

21 CFR Parts 314 and 601
New Drug, Antibiotic, and Biological Drug Product Regulations; Accelerated Approval; Final Rule
DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 314 and 601

[Dock No. 911-0278]

RIN 0905-AD66

New Drug, Antibiotic, and Biological Drug Product Regulations; Accelerated Approval

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is issuing final regulations under which the agency will accelerate approval of certain new drugs and biological products for serious or life-threatening illnesses, with provisions for any necessary continued study of the drugs' clinical benefits after approval or for restrictions on distribution or use, if necessary. These new procedures are intended to provide expedited marketing of drugs for patients suffering from such illnesses when the drugs provide meaningful therapeutic benefit compared to existing treatment. Accelerated approval will be considered in two situations: (1) When approval can be reliably based on evidence from adequate and well-controlled studies of the drug's effect on a surrogate endpoint that reasonably suggests clinical benefit or on evidence of the drug's effect on a clinical endpoint other than survival or irreversible morbidity, pending completion of studies to establish and define the degree of clinical benefits to patients; and (2) when FDA determines that a drug, effective for the treatment of a disease, can be used safely only if distribution or use is modified or restricted. Drugs or biological products approved under this final rule will have met the requisite standards for safety and effectiveness under the act or the PHS Act and, thus, will have full approval for marketing (21 CFR 314.510, 314.520, 601.41, and 601.42). Ordinarily, products used to treat serious or life-threatening illnesses, for which approval is based on a surrogate endpoint that is recognized as valid by definitive studies, will be considered for approval under the traditional process rather than under accelerated approval.

B. Criteria for Approval

Accelerated approval will be considered in two situations: (1) When approval can be reliably based on evidence of the drug's effect on a surrogate endpoint that reasonably suggests clinical benefit or on evidence of the drug's effect on a clinical endpoint other than survival or irreversible morbidity, pending completion of studies to establish and define the degree of clinical benefits to patients; and (2) when FDA determines that a drug, effective for the treatment of a disease, can be used safely only if distribution or use is modified or restricted. Drugs or biological products approved under this final rule will have met the requisite standards for safety and effectiveness under the act or the PHS Act and, thus, will have full approval for marketing (21 CFR 314.510, 314.520, 601.41, and 601.42). Ordinarily, products used to treat serious or life-threatening illnesses, for which approval is based on a surrogate endpoint that is recognized as valid by definitive studies, will be considered for approval under the traditional process rather than under accelerated approval.

C. Postmarketing Studies

Where a drug's approval under these provisions is based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity, the applicant will be required to conduct clinical studies necessary to verify and describe the drug's clinical benefit and to resolve remaining uncertainty as to the relation of the surrogate endpoint upon which approval was based to clinical benefit, or the observed clinical benefit to ultimate outcomes. The requirement for any additional study to demonstrate actual clinical benefit will not be more stringent than those that would normally be required for marketing approval; it is expected that the studies will usually be underway at the time of approval. The proposed regulations have been revised to clarify that required postmarketing studies must also be adequate and well-controlled (21 CFR 314.510 and 601.41).

D. Restrictions on Use After Marketing

FDA may grant marketing approval of a drug or biological product shown to be effective where safe use can only be assured if distribution or use is restricted. Under this final rule, FDA may: (1) Restrict distribution to certain facilities or to physicians with special training or experience, or (2) condition distribution on the performance of other studies.
IV. Comments on the Proposed Rule

FDA received 54 comments on the proposed rule. The comments came from individuals, specific disease organizations, universities, pharmaceutical manufacturers, trade associations, health professionals, and professional societies. The comments reflect broad support and acceptance of the goal of expediting the approval of drugs intended for the treatment of serious and life-threatening illnesses. A number of comments asked that the proposal be finalized expeditiously without change. Many comments posed specific questions and raised important concerns.

A. General Comments

1. One comment suggested that the term “conditional approval” was less confusing and ambiguous than the term “accelerated approval.” The comment also referred to the statement in the proposal that “Drugs * * * approved under this proposal will have met the requisite standards * * * under the (act)” and argued that because postmarketing conditions may be imposed, this statement can only be read to say that the requisite standards under the act can only be met by a lower standard of evidence in hand, combined with assurance that further evidence will be obtained.

G. Termination of Requirements

In response to comments, the final rule provides that the requirements set forth in §§ 314.520, 314.530, and 314.550 for new drugs and antibiotics and §§ 801.42, 601.43, and 601.45 for biological products will be retained when FDA determines that the results of required postmarketing studies have demonstrated that the drug or biological product has clinical benefit, or, where restrictions on distribution or use have been imposed, when FDA determines that safe use of the drug or biological product can be ensured without such restrictions, e.g., through appropriate labeling. FDA will notify the applicant when these requirements no longer apply (21 CFR 314.580 and 601.46).

III. Effective Date

This regulation will become effective on January 11, 1993.

clinical outcome, a surrogate indicator is no more than a hypothetical construct. The comment asserted that the proposed rule’s endorsement of the use of unvalidated surrogate endpoints, therefore, appears to represent a significant departure from traditional agency interpretations of “substantial evidence” within the meaning of the act because it allows belief rather than evidence to serve as the basis for a conclusion about the effectiveness of a new drug.

Three comments asserted that the new regulations are not needed to approve drugs intended to treat serious or life-threatening illnesses. Two comments cited FDA’s approval, without new regulations, of didanosine (formerly called ddl) and zalcitabine (formerly called ddc) in combination with zidovudine (formerly called AZT) based on surrogate markers of CD4 cell counts in C4D4 cell counts and the “subpart E” procedures at 21 CFR part 312, which address the need for expediting the development, evaluation, and marketing of new therapies intended to treat life-threatening or severely debilitating illnesses as examples of existing mechanisms for the expedited approval of important new drugs. One comment argued that the act requires that drugs be shown to be “safe” and “effective,” and proof of effectiveness is not limited by the act to demonstration of an effect on “survival or irreversible morbidity,” as the proposed rule seems to assume. The comment further argued that FDA has considerable statutory discretion to define what type of data constitutes proof of effectiveness, and demonstration of an effect on a surrogate marker is one type of such proof.

The agency believes that what the procedures are called is much less important than what the procedures are. The shorthand term selected by the agency reflects the intent of the rule, especially that part related to use of surrogate markers, which is to make drugs that provide meaningful improvement over existing therapies for serious illnesses widely available (through marketing) at the earliest time consistent with the law. The essence of the proposal is thus acceleration, not the imposition of conditions. Approval under these procedures is dependent on compliance with certain additional requirements, such as timely completion of studies to document the expected clinical benefit. The evidence available at the time of approval under this rule will meet this surrogate standard, in that there must be evidence from adequate and well-controlled studies showing that the drug will have
the benefit and labeling will refer to the well-controlled studies, must, in the judgment of the agency, be clinically meaningful. Moreover, the safety standard in the act, that a drug must be shown to be safe for its intended use, implies a risk/benefit judgment. The effect shown must be such as to outweigh the risks of the treatment under the conditions of use. Approval under this rule requires, therefore, that the effect shown be, in the judgment of the agency, clinically meaningful, and of such importance as to outweigh the risks of treatment. This judgment does not represent either a "lower standard" or one inconsistent with section 505(d) of the act, but rather an assessment about whether different types of data show that the same statutory standard has been met.

Approval based on surrogate endpoints is not new, although the issue has not previously been considered in regulations. The agency has, in a number of instances, approved drugs based on surrogate endpoints. For example, drugs for hypertension have been approved based on their effects on blood pressure rather than on survival or stroke rate. Similarly, drugs for hypercholesterolemia have been approved based on effects on serum cholesterol rather than on coronary artery disease (angina, heart attacks). But, in those cases there was very good evidence from clinical trials (in the case of blood pressure reduction) and epidemiologic and animal studies (in the case of hypercholesterolemia) that improving the surrogate would lead to or is associated with the desired effects on morbidity and mortality. Even so, there is still some debate about who will benefit from cholesterol lowering. Controlled trials assessing effects on clinical endpoints of morbidity and mortality from use of cholesterol-lowering drugs have been, and are being, conducted. Reliance on a surrogate endpoint almost always introduces some uncertainty into the risk/benefit assessment, because clinical benefit is not measured directly and the quantitative relation of the effect on the surrogate to the clinical effect is rarely known. The expected risk/benefit relationship may fail to emerge because: (1) The identified surrogate may not in fact be causally related to clinical outcome (even though it was thought to be) or (2) the drug may have a smaller than expected benefit and a larger than expected adverse event that could not be recognized without large-scale clinical trials of long duration. Reliance on surrogate markers therefore requires an additional measure of judgment, not only weighing benefit versus risk, as always, but also deciding what the therapeutic benefit is based upon the drug effect on the surrogate.

The sections of the final rule that address approval based upon a drug effect on a surrogate endpoint specifically clarify the regulatory approval criteria when the agency relies on a surrogate endpoint that, while "reasonably likely" to predict clinical benefit, is not so well established as the surrogate endpoint that is of the kind specified by section 505(f). Because postmarketing studies, the effect on the surrogate is not shown to correspond to a favorable effect on clinical benefit, the rule provides an expedited means of removing the drug from the market.

Approval of didanosine and zalcitabine under current procedures does not show that the rule is of no value. Although approval did rely on a surrogate endpoint that is of the kind specifically addressed by the rule, the fact that studies to define clinical benefit were nearly complete and were being conducted under the auspices of the National Institute of Allergy and Infectious Diseases made it less crucial to have additional guarantees that such studies would be conducted promptly. Moreover, the sponsors of didanosine and zalcitabine agreed prior to approval to expedited withdrawal of the drug from the market if benefit were not shown. The provisions of the final rule will ensure that safeguards exist for timely generation of data on actual clinical benefit, for appropriate promotional information about labeled indications, and for prompt withdrawal of the drug from the market if clinical benefit is not confirmed.

2. Pointing to a statement in the preamble to the proposed rule that it is in the public interest to make promising new treatments available at the earliest possible point in time for use in life-threatening and serious illnesses, one comment expressed concern that the proposed rule may lead to the marketing of large numbers of clinically ineffective, but pharmacologically active, drugs and this may not be in the interest of the public health. The comment argued that early access to so-called "promising" drugs is not the same as early access to safe and effective drugs, and the number of potential markers that may be advanced as surrogates of clinical outcome is exceedingly large. The comment suggested that it may be more appropriate to seek adoption of the proposed requirements through an amendment to the act.

FDA agrees with the contention that providing people who have serious or life-threatening illnesses with numerous clinically ineffective drugs would not be helpful. However, the agency does not agree that the rule can be expected to have this result. Although studies using surrogate endpoints may provide less assurance of clinical benefit than studies using clinical endpoints, FDA believes compliance with all of the elements of the accelerated approval program will not result in the marketing of large numbers of clinically ineffective drugs. The new procedures apply to a limited group of circumstances, namely, to drugs intended for serious or life-threatening illnesses when the drugs provide a meaningful therapeutic benefit over existing therapy. Reliance on a surrogate endpoint is not equivalent to reliance on any evidence of pharmacologic activity. The endpoint must be reasonably likely, based on epidemiologic, therapeutic, pathophysiological, or other evidence, to predict clinical benefit.

Whether a given endpoint is, in fact, reasonably likely to predict clinical benefit is inevitably a matter of judgment. FDA, using available internal and external expertise, will have to make informed judgments in each case presented, just as it does now. The agency acknowledges that there are well-recognized reasons for caution when surrogate endpoints are relied on. Certain putative surrogates have ultimately been shown not to correlate with clinical benefit. Perhaps the most noteworthy example is the failure of antiarrhythmic agents in the Cardiac Arrhythmia Suppression Trial (CAST) to improve survival by depressing ventricular ectopic beats; effective suppression of ectopic beats was associated with increased mortality. A sponsor must persuasively support the reasonableness of the proposed surrogate as a predictor and show how the benefits of treatment will outweigh the risks. Such proof is more likely to be persuasive only when the disease to be treated is particularly severe (so...
that considerable risk is acceptable) and/or when the surrogate endpoint is well supported. In addition, it will be the sponsor’s clear obligation to resolve any doubts as to clinical value by carrying out definitive studies. FDA does not agree that it would be more appropriate to seek an amendment to the act than to adopt the proposed requirements. As discussed in the preamble to the proposed rule as well as elsewhere in this preamble to the final rule, existing provisions of the act and the PHS Act authorize promulgation of the requirements in the final regulations.

3. One comment expressed concern that because the proposed rule would establish conditions for a drug’s approval, third-party payors may decline reimbursement because the so-called approval would have attributes of investigational status. The agency expects that, because drugs approved under the accelerated approval process meet the statutory standards for safety and effectiveness, they would be eligible for reimbursement under State Medicaid programs or other third-party plans. Drug products granted accelerated approval will not be, under the law, investigational, as suggested by the comment.

4. One comment asked if all drugs covered for accelerated approval must be reviewed by an advisory committee. The comment stated that because advisory committees meet infrequently, waiting for the next meeting may slow down the approval process. FDA is not required to consult with an advisory committee before approving an application under these accelerated approval regulations, or any other regulation. However, FDA intends to consult the appropriate committee in most instances. Advisory committee meetings can usually be scheduled to avoid significant delays in the review process. The agency will consider any request by an applicant for referral of the application to an advisory committee.

B. Scope

5. Four comments asked for further clarification of what diseases are covered by the rule. One comment stated that the terms “serious,” and “life-threatening,” are defined in the proposal by reference to 21 CFR 312.34, followed by a brief statement explaining the role of judgment and examples of diseases that are currently judged to be serious. The comment asked that FDA also describe: (1) Diseases that are not currently included in the category of “serious,” (2) examples of diseases that are currently judged “life-threatening,” and (3) examples of diseases that are not currently included in the category “life-threatening.”

One comment contended that the statement in the preamble that “seriousness of a disease is a matter of judgment, but generally is based on its impact on such factors as survival, day-to-day functioning, or the likelihood that the disease, if left untreated, will progress from a less severe condition to a more serious one” too narrowly limits diseases covered by the proposed rule (57 FR 13234 at 13235). The comment argued that some “less severe” diseases, even if treated, may progress to a more serious state, and that these diseases should also be covered by the rule. On the other hand, two comments argued that the language in the preamble that classifies diseases as “serious” was overly broad and subjective and far too large a number of illnesses could be eligible as being “serious.”

FDA discussed the meaning of the terms “serious” and “life-threatening” in its final rules on “treatment IND’s” (52 FR 19466 at 19467, May 22, 1987) and “subpart E” procedures (54 FR 41516 at 41518-41519, October 21, 1988). The use of these terms in this rule is the same as FDA defined and used the terms in those rulemakings. It would be virtually impossible to name every “serious” and “life-threatening” disease that would be within the scope of this rule. In FDA’s experience with “treatment IND’s” and drugs covered by the “subpart E” procedures there have not been problems in determining which diseases fall within the meaning of the terms “serious” and “life-threatening,” and FDA would expect no problems under this accelerated approval program. The likelihood of progression to a serious condition with available treatments would also be considered in assessing whether the disease is within the scope of the final rule. The preamble to the proposed rule (57 FR 13234 at 13235) referred to chronic illnesses that are generally well managed by available therapy, but can have serious outcomes for certain populations or in some or all of their phases. Applicants are encouraged to consult with FDA’s reviewing divisions early in the drug development process if they have questions about whether their specific product is within the scope of this rule. The concerns expressed in these and other comments about considering too many illnesses eligible for consideration under the accelerated approval procedures may arise from the underlying fear that reliance on surrogate endpoints will become routine, the “normal” way drugs are brought to the market. This fear is groundless. The vast majority of drugs are directed at symptomatic or short-term conditions (pain, heart failure, acute infections, gastrointestinal complaints) whose response to drugs, if it occurs, is readily measured and where there is no need to consider surrogates. Surrogates, with few exceptions, are of interest in the following situations: (1) Where the clinical benefit, if there is one, is likely to be well in the future; and (2) where the implications of the effect on the surrogate are great because the drug has no treatment at all or the drug seems to treat people with no alternative (e.g., because they cannot tolerate the usual effective treatment). In the first case, great care is needed, and would be given, as there would generally be no experience linking an effect on the surrogate to clinical success, and there have been conspicuous examples of lack of linkage (CAST, referred to above; drugs that increase cardiac output in patients with heart failure but that decrease survival; imperfect agreement of effects on coronary artery patency and effects on survival in patients with myocardial infarction; lack of beneficial effect on bone fracture rate despite favorable effects on bone density in patients with osteoporosis). FDA and outside experts will be aware of these examples as proposed surrogates are considered. The implication is especially great when considering prophylactic therapy, i.e., treatments to prevent chronic illness (coronary artery disease, cancer), in an essentially well population. In the second case, there will generally have been experience (with the standard therapy) to evaluate in considering linkage of the surrogate to benefit; this was, for example, the case with didanosine, where evidence from zidovudine studies of the relationship of an effect on CD4 lymphocytes and clinical outcome could be assessed. Similarly, there is considerable experience to show that durable complete responses in many cancers correspond to improved survival, so that an agent inducing them in refractory illness or in primary

EX. 8 pg. 018

App. 0120
disease that had previously been poorly responsive would generally be seen as reasonably likely to provide a clinical benefit.

6. One comment stated that epilepsy is a serious and life-threatening condition and asked that it be included within the scope of the proposal. The preamble cited, among other illnesses, depression and psychoses as examples of chronic illnesses that can have serious outcomes even if they are generally well managed. One comment asserted that neither epilepsy nor psychosis is a disease, nor is either one serious or life-threatening. The comment stated that depression and psychosis are diagnoses. The comment urged the agency to remove them from the definition of “illnesses” or “diseases.” With respect to epilepsy, FDA notes that in the “treatment IND” final rule (52 FR 19466 at 19467, May 22, 1987), the agency listed “certain forms of epilepsy” as an example of a disease or stage of disease that would normally be considered “serious.” Certain forms of epilepsy may also be considered “serious” under the accelerated approval program. It is unlikely, however, that a surrogate endpoint would be utilized in such a case, as seizure frequency, a clinical endpoint, is readily measured.

FDA’s reference to depression and psychosis is intended to give examples of conditions or diseases that can be serious for certain populations or in some or all of their phases. While drugs for the treatment of depression and psychosis would be examples of those that could be covered by the accelerated approval program, it is not the use of surrogate endpoints that would be expected; the symptoms and signs of these diseases are readily studied. On the other hand, some of these drugs have been quite toxic (e.g., clozapine for refractory psychoses) and might be considered for approval with restrictions to ensure safe use.

7. Two comments asked how FDA will decide that a drug is eligible for accelerated approval. One comment asserted that the decision should be an option for the applicant to consider, not a decision for FDA to make unilaterally. Pointing to a statement in the preamble (57 FR 13234 at 13235) that FDA reserves the right not to apply accelerated approval procedures when it believes in good faith that the drug’s foreseeable use is reasonably likely to be outside the scope of “life-threatening diseases without meaningful therapeutic benefit over existing therapy,” the comments argued that, if there are patients with life-threatening conditions that can benefit from expedited approval, the needs of the patients should determine the procedures used to approve the drug. One comment contended that applicants of products considered candidates for accelerated approval may have their drug or biological product “forced” into the accelerated approval process and be forced to conduct a program of studies to substantiate that surrogate endpoints actually predict significant clinical benefits.

The medical review divisions within FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) will determine the type of regulatory review that FDA may apply to a particular drug. FDA encourages sponsors to meet with FDA early in the drug development process to discuss the applicability of the accelerated approval program to their product; however, FDA reserves the discretion to determine whether these procedures are applicable to a specific product.

With respect to the preamble statement cited by one comment, the comment misreads the preamble statement, which does not say that FDA will, in all cases, apply FDA’s traditional approval mechanisms rather than this accelerated process for drugs where a majority of the drug’s foreseeable uses are outside the scope of “life-threatening diseases without meaningful therapeutic benefit over existing therapy.” The statement merely informs applicants that FDA will consider the possible impact of widespread use of a drug for uses other than the one supporting accelerated approval; drugs approved under this program would often have only small safety data bases so that widespread off-label use might have serious implications. The agency does not believe that such a situation would regularly lead to exclusion from these provisions.

FDA does not agree that applicants seeking approval to market drug and biological products that would be considered eligible for accelerated approval will be forced to use the accelerated approval mechanism. It is true, however, that some proposed surrogate endpoints would not be considered acceptable bases for approval without assurance that the clinical studies to show clinical benefit will be conducted. A sponsor that wishes the application to be considered under the traditional approval process may request and receive such consideration.

The agency wishes to clarify the circumstances in which the accelerated approval regulations will apply. Sections 314.500 and 601.40 describe aspects of the scope of these regulations. Moreover, these regulations are intended to apply to applications based on surrogate endpoints whose validity is not fully established, to applications based on clinical endpoints that leave unanswered major questions about the product’s effect on ultimate outcome, and to applications for products whose safe and effective use requires limitations on distribution or use. In all other situations, accelerated approval requirements will not apply.

Where approval is based on a surrogate endpoint that is accepted as validated to predict or correlate with clinical benefit, the product will be considered under the traditional process, and the postmarketing requirements under accelerated approval will not apply. Approvals of products for serious or life-threatening illnesses based on clinical endpoints other than survival or irreversible morbidity will usually also be considered under traditional procedures. Approvals based on such clinical endpoints will be considered under the accelerated approval regulations only when it is essential to determine effects on survival or irreversible morbidity in order to confirm the favorable risk/benefit judgment that led to approval.

The agency also wishes to clarify that whenever an application is approved under §§ 314.510 or § 601.41, postmarketing studies confirming the product’s clinical benefit will thus be required. Therefore, in order to eliminate potential confusion, the agency has amended §§ 314.510 and 601.41 to clarify these points.

FDA also recognizes that over time a particular surrogate, once acceptable as a basis for approval only under the accelerated approval regulations, could become recognized as validated by definitive studies (just as high blood pressure, for example, over time became validated as a surrogate with clinical significance). In such cases, a future application relying on such a surrogate would not require postmarketing studies confirming the surrogate’s clinical benefit and the application would be considered under traditional procedures.

8. Two comments asked for clarification of the phrase “meaningful therapeutic benefit.”
C. Criteria for Approval

11. Two comments expressed concern that the proposal did not provide enough detail on what constitutes an appropriate surrogate endpoint. One comment recommended that FDA adopt specific criteria for what constitutes an appropriate surrogate endpoint. The comment suggested that such criteria should include: (1) The surrogate endpoint must be biologically plausible in that it must be consistent with what is known about the pathophysiology and pathogenesis of the disease; (2) the surrogate endpoint must be present or abnormal in a large percentage of people who have the disease; (3) the surrogate endpoint must be a good predictor of the disease progression and should correlate closely with the significant clinical endpoint; (4) there should be a correlation between the quantitative aspect of the surrogate endpoint and the progression of the disease (e.g., the more severe the disease, the more deviant the surrogate endpoint from normal); (5) the regression of the surrogate endpoint should be significantly associated with clinical improvement (e.g., those with the greatest improvement in the surrogate endpoint should also show the greatest clinical effects); conversely, the lack of regression of the surrogate endpoint should be commonly associated with a lack of clinical improvement; and (6) the incidence of regression or improvement from the surrogate endpoint should be significantly greater in treated than untreated patients.

One comment asked if the use of microalbuminuria data is a surrogate for diabetic nephropathy and if all drugs relying on surrogate endpoints would be eligible for accelerated approval, e.g., an angiotensin receptor antagonist with potential utility for treatment of congestive heart failure. The comment also asked what would happen if postmarketing studies demonstrate beneficial changes of surrogate endpoints but not beneficial clinical endpoints. The comment also asked if FDA will consider publishing guidelines on which surrogate endpoints would be appropriate for the diseases that may be affected by the proposed rule. Another comment expressed the belief that there is no evidence that surrogate endpoints are necessarily good indicators of therapeutic benefit. The comment stated that a drug may have an effect on a surrogate endpoint, but will not make any clinical difference because the advanced stage of the patient’s disease precludes any effective therapy or the surrogate marker is not synchronous with the patient’s clinical condition. Another comment asserted that the requirement to base an approval on a surrogate endpoint that is “reasonably likely” to show benefit is necessarily good indicators of therapeutic benefit. The comment expressed the belief that there is no evidence that surrogate endpoints are necessarily good indicators of therapeutic benefit. The comment argued that until a correlation is shown, the use of surrogate endpoints is not a meaningful benefit and would be a waste of the agency’s time and resources by applying accelerated approval procedures when a drug previously approved under the accelerated approval provisions because the drug exhibits a “clear improvement” over an existing drug that was also granted accelerated approval, then specific restrictions will be placed on the prior approved drug to limit its use only to patients who do not tolerate the new drug or whose physicians assess that a change to the new drug might involve significant risks to the patient that outweigh the benefits. One comment asked that the term “meaningful therapeutic benefit over existing therapy” be interpreted and consistently applied to all drugs and biological products.

FDA believes that the examples given to help clarify the phrase “meaningful therapeutic benefit over existing therapy” (ability to treat unresponsive or intolerant patients or improved response compared to available therapy) are readily understood illustrations of the intent of the requirement. A drug that is essentially the same as an existing treatment that is as effective as a “me too” drug will not have a credible claim to a meaningful therapeutic benefit over that existing treatment and this should be easily detected. With respect to restricting use of a drug previously approved under accelerated approval procedures when a new drug granted accelerated approval is a clear improvement over the prior approved drug, this would rarely be appropriate. Although, in some instances, certain therapies are identified as “second-line,” this requires essentially unequivocal evidence of an advantage of alternative therapy, not likely on the basis of a surrogate endpoint. Labeling for both approved drug and the prior drug properly.

9. One comment asked if a change in the route of administration would be considered as a meaningful benefit and within the scope of the proposal. A change in the route of administration may be a candidate for accelerated approval depending upon the particular evidence presented.

10. One comment asked if subpart E drugs currently under investigation will be considered for accelerated approval. The comment assumed that new drug applications (NDA’s) and supplemental NDA’s considered for accelerated approval will have the highest priority for review.

Subpart E drugs will be considered for accelerated approval if they satisfy both eligibility criteria for accelerated approval, i.e., if they are being developed for the treatment of serious or life-threatening illnesses and the products will provide meaningful therapeutic benefits to patients over existing treatment. As discussed above, applicants should consult with FDA early in the development process to determine the nature of the regulatory review. Early consultations are a critical part of subpart E procedures. Drugs being reviewed under accelerated approval procedures will receive high priority review. However, applications for drugs for acquired immunodeficiency syndrome (AIDS) and human immunodeficiency virus (HIV)-related conditions will receive the highest priority review.

F. Regulatory Action

12. On December 21, 1989, the FDA announced the adoption of the proposed rule. 54 Federal Register / Vol. 57, No. 239 / Friday, December 11, 1992 / Rules and Regulations 58947
regulation. Any given specifications may not be applicable to a particular case. For example, the thoughtful suggested criteria supplied by the comment would rarely, if ever, be applicable to the first effective drug for a disease, because criterion 5 requires that regression of the surrogate endpoint be associated quantitatively with clinical improvement. If there had never been effective treatment, this would never be known. Yet the surrogate could be persuasive on other grounds, such as a well-documented etiologic relation. In general, it is likely that one or another strongly supportive piece of evidence might outweigh gaps in other areas.

In developing informal guidance on surrogate endpoints, FDA will consider the suggestions in this comment. Interested persons will have an opportunity to comment on any guidance documents in this area developed by the agency. In some cases, new or revised drug class, or disease-specific, clinical guidelines may refer to surrogate endpoints. FDA is not prepared, at this time, to comment on the acceptability of an endpoint that it has not specifically considered, e.g., microalbuminuria.

The final regulations make it clear that not all drugs submitted for approval based on surrogate endpoint data are eligible for accelerated approval (§§ 314.500 and 601.40). The drug in question must be for a serious or life-threatening condition and must provide meaningful therapeutic benefit over existing therapy. In the case of an angiotensin receptor antagonist posed by the comment, there is existing documented life-prolonging treatment for congestive heart failure. An application for a new agent, to be eligible for accelerated approval, would have to show potential benefit over available therapy as well as identify a reasonable surrogate endpoint. This is problematic since no accepted surrogate endpoint for studies to treat congestive heart failure has been identified to date. For example, some drugs with favorable effects on hemodynamic measures in heart failure patients have been clinically ineffective.

The regulations are clear in requiring that, for drugs approved under these provisions based on surrogate endpoints, the postmarketing studies must show clinical benefit, not just the previously shown effect on the surrogate (§§ 314.510, 314.530, 601.41, and 601.43).

Surrogates, or proposed surrogates, are not always good, nor necessarily bad. Indicators of therapeutic benefit and must be judged on a case-by-case basis. Even very good surrogates may not be perfect: Blood pressure lowering has been a better predictor of effect on stroke than on coronary artery disease, cholesterol lowering has had a clearer effect on coronary artery disease than on survival. Moreover, a surrogate may be persuasive for a phase of disease with short expected survival but much less so in an earlier phase of the disease. Caution is always appropriate in evaluating surrogate endpoints and the particular therapeutic setting should always be considered. The agency believes that the evaluation of surrogate endpoint data and the safeguards built into these accelerated approval procedures will provide adequate consumer protection.

12. One comment expressed concern that if there is no accepted surrogate endpoint, an applicant's only option is to conduct a study using some clinical event as an endpoint, which may result in long, large studies that delay approval to the detriment of patients and sponsors. One comment suggested as an alternative that FDA permit approval of a drug based on a study using a clinical endpoint, but accept a less rigorous standard of statistical significance, e.g., 0.20 or 0.15 instead of 0.05. The comment further suggested that the sponsor could then complete postmarketing studies to establish statistical significance at conventional levels. The comment argued that this alternative is totally consistent with FDA's willingness to accept greater uncertainty in approving drugs for serious and life-threatening illnesses.

The intent of the rule is to allow FDA to utilize a particular kind of evidence, an effect on a surrogate endpoint, as a basis for approval, and, where appropriate, to ensure that remaining doubts about the relationship of the effect on the surrogate to clinical benefit are resolved by additional adequate and well-controlled studies with clinical endpoints. The rule is not intended to place into the market drugs with little evidence of usefulness. Although there is no statutory requirement for significance testing of any particular value, there are well-established conventions for assessing statistical significance to support the statistically required conclusion that the well-controlled studies have demonstrated that a drug will have the effect it is represented to have. There is nothing about serious or life-threatening diseases that make them uniquely difficult to study. A meaningful effect on survival or morbidity where there is no effective therapy should be readily discerned. The study should be long and large only when the effect is small or difficult to detect. In that event, proper assessment of benefit, and valid weighing of its relation to risk, is especially critical.

13. One comment asked that FDA clarify that one study could be the basis of approval and that postmarketing study should be all that is needed to establish the link between the endpoint used for approval and some relevant clinical benefit. FDA interprets the statute, and good science, as requiring at least two adequate and well-controlled studies to establish effectiveness. In some instances, drugs have been approved on the basis of a single well-controlled study; this has been done where the study was of excellent design, showed a high degree of statistical significance, involved multiple study centers, and showed some evidence of internal replicability, e.g., similar effects in different study subsets. Interested persons are encouraged to discuss with FDA early in a drug's development the basis for the applicant's choice of a specific endpoint, and, where applicable, the basis for its belief that a single study would be a sufficient basis for approval. With respect to postmarketing studies, FDA anticipates that the requirement will usually be met by studies already underway at the time of approval. As stated in the proposed rule, the requirement for any additional study to demonstrate actual clinical benefit will not be more stringent than those that would normally be required for marketing approval of the same drug for the same claim.

14. One comment expressed concern that the preamble to the proposed rule implied that a sponsor of an AIDS drug might have to do a postmarketing study to establish an effect on survival after showing an effect on such endpoints as weight or incidence of opportunistic infection (57 FR 13234 at 13235-13236). The comment stated that FDA's own advisory committee indicated that it was pleased to see an effect from a nucleoside analogue on the incidence of opportunistic infections with AIDS patients but did not suggest that further work should be done to show an effect on mortality. The comment argued that in some cases direct correlation with clinical endpoints such as mortality is difficult to prove and urged FDA to be flexible on this issue to encourage sponsors to go through the accelerated approval process.

Ordinarily, an effect on a meaningful clinical endpoint, e.g., on rate of opportunistic infections in AIDS, is a sufficient basis for approval without need for followup studies. Other endpoints, however, might issue major questions unanswered. For example,
modest effect on weight gain in AIDS without other demonstrated benefit, if considered an adequate basis for approval, while a clinical endpoint, might leave sufficient doubt as to the ultimate value of the effect so that further studies would be necessary. FDA intends to interpret this provision of the regulations with flexibility. This provision should also serve as a reminder, however, that for life-threatening diseases, the ultimate aim of therapy is improved survival as well as improved symptoms.

15. One comment asked FDA to clarify what a sponsor’s obligation is to continue supplying medication on a compassionate basis. The comment stated that it is not demonstrated that the patient’s safety is demonstrated. For instance, one comment contended that the likelihood of a drug’s effectiveness is not established by FDA’s satisfaction in postmarketing studies but will be the responsibility of the physician. One comment considered requiring advance submission of promotional materials unreasonable because companies are not required to do so now. One comment questioned the legal authority for requiring presubmission of promotional material following approval of a drug product, and the reason for the requirement. The agency believes that the requirement for submission of promotional materials in the context of accelerated approval is authorized by statute. Subsections 505(d)(4) and (d)(5) of the act provide that, in determining whether to approve a drug as safe and effective, the agency may consider not only information such as data from clinical studies but also “any other information” relevant to safety and effectiveness under the proposed conditions of use. Such information may include information about how the drug would be promoted. In determining whether the drug’s proposed labeling would be “false or misleading” under section 505(d)(7) of the act, the agency is similarly authorized to evaluate “all material facts” during the approval process, including the facts about promotion.

FDA is also authorized by section 505(k) of the act to require reporting of information subsequent to approval necessary to enable the agency to determine whether there may be grounds for withdrawing the approval. Among the grounds for withdrawal specified in section 505(e) of the act are that the evidence reveals the drug is not shown to be safe and effective under its conditions of use. In addition, drug approval may be withdrawn if information shows the labeling to be false or misleading. Information on how the drug will be promoted is important to the ultimate value of the effect so that there may be grounds for withdrawing the approval. The agency believes that advance submissions of promotional materials for drugs intended to treat serious diseases are more likely to be misleading than for other types of drugs because any such assumption would be unfounded. One comment argued that if an advertisement or labeling is inaccurate, the product is mislabeled and FDA could then obtain injunctive relief, seize the product, and/or initiate criminal proceedings. Another comment considered requiring advance submission of promotional materials unreasonable because companies are not required to do so now. One comment questioned the legal authority for requiring presubmission of promotional material following approval of a drug product, and the reason for the requirement.

The agency believes that the requirement for submission of promotional materials in the context of accelerated approval is authorized by statute. Subsections 505(d)(4) and (d)(5) of the act provide that, in determining whether to approve a drug as safe and effective, the agency may consider not only information such as data from clinical studies but also “any other information” relevant to safety and effectiveness under the proposed conditions of use. Such information may include information about how the drug would be promoted. In determining whether the drug’s proposed labeling would be “false or misleading” under section 505(d)(7) of the act, the agency is similarly authorized to evaluate “all material facts” during the approval process, including the facts about promotion. FDA is also authorized by section 505(k) of the act to require reporting of information subsequent to approval necessary to enable the agency to determine whether there may be grounds for withdrawing the approval. Among the grounds for withdrawal specified in section 505(e) of the act are that the evidence reveals the drug is not shown to be safe and effective under its conditions of use. In addition, drug approval may be withdrawn if information shows the labeling to be false or misleading. Information on how the drug will be promoted is important to the ultimate value of the effect so that there may be grounds for withdrawing the approval. The agency believes that advance submissions of promotional materials for drugs intended to treat serious diseases are more likely to be misleading than for other types of drugs because any such assumption would be unfounded. One comment argued that if an advertisement or labeling is inaccurate, the product is mislabeled and FDA could then obtain injunctive relief, seize the product, and/or initiate criminal proceedings. Another comment considered requiring advance submission of promotional materials unreasonable because companies are not required to do so now. One comment questioned the legal authority for requiring presubmission of promotional material following approval of a drug product, and the reason for the requirement.

The agency believes that the requirement for submission of promotional materials in the context of accelerated approval is authorized by statute. Subsections 505(d)(4) and (d)(5) of the act provide that, in determining whether to approve a drug as safe and effective, the agency may consider not only information such as data from clinical studies but also “any other information” relevant to safety and effectiveness under the proposed conditions of use. Such information may include information about how the drug would be promoted. In determining whether the drug’s proposed labeling would be “false or misleading” under section 505(d)(7) of the act, the agency is similarly authorized to evaluate “all material facts” during the approval process, including the facts about promotion. FDA is also authorized by section 505(k) of the act to require reporting of information subsequent to approval necessary to enable the agency to determine whether there may be grounds for withdrawing the approval. Among the grounds for withdrawal specified in section 505(e) of the act are that the evidence reveals the drug is not shown to be safe and effective under its conditions of use. In addition, drug approval may be withdrawn if information shows the labeling to be false or misleading. Information on how the drug will be promoted is important to the ultimate value of the effect so that there may be grounds for withdrawing the approval. The agency believes that advance submissions of promotional materials for drugs intended to treat serious diseases are more likely to be misleading than for other types of drugs because any such assumption would be unfounded. One comment argued that if an advertisement or labeling is inaccurate, the product is mislabeled and FDA could then obtain injunctive relief, seize the product, and/or initiate criminal proceedings. Another comment considered requiring advance submission of promotional materials unreasonable because companies are not required to do so now. One comment questioned the legal authority for requiring presubmission of promotional material following approval of a drug product, and the reason for the requirement.
be helpful but are always somewhat delayed. Under the circumstances of accelerated approval, FDA believes that it is far preferable to avoid problems by reviewing the promotional materials in advance of approval and of dissemination of the materials.

17. Two comments supported the provision about submission of promotional materials. One comment urged the agency to require that specific patient information be included in promotional materials to indicate the fact that the drug's clinical benefit has not yet been established. For drugs approved under the restricted use provision, the comment recommended that the labeling specify in detail the exact restrictions placed on the drug. In both cases, the comment recommended that this patient information appear as boxed warnings.

Section 520.2(f) of the act and regulations at § 302.1(f)(1) (21 CFR 302.1(f)(1)) require prescription drug advertisements (promotional material) to contain, among other things, a true statement of information in brief summary relating to side effects, contraindications, and effectiveness, which would include warnings, precautions, and limitations on use. The information in brief summary relating to side effects, contraindications, and effectiveness is required to be included solely on the approved labeling. Therefore, to the extent that a drug's labeling reflects the extent of clinical exposure and includes appropriate warnings, a drug's promotional material would also include this information.

FDA regulations governing prescription drug labeling (21 CFR 201.56 and 201.57) require that serious adverse reactions and potential safety hazards, as well as limitations in use imposed by them, be included in the "Warning" section of the labeling. In the case of approval based upon effect on a surrogate endpoint, the "Indications and Usage" section of the labeling would reflect the nature of the demonstrated effect. If the approval is based on use restrictions, the label would also specify the restrictions.

FDA may require boxed warnings if there are special problems associated with a drug, particularly those that may lead to death or serious injury (21 CFR 201.57(c)). The agency does not agree that information related to clinical benefit or use restrictions for accelerated approval drugs would necessarily always require a boxed warning. As indicated by §§ 314.550 and 601.45 of the final rule, applicants will be required to submit all promotional materials prior to approval and in advance of dissemination subsequent to approval whether the product is a new drug, an antibiotic, or a biological product.

18. One comment contended that FDA review and approval of all promotional pieces before their use will indefinitely delay product marketing campaigns and other patient and physician educational activities, which are essential to market a product, thereby significantly diminishing the advantage of securing an early approval for the applicant. The comment further contended that the requirement to submit "all promotional materials * * * intended for dissemination or publication upon marketing approval" will be overly burdensome for FDA and will unnecessarily slow down the process for review of all materials, not just those for products subject to this proposed rule. The comment recommended that FDA only request for review the primary advertising pieces, such as the introductory letter to physicians, the main detail piece, and the main journal advertising, but not the secondary materials, e.g., a letter to pharmacists, of the initial promotional campaign.

As previously discussed in this preamble, FDA will be reviewing an applicant's planned promotional materials both prior to approval of an application (reflecting the initial campaign) and subsequent to approval to ascertain whether the materials might adversely affect the drug's sensitive risk/benefit balance. Because all promotional materials, including those referred to by the comment as "secondary" materials, can have significant adverse effects if they are misleading, the agency does not agree that such materials should, as a matter of course, not be requested for review. Insofar as such materials may be directly derived from the introductory letter to physicians, or other materials characterized by the comment as "primary" materials, the additional time to review the derivative materials should not be extensive.

The agency does not agree with the comment's contention that the requirement to submit all promotional materials prior to and subsequent to approval will indefinitely delay marketing campaigns and educational activities or be overly burdensome to FDA reviewers. FDA is committed to rapid review and evaluation of all drugs considered for approval under this rule and will promptly review the promotional materials.

19. One comment suggested a passive, time-limited clearance system for review of materials prior to and after the initial promotional campaign such as that used for review of IND's, which would allow the sponsor to proceed to use promotional materials after an allotted timeframe, such as 30 days, unless otherwise notified by FDA. As indicated by this comment and others, additional confusion regarding both timing and content of the submissions of promotional materials seems useful. Therefore, the agency is revising proposed §§ 314.550 and 601.45 to make it clear that, unless otherwise informed by the agency, applicants must submit during the preapproval review period copies of all promotional materials intended for dissemination or publication within the first 120 days following marketing approval. The initial promotional campaign, sometimes referred to as the "launch campaign," often has a significant effect on the climate of use for a new product. As discussed elsewhere in this preamble, the risk/benefit balance of accelerated approval products is especially sensitive, and inappropriate promotion may adversely affect the balance with resulting harm.

There may be some instances in which promotional materials that had not been completed and submitted by the applicant prior to approval would be beneficial in fostering safe and effective use of the product during the first 120 days. Under revised §§ 314.550 and 601.45, FDA would consider such materials at a later time. An applicant who requested permission to include additional materials among those disseminated within the first 120 days following product approval would be notified of FDA's determination. If FDA agreed that dissemination of such materials was acceptable, the materials could then be disseminated or published upon notification.

For promotional materials intended for dissemination subsequent to the initial 120 days under §§ 314.550 and 601.45, FDA would review the submitted materials within 30 days of receipt. This 30-day period is meant to be time-limited, so that the applicant will be assured of no unnecessary delay. It will be important for the applicant to identify the materials being submitted appropriately, so that it is clear that the materials are subject to the 30-day review period. The agency intends to review all such materials promptly, and to notify the applicant of any identified problems as soon as possible. The agency expects that, if the agency notifies the applicant of significant objections to the proposed materials, no materials will be disseminated until such objections are resolved. The applicant should plan to allow sufficient time after receiving
FDA's comments for resolving differences and incorporating requested changes in the submitted materials prior to dissemination or publication. When FDA removes the requirement for advanced submission of promotional material, the agency will continue to offer a prompt review of all voluntarily submitted promotional material.

E. Postmarketing Restrictions

FDA received many comments on the proposed requirement to limit distribution to certain facilities or physicians with special training or experience, or condition distribution on the performance of specified medical procedures if such restrictions are needed to counterbalance the drug's known safety concerns. Several comments questioned FDA's authority to impose restrictions on distribution or use after an approved drug is marketed. Two comments disagreed with the statutory provisions cited by FDA in the proposed rule as its authority to impose restrictions on distribution or use stating that they refer only to FDA's general authority to ensure that drugs are not misbranded, which is an entirely separate issue. Another comment argued that section 503(b) of the act (21 U.S.C. 353(b)) contemplates that the issues warranting a restriction as to distribution are not factors in whether a drug product is "safe" for purposes of approval, but rather only whether the product must be limited to prescription status. Two comments said that, in the absence of specific statutory authority, the courts clearly have refused to permit FDA to impose restrictions on distribution and cited American Pharmaceutical Association (APHA) v. Weinberger, 377 F. Supp. 824, 829 n. 9 (D.D.C. 1974), aff'd sub nom. APHA v. Mathews, 530 F.2d 1034 (D.C. Cir 1976), a case concerning conditions placed on the approval of the drug methadone.

Some comments asserted that placing restrictions on the distribution of an approved drug to only certain facilities or physicians, or restricting use to certain medical procedures interferes with the practice of medicine and pharmacy, which the comments contended FDA does not have the authority to regulate. The agency believes that the restrictions to ensure safe use contemplated for approvals under §§ 314.520 and 601.42 are authorized by statute. As discussed in the preamble to the proposed rule (57 FR 13234 at 13237), sections 501, 502, 503, 505, and 701 of the act provide broad authority for FDA to issue regulations to help assure the safety and effectiveness of new drugs. The agency does not agree with the comments' contention that the misbranding provisions of the act are irrelevant. Section 502(a) of the act prohibits false or misleading labeling of drugs, including (under section 201(n) of the act) failure to reveal material facts relating to potential consequences under customary conditions of use. Section 502(f) of the act requires drugs to have adequate directions for use and adequate warnings against unsafe use, such as methods of administration, that may be necessary to protect users. In addition, section 502(j) of the act prohibits use of drugs that are dangerous to health when used in the manner suggested in their labeling. Each of these misbranding provisions is intended, in significant part, to protect consumers against the marketing of drugs that would not be safe under certain conditions of use. Section 701(a) of the act authorizes FDA to issue regulations for the efficient enforcement of the act. The restrictions use contemplated by §§ 314.520 and 601.42 help to ensure that products that would be misbranded under section 502 of the act are not marketed.

The restrictions on use imposed under section 505 of the act, which relate to prescription use limitations, primarily concern whether a drug is safe for use except under the supervision of a licensed practitioner. While the agency agrees that the restrictions imposed under §§ 314.520 and 601.42 concerning distribution to certain facilities or physicians with special training or experience would be in addition to ordinary prescription limitation, FDA believes these restrictions are consistent with the spirit of section 503 of the act, as well as the other provisions of the act referred to, in ensuring safe use.

New drugs may be approved under section 505 of the act only if they are safe for use under the conditions prescribed, recommended, or suggested in the proposed labeling. In addition, for approval, a drug's labeling must not be false or misleading based on a fair evaluation of all material facts, which would include details about the conditions of use. For biological products, section 351(d) of the PHS Act also authorizes the imposition of restrictions through regulations "designed to assure the continued safety, purity, and potency" of the products. The agency disagrees with the comments' implication that the courts' rulings in American Pharmaceutical Association (APHA) v. Weinberger mean there is no statutory authority to impose restrictions on distribution for accelerated approval drugs. The situation considered in that case is readily distinguishable from the situation addressed in §§ 314.520 and 601.42 of the accelerated approval regulations. The APHA case concerned a regulation that withdrew approval of NDA's for methadone, but permitted distribution to certain maintenance treatment programs and certain hospital and community pharmacies. Because methadone is a controlled substance within the provisions of the Controlled Substances Act, which is implemented by the Drug Enforcement Administration with the Justice Department, the district court concluded that the question of permissible distribution of the drug was within the jurisdiction of the Justice Department, not FDA. The Court of Appeals determined that the type of misuse associated with methadone, i.e., misuse by persons who have no intent to try to use drugs for medical purposes, differed from safety issues contemplated for control under section 505 of the act. In contrast, the restrictions contemplated under §§ 314.520 and 601.42 are precisely those deemed necessary to ensure that section 505 criteria have been met, i.e., restrictions to ensure that the drug will be safe under its approved conditions of use. It is clearly FDA's responsibility to implement the statutory provisions regarding new drug approval.

Nor does FDA agree that the provisions placing restrictions on distribution to certain facilities or physicians, or conditioned on the performance of certain medical procedures, impermissibly interfere with the practice of medicine and pharmacy. There is no legal support for the theory that FDA may only approve sponsors' drugs without restriction because physicians or pharmacists may wish to prescribe or dispense drugs in a certain way. The restrictions under these provisions would be imposed on the sponsor only as necessary for safe use under the extraordinary circumstances of the particular drug and use. Without such restrictions, the drugs would not meet the statutory criteria, could not be approved for distribution, and would not be available for prescribing or dispensing. The agency, as a matter of longstanding policy, does not wish to interfere with the appropriate practice of medicine or pharmacy. In this instance, the agency believes that rather than interfering with physician or pharmacy practice, the regulations permit, in exceptional cases,
approval of drugs with restrictions so
that the drugs may be available for
prescribing or dispensing.
21. One comment asserted that
postmarketing restrictions on
distribution to certain facilities or
physicians with certain training or
experience should be limited to rare
occasions in cases of extreme hazard to
patient safety in which toxicity of a
particular drug may require it, but
should not be applied because of
insufficient data. Some comments argued
that safety issues in the context of drug use
should be addressed through patient management
and effective product labeling, not
through restricted distribution. In
support of this argument, the comments
cited the labeling of oncologic drugs,
which provides physicians with
adequate warnings and
recommendations for their use without
limiting distribution. FDA agrees with these comments in part
and intends to impose restrictions on
distribution or use under this rule
only in those rare instances in which
the agency believes carefully worded
labeling for a product granted
accelerated approval will not assure the
product’s safe use. As stated in the
proposed rule (57 FR 13243 at 13247), FDA believes that the
safe use of most prescription drugs will be
assured through traditional patient management
by health professionals and through
appropriate labeling.
22. Two comments asked who will
determine if restricted distribution
should occur and what facilities or
physicians with special training or
experience will participate. Several
comments expressed concern that
restricted distribution and/or
conditional use may not include all
health care professionals who should
participate in safe and effective patient
care. Two organizations representing
pharmacists asked that FDA develop
functional and objective criteria that
clearly establish the activities of
pharmacists, physicians, and others in
the care of patients receiving a drug
under restricted distribution. The
comments asserted that any health care
professional that met these criteria
should be allowed to participate in
distribution of the drug and care of the
patient. One comment recommended
that any postmarketing restrictions on
distribution or use of a drug approved
under the accelerated approval process
be developed by appropriate FDA
advisory committees or panels
expanded to include physicians and
pharmacists with expertise in the
therapeutic area being considered and
in relevant drug distribution systems. Where appointment of pharmacists to
these committees or panels is not
feasible, the comment recommended
that FDA use pharmacists in a
consultant capacity. Another comment
argued that current systems for drug
distribution incorporate “checks and
balances” such that prescribers and
pharmacists work together to assure safe
use of a drug by patients. Two
comments would oppose any restricted
distribution system that allows
manufacturers exclusively to deliver
prescription drugs directly to patients.
One comment asked whether FDA or
the applicant would monitor the criteria
for restricted distribution sites or
physicians.
23. One comment recommended that
proposed § 314.520 be modified to
include therapeutic outcomes
monitoring as a third example of a
permissible postmarketing restriction.
The comment defined therapeutic
outcomes monitoring as the systematic
and continual monitoring of the clinical
and psychosocial effects of drug therapy
on a patient which achieves the
objective of preventing problems with
drug therapy. Some comments argued
that through therapeutic outcomes
monitoring, a physician and pharmacist,
and a patient can work together to
prevent problems with drug therapy
by being constantly alert to signs of trouble.
One comment said that indicators data
can be routinely reported to a central
collection point for further review by
health care professionals, followed by
educational programs to further improve
the efficacy of drug therapy.
24. Some comments asked that FDA
clarify how products will move from
restrictive status to a regular
prescription drug status. The comments
asserted that all conditions associated
with accelerated approval should
automatically terminate following
completion of confirmatory clinical
trials; one comment urged FDA to
explicitly state this in the final rule. One
comment asserted that the conditions
should automatically be removed 180
days after a supplemental application
containing the data from the
postmarketing study has been filed if
FDA has not yet acted upon the
supplemental application and if the product
should be deemed approved as
by “traditional” procedures and all
other provisions of the act should apply,
e.g., the applicant must have a formal
hearing before removal of the product
from the market.
FDA will notify the applicant when a
particular restriction is no longer
necessary for safe use of the product. In
the case of drugs approved with a
requirement for postapproval studies,
FDA would expect that all of the
postapproval requirements set forth in
this rule, i.e., submission of promotional
material and use of expedited
withdrawal procedures, would no
longer apply after postmarketing studies
have verified and described the drug’s
clinical benefit. Concurrent with the
review of the postmarketing studies, if
requested, FDA will also review the
need to continue any restrictions on
distribution that have been imposed. In
the case where restrictions on
distribution or use have been imposed,
such restrictions would be eliminated
only if FDA determines that safe use of
the product can be assured without
them, through appropriate labeling. In
some cases, however, that assurance could not be expected and the nature of the specific safety issue raised by the product could not be evaluated. Restrictions. FDA has added new §§ 314.520 and 601.46 to state when postapproval requirements will no longer apply and state that the applicant may petition the agency, in accordance with 21 CFR 314.50, at any time to remove specific postapproval requirements. With respect to the suggested time period for removing restrictions on distribution or use following submission of a supplemental application containing the data from a postmarketing study, FDA does not believe it should prescribe any specific time period. These applications will receive a priority rating and FDA is firmly committed to expedited review of an application considered for accelerated approval and all data submitted from a postmarketing study to verify clinical benefit and believes most reviews will be completed and action taken within 180 days.

25. One comment argued that, as proposed, it is not clear how accelerated approval would apply to drugs which fall under the conditions described in §§ 314.520 and 601.42, which state the postmarketing restrictions on distribution or use that FDA may apply, because the language of these sections explicitly states that the sections apply to products "shown to be effective," which are already adequately covered by the act. To the comment, the language "shown to be effective" implies that full Phase 3 efficacy trials have been conducted, assessed, and deemed to demonstrate that the drug is effective for its proposed use. If the clinical data demonstrate that the product has an acceptable safety profile, the safe use of the drug should be addressed in the product labeling. Thus, the comment argued that §§ 314.520 and 601.42 should not be included in new subpart H of part 314 and subpart E of part 601, respectively, which deal with accelerated approval because these sections explicitly apply to products shown to be effective under a full drug development program. Sections 314.520 and 601.42 apply not only to drugs and biological products approved on the basis of an effect on a surrogate endpoint but also to drugs and biological products that have been studied for their safety and effectiveness in treating serious or life-threatening illnesses using clinical endpoints and that have serious toxicity. In either case, if the products are so potentially harmful that their safe use cannot be assured through carefully worded labeling, FDA will approve the products for early marketing only if postmarketing restrictions on distribution or use are imposed. The phrase "shown to be effective" was not intended to distinguish drugs approved under new subpart H from drugs approved under any other subpart of the regulations. All drugs approved will have had effectiveness demonstrated on the basis of adequate and well-controlled studies, whether the endpoint of the studies is a surrogate endpoint or a clinical endpoint.

26. One comment expressed concern that the proposed restricted distribution or use provisions would restrict or eliminate the wholesale distribution of drugs approved through the accelerated approval process. The limitations on distribution or use required under this rule are imposed on the applicant. Therefore, the burden is on the applicant to ensure that the conditions of use under which the applicant's product was approved are being followed. This rule does not specify how a manufacturer will distribute its product to those receiving the product under the approval terms. FDA will only determine which facilities or physicians may receive the drug, and the applicant will have agreed to this limitation of distribution or use.

27. One comment expressed concern that the proposed postmarketing restriction provision does not preclude a physician to whom restricted distribution applies from prescribing drugs approved under the accelerated approval process for unapproved (off-label) uses. The comment is correct that this rule does not itself prevent a physician from prescribing a drug granted accelerated approval for an unapproved use. Under the act, a drug approved for marketing may be labeled, promoted, and advertised by the manufacturer only for those uses for which the drug's safety and effectiveness have been established and that FDA has approved. Physicians may choose to prescribe the drug for a condition not recommended in labeling. Such off-label use would, of course, be carried out under the restrictions imposed under this section. FDA also believes that physicians will be cognizant of the product's special risks and will use such drugs with particular care. The labeling of products approved under this rule will include all necessary warnings and full disclosure labeling would generally reflect the extent of clinical exposure to the drug.

F. Postmarketing Studies

28. Three comments argued that FDA does not have the authority to require postmarketing studies to be performed as a condition of approval based on a "surrogate" endpoint. One comment stated that it is widely accepted that the act empowered the agency to define the type and extent of efficacy data necessary to approve a product application. If a surrogate marker can be shown to be sufficiently related to actual patient benefit, then, the comment asserted, data regarding the effect of a drug on a surrogate marker constitute acceptable proof of efficacy under the act. Two comments urged FDA to continue to ask applicants to agree voluntarily to perform postmarketing studies if medically warranted as is the current policy under the traditional approval process. One comment expressed concern that requiring postmarketing studies may become the norm rather than the exception.

The agency's response to comment 1. explained the circumstances in which FDA might conclude that a drug should be marketed on the basis of an effect on a surrogate endpoint reasonably likely to predict clinical benefit only if studies were carried out to confirm the presence of the likely benefit. As discussed in the preamble to the proposed rule (57 FR 13234 at 13236), FDA believes that it is authorized by law to require postmarketing studies for new drugs and biological products. Section 505(d) of the act provides for the approval of new drugs for marketing if they meet the safety and effectiveness criteria set forth in section 505(d) of the act and the implementing regulations (21 CFR part 314). As discussed in the proposed rule, to demonstrate effectiveness, the law requires evidence from adequate and well-controlled clinical studies on the basis of which qualified experts could fairly and reasonably conclude that the drug has the effect it is purported to have. Under section 505(e) of the act, approval of a new drug application is to be withdrawn if new information shows that the drug has not been demonstrated to be either safe or effective. Approval may also be withdrawn if new information shows that the drug's labeling is false or misleading.

Section 505(k) of the act authorizes the agency to promulgate regulations requiring applicants to make records and reports of data and other information that are necessary to enable the agency to determine whether there is reason to withdraw approval of an NDA. The agency believes that the referenced reports can include additional studies to evaluate the clinical efficacy of a drug approved on the basis of an effect on a surrogate endpoint. Section 701(a) of the act generally authorizes FDA to issue
With respect to biological products, regulation 58 postmarketing studies for these products are required legal authority for the agency to require products "prescribed in regulations (42 (21CFR 600.3(s)).

prerequisite for approval for some drugs FDA require that specific timelines for postmarketing studies be included in (see 37 FR 201, January 7, 1972; and 37 comment further suggested that, if the sponsor fails to meet its timelines, withdraw approval of the drug for withhold information from FDA penalties for sponsors that deliberately should establish substantial fines and the progress of their postmarketing studies, or delay the completion of such (the required postmarketing studies on time. These recommendations were, that once a manufacturer is granted approval for its product, the manufacturer will have little incentive to complete postmarketing studies in a timely manner, especially if the preliminary results of such studies indicate that the drug may not be safe and/or effective. Another comment urged FDA to include in the final rule language that requires the participation of pharmacists in postmarketing studies because pharmacists can serve as an additional source of information on therapeutic outcomes of patients taking drugs approved under this rule and monitoring for such drugs.

The agency expects that the requirement for postmarketing studies will usually be met by studies already underway at the time of approval and that there will be reasonable enthusiasm for resolving the questions posed by those studies. The plan for timely completion of the required postmarketing studies will be included in the applicant's marketing application. In addition, in accord with the annual reporting requirements at § 314.81(b)(2)(vii) (21 CFR 314.81(b)(2)(vii), an NDA applicant is required to provide FDA with a statement of the current status of any postmarketing studies. FDA declines to impose the sanctions suggested by the comment for failure of an applicant to meet its plans for completion of a postmarketing study. FDA believes this rule applies appropriate regulatory sanctions. Under the proposed rule and this final rule, FDA may withdraw approval of an application if the applicant fails to perform the required postmarketing study with due diligence. FDA believes that it is not within the scope of this rule to establish the role of pharmacists in postmarketing studies. That role should more properly be defined by the clinical investigator and the institution or facility at which postmarketing study is conducted.

30. One comment asserted that the proposal sets forth an inherent contradiction between the way FDA evaluates the benefit-risk for drugs today and the way the proposal contemplates. The comment argued that, now, if postmarketing data raise questions about the risk associated with a drug product, FDA considers that data along with the other data known about the product, and determines whether, based on the overall knowledge about the drug, there is a need to seek withdrawal of approval. Under this proposal, if the postmarketing study data raised questions about the risk of the product, FDA would seek withdrawal of approval, whether or not the new data really made a fundamental difference to what is known about the benefit and risk of the product.

FDA does not agree that the contradiction described by the comment exists. Under the circumstances of accelerated approval, approval would be based on a weighing of the benefit suggested by the effect on the surrogate endpoint against known and potential risks of the drug. Should well-designed postapproval studies fail to demonstrate the expected clinical benefit, the benefit expected at the time of approval (reasonably likely to exist) would no longer be expected and the totality of the data, showing a clinical benefit, would no longer support approval. This evaluation of the data is not different from considerations that would apply in evaluating data in the case of a drug approved under other provisions of the regulations.

31. Two comments expressed the view that the proposed requirement for postmarketing studies may raise important ethical questions because once a drug product is approved, it may be unethical, depending on the circumstances, for a physician to conduct a study using a placebo control. One comment also suggested that a postmarketing study requirement could compromise the NDA holder’s ability to enroll sufficient numbers of patients in the study when the new approved drug and possible alternative therapies are widely available to patients.

Usually, and preferably, because of problems suggested in the comment, the requirement for postmarketing studies will be met by studies already underway at the time of approval, or a completion of studies that showed an effect on the surrogate. FDA recognizes that ethical considerations will play a central role in the type of study carried out, a choice that will depend upon the type and seriousness of the disease being treated, availability of alternative therapies, and the nature of the drug and the patient population. There are also alternatives to use of a placebo control, including active control designs and non-response studies that can satisfy both the demands of ethics and adequacy of design.

32. One comment contended that the term “postmarketing study” is used inconsistently in the proposed rule. The comment argued that “postmarketing study” is an acceptable regulatory term of art which, to this point, has referred to traditional postmarketing studies are intended. The comment also suggested changing the term “postmarketing study” to “Phase 3 study” without necessarily safety, although safety data will be collected. To prevent confusion and to differentiate between these required postmarketing confirmatory efficacy studies and safety studies traditionally conducted after approval and to clarify that products granted accelerated approval have been approved on the basis of Phase 2 (surrogate endpoint) data, the comment suggested changing the term “postmarketing study” to “Phase 3 study” in this rule except where traditional postmarketing studies are intended. The comment also suggested that the term “Phase 3 study” be defined as a study required to confirm findings of efficacy based upon surrogate data collected in Phase 2, which will be conducted after an accelerated approval has been granted and will be required before restrictions set forth in § 314.520 are removed.

The agency does not believe that the comment has accurately described accepted meanings of various terms.
The term postmarketing study does not refer to any particular kind of study, but to studies carried out after a drug is marketed, often as part of an agreement by the manufacturer to do so. These have included pharmacokinetic, drug-drug interaction, and pediatric studies, studies of dose-response or of higher doses, and studies of new uses. The term is not limited to safety studies. Moreover, Phase 2 and 3 studies are not distinguished by the endpoints chosen. Phase 3 hypertension studies, for example, still measure blood pressure, not stroke rate. The agency believes that the use of the "postmarketing study" in the APA is appropriate and consistent.

6. Withdrawal of Approval

33. One comment supported the proposed withdrawal of approval procedure. Other comments asserted that the proposed procedure does not provide the applicant with the procedural safeguards of a formal evidentiary hearing guaranteed by section 505(e) of the act and the Administrative Procedure Act (APA). Another example, the comments said that based on a finding of a single study failing to show clinical benefit or misuse of any promotional material, an approval could be withdrawn from the market with only a minimal opportunity for the NDA holder to be heard. The comments argued that section 505(e) of the act guarantees applicants "due notice and opportunity to present any data and information they believe to be relevant to the continued marketing of their product. The proposed process also would have permitted the presiding officer, the advisory committee members, a representative of the applicant, and a representative of the Center that initiates the withdrawal proceedings to question any person during or at the conclusion of the person's presentation. As discussed below in response to a comment, FDA has decided to allow up to three representatives of the applicant and of the Center to question presenters. Participants could comment on or rebut information and views presented by others. As with ordinary 21 CFR part 15 hearings, the hearing will be transcribed. Subsequent to the hearing, the Commissioner of Food and Drugs would render a final decision on the matter. The agency believes that the administrative record created through this process would be sufficient for judicial review.

The agency emphasizes that, as part of the approval process under this rule, applicants will have agreed that these withdrawal procedures apply to the drug for which they seek approval; applicants objecting to these procedures may forego approval under the accelerated procedure or if restrictions do not lead to safe use, the surrogate endpoint will enable safe use. If the effect on the surrogate does not translate into a clinical benefit, or if restrictions do not lead to safe use, the risk/benefit assessment for these drugs changes significantly. FDA believes that if that occurs, rapid withdrawal of approval as set forth in this rule is important to the public health.

34. One comment noted that the hearing was necessarily legally required (see 40 FR 40682 at 40681, September 3, 1975). In promulgating its procedural regulations, FDA also determined that a formal evidentiary hearing is not required before withdrawing approval of biological products, but that it would be appropriate to apply the same procedures to biological products as to drug removal (see 40 FR 40682 to 40691).

Through the hearing process in this final rule, as in the proposed rule, applicants will be afforded the opportunity to present any data and information they believe to be relevant to the continued marketing of their product. The proposed process also would have permitted the presiding officer, the advisory committee members, a representative of the applicant, and a representative of the Center that initiates the withdrawal proceedings to question any person during or at the conclusion of the person's presentation. As discussed below in response to a comment, FDA has decided to allow up to three representatives of the applicant and of the Center to question presenters. Participants could comment on or rebut information and views presented by others. As with ordinary 21 CFR part 15 hearings, the hearing will be transcribed. Subsequent to the hearing, the Commissioner of Food and Drugs would render a final decision on the matter. The agency believes that the administrative record created through this process would be sufficient for judicial review.

The agency emphasizes that, as part of the approval process under this rule, applicants will have agreed that these withdrawal procedures apply to the drug for which they seek approval; applicants objecting to these procedures may forego approval under the accelerated procedure or if restrictions do not lead to safe use, the surrogate endpoint will enable safe use. If the effect on the surrogate does not translate into a clinical benefit, or if restrictions do not lead to safe use, the risk/benefit assessment for these drugs changes significantly. FDA believes that if that occurs, rapid withdrawal of approval as set forth in this rule is important to the public health.

35. Under the proposed withdrawal procedures, in addition to other persons, one representative of the Center that initiates the withdrawal proceedings may question participants at a withdrawal of approval hearing. One comment objected to limiting the Center to one representative because detailed knowledge about a drug product is likely to be available from several scientists. The proposed limitation of questioning to single representatives of the initiating Center and the applicant was intended to make the proceedings manageable. On further consideration, the agency has determined that it would be appropriate and manageable to allow up to three persons to be designated as questioners for the applicant and for FDA. Sections 314.530(e)(2) and 601.43(e)(2) have been revised accordingly.

36. Some comments questioned FDA's ability to withdraw approval under the proposed procedures efficiently or effectively because of: (1) The lack of assurance that the results of postmarketing studies will be promptly provided to FDA; (2) limited agency resources to review study results and act upon them promptly; (3) the difficulties associated with establishing that an adverse event is substantially related to the drug, and (4) political pressure not to rescind the approval of NDA's for drug products that may lack evidence of effectiveness.
especially if no clearly effective alternative treatments are available. One comment offered the opinion that where a drug shows only modest evidence of benefit, perhaps on a surrogate endpoint, and only shows equivocal evidence of clinical efficacy in postmarketing studies it would be difficult and socially disruptive to withdraw approval and remove the drug from the market if the drug has become well established and accepted, and there is no issue of toxicity. Another comment believed it would be difficult to withdraw approval of a drug that may be beneficial in a subpopulation but which, in fact, has not been shown to be efficacious in broader patient population studies. The comments suggested the need for a lesser sanction.

Another comment suggested that expediting removal of a product from the market could be accomplished by using a procedure like the “imminent hazard” provision of the act, i.e., immediate removal of the drug from the market if any of the conditions listed in proposed §314.530 were met followed by a hearing.

Although the potential difficulties cited by the comments are real, they are not fundamentally different from determinations FDA regularly must make in carrying out its responsibilities. The new regulations provide for an expedited procedure to withdraw approval; they do not guarantee that results of studies will be wholly unambiguous or that FDA will always be able to prevail in its view as to the need for withdrawal, any more than current withdrawal procedures do. The studies that will be carried out under these provisions will be conspicuous and important and their completion will be widely known. There is no reason to believe their results would or could be long hidden. A study that fails to show clinical effectiveness does not prove a drug has no clinical effect but it is a study that, under §314.530, will lead to a withdrawal procedure because it has failed to show that the surrogate endpoint on which approval was based can be correlated with a favorable clinical effect. This may have occurred because the study was poorly designed or conducted; while FDA will make every effort to avoid this, the commercial sponsor has the responsibility for providing the needed evidence confirming clinical benefit. As previously discussed, §§314.510 and 601.43 have been revised to clarify that required postmarketing studies must also be adequate and well-controlled.

The possibility that an ineffective drug has become “accepted” is not a basis for continued marketing. FDA intends to implement the provisions of §314.530 as appropriate; data that are ambiguous will inevitably lead to difficult judgments.

A drug with clear clinical effectiveness in a subset of the population, but not in the population described in labeling, would have its labeling revised to reflect the data. Withdrawal would be inappropriate under such circumstances.

If an insignificant hazard to the public health exists, the Secretary of Health and Human Services may suspend approval of an application and then afford the applicant an opportunity for an expedited hearing. In the absence of a significant hazard requiring immediate withdrawal, FDA believes the expedited procedure described in the rule satisfies the need for prompt action while, at the same time, allowing opportunity for discussion and debate before withdrawal.

37. One comment noted that the proposed rule would allow FDA to withdraw approval for failure to perform the required postmarketing studies with due diligence. The comment asserted that the act does not permit FDA to withdraw approval on this ground. Another comment, however, suggested that because proposed §§314.530 and 601.43 cite grounds for withdrawal of approval that are not grounds under the act, the language of these proposed sections should be revised to use language that closely aligns to that used in the act, e.g., describe a “postmarketing study” in statutory language.

FDA reaffirms the position expressed in the preamble to the proposal (57 FR 13234 at 13239) that there is adequate authority under the act to withdraw approval of an application for the reasons stated under proposed §§314.530 and 601.43, which include failure of an applicant to perform the required postmarketing study with due diligence. Section 505(s) of the act authorizes the agency to withdraw approval of an NDA if new information shows that the drug has not been demonstrated to be either safe or effective. Approval may also be withdrawn if the applicant has failed to maintain required records or make reports. In addition, approval may be withdrawn if new information, along with the information considered when the application was approved, shows the labeling to be false or misleading.

For biological products, section 351(d) of the PHS Act authorizes withdrawal approval for failure of an application to conform to the standards designed to ensure continued safety, purity, and potency. "Potency" for biological products includes effectiveness (21 CFR 600.3(a)). The PHS Act does not specify license revocation procedures, except to state that licenses may be suspended and revoked "as prescribed by regulations." For drugs approved under §314.510, FDA will have determined that reports of postmarketing studies are critical to the risk/benefit balance needed for approval; if these reports are not forthcoming, then, under authority of section 505(d) of the act, the drug cannot on an ongoing basis meet the standards of safety and efficacy required for marketing under the act. Therefore, it is important to ensure that the applicant make a good faith effort to complete any required postmarketing studies in a timely manner so that FDA can rapidly determine whether the surrogate endpoint upon which the drug was approved has been confirmed to correlate with clinical benefit. Failure to submit the study results in a timely fashion would also constitute failure to make a required report. Similarly, without submission of the information from required postmarketing studies on biological products approved under these procedures, the biological product is not assured of continued safety and effectiveness. The license application may, therefore, appropriately be revoked as described in §601.43.

FDA does not find the statements of the grounds for withdrawal of approval under §§314.530 and 601.43 of this rule inconsistent with statutory language or ambiguous. The agency notes that in the event none of the grounds for withdrawal specifically listed in §314.530 or §601.43 applies, but another ground for withdrawal under section 505 of the act or section 351 of the PHS Act and implementing regulations at 21 CFR 314.150 or 601.5 does apply, the agency will proceed to withdraw approval under traditional procedures.

38. Two comments expressed concern that it may be difficult for the agency to enforce the requirement that postmarketing studies be pursued with due diligence. The comments asked what would happen if a sponsor using due diligence is unable to recruit enough patients, or if the sponsor questions the validity of the data from the required postmarketing study, and would clumsy data management be seen as sufficient reason to rescind approval for a marketed drug? Another comment stated that once a product is approved and, by definition, provides a "meaningful therapeutic benefit over existing therapy," study accrual may drop off dramatically as patients may refuse to receive the "old" therapy or...
placebo, or physicians may consider it unethical not to treat all patients with the approved indication with the new drug or biological product. Under these circumstances, the comment expressed the opinion that neither the sponsor nor the product should be penalized, nor should there be a threat to withdraw approval. Based on FDA's past history in postmarketing studies, which one segment characterized as resulting in poorly done studies, studies conducted much later than agreed upon, or not at all, the comment expressed the opinion that the "due diligence" with which applicants are expected to carry out postmarketing studies may be an overly great expectation. One comment asked FDA to give examples of when it may be withdraw approval if "other evidence demonstrates that the drug product is not shown to be safe or effective under its conditions of use under §§314.530(a)(6) and 601.43(a)(6)).

FDA does not agree that it will be difficult to enforce the "due diligence" provision of this rule. The "due diligence" provision was designed to ensure that the applicant makes a good faith effort to conduct a required postmarketing study in a timely manner to confirm the predictive value of the surrogate marker or other indicator. Any requirement for postmarketing studies will have been agreed to by the applicant at the time of approval, and if the study is not conducted in a timely manner as agreed to by the applicant, approval of the applicant's application will be withdrawn. FDA will expect any required postmarketing studies will be conducted in consultation with the agency. Therefore, should the applicant encounter problems with subject enrollment in a study or ethical difficulties about the type of study to conduct, FDA expects the applicant to discuss these problems with the agency and reach agreement on their resolution.

Examples of other evidence demonstrating the drug product is not shown to be safe and effective could include further studies of the effect of the drug and the surrogate endpoint that fail to show the effect seen in previous studies, new evidence casting doubt on the validity of the surrogate endpoint as a predictor of clinical benefit, or new evidence of significant toxicity.

Some comments objected to withdrawal of approval of a drug product approved under the accelerated approval process because of perceived misconduct by the applicant, such as failure to perform a required postmarketing study with due diligence or use of promotional materials that are false or misleading. The comments argued that the primary purpose of the accelerated approval process is to provide improved treatments to desperately ill patients at the earliest possible time, and withdrawal of approval of the new treatments for reasons not directly related to safety or efficacy undermines the purpose of the proposed rule. Two comments suggested that correction of the promotional material without interruption of access to the drug would be a better approach. Another comment suggested that there may be circumstances where continued access to the drug, if accompanied by informed consent, would be appropriate even if substantial questions arise about a product's safety and effectiveness. One comment urged that anticipated withdrawal of approval be preceded by measures to ensure that patients and their physicians will have an uninformed alternative treatment arrangements can be made.

The need for "due diligence" in conducting the agreed to postmarketing studies is discussed in paragraph 37. The reasons for concern about misleading promotional materials are discussed under paragraph 16. With respect to promotional materials, FDA expects that, in most cases, any disagreements between the applicant and FDA will be resolved through discussion and modification of the materials, so that the drug or biological product can continue to be marketed. If, however, FDA concludes that the promotional materials adversely affect the risk/benefit conclusion supporting the drug's marketing, the agency intends to minimize the risk to the public health by removing the product from the market through the withdrawal procedures in this rule.

One comment expressed concern that the proposed withdrawal procedure may give the appearance of bias or preconceived notions on the part of the agency because the final decision to withdraw approval of a drug would be made by the Commissioner of Food and Drugs and the intention to withdraw approval of the drug will already have been determined by the agency. Under the withdrawal provisions of this rule, FDA's CDER or CBER, rather than the Commissioner, will initiate the withdrawal proceedings. The withdrawal process will begin with a letter from CDER or CBER notifying the applicant that the Center proposes to withdraw marketing approval and stating the reasons for the proposed action. Although separation of functions will not apply under the provisions of §§ 314.530 or 601.43, the Commissioner's decision regarding withdrawal would not occur until after the applicant had an opportunity for hearing as described in those sections. The Commissioner would then expect to review the issues with objectivity and fairness having had the benefit of the presentations and discussions at the hearing and of the agency's recommendations.

H. Safeguards for Patient Safety

41. One comment asked if drugs approved under the accelerated approval process will be held to the same standards concerning postmarketing safety as drugs approved by the traditional process. As discussed in the preamble to the proposed rule, applicants gaining approval for new drugs through the accelerated approval procedures will also be expected to adhere to the agency's longstanding requirements for postmarketing monitoring and reporting (see 21 CFR 314.80 and 314.81). Information that comes to FDA from the applicant or elsewhere that raises potential safety concerns will be evaluated in the same manner that such information is evaluated for drugs approved under the agency's traditional procedures. If the postmarketing information shows that the risk/benefit assessment is no longer favorable, the agency will act accordingly to remove the drug from the market.

42. One comment urged FDA, if the proposed rule were adopted, to require written informed consent so that patients would know that the drugs for which they were being treated had risks and that the benefits had not been adequately established.

The agency does not agree that patients using drug products approved under the accelerated approval regulations should be asked to provide written informed consent. Drugs approved under these provisions are not considered experimental drugs for their approved uses. Like all approved drugs, drugs approved under these provisions will have both risks and benefits. As previously discussed in this preamble, for drugs approved based on studies showing an effect on a surrogate endpoint, the approved labeling will describe that effect. In addition, the labeling will contain information on known and potential safety hazards and precautionary information. As with all prescription drugs, the physician has the responsibility for appropriately advising the patient regarding the drug being prescribed.

43. One comment asked that FDA require manufacturers to maintain an updated list of names, addresses, and phone numbers of physicians prescribing their products approved.
under this rule, and in the case of recall or withdrawal of approval, require manufacturers to contact their physicians and encourage them to notify their patients.

FDA does not believe such a procedure is necessary. Furthermore, maintaining such a registry for drugs prescribed through pharmacies would be very difficult. Agency experience with recalls and product withdrawals indicates that the methods of notification that have been developed for such circumstances are adequate.

44. One comment recommended that FDA require patient package inserts (PPI's) for all drugs granted accelerated approval that would state the specific restrictions placed on a drug product and/or the reason for requiring postmarketing studies. In addition, the comment recommended that FDA require the manufacturer to include an adverse drug reaction “hotline” phone number in the PPI along with an FDA phone number. The PPI should inform the patient to report immediately any adverse drug reaction experienced to his or her doctor, the manufacturer, and FDA, and the manufacturer should be required to contact FDA immediately after receiving a report of a serious adverse reaction.

FDA concludes that patient package inserts are not routinely needed for drugs granted accelerated approval, although if circumstances make one appropriate, one would be developed for a particular drug. With any prescription drug, the approved labeling for an accelerated approval will contain information about the safe and effective use of the product, including all necessary warnings and the extent of clinical exposure. In addition, the conditions of use will be carefully worded to reflect the nature of the data supporting the product’s approval. Physicians have the responsibility to inform patients about the safe and effective use of an approved product. Labeling includes suggestions to the physician concerning information to be provided to patients.

The agency notes that this final rule limits editorial changes have been made to the wording of the proposed rule. The agency has determined that these changes do not affect the intent of the proposed rule.

V. Economic Impact

In accordance with Executive Order 12291, FDA has carefully analyzed the economic effects of this final rule and has determined that it is not a major rule as defined by the Order. Indeed, because firms will not be forced to use the accelerated approval mechanism, applicants will most probably choose to take advantage of the program only where its use is expected to reduce net costs. Similarly, the final rule does not impose a significant economic impact on a substantial number of small entities so as to require a regulatory flexibility analysis under the requirements of the Regulatory Flexibility Act of 1980.

VI. Environmental Impact

The agency has determined under 21 CFR 25.24(a)(6) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

VII. Paperwork Reduction Act of 1980

This rule does not contain new collection of information requirements. Section 314.540 does refer to regulations that contain collection of information requirements that were previously submitted for review to the Director of the Office of Management and Budget (OMB) under section 3506 of the Paperwork Reduction Act of 1980 (Adverse Drug Experience Reporting, OMB No. 0910-0230).

List of Subjects

21 CFR Part 314

Administrative practice and procedure, Confidential business information, Drugs, Reporting and recordkeeping requirements.

21 CFR Part 601

Biologics, Confidential business information.

Therefore, under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and under authority delegated to the Commissioner of Food and Drugs, 21 CFR parts 314 and 601 are amended as follows:

PART 314—APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG OR AN ANTIBIOTIC DRUG

1. The authority citation for 21 CFR part 314 continues to read as follows:


2. Subpart H consisting of §§ 314.500 through 314.560 is added as read as follows:

Subpart H—Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses

Sec. 314.500 Scope.

Sec. 314.510 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.

Sec. 314.520 Approval with restrictions to assure safe use.

Sec. 314.530 Withdrawal procedures.

Sec. 314.540 Postmarketing safety reporting.

Sec. 314.550 Promotional materials.

Sec. 314.560 Termination of requirements

Subpart I—Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses

Sec. 314.500 Scope.

This subpart applies to certain new drug and antibiotic products that have been studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit to patients over existing treatments (e.g., ability to treat patients unresponsive to, or intolerant of, available therapy, or improved patient response over available therapy).

Sec. 314.510 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.

FDA may grant marketing approval for a new drug product on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit or the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. Approval under this section will be subject to the requirement that the applicant study the drug further, to verify and describe its clinical benefit, where there is uncertainty as to the relation of the surrogate endpoint to clinical benefit, or of the observed clinical benefit to ultimate outcome.

Postmarketing studies would usually be studies already underway. When required to be conducted, such studies must also be adequate and well-controlled. The applicant shall carry out any such studies with due diligence.

Sec. 314.520 Approval with restrictions to assure safe use.

(a) If FDA concludes that a drug product shown to be effective can be safely used only if distribution or use is restricted, FDA will require such postmarketing restrictions as are needed to assure safe use of the drug product, such as:

(1) Distribution restricted to certain facilities or physicians with special training or experience; or

EX. 8 pg. 031
Section 601.40 Scope.

This subpart applies to certain biological products that have been studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit to patients over existing treatments (e.g., ability to treat patients unresponsive to, or intolerant of, available therapy, or improved patient response over available therapy).

§601.41 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.

FDA may grant marketing approval for a biological product on the basis of adequate and well-controlled clinical trials establishing that the biological product has an effect on a surrogate endpoint that is reasonably likely, based on epidemiologic, therapeutic,

EX. 8 pg. 032

App. 0134
pathophysiologic, or other evidence, to predict clinical benefit or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. Approval under this section will be subject to the requirement that the applicant study the biological product further, to verify and describe its clinical benefit, where there is uncertainty as to the relation of the surrogate endpoint to clinical benefit, or of the observed clinical benefit to ultimate outcome. Postmarketing studies would usually be studies already underway. When required to be conducted, such studies must also be adequate and well-controlled. The applicant shall carry out any such studies with due diligence.

§ 601.42 Approval with restrictions to assure safe use.

(a) If FDA concludes that a biological product shown to be effective can be safely used only if distribution or use is restricted, FDA will require such postmarketing restrictions as are needed to assure safe use of the biological product, such as:
   (1) Distribution restricted to certain facilities or physicians with special training or experience; or
   (2) Distribution conditioned on the performance of specified medical procedures.

(b) The limitations imposed will be commensurate with the specific safety concerns presented by the biological product.

§ 601.43 Withdrawal procedures.

(a) For biological products approved under §§ 601.40 and 601.42, FDA may withdraw approval, following a hearing as provided in part 15 of this chapter, as modified by this section, if:
   (1) A marketing clinical study fails to verify clinical benefit;
   (2) The applicant fails to perform the required postmarketing study with due diligence;
   (3) Use after marketing demonstrates that postmarketing restrictions are inadequate to ensure safe use of the biological product;
   (4) The applicant fails to adhere to the postmarketing restrictions agreed upon;
   (5) The promotional materials are false or misleading; or
   (6) Other evidence demonstrates that the biological product is not shown to be safe or effective under its conditions of use.

(b) Notice of opportunity for a hearing. The Director of the Center for Biologics Evaluation and Research will give the applicant notice of an opportunity for a hearing on the Center’s proposal to withdraw the approval of an application approved under § 601.40 or § 601.41. The notice, which will ordinarily be a letter, will state generally the reasons for the action and the proposed grounds for the order.

(c) Submission of data and information. (1) If the applicant fails to file a written request for a hearing within 15 days of receipt of the notice, the applicant waives the opportunity for a hearing.

(2) If the applicant files a timely request for a hearing, the agency will publish a notice of hearing in the Federal Register in accordance with §§ 12.32(e) and 15.20 of this chapter.

(3) An applicant who requests a hearing under this section must, within 30 days of receipt of the notice of opportunity for a hearing, submit the data and information upon which the applicant intends to rely at the hearing.

(d) Separation of functions. Separation of functions (as specified in § 10.55 of this chapter) will not apply at any point in withdrawal proceedings under this section.

(e) Procedures for hearings. Hearings held under this section will be conducted in accordance with the provisions of part 15 of this chapter, with the following modifications:

   (1) An advisory committee duly constituted under part 14 of this chapter will be present at the hearing. The committee will be asked to review the issues involved and to provide advice and recommendations to the Commissioner of Food and Drugs.

   (2) The presiding officer, the advisory committee members, up to three representatives of the applicant, and up to three representatives of the Center may question any person during or at the conclusion of the person’s presentation. No other person attending the hearing may question a person making a presentation. The presiding officer may, as a matter of discretion, permit questions to be submitted to the presiding officer for response by a person making a presentation.

(f) Judicial review. The Commissioner’s decision constitutes final agency action from which the applicant may petition for judicial review. Before requesting an order from a court for a stay of action pending review, an applicant must first submit a petition for a stay of action under § 10.35 of this chapter.

§ 601.44 Postmarketing safety reporting.

Biological products approved under this program are subject to the postmarketing recordkeeping and safety reporting applicable to all approved biological products.

§ 601.45 Promotional materials.

For biological products being considered for approval under this subpart, unless otherwise informed by the agency, applicants must submit to the agency for consideration during the preapproval review period copies of all promotional materials, including promotional labeling as well as advertisements, intended for dissemination or publication within 120 days following marketing approval. After 120 days following marketing approval, unless otherwise informed by the agency, the applicant must submit promotional materials at least 30 days prior to the intended time of initial dissemination of the labeling or initial publication of the advertisement.

§ 601.46 Termination of requirements.

If FDA determines after approval that the requirements established in § 601.42, § 601.43, or § 601.45 are no longer necessary for the safe and effective use of a biological product, it will so notify the applicant. Ordinarily, for biological products approved under § 601.41, those requirements will no longer apply when FDA determines that the required postmarketing study verifies and describes the biological product’s clinical benefit and the biological product would be appropriate for approval under traditional procedures. For biological products approved under § 601.42, the restrictions would no longer apply when FDA determines that safe use of the biological product can be assured through appropriate labeling. FDA also retains the discretion to remove specific postapproval requirements upon review of a petition submitted by the sponsor in accordance with § 10.30.


David A. Kessler,
Commissioner of Food and Drugs.

Louis W. Sullivan,
Secretary of Health and Human Services.
[FR Doc. 92-30129 Filed 12-9-92; 9:51 am]
Exhibit 9

2002 Citizen Petition
BEFORE THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION

Citizen Petition re: Request for
Stay and Repeal of the Approval of
Mifepristone (mifepristone) for the Medical
Termination of Intrauterine Pregnancy
through 49 Days’ Gestation

CITIZEN PETITION AND REQUEST FOR ADMINISTRATIVE STAY

The American Association of Pro Life Obstetricians and Gynecologists ("AAPLOG"),
the Christian Medical Association ("CMA"), and Concerned Women for America ("CWA")
(collectively, "the Petitioners") submit this Petition pursuant to 21 C.F.R. §§ 10.30 and 10.35;
21 C.F.R. Part 314, Subpart H (§§ 314.500-314.560); and Section 505 of the Federal Food, Drug
and Cosmetic Act (21 U.S.C. § 355). The Petitioners urge the Commissioner of Food and Drugs
to impose an immediate stay of the approval by the Food and Drug Administration ("FDA" or
"agency") of Mifeprex™ (mifepristone; also, "RU-486"), thereby halting all distribution and
marketing of the drug, pending final action on this Petition. In addition the Petitioners urge the
Commissioner to revoke FDA’s approval of Mifeprex and request a full FDA audit of the
Mifeprex clinical studies.

as amended at 21 U.S.C. §§ 301 et seq.).

2 The New Drug Application for Mifeprex, which was filed by the Population Council, was approved on September

3 The Petitioners will, at times, cite to documents contained in FDA’s January 31, 2002 public release of documents
(approximately 9,000 pages in 94 files) made pursuant to a Freedom of Information Act request ("FDA FOIA
Release") filed by the non-profit organization, Judicial Watch. These bracketed citations will reflect the page
numbering FDA has stamped on the bottom of each page, for example: [FDA FOIA Release: MIF 000001-05]. The
FDA webpage posting the 94 files is: <http://www.fda.gov/cder/archives/mifepristone/default.htm>. Since the
initial release FDA has edited some of the 94 files. However, the stamped page numbers have not changed.
Additionally, many footnotes refer to Appendix A to this Petition, which contains a selected bibliography.
I. ACTION REQUESTED

The Petitioners respectfully request that the Commissioner immediately stay the approval of Mifeprex, thereby halting all distribution and marketing of the drug pending final action on this Petition. They urge the Commissioner to revoke market approval for Mifeprex in light of the legal violations and important safety concerns explained below. In addition, they request a full FDA audit of all records from the French and American clinical trials offered in support of the Mifeprex NDA.

II. INTEREST OF THE PETITIONERS

While it is true that the Petitioners have consistently opposed abortion and continue to do so, a careful examination of the claims made in this petition should alert people of conscience on either side of this issue that women are being harmed. Regardless of one’s position on abortion, FDA’s violations of its standards and rules have put women’s health and lives at risk. The Petitioners are non-profit organizations that share a great concern about women’s health issues. The American Association of Pro-Life Obstetricians and Gynecologists (“AAPLOG”) is a recognized interest group of the American College of Obstetricians and Gynecologists (“ACOG”), currently representing over 2,000 obstetricians and gynecologists throughout the United States of America. The Christian Medical Association, founded in 1931, is a professional organization with thousands of physician members representing every medical specialty. Concerned Women for America (“CWA”), founded in 1979, is the largest public policy women’s organization in the United States with members in every State and a total membership exceeding 500,000.
III. STATEMENT OF GROUNDS

A. SUMMARY OF THE PETITIONERS’ ARGUMENTS

Good cause exists to grant an immediate stay of the agency's September 28, 2000 Mifeprex approval.\(^4\) Good cause also exists for the subsequent revocation of that approval.\(^5\) As established herein, (1) the approval of Mifeprex violated the Administrative Procedure Act’s prohibition on agency action that is arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law;\(^6\) (2) FDA’s approval of Mifeprex violated 21 U.S.C. § 355 because the drug does not satisfy the safety and labeling requirements of that section; and (3) the agency approved Mifeprex despite the presence of substantial risks to women’s health.

This Petition represents the latest attempt by members of the medical community and other concerned observers to warn FDA of the dangers posed by Mifeprex abortions to the health of women.\(^7\) Women undergoing Mifeprex abortions risk, among other problems, uncontrolled fatal hemorrhage and serious bacterial infections. Mifeprex abortions particularly endanger women with ectopic pregnancies and those whose pregnancies have progressed beyond 49 days.\(^8\)

\(^4\) When FDA approved the Population Council’s NDA for mifepristone, it approved the drug for use in conjunction with misoprostol. In this Petition, “Mifeprex Regimen” will refer to the combined use of Mifeprex and misoprostol to effect an abortion.

\(^5\) See 21 C.F.R. § 314.530 (“Withdrawal Procedures”).


\(^7\) On February 28, 1995, Americans United for Life and other groups and individuals filed a Citizen Petition with FDA requesting it to “refuse to approve any NDA for RU 486 for use as a pharmaceutical abortifacient that does not contain adequate evidence that the drug has undergone nonclinical and clinical safety and effectiveness trials.” The petitioners also set forth a number of factors for the agency to consider. Americans United for Life et al., Citizen Petition (Feb. 28 1995)[FDA FOIA Release: MIF 006144-6248]; see also, Letter, Ronald G. Chesebrough, Associate Commissioner for Regulatory Affairs, FDA, to Gary L. Yingling, McKenna & Cuneo (March 20, 1995) (one-page letter suggesting that the petition was prematurely filed and claiming to be a “full response”)[FDA FOIA Release: MIF 006250].

\(^8\) The gestational age of a pregnancy is based on the first day of a woman’s last menstrual period, which is designated as Day 1 of the pregnancy. On Day 49, a woman is deemed to be seven weeks pregnant, which means she has experienced 49 days of amenorrhea (time elapsed since the beginning of her last menstrual period).
Warnings about these dangers, together with FDA's own concerns about the safety of the abortion regimen, went unheeded. On September 28, 2000, FDA approved the new drug application ("NDA") for Mifeprex. The initial reports of life-threatening and fatal adverse events appear to bear out the safety concerns underlying the pre-approval warnings. The Petition highlights a number of agency actions that were arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with the law. These serious departures from standard agency practice allowed the NDA for Mifeprex, a drug that is not safe for its intended use, to be approved by FDA.

First, the approval of Mifeprex violated the legal requirements of FDA's Accelerated Approval Regulations found in Subpart H. Mifeprex is not a drug for the treatment of a serious or life-threatening illness. It does not demonstrate the potential to address an unmet medical need because a less dangerous and more effective alternative for performing abortions already exists. It appears that FDA's decision to use Subpart H was motivated by its concern that, without restrictions, the drug could not be used safely. Rather than attempting to compensate for

---

Ovulation for the small percentage of woman with a perfect 28 day cycle typically takes place between Days 12 and 14 and fertilization typically takes place 24 to 48 hours later.


10 FDA's unlawful approval of Mifeprex may not be unprecedented. The medical-scientific community and the mainstream press have called attention to a number of other instances in which one could question whether drugs and medical devices have been improperly approved. See, e.g., Richard Horton, "Lotronex and the FDA: A Fatal Erosion of Integrity," Lancet 357 (May 19, 2001): 1544-1545; David Willman, "How a New Policy Led to Seven Deadly Drugs," Los Angeles Times (Dec. 20, 2000): at A1; Kit R. Roane, "Replacement Parts: How the FDA Allows Faulty, and Sometimes Dangerous, Medical Devices onto the Market," U.S. News & World Report (July 29, 2002): 54-59 (discussing FDA's recent approval policies regarding medical devices).

11 21 C.F.R. §§ 314.500-314.560. FDA's Accelerated Approval Regulations are set forth at 21 C.F.R. Part 314, Subpart H ("Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses") ("Accelerated Approval Regulations" or "Subpart H"). The Accelerated Approval Regulations were promulgated by FDA after notice and comment: New Drug, Antibiotic, and Biological Product Regulations; Accelerated Approval, Proposed Rule, 57 Fed. Reg. 13234 (April 15, 1992) ("Subpart H Proposed Rule") and New Drug, Antibiotic, and Biological
the inherent dangerousness of Mifeprex by inappropriately resorting to the Subpart H approval mechanism, FDA should simply have refused to approve Mifeprex. (See Section III.D., infra.)

Second, Mifeprex was not proven to be “safe and effective” as required by law. The scientific quality of the trials used to support the NDA was undeniably deficient according to Congress’s statutory requirements and FDA’s well-established standards. The trials were not blinded, randomized, or concurrently controlled. FDA failed to explicitly waive its rules or offer a reasoned explanation for defying its own standards. (See Section III.E., infra.)

Third, the Mifeprex Regimen requires that Mifeprex be used in conjunction with another drug, misoprostol. FDA, however, has never approved misoprostol as an abortifacient. Although FDA normally opposes the promotion of off-label uses, in connection with the Mifeprex NDA, the agency sanctioned and itself participated in the promotion of the off-label use of misoprostol. Mifeprex, the label of which creates the false impression that misoprostol is approved for use as an abortifacient, is misbranded. (See Section III.F., infra.)

Fourth, and most critically, the Mifeprex Regimen is dangerous. FDA sought, without success, to convince the drug sponsor to place safety restrictions on Mifeprex. When that failed, on June 1, 2000, FDA itself proposed restrictions intended to reduce the unacceptable health risks associated with mifepristone abortions. Nevertheless, the agency, under concerted pressure from abortion advocates and politicians, ultimately approved mifepristone for use in a deregulated regimen that lacks key safeguards. For example, the regimen does not include a requirement that transvaginal ultrasound be used to date pregnancies and rule out ectopic


13 See 21 C.F.R. § 314.126.
pregnancies, which cannot be treated with the Mifeprex Regimen. In addition, FDA failed to restrict access to mifepristone to physicians trained in the provision of Mifeprex and surgical abortions and capable of treating complications arising from abortions. Concerns about the dangers of Mifeprex were confirmed when Danco and FDA announced publicly on April 17, 2002, a number of serious adverse events, including two deaths. (See Section III.G., infra.)

Fifth, the drug’s sponsor has neglected to require Mifeprex providers to adhere to the limited restrictions contained in the approved regimen. The sponsor’s inaction is surprising in light of the fact that these restrictions are being flouted openly. Section 314.530 authorizes FDA to withdraw the approval of a Subpart H drug if a drug’s sponsor does not fulfill its responsibility of ensuring compliance with the restrictions on the use of the drug. (See Section III.H., infra.)

Sixth, the safeguards employed in the U.S. Clinical Trial are not mirrored in the regimen that FDA approved. Transvaginal ultrasounds, for example, although employed in the U.S. Clinical Trial, are not required under FDA’s approved regimen. Nor are the trial requirements governing emergency care reproduced in the approved regimen. (See Section III.I., infra.)

Seventh, FDA’s waiver of its rule, 21 C.F.R. § 314.55, requiring the testing of all new drugs for their potential effects on children, has jeopardized the health and safety of American teenage girls who may have abortions. FDA expressly contemplated the pediatric use of Mifeprex, but waived, without an adequately reasoned justification, the requirement that the drug undergo pediatric testing. (See Section III.J., infra.)

Eighth, FDA did not require the sponsor of Mifeprex to honor its commitments for Phase IV studies, which provide the opportunity to study in-depth the drug’s safety and effectiveness after approval. When FDA approved Mifeprex, the agency permitted the Population Council to replace the six Phase IV study commitments it had made in 1996 with two much narrower...
commitments. The modified studies will not adequately address outstanding questions, such as the effects of mifepristone abortions on women outside the tested age range of 18 to 35 years.  

(See Section III.K., infra.)

In sum, FDA, in approving Mifeprex, acted in a manner inconsistent with its statutory authorization, regulations, and well-established policies. FDA did not provide a contemporaneous explanation of its numerous departures from past practice. Its aberrant actions coupled with the absence of explanations violated a fundamental principle of administrative law; an agency must either adhere to prior policies or fully explain why it is not doing so. The approval of Mifeprex was, therefore, arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law. It must be reversed.

B. FDA APPROVAL OF THE MIFEPRLEX REGIMEN

1. The Introduction of Mifepristone into the United States

Roussel Uclaf, a French pharmaceutical firm, first developed and tested mifepristone ("RU-486") as an abortifacient. By April 1990 the drug had become permanently available in

---

14 An agency must explain its reasons for acting in a particular manner. See, e.g., Securities & Exchange Commission v. Chenery Corp., 332 U.S. 194, 196-97 (1947) (noting that a court should not "be compelled to guess at the theory underlying the agency's action," but rather "[i]f the administrative action is to be tested by the basis upon which it purports to rest, that basis must be set forth with such clarity as to be understandable."). *Post hoc* rationalizations cannot salvage the agency's action with respect to Mifeprex. See, e.g., *Martin v. Occupational Safety and Health Review Commission*, 499 U.S. 144, 156-57 (1991) (*post hoc* rationalizations of counsel "do not constitute an exercise of the agency's delegated lawmaking powers"); *Investment Company Institute v. Camp*, 401 U.S. 617, 628 (1971) ("Congress has delegated to the administrative official and not to appellate counsel the responsibility for elaborating and enforcing statutory commands.").

15 See, e.g., *Greater Boston Television Corp. v. FCC*, 444 F.2d 841, 852 (D.C. Cir. 1970) ("[A]n agency changing its course must supply a reasoned analysis indicating that prior policies and standards are being deliberately changed, not casually ignored, and if an agency glosses over or swerves from prior precedents without discussion it may cross the line from the tolerably terse to the intolerably mute.") (footnote omitted) (citing approvingly *Motor Vehicle Manufacturers Ass'n v. State Farm Mutual Automobile Ins. Co.*, 463 U.S. 29, 57 (1983)); *JSG Trading Corp. v. USDA*, 176 F.3d 535, 544 and 545 (D.C. Cir. 1999) (remanding agency action where "the agency manifestly failed to explain its abrupt departure from prior precedent" and noting that the agency "was obligated to articulate a principled rationale for departing from [its prior] test") (citations omitted); *Gilbert v. National Labor Relations Board*, 56 F.3d 1438, 1445 (D.C. Cir. 1995) ("It is, of course, elementary that an agency must conform to its prior decisions or explain the reason for its departure from such precedent.").
France. According to Dr. André Ulmann, the Roussel project manager for the development of
RU-486, Roussel prohibited the commencement of any new studies in the United States and took
the position that “under no circumstance[s]” would it permit a new drug application to be filed
with FDA. In fact, “the chairman of Hoechst [the parent company to Roussel] had officially
declared that mifepristone was not compatible with the ethics of the company.”

Undeterred by Hoechst’s reluctance to bring the drug to the United States, on January 22,
1993, President Clinton directed Department of Health and Human Services (“HHS”) Secretary
Donna Shalala to assess initiatives to promote the testing and licensing of mifepristone or other
antiprogesterons in the United States. Further signaling that approval of mifepristone by FDA
was a top priority of his Administration, President Clinton reportedly “wrote to Hoechst asking
the company to file a new drug application with the FDA (an unprecedented situation in the
pharmaceutical industry!), which Hoechst intransigently refused to do.”

In early 1993, Secretary Shalala and FDA Commissioner David Kessler “communicated
with senior Roussel Uclaf officials to begin efforts to pave the way for bringing RU-486 into the
American marketplace.” On May 16, 1994, the Population Council reached an agreement with
Roussel Uclaf, pursuant to which the European drug maker transferred “without remuneration,
its United States patent rights for mifepristone (RU-486) to the Population Council . . . .”\(^{21}\)

Secretary Shalala was instrumental in bringing about the transfer of the patent rights to the Population Council\(^{22}\) and even set a deadline – May 15, 1994 – for the transfer.\(^{23}\)

After obtaining the American patent rights to mifepristone, the Population Council conducted clinical trials in the United States and filed a new drug application in 1996. The Population Council established a non-profit corporation, American Health Technologies (“AHT”), to assist in the effort to bring the drug to the market.\(^{24}\) The Population Council ultimately granted Danco Laboratories, LLC (“Danco”), which was incorporated in the Cayman Islands in 1995, “an exclusive license to manufacture, market, and distribute Mifeprex in the United States.”\(^{25}\)

Danco, after a difficult search,\(^{26}\) selected the Chinese drug manufacturer,
Shanghai Hua Lin Pharmaceutical Company, to manufacture the drug. Abortion advocates eagerly awaited the approval of mifepristone in the United States because, among other reasons, they anticipated that it would enhance women's access to abortion.

2. FDA Approval of Mifepristone


Abortion advocates eagerly awaited the approval of mifepristone in the United States because, among other reasons, they anticipated that it would enhance women's access to abortion.

The application was dated March 14, 1996 and received by FDA on March 18, 1996. See Letter, FDA/CDER to Ann Robbins, Population Council (Sept. 18, 1996) at 1 (“1996 Mifepristone Approvable Letter”).

stating that the application was approvable and requested more information from the sponsor.\(^{31}\)

FDA issued a second approvable letter for mifepristone, dated February 18, 2000, setting forth the remaining prerequisites for approval.\(^{32}\) The 2000 Mifepristone Approvable Letter announced that FDA had “considered this application under the restricted distribution regulations contained in 21 CFR 314.500 (Subpart H) and [had] concluded that restrictions as per [21] CFR 314.520 on the distribution and use of mifepristone are needed to assure safe use of this product.”\(^{33}\)

On September 28, 2000, FDA approved mifepristone ("Mifeprex\(^{TM}\)”) “for the medical termination of intrauterine pregnancies through 49 days’ pregnancy.”\(^{34}\) Mifeprex was approved under Subpart H, which, FDA explained, “applies when FDA concludes that a drug product shown to be effective can be safely used only if distribution or use is restricted, such as to certain physicians with certain skills or experience.”\(^{35}\) The approved regimen requires at least three office visits.\(^{36}\) FDA required the Population Council to include, on the Mifeprex Label, a “black box warning for special problems, particularly those that may lead to death or serious injury.”\(^{37}\)

---

\(^{31}\) 1996 Mifepristone Approvable Letter at 1.

\(^{32}\) 2000 Mifepristone Approvable Letter at 1.

\(^{33}\) 2000 Mifepristone Approvable Letter at 5.

\(^{34}\) Letter, FDA/CDER to Sandra P. Arnold, Population Council (Sept. 28, 2000): at 1 ("Mifeprex Approval Letter"). In conjunction with the Mifeprex Approval Letter, FDA issued a memorandum that expanded upon the basis for and the restrictions on the approval of Mifeprex. See Memorandum, FDA/CDER to "NDA 20-687 MIFEPREX (mifepristone) Population Council" (Sept. 28, 2000): at 6 ("Mifeprex Approval Memo").

\(^{35}\) Mifeprex Approval Memo at 6.

\(^{36}\) Pursuant to the approved regimen, on "Day One: Mifeprex Administration" the patient reads the Medication Guide, signs the Patient Agreement, and ingests 600 mg of Mifeprex; on "Day Three: Misoprostol Administration" the patient ingests 400 micrograms of misoprostol orally (unless abortion has occurred and been confirmed by clinical examination or ultrasonographic scan); and, on or about "Day 14: Post-Treatment Examination" the patient returns to the practitioner for verification through a clinical examination or ultrasound that the pregnancy has been successfully terminated. See Mifeprex Label ("Dosage and Administration") (available at: <http://www.fda.gov/cder/foi/label/2000/20687lbl.pdf>).

\(^{37}\) Mifeprex Approval Memo at 2 (citing 21 CFR 201.57(c), which authorizes FDA to require such a warning). The terms "label," "labeling," and "package insert" are often used interchangeably in food and drug law literature. In this Petition, "Label" describes the fine-print "package insert" that accompanies a drug when it is purchased. However, the FD&C Act defines "label" as "a display of written, printed, or graphic matter upon the immediate container of any article . . . ." 21 U.S.C. § 321(k). The term "labeling," which will also appears in this Petition.
FDA also outlined the Population Council’s post-approval, Phase IV study commitments\(^ {38} \) and waived, without explanation, FDA’s regulations providing that all new drugs must be tested for safety and effectiveness in children.\(^ {39} \)

C. BACKGROUND ON FDA’S DRUG APPROVAL PROCESS

1. FDA’s Default Rules for Establishing Drug Safety and Effectiveness

FDA’s regulations state that “[t]he purpose of conducting clinical investigations of a drug is to distinguish the effect of a drug from other influences, such as spontaneous change in the course of the disease, placebo effect, or biased observation.”\(^ {40} \) FDA’s default criteria for establishing safety and effectiveness are commonly referred to as the agency’s “gold standard.”\(^ {41} \) At the core of this default standard is FDA’s recognition, reflecting the development of the scientific method and its application to pharmacology, that human bias and misperceptions are pervasive and that every precaution must be taken to avoid them. “The history of experimental medicine and research psychology,” Michael Greenberg writes, “had demonstrated that uncontrolled, unblinded clinical trials were systematically vulnerable to experimenter bias, placebo effects, and the like.”\(^ {42} \) Consequently, rigorous policies have been set forth by FDA and, encompasses “all labels and other written, printed, or graphic matter (1) upon any article or any of its containers or wrappers, or (2) accompanying such article.” 21 U.S.C. § 321(m). “Labeling” may even describe promotional materials used by the drug manufacturer including “[b]rochures, booklets, mailing pieces, ... price lists, catalogs, house organs, letters, motion picture films, film strips, lantern slides, ... and reprints and similar pieces of printed, audio or visual matter descriptive of a drug and references published (for example, the Physician’s Desk Reference) for use by medical practitioners, pharmacists, or nurses . . . .” 21 C.F.R. § 202.1(l)(2). FDA has provided more information on this terminology at: <http://www.fda.gov/cder/handbook/advertdef.htm>.

\(^ {38} \) See Mifeprex Approval Memo at 7.
\(^ {39} \) See FDA Mifeprex Approval Letter at 3.
\(^ {40} \) 21 C.F.R. § 314.126(a).
\(^ {41} \) See Jennifer Kulynych, “Will FDA Relinquish the ‘Gold Standard’ for New Drug Approval? Redefining ‘Substantial Evidence’ in the FDA Modernization Act of 1997,” Food and Drug Law Journal 54 (1999): 127-149, at 129. We will refer to these criteria as the “default standard.”
more recently, by the International Conference on Harmonisation ("ICH") to eliminate bias from
the evaluation of drug safety and effectiveness.43

FDA has been criticized for its zealous implementation of this policy,44 but there is
widespread recognition of the value of the default standard. The 1962 statutory amendments to
the FD&C Act "authorized the agency to review all NDAs, not only to assess drug safety, but
also to determine whether a manufacturer has provided 'substantial evidence' from 'adequate
and well-controlled investigations' that a drug is effective for its intended use."45 In
implementing regulations, FDA "required that the evidence include at least one (and usually two)
well-controlled (preferably 'blind') trials showing statistically significant results for treatment of
humans with the new drug."46 "[B]arring unusual circumstances, the agency ordinarily requires
two successful and well-controlled clinical trials for new drug approval."47 FDA’s mandate for
clinical trials "has two very important elements:"

(1) a "controlled" trial, in which an experimental drug is compared to a placebo, or a
known effective treatment in order to establish the comparative efficacy of the drug, and
(2) a "double-blind" trial, which involves random assignment of research subjects to the

---

43 FDA, "International Conference on Harmonisation; Guidance on General Considerations for Clinical Trials," Notice, 62 Fed. Reg. 66113 (Dec. 17, 1997) (FDA Guidance (ICH: E8): General Considerations). The homepage, (www.ich.org), for the ICH describes the organization as follows: "The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) is a unique project that brings together the regulatory authorities of Europe, Japan and the United States and experts from the pharmaceutical industry in the three regions to discuss scientific and technical aspects of product registration. The purpose is to make recommendations on ways to achieve greater harmonisation in the interpretation and application of technical guidelines and requirements for product registration in order to reduce or obviate the need to duplicate the testing carried out during the research and development of new medicines. The objective of such harmonisation is a more economical use of human, animal and material resources, and the elimination of unnecessary delay in the global development and availability of new medicines whilst maintaining safeguards on quality, safety and efficacy, and regulatory obligations to protect public health."

45 Kulynych, infra Appendix A, at 129 (citing 21 U.S.C. § 355(d)).
47 Kulynych, infra Appendix A, at 130.
experimental and control groups, under conditions in which neither the doctors nor the
research subjects know who is getting the experimental drug and who the control.\(^\text{48}\)

Each of the mandated features helps to eliminate bias in trial results. First, in “double-
blinded” studies neither the patient nor the provider team (physician, nurse, etc.) knows the
identity of the drug administered. If that is not possible, the person evaluating the trial results
will not know which treatment has been administered to which subject. Second, a “randomized”
study requires a random determination of which subject receives which treatment. This
determination is often effected through computer-generated assignments done before clinical
testing begins. Finally, comparison-control (also known as “comparator-control”) requires that
the experimental drug be compared \(\textit{concurrently}\) to the current best treatment, or, alternatively,
to a placebo. A placebo is used when the drug being tested represents the first treatment of its
kind for the particular indication and no established treatment exists.

2. FDA Initiatives to Expedite the Approval of Drugs for the Very Sick

Largely in response to FDA’s perceived slowness in approving drugs for human
immunodeficiency virus (“HIV”) patients, the agency undertook several initiatives to either
expedite the ability of seriously or terminally-ill patients to have access to experimental drugs or
to provide processes “intended to move drugs to market more quickly by compressing clinical
development and FDA review times.”\(^\text{49}\) In 1988, FDA adopted an interim rule establishing
Subpart E of 21 C.F.R. Part 312 (“Drugs Intended to Treat Life-Threatening and Severely-

\(^{48}\) Greenberg, \textit{infra} Appendix A, at 307-8 (footnotes omitted).

\(^{49}\) Sheila R. Shulman and Jeffrey S. Brown, “The Food and Drug Administration’s Early Access and Fast-Track
Debilitating Diseases”). Subpart E embodied several of the new procedures that FDA had used to bring the HIV medication, AZT (zidovudine), to market quickly. Subpart E also created a “collaborative framework in which early and repeated consultation between the FDA and pharmaceutical manufacturers served to facilitate clinical trials, and to insure ex ante that prospective research designs would meet with subsequent regulatory approval.” “Taken together,” the innovations found in Subpart E, “served to radically alter the new drug approval process with regard to life-threatening illnesses, particularly for AIDS.”

On April 15, 1992, FDA took its procedural innovations further when it proposed an “Accelerated Approval” process (i.e., Subpart H). Shulman and Brown believe that Subpart H “represented the most significant departure from the traditional FDA standards for drug approval.” Subpart H’s “major point of departure” from previously existing approval regimes was its focus on granting drug approval “on the basis of the drug’s effect on a surrogate endpoint that is reasonably likely to predict clinical benefit over time.” A “surrogate endpoint” or “surrogate marker” is “a laboratory parameter or physical sign that is used in a clinical trial as a substitute for a clinically meaningful end point, such as mortality.” The value of surrogate

---

51 See Greenberg, infra Appendix A, at 321.
52 Greenberg, infra Appendix A, at 321 (citation omitted).
53 Greenberg, infra Appendix A, at 323.
54 Shulman and Brown, infra Appendix A, at 514.
55 Shulman and Brown, infra Appendix A, at 514. Likewise, Greenberg observed that the “essential element of the accelerated approval regulations [i.e., Subpart H] was the provision that ‘surrogate endpoints’ could be employed as the empirical basis for FDA approval of a new drug.” Greenberg, infra Appendix A, at 323 (citation omitted).
endpoints lies in their ability to predict clinical outcomes. As "examples of surrogate endpoints that have been proven to be excellent predictors of clinical outcomes and, hence, have saved both money and precious time expediting drugs to the patient care arena," Dean Dennis Thompson cites "a diverse group of antihypertensive drugs approved on the basis of reduced blood pressure effects [that] has shown clear benefits in reducing cardiovascular events and mortality." With the passage of the Food and Drug Administration Modernization Act of 1997 ("FDAMA"), Congress effectively codified Section 314.510, the surrogate endpoint provision of Subpart H.

Neither Shulman and Brown nor Greenberg focused on a second type of drug approval included in Subpart H – codified now at 21 C.F.R. § 314.520. This second avenue for Subpart H approval is reserved for circumstances in which "FDA determines that a drug, effective for the treatment of a disease, can be used safely only if distribution or use is modified or restricted." Pursuant to this provision "FDA may approve a treatment subject to special

57 See Thompson, infra Appendix A, at 170.
58 Thompson, infra Appendix A, at 170.
59 This codification was part of Congress’s major reauthorization and modernization of the Federal Food, Drug & Cosmetic Act. Section 506(b) of FDAMA (21 U.S.C. § 356) “in effect, codifie[d] in statute FDA’s Accelerated Approval Rule . . . , made final in 1992, which allows expedited marketing of certain new drugs or biological products intended to treat serious or life-threatening illnesses and that appear &provide meaningful therapeutic benefits to patients compared with existing treatments.” FDA Centers for Drug Evaluation and Research and for Biologics Evaluation and Research, Guidance for Industry: Fast Track Drug Development Programs – Designation, Development, and Application Review, at 2 (Sept. 1998) (footnote omitted). While clearly codifying Subpart H’s surrogate endpoint provision at 21 U.S.C. § 356(b)(1), Congress does not appear to have enacted a parallel provision to Section 314.520, which pertains to “restricted use” drugs, under which Mifepristone was approved.
60 Section 314.520 (Approval with restrictions to ensure safe use.) states:
(a) If FDA concludes that a drug product shown to be effective can be safely used only if distribution or use is restricted, FDA will require such postmarketing restrictions as are needed to ensure safe use of the drug product, such as:
(1) Distribution restricted to certain facilities or physicians with special training or experience; or
(2) Distribution conditioned on the performance of specified medical procedures.
(b) The limitations imposed will be commensurate with the specific safety concerns presented by the drug product.
distribution or use restrictions that address outstanding safety issues."62 Section 314.520 balanced FDA’s desire to bring clinically beneficial drugs to the market with the agency’s concern that “[s]ome drugs, however, are so inherently toxic or otherwise potentially harmful that it is difficult to justify their unrestricted use.”63 The agency explained “that some clinically beneficial drugs can be used safely only if distribution and use are modified and restricted.”64

Section 314.520 is intended for drugs that are vitally necessary, but which may impose greater than normal risks for the patient.65 FDA was willing “to approve such high risk drugs for early marketing if the agency can be assured that postmarketing restrictions will be in place to counterbalance the known safety concerns.”66 Postmarketing restrictions would be designed “to enhance the safety of a drug whose risks would outweigh its benefits in the absence of the restriction.”67 FDA intended to employ restrictions on distribution “only in those rare instances in which the agency believes carefully worded labeling for a product granted accelerated approval will not assure the product’s safe use.”68 In the absence of restrictions, which “may vary with the circumstances of each drug[,] . . . the drug would be adulterated under Section 501 of the act, misbranded under Section 502 of the act, or not shown to be safe under Section 505 of the act.”69 In short, “[w]ithout such restrictions, the drugs would not meet the statutory criteria,

---

65 Of course, “[v]irtually all drug[s] can be toxic to humans, and no drug is completely free of risk,” but, as the seriousness of an illness and the effect of the drug on that illness increase, “the greater the acceptable risk from the drug.” Subpart H Proposed Rule, 57 Fed. Reg. at 13236.
68 Subpart H Final Rule, 57 Fed. Reg. at 58952 (emphasis added).
could not be approved for distribution, and would not be available for prescribing or dispensing.”

Mifeprex was the third of four drugs approved pursuant to Section 314.520.  

D.  FDA’S APPROVAL OF MIFEPREX UNDER ITS ACCELERATED APPROVAL REGULATIONS (SUBPART H) WAS ARBITRARY, CAPRICIOUS, AN ABUSE OF DISCRETION, OR OTHERWISE NOT IN ACCORDANCE WITH LAW

FDA’s accelerated approval regulations (Subpart H) apply to certain new drug products “that have been studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit to patients over existing treatments (e.g., ability to treat patients unresponsive to, or intolerant of, available therapy, or improved patient response over available therapy.)” When it proposed Subpart H in 1992, FDA observed that the following types of illness would fall within the reach of Subpart H:

The terms “serious” and “life-threatening” would be used as FDA has defined them in the past. The seriousness of a disease is a matter of judgment, but generally is based on its impact on such factors as survival, day-to-day functioning, or the likelihood that the disease, if left untreated, will progress from a less severe condition to a more serious one. Thus, acquired immunodeficiency syndrome (AIDS), all other stages of human immunodeficiency virus (HIV) infection, Alzheimer’s dementia, angina pectoris, heart failure, cancer, and many other diseases are clearly serious in their full manifestations. Further, many chronic illnesses that are generally well-managed by available therapy can have serious outcomes. For example, inflammatory bowel disease,

70 Subpart H Final Rule, 57 Fed. Reg. at 58951. The agency continued: “The agency, as a matter of longstanding policy, does not wish to interfere with the appropriate practice of medicine or pharmacy. In this instance, the agency believes that rather than interfering with physician or pharmacy practice, the regulations permit, in exceptional cases, approval of drugs with restrictions so that the drugs may be available for prescribing or dispensing.” Id. at 58951-52.

71 On June 7, 2002, the drug Lotronex (alosetron hydrochloride) was reintroduced to the market after a Supplemental NDA was approved pursuant to Subpart H’s redistricted distribution provision. See Letter, FDA/CDER, Florence Houn, M.D., Director, Office of Drug Evaluation III to Olivia Pinkett, Product Director, Regulatory Affairs, GlaxoSmithKline (June 7, 2002): at 1 (“This supplemental application, considered for approval under 21 CFR 314, Subpart H at your request, narrows the original approved indication to use of the drug in a population for whom the benefits of the drug may outweigh the risks and provides for a risk management program. . . . You have indicated your agreement with approval under restricted conditions.”).

Asthma, rheumatoid arthritis, diabetes mellitus, systemic lupus, erythematous, depression, psychoses, and many other diseases can be serious for certain populations or in some or all of their phases.  

According to FDA, the agency has approved 38 NDAs, including the Mifeprex application, under Subpart H. Of these approvals, 20 were for the treatment of HIV and HIV-related diseases, nine were for the treatment of various cancers and their symptoms, four were for severe bacterial infections, one was for erythema nodosum leprosum (leprosy), one was for hypotension, and, finally, one was for the termination of unwanted pregnancies.

Pregnancy, without major complications, is not a “serious or life-threatening illness” for purposes of Subpart H. It is, rather, a normal physiological state experienced by most females one or more times during their childbearing years, and it is rarely accompanied by complications that threaten the life of the mother or the child. Following delivery, almost all women return to a normal routine without disability. Thus, pregnancy is not the kind of exceptional circumstance that falls within the scope of Subpart H. The fact that the Mifeprex Regimen is intended for healthy women provides further evidence of this point.

Subpart H Proposed Rule, 57 Fed. Reg. at 13235. In the Subpart H Final Rule, FDA asserted that “serious and life-threatening illnesses” would be readily identifiable: “FDA discussed the meaning of the terms ‘serious’ and ‘life-threatening’ in its final rules on ‘treatment IND’s’ (52 FR 19466 at 19467, May 22, 1987) and ‘subpart E’ procedures (54 FR 41516 at 41518-41519, October 21, 1988). The use of these terms in this rule is the same as FDA defined and used the terms in those rulemakings. It would be virtually impossible to name every ‘serious’ and ‘life-threatening’ disease that would be within the scope of this rule. In FDA’s experience with ‘treatment IND’s’ and drugs covered by the ‘subpart E’ procedures there have not been problems in determining which diseases fall within the meaning of the terms ‘serious’ and ‘life-threatening,’ and FDA would expect no problems under this accelerated approval program.” Subpart H Final Rule, 57 Fed. Reg. at 58945.

These estimates are based on the version of FDA’s webpage, dated February 5, 2002, listing Subpart H approvals, infra Appendix A.

See FDA/CDER webpage, “NDAs Approved under Subpart H,” infra Appendix A. A copy of the most recently available version is reproduced in Appendix C (available at: <http://www.fda.gov/cder/rdmt/accapp.htm>). See also “NDA Supplements Approved under Subpart H” (available at: <http://www.fda.gov/cder/rdmt/accappr1.htm>) (supplemental approvals are not included in the figures set forth in the text because they refer to FDA actions regarding drugs that have already been approved).
In fact, the Population Council argued strenuously that its application for mifepristone did not fall within the scope of Subpart H. In a letter to FDA written approximately three weeks before the final approval of the mifepristone NDA, the Population Council’s Sandra P. Arnold protested, “... it is clear that the imposition of Subpart H is unlawful, unnecessary, and undesirable. We ask FDA to reconsider.” Arnold argued correctly that “[n]either pregnancy nor unwanted pregnancy is an illness, and Subpart H is therefore inapplicable for that reason alone.” She continued, stating, “Neither is pregnancy nor unwanted pregnancy a ‘serious’ or ‘life-threatening’ situation as that term is defined in Subpart H.” In the next paragraph, after directly quoting the Subpart H Final Rule, Ms. Arnold asserted that “[t]he plain meaning of these terms does not comprehend normal, everyday occurrences such as pregnancy and unwanted pregnancy.” She added that, unlike HIV infection, pulmonary tuberculosis, cancer, and other illnesses, “pregnancy and unwanted pregnancy do not affect survival or day-to-day functioning as those terms are used in Subpart H.” She continued that, “although a pregnancy ‘progresses,’ the development of a pregnancy ‘is hardly the same as the worsening of a disease that physicians call progression.’

---

76 The Population Council appears to have been concerned about getting the drug approved “without invoking the Subpart H regulatory provisions that signal ‘big deal’ to the pharmaceutical industry.” Letter, Sandra Arnold to FDA/CDER, Office of Drug Evaluation III, Division of Reproductive and Urologic Products (Sept. 6, 2000): at 4 [FDA FOIA Release: MIF 001333-49] (“Sandra Arnold Letter”). Sandra Arnold was “Vice President, Corporate Affairs” of the Population Council.
77 Sandra Arnold Letter at 1.
78 Sandra Arnold Letter at 1-2.
79 Sandra Arnold Letter at 2.
80 Sandra Arnold Letter at 2.
81 Sandra Arnold Letter at 2.
82 Sandra Arnold Letter at 2. Ms. Arnold also warned the agency that extending the scope of Subpart H to include pregnancy and unwanted pregnancy by exercising agency “judgment” was not defensible; the exercise of such judgment should go to whether or not “a particular disease actually is serious, not [act as] a means of stretching the meaning of serious to cover entirely new categories of non-serious situations.” Id.
Additionally, Mifeprex fails to meet the second requirement set forth in Section 314.500 that drugs approved under Subpart H “provide meaningful therapeutic benefit to patients over existing treatments (e.g., ability to treat patients unresponsive to, or intolerant of, available therapy, or improved patient response over available therapy.)” As was noted above, the Mifeprex Approval Memo contends “that the termination of an unwanted pregnancy is a serious condition within the scope of Subpart H [and] [t]he meaningful therapeutic benefit over existing surgical abortion is the avoidance of a surgical procedure.” By defining the “therapeutic benefit” solely as the avoidance of the current standard of care’s delivery mechanism, FDA effectively guarantees that a drug will satisfy this second prong of Subpart H as long as it represents a different method of therapy. It does not appear that such considerations formed the basis of any other Subpart H approval.

When FDA adopted Subpart H, it cited as “readily understood illustrations of the intent of the [meaningful therapeutic benefit] requirement” an “improved response compared to available therapy” and the “ability to treat unresponsive or intolerant patients.” Based on these illustrations, Mifeprex does not fall within the intent of the requirement. First, there is a less dangerous, more effective alternative to Mifeprex available for the termination of pregnancies: namely, surgical abortions. Dr. Jeffrey Jensen conducted a study to compare the safety and

---

83 Mifeprex Approval Memo at 6.
84 The view that merely making a different mode of therapy available per se produces a benefit is inconsistent with the position the agency has articulated elsewhere. MAPP 6020.3, which defines eligibility for FDA priority review, suggests that drug therapies are not inherently superior to non-drug therapies. Specifically, a drug may be afforded priority review if it would provide a significant improvement when compared with “marketed products . . . including non-“drug” products/therapies.” See FDA/CDER, “Review Management: Priority Review Policy,” MAPP 6020.3, at 1 (Apr. 22, 1996).
efficacy of medical abortion with that of surgical abortion. The study compared 178 patients who, as participants in the U.S. clinical trial in support of the Mifeprex NDA, underwent mifepristone/misoprostol abortions, with 199 patients who later received surgical abortions at the same clinical site. The primary procedure failed (i.e., there was a subsequent surgical intervention) in 18.3 percent of the mifepristone/misoprostol patients and 4.7 percent of the surgical patients. Of the mifepristone/misoprostol patients who failed their primary procedure, 12.5 percent required surgical intervention for acute bleeding, 43.8 percent for persistent bleeding, 15.6 percent for incomplete abortion, and 28.1 percent for ongoing pregnancy. By contrast, the sole cause for surgical intervention among the surgical patients who failed their primary procedure was persistent bleeding. In addition, mifepristone/misoprostol patients “reported significantly longer bleeding” and “significantly higher levels of pain . . ., nausea . . ., vomiting . . ., and diarrhea” than their surgical counterparts.

Second, Mifeprex does not treat a subset of the female population that is unresponsive to, or intolerant of surgical abortion. To the contrary, because “medical abortion failures should be managed with surgical termination” the option for surgical abortion must be available for any Mifeprex patient. As the U.S. trial conducted in support of the NDA indicated, the possibility

---

87 See Jensen Study, infra Appendix A, at 155, Table 2.
88 See Jensen Study, infra Appendix A, at 156, Table 3.
89 See Jensen Study, infra Appendix A, at 156, Table 3.
90 See Jensen Study, infra Appendix A, at 156.
91 Mifeprex Label ("Warnings").
for failure is substantial. Thus, any patient who would be intolerant of surgical abortion, if such a class of patients exists, cannot use the Mifeprex Regimen.

As discussed below, FDA approved Mifeprex pursuant to Section 314.520 in order to impose safety restrictions to counteract the risks it had identified. FDA, confronted by the sponsor’s refusal to establish voluntary restrictions on distribution, viewed Subpart H as the only available regulatory vehicle that had the potential to make Mifeprex safe. The inappropriate application of Section 314.520 served the agency’s immediate need of conditioning the drug’s approval on certain safety measures. However, Mifeprex fails to satisfy the Subpart H requirements because, although it presents great risk to the user, it neither treats a serious or life-threatening illness nor provides a therapeutic benefit above existing treatments. A drug with such characteristics should not have been approved.

---

92 FDA, “Medical Officer’s Review of Amendments 024 and 033: Final Reports for the U.S. Clinical Trials Inducing Abortion up to 63 Days Gestational Age and Complete Responses Regarding Distribution System and Phase 4 Commitments,” at 11 (Table 1) (reporting a failure rate of 8% for pregnancies less than or equal to 49 days’ duration) (“Medical Officer’s Review”).

93 Early in the approval process, FDA anticipated that the Population Council would cooperate, thus obviating the need for Subpart H restrictions: “[B]ecause the applicant has voluntarily proposed a system of limited distribution, imposition of further distribution restrictions under the Agency’s Subpart H regulations does not appear warranted.” See Memorandum, FDA/CDER to NDA 20-687 File (Sept. 16, 1996); at 2 [FDA FOIA Release MIF 000560-62]. The voluntary restrictions placed on the drug Accutane, a drug for severe acne, illustrate that a cooperative drug sponsor may be able to obviate the need for Subpart H restrictions. Because Accutane can cause birth defects, the restrictions are designed to ensure that women taking the drug are not and do not become pregnant. The “System to Manage Accutane Related Teratogenicity™ (S.M.A.R.T.™),” controls the distribution of the drug through the issuance of yellow Accutane Qualification Stickers. These stickers are distributed to physicians who meet a number of qualifications and they, in turn, distribute them to patients, who must undergo two tests to confirm they are not pregnant and must commit to use two forms of contraception. Pharmacists may fill prescriptions for the drug only if they bear the qualification sticker, were issued within the past week, and prescribe no more than 30 days’ worth of the drug. See Accutane Label.

94 This interpretation of the agency’s actions is supported by FDA spokeswoman Crystal Rice, who said “that outside of Subpart H, the FDA does not have another regulatory program to mandate safety restrictions on drug marketing for drugs used to treat ‘serious or life-threatening illnesses’” and “that ‘other agreements [or restrictions on the drug] not under Subpart H worked out between FDA and a sponsor would be essentially voluntary.’” “Danco Medical Director Explains Mifepristone's FDA Approval Not Fast-Track or Accelerated, Despite Media Reports,” Kaiser Daily Reproductive Health Report (March 29, 2001) (available at: <http://report.kff.org/archive/repro/2001/3kr010329.5.htm>).

---

EX. 9 pg. 023
E. THE CLINICAL TRIALS DID NOT PRESENT "SUBSTANTIAL EVIDENCE" THAT THE MIFEPRExX REGIMEN IS SAFE AND EFFECTIVE

FDA’s approval of the Mifeprax NDA ran counter to Congress’s statutory requirements, the agency’s regulations and guidance documents, and FDA’s well-established standards for the quality and quantity of scientific evidence needed to support an agency finding that a new drug is safe and effective. The clinical trials submitted by the Population Council to support its NDA did not use the full set of design features FDA typically requires to produce unbiased investigations of drug safety and effectiveness. Because these trials were not blinded, randomized, or concurrently controlled, they did not establish the safety and effectiveness of the Mifeprax Regimen. Inexplicably, FDA failed to perform a statistical analysis of the data from the American trial. Furthermore, FDA’s approval of Mifeprax pursuant to Subpart H compounds the deficiencies in the trials because sponsors of Subpart H drugs must demonstrate that the drug for which approval is being sought provides a “meaningful therapeutic benefit over existing therapy.” Because Mifeprax was approved in reliance on French and American trials that did not compare the Mifeprax Regimen with the existing standard of care for ending pregnancies (i.e., surgical abortion), the trials cannot support this Subpart H approval.

1. The Clinical Trials Underlying FDA’s Approval of Mifeprax

FDA based its approval of Mifeprax on safety and effectiveness data derived from two French clinical trials (“French Clinical Trials”) and one U.S. clinical trial (“U.S. Clinical Trial”). Neither the French Clinical Trials nor the U.S. Clinical Trial was blinded, randomized,
or concurrently controlled – the hallmarks of unbiased, scientific analysis generally relied upon by FDA.

a. **The French Clinical Trials**

The French Clinical Trials, which formed the basis for the Population Council’s original NDA submission in 1996, were open-label, multi-center studies. One of these trials consisted of 1,286 patients at 24 centers in France ("French Trial I"). The trial was limited to women who had pregnancies of no more than 49 days’ gestational age, as established by ultrasound, if available, or by the patient’s estimate. On the first day of the procedure, the patient received 600 mg of mifepristone orally “in the presence of a study investigator.” Approximately 48 hours later, she returned and, unless the abortion had already taken place, ingested 400 micrograms of misoprostol “in the presence of a study investigator.” The patient remained under observation for four hours or more after the ingestion of misoprostol and returned for “a final assessment of the pregnancy termination procedure” eight to 15 days later.

96 FDA’s Reproductive Health Drugs Advisory Committee ("FDA Advisory Committee"), which met in July 1996 to consider the mifepristone NDA, based its conclusion primarily on the French trial along with preliminary data from the U.S. Clinical Trial. See FDA Advisory Committee, Hearings on New Drug Application for the Use of Mifepristone for Interruption of Early Pregnancy, at 6, 132-33 (July 19, 1996) (FDA Hearings Transcript) [FDA FOIA Release: MIF 005200-90]. Committee member Dr. Mary Jo O’Sullivan asked why the Committee meeting was being held “at this time when the data is not finalized.” Id. at 37. Dr. C. Wayne Bardin, who was responsible for overseeing the Population Council’s NDA preparation, responded that “we have sufficient data . . . [f]rom the non-U.S. data to allow us to submit an application to the FDA.” Id.


98 See Statistical Review, infra Appendix A, at 2. “Since the ultrasound estimate of gestational age was more reliable than the patient’s estimate . . . gestational age based on the ultrasound examination was used if available.” Id. Investigators, in violation of study protocol, included some women with pregnancies of more than 49 days. See Statistical Review, infra Appendix A, at 3.


The efficacy analysis of French Trial I encompassed only 1,205 patients, while the safety analysis included all 1,286 participants. The regimen resulted in “complete expulsion” in 95.4 percent of the 1,189 participants whose pregnancies were 49 days or less. The rate of complete expulsion declined with increased gestational age. Sixty-one women had complete expulsions before taking misoprostol. Almost 86 percent of patients in French Trial I experienced at least one adverse event as a result of the procedure.

The second French clinical trial (“French Trial II”) enrolled 1,194 patients at 11 centers. The trial was limited to women who had pregnancies of no more than 63 days’ gestational age, as established by ultrasound, if available, or by the patient’s estimate. The regimen used in French Study II was essentially the same as that described above in connection with French Study I, except that an additional 200 micrograms of misoprostol was administered if complete expulsion did not occur within three hours after taking the initial 400 microgram dose of misoprostol. Patients who received the second dose of misoprostol remained under observation for a total of five hours.

---

103 See Statistical Review, infra Appendix A, at 3. Patients for whom expulsion of the embryo was complete at the end of the process were categorized as successes, while patients with incomplete expulsions (2.8%), ongoing pregnancies (1.5%), and those who needed surgical procedures for bleeding (.3%) were classified as failures. See id. at 3 and 9 (Table 1).
104 See Statistical Review, infra Appendix A, at 3 (“There was a statistically significant . . . inverse relationship between gestational age and the success rate as the success rate generally declined with increasing gestational age.”).
105 See Statistical Review, infra Appendix A, at 3. Twenty-six of these women received misoprostol anyway, because the investigators did not realize that they had had complete abortions. See id.
107 See Statistical Review, infra Appendix A, at 4-7. This French trial is designated as FF/92/486/24.
The efficacy analysis of French Trial II encompassed only 1,104 patients, while the safety analysis included all 1,194 participants.\textsuperscript{111} The regimen resulted in “complete expulsion” in 92.8 percent of the participants.\textsuperscript{112} The rate of complete expulsion declined with increased gestational age.\textsuperscript{113} Twenty-six women had complete expulsions before taking misoprostol.\textsuperscript{114} Almost 93 percent of patients in French Trial II experienced at least one adverse event as a result of the procedure.\textsuperscript{115}

Among the deficiencies that characterized both French Clinical Trials was the absence of an appropriate control group. Consequently, as an FDA statistician concluded after reviewing the data from the French Clinical Trials: “In the absence of a concurrent control group in each of these studies, it is a matter of clinical judgment whether or not the sponsor’s proposed therapeutic regimen is a viable alternative to uterine aspiration for the termination of pregnancy.”\textsuperscript{116}

b. The U.S Clinical Trial

The U.S. Clinical Trial was carried out from September 13, 1994 to September 12, 1995 at various qualified university hospitals and clinics.\textsuperscript{117} Patients had to satisfy a number of criteria

\textsuperscript{111} See Statistical Review, \textit{infra} Appendix A, at 5.

\textsuperscript{112} See Statistical Review, \textit{infra} Appendix A, at 6. As in French Study I, patients for whom expulsion of the embryo was complete at the end of the process were categorized as successes, while patients with incomplete expulsions (4.0%), ongoing pregnancies (2.3%), and those who needed surgical procedures for bleeding (.9%) were classified as failures. \textit{See id. at 5 and 12 (Table 4).}


\textsuperscript{115} See Statistical Review, \textit{infra} Appendix A, at 7

\textsuperscript{116} Statistical Review, \textit{infra} Appendix A, at 7-8.

\textsuperscript{117} See Medical Officer’s Review, \textit{infra} Appendix A, at 6. More specifically, the U.S. Clinical Trial consisted of “two prospective, open-label, multicenter clinical trials in the United States according to two identical protocols.” Medical Officer’s Review, \textit{infra} Appendix A, at 6 and 9. In this Petition, the trials will be referred to as “the U.S. Clinical Trial,” because the protocols employed were identical, the results of the two trials were analyzed jointly, and the results were published in the same article. See Irving M. Spitz, M.D., C. Wayne Bardin, M.D., Lauri

EX. 9 pg. 027
to be included in the study. All patients were screened by pelvic examination and ultrasound to ensure that their pregnancies were not too advanced for the procedure. On their first visit, patients took 200 mg of mifepristone orally "in the presence of the investigator." Patients returned 36 to 60 hours later to ingest 400 micrograms of misoprostol orally in the presence of the investigator, unless the investigator determined that the termination was already complete. Following ingestion of misoprostol, patients were observed for a minimum of four hours. Patients were instructed to return again 12 days later for a follow-up assessment. A patient’s pregnancy was terminated surgically “at any time if the investigator believed there was a threat to a woman’s health (medically indicated), at a woman’s request, or at the end of the study for an ongoing pregnancy or incomplete abortion.”

Benton, M.D., and Ann Robbins, “Early Pregnancy Termination with Mifepristone and Misoprostol in the United States,” New England Journal of Medicine 338 (Apr. 30, 1998): 1241-47 (“Spitz Article”) (FDA FOIA Release: MIF 006692-97). The members of the FDA Advisory Committee who were still working for FDA at the time of publication received a copy of the Spitz Article. See Medical Officer’s Review, infra Appendix A, at 29. Although FDA considered data from the entire U.S. Clinical Trial, it appears that the agency formally approved Mifeprex based only on the portion of the U.S. Clinical Trial data that was generated among women whose pregnancies were no more than 49 days’ gestational age. See Mifeprex Approval Memo, infra Appendix A, at 1 ("The U.S. trial consisted of 859 women providing safety data and 827 women providing effectiveness data for gestations of 49 days or less, dated from the last menstrual period."). See also Mifeprex Label ("Clinical Studies").

118 Among the inclusion criteria were requirements that a patient be at least 18 years old, be in good health, have an intrauterine pregnancy of no more than 63 days (confirmed by a pelvic examination and ultrasound), and have agreed to a surgical abortion if the mifepristone-misoprostol abortion failed. Medical Officer’s Review, infra Appendix A, at 7-8. The study excluded women with certain health problems, such as liver, respiratory, or renal disease, cardiovascular disease, chronic hypertension, anemia, clotting problems, pelvic inflammatory disease, and ectopic pregnancies. See id. at 8. In addition, women who were over 35 and smoked, had IUDs, were breastfeeding, were unlikely to comply with study requirements, or who “[l]ived or worked more than one hour from the emergency care facility” were excluded. See id. at 8-9.

119 See Medical Officer’s Review, infra Appendix A, at 8.

120 Medical Officer’s Review, infra Appendix A, at 9.

121 See Medical Officer’s Review, infra Appendix A, at 9.

122 See Medical Officer’s Review, infra Appendix A, at 7.

123 See Medical Officer’s Review, infra Appendix A, at 7.

124 Medical Officer’s Review, infra Appendix A, at 16.
The U.S. Clinical Trial consisted of 2,121 subjects. Of these patients, 2,015 were evaluated for efficacy, which "was defined as the termination of pregnancy with complete expulsion of the conceptus without the need for a surgical procedure." The remaining 106 patients did not return for the third visit. The mifepristone-misoprostol combination was effective in 92 percent of patients with pregnancies no greater than 49 days, 83 percent of patients with pregnancies between 50 and 56 days, and 77 percent of women with pregnancies between 57 and 63 days. All 2,121 subjects were evaluated for safety. Ninety-nine percent of patients experienced adverse events and most of these experienced multiple adverse events. Twenty-three percent of the adverse effects experienced by each gestational age group were "severe."

Finally, FDA did not conduct a statistical review of the results of the U.S. Clinical Trial. FDA’s statistical reviewer explained this failure by noting that “[a] statistical evaluation of the European studies was completed previously” and “[t]he clinical results of the supporting U.S.

---

125 See Medical Officer’s Review, infra Appendix A, at 10.
126 See Medical Officer’s Review, infra Appendix A, at 10.
127 Medical Officer’s Review, infra Appendix A, at 16. The failure to establish a pre-trial, statistical definition for drug efficacy was a defect in trial design.
128 See Medical Officer’s Review, infra Appendix A, at 16. It would have been appropriate to include these 106 patients in the efficacy analysis as "failures," if for no other reason than that they did not appear for all three required visits. Although “[f]or 92 of these patients, there was some information suggesting a successful outcome,” id. at 10, there was neither definitive evidence of complete abortion nor, apparently, any information with respect to whether these women subsequently experienced any adverse effects. In fact, during their second visit, five of these 106 women were diagnosed as having continuing pregnancies. Id. at 10. See also Spitz Article, infra Appendix A, at 1246 ("The ultimate outcome of these pregnancies is unknown, despite our repeated attempts to contact the women.").
129 See Medical Officer’s Review, infra Appendix A, at 11 (Table 1).
130 See Medical Officer’s Review, infra Appendix A, at 10.
131 See Medical Officer’s Review, infra Appendix A, at 11.
132 See Medical Officer’s Review, infra Appendix A, at 11.
studies . . . are similar enough to the results of the European studies that, in the opinion of the medical reviewer, a statistical evaluation of the results of the U.S. studies is not required.\footnote{FDA, "Statistical Comments on Amendment 024," Memorandum to File NDA 20-687 (Feb. 14, 2000). This document is available along with the agency’s Statistical Review. See Statistical Review, infra Appendix A.}

2. **Requirements for Proving Drug Safety and Effectiveness**

FDA has developed a rigorous default standard for scientific demonstrations of safety and effectiveness of human drug products.\footnote{See the discussion of the development and requirements of FDA’s "gold standard," supra Section III.C.1.} Section 505(d)(5) of the FD & C Act provides, in relevant part, that FDA shall refuse to approve a new drug application when "there is a lack of substantial evidence that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the proposed labeling."\footnote{21 U.S.C. § 355(d)(5).} Section 505(d) defines “substantial evidence” to mean “evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved . . . ”\footnote{21 U.S.C. § 355(d) ("the term ‘substantial evidence’ means evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be concluded by such experts that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling or proposed labeling thereof.")} FDA has stated that “substantial evidence” requires a showing of clinically significant evidence of effectiveness rather than mere statistical evidence of significance.\footnote{See Warner-Lambert Co. v. Heckler, 787 F.2d 147, 155 (D.C. Cir. 1986) ("It is important to note that the Commissioner does not contend that the effectiveness shown must amount to a ‘medical breakthrough’, as ARW complains, but contends in his brief that he would be satisfied with even a modest clinical or therapeutic effect.").} No such showing was made for Mifepristone, which has been demonstrated to be less effective than surgical abortion for all segments of the population.

\footnotetext[133]{FDA, "Statistical Comments on Amendment 024," Memorandum to File NDA 20-687 (Feb. 14, 2000). This document is available along with the agency’s Statistical Review. See Statistical Review, infra Appendix A.}

\footnotetext[134]{See the discussion of the development and requirements of FDA’s "gold standard," supra Section III.C.1.}

\footnotetext[135]{21 U.S.C. § 355(d)(5).}

\footnotetext[136]{21 U.S.C. § 355(d) ("the term ‘substantial evidence’ means evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be concluded by such experts that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling or proposed labeling thereof.").}

\footnotetext[137]{See Warner-Lambert Co. v. Heckler, 787 F.2d 147, 155 (D.C. Cir. 1986) ("It is important to note that the Commissioner does not contend that the effectiveness shown must amount to a ‘medical breakthrough’, as ARW complains, but contends in his brief that he would be satisfied with even a modest clinical or therapeutic effect.").}
Section 314.126 of FDA’s rules states that “[r]eports of adequate and well-controlled investigations provide the primary basis for determining whether there is ‘substantial evidence’ to support the claims of effectiveness for new drugs.” The rule states that a major purpose of an adequate and well-designed study is to “permit[ ] a valid comparison with a control to provide a quantitative assessment of drug effect.” According to Section 314.126(b), an adequate and well-controlled study serves to ensure that the subjects of the trial have the disease or condition being studied, that the method of assigning patients to treatment and control groups minimizes bias (e.g., using randomization), and, that “[a]dequate measures are taken to minimize bias on the part of the subjects, observers, and analysts of the data” (e.g., blinding). The criteria that the rule establishes “have been developed over a period of years and are recognized by the scientific community as the essentials of an adequate and well-controlled clinical investigation.”

Agency guidance provides that FDA may approve an NDA based on only one, not two, effectiveness trials for drugs in one of the following three categories:

1) when effectiveness may be demonstrated adequately with existing studies of another claim or dose (e.g., approval for pediatric use on the basis of studies in adults); 2) when a controlled trial of a specific new use is supported by evidence from adequately controlled trials from related uses, dosages, or endpoints; and 3) when a single multicenter trial provides statistically convincing and clinically meaningful evidence of effectiveness, supported by confirmatory research.

---

138 21 C.F.R. § 314.126(a) (“Adequate and well-controlled studies.”).
139 21 C.F.R. § 314.126(b)(2) (describing “placebo concurrent control,” “dose-comparison concurrent control,” “no treatment concurrent control,” “active treatment concurrent control,” and “historical control”).
140 21 C.F.R. § 314.126(b)(3).
141 21 C.F.R. § 314.126(b)(4).
142 21 C.F.R. § 314.126(b)(5).
143 21 C.F.R. § 314.126(a).
144 Kulynych, infra Appendix A, at 146 (citing FDA, Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products (May 1998) at 5-17 (FDA Effectiveness Guidance).
Mifepristone did not fall within any of these categories. The first and second categories were inapposite because mifepristone had not been approved for any use in any population in the United States; additionally, no evidence from adequate and well-controlled trials had ever been presented to FDA regarding any use for mifepristone. Because neither the French Clinical Trials nor the U.S. Clinical Trial was randomized, blinded,\textsuperscript{145} or comparator-controlled, none of these trials could provide the type of data necessary for the third category either. Furthermore, these studies lacked "clear, prospectively determined clinical and statistical analytic criteria."\textsuperscript{146}

Even though FDA takes the position elsewhere that the extent to which a trial's design controls for various types of bias "is a critical determinant of its quality and persuasiveness,"\textsuperscript{147} neither the French Clinical Trials nor the U.S. Clinical Trial were randomized, concurrently controlled, or blinded. A control group "allow[s for] discrimination of patient outcomes (for example, changes in symptoms, signs, or other morbidity) caused by the test treatment from outcomes caused by other factors, such as the natural progression of the disease, observer or patient expectations, or other treatment."\textsuperscript{148} Control groups also enable investigators to

\textsuperscript{145} Blinding is the normal method by which those who evaluate a medication's effectiveness and side effects, are kept unaware of whether they are evaluating the comparator drug (sometimes a placebo), or the new medication (or procedure) under study. If possible, the patient is also blinded and not allowed to know which treatment she is receiving ("double-blinding"). According to standard scientific and medical practice and the standards to which FDA holds pharmaceutical sponsors, all clinical research studies investigating the effects of new drugs should be subjected to an assessment by a blinded evaluator. Conducting a concurrently-controlled, randomized trial comparing surgical abortion with the mifepristone-misoprostol regimen is readily achievable. There are study designs that would have also allowed for blinding. Had blinding proved too difficult to perform, the requirement could have been waived based upon a satisfactory showing by the sponsor.

\textsuperscript{146} FDA Effectiveness Guidance, infra Appendix A, at 12.


\textsuperscript{148} FDA Guidance (ICH: E10): Choice of Control Group, infra Appendix A, at 3 (§ 1.2) (Introduction, "Purpose of Control Group").
determine “what would have happened to patients if they had not received the test treatment or if they had received a different treatment known to be effective.”

A trial that employs a concurrent control group drawn from the same population yields the most robust data. Concurrent control groups are chosen from the same population as the test group and are “treated in a defined way as part of the same trial that studies the test treatment, and over the same period of time.” When concurrent control groups are used, the treatment and non-treatment groups are similar in all baseline and non-treatment variables that could influence the outcome or introduce bias into the study.

By contrast, in a trial using external or historical controls “the control group consists of patients who are not part of the same randomized study as the group receiving the investigational agent; i.e., there is no concurrently randomized control group.” FDA cautions:

“The external control may be defined (a specific group of patients) or non-defined (a comparator group based on general medical knowledge of outcome). Use of the latter comparator is particularly treacherous (such trials are usually considered uncontrolled) because general impressions are so often inaccurate.”

In such a trial, “[t]he control group is thus not derived from exactly the same population as the treated population.” If, as is most common, the external control group is composed of “a well-documented population of patients observed at an earlier time,” the trial is said to be

---

149 FDA Guidance (ICH: E10): Choice of Control Group, infra Appendix A, at 3 (§ 1.2).
150 FDA Guidance (ICH: E10): Choice of Control Group, infra Appendix A, at 3 (§ 1.2).
151 See FDA Guidance (ICH: E10): Choice of Control Group, infra Appendix A, at 3 (§ 1.2). “Bias here . . . means the systematic tendency of any aspects of the design, conduct, analysis, and interpretation of the results of clinical trials to make the estimate of a treatment effect deviate from its true value.” Id.
152 FDA Guidance (ICH: E10): Choice of Control Group, infra Appendix A, at 26 (§ 2.5.1).
153 FDA Guidance (ICH: E10): Choice of Control Group, infra Appendix A, at 5 (§ 1.3.5).
154 FDA Guidance (ICH: E10): Choice of Control Group, infra Appendix A, at 26 (§ 2.5.1).
“historically” controlled. Blinding and randomization are also not available to minimize bias when external or historical controls are used.

According to FDA, the “inability to control bias is the major and well-recognized limitation of externally controlled trials and is sufficient in many cases to make the design unsuitable.” A legal commentator recently cautioned courts about the scientific validity of experiments and trials that have no concurrent control. She explained that “historically controlled subjects have not been subjected to exactly the same conditions as the test subjects.” Consequently, “one must be wary of” non-concurrently controlled studies (i.e., historical, external, or uncontrolled studies) because their conclusions can be manipulated more easily than if concurrent controls are used.

3. FDA’s Acceptance of the French and U.S. Clinical Trial Data Violated Section 314.126(e) of the Agency’s Rules

Section 314.126(e) of FDA’s rules states unequivocally that “uncontrolled studies or partially controlled studies are not acceptable as the sole basis for the approval of claims of effectiveness.” The section authorizes the use of uncontrolled trials merely to present supporting evidence for controlled trials; uncontrolled trials, if they are “carefully conducted and

155 See FDA Guidance (ICH: E10): Choice of Control Group, infra Appendix A, at 26 (§ 2.5.1) (“but it could be a group at another institution observed contemporaneously, or even a group at the same institution but outside the study.”).

156 FDA Guidance (ICH: E10): Choice of Control Group, infra Appendix A, at 27 (§ 2.5.2).

157 FDA Guidance (ICH: E10): Choice of Control Group, infra Appendix A, at 26 (§ 2.5.2).


159 Beecher-Monas, infra Appendix A, at 1628, n.357.


161 21 C.F.R. § 314.126(e)(emphasis added).
documented, may provide corroborative support of well-controlled studies regarding efficacy and may yield valuable data regarding safety of the test drug.” 162

FDA recognizes a limited role for external, historically controlled studies. The agency takes the position that “[h]istorical (external) controls can be justified in some cases, but particular care is important to minimize the likelihood of erroneous inference.” 163 Similarly, Section 314.126 cautions that “[b]ecause historical control populations usually cannot be as well assessed with respect to pertinent variables as can concurrent controlled populations, historical control designs are usually reserved for special circumstances.” 164 FDA cites as an example, “studies of diseases with high and predictable mortality (for example, certain malignancies),” 165 in which a decision might be made to offer all trial participants a potentially effective drug. Externally controlled studies also may suffice because “the effect of the drug is self-evident (general anesthetics, drug metabolism).” 166

The French and U.S. Clinical Trials, which did not employ either external or historical control groups, were uncontrolled. During the Advisory Committee Hearings, FDA’s Dr. Ridgley C. Bennett, who summarized the data from the French Clinical Trials, stated:

There are very few studies comparing medical methods and vacuum aspiration for termination of early pregnancy. To date, no large randomized controlled trials have compared mifepristone plus misoprostol with suction curettage abortion. However, large published series have demonstrated morbidity rates associated with mifepristone plus prostaglandin to be similar to those of suction-curettage. 167

---

162 21 C.F.R. § 314.126(e).
164 21 C.F.R. § 314.126(b)(2)(v) (“Historical control.”).
165 21 C.F.R. § 314.126(b)(2)(v).
166 21 C.F.R. § 314.126(b)(2)(v).
167 FDA Hearings Transcript, infra Appendix A, at 130. Jensen and his fellow researchers conducted “[a] prospective, noncurrent, single center cohort comparison.” See Jensen Study, infra Appendix A, at 153. The study
“Published scrics” and uncontrolled studies cannot serve as a substitute for the well controlled clinical trials that FDA requires. A concurrent control group would have been feasible because the trial participants were prepared to receive surgical abortion in the event of a failed mifepristone abortion.

The unusual circumstances that sometimes justify relying on externally controlled trials are not applicable with respect to pregnancy termination, generally, or the termination using mifepristone and misoprostol, specifically. Randomized, concurrently-controlled, blinded trials would have allowed investigators to compare not only the relative rates of complete termination and expulsion, but also the nature, intensity, and duration of the numerous side effects. In the absence of concurrent controls and blinding, the duration and intensity of cramping, nausea, bleeding, pain, and any emotional or psychological effects of the treatments would be subject to investigator and patient bias. The design of the U.S. Clinical Trial precluded unbiased comparison groups that could have helped analysts arrive “at a complete understanding of potential advantages, disadvantages and differences” between medical and surgical abortion.\(^{168}\)

FDA’s *de facto* waiver of Section 314.126(e) constituted a gross departure from its past practice and announced standards for the conduct of adequate and well-controlled clinical trials.\(^{169}\)

\(^{168}\) See Jensen Study, *infra* Appendix A, at 156. Dr. Cassandra Henderson, a member of the FDA Advisory Committee, wondered about this point as well: “Since this regimen is not without any side effects and we know that spontaneous abortion is not an infrequent occurrence, is it appropriate to use historical controls in trying to evaluate the efficacy of this regimen and not a randomized placebo trial?” FDA Hearings Transcript, *infra* Appendix A, at 131 (FDA’s Dr. Ridgely C. Bennett gave the following puzzling response: “Well, I think it would be difficult to do a randomized trial of this nature. But I think it is fair to use a historical control for efficacy.”).

\(^{169}\) There is no evidence that FDA formally issued a waiver under Section 314.126(c) of the requirement for well-controlled studies or that the Population Council ever requested such a waiver.
4. Subpart H’s Standard for Proving Drug Effectiveness

The approval of a drug under Subpart H does not lower the applicable standards for proving the drug’s effectiveness. As FDA stated when it adopted Subpart H, “[a]ll drugs approved [under Subpart H] will have had effectiveness demonstrated on the basis of adequate and well-controlled studies.” In fact, Subpart H is available only for drugs “that have been studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit to patients over existing treatments (e.g., ability to treat patients unresponsive to, or intolerant of, available therapy, or improved patient response over available therapy).” Neither the French nor the U.S. Clinical Trials yielded scientifically valid comparisons with the existing therapy, surgical abortion, to support a finding of a “meaningful therapeutic benefit over existing treatments.” FDA should have required the concurrent testing of mifepristone with surgical abortion to test the proposition that mifepristone has a meaningful therapeutic benefit over the standard method for terminating pregnancies. FDA did not require the drug sponsor to perform such trials for Mifeprex, which departs from FDA’s normal treatment of Subpart H drugs generally and for the other drugs approved under the restricted distribution provisions in Section 314.520.

Mifeprex appears to be the only drug that FDA has approved under Section 314.520 of Subpart H without requiring compliance with the statutory and regulatory requirements that safety and efficacy be scientifically demonstrated through blinded, comparator-controlled, and randomized clinical trials capable of providing data for subjection to rigorous statistical analysis.

171 21 C.F.R. § 314.500 (emphasis added). The class of “existing treatments” to which there must be a comparison, as specified in this rule section, is not limited to pharmaceuticals. For example, a potential chemotherapeutic agent might be compared to radiation therapy.
Aside from Mifeprex, only four drugs have been approved pursuant to Section 314.520, the restricted distribution prong of Subpart H. Each of these drugs, Xeloda, Thalomid, Actiq, and Tracleer, was an appropriate candidate for approval under Section 314.520. Moreover, in each case, studies were performed that allowed for a meaningful statistical analysis of the effectiveness of this drug in comparison with the current available standard of care. FDA’s decision to require randomized, comparator-controlled, blinded trial design for each drug, even in the face of urgent need for the treatments at issue, supports the claim that FDA’s treatment of the mifepristone NDA was aberrant.

Xeloda™ (capecitabine) was approved for use in treating patients with widely metastatic (“Stage IV”) terminal breast cancer, for whom all other modalities of chemotherapy have failed or are contraindicated. The average lifespan of a patient with multi-drug resistant tumors participating in the clinical trials for this drug was only 8.5 months. Because Xeloda was only modestly effective (25% of the recipients improved for an average of five months), exhibited significant toxicity, and was a last resort treatment for dying patients, FDA approved it under Section 314.520 with use restrictions and commitments to further study the drug. Subsequent randomized, concurrent controlled, blinded evaluator trials demonstrated Xeloda’s statistical superiority to the standard of care for metastatic colon and breast cancers.

172 NDA 20896.
173 NDA 20785.
174 NDA 20747.
175 NDA 21290.
176 See “NDAs Approved under Subpart H,” infra Appendix A. The current version of the Subpart H approval chart (updated Aug. 8, 2002) indicates that Xeloda is a “surrogate endpoint” drug, rather than a restricted distribution drug. However, the two previous postings of the chart state the opposite. Furthermore, FDA’s approval letter states that the NDA “[was] approved under 21 CFR 314.520.” Letter, FDA/CDER to Cynthia Dinella, Group Director, Regulatory Affairs, Hoffman-La Roche Inc. (Apr. 30, 1998).
177 See Xeloda package insert.
Thalidomide (Thalomid™) was approved under Section 314.520 for the treatment of leprosy, a disfiguring, chronically disabling, and often lethal skin infection. Thalidomide is a drug the severe toxicity of which, particularly to fetuses, is well-documented. Children exposed to this drug in utero suffer dramatic birth defects, namely the partial absence of hands, feet, arms and legs. The public outcry following the discovery that thalidomide causes these alarming malformations helped to spur the scientific modernization of FDA drug approval policy and practices in the 1960s. Clinical trials involving leprosy are difficult and require long periods of time because the disease is very rare in the United States. Three randomized, double-blinded comparator-controlled clinical trials were performed to support the Thalomid NDA.

Oral fentanyl citrate (Actiq™) was approved under Section 314.520 as a powerful sedating narcotic painkiller, primarily for use to relieve the suffering of dying cancer patients. Actiq can be lethal, particularly to children, because it quickly abolishes a patient’s drive to breathe, unless the patient is already accustomed to narcotic analgesics. Moreover, Actiq, a powerful narcotic, has a high potential for abuse and diversion into the illegal drug market. Actiq was evaluated in a “double blinded, placebo controlled” study for the treatment of breakthrough cancer pain and was shown to “produce statistically significantly more pain relief compared with placebo.” Actiq is restricted for use only by oncologists and pain specialists who are familiar with the management of the side effects and complications of the drug’s use as approved.

---

178 See “NDAs Approved under Subpart H,” infra Appendix A.
179 See Thalomid package insert.
180 See “NDAs Approved under Subpart H,” infra Appendix A.
181 Actiq package insert.
Tracleer™ (bosentan tablets) was approved pursuant to Section 314.520 for use in treating pulmonary hypertension, a life threatening and frequently progressive condition of excessively high blood pressure in the lung blood vessels resulting from chronic scarring and injury of the lung tissue. Tracleer can cause liver damage and major birth defects. Two randomized, double-blinded, placebo-controlled clinical trials demonstrated the superiority of the drug over a placebo. Tracleer was compared to a placebo because there is no alternate standard of care for pulmonary hypertension. Despite its potential toxicity, Tracleer was approved subject to usage restrictions under Section 314.520 because it is the only treatment available for a life threatening and debilitating condition.

5. FDA Failed to Require a Comprehensive Audit of French Clinical Trial Data after Discovering Violations of Good Clinical Practices

In June 1996, FDA inspected the trial records of a “French government-supported abortion clinic” that participated in the French Clinical Trials. FDA issued a Form 483 detailing problems uncovered during the inspection. The problems identified by the investigator suggested carelessness, fraud, evidence tampering, and the systematic under-reporting of serious adverse events. The inspection “revealed a failure to maintain complete and accurate records.” The violations that were discovered included: “laboratory reports that were missing” for 11 patients, “missing ultrasound documents” for 20 patients, “pages missing from the case record files and unreported aspirations,” inclusion of 4 ineligible patients, and “consent forms were dated after the start of study for some subjects, and the investigator had signed consent form

---

182 See "NDAs Approved under Subpart H," infra Appendix A.
183 See Tracleer package insert.
sometimes in advance, up to 4 days before the subjects had signed.” There were also “under-reported side effects” such as “a patient bleeding with two subsequent aspirations; convulsions reported as fainting; and expulsion which was actually a surgical evacuation; bleeding, nausea and contractions, or bleeding and pelvic pain.” After elaborating on the deficiencies found, the FDA inspector concluded: “Notwithstanding these objectionable conditions, [redacted name of an FDA official] assured Dr. Aubeny that he would not recommend that the studies not be included in the evaluation of the NDA application.”

FDA should not have allowed tainted data to support the Mifeprex NDA. A complete audit of all French Clinical Trial data is warranted to determine whether another set of clinical trials must be performed to replace the tainted French trial data.

F. THE AGENCY'S DE FACTO APPROVAL OF MISOPROSTOL'S NEW USE WAS ARBITRARY, CAPRICIOUS, AN ABUSE OF DISCRETION, OR OTHERWISE NOT IN ACCORDANCE WITH LAW

When FDA approved Mifeprex, it also took action with respect to a second drug – misoprostol. Taken alone, mifepristone is ineffective as an abortifacient. In order to achieve an abortion rate greater than 90 percent, the administration of mifepristone is followed approximately two days later by a prostaglandin to complete the abortion. In the U.S. Clinical

---

184 Summary of Findings, Memorandum Accompanying FDA Form 483 Issued to Dr. Elizabeth Aubeny (June 28, 1996): at 1 [FDA FOIA Release: MIF 004135-45].
185 Summary of Findings, Memorandum Accompanying FDA Form 483 Issued to Dr. Elizabeth Aubeny (June 28, 1996): at 1.
186 Summary of Findings, Memorandum Accompanying FDA Form 483 Issued to Dr. Elizabeth Aubeny (June 28, 1996): at 9.
187 Although some studies using mifepristone alone have produced completion rates as high as 60 to 80 percent, it is widely recognized that, on its own, mifepristone is not a viable substitute for surgical abortion. See, e.g., Mitchell D. Creinin, “Early Medical Abortion with Mifepristone or Methotrexate: Overview,” Early Medical Abortion with Mifepristone or Methotrexate: Overview and Protocol Recommendations (Washington, D.C.: National Abortion Federation, 2001) at 3 (reporting that “[f]or gestations up to 49 days, complete abortion occurs in approximately 60 to 80%” of women using mifepristone alone); Helena von Hertzen, M.D., “Research on Regimens for Early Medical Abortion,” Journal of the American Medical Women’s Association 55 (Supplement 2000): 133-36.
Trial, the prostaglandin used was misoprostol, which was distributed by G.D. Searle & Co. ("Searle") as the anti-ulcer drug Cytotec™. Ultimately, FDA based its approval of Mifeprex on the combined action of a mifepristone and misoprostol regimen. On the day FDA approved mifepristone, it notified Searle that "[t]he drug mifepristone is now approved in a regimen with misoprostol for termination of pregnancy of 49 days or less."\textsuperscript{189}

Searle, which opposed the use of its drug in conjunction with Mifeprex as an abortifacient,\textsuperscript{190} did not file a Supplemental NDA for the use of misoprostol as part of an abortion regimen.\textsuperscript{191} Absent such an application, FDA lacked the basis for sanctioning a new indication for misoprostol. As Peter Barton Hutt, former FDA general counsel, observed, the agency’s treatment of misoprostol “set[ ] an extraordinary precedent” because FDA was “seemingly...
encouraging a drug's unapproved use.” He added that the agency is in an “embarrassing and uncomfortable position.” FDA did more than encourage the unapproved use of misoprostol; it mandated the unapproved use.

1. Misoprostol’s Use as an Abortifacient is a New Indication for which the Requisite Supplemental New Drug Application Was Not Filed

A drug that differs in any material way (including in composition, effect, or intended use) from an approved drug is a new drug that must independently be established to be safe and effective. Furthermore, a drug already being used to treat one disease or part of the body may be a new drug when used to treat another disease or part of the body. Misoprostol’s new use as an abortifacient, therefore, marks it as a “new drug.”

New drugs must be shown to be safe and effective. Specifically, FDA requires that “[a]ll indications shall be supported by substantial evidence of effectiveness based on adequate and well-controlled studies as defined in § 314.126(b) . . . unless the requirement is waived . . . .”

---

193 Zimmerman at B1.
194 See Thompson v. Western Medical Center, Brief for the Petitioners (filed by the Solicitor General of the United States), No. 01-344 (Dec. 2001): at 4 (“See United States v. Generix Drug Corp., 460 U.S. 453, 460-461 (1983) (determination whether a product is a new drug takes into account both active and inactive ingredients); 21 C.F.R. 310.3(h) (discussing factors that make a drug a ‘new drug’).
195 A drug may be deemed “new” because of “[t]he newness of use of such drug in diagnosing, curing, mitigating, treating, or preventing a disease, or to affect a structure or function of the body, even though such drug is not a new drug when used in another disease or to affect another structure or function of the body.” 21 C.F.R. § 310.3(h)(4).
196 The “newness” of misoprostol in this indication was heightened by the fact that, when Mifeprex was approved, misoprostol was explicitly contraindicated for pregnant women. The misoprostol label included the following black-box warning: “CYTOTEC (MISOPROSTOL) ADMINISTRATION BY ANY ROUTE IS CONTRAINDICATED, BECAUSE IT CAN CAUSE ABORTION, IN WOMEN WHO ARE PREGNANT . . . .” In April 2002, the Cytotec label was changed to “remove[] the contraindication and precaution that Cytotec should not be used in women who are pregnant.” FDA, “Major Changes to Cytotec Labeling” (April 17, 2002). The label now restricts the contraindication to pregnant women who are using Cytotec as a non-steroidal anti-inflammatory drug (“NSAID”). The revised Cytotec label and, more specifically, the “Indications and Usage” section, however, continue to lack any reference to the use of misoprostol in the Mifeprex Regimen.
197 21 C.F.R. § 201.57(c)(2). To the best of the Petitioners’ knowledge, FDA did not formally waive the requirement for misoprostol as part of an abortion regimen.
A Supplemental NDA provides the necessary evidence in support of a new indication. Absent a waiver, a Supplemental NDA permits FDA to consider the evidence in support of the proposed change and approve related labeling changes in advance. Even though a new use for misoprostol is an integral part of the Mifeprex Regimen, FDA sanctioned this new misoprostol indication without having received and considered a Supplemental NDA.

Among the changes for which FDA approval is necessary are changes to statements in a drug’s labeling indicating whether “[t]he drug, if used for a particular indication only in conjunction with a primary mode of therapy, e.g., diet, surgery, or some other drug, is an adjunct to the mode of therapy.” A well-known treatment regimen illustrates how FDA has typically dealt with the labeling of two drugs that have been approved for combined use. The regimen pairs methotrexate and Leucovorin Rescue. Methotrexate, a chemotherapeutic agent, kills cancer cells by depriving them of folic acid which is necessary for DNA synthesis, but, in the process, methotrexate deprives normal bone marrow cells of the folic acid they need. Leucovorin Rescue serves as an antidote to the toxic effects of methotrexate. The labeling for Leucovorin Rescue refers to its use “after high-dose methotrexate therapy in osteosarcoma,” which is an approved indication.

---

198 A recent article noted: “To obtain FDA approval for an additional use of a previously approved drug, the sponsor must submit a supplemental application (sNDA, sBLA, or sPMA) demonstrating the safety and efficacy of the drug when used in the new way or for the new indication. The supplemental application typically requires clinical data similar to those in the original application, but does not require the same extensive chemistry, manufacturing and controls, and preclinical pharmacology and toxicology data as in the original application.” Shane M. Ward, “Washington Legal Foundation and the Two-Click Rule: The First Amendment Inequity of the Food and Drug Administration’s Regulation of Off-Label Drug Use Information on the Internet,” Food and Drug Law Journal 56 (2001): 41-56, at 44 (citations omitted).

199 See 21 C.F.R. § 314.70(b). See also Richard A. Merrill, “The Architecture of Government Regulation of Medical Products,” Univ. of Virginia Law Review 82 (1996): 1753-1866, at 1775 (“FDA takes the position, which no manufacturer has sought to challenge in court, that any potentially significant modification of an approved new drug [application] likewise requires advance agency approval. As a consequence, not only attempts to expand the indications for a drug but other changes in labeling, in inactive ingredients, in the method or location of manufacture, or in packaging must first be the subject of an approved Supplemental New Drug Application.”).

200 See 21 C.F.R. § 201.57(c)(1)(iv).
indication for methotrexate.\footnote{See Leucovorin Calcium for Injection Package Insert ("Indications and Usage") ("Leucovorin calcium rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Leucovorin calcium is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists."). The package insert is available at: <http://www.xanodyne.com/leucovorin_cacium_pi_2002.pdf>.

\footnote{The methotrexate package insert states that "[m]ethotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor." The package insert is available at: <http://www.rxlist.com/cgi/generic/mtx_ids.htm>.

\footnote{A recent approval of a biologic product also illustrates the principle that FDA-approved labeling lists only approved indications. On February 19, 2002, FDA approved Zevalin for use in combination with Rituxan (rituximab) to treat low-grade B-cell non-Hodgkins Lymphoma (NHL). Rituxan had been approved previously and was already indicated "for the treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma." See Rituxan Package Insert ("Indications and Usage"). Rituxan and Zevalin are monoclonal antibodies that can significantly shrink tumors by targeting white blood cells (B-cells) including malignant B cells. The "Indications and Usage" section of Zevalin's label describes the drug as being "part of the ZEVALIN therapeutic regimen (see Dosage and Administration)." The "Dosage" section directs that Rituxan be administered and then followed by Zevalin on Day One and then again seven to nine days later. After the Zevalin NDA was approved, detailed information about the administration of the "Zevalin Therapeutic Regimen" was added to the Rituxan label. On February 19, 2002, FDA's Center for Biologics Evaluation and Research approved a supplement to the Rituximab biologics license application "to revise the dosage and administration section of the package insert to include information regarding the use of Rituximab as a component of the Zevalin therapeutic regimen..." Letter, Dr. Karen D. Weiss, M.D., Director, Division of Clinical Trial Design and Analysis, Office of Therapeutics Research and Review, Center for Biologics Evaluation and Research, to Alice Wei, IDEC Pharmaceuticals (Feb. 19, 2002) (see <http://www.fda.gov/cber/approvltr/rituide021902L.htm>).} Similarly, methotrexate's labeling refers to an approved use of Leucovorin Rescue.\footnote{Leucovorin Rescue.}
2. FDA Sanctioned the Promotion of Misoprostol for an Unapproved Use as Part of the Mifeprex Regimen

The use of misoprostol as an abortifacient is an unapproved or "off-label" use. FDA objects to the promotion of off-label uses of drugs by manufacturers. "Off-label" uses of drugs are common as physicians explore new ways of using approved drugs, but normally FDA strives to ensure that physicians and patients are not misled into believing that FDA has approved such uses. In an effort to curb the promotion of off-label uses by pharmaceutical manufacturers, FDA issued regulatory guidance in 1996 pertaining to the dissemination of off-label use information.

In this case, however, FDA not only sanctioned, but participated in, the promotion of an off-label use of misoprostol. FDA oversaw the creation of the promotional materials for Mifeprex, which discussed the off-label use of misoprostol. FDA itself disseminated information about

---

204 See generally James M. Beck and Elizabeth D. Azari, "FDA, Off-Label Use, and Informed Consent: Debunking Myths and Misconceptions," Food & Drug Law Journal 53 (1998): 71-104, at 71 n.2, which explains "off-label" use as follows:

"Off-label" has more accurately been termed "extra label" use. It means only that a product is used for a condition or in a way not appearing on its FDA-regulated labeling, not that the agency has judged the use adversely. See, e.g., Washington Legal Found. v. Kessler, 880 F.Supp. 26, 28 n.1 (D.D.C. 1995). . . . Off-label can mean many things. "[U]sing an approved drug to treat a disease that is not indicated on its label, but is closely related to an indicated disease, treating unrelated, unindicated diseases, and treating the indicated disease but varying from the indicated dosage, regimen, or patient population may all be considered off-label use." William L. Christopher, Off-Label Drug Prescription: Filling the Regulatory Vacuum, 48 FOOD & DRUG L.J. 247, 248 (1993) (footnotes omitted).

205 See, e.g., Subpart H Final Rule, 57 Fed. Reg. at 58,853 ("Under the act, a drug approved for marketing may be labeled, promoted, and advertised by the manufacturer only for those uses for which the drug’s safety and effectiveness have been established and that FDA has approved.").


207 FDA reminded the Population Council in the Mifeprex Approval Letter that, pursuant to 21 C.F.R. § 314.550, the drug sponsor is obligated to submit Mifeprex promotional material for review by the agency prior to dissemination to physicians and the public. See Mifeprex Approval Letter at 3.

208 A Danco Laboratories webpage, for example, contains the following question and answer:

Q: How Does Mifeprex Work?
A: Mifeprex blocks progesterone, a hormone necessary for a pregnancy to continue. You take Mifeprex followed by a prostaglandin, misoprostol, which causes uterine contractions that help to end pregnancy.

In more detail, Mifeprex blocks progesterone, a naturally produced hormone that prepares the lining of the uterus for a fertilized egg and helps maintain pregnancy. Without progesterone, the lining of the uterus
the off-label use of misoprostol in documents such as the press release announcing the approval of Mifeprex for use in conjunction with misoprostol. Recently it did so again when the agency emphasized the importance of adhering to the approved regimen, including the off-label use of misoprostol.


The labeling for Mifeprex is misleading because it directs physicians to use misoprostol for a purpose that FDA never approved. FDA’s ability to regulate the marketing and distribution of drugs rests largely on its legal capacity to strictly control the content of a drug’s labeling. A fundamental tenet of drug regulation is that FDA requires approval for every indication listed in the labeling of a drug. FDA would undercut its own authority if it did not also apply this rule to uses for a drug referenced on another drug’s labeling.

The Mifeprex labeling creates false expectations about misoprostol. Physicians and patients are justified in believing that any use or indication for a drug, included in the “Indication

[Electronic version of the Mifeprex Label contains a hyperlink to the Dance Laboratories website, <www.earlyoptionpill.com>, which contains the above-referenced webpage. (When printed, the hyperlink appears to be ordinary text.)

209 See, FDA, Press Release, “FDA Approves Mifepristone for the Termination of Early Pregnancy” (Sept. 28, 2000) (“Under the approved treatment regimen, a woman first takes 600 milligrams of mifepristone (three 200 milligram pills) by mouth. Two days later, she takes 400 micrograms (two 200-microgram pills) of misoprostol, a prostaglandin.”).

210 See FDA webpage, infra Appendix A, “Mifepristone Questions and Answers 4/17/2002,” at Question 6. In this same document, however, FDA cautions health care providers against “using misoprostol ‘off-label,’” in other words, using misoprostol vaginally at different doses . . . .” Id. at Question 9.

211 Misoprostol receives more than a passing mention on the Mifeprex Label; the word “misoprostol” appears 34 times (compared to 57 appearances of “mifepristone” and 34 appearances of “Mifeprex”).
and Usage" section of an FDA-approved label, has been subjected to the rigorous approval process set forth in Section 505 of the FD&C Act. Section 201.6(a) of the Agency’s rules states that misbranding may arise from “a false or misleading representation with respect to another drug.”

“When a physician, manufacturer, or other third party steps in to promote an unapproved use of a drug by advertising or distribution to other physicians, the drug may become unlawful under Section 301(k) the FD&C Act, 21 U.S.C. § 331(k)(1994), which prohibits misbranding, and Section 502(f)(1), 21 U.S.C. § 352(f)(1)(1994), which requires a drug’s labeling to bear ‘adequate directions for use.’” Mifepristone is, therefore, misbranded.

Mifepristone is also misbranded because it is unsafe when used as directed in the approved labeling. Section 502(j) of the FD&C Act states that “[a] drug or device shall be deemed to be misbranded . . . [i]f it is dangerous to health when used in the dosage or manner, or with the frequency or duration prescribed, recommended, or suggested in the labeling thereof.” As discussed in the next section, FDA’s approved regimen is unsafe because it lacks important safeguards.

---


213 See 21 C.F.R. § 201.6(a).

214 Merrill, infra Appendix A, at n.318 (emphasis added). See also 21 C.F.R. § 314.530(a)(5) (authorizing the Secretary to withdraw approval of a Subpart H drug if “[t]he promotional materials are false or misleading.”).

215 21 U.S.C. § 352(j). See also Jeffrey N. Gibbs and Judith E. Beach, “Chapter 7: Adulteration and Misbranding of Drugs” in Fundamentals of Law and Regulation: An In-Depth Look at Therapeutic Products (David G. Adams, Richard M. Cooper, and Jonathan S. Kahan, eds.), vol. II (Washington, D.C.: Food and Drug Law Institute, 1997): at 229 (“When the drug is dangerous to the health of the user even when used as recommended on the label, it is misbranded.”).
G. WOMEN'S LIVES ARE BEING ENDANGERED BY THE LACK OF SAFEGUARDS IN FDA'S APPROVED REGIMEN

On February 18, 2000, FDA informed the Population Council that "adequate information ha[d] not been presented to demonstrate that [mifepristone], when marketed in accordance with the terms of distribution proposed [by the Population Council], is safe and effective for use as recommended." Over the next several months, the Population Council and Danco refused to supplement its distribution plan with a meaningful patient safety component. This prompted FDA, on June 1, 2000, to privately convey to the sponsor a set of proposed restrictions intended to rectify the sponsor's omission. The agency's proposed restrictions were soon leaked to the public. Amidst a vigorous political and editorial backlash, the sponsor not only rejected FDA's proposal but, in what was described by FDA as a "very significant change," repudiated restrictions the sponsor itself had proposed in 1996. FDA succumbed and soon approved a regimen that did not embody restrictions sufficient to address the agency's legitimate safety concerns.

Early in the approval process, FDA expressed its intention to place restrictions on the use of mifepristone. FDA's position was informed, in part, by the international experience with


217 See FDA Email (June 23, 2000): at 1 (explaining that the Population Council's attorney "affirmed that the 1996 proposals for distribution system as presented by the Pop Council then and agreed to by the [FDA Advisory Committee] and FDA are NOT what the Pop Council wants today. I explained that this change is very significant and that they need to provide their justification/rationale.") [FDA FOIA Release: MIF 002523].

218 In order to allay concerns of the drug's European owner, FDA pledged, in the course of securing the U.S. patent rights for the Population Council, to "take appropriate measures . . . to assist through the NDA-approval process in the creation of a regime for the distribution and use that will protect against misuse of the drug." Letter, David A. Kessler, Commissioner of Food and Drugs, to the President & CEO of Roussel Uclaf [name redacted] and to Margaret Catley-Carlson, President of Population Council (May 16, 1994): at 1 [FDA FOIA Release: MIF 004992-93].
mifepristone.\textsuperscript{219} The NDA submitted by the Population Council on March 14, 1996 included a plan that would have limited distribution of mifepristone to “licensed physicians (with prior training in assessing the length of pregnancy, in diagnosing ectopic pregnancy, and [redacted]), who will attend educational seminars on the safe use of this regimen.”\textsuperscript{220}

The FDA Advisory Committee, when it met in July 1996, was not satisfied with the restrictions proposed by the Population Council and expressed “serious reservations on how [the proposed drug distribution system] is currently described in terms of assuring safe and adequate credentialing of providers.”\textsuperscript{221} The Committee recommended additional restrictions designed to ensure “that this drug not be expanded to hands of physicians who are not already skilled in managing pregnancies, terminations, and complications of both.”\textsuperscript{222} Accordingly, FDA’s 1996 Approvable Letter required the submission of “a comprehensive description of the proposed distribution system.”\textsuperscript{223}

In subsequent submissions, however, the Population Council insisted that the drug was safe and proffered restrictions designed primarily to control the manufacturing and retailing of the drug product. On August 18, 1999, the Population Council proposed to:\textsuperscript{224} (i) limit the number and type of distributors; (ii) limit distribution to distributor-registered physicians who

\begin{footnotesize}
\begin{itemize}
\item \textsuperscript{219} In Europe, for example, mifepristone is used under more highly controlled conditions than were ultimately required in the United States. See Amendment to NDA 20-687, International Product Labeling with English Translations (submitted March 21, 2000) (presenting English translation of mifepristone product label, approved July 6, 1999, used in Austria, Belgium, Denmark, France, Germany, Greece, the Netherlands and Spain) [FDA FOIA Release: MIF 000493-506].
\item \textsuperscript{220} Memorandum, FDA/CDER to NDA 20-687 File (Sept. 16, 1996): at 2 [FDA FOIA Release MIF 000560-62].
\item \textsuperscript{221} FDA Advisory Committee, Minutes of July 19, 1996 Meeting (approved July 23, 1996): at 7 [FDA FOIA Release: MIF 000534-45].
\item \textsuperscript{222} FDA Memorandum, “Highlights of the July 19, 1996 Reproductive Health Products Advisory Committee (AC) Meeting on Mifepristone: Outstanding Issues for FDA to Address” (undated): at 3-4 [FDA FOIA Release: MIF 000534-38].
\item \textsuperscript{223} 1996 Mifepristone Approvable Letter, infra Appendix A, at 1.
\end{itemize}
\end{footnotesize}
had provided certain assurances; and, (iii) make available “training materials and information” and medical consultation to health care providers and product information to patients. On January 21, 2000, Danco opined that “[r]egardless of the distribution system for mifepristone, the medical safety of this drug is well documented.” and proposed a distribution system that was designed only to ensure that Danco would “exert[ ] positive control over distribution of Mifeprex® through all phases of manufacturing, storage, shipment and administration from manufacturer to patient.”

In reaction to the sponsor’s recalcitrance, FDA took the position “that restrictions as per CFR 314.520 on the distribution and use of mifepristone are needed to assure safe use of this product.” The agency nevertheless continued to encourage the sponsor to take an active role in devising appropriate restrictions on the use of mifepristone. Instead, in March 2000, the Population Council again protested that such restrictions were unwarranted. It submitted a
distribution plan that it characterized as “detailed and comprehensive” and “surely equal to its
purpose.” Once again, the plan consisted of restrictions intended only to control the
manufacturing and retailing of the drug product. Again FDA objected that “[t]he proposed
distribution system as submitted primarily addresses security for the manufacturer and
distributor; it must also include safeguards for the patient.” The agency requested “that
sponsor present a proposal regarding provider qualifications that addresses safety concerns of
patients receiving the drug product.”

On June 1, 2000, FDA proposed the following set of “Qualifications for Physician
Recipients:” (1) the physician must demonstrate that she is licensed to practice medicine; (2) the
physician must be “trained and authorized by law” to perform surgical abortions; (3) the
physician must have “been trained to and have the ability to assess the age of a pregnancy
accurately by ultrasound examination, to monitor abortion by ultrasound examination, and to
diagnose an ectopic pregnancy by ultrasound examination;” (4) the physician must have
“satisfactorily completed training certified by the distributor in the mifepristone treatment
procedure, including mechanism of action, appropriate use, proper administration, follow-up,
efficacy, adverse events, adverse event reporting, complications, and surgical indications;” and

exceptionally safe and effective.”


Teleconference Meeting Minutes (between FDA staff and representatives of Population Council and Danco)
(5) the physician must have “continuing access (e.g., admitting privileges) to a medical facility equipped for instrumental pregnancy termination, resuscitation procedures, and blood transfusion at the facility or [one hour’s] drive from the treatment facility.”

FDA’s proposals were intended to address concerns about the safety of the women undergoing mifepristone-misoprostol abortions that the Population Council and Danco had refused to take into account in crafting restrictions for the drug.

The Population Council and Danco objected strenuously to the proposed restrictions and aired their complaints in public. FDA reprimanded the Population Council for leaking the restrictions to the public and misrepresenting the nature of the restrictions. The Executive Vice President of the American College of Obstetricians and Gynecologists submitted an analysis of the leaked restrictions to FDA. The editorial and political reaction, together with the

235 See FDA, “FDA Proposed Restricted Distribution System for NDA 20-687 on 6/1/00” (June 1, 2000) [FDA FOIA Release: MIF 000522]. See also American College of Obstetricians and Gynecologists, “Analysis of the Possible FDA Mifepristone Restrictions” (July 27, 2000): at 1 (setting forth FDA’s second proposed restriction, which is redacted in the publicly available copy of FDA’s proposal; also providing the redacted portion of the fifth restriction) [FDA FOIA Release: MIF 001366-69].

236 It should be noted, that even these restrictions would not have been sufficient to make mifepristone-misoprostol abortions safe. Among the key safeguards missing from FDA’s proposal were requirements that every prospective patient undergo an ultrasound and that prescribing physicians be required to have admitting privileges at facilities able to provide emergency care.

237 Paul Blumenthal, M.D., Jane Johnson, and Felicia Stewart, M.D., “The Approval of Mifepristone (RU486) in the United States: What’s Wrong with this Picture?” Medscape Women’s Health 5 (2000) (reproduced in an internal FDA email) [FDA FOIA Release: MIF 00002597-99] (“At a meeting of early abortion providers and abortion advocates, the Population Council and Danco revealed that the U.S. Food and Drug Administration (FDA) had made a series of proposals regarding the labeling and distribution of mifepristone that would severely limit women’s access to the drug if and when it is approved.”).

238 See Teleconference Meeting Minutes (between FDA staff and representatives of the Population Council and Danco) (June 7, 2000): at 1 (“Meeting Objective: . . . to discuss the misrepresentations by the Press regarding the proposed distribution system, and to agree on the need for serious, candid, and confidential discussions to resolve deficiencies of the application.”) [FDA FOIA Release: MIF 002136-37]; FDA internal email (June 23, 2000): at 1 (re: telephone conversation with Population Council attorney, Nancy Huc, on 6/23/00) (“I also said that we were looking to Pop Council to be a responsible entity in manufacturing, distributing, and shepherding this drug and that most responsible entities make proposals rather than expect FDA to write labels and distribution systems and obtain comments through the media.”) [FDA FOIA Release: MIF 002523].

239 See Letter, Ralph Hale, M.D. (Executive Vice President, ACOG) to Jane Henney, M.D. (July 24, 2000) and enclosure: ACOG, “Analysis of the Possible FDA Mifepristone Restrictions” (July 27, 2000) [FDA FOIA Release: MIF 001366-69]. ACOG and the American Medical Association (“AMA”) also attempted to secure a meeting with
impending approval deadline of September 30, 2000, however, had the desired effect of undermining FDA’s resolve.

At a meeting on July 19, 2000, FDA yielded to the Population Council and Danco on a number of important issues. FDA abandoned its proposal for auditable physician qualifications and agreed instead to permit physicians to attest to their own qualifications. Instead of requiring formal training, FDA merely “request[ed] that the physician also attest to having read and understood the training materials and labeling.” FDA also agreed not to

Dr. Jane Henney, FDA Commissioner, and her staff, in order to further discuss their opinion of the restrictions. See Letter, Ralph Hale, M.D. (Executive Vice President, ACOG) and E. Ratcliffe Anderson, Jr., M.D. (Executive Vice President, AMA) to Jane Henney, M.D. (July 24, 2000): at 1 (“The undersigned organizations...are very concerned about restrictions...[FDA] has proposed for...mifepristone...We would like the opportunity to meet with you and your staff to discuss this important issue. It’s imperative that the FDA fully understands the effect that these proposals would have on the quality of health care. It’s equally imperative that the FDA’s work be based solely on evidence from the drug’s clinical trials, and be entirely from political influence.”)[FDA FOIA Release: MIF 001363]. They were permitted only to meet with officials in FDA’s Office of Women’s Health, an office within the agency that was not involved in reviewing the NDA. See Letter, Jane Henney to Hale and Anderson (Aug. 11, 2000): at 1-2 [FDA FOIA Release: MIF 001361]. The questionable scientific basis for this challenge to FDA’s proposed restrictions was recently brought to the attention of ACOG by one of the Petitioners. Letter, Donna Harrison, M.D. (Chairperson, AAPLOG Committee on Mifepristone Use) to Ralph Hale, M.D. (Executive Vice President, ACOG) (May 23, 2002) (available at <http://www.aaplog.org/acogmifeprexletter.htm>).

See, e.g., Letter, U.S. Senator Barbara Boxer to Dr. Jane Henney (June 9, 2000): at 1 (“According to news reports, the FDA is considering placing draconian restrictions on the accessibility of RU-486 as a condition of its approval...In 1996, the FDA found RU-486 to be safe and effective. Therefore, it is a mystery to me why the FDA would even consider restricting access to it.”)[FDA FOIA Release: MIF 006376]; Letter, Mark Green, Public Advocate for the City of New York, to Dr. Jane Henney (Sep. 22, 2000): at 1 (“Earlier this week Planned Parenthood of New York City, NARAL-New York, the Access Project and Physicians for Reproductive Health and Choice joined me in convening a public hearing in New York City on pending action by [FDA] on mifepristone...[I am] also concerned about the restrictions on access to RU-486 that FDA is said to be considering.”)[FDA FOIA Release: MIF 001288-1302]; Sheryl Gay Stolberg, “F.D.A. Adds Hurdles in Approval of Abortion Pill,” New York Times (June 8, 2000): at A21 (“The long-running effort to bring the French abortion pill to women in this country has encountered yet another obstacle: a suggestion by [FDA] that it may place tight restrictions on how the drug, RU-486, is distributed and who can prescribe it.”); Letter, U.S. Representative Lynn Woolsey to Dr. Jane Henney (June 22, 2000): at 1 (“However, I am deeply concerned about recent press reports about proposed restrictions”)[FDA FOIA Release: MIF 006372].

As noted above, because FDA had accorded priority review to mifepristone, the approval process was slated for completion by September 30, 2000.


See id. at 2.

Id. at 2.
require pre-procedure ultrasounds. Furthermore, FDA stated “that it is not necessary to require the patient to take the drugs in the presence of health care provider.”

Among the unresolved issues at the conclusion of the July 19, 2000 meeting was the question of whether prescribing physicians should be limited to those who were able to perform surgical abortions, a provider qualification FDA believed was necessary:

FDA requests that the ability to perform vacuum aspirations and/or D&Cs be added to provider qualifications. Providers also need to have access to emergency services. The need for surgical intervention is predictable unlike with other drugs. All OB/GYNs and other practitioners of women’s health have these skills. The countries with experience with mifepristone have tight provision of complete services and have a long record of good outcomes.

The Population Council later rejected FDA’s request, and the agency acquiesced.

Despite its persistent concerns, FDA approved a regimen that posed the very risks to women’s health that the agency had previously identified. When it approved Mifeprex, FDA stated that “[u]nder 21 CFR 314.520, distribution of the drug is restricted as follows:”

Mifeprex must be provided by or under the supervision of a physician who meets the following qualifications:

- Ability to assess the duration of pregnancy accurately.
- Ability to diagnose ectopic pregnancies.
- Ability to provide surgical intervention in cases of incomplete abortion or severe bleeding, or have made plans to provide such care through other qualified physicians, and are able to assure patient access to medical facilities equipped to provide blood transfusions and resuscitation, if necessary.
- Has read and understood the prescribing information of Mifeprex.

245 See id. at 3.
246 Id. at 3.
247 Id. at 3.
248 See Amendment 054 to the NDA, re: Further Response Regarding Labeling and Distribution: Follow up to July 19, 2000 Meeting (July 27, 2000): at 6 (arguing that bolstering the provider qualifications in this way would be “not only unnecessary, but also in fact potentially counterproductive for patients”)[FDA FOIA Release: MIF 0001373-81].
• Must provide each patient with a Medication Guide and must fully explain the procedure to each patient, provide her with a copy of the Medication Guide and Patient Agreement, give her an opportunity to read and discuss both the Medication Guide and the Patient Agreement, obtain her signature on the Patient Agreement, and must sign it as well.

• Must notify the sponsor or its designate in writing as discussed in the Package Insert under the heading DOSAGE AND ADMINISTRATION in the event of an ongoing pregnancy, which is not terminated subsequent to the conclusion of the treatment procedure.

• Must report any hospitalization, transfusion or other serious events to the sponsor or its designate.

• Must record the Mifeprex™ package serial number in each patient’s records.250

In addition, the restrictions include a requirement that distribution be carried out in accordance with the plan submitted to FDA by the Population Council in a March 30, 2000 submission.251

Even as it assented to a regimen that lacked critical safeguards, FDA took a number of steps that indicated its lingering concerns about the safety of the drug. First, FDA ultimately decided to rely on an infrequently used provision in Subpart H in hopes of ensuring that mifepristone would be used safely and, if necessary, could be withdrawn from market rapidly.252 Second, the staff insisted that the mifepristone label “include a black boxed warning describing the major requirements and conditions for use.”253 “FDA generally reserves boxed warnings for serious or

---

250 Mifeprex Approval Letter at 2.
251 See Mifeprex Approval Letter at 2.
253 FDA, Memorandum, re NDA 20-687 (Feb. 17, 2000): at 2. The Population Council, which opposed the inclusion of such a warning, ultimately persuaded FDA to agreed to a pared-down Black Box Warning, which would merely direct the prescribing physician (i) to plan in advance for emergency care, and (ii) to make available to the patient and provide her with the opportunity to discuss the patient information and patient agreement. See Amendment 054 to the NDA, re: Further Response Regarding Labeling and Distribution: Follow up to July 19, 2000 Meeting (July 27, 2000): at 1-2 [FDA FOIA Release MIF 0001373-81].
life-threatening risks that best can be minimized by conveying critical information to the
prescribing doctor in a highlighted manner.”

FDA’s willingness to tailor the restrictions on Mifepristone to suit the demands of the
Population Council and Danco will continue to manifest itself in serious adverse events among
the women who use the Mifepristone Regimen. Some of the most critical flaws in the approved
regimen are discussed below along with serious adverse events that have already been reported.

1. The Approved Regimen Is Unsafe Because It Does Not Require Ultrasound

a. Ultrasound Is Necessary to Accurately Date Pregnancies

The gestational age of a woman’s pregnancy is a critical factor in determining whether
she is an appropriate candidate for a mifepristone abortion. In order to minimize the risks of
hemorrhage, incomplete abortion and continuing pregnancy, the gestational age of the pregnancy
must be less than or equal to 49 days. The authors of the Spitz Article, for example, found that
“[f]ailures, defined as cases requiring surgical intervention for medical reasons or because the
patient requested it, the abortion was incomplete, or the pregnancy was ongoing, increased with
increasing duration of the pregnancy.” Through the combination of mifepristone and

254 Judith E. Beach et al., “Black Box Warnings in Prescription Drug Labeling: Results of a Survey of 206 Drugs,”

255 As noted above, the gestational age of a pregnancy is based on the first day of a woman’s last menstrual period,
which is designated as Day 1 of the pregnancy.

256 Spitz Article, infra Appendix A, at 1241. “The largest increase was in failures representing ongoing pregnancy,
which increased from 1 percent in the [less than or equal to] 49-days group to 9 percent in the 57-to-63 days group
(P<0.001).” Children born from ongoing pregnancies, after a failed application of the Mifepristone Regimen, may
suffer birth defects, fertility problems, or other health problems later in life. Researchers have found evidence
linking misoprostol and birth defects such as missing or deformed limbs and misshapen skulls. Much of this
research was conducted in Brazil, where numerous women have attempted to induce abortions using misoprostol
Aug. 2001) (“Several studies in Brazil, where up to 75 percent of clandestine abortions involve misoprostol, suggest
the drug causes birth defects such as fused joints, growth retardation and a condition known as Möbius syndrome,
which is characterised by paralysis of the face.”); Ieda M. Orioli and Eduardo E. Castilla, “Epidemiological
misoprostol, “pregnancy was terminated in 762 of the 827 women pregnant for [less than or equal to] 49 days (92 percent), 563 of the 678 women pregnant for 50 to 56 days (83 percent), and 395 of the 510 women pregnant for 57 to 63 days (77 percent) . . . .”257 The study also found that “[a]bdominal pain, nausea, vomiting, diarrhea, and vaginal bleeding also increased with advancing gestational age.”258 Due to the significant increase in failures and complications with increasing gestational age, FDA approved Mifeprax only for pregnancies of less than or equal to 49 days’ gestation.259

The only way to date a pregnancy with the degree of accuracy necessary to exclude women whose pregnancies are beyond 49 days’ gestation is by use of transvaginal ultrasound. FDA severely undermined the limitation on gestational age, however, when it failed to require the assessment of Misoprostol Tetratogenicity,” British Journal of Obstetrics and Gynaecology 107 (April 2000): 519-23, at 522 (“. . . there is an association of prenatal use of misoprostol as an abortifacient and congenital defects of vascular disruption type.”); F.R. Vargas et al., “Prenatal Exposure to Misoprostol and Vascular Disruption Defects: A Case-Control Study,” American Journal of Medical Genetics 95 (2000): 302-306, at 306 (“add[ing] epidemiological basis to the growing body of evidence that prenatal exposure to misoprostol is related to the occurrence of vascular disruption defects in some exposed fetuses.”). FDA determined that data submitted by the Population Council from a survey of fetal abnormalities in 82 pregnancies that were exposed to mifepristone alone or in combination with misoprostol was inconclusive. See FDA Mifeprax Approval Memorandum, infra Appendix A, at 4. FDA acknowledged, however, the possible link between misoprostol and birth defects. See Medical Officer’s Review, infra Appendix A, at 18 (“. . . medical follow-up is required to ensure that surgical termination is performed in case the medical termination attempt fails since misoprostol has been reported to be teratogenic in humans (limb defects and skull defects”). The need for a study of the possible joint effects of mifepristone and misoprostol on babies born after a failed application of the Mifeprax Regimen was highlighted by the abnormalities discovered in a fetus exposed to misoprostol and mifepristone. See Office of Postmarketing Drug Risk Assessment, AERS Report, ISR Number 3877547-X (March. 1, 2002) (French report of numerous deformaties in fetus that was exposed to mifepristone and misoprostol but survived until a subsequent surgical abortion was performed; “The anatopatohologic examination showed a meningo-encephalocele. The left hand was constituted of only two fingers (oligodactyly), left and right foot were constituted of only one finger (monodactyly). There was a facial dysmorphia.”).

257 Spitz Article, infra Appendix A, at 1241.
258 Spitz Article, infra Appendix A, at 1241. In order to treat vaginal bleeding, “[t]wo percent of the women in the [less than or equal to] 49-days group, as compared with 4 percent in each of the other two groups, were hospitalized, underwent surgical intervention, and received intravenous fluids (P=0.008).” Id.
259 FDA’s Medical Officer’s Review noted: “The success of medical termination of pregnancy decreased with advancing gestational age and the incidence of adverse events increased with advancing gestational age.” Medical Officer's Review, infra Appendix A, at 18. The review stated further: “This method of pregnancy termination is of limited value because of the relatively short window of opportunity, in which it can be employed. Its safety and effectiveness is based on its use during the seven weeks following the first day of the last menstrual period.” Id.
the ultrasound dating of pregnancies. FDA’s approved regimen relies instead on a patient’s recollection of her menstrual history and a physical examination. Dating based on menstrual history is inherently inaccurate because women may not have a perfect 28-day menstrual cycle and because 25 percent of women experience bleeding during the early stages of pregnancy.

Gestational dating through physical examination, even when carried out by experienced clinicians, can also be inaccurate. Factors such as patient body size, uterine fibroids, previous parity, and uterine position may impair a clinician’s ability to assess uterine size. Transvaginal ultrasound, by contrast, is accurate within plus or minus 3 days at gestational ages of 5 to 7 weeks. "Transvaginal ultrasonographic examination is necessary to ensure accurate gestational age estimation using fetal crown-rump measurements."
dating for provision of medical abortion according to current standards in clinical guidelines established by the National Abortion Federation.**

b. Ultrasound Is Necessary to Identify Ectopic Pregnancies

Approximately two percent of all pregnancies in the United States are "ectopic pregnancies," in which the pregnancy is located outside the uterus — often in the fallopian tube. Mifeprex does not terminate ectopic pregnancies. Therefore, if a woman who has an ectopic pregnancy undergoes a mifepristone-misoprostol abortion, she is at risk for tubal rupture and subsequent hemorrhage due to delay in diagnosis and delay in treatment. The symptoms of an ectopic pregnancy — vaginal bleeding, pelvic pain, and cramping — are confusingly similar to certain side effects of the Mifeprex Regimen. A woman with an ectopic pregnancy is at risk of suffering massive intra-abdominal hemorrhage, damage to her reproductive organs, permanent

by the transvaginal ultrasonographic examination only 48% to 56% of the time when a gestational sac was present and only 55% to 64% of the time when an embryonic pole was present. These results, though, do not even include those women who were excluded from the studies because the ultrasonographic examination findings were so different from the dates by LMP that the estimation of gestational age was changed too much for them to be included." Id.


Centers for Disease Control, "Ectopic pregnancy — United States, 1990-1992," *Morbidity and Mortality Weekly Report (MMWR)* 44 (No. 3) (Jan. 27, 1995): at 46. The number of ectopic pregnancies may be even higher now because sexually transmitted diseases and other causes of ectopic pregnancy are more widespread than they were in 1992 — the latest year for which the Centers for Disease Control have reported the number of ectopic pregnancies. Id. at 46-7.


See American College of Obstetricians and Gynecologists, "Medical Management of Abortion," *ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists* 26 (April 2001): at 6 (noting that in medical abortions, "women may even experience symptom resolution consistent with a complete medical abortion and still have a persistent gestational sac or even an ectopic pregnancy") ("ACOG Practice Bulletin"). Vaginal bleeding, for example, is a normal consequence of the Mifeprax Regimen and may continue for weeks after a woman ingests Mifeprax and misoprostol. See, e.g., Spitz, *infra* Appendix A, at 1243 ("Vaginal bleeding is a natural consequence of the abortion process, and it occurred in all the women whose pregnancies were terminated")**
sterility, and even death if not promptly treated by emergency surgery. The authors of a French mifepristone study in which a participant with an ectopic pregnancy underwent emergency surgery to stop heavy bleeding, concluded that:

The case of undiagnosed ectopic pregnancy, which ruptured suddenly 2 days after misoprostol intake, indicates that (1) mifepristone plus misoprostol is not an effective treatment of ectopic pregnancies and should not be used for this purpose, and (2) all medical means of detecting an ectopic pregnancy should be used before prescribing mifepristone plus misoprostol.269

Although the Mifeprex Label states that the Mifeprex Regimen is contraindicated for women with a “[c]onfirmed or suspected ectopic pregnancy,”270 FDA did not require that ultrasound be used to exclude women with ectopic pregnancies. Instead, the approved regimen relies solely on a self-certification by the prescribing physician that she has the “[a]bility to diagnose ectopic pregnancies.”271 A physical examination alone cannot accurately identify ectopic pregnancies. Ultrasound, “[i]n addition to providing the best information for gestational age determination . . . can also provide useful diagnostic information regarding a wide variety of pathologies of early pregnancy,” including ectopic pregnancies.272

---


270 See Mifeprex Label (“Contraindications”).

271 See Mifeprex Prescriber’s Agreement.

2. FDA’s Approved Regimen Is Not Restricted to Properly Trained Physicians who Have Admitting Privileges to Emergency Facilities

FDA’s approved regimen lacks any objective qualifications for prescribing physicians and administering health care providers. The health care provider administering the Mifeprex Regime need not undergo training, may not necessarily be an obstetrician or gynecologist, may not have any surgical training or training in the management of abortion complications, and may not even be a physician. For example, the Mifeprex Regimen could be administered by a nurse untrained in any type of abortion and under the remote supervision of a family practitioner who does not regularly practice obstetrics and is incapable of providing emergency care.

Physicians and the health care staff that they supervise require formal training in both pharmaceutical and surgical abortion to minimize the morbidity inherent in performing mifepristone abortions. National Abortion Federation guidelines provide that “[a]ll personnel performing abortions must receive training in the performance of abortions and in the prevention, detection, and management of complications.”

273 Self-certifications do not provide an effective substitute for imposing objective, auditable requirements. The Mifeprex Prescriber’s Agreement, for example, merely requires that the prescribing physician profess to have the “[a]bility to assess the duration of pregnancy accurately.” The vacuity of this stipulation is illustrated in remarks made by Dr. Susan Allen (who later became an FDA official) before the FDA Advisory Committee. Dr. Allen stated, “If you also recall when you go through medical school you learn how to date a pregnancy.” FDA Hearings Transcript, infra Appendix A, at 319.

274 See Teleconference Meeting Minutes, re: status of pending review issues pertaining to this drug product (Aug. 11, 2000): at 1 (“the distribution system would allow for physicians to obtain the drug product after meeting all qualifications, but Mifeprex could be administered by someone who is under the supervision of that physician such as midwives or nurse practitioners”)[FDA FOIA Release: MIF 004587-88]; see also, Mifeprex Approval Memo, infra Appendix A, at 4-5 (“Thus, physicians remain the initial population who will receive this drug for dispensing. This does not preclude another type of health care provider, acting under the supervision of a qualified physician from dispensing the drug to patients, provided state laws permit this.”).

275 A survey of methotrexate abortion providers underscores the necessity of training in both medical and surgical abortion. See S. Marie Harvey, Linda J. Beckman, and Sarah J. Satre, “Experiences and Satisfaction with Providing Methotrexate-Induced Abortions among U.S. Providers,” Journal of the American Medical Women’s Association 55 (2000): 161-63, at 162 (In a study comparing methotrexate and surgical abortion, “[m]ost providers felt strongly that all clinic staff should be familiar with both procedures and, thus, the training needs would be equivalent. This thought was echoed not only by physicians, who must be prepared to perform an emergency surgical abortion if methotrexate fails, but also by other clinic personnel. Thirty-nine percent of providers thought that medical abortion
recognition, and management of complications.\footnote{276} Additionally, ACOG recommends that “[c]linicians other than obstetrician-gynecologists who wish to provide medical abortion services should work in conjunction with an obstetrician-gynecologist or be trained in surgical abortion in order to offer medical abortion treatment.”\footnote{277} The necessity for training in surgical abortion as well as mifepristone abortion stems primarily from the high failure rate of the Mifeprex Regimen. In the U.S. Clinical Trial, the Mifeprex Regimen failed for 8 percent of women with pregnancies of less than or equal to 49 days’ gestational age.\footnote{278}

Excessive bleeding, which is much more common following a Mifeprex abortion than a surgical abortion, is particularly likely to necessitate urgent surgical intervention. Based on an international study comparing surgical and medical abortion, FDA’s Medical Officer noted that “[o]n the whole, medical abortion patients reported significantly more blood loss than did surgical abortion patients” and characterized this as a “serious potential disadvantage of the medical method.”\footnote{279} In the U.S. Clinical Trial among patients whose pregnancies were of no more than 49 days’ gestation, excessive bleeding resulted in one blood transfusion, two hospitalizations, two emergency room treatments, and thirteen surgical interventions.\footnote{280} In


\footnote{277} ACOG Practice Bulletin, \textit{infra} Appendix A, at 6.

\footnote{278} See Medical Officer’s Review, \textit{infra} Appendix A, at Table 1. Seventeen percent of women with pregnancies of between 50 and 56 days’ gestational age and 23 percent of women with pregnancies between 56 and 63 days were failures. \textit{See id.} In an international study reviewed by the Medical Officer, failure rates for mifepristone abortion were 5.2 percent, 8.6 percent and 16 percent in India, China and Cuba respectively, while comparable failure rates for surgical abortion were 0, 0.4 percent, and 4.0 percent. \textit{See Medical Officer’s Review, infra} Appendix A, at 19.

\footnote{279} Medical Officer’s Review, \textit{infra} Appendix A, at 19 (no citation by FDA Medical Officer).

\footnote{280} Medical Officer’s Review, \textit{infra} Appendix A, at 17.
addition, 5 percent of the patients in this group received uterotonic agents to stem bleeding. 281 A delay in intervention may be life-threatening, 282 as was illustrated by the experience of one of the participants in the U.S. Clinical Trial. The treating physician described the incident to the FDA Advisory Committee:

In November of 1994, I was called to the [emergency room] for a woman who was bleeding due to a miscarriage, and was in obvious shock. A blood test showed that she had lost between one-half to two thirds of her blood volume. . . .

I had thought she was having an incomplete miscarriage, but her husband . . . told me that she had taken RU486 approximately 2 weeks before. It was my clinical opinion that she would die soon if she did not have an immediate [dilation and curettage].

Without even doing the routine preparation we normally do for surgery, I realized that I had to take her immediately to surgery to save her life. I took her to the operating room and removed the contents of her uterus surgically. I gave her two units of packed red blood cells intraoperatively.

Even later that evening, . . . [s]he required two more units of blood because she was still orthostatic and symptomatic. 283

The Mifeprex Regimen is contraindicated for “any patient who does not have adequate access to medical facilities equipped to provide emergency treatment.” 284 FDA’s approved regimen, however, does not require prescribing physicians to have admitting privileges to emergency facilities. The approved regimen requires only that a physician who is not able “to provide surgical intervention in cases of incomplete abortion or severe bleeding . . . ma[k]e plans to provide such care through others, and [be] able to assure patient access to medical facilities equipped to provide blood transfusions and resuscitation, if necessary.” 285 Plans for back-up care

281 Medical Officer’s Review, infra Appendix A, at 17.
282 When surgery is indicated because of acute bleeding, significant, or even life threatening blood loss, has already taken place. The preoperative preparation of the patient is often compromised in the rush to complete the surgery, which results in higher infection rates and more anesthetic complications, such as aspiration during intubation.
283 FDA Hearings Transcript, infra Appendix A, at 223-25 (testimony of Dr. Mark Louviere).
284 See Mifeprex Label (“Contraindications”).
285 Mifeprex Prescriber’s Agreement. FDA, however, took two steps that suggested that it has lingering concerns about the absence of a surgical intervention qualification for Mifeprex prescribers. First, the Mifeprex Label includes a “black box” warning governing surgical back-up. Second, FDA required the Population Council to perform a post-approval study “to ensure that the quality of care is not different for patients who are treated by
may be nothing more than "having the ability and responsibility to direct patients to hospitals, if needed." Moreover, the approved regimen does not include an objective geographical limitation to ensure that the patient has easy access to the designated emergency care facility.

3. The Sponsor’s Recent “Dear Doctor Letter” and FDA’s Explanatory Webpage Announcing Serious Adverse Events Validate the Petitioners’ Concerns

On April 17, 2002, Danco, with FDA’s assistance, issued a letter to health care providers to alert them to “New Safety Information,” to remind them that Mifeprex was approved for use in a prescribed regimen, and to encourage them to provide patient counseling and report adverse events. The “New Safety Information” consisted of a number of reports of serious adverse events that had been experienced by women who were undergoing or had physicians who have the skill for surgical intervention (as in the clinical trials) compared to those treated by physicians who must refer patients for surgical intervention . . . .” Mifeprex Approval Memo, infra Appendix A, at 5.

The Chinese experience with mifepristone suggests that mifepristone should not be administered in facilities unable to provide potentially necessary emergency services. Thus, recently, the Chinese State Drug Administration responded to concerns that women were suffering as a result of lax controls on mifepristone by reiterating its policy that the drug “can only be administered at a hospital under a doctor’s supervision and cannot be sold at pharmacies even with a prescription.” See Kaiser Family Foundation, “China Reaffirms Restrictions on Unsupervised Mifepristone Use,” Kaiser Daily Reproductive Health Report (Oct. 15, 2001) (available at: <http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=2&DR_ID=7453>) (reporting also that, “[t]hree years ago, the Shanghai Health Bureau restricted the use of mifepristone to certain hospitals in the area because of fears of complications”).

The letter bears the date, April 19, 2002, but was disseminated to the public on April 17, 2002.

Danco Laboratories, Open Letter to Health Care Providers (Apr. 19, 2002) (“Dear Doctor Letter”) (available at: <http://www.fda.gov/medwatch/SAFETY/2002/mifeprex_deardoc.pdf>) Coincidentally, on the same day FDA and Danco publicized these serious adverse events, the agency also announced major changes to the Cytotec (misoprostol) label. See FDA, “Major Changes to Cytotec Labeling” (April 17, 2002). Pursuant to these labeling changes, pregnancy was removed from the list of contraindications on the Cytotec label and the black box warning cautioning pregnant women not to take the drug was also removed.
recently completed the Mifeprex Regimen. A number of patients had suffered from ruptured ectopic pregnancies and one of these women died from hemorrhage. The letter also reported "[t]wo cases of serious systemic bacterial infection (one fatal)." The fatality apparently precipitated a halt in the Population Council's Canadian clinical trials of mifepristone. Finally, a 21 year old woman suffered a heart attack three days after she completed the Mifeprex Regimen. These and other adverse events had been reported to FDA through its Adverse Event Reporting System (AERS). Two of the patients who were reported to have suffered life-threatening adverse events were 15 years old. These incidents bear out the concerns about the safety of the regimen detailed above, and the relatively high rate of serious adverse events among adolescents is of particular concern.

290 The letter did not specify the number of adverse events about which Danco had been informed, but five individual cases were discussed.
291 See Dear Doctor Letter, infra Appendix A, at 1.
292 See Dear Doctor Letter, infra Appendix A, at 1.
293 It appears that the woman reported to have died from a systemic bacterial infection was a Canadian trial subject. See Marnie Ko, "A Volunteer Dies While Testing a Controversial New Drug, Bringing the Trial to a Halt," The Report (Oct. 8, 2001) (available at: <http://report.ca/archive/report/20011008/p48ai011008f.html>). See also Henry P. Kaiser Family Foundation, "Population Council Announces Death of Woman Involved in Canadian Mifepristone/Misoprostol Trial," Daily Reproductive Health Report (Sept. 11, 2001) (available at: <http://www.kaisernetwork.org/Daily_reports/rep_index.cfm?DR_ID=687>). A Clostridium sordellii infection apparently caused the woman to suffer septic shock. See generally G.L. Mandell, J.E. Bennett, and R. Dolin, Principles and Practice of Infectious Diseases (5th ed. 2000): at 2551 (explaining that a disease process in which "clostridia clearly play a major pathogenic role [s] uterine gas gangrene, now a rare complication that was previously seen in the setting of septic abortion." "C. sordellii has been reported as a cause of uterine gas gangrene . . . . "). See also FDA Q & A's, infra Appendix A, at Question 3 ("Serious systemic bacterial infection is a severe life-threatening infection that spreads throughout the body and can cause death.").
294 See Dear Doctor Letter, infra Appendix A, at 1.
295 See, e.g., Office of Postmarketing Drug Risk Assessment, AERS Report, ISR Numbers 3819498-2 (Nov. 2, 2001) (intervention to prevent permanent impairment or damage); 3806144-7 (Oct. 9, 2001) (death of a patient with an ectopic pregnancy); 3769840-6 (July 30, 2001) (hospitalization of patient with an ectopic pregnancy); 3769842-X (July 30, 2001) (intervention to prevent permanent impairment or damage); 3719885-7 (May 8, 2001) (death in conjunction with the use of misoprostol and Mifegyne, which is the trade name of mifepristone distributed in France); 3713452-7 (Apr. 27, 2001) (intervention to prevent permanent impairment or damage); and, 3769838-8 (July 30, 2001) (intervention to prevent permanent impairment or damage). The AERS depends on voluntary reporting and the accuracy of these reported adverse events cannot be verified, nor can the cause of these events be identified with certainty. There may have been other adverse events that were not reported.
Simultaneously with Danco's distribution of the Dear Doctor Letter, FDA published a webpage with 14 questions and answers related to mifepristone in an attempt to answer some of the questions likely to be prompted by the letter and to urge health care providers to adhere to the approved regimen. FDA's answers, however, leave much to be desired from a medical and scientific standpoint.

First, FDA has understated the possibility that the Mifeprex Regimen caused the serious adverse events reported in the letter. FDA did not adequately explain why women who were apparently healthy prior to undergoing the Mifeprex Regimen experienced life-threatening or fatal complications such as ruptured ectopic pregnancies, heart attacks, and systemic bacterial infections.

Second, FDA inappropriately attempted to link these adverse events to the unapproved vaginal administration of misoprostol. It was reckless for FDA to suggest that the vaginal administration of misoprostol caused these adverse events while overlooking critical flaws in the...

298 See Dear Doctor Letter, infra Appendix A, at 1 (“No causal relationship between any of these events and use of Mifeprex and misoprostol has been established.”). An FDA official interviewed (without attribution) downplayed the connection between the Mifeprex Regimen and the adverse events. See Susan Okie, “Physicians Sent Abortion Pill Alert: Six Women Using RU-486 Taken Ill, and Two Died, Letter Says,” Washington Post (Apr. 18, 2002): at A2 (“These are, in fact, a very small number of events. Some of them were clearly not caused by the drug regimen.”).
299 The repeated references to the unapproved vaginal use of misoprostol in the FDA Q & As give rise to the inference that the reported adverse events are attributable to this single departure from the Mifeprex Regimen. See, e.g., FDA Q & As, infra Appendix A, at Question 1 (“In all of these cases, misoprostol was given vaginally, not orally, which is the approved regimen. FDA has not reviewed data on the safety and effectiveness of vaginal administration of misoprostol.”); id. at Question 4 (“We do not know what role, if any, Mifeprex and ‘off-label’ use of vaginal misoprostol may have in developing serious infections.”); id. at Question 9 (“Why are physicians using misoprostol ‘off-label,’ in other words, using misoprostol vaginally at different doses? There are published studies of the use of mifepristone with vaginal administration of misoprostol for abortion. The misoprostol doses used in these studies are higher than those described in the Mifeprex labeling . . . .”); id. at Question 10 (“Are there risks with vaginal use of misoprostol?”).
approved regimen for Mifeprex use in the United States. FDA should have first assessed essential aspects of this regimen.

It is clear, for example, that absent ultrasonographic screening for ectopic pregnancy, there is increased risk that an intact or rupturing ectopic pregnancy will be misdiagnosed as a normally progressing Mifeprex abortion. Additionally, Mifeprex abortions may be performed by practitioners who are not physicians, who cannot perform surgical abortions, or who are unable to diagnose ectopic pregnancies and their complications.

Nor is there reason to believe that systemic bacterial infection is more likely to occur following vaginal, rather than oral, administration of misoprostol. Misoprostol is commonly administered vaginally for the induction of labor without higher reported rates of either intrauterine or systemic infection when compared to orally administered misoprostol or other methods of labor induction. Rather, the occurrence of life-threatening infection in women undergoing a Mifeprex abortion should raise questions about whether prolonged genital tract bleeding in the artificial hormonal milieu created by the Mifeprex Regimen might foster or promote infectious complications. In addition, infection might occur in women who, believing that their abortion is complete and unaware that their uterus actually contains dead tissue, fail to return for follow-up visits. A French woman undergoing a mifepristone abortion suffered a fatal heart attack in 2002. This may be a particular problem when the Mifeprex Regimen is prescribed to adolescents.

The occurrence of a heart attack in a 21 year old woman is always cause for significant concern. A French woman undergoing a mifepristone abortion suffered a fatal heart attack in

300 A. Karen Kreutner, M.D., "Postabortion Infections," Contemporary Ob/Gyn 1 (2001): at 37-42 ("... because medical termination may be incomplete in between 3% and 23% of patients, retained tissue and subsequent infection may go unrecognized in those lost to follow up. ... Some experts fear there will be compliance problems with the third visit, especially when the patient terminates early. In these cases, retained tissue, thought by the patient to be normal bleeding, could lead to endometritis.")
1991. A different prostaglandin (Sulprostone) administered by injection was used in that case. This new case highlights the need for further investigation into a possible causal link between mifepristone-prostaglandin abortions and myocardial infarction. The ratio of serious adverse events to total uses of the Mifeprex Regimen cannot be ascertained because serious adverse event reporting is likely incomplete and because it is not publicly known how many times the Mifeprex Regimen has been used. Regardless of the relative number of serious adverse events, the nature of these events demands immediate FDA action to prevent future patient injuries and deaths. The Joint Commission on the Accreditation of Healthcare Organizations (“JCAHO” or “Joint Commission”) has developed an approach for investigating adverse events similar in gravity to those that prompted the issuance of the Dear Doctor Letter. The JCAHO looks for “sentinel events” which are “unexpected occurrence[s] involving death or serious physical or psychological injury, or the risk thereof.” “Sentinel events” signal the need for the commencement of a “root cause

---

301 See “Noticeboard: A Death Associated with Mifepristone/Sulprostone,” Lancet 337 (April 20, 1991): at 969-70 (“A spokeswoman for Roussel-Uclaf SA, the company that manufactures mifepristone, said ‘the death was clearly from cardiovascular shock following ‘Nalador’ (Schering) injection.”)

302 The Mifeprex Regimen should be contraindicated for women with cardiovascular risk factors until further clinical experience indicates that such contraindication is unnecessary.

303 Even FDA acknowledged the rarity of the events referenced in the Dear Doctor Letter. With respect to bacterial infection, for example, FDA observed that “the rate of serious infection as a complication of pregnancy is 3.5 per 1000 pregnancies. Uterine infection occurs in 0.1-4.7% of first trimester surgical abortions and in 0.0-6.1% of medical abortions. In the past, it was most often associated with illegal abortions. It rarely occurs with pelvic surgery or even with otherwise normal childbirth.” FDA Q & A’s, infra Appendix A, at Question 3. FDA similarly noted the unusual nature of a heart attack in a young woman: “The single heart attack occurred in a 21 year old. A heart attack in very young women is extremely rare. . . . In 1997, the rate among US women aged 20-24 years was 0.19 per 100,000 women.” See id. at Question 4.

304 The Joint Commission “evaluates and accredits nearly 18,000 health care organizations and programs in the United States. An independent, not-for-profit organization, JCAHO is the nation’s predominant standards-setting and accrediting body in health care. Since 1951, JCAHO has developed state-of-the-art, professionally based standards and evaluated the compliance of health care organizations against these benchmarks.” Joint Commission webpage at: <http://www.jcaho.org/whatwedo_frm.html>.

analysis" of the event(s), with the goal of developing an appropriate administrative response from the health care organization that will prevent the occurrence of future serious adverse events. A root cause analysis of sentinel events is performed before a statistically significant number of injuries or deaths occurs. It seeks to discern the facts surrounding each occurrence, distinguish factors peculiar to individuals from those pointing to procedural or administrative deficiencies, and recommend corrective measures to such systemic failures in the delivery of a particular therapy.

It is particularly important that FDA react to these sentinel events because the clinical trials underlying the approval of the Mifeprex Regimen did not adhere to FDA's endorsed scientific methodology for such trials. The substandard trial design of the U.S. and French Clinical Trials precluded an accurate estimation of the safety of the Mifeprex Regimen compared to the existing available alternatives. Moreover, FDA did not require the sponsor to conduct rigorous Phase IV studies, which could have compensated for some of these deficiencies by generating additional safety data. The agency has not performed a root cause analysis, but has instead hastily postulated that the vaginal administration of misoprostol is the underlying cause of the adverse events. The Petitioners believe that there are probably more scientifically sound explanations for these adverse events and that the supposed safety of the Mifeprex Regimen has been called into question. The occurrence of the adverse events related to ectopic pregnancies and life-threatening systemic bacterial infections adds significant weight to the concerns of those

306 The Joint Commission defines “root cause analysis” as “a process for identifying the basic or causal factors that underlie variation in performance, including the occurrence or possible occurrence of a sentinel event. A root cause analysis focuses primarily on systems and processes, not individual performance. It progresses from special causes in clinical processes to common causes in organizational processes and identifies potential improvements in processes or systems that would tend to decrease the likelihood of such events in the future, or determines, after analysis, that no such improvement opportunities exist.” Joint Commission webpage at: <http://www.jcaho.org/sentinel/se_pp.html#Root cause analysis>. 
who have long warned that mifepristone-misoprostol abortions are dangerous. FDA has previously dismissed such concerns but now must respond to the accumulating evidence and act accordingly. Withdrawal of the approval is warranted.308

H. FDA'S APPROVAL OF MIFEPRLEX SHOULD BE WITHDRAWN BECAUSE THE SPONSOR IS NOT ENFORCING THE LIMITED RESTRICTIONS ON THE USE OF MIFEPRLEX

Mifeprlex abortion providers openly flout the restrictions included in the approved regimen without any reaction from FDA, Danco, or the Population Council.309 Shortly after approval, FDA asserted that “[i]f restrictions are not adhered to, FDA may withdraw approval.”310 Subpart H authorizes FDA to withdraw approval of a drug approved under Section 314.520 if “[t]he applicant fails to adhere to the postmarketing restrictions agreed upon.”311 When it adopted Subpart H, FDA explained that “[t]he burden is on the applicant to ensure that

307 See FDA Q & As, infra Appendix A, at Nos. 1, 4, 9, 10, and 11.
308 The Secretary of HHS is authorized by 21 C.F.R. § 314.530(a) to withdraw approval of a Subpart H drug, subject to the applicant’s right to a hearing, if, among other things, “(3) [u]se after marketing demonstrates that postmarketing restrictions are inadequate to assure safe use of the drug; (4) [t]he applicant fails to adhere to the postmarketing restrictions agreed upon; (5) [t]he promotional materials are false or misleading; or (6) [o]ther evidence demonstrates that the drug product is not shown to be safe or effective under its conditions of use.”
309 The absence of a reaction from Danco may not be surprising in light of the cavalier attitude towards the FDA approval process exhibited by Dr. Richard Hausknecht, who is Danco’s medical director. As early as July 1994, Dr. Hausknecht, had used methotrexate and misoprostol in clinical tests in the U.S. that Dr. Mitchell Creinin, a prominent abortion researcher, described as “downright unethical” and which Sandra Waldman of the Population Council described as being “very risky.” Dr. Hausknecht stopped these experiments in September 1994 when the FDA told him to “stop performing the abortions unless he gets the backing of a medical institution and submits his data and procedures to the FDA for review.” Carol Jouzaitis, “Doctor’s Abortion-Drug” Technique Draws Fire,” Chicago Tribune (Sept. 12, 1994): at 1 & 14. Dr. Hausknecht admitted, “‘This is a little bit uncharted.’ . . . . But he declared: ‘Damn it. I’m not going to wait. This is a step forward. This is important. I want to see this available to women where it’s not available now.’” Id. In addition, Dr. Hausknecht’s website explains step two of the Mifeprlex procedure that he employs: “At the conclusion of the [first] visit, the patient receives a packet containing tablets of misoprostol which are to be taken orally or placed in the vagina depending on the regimen you and Dr. Hausknecht choose.” Available at: <http://www.safeabortion.com/procedure.htm> (visited July 7, 2002). Both the home use and the vaginal administration of misoprostol contravene FDA’s approved regimen.
311 21 C.F.R. § 314.530(a)(4).
the conditions of use under which the applicant’s product was approved are being followed.”

FDA should exercise its authority to withdraw its approval for Mifeprex.

Among the common departures from the approved regimen is the practice of offering the Mifeprex Regimen to women with pregnancies beyond seven weeks. The “Mifepristone Medication Guide” directs women not to take Mifeprex if “[i]t has been more than 49 days (7 weeks) since your last menstrual period began.” Moreover, women who use the Mifeprex Regimen sign a Patient Agreement, which includes a representation by the patient that “I believe I am no more than 49 days (7 weeks) pregnant.” Thus, the practice of offering Mifeprex to women beyond seven weeks not only contravenes the approved regimen, but it also effectively requires patients to make an untruthful representation in the Patient Agreement. The Los Angeles Times explained that, “[B]y offering mifepristone up to the ninth week of pregnancy,” Family Planning Associates, “the nation’s largest for-profit abortion chain,” “obtains a competitive edge over Planned Parenthood, which stays within the seven-week guideline.”

In another common deviation from the approved regimen, some abortion providers have eliminated the second of the three prescribed visits. During the initial visit, these providers give

---

312 Subpart H Final Rule, 57 Fed. Reg. at 58952.
313 Liberty Women’s Health Care of Queens, NY, openly acknowledges its use of Mifeprex beyond seven weeks: “While the FDA has approved mifepristone for non-surgical abortions only up to 7 weeks, we use a modified method to extend this period of eligibility in selected patients an additional 14 days up to 9 weeks.” Available at: <http://www.abortbypill.com/2.html> (visited Dec. 31, 2001). Likewise, Preterm, an abortion clinic in Cleveland, Ohio, states that abortion using Mifeprex “is effective in terminating pregnancies up to 63 days (9 weeks) from the last normal menstrual period.” Available at: <http://www.preterm.org/nonsurg.htm> (visited July 7, 2002).
314 See Item 4 of the Patient Agreement for Mifepristone (mifepristone) Tablets (“Patient Agreement”).
315 Denise Gellene, “RU-486 Abortion Pill Hasn’t Caught on in U.S.,” Los Angeles Times (May 31, 2000): at A1 (quoting Family Planning Associates’ official as saying, “You can catch a lot of women in those two [extra] weeks”). Family Planning Associates’ website confirmed that the abortion provider offers Mifeprex to women with pregnancies up to nine weeks’ gestational age. Available at: <http://www.webworldinc.com/fpamg/abortionpill.htm> (visited July 7, 2002) (“Medical abortion is limited to patients less than nine weeks pregnant as verified by ultrasound.”).
the patient misoprostol, typically with instructions to administer it to herself vaginally at home two days later. Yet home administration of misoprostol runs counter to what patients agree to in the Patient Agreement, which states that “I will . . . return to my provider’s office in 2 days (Day 3) to check if my pregnancy has ended. My provider will give me misoprostol if I am still pregnant.” The Population Council argued in favor of and FDA considered the benefits of self-administration at home, which is the reduced burden on abortion providers and their facilities, but the agency concluded that these benefits are outweighed by the significant risks to women. The second visit affords the physician the opportunity to monitor the status of

---

316 The likely reason that FDA’s approved regimen calls for oral administration is that it is the only mode of administering misoprostol that is currently approved by the FDA. As discussed above, however, the use of misoprostol in conjunction with mifepristone to effect abortions is itself an unapproved indication.

317 Presidential Women’s Center in West Palm Beach, Florida, for example, gives women “four Misoprostol 200 mcg tablets to take home. Forty eight hours after the Mifepristone tablets have been administered the woman moistens four Misoprostol tablets with tap water and inserts them high into her vagina with her fingers.” Available at: <http://www.presidentialcenter.com/medical.html> (visited July 7, 2002). See also: <http://www.heritageclinic.com/abortion/medical_abortion_pill.htm> (visited July 4, 2002) (Two days after the patient takes mifepristone, she “inserts Cytotec vaginally, which causes the uterus to contract and expel the embryo. This is very similar to the procedure that was FDA approved in 2000 and is approximately 98% effective. Note: The FDA approved protocol calls for 3 Mifepris pills taken orally the first day and 2 Cytotec pills taken orally two days later. However, subsequent studies have show[n] 1 oral Mifepris and 4 vaginal Cytotec to be as effective with less gastro-intestinal upset.”); see also: <http://www.fwhc.org/concord/pages/mifepristone.html> (visited July 7, 2002) (Concord Feminist Health Center’s web site describes the second phase of the procedure: “In a few days she inserts misoprostol tablets into her vagina. The pregnancy usually ends at home within four hours.”); see also: <http://www.gynemed.org/ru.html> (visited July 7, 2002) (Gynemed Surgi-Center’s web site states: “You will be given two doses of Misoprostol tablets and instructions on how to insert them into your vagina, which you will[i] do 48 hours after taking RU486.”); see also: <http://www.hopeclinic.com/medab.htm> (visited July 7, 2002) (Hope Clinic for Women, Ltd. Explains: “You will receive pills, misoprostol (“miss o pross tul”) to take home with you. You will be instructed when to use them; they are placed vaginally.”). Even the National Abortion Federation, which initiated a nationwide advertising campaign for Mifeprex, sanctions home administration of misoprostol in its “Medical Abortion Start-Up Packet.” See National Abortion Federation, “Protocol Recommendations for Use of Mifepristone and Misoprostol in Early Abortion,” Early Medical Abortion with Mifepristone or Methotrexate: Overview and Protocol Recommendations (Washington, D.C.: National Abortion Federation, 2001) at 36 (“Home administration of vaginal misoprostol has been found to be safe and effective up to 63 days’ gestation and is highly acceptable to patients.”).
the termination and assess the need for misoprostol — tasks which cannot be delegated to the patient. In addition, the second visit enables patients whose abortions are complete to avoid having to take misoprostol.

Danco and the Population Council have not effectively constrained providers of Mifeprex to adhere to the approved regimen. It appears instead that Danco and the Population Council have ignored well-publicized departures from that regimen. Deviations from the approved regimen are particularly troubling because the patient is told to disregard the regimen that she reads about in the Medication Guide and pledges to follow in the Patient Agreement. When a drug is approved under Subpart H, the drug’s sponsor is responsible for ensuring compliance.

Because of the complications that can arise, periodic monitoring during the termination process is important. For the significant percentage of patients that fail to return for the third visit, the second visit may be the last opportunity for a health care provider to monitor the termination. In the U.S. Clinical Trial, five percent of patients failed to return for the third visit. See Medical Officer’s Review, infra Appendix A, at 10. In other studies, the “loss to follow-up has ranged from three to eleven percent.” See Spitz Article, infra Appendix A, at 1246 (citations omitted). The rate of patients who do not complete the entire regimen in routine clinical practice is likely to be even higher as they will not necessarily be subject to the U.S. Clinical Trial’s exclusion criteria, which, among other things, excluded women who were “unlikely to understand and comply with the requirements of the study.” Medical Officer’s Review, infra Appendix A, at 9.

See ACOG Practice Bulletin, infra Appendix A, at 6 (citing Mitchell Creinin, et al., “Methotrexate and Misoprostol for Early Abortion: A Multicenter Trial,” Contraception 53 (1996); at 321-27) (“Women as well as their practitioners are often unable to judge correctly if the women have aborted by evaluating symptomatology. In clinical trials with methotrexate and misoprostol, only about half of women who thought they had aborted actually had done so.”); Beth Kruse et al., “Management of Side Effects and Complications in Medical Abortion,” American Journal of Obstetrics and Gynecology 183 (2000): S65-375, S73 (“Studies demonstrate that women may be unable to judge correctly on the basis of symptoms whether abortion has occurred.”).

For those patients whose abortions are not complete, the benefits of in-clinic misoprostol use would be enhanced if patients were required to spend several hours afterward in the abortion facility, where they would have ready access to pain medication and other medical help even if the abortion does not occur during the observation period. The Population Council persuaded FDA not to include this requirement, which was included in the protocol for the U.S. Clinical Trial. Forty-nine percent of the participants expelled their pregnancies during the four-hour observation period after the administration of misoprostol. See Spitz Article, infra Appendix A, at 1243.

Nevertheless, a post-misoprostol waiting period was likely disfavored because the protracted presence of large numbers of bleeding and cramping women could place a strain on abortion facilities.
with the restrictions included in the approved regimen for use of the drug. The Population Council and Danco have shirked this responsibility. FDA, therefore, should withdraw its approval of Mifeprex.

I. THE U.S. CLINICAL TRIAL FOR MIFEPRISTONE DID NOT MIRROR THE ANTICIPATED CONDITIONS FOR THE ULTIMATE USE OF THE DRUG

As a general rule, "Phase 3 trials are usually [conducted] in settings similar to those anticipated for the ultimate use of the drug." FDA, however, approved a regimen that does not contain important safeguards that were employed in the U.S. Clinical Trial. In the U.S. Clinical Trial, for example, the investigators relied on transvaginal ultrasonography (along with menstrual history and pelvic examination) to confirm the gestational age of each pregnancy. The use of ultrasonography also excluded women with ectopic pregnancies. Moreover, physicians participating in the U.S. Clinical Trial had experience in performing surgical abortions, were trained in the administration of the mifepristone-misoprostol procedure, and had admitting privileges at medical facilities that could provide emergency care and hospitalization. In addition, "[a]ll patients were within one hour of emergency facilities or the

323 See Subpart H Final Rule, 57 Fed. Reg. at 58953 ("The limitations on distribution or use required under this rule are imposed on the applicant. Therefore, the burden is on the applicant to ensure that the conditions of use under which the applicant's product was approved are being followed.").


325 The French Clinical Trials, which were not performed by the Population Council, are not discussed here because they were not conducted for the purpose of supporting the mifepristone NDA and, therefore, were not designed to reflect American conditions of use.

326 See Spitz Article, infra Appendix A, at 1242.

327 "The types of skills physicians had in the U.S. clinical trial were: 1) the ability to use ultrasound and clinical examination to date pregnancies and diagnose ectopic pregnancies, 2) the ability to perform surgical procedures, including dilation and curettage, vacuum suction, and/or surgical abortions, for bleeding or incomplete abortion, and, 3) they had privileges at medical facilities to provide emergency resuscitation, transfusion, hospitalization, etc. Physicians were trained to use the drug per protocol. Fourteen of the seventeen physicians in the U.S. clinical trial were obstetricians/gynecologists." Mifeprex Approval Memo, infra Appendix A, at 5. Medical Officer's Review,
facilities of the principle [sic] investigator."328 In the U.S. Clinical Trial, after taking
misoprostol, "women were monitored for four hours for adverse events."329 FDA has not
retained these requirements governing physician training, ultrasound, the post-misoprostol
waiting period, or physician privileges at facilities that provide emergency care.330 FDA should
not have extrapolated conclusions about the safety and efficacy of FDA’s approved regimen
from data generated under trial conditions not mirroring the approved regimen. Effectively,
therefore, the agency approved a drug regimen that it had not tested.

J. BY WAIVING THE PEDIATRIC STUDY REQUIREMENT, FDA MAY
HAVE ENDANGERED THE HEALTH OF ADOLESCENT GIRLS

FDA’s approval of Mifeprex violated FDA’s regulations, effective April 1, 1999,
requiring that new drugs be tested for safety and effectiveness in the pediatric population
(collectively, the “Pediatric Rule”).331 Requiring data on girls age 18 and under also would have
been consistent with the guidelines for trials in the pediatric population that FDA accepted at the

infra Appendix A, at 6 (The U.S. Clinical Trial was “conducted at centers that could perform abortions by either
vacuum aspiration or dilatation and curettage and had access to facilities that provided blood transfusions and
performed routine emergency resuscitation procedures.”).

328 Mifeprex Approval Memo, infra Appendix A, at 5. The “one hour travel distance restriction in the clinical trial
was intended to ensure access by patients to emergency or health care services.” Id. FDA contends that concerns
arising from the elimination of the geographical proximity rule have “been dealt with through labeling, which makes
it clear that if there isn’t adequate access to emergency services, the medication is contraindicated.” Mifeprex
Approval Memo at 5.

329 See Spitz Study, infra Appendix A, at 1242.

330 The Prescriber’s Agreement requires only that the supervising physician be “able to assure patient access to
medical facilities equipped to provide blood transfusions and resuscitation, if necessary.” By contrast, the protocol
for the U.S. Clinical Trial required that the physician have “privileges at medical facilities to provide emergency
resuscitation, transfusion, hospitalization, etc.” Mifeprex Approval Memo, infra Appendix A, at 5. The shift in
focus from access by the provider of the abortion to access by the woman who has the abortion, attenuated the link
between the abortion provider and the emergency care provider, a link that is critical to ensuring that women receive
timely emergency care.

331 See Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drugs and Biological
notice of proposed rulemaking was released as: Regulations Requiring Manufacturers to Assess the Safety and
Effectiveness of New Drugs and Biological Products in Pediatric Patients, Proposed Rule, 62 Fed. Reg. 43900
(Aug. 15, 1997).
International Conference on Harmonization. Nevertheless, in the Mifeprex Approval Letter, FDA stated, “We are waiving the pediatric study requirement for this action on this application.” Thus, FDA approved Mifeprex for use without requiring safety and effectiveness testing for the pediatric population.

As FDA noted when it adopted the Pediatric Rule, “many of the drugs and biological products that are widely used in pediatric patients carry disclaimers stating that safety and effectiveness in pediatric patients have not been established.” FDA observed that “the absence of pediatric labeling information poses significant risks for children.” The ICH has noted that adolescence “is a period of sexual maturation; medicinal products may interfere with the actions of sex hormones and impede development.” Such hormonal changes may “influence the results of clinical studies.” These concerns for the health of infants, children, and adolescents

---

332 FDA Guidance: E11 Clinical Testing for Pediatric Uses at 9 and 11 (Heading for Section 2.5.5). FDA, cognizant of the need for such studies, obtained a commitment from the sponsor in 1996 to conduct Phase IV studies to examine the safety and efficacy of the regimen in girls under 18 years of age. FDA subsequently curtailed this Phase IV study requirement when it approved the Mifeprex NDA.

333 Mifeprex Approval Letter at 3.

334 The Mifeprex Label accordingly included the standard disclaimer employed in drug labeling when the drug sponsor has not provided sufficient information to support a pediatric use for the drug: “Safety and effectiveness in pediatric patients have not been established.”


337 FDA, “Guidance for Industry: E11 Clinical Investigation of Medicinal Products in the Pediatric Population” (Rockville, Md.: Dec. 2000): at 11 (§ 2.5.5) (“FDA Guidance: E11 Clinical Testing for Pediatric Uses”). Section 2.5.5 states that the adolescent subgroup should extend from “12 to 16-18 years (dependent on region).” Id. at 11-12 (§ 2.5.5).

338 See FDA Guidance (ICH: E11): Clinical Testing for Pediatric Uses at 12 (§ 2.5.5). These ICH concerns, quoted below, pertaining to the difficulty of testing drugs in the adolescent population amplify the need for FDA to have required clinical study of the difficulties that might arise when teenage girls undergo the Mifeprex Regimen:

Many diseases are also influenced by the hormonal changes around puberty (e.g., increases in insulin resistance in diabetes mellitus, recurrence of seizures around menarche, changes in the frequency and severity of migraine attacks and asthma exacerbations). Hormonal changes may thus influence the results of clinical studies.

Within this age group, adolescents are assuming responsibility for their own health and medication. Noncompliance is a special problem, particularly when medicinal products (for example, steroids) affect
prompted FDA to begin the rulemaking that culminated with the issuance of the Pediatric Rule, establishing "a presumption that all new drugs and biologics will be studied in pediatric patients" unless the requirement is waived. More specifically, the Pediatric Rule requires that applicants seeking approval for new chemical entities, new biological products, new active ingredients, new indications, new dosage forms, new dosing regimens, and new routes of administration contain safety and effectiveness information on relevant pediatric age groups.

FDA made clear that the Mifeprex NDA was covered by the Pediatric Rule. Nevertheless, FDA fully waived the rule for Mifeprex without explanation. Full or partial

appearance. In clinical studies compliance checks are important. Recreational use of unsupervised drugs, alcohol, and tobacco should be specifically considered.

The upper age limit varies among regions. It may be possible to include older adolescents in adult studies, although issues of compliance may present problems. Given some of the unique challenges of adolescence, it may be appropriate to consider studying adolescent patients (whether they are to be included in adult or separate protocols) in centers knowledgeable and skilled in the care of this special population.

Id. at 12 (§ 2.5.5).

Pediatric Adopting Release, 63 Fed. Reg. at 66634 (introduction to "II. Highlights of the Final Rule"). The importance of testing drugs in children was highlighted during the recent controversy surrounding FDA's attempt to suspend the Pediatric Rule. FDA's planned two-year suspension came in response to the passage of the Best Pharmaceuticals for Children Act, which offers incentives for manufacturers to test drugs in children. Public Law No. 107-109, 115 Stat. 1408 ("BPCA"). See also Association of American Physicians and Surgeons, Inc. v. FDA, Defendants' Motion for Stay of Proceedings, Civil Action No. 00-2898 (HHK) (Mar. 18, 2002). FDA later reversed its position in response to criticism from physicians and members of Congress. FDA's attempt to suspend the Pediatric Rule prompted the introduction of identical legislation in the House of Representatives and the Senate to codify the Pediatric Rule. See S. 2394, 107th Congress, 2nd Session (2002) (co-sponsors: Senators Hillary Rodham Clinton (D-NY), Mike DeWine (R-OH), and Chris Dodd (D-CT)); and H.R. 4730, 107th Congress, 2nd Session (2002) (co-sponsors: Representatives John D. Dingell (D-MI), Henry A. Waxman (D-CA), Rosa DeLauro (D-CT), Anna Eshoo (D-CA), and Sherrod Brown (D-OH)). As Senator Hillary Rodham Clinton, a co-sponsor of the Senate bill explained, "if we want to protect our children over the long term, then we in Congress need to step in and make the Pediatric Rule the law of the land. Short of taking that action, we risk denying children the protection that we require for adults." Press Release, "Senators Will Introduce Legislation to Codify Pediatric Rule" (Apr. 17, 2002) (available at: <http://clinton.senate.gov/~clinton/news/2002/04/2002417811.html>). See also Marc Kaufman and Ceci Connolly, "U.S. Backs Pediatric Tests In Reversal on Drug Safety," Washington Post (April 20, 2002): at A3.

Pediatric Adopting Release, 63 Fed. Reg. at 66634 ("A. Scope of the Rule"), and as required pursuant to 21 C.F.R. § 314.55(a).

The Mifeprex Approval Letter stated: "Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 FR 66632). We are waiving the pediatric study requirement for this action on this application." Mifeprex Approval Letter at 3. Because the Mifeprex NDA was filed before the Pediatric Rule went
waivers of the pediatric study requirement may be granted either upon request of the applicant or by FDA on its own motion.\textsuperscript{342} Both FDA-initiated and sponsor-requested waivers must satisfy certain criteria. FDA is required to grant a full or partial waiver “if the agency finds that there is a reasonable basis on which to conclude that one or more of the grounds for waiver … have been met.”\textsuperscript{343}

Section 314.55 provides three procedural tracks by which an applicant may obtain a waiver of the study requirement. The first requires that two conditions being met:\textsuperscript{344} (1) “[t]he drug product does not represent a meaningful therapeutic benefit over existing treatments for pediatric patients,” and (2) the drug product “is not likely to be used in a substantial number of pediatric patients.” With respect to this basis for waiver, FDA has “emphasize[d] that the study requirement applies to a product that offers a meaningful therapeutic benefit even if it is not used in a substantial number of pediatric patients, and vice versa.”\textsuperscript{345} As noted above, FDA, in connection with its determination to approve Mifepric under Subpart II, concluded that the Mifepric Regimen provides a therapeutic benefit over the existing treatment — surgical

\textsuperscript{342} Although it appears that FDA waived the rule sua sponte, FDA should have required the manufacturer to provide certain information to support the waiver. The agency has not released such documents to the public in response to FOIA requests. When it adopted the Pediatric Rule, the agency noted: “FDA agrees that the burden is on the manufacturer to justify waivers, but believes that the rule already adequately imposes that burden. The rule requires both a certification from the manufacturer that the grounds for waiver have been met and an adequate justification for the waiver request.” Pediatric Adopting Release, 63 Fed. Reg. at 66648 (§ 29).

\textsuperscript{343} 21 C.F.R. § 314.55(c)(4)(“FDA action on waiver.”).

\textsuperscript{344} 21 C.F.R. § 314.55(c)(2)(i).

\textsuperscript{345} Pediatric Adopting Release, 63 Fed. Reg at 66635 (“II.D.2. Waiver of the Study Requirement,” see first paragraph).
abortion. This conclusion by itself precludes FDA from using the first method for granting waiver of the Pediatric Rule.

Even if FDA had not judged the Mifeprex Regimen to offer a "meaningful therapeutic benefit," the second requirement for waiver in this first track is not met because Mifeprex can be expected to be used in a "substantial number of pediatric patients," which FDA defines as "50,000 pediatric patients with the disease for which the drug or biological product is indicated." In the Pediatric Adopting Release, FDA stated that the "relevant age groups will . . . be defined flexibly." With respect to Mifeprex, it would have been appropriate to classify girls under the age of 18 as pediatric patients because safety and effectiveness in this population had not been studied. If the pediatric population comprises all girls age 17 and under, then we estimate that there were 357,200 pediatric pregnancies per year from 1995 to 1997 in the United States. If the pediatric population comprises all girls age 16 and under, then we estimate that there were a total of 196,520 pregnancies per year from 1995 to 1997. Even if the pediatric population encompasses only girls age 15 and under, we estimate that there were

345 See Mifeprex Approval Memo at 6.
346 FDA noted that, for purposes of the Pediatric Rule, it would rely "in part, on CDER's current administrative definition of a 'Priority' drug, applied to pediatric populations" to define "meaningful therapeutic benefit." The phrase, "meaningful therapeutic benefit," appears identical in the Subpart H and Priority review contexts. As noted above, Mifeprex was accorded priority review. The modifications to "meaningful therapeutic benefit" for purposes of the Pediatric Rule appear to have broadened the scope of the phrase. See Pediatric Rule, 63 Fed. Reg. at 66646.
348 Pediatric Rule, 63 Fed. Reg. at 66634 ("C. Age Groups"). After noting comments to the proposed rule that argued for flexibility in setting age definitions (including a comment arguing for "pediatric patient" to include those "from 0 to 21 years"), FDA stated that "the age ranges identified in the proposal may be inappropriate in some instances" and that it had "deleted the references in the rule to specific age ranges." Id. at 66651.
349 Although FDA acknowledged that the safety and effectiveness of Mifeprex were not studied in girls under age 18 and required a statement to that effect in the labeling, the agency anticipated and even encouraged use in this population when it stated that: "there is no biological reason to expect menstruating females under age 18 to have a different physiological outcome with the regimen. The Spitz data actually suggests a trend towards increased success of medical abortion with younger patients." Mifeprex Approval Memo at 7.
350 See infra Appendix B at B-3.
351 See infra Appendix B at B-4.
85,960 pregnancies per year from 1995 to 1997 in this age range. Thus, under any definition of the pediatric population, the 50,000 patient cut-off set forth in the Pediatric Adopting Release is exceeded. In sum, neither of the requisite conditions for a waiver of the Pediatric Rule under the first waiver track provided in Section 314.55 is satisfied.

Second, FDA may also waive the pediatric study requirements if the “necessary studies are impossible or highly impractical because, e.g., the number of such patients is so small or geographically dispersed.” FDA explained that “that this ground for waiver [must] be interpreted narrowly.”

Although the number of patients necessary to permit a study must be decided on a case-by-case basis, FDA agrees that there are methods available to conduct adequate studies in very small populations. . . . Because of the speed and efficiency of modern communications tools, geographic dispersion will justify a waiver only in extraordinary circumstances and will generally have to be coupled with very small population size. FDA is not persuaded that inability to recruit patients because of parental fears associated with administration of the drug is an adequate basis to conclude that studies are impractical where there is also evidence that similar products are regularly prescribed to pediatric patients outside of clinical trials.

Pediatric Mifeprx studies would not have been either “impossible or highly impractical.” As described above and in Appendix B, the population of pediatric females that becomes pregnant each year is large and the female population is evenly distributed throughout the United States. Thus, this second waiver track available under Section 314.55 could not have been satisfied (and FDA apparently has not taken a position to the contrary).

FDA may waive the pediatric study requirement under Section 314.55’s third waiver track when “[t]here is evidence strongly suggesting that the drug product would be ineffective or ineffective or ineffective or
unsafe in all pediatric age groups." As noted above, FDA endorsed the proposition that "there is no biological reason to expect menstruating females under age 18 to have a different physiological outcome with the regimen." Thus, by suggesting that Mifeprex could be used appropriately in the pediatric population, FDA eliminated this third track as a possible basis for waiver.

Absent a waiver or deferral, the Pediatric Rule requires any drug application to "contain data that are adequate to assess the safety and effectiveness of the drug product for the claimed indication in all relevant pediatric subpopulations . . . ." FDA is authorized instead to extrapolate such data from adult studies "[w]here the course of the disease and the effects of the drug are sufficiently similar in adults and pediatric patients." The underlying adult studies, however, must be "adequate and well-controlled." As noted above, the Population Council did not provide evidence from adequate and well-controlled studies as to the safety and effectiveness of Mifeprex in the adult population. Reliance on these flawed adult studies for a determination of the safety and effectiveness of Mifeprex in the pediatric population was inappropriate.

Furthermore, to assume that the effects of a potent antiprogesterone, mifepristone, and a

358 21 C.F.R. § 314.55(c)(2)(iii).
359 Mifeprex Approval Memo at 7.
360 21 C.F.R. § 314.55(a). FDA stated that it was waiving the Pediatric Rule. Mifeprex Approval Letter at 3. The agency did not assert that it had made a determination that pediatric studies were not required because the adult trials were sufficient to support extrapolation of conclusions as to safety and effectiveness in the pediatric population. However, because FDA failed to provide any justification for its waiver, it is difficult to determine whether the agency was, in fact, relying on this provision to eliminate the pediatric study requirement for Mifeprex.
361 See 21 C.F.R. § 314.55(a).
362 See 21 C.F.R. § 314.55(a).
powerful prostaglandin analogue, misoprostol, in pregnant adults can be extrapolated to pregnant adolescents, who are still developing physiologically and anatomically, is medically unsound.\textsuperscript{363}

FDA violated its own rules when it waived the Pediatric Rule in the face of explicit criteria that necessitated compliance with the rule.\textsuperscript{364} Furthermore, FDA offered no explanation for its determination to waive the rule. As FDA’s treatment of other drugs illustrates, a waiver would have been appropriate only if Mifeprex had already been tested in children and labeled accordingly, or if the Pediatric Rule’s criteria for waiver were satisfied.\textsuperscript{365} Because FDA waived the study requirement in the face of explicit criteria that appear to prohibit such action in this instance, the agency violated its rule. In addition to violating Section 314.55, FDA’s unexplained waiver of the Pediatric Rule for the Mifeprex NDA constitutes agency action that is arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law.\textsuperscript{366}

\textsuperscript{363} The Mifeprex Regimen acts upon the reproductive system, which changes dramatically during adolescence. Adolescents, for example, could face disruptions in ovulatory function as a result of concentrations of mifepristone in developing ovarian follicles, or other health problems. Moreover, teenagers may face heightened risks arising from decreased compliance with the full regimen, poor recall of their last menstrual period, and their reluctance to tell others about their pregnancies.

\textsuperscript{364} Of course, a partial waiver of the study requirement is appropriate for the non-adolescent pediatric sub-groups. See 21 C.F.R. § 314.55(c)(3). According to FDA Guidance (ICH: E11): Clinical Testing for Pediatric Uses, the pediatric sub-populations other than “adolescents” are: 1) preterm newborn infants; 2) term newborn infants (0 to 27 days); 3) infants and toddlers (28 days to 23 months); 4) children (2 to 11 years). FDA Guidance (ICH: E11): Clinical Testing for Pediatric Uses at 9 (§ 2.5).

\textsuperscript{365} In April 2000, FDA approved a suitability petition for Pamidronate Disodium Injection, 3 mg/mL, 10 mL vials, and 9 mg/mL, 10 mL vials, the listed drug products for which are Aredia (Pamidronate Disodium for Injection), 30 mg/vial and 90 mg/vial, and determined that the “proposed change in dosage form is subject to the Pediatric Rule but that a full waiver of the pediatric study requirement . . . is appropriate.” See Letter, FDA to Mitchell G. Clark (April 18, 2000): at 1 (Docket No. 00P-0091/CPI) (concluding “that investigations are not necessary to demonstrate the safety and effectiveness of your proposed product in the pediatric population since the necessary studies are impossible or highly impractical because the number of patients is small and geographically dispersed”). See also Letter, FDA to The Weinberg Group, Inc. (June 13, 2000), at 1-2 (Docket No. 99P-5447/CPI) (approving a generic manufacturer’s petition to file an Abbreviated New Drug Application for Cefaclor Chewable Tablets, 125 mg, 187 mg, 250 mg, and 375 mg, the listed drug products for which are Cefaclor (Cefaclor) for Oral Suspension, 125 mg/5mL, 187 mg/5mL, 250 mg/5mL, and 375 mg/5mL because FDA determined that the “proposed change in dosage form is subject to the Pediatric Rule” but “that investigations are not necessary to demonstrate the safety and effectiveness of your proposed products in the pediatric population, because the specific drug products that you reference are adequately labeled for pediatric use”).

\textsuperscript{366} FDA has required numerous drug sponsors to comply with the Pediatric Rule, but it approved Mifeprex without stating its basis for waiving the requirement. See, e.g., Letter, FDA to King & Spalding (June 13, 2000): at 1

83

EX. 9 pg. 083
K. FDA'S UNEXPLAINED REDUCTION OF THE SPONSOR'S PHASE IV REQUIREMENTS WAS ARBITRARY, CAPRICIOUS, AN ABUSE OF DISCRETION, OR OTHERWISE NOT IN ACCORDANCE WITH LAW

Not only did FDA improperly and without explanation waive its own pediatric testing requirements, but it also inexplicably narrowed the scope of the Population Council's commitments to conduct post-approval Phase IV studies. As a general rule, the clinical trials required by FDA to support an NDA are adequate to establish short-term drug safety and effectiveness. The standard pre-approval clinical trials, however, are typically incapable of providing either the amount or type of data necessary to assess a drug's long-term effects.

Phase IV, which occurs after a drug is approved, provides the opportunity to "monitor[ ] the safety of the new drug under actual conditions of use in large numbers of patients." Not only

---

367 A.G. Gilman, T.W. Rall, A.S. Nies, P. Taylor, eds., The Pharmacological Basis of Therapeutics, 8th ed. (New York: Pergamon Press, 1990): at 77 ("Although assessment of risk is a major objective of [clinical trials], this is far more difficult than is the determination of whether a drug is efficacious for a selected condition. Usually about 500 to 300 carefully selected patients receive a new drug during phase-3 clinical trials . . . . Thus, the most profound and overt risks that occur almost immediately after the drug is given can be detected in a phase-3 study, if these occur more often than once per 100 administrations. Risks that are medically important but delayed or less frequent than 1 in 1000 administrations may not be revealed prior to marketing. It is thus obvious that a number of unanticipated adverse and beneficial effects of drugs are only detectable after the drug is used broadly.").

368 Bertram G. Katzung, M.D., ed., Basic and Clinical Pharmacology, 4th ed. (Norwalk, CT: Appleton & Lange, 1989): at 56. "Final release of a drug for general prescription use should be accompanied by a vigilant postmarketing surveillance program. The importance of careful and complete reporting of toxicity after marketing approval by the FDA can be appreciated by noting that many drug-induced effects have an incidence of 1:10,000 or less. . . . Because of the small numbers of subjects in phases 1-3, such low-incidence drug effects will not generally be detected before Phase 4, no matter how carefully the studies are executed. Phase 4 has no fixed duration." Id. at 56-7.
did FDA approve the NDA on the basis of clinical trials so defective with respect to their design and execution as to render them insufficient to establish short-term safety and effectiveness, but FDA also permitted the Population Council to substantially pare down the Phase IV trials that it would perform.

In response to an FDA request, on September 16, 1996, the Population Council agreed to conduct a set of Phase IV studies. FDA “reminded” the Population Council of these commitments in both the 1996 and 2000 Approvable Letters. The Population Council agreed to perform studies with the following objectives:

1. To monitor the adequacy of the distribution and credentialing system.
2. To follow-up on the outcome of a representative sample of mifepristone-treated women who have surgical abortion because of method failure.
3. To assess the long-term effects of multiple use of the regimen.
4. To ascertain the frequency with which women follow the complete treatment regimen and the outcome of those who do not.
5. To study the safety and efficacy of the regimen in women (1) under 18 years of age, (2) over age 35, and (3) who smoke.
6. To ascertain the effect on children born after treatment failure.

These studies would have addressed some of the health issues that were not evaluated during pre-approval testing.

The Mifeprex Approval Letter released on September 28, 2000, however, contains only two Phase 4 study obligations, a radical curtailment of the earlier commitments. The letter

---

369 FDA made its request on August 22, 1996, after it had received Phase IV study recommendations from the FDA Advisory Committee. See Medical Officer’s Review, infra Appendix A, at 20-24.
stated that “the following Phase 4 commitments, specified in [the Population Council’s] submission dated September 15, 2000 . . . replace all previous commitments . . . .” 373

(1) “A cohort-based study of safety outcomes of patients having medical abortion under the care of physicians with surgical intervention skills compared to physicians who refer their patients for surgical intervention.” 374

(2) “A surveillance study on outcomes of ongoing pregnancies.” 375

FDA stated that “[p]revious study questions related to age, smoking, and follow-up on day 14 (compliance with return visit) will be incorporated into this cohort study, as well as an audit of signed Patient Agreement forms.” 376 The agency, thus, compounded its failure to require the Population Council and Danco to comply with the strictures of the Pediatric Rule when it permitted them to consider the effect of the Mifeprex Regimen on patients under 18 as part of another study rather than as a separate Phase IV study. 377 The Approval Letter explained that

373 Mifeprex Approval Letter, infra Appendix A, at 2.

374 Mifeprex Approval Letter, infra Appendix A, at 3. The Population Council acknowledged three weaknesses of this study. First, the sample size would be limited so that the sponsor “will only be able to determine whether the combined safety rates of hospitalizations, medically necessary surgical interventions, and IV fluids in each of the two cohorts are within plus or minus 5 percentage points of the expected 2% rate. We will not be able to detect differences of individual safety outcomes such as blood transfusions and deaths.” See Amendment 062 to the NDA, Revised Materials (Sept. 19, 2000): at 3. [FDA FOIA Release: MIP 00789679031]. Second, the Population Council predicted that it might have difficulty finding women who were referred to another provider for care. Id. at 3-4. Third, it might be difficult to find women who did not return for their follow-up visit. Id. at 4. These three study weaknesses appear, at least in part, to stem from faulty selection criteria for study subjects. Patients should not be enrolled in a study unless they are willing to comply with follow-up visits and telephone inquiries. Additionally, informed consent forms authorize investigators to request medical records from other health care providers.

375 Mifeprex Approval Letter, infra Appendix A, at 3.

376 Mifeprex Approval Letter, infra Appendix A, at 3. These issues were characterized by the sponsor as “Secondary Study Objectives.” See Amendment 062 to the NDA (Sept. 19, 2000): at 1. The failure to consider each issue in a separate study is likely to compromise the quality of the data generated. Because the study is primarily focused on a provider-level variable (ability to provide surgical intervention), the study will not necessarily yield a meaningful sample size for each of the relevant patient-level variables (age and smoking status). Patients will be enrolled “consecutively from each provider until the provider’s quota is met.” See id. at 2.

377 The Population Council submitted data from the Spitz Study on 106 women age 35 and older and 51 patients under age 20. See Mifeprex Approval Letter, infra Appendix A, at 7. However, the effects and potential age-specific risks of the Mifeprex Regimen on women outside the tested age range deserve separate consideration in studies with far more subjects. Approximately 279,000 girls nineteen and younger and more than 84,000 women over the age of 35 obtain abortions in the United States annually. See Appendix B, infra, at B-4 (§§ 5 and 6). The Mifeprex Regimen, which directly interacts with the reproductive system, could conceivably interfere with pubertal development, as discussed above, and might pose unique risks to women who are nearing the end of their reproductive years.
“the changes in postmarketing commitments reflect current postmarketing questions given establishment of final labeling, Medication Guide, and distribution system, along with availability of additional clinical data with the drug since 1996.”

It appears, however, that the modifications came largely in response to the Population Council’s unwillingness to explore the ramifications of the Mifeprex Regimen. On August 18, 1999, the Population Council acknowledged its Phase IV commitments, but stated that “[w]e plan to discuss in more detail and develop a consensus with the FDA post-NDA approval.”

The Population Council complained, for example, that “[a] prospective study of the long-term effects of multiple use of the regimen in all American women would be unduly burdensome, might result in an invasion of women’s privacy and would not likely produce a meaningful scientific result for decades.” Similarly, the Population Council informed FDA that it was “not able to commit to tracking down those women who are lost to follow-up because this would be very difficult and extraordinarily expensive. We are also concerned about the ethics of doing

378 Mifeprex Approval Memo, infra Appendix A, at 7. FDA’s conclusion that the reduction to only two Phase IV studies “reflect[s] current postmarketing questions” ignores a number of issues about Mifeprex that remain unexplored. Because mifepristone interferes with pregnancy by binding to the progesterone receptor in the placenta, there is concern that the drug may affect not only the uterus, but the brain, breasts, adrenal glands, ovaries, and immune cells, all of which also have progesterone receptors. Concerns that mifepristone may have a carcinogenic effect on breast tissue have also been expressed. See, e.g., Testimony of Dr. Joel Brind, FDA Hearings Transcript, infra Appendix A, at 172-175. Mifepristone also could affect the pituitary gland, the adrenal glands, and immune cells, all of which have glucocorticoid receptors. In addition, it is unclear whether a woman who undergoes multiple mifepristone-misoprostol abortions could suffer adverse effects. See ACOG Practice Bulletin, infra Appendix A, at 9 (“No well-designed prospective studies address the issue of repeat medical abortion.”). Questions also remain about possible effects on the children born to women who have terminated a previous pregnancy with the Mifeprex Regimen. See, e.g., P. Van de Schoot and R. Baumgarten, “Effects of Treatment of Male and Female Rats in Infancy with Mifepristone on Reproductive Function in Adulthood,” Journal of Reproduction and Fertility 30 (1990): 255-66 (finding that rats exposed to mifepristone in their infancy suffered infertility in adulthood)[FDA FOIA Release: MIF 007165- 007176].

379 Medical Officer’s Review, infra Appendix A, at 24 (quoting from the Population Council’s submission to FDA on Aug. 18, 1999).

380 Medical Officer’s Review, infra Appendix A, at 24 (quoting from the Population Council’s submission to FDA on Aug. 18, 1999); see also Mifeprex Approval Memo at 7 (agreeing with the Population Council’s reasoning).
this, as it could violate women’s privacy.” The Population Council’s concerns about privacy lack merit. Patients who participate in clinical trials give their consent to participate and to be monitored, thus eliminating concerns about privacy. Similarly, FDA should not have accorded undue weight to the Population Council’s protestations about the potential expense of the trials; drug sponsors, who stand to profit from a drug’s sales, are responsible for bearing the expenses incurred in establishing the safety and efficacy of a drug.

FDA’s acquiescence in the Population Council’s reduction in its Phase IV commitments compounded the Agency’s earlier failure to require the sponsor to conduct clinical trials in accordance with the requirements of Section 314.126 of FDA’s rules. FDA’s inadequately justified curtailment of the sponsor’s Phase IV study commitments was arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law.

381 Medical Officer’s Review, infra Appendix A, at 24 (quoting from the Population Council’s submission to FDA on Aug. 18, 1999). The necessity of long-term monitoring is particularly critical to compensate for the unusually short tracking periods employed in the U.S. Clinical Trial, in which investigators generally did not track patients after their third visit. See Spitz Article, infra Appendix A, at 1242. “Follow-up was extended beyond visit 3 if there was uncertainty about the completeness of the abortion or if bleeding persisted.” Id. Five percent of the participants in the U.S. Clinical Trial were not tracked through the third visit (which would have occurred on Day 15) because they failed to return for it, suggesting that each of these women was last seen on Day 3, only 2 days after the initial administration of mifepristone. See Medical Officer’s Review, infra Appendix A, at 10. Abbreviated follow-up periods run counter to ICH standards, which state that in clinical trials of drugs intended for use during pregnancy, “followup of the pregnancy, fetus, and child is very important.” FDA Guidance (ICH: E8): General Considerations, infra Appendix A, 62 Fed. Reg. at 66117 (§ 3.1.4.3) (“Special populations”).

IV. PETITIONERS SEEK LEAVE TO AMEND

The Petitioners respectfully inform FDA that they may file amendments to this Petition as information becomes available from Freedom of Information Act requests made before the filing date of this document.\textsuperscript{383}

V. CONCLUSION

For the foregoing reasons, the Petitioners respectfully request that the Commissioner immediately enter an administrative stay to halt any further distribution and marketing of Mifeprex until final agency action is taken on this Petition. The Petitioners also respectfully request that the Commissioner revoke approval of Mifeprex for the medical termination of pregnancies less than 49 days’ gestation. On the basis of the evidence presented above, the Petitioners respectfully request a full FDA audit of the French and U.S. Clinical Trials.\textsuperscript{384}

\textsuperscript{383} The Petitioners have filed numerous Freedom of Information Act ("FOIA") requests with FDA that remain unanswered, including: 1) FOIA Request, filed by Wendy Wright, Director of Communications, CWA (Aug. 31, 2001) (seeking "an entire copy of FDA's letter to the Population Council dated, or mailed, on or about June 1, 2000, along with any attachments, appendices, and other accompanying materials"); 2) FOIA Request, filed by Wendy Wright, Director of Communications, CWA (Aug. 31, 2001) (seeking "an entire copy of the new drug application... filed... on or about March 18, 1996 (NDA 20-687)"); 3) FOIA Request, filed by Wendy Wright, Director of Communications, CWA (Sept. 14, 2001) (seeking a copy of data submitted by the sponsor "related to the use of mifepristone by women over the age of thirty-five, females under the age of eighteen, and women who smoke" and of the Phase IV study protocols submitted by the Sponsor and any Phase IV trial data); and, 4) FOIA Request, filed by Wendy Wright, Director of Communications, CWA (Feb. 6, 2002) (seeking a correct listing of all drug applications approved pursuant to 21 C.F.R. § 314.520 and documents detailing FDA's reasoning for approving drugs under this section of its rules).

\textsuperscript{384} An audit of the U.S. Clinical Trial is additionally warranted because of an unusual data management decision made by the Population Council with the apparent approval of the FDA:

Thank you for speaking with me the other day about our data dilemma. In response to our conversation, we have decided to create two versions of our electronic database from the mifepristone study. The first will reflect exactly the physical copies of the patient record forms, and will be used as the basis for our regulatory submissions to you. The second version will closely match the first, particularly on safety and efficacy indicators, but certain variables will be modified to create an internally consistent database that we can use easily for our planned scholarly publications on the topic. We will keep careful track of the changes we make and we will be able to explain them to an FDA auditor should the need arise. One result...
VI. ENVIRONMENTAL IMPACT

This Petition for withdrawal of approval of an NDA is categorically excluded under 21 C.F.R. § 25.31(d). An environmental impact statement is, thus, not required.

VII. ECONOMIC IMPACT

The Economic Impact information shall be submitted only when and if requested by the Commissioner following review of the Petition, in accordance with 21 C.F.R. § 10.30.

CERTIFICATIONS AND SIGNATURES

On behalf of the petitioner organizations listed below, we the undersigned hereby certify that, to the best of petitioners' knowledge, this Citizen Petition is true and accurate. It includes all available information relevant to this Petition, including information both favorable and unfavorable to Petitioners' position in this matter.

So executed this 15th day of August 2002.

[Signature]
Donna Harrison, M.D.
Chairperson, Subcommittee on Mifeprex American Association of Pro-Life Obstetricians and Gynecologists
P.O. Box 414
Eau Claire, MI 49111
Phone: (616) 921-2513

of this approach to handling the data is that certain aspects of our future publications may differ from tabulations that appear in our regulatory submissions.

Letter, Charlotte Eilerston, Population Council, to [Redacted], FDA/CDER (July 28, 1997); at 1 [FDA FOIA Release: MIF 006489].
So executed this 13th day of August 2002.

Gene Rudd, M.D.
Associate Executive Director
Christian Medical Association
P.O. Box 7500
Bristol, TN 37621
Phone: (423) 844-1000
So executed this 20th day of August 2002.

Sandy Rios
President
Concerned Women for America
1015 Fifteenth Street, N.W.
Suite 1100
Washington, D.C. 20005
Phone: (202) 488-7000
## Citizen Petition (Mifeprex) Documents

<table>
<thead>
<tr>
<th>Description of Article/Document</th>
<th>TAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exhibit A: Selected Bibliography.</td>
<td>A</td>
</tr>
<tr>
<td>Exhibit B: Statistics Used in the Petition.</td>
<td>B</td>
</tr>
<tr>
<td>Exhibit C: FDA's Subpart H Webpage (Chart).</td>
<td>C</td>
</tr>
<tr>
<td>Exhibit D: Printouts from Mifeprex abortion websites illustrating deviations from the approved regimen.</td>
<td>D</td>
</tr>
<tr>
<td>F-D-C Reports, &quot;RU-486 Action Date is Sept. 30,&quot; The Pink Sheet (June 12, 2000): 14.</td>
<td>F</td>
</tr>
<tr>
<td>Description of Article/Document</td>
<td>TAB</td>
</tr>
<tr>
<td>------------------------------------------------------------------------------------------------</td>
<td>-----</td>
</tr>
</tbody>
</table>
Exhibit 10

FDA Letter to Population Council
re: NDA (Feb. 18, 2000)
NDA 20-687

Population Council
Attention: Sandra P. Arnold
1230 York Avenue
New York, NY 10021

Dear Ms. Arnold:

Please refer to your new drug application (NDA) dated March 14, 1996, received March 18, 1996, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for mifepristone 200 mg tablets.

We acknowledge receipt of your submissions dated September 18 and 26, 1996; January 30, March 6 and 31, July 28, August 5, September 3 and 24, November 26, 1997; January 30, February 19, April 27, June 25, October 26, December 7 and 8, 1998; February 8, 22, March 31, April 28, May 10, 20, June 3 (2), 15, 25, 30, July 14, 22, August 3, 13, 18, 30, September 3, 8, 13, 30, October 5, 26, 28, November 16, 29 (2), December 6, 7, 23, 1999; January 21, 28 (2), and February 16, 2000. Your submission of August 18, 1999 constituted a complete response to our September 18, 1996 action letter.

We have completed the review of this application, as amended, and it is approvable. Before this application may be approved, however, it will be necessary for you to address the following:

Chemistry

Drug Substance
Redacted 1
pages of trade secret and/or confidential commercial information
NDA 20-687
Mifepristone
Population Council
Page 4

Labeling

Address the recommendations in the enclosed draft labeling for the Physician Insert and Patient Package Insert.
It will be necessary for you to submit revised draft labeling for the drug. We recommend that the

EX. 10. pg. 004
NDA 20-687
Mifepristone
Population Council
Page 5

labeling be identical in content to the enclosed draft labeling (text for the Physician Package Insert and Patient Package Insert).

If additional information relating to the safety or effectiveness of this drug becomes available, revision of the labeling may be required.

**Phase 4 Commitments**

We remind you of your commitments dated September 16, 1996, to perform the following Phase 4 studies:

1. To monitor the adequacy of the distribution and credentialing system,

2. To follow-up on the outcome of a representative sample of mifepristone-treated women who have surgical abortion because of the method failure,

3. To assess the long-term effects of multiple use of the regimen,

4. To ascertain the frequency with which women follow the complete treatment regimen and the outcome of those who do not,

5. To study the safety and efficacy of the regimen in women (1) under 18 years of age, (2) over age 35, and (3) who smoke,

6. To ascertain the effect of the regimen on children born after treatment failure.

**Distribution Plan**

We have completed our review of this application, including the restrictions on the distribution and use of this product proposed in your January 21, 2000 submission, entitled “Distribution Plan”. We have concluded that adequate information has not been presented to demonstrate that the drug, when marketed in accordance with the terms of distribution proposed, is safe and effective for use as recommended. The restrictions on distribution will need to be amended.

We have thus considered this application under the restricted distribution regulations contained in 21 CFR 314.500 (Subpart H) and have concluded that restrictions as per CFR 314.520 on the distribution and use of mifepristone are needed to assure safe use of this product.
Promotional Activities

Please note that promotional activities for this NDA are subject to 21 CFR 314.550. As such, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please send one copy to the and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

Under 21 CFR 314.50(d)(5)(vi)(b), we request that you update your NDA by submitting all safety information you have regarding your new drug. Please provide updated information as listed below. The update should cover all studies and uses of the drug including: (1) those involving indications not being sought in the present submission, (2) other dosage forms, and (3) other dose levels, etc.

1. Retabulation of all safety data including results of trials that were still ongoing at the time of NDA submission. The tabulation can take the same form as in your initial submission. Tables comparing adverse reactions at the time the NDA was submitted versus now will certainly facilitate review.

2. Retabulation of drop-outs with new drop-outs identified. Discuss, if appropriate.

3. Details of any significant changes or findings.

4. Summary of worldwide experience on the safety of this drug.

5. Case report forms for each patient who died during a clinical study or who did not complete a study because of an adverse event.

6. English translations of any approved foreign labeling not previously submitted.

7. Information suggesting a substantial difference in the rate of occurrence of common, but less serious, adverse events.

Within 10 days after the date of this letter, you are required to amend the application, notify us of your intent to file an amendment, or follow one of your other options under 21 CFR 314.110. In the absence of any such action FDA may proceed to withdraw the application. Any amendment should respond to all the deficiencies listed. We will not process a partial reply as a major amendment nor will the review clock be reactivated until all deficiencies have been addressed.
NDA 20-687
Mifepristone
Population Council
Page 7

The drug product may not be legally marketed until you have been notified in writing that the application is approved.

If you have any questions, call

Sincerely,

/S/

Center for Drug Evaluation and Research

Enclosure

APPEARS THIS WAY ON ORIGINAL
Exhibit 11

FDA Approval Memo. to Population Council re: NDA 20-687Mifeprex (mifepristone)
(Sept. 28, 2000)
MEMORANDUM

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

DATE: September 28, 2000

FROM: /S/

SUBJECT: NDA 20-687 MIFEPRIST (mifepristone) Population Council

TO:

This memo documents the approval action concerning the Population Council's NDA for mifepristone for the medical termination of intrauterine pregnancy through 49 days' pregnancy. The application was initially submitted to the Food and Drug Administration (FDA) on March 14, 1996. The Reproductive Health Drugs Advisory Committee met on July 19, 1996 and voted that benefits exceeded risk for this drug product with 6-yes, 0-no, and 2 abstentions. An approvable action letter was issued September 18, 1996 citing deficiencies in areas of Clinical (distribution system), Chemistry/Manufacturing and Controls, Biopharmaceutics, and Labeling. A complete response was received August 18, 1999. The last action by the Office was on February 18, 2000. That approvable action letter listed application deficiencies consisting of Chemistry/Manufacturing and Controls, Labeling, and the Distribution System issues. The Population Council submitted a complete response on March 30, 2000. After a brief summary of effectiveness and safety, this memo addresses those outstanding issues listed in the last action letter, Phase 4 commitments, and other issues.

Summary of Effectiveness and Safety
Effectiveness and safety data were derived from one U.S. clinical trial and two French trials. Effectiveness was defined as the complete expulsion of products of conception without the need for surgical intervention.

The U.S. trial consisted of 859 women providing safety data and 827 women providing effectiveness data for gestations of 49 days or less, dated from the last menstrual period. Demographic data showed racial composition of the U.S. trial was similar to the overall U.S. general population. Medical abortion was complete in 92.1% of 827 subjects. Surgical intervention was performed in 7.9% of subjects: 7.6% had medically indicated interventions (1.2% for heavy bleeding), 4.7% had incomplete abortions, 1.0% had ongoing pregnancies, and 0.6% had intervention at the patient’s request. One of the 859 patients received a blood transfusion.

The two French trials enrolled a total of 1,681 women providing effectiveness outcomes and 1,800 women providing safety information. Medical abortion was complete in 95.5% of the 1,681 subjects. Surgical intervention was performed in 4.5% of subjects: 0.3% for bleeding, 2.9% for incomplete abortions, and 1.3% for ongoing pregnancies. Of the 1,800 women, 2 patients received blood transfusions.

The Advisory Committee reviewed the French data in 1996 and voted 6-yes and 2-no for data supporting efficacy, 7-yes and 1-abstention for data supporting safety. As stated above, the overall vote for benefits exceeding risk was 6-yes, 0-no, and 2-abstentions. During the second review cycle in 1999, the committee received a copy of the U.S. study report, as they requested, to provide FDA with comments. None were received. The U.S. trial data confirms the effectiveness and safety of the product.
Chemistry/Manufacturing
In May, 2000 the Population Council informed the Division of Reproductive and Urologic Drug Products that the bulk drug substance maker had changed manufacturing processes last summer. New analytic, physical, and stability data were received and reviewed and found to be adequate to ensure the quality of the drug manufacturing was preserved.

An inspection of the bulk drug substance maker was performed on July 24-28, 2000. Deficiencies were cited and the manufacturer corrected these. These corrections were found acceptable.

Because the drug is being distributed directly to qualified physicians, there is minimal chance for drug name confusion and I agree with the name, Mifeprex.

Labeling
Labeling is important to educate prescribers and patients about the safe and effective use of the drug and to inform health professionals about adverse event risks. The 1996 Advisory Committee strongly supported education of users of mifepristone. By coupling professional labeling with other educational interventions such as the Medication Guide, Patient Agreement, and Prescriber’s Agreement, along with having physician qualification requirements of abilities to date pregnancies accurately and diagnose ectopic pregnancies (and other requirements), goals of safe and appropriate use may be achieved. The drug’s labeling is now part of a total risk management program that will be summarized below. The professional labeling, Medication Guide, Patient Agreement, and Prescriber’s Agreement will together constitute the approved product labeling to ensure any future generic drug manufacturers will have the same risk management program.

The labeling for mifepristone has been revised to provide information about how to report adverse events. FDA and the Population Council agree that a black box will highlight special items related to the drug. In addition, FDA has determined that a Medication Guide for this drug will help ensure dispensers provide important information to patients to enhance compliance with the regimen for safety and efficacy. Furthermore, a patient agreement fosters active patient education and participation in this regimen. The Population Council will provide these educational materials (the professional labeling, the Medication Guide, the patient agreement form, and the Prescriber’s Agreement form). The professional labeling, Medication Guide, Patient Agreement, and Prescriber’s Agreement must be read, understood, and attested to by physicians who meet prescribing qualifications (discussed below).

Black Box
21 CFR 201.57(e) permits FDA to require a black box warning for special problems, particularly those that may lead to death or serious injury. The Population Council agreed in its July 5, 2000 submission to a black box warning. It was agreed that the box would contain the following:

“If Mifeprex results in incomplete abortion, surgical intervention may be necessary. Prescribers should determine in advance whether they will provide such care themselves or through other providers. Prescribers should also give patients clear instructions of whom to call and what to do in the event of an emergency following administration of Mifeprex.

Prescribers should make sure the patients receive and have an opportunity to discuss the Medication Guide and Patient Agreement.”

Misoprostol Administration
The approvable letter issued by FDA on 2/18/2000 agreed to the Population Council’s statement that women could have the option of taking misoprostol on Day 3 either at home or at the prescriber’s office. However, data provided by the Population Council supporting home use was re-reviewed and found not to provide substantial evidence for safety and efficacy. The data were anecdotal off-label experience with
a vaginal misoprostol regimen, an observational study about home use in Guadeloupe, and a U.S. clinical study of home use of a different regimen with different drug doses. The only study that commented on whether home use led to correct use was the Guadeloupe study reporting that 4% of patients who took misoprostol at home did it incorrectly. Returning to the health care provider on Day 3 for misoprostol, as in the U.S. clinical trial, assures that the misoprostol is correctly administered. This requirement has the additional advantage of contact between the patient and health care provider to provide ongoing care and to reinforce the need to return on Day 14 to confirm that expulsion has occurred.

Early in drug development, a mandatory observation period of 3-4 hours was instituted in clinical trials worldwide when a prostaglandin analogue, sulprostone, was used with mifepristone and felt to have some cardiovascular risk. This drug is no longer being used with mifepristone and is not a marketed drug in the U.S.; therefore, the rationale for an observation period is moot. There is no more likelihood of an adverse event occurring in the few hours after misoprostol administration than during the entire study period.

Therefore, as a consequence of this re-evaluation, the labeling currently reads that the patient returns on Day 3 for misoprostol and is given instructions about adverse events and whom to contact for questions and emergencies.

Access to Health Care and Emergency Services
FDA agreed with the Population Council that access to health care and emergency services is critical for the safe and effective use of the drug. The clinical trials ensured access to services. The labeling has a black box highlighting the possible need for surgical intervention and either the provision of access to these services by the prescriber or through referral. The labeling has a contraindication if there is no access to medical facilities for emergency services. The Patient Agreement emphasizes the need to know what to do in the case of an emergency.

Patient Agreement Form
Patients should be informed about the indication of the drug and how it is given. They must understand the type of regimen they are about to commit to and its risks and benefits. The signed agreement form will be given to the patient for her reference and another kept in the medical record. The Population Council has committed to auditing prescribers to ascertain whether they have obtained signed copies of the Patient Agreement forms.

Biopharmaceutics
This review cycle, the clinical biopharmaceutical reviewers evaluated new data in the published literature regarding the metabolism of mifepristone by the P450 3A4 system. Mifepristone is a substrate and this may inhibit drug metabolism of certain drugs and induce metabolism of others. This information was placed in the professional labeling and patients are instructed in the Medication Guide that use of other drugs may interfere with actions of mifepristone and misoprostol.

Pharmacology-Toxicology
Current literature on the effects of human fetal exposure to mifepristone and misoprostol or mifepristone alone was reviewed to ensure risk information was current. Many of the case reports of malformation concern the unsuccessful use of misoprostol for abortion, resulting in limb, facial, cranial, and other abnormalities. Many reports were retrospective in nature, subject to reporting and recall bias. Nevertheless, the risk of malformation is very important to address. This drug’s indication is for pregnancy termination. The labeling, Medication Guide, process of obtaining patient agreement on medical abortion, and the commitment of the physicians through their signed Prescriber’s Agreement are all meant to ensure women are completely informed about the process and make a commitment to follow through.
The labeling for Mifeprisone states that it is used with misoprostol for termination of pregnancy of 49 days or less. Human data on mifepristone and misoprostol used in this timeframe is available. Safety Update Report #3 submitted on March 31, 2000 contains _______ Periodic Safety Update Report #9 for the period of September 1, 1998 to November 30, 1999. It lists 38 on-going pregnancies with mifepristone plus misoprostol. The Lancet published a letter in July 1998 from _______ in which they mention that they had reviewed 71 cases of continuing pregnancies after failed early termination of pregnancy occurring from 1987 to 1998 and found no reported cases of malformation associated with use of mifepristone and misoprostol. There was one report of sirenomelia and cleft palate in a patient who had a therapeutic termination at week 7 gestation associated with mifepristone use alone. On July 6, 1999 the European Summary of Product Characteristics contains a statement for mifepristone that in humans, the reported cases do not allow a causality assessment for mifepristone use alone or used with a prostaglandin. On August 21, 2000 the sponsor provided _______ to 5/31/00 Periodic Safety Update on pregnancy outcomes following early pregnancy exposure. The current labeling has these new data on 82 pregnancies exposed to mifepristone only (40) and mifepristone used with misoprostol (42). FDA agrees that no conclusion can be made from the data at this time. Information on the possibility of a risk of malformation, including the above information as well as the anecdotal reports, is nevertheless included in the professional labeling, Medication Guide, and Patient Agreement. The Population Council has committed to continuing ongoing surveillance of human malformation risk.

Medication Guide
This product will be approved with a Medication Guide which dispensers must provide with the drug. It is important for patients to be fully informed about the drug, as well as the need for follow up, especially on Day 14 to confirm expulsion. A Medication Guide was determined to be necessary to patients’ safe and effective use of the drug. The drug product is important to the health of women and the Medication Guide will encourage patient adherence to directions for use. Patient adherence to directions for use and visits is critical to the drug’s effectiveness and safety.

Distribution System
Since 1996, FDA and the Population Council have agreed, as publicly discussed with the Reproductive Drug Products Advisory Committee, that once approved, the drug will be distributed directly to physicians. It will not be available from pharmacies. There were also discussions about the qualifications of the physicians receiving mifepristone for dispensing. The Committee also stated it was important that women have access to medical abortion as this new therapeutic option may offer women avoidance of a surgical procedure.

In January 2000, the Population Council provided its initial plan for drug distribution. This plan was resubmitted in its complete response of March 30, 2000. This plan had acceptably addressed the issue of physical security of the drug. The distribution system plan stated specific requirements imposed on and by distributors of the drug, including procedures for storage, dosage tracking, damaged product returns, and other matters. See Subpart H of this memo for more details. Other aspects of the distribution system are addressed below.

Physician Qualifications
Physician qualifications were discussed within CDER, the Agency, and with the Population Council. FDA also discussed physician qualifications with a special government employee with expertise in early pregnancy. The Population Council proposed that the drug be directly distributed to qualified physicians, as opposed to other types of health care professionals (midwives, physician’s assistants, nurse practitioners, etc.). This restriction was supported by the discussions of the 1996 Advisory Committee. In fact, the clinical trial data was derived from the experience of physicians using this drug. Thus, physicians remain the initial population who will receive this drug for dispensing. This does not preclude another type of health care provider, acting under the supervision of a qualified physician, from
dispensing the drug to patients, provided state laws permit this. Should data be provided to amend the restriction to physicians, FDA will consider them.

The types of skills physicians had in the U.S. clinical trial were: 1) the ability to use ultrasound and clinical examination to date pregnancies and diagnose ectopic pregnancies, 2) the ability to perform surgical procedures, including dilation and curettage, vacuum suction, and/or surgical abortions, for bleeding or incomplete abortion, and, 3) they had privileges at medical facilities to provide emergency resuscitation, transfusion, hospitalization, etc. Physicians were trained to use the drug per protocol. Fourteen of the seventeen physicians in the U.S. clinical trial were obstetricians/gynecologists. All patients were within one hour of emergency facilities or the facilities of the principle investigator.

The role of ultrasound was carefully considered. In the clinical trial, ultrasound was performed to ensure proper data collection on gestational age. In practice, dating pregnancies occurs through using other clinical methods, as well as through using ultrasound. Ultrasound information can be provided to the prescribing physicians to guide treatment, but this information can be obtained through consultation referral from an ultrasound provider and does not necessarily need to be obtained by the prescriber him/herself. The labeling recommends ultrasound evaluation as needed, leaving it to the medical judgement of the physician.

The Population Council proposed that any physician who could date pregnancies and diagnose ectopic pregnancies should be able to receive the drug from the distributor. These two qualifications alone limit the number of physicians who will be eligible to receive mifepristone from the Population Council's distributor(s) to those physicians who are very familiar with managing early pregnancies. These two qualifications also are performance-based standards and do not limit providers of mifepristone to specific medical subspecialties. Education about the use of the drug is described above in the Labeling section of this memo. Because qualified physicians will be using this drug, there is no need for special certification programs. The current labeling and distribution system states physician need not have skills for handling surgical interventions, but could provide referral to services for incomplete abortion and emergency care. The Population Council stated that current medical practice is structured on referral of patients who need surgery (for example, women with a spontaneous incomplete abortion or a cardiologist's patient who needs by-pass grafts) to a physician possessing the skills to address the problem. Moreover, within the U.S. clinical trial, 11 patients out of roughly 850 patients needed surgical intervention to handle bleeding, the most important urgent adverse event associated with this drug, and 3 of these patients were handled by non-principal investigators such as the emergency room and non-study gynecologist. This suggests that patients will get the needed surgical intervention by either their physician or another physician with the needed skills. Referral to a hospital for emergency services does not mean having admitting privileges, but having the ability and the responsibility to direct patients to hospitals, if needed. The professional labeling and the Medication Guide highlight that surgery may be needed and patients need to know if the provider of mifepristone will furnish surgical intervention or if the patient will be referred. If the latter, the treating health care provider must give the patient the name, address, and phone number of this referred provider. To ensure that the quality of care is not different for patients who are treated by physicians who have the skill for surgical intervention (as in the clinical trials) compared to those treated by physicians who must refer patients for surgical intervention, FDA has proposed and the Population Council has agreed to structure a Phase 4 monitoring study. This monitoring study incorporates study questions of four of the original six Phase 4 commitments. See Phase 4 Commitments for additional information.

Finally, the one hour travel distance restriction in the clinical trial was intended to ensure access by patients to emergency or health care services. This concern has been dealt with through the labeling, which makes it clear that if there isn't adequate access to emergency services, the medication is contraindicated.
Subpart II

In the February 18, 2000 approvable letter, FDA stated that the eventual approval of this drug would be under Subpart H. (21 CFR 314.500-314.560). This subpart applies to certain new drugs that have been studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit to patients over existing treatments. FDA has determined that the termination of an unwanted pregnancy is a serious condition within the scope of Subpart H. The meaningful therapeutic benefit over existing surgical abortion is the avoidance of a surgical procedure. Subpart H applies when FDA concludes that a drug product shown to be effective can be safely used only if distribution or use is restricted, such as to certain physicians with special skills or experience. In the case of mifepristone, the Population Council proposed and FDA agreed that this drug will be directly distributed via an approved plan that ensures the physical security of the drug to physicians who meet specific qualifications. Under 21 CFR 314.520, distribution of mifepristone is restricted as described below.

- Mifepristone must be provided by or under the supervision of a physician who meets the following qualifications:
  - Ability to assess the duration of pregnancy accurately
  - Ability to diagnose ectopic pregnancies
  - Ability to provide surgical intervention in cases of incomplete abortion or severe bleeding, or have made plans to provide such care through other qualified physicians, and are able to assure patient access to medical facilities equipped to provide blood transfusions and resuscitation, if necessary
  - Has read and understood the prescribing information of Mifeprex
  - Must provide each patient with a Medication Guide and must fully explain the procedure to each patient, provide her with a copy of the Medication Guide and Patient Agreement, given her an opportunity to read and discuss both the Medication Guide and the Patient Agreement, obtain her signature on the Patient Agreement and must sign it as well
  - Must notify the sponsor or its designate in writing as discussed in the Package Insert under the heading DOSEAGE AND ADMINISTRATION in the event of an on-going pregnancy, which is not terminated subsequent to the conclusion of the treatment procedure
  - Must report any hospitalization, transfusion or other serious events to the sponsor or its designate
  - Must record the Mifeprex package serial number in each patient’s record

- With respect to the aspects of distribution other than physician qualifications described above, distribution of Mifeprex will be in accordance with the system described in the Population Council’s submission of March 30, 2000, which includes the following:
  - Secure manufacturing, receiving, and holding areas for the drug
  - Secure shipping procedures, including tamper-proof seals
  - Controlled returns procedures
  - Tracking system ability to trace individual packages to the patient level, while maintaining patient confidentiality
  - Use of authorized distributors and agents with necessary expertise to handle distribution requirements for the drug
  - Provision of drug through a direct, confidential physician distribution system that ensures only qualified physicians will receive the drug for patient dispensing

The Population Council agreed to approval under Subpart H in their letter of September 15, 2000.
Phase 4 Commitments

In 1996, the Population Council committed to 6 post-marketing studies: 1) to monitor the adequacy of the distribution and credentialing system; 2) to follow up on the outcome of a representative sample of mifepristone treated women who have surgical abortion because of method failure; 3) to assess the long term effects of multiple use of the regimen; 4) to ascertain frequency with which women follow the complete treatment regimen and the outcome of those who do not; 5) to study the safety and efficacy of the regimen in women under age 18, over age 35, and who smoke; 6) to ascertain the effect of the regimen on children born after treatment failure.

During this review cycle, items 1, 2, 4 and 5 were revised and integrated into a monitoring study to ensure providers who did not have surgical intervention skills and referred patients for surgery had similar patient outcomes as those patients under the care of physicians who possessed surgical skills (such as those in the clinical trial). This study specifically addresses adequacy of qualifications (#1). FDA reviewed the protocols from the Population Council submitted on September 7, 2000 and provided a revised protocol on September 13, 2000 in which the investigators collect data on safety outcomes (#2), return for their follow up visits (#4), and include all ages (#5) and collect smoking status (#5).

Commitment #2 was defined by the Advisory Committee discussions of 1996 surrounding the question of whether certain physician specialties would have higher rates of problems encountered with medical abortion. This study specifically will investigate the performance of specialties with surgical skills compared to those that refer for surgical interventions with respect to incidence of medical abortion failures.

The Population Council agrees to study ongoing pregnancies and their outcomes through a surveillance, reporting, and tracking system (#6). This protocol summary and a summary for the monitoring system was received on September 19, 2000 and both were found to be adequate.

The Population Council asked that Commitment #3 (to assess the long term effects of multiple use of the regimen) be waived because it would not be feasible to identify and enroll sufficient numbers of repeat users of the drug, especially given privacy issues. In addition, the pharmacology of mifepristone does not suggest any carry over effect after one-time administration. The Agency agrees with this assessment.

As a note, this cycle the Population Council provided new data concerning Commitment #5 (to study the safety and efficacy of the regimen in women under age 18, over age 35, and who smoke), from Spitz et al. This study had 106 women ages 35 years or older as well as 51 subjects under age 20, all of whom were 49 days or less since their last menstrual period. The data on the older women is informative and of meaningful sample size. FDA agrees there is no biological reason to expect menstruating females under age 18 to have a different physiological outcome with the regimen. The Spitz data actually suggests a trend towards increased success of medical abortion with younger patients. However, as these age groups were not part of the NDA indication and the data on safety and effectiveness were only reviewed for the indication’s age group (18-35 years of age), the trials excluded patients younger than 18 years old, and the raw data from Spitz have not been submitted for review, the labeling states the safety and efficacy in these groups have not been studied. The Population Council will collect outcomes in their Phase 4 studies of women of all ages to further study this issue. With respect to smokers, the Population Council will study smokers of various ages to collect safety information. In sum, the changes in postmarketing commitments reflect current postmarketing questions given establishment of final labeling, Medication Guide, and distribution system, along with availability of additional clinical data with the drug since 1996.

The postmarketing audit of signed Patient Agreement forms was discussed above.
Public Comments Considered
The Food and Drug Administration received over 1,000 letters or emails from the public about mifepristone. Most comments objected to various restrictions of the drug’s distribution. For example, many letters opposed press reports of an alleged FDA public registry of doctors who dispense mifepristone. Other letters focused on the research uses of mifepristone for neurologic and oncologic diseases and the concern that restricting distribution after approval would constrain off-label uses. Still other letters expressed misunderstanding that experimental indications that are subject to INDs would be limited by an approval of mifepristone with distribution restrictions. These comments were reviewed and considered.

Risk Management Program
Risk management for a drug has the goal of optimizing the use of a product by maximizing its benefits and minimizing its risks. Interventions to manage risk include education to physicians, patients, and the public, labeling (including warnings, precautions, contraindications, dosage and administration, and Medication Guide), restriction of product use or supply, and packaging changes. This drug is being approved under Subpart H (restrictions on distribution) as part of the risk management program. The Population Council and FDA have identified the areas below, among others, that contribute to drug safety and effectiveness:

1. Proper selection of patients via physicians who are qualified to do so by dating pregnancies and diagnosing ectopics,
2. Qualified physicians to administer or supervise the administration of the medication
3. Compliance with the regimen by physicians and patients through education and monitoring
4. Safety and effectiveness information that fully informs patients and physicians about the risks and benefits of the treatment
5. Evaluation of physician qualifications through Phase 4 studies has been discussed in above sections.
6. Physical packaging in unit of dosing to ensure proper dose and provision of Medication Guide with each dose
7. Active patient participation in the treatment through the Patient Agreement and Medication Guide with an audit of signed Patient Agreement to ensure compliance
8. Active programs to get physicians to report adverse events and ongoing pregnancies to provide accurate risk information
9. Commitment to review and revise the risk management program for improved public health

All components of this risk management program have been discussed above, including the Medication Guide, the labeling that includes the Prescriber’s and Patient Agreement forms, approval under Subpart H, and Phase 4 studies to evaluate risk management interventions and to gather data on risks.

In summary, all approval issues related to the NDA have been addressed adequately.
Exhibit 12

2000 FDA Approval Letter for Mifeprex (mifepristone) Tablets at 1 (Sept. 28, 2000)
Population Council  
Attention: Sandra P. Arnold  
Vice President, Corporate Affairs  
1230 York Avenue  
New York, NY 10021

Dear Ms. Arnold:

Please refer to your new drug application (NDA) dated March 14, 1996, received March 18, 1996, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for MIFEPRAX™ (mifepristone) Tablets, 200 mg.

We acknowledge receipt of your submissions dated April 19, June 20, July 25, August 15 and September 16 and 26, 1996; January 30, March 31, July 28, August 5, September 24, November 26, 1997; January 30, 2(2), February 19, April 27, June 25, October 26, December 8, 1998; February 8 and 22, March 31, April 28, May 10 and 20, June 3 (2), 15, 23, 25, and 30, July 14 (2) and 22, August 3, 13, 18 and 30, September 3, 8, 13 and 30, October 5, 26 and 28, November 16 and 29 (2), December 6, 7 and 23, 1999, and January 11, 21 and 28 (2), February 16 and 24, March 3, 6, 9, 10, 30 and 31 (2), April 20, May 3, 11 and 17, June 22 and 23, July 11, 13, 25 and 27, August 18, 21 and 24, September 8, 12, 15 (2), 19 (2), 20, 21, 22, 26 (2), and 27 (2), 2000. Your submission of March 30, 2000 constituted a complete response to our February 18, 2000 action letter.

This new drug application provides for the use of Mifeprax™ for the medical termination of intrauterine pregnancy through 49 days' pregnancy.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to approve Mifeprax™ (mifepristone) Tablets, 200 mg, for use as recommended in the agreed upon labeling text. The application is approved under 21 CFR 314 Subpart H. Approval is effective on the date of this letter. Marketing of this drug product and related activities are to be in accordance with the substance and procedures of the referenced regulations.

The final printed labeling (FPL) [including the professional labeling (Package Insert), the Medication Guide required for this product under 21 CFR Part 208, the Patient Agreement Form, and the Prescriber’s Agreement Form] must be identical to the submitted draft labeling (Package Insert, Medication Guide, Patient Agreement Form, and the Prescriber’s Agreement Form submitted September 27, 2000, and the immediate container and carton labels submitted July 25, 2000). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. Alternatively, you may submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format - NDAs (January 1999). For administrative
purposes, this submission should be designated "FPL for approved NDA 20-687." Approval of this submission by FDA is not required before the labeling is used.

Under 21 CFR 314.520, distribution of the drug is restricted as follows:

Mifepristone™ must be provided by or under the supervision of a physician who meets the following qualifications:

- Ability to assess the duration of pregnancy accurately.
- Ability to diagnose ectopic pregnancies.
- Ability to provide surgical intervention in cases of incomplete abortion or severe bleeding, or have made plans to provide such care through other qualified physicians, and are able to assure patient access to medical facilities equipped to provide blood transfusions and resuscitation, if necessary.
- Has read and understood the prescribing information of Mifepristone™.
- Must provide each patient with a Medication Guide and must fully explain the procedure to each patient, provide her with a copy of the Medication Guide and Patient Agreement, give her an opportunity to read and discuss both the Medication Guide and the Patient Agreement, obtain her signature on the Patient Agreement and must sign it as well.
- Must notify the sponsor or its designate in writing as discussed in the Package Insert under the heading DOSAGE AND ADMINISTRATION in the event of an ongoing pregnancy, which is not terminated subsequent to the conclusion of the treatment procedure.
- Must report any hospitalization, transfusion or other serious events to the sponsor or its designate.
- Must record the Mifepristone™ package serial number in each patient’s record.

With respect to the aspects of distribution other than physician qualifications described above, the following applies:

- Distribution will be in accordance with the system described in the March 30, 2000 submission. This plan assures the physical security of the drug product and provides specific requirements imposed by and on the distributor including procedures for storage, dosage tracking, damaged product returns, and other matters.

We also note the following Phase 4 commitments, specified in your submission dated September 15, 2000. These commitments replace all previous commitments cited in the September 18, 1996 and the February 18, 2000 approvable letters. These Phase 4 commitments are:

1. A cohort-based study of safety outcomes of patients having medical abortion under the care of physicians with surgical intervention skills compared to physicians who refer their patients for surgical intervention. Previous study questions related to age, smoking, and follow-up on day 14 (compliance with return visit) will be incorporated into this cohort study, as well as an audit of signed Patient Agreement forms.
2. A surveillance study on outcomes of ongoing pregnancies.

You have agreed to provide the final Phase 4 protocols for these studies within six months.

Protocols, data, and final reports should be submitted to your IND for this product and a copy of the cover letter sent to this NDA. If an IND is not required to meet your Phase 4 commitments, please submit protocols, data and final reports to this NDA as correspondence. In addition, under 21 CFR 314.81(b)(2)(vii), we request that you include a status summary of each commitment in your annual report to this NDA. The status summary should include the number of patients entered in each study, expected completion and submission dates, and any changes in plans since the last annual report. For administrative purposes, all submissions, including labeling supplements, relating to these Phase 4 commitments must be clearly designated "Phase 4 Commitments."

We also remind you that, under 21 CFR 314.550, after the initial 120 day period following this approval, you must submit all promotional materials, including promotional labeling as well as advertisements, at least 30 days prior to the intended time of initial dissemination of the labeling or initial publication of the advertisement.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 FR 66632). We are waiving the pediatric study requirement for this action on this application.

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call

Sincerely,

[Signature]

Center for Drug Evaluation and Research

APPEARS THIS WAY ON ORIGINAL
Exhibit 13

October 10, 2003

VIA HAND DELIVERY

Dockets Management Branch
U.S. Food and Drug Administration
Document Control Room
5630 Fishers Lane, First Floor
Room 1061 (HFA-305)
Rockville, Maryland 20852

Re: Docket No. 02P-0377
Response to Opposition Comments filed by The Population Council, Inc. and Danco Laboratories, LLC

We submit these comments on behalf of The American Association of Pro Life Obstetricians and Gynecologists ("AAPLOG"), the Christian Medical Association ("CMA"), and Concerned Women for America ("CWA") (collectively, "the Petitioners"), in response to Opposition Comments filed by the makers/distributors of Mifeprex™ (mifepristone) 200 mg tablets (NDA 20-687). 1 In particular, The Population Council, Inc. ("the Council") and Danco Laboratories, LLC ("Danco") (collectively, "the Sponsor") submitted comments on March 13, 2003 opposing the Citizen Petition and Request for Administrative Stay ("Petition") filed by the Petitioners on August 20, 2002. 2

Not surprisingly, the Council and Danco ask the Food and Drug Administration ("FDA") to maintain the status quo, so that they can continue to sell Mifeprex, a "non-surgical" alternative to abortion. By contrast, the Petitioners seek to protect women from the unknowing use of a dangerously unsafe drug by pursuing an immediate stay and withdrawal of FDA’s approval of the new drug application ("NDA") for mifepristone.

Although opposing comments were inevitable, the Petitioners are concerned that the Sponsor has refused to acknowledge any problems regarding the safety, effectiveness and overall

1 Opposition of The Population Council, Inc. and Danco Laboratories, LLC to Citizen Petition and Request for Administrative Stay Regarding Mifeprex® (Mifepristone), Docket No. 02P-0377 (March 13, 2003) ("Opposition Comments") (available at: <http://www.fda.gov/ohrms/dockets/dailys/03/Mar03/031303/031303.htm>).

medical suitability of the Mifeprex Regimen.\(^3\) The Petitioners are not surprised, however, that
the Sponsor has failed to produce medical-scientific data and adequate explanations for the
administrative irregularities described in the Petition. This failure is consistent with the
Petitioners’ contention that the clinical data in support of the Mifeprex Regimen are scarce, not
the product of adequate and well-controlled trials, and cannot support a reasoned risk-benefit
analysis by FDA. Instead, the available evidence points to the fact that Mifeprex should never
have been approved by FDA.

We have set forth below our responses to the Sponsor’s Opposition Comments, along
with additional evidence that the safety and effectiveness of Mifeprex have not been established
in accordance with FDA’s regulations. In particular, the drug, which was not lawfully entitled to
consideration under Subpart H, could not have been approved apart from that provision’s special
distribution restrictions; the clinical trials relied on to support the NDA were legally and
clinically insufficient; the inclusion of misoprostol in the Mifeprex Regimen without a
 correspondingly misoprostol approval was unlawful; and the Regimen’s use is inherently unsafe,
as proven by recent life-threatening adverse events and even deaths. With this evidence, FDA is
both statutorily empowered and obligated to grant an Administrative Stay to suspend the
Mifeprex NDA approval and expedite withdrawal proceedings.

I. The Safety and Effectiveness of Mifeprex Have Not Been Established in Accordance
with FDA’s Regulations.

FDA’s approval of a drug product must rest on the Agency’s conclusion that the drug is
safe and effective for its labeled conditions for use. In the case of Mifeprex, the Petitioners
previously provided evidence that the NDA should not have been approved, and the Sponsor’s
Opposition Comments did not rebut that evidence. In fact, as described below, although the
Opposition Comments reiterate the Sponsor’s confidence in the safety and efficacy of the
Mifeprex Regimen, they also expose the dearth of pre- or post-approval evidence for that
position. Consequently, given the body of evidence now before FDA, the Agency should
withdraw its approval of the Mifeprex NDA at this time.

A. Subpart H Enables FDA to Place Special Restrictions on Especially Risky
Drugs like Mifeprex.

Although Petitioners maintain their original position that FDA’s reliance on Subpart H
was unlawful for this drug, the Sponsor’s response that Mifeprex could have been approved
alternatively under Section 505 is incorrect. The Sponsor’s Opposition Comments repeat an
argument that the Sponsor made when it was trying to convince FDA not to use Subpart H – that
“[t]he restrictions FDA imposed under Subpart H could as well have been imposed (and
enforced) under Section 505 [of the FD&C Act] itself, without reference to Subpart H.”\(^5\) The

\(^3\) When FDA approved the Population Council’s NDA for mifepristone, it approved the drug for use in conjunction
with misoprostol. In this Response, “Mifeprex Regimen” will refer to the combined use of Mifeprex and
misoprostol to effect an abortion.

as amended at 21 U.S.C. §§ 301 et seq.).
fact that FDA proceeded under Subpart H suggests that the Agency did not subscribe to this argument. Indeed, had FDA taken this position, it would not have promulgated the restricted distribution prong of Subpart H, but would simply have relied on Section 505 to impose restrictions. When FDA adopted Subpart H, it noted that “the restrictions to ensure safe use contemplated for approvals under [Subpart H] are authorized by statute.” FDA went on to explain that Subpart H would enable the Agency to impose on drugs restrictions “necessary to ensure that section 505 criteria have been met, i.e., restrictions to ensure that the drug will be safe under its approved conditions of use.” Additional restrictions are necessary because Mifeprex and other Subpart H drugs carry greater risks than drugs approved through the typical new drug approval processes. In short, when FDA adopted Subpart H, it added a new tool to its regulatory toolbox enabling it to approve drugs that otherwise could not have been approved because the safe usage mandates in Section 505 would not have been satisfied. Therefore, the Sponsor errs in asserting that the approval of the Mifeprex NDA is independently grounded in Section 505(d).

The Sponsor also claimed that its cooperation with FDA to devise restrictions obviates the need to rely on Subpart H. The Sponsor’s unfailing confidence in the safety of mifepristone even in the face of scientific evidence to the contrary is part of the reason that restrictions under section 505 could not be effective. The Sponsor’s bias in favor of Mifeprex clouds its analysis of the inherent hazards of the Regimen. In fact, the Sponsor refused to participate in devising restrictions that were designed to protect Mifeprex patients.

As “evidence” of its cooperation, the Sponsor pointed to the restricted distribution plan it proposed to an FDA advisory committee in 1996. The FDA Advisory Committee’s reaction to

---


6 21 C.F.R. § 314.520.


8 Subpart H Final Rule, 57 Fed. Reg. at 58951, § 20. See also New Drug, Antibiotic, and Biological Product Regulations; Accelerated Approval, Proposed Rule, 57 Fed. Reg. 13234, 13237, sec. III.B.3. (April 15, 1992) (“Subpart H Proposed Rule”) (noting that without Subpart H restrictions, the drug “would be adulterated under section 501 of the act, misbranded under section 502 of the act, or not shown to be safe under section 505 of the act”).

9 See Subpart H Final Rule, 57 Fed. Reg. at 58952, § 23 (“The postmarketing restrictions set forth in the proposal and in this final rule are intended to enhance the safety of a drug whose risks would outweigh its benefits in the absence of the restriction.”).

10 FDA explained that “rather than interfering with physician or pharmacy practice, the regulations permit, in exceptional cases, approval of drugs with restrictions so that the drugs may be available for prescribing or dispensing.” Subpart H Final Rule, 57 Fed. Reg. at 58951-52, § 20.

11 See Opposition Comments at 5-6.

12 See Opposition Comments at 4. The Sponsor was referring to a plan presented to FDA’s Reproductive Health Drugs Advisory Committee (“FDA Advisory Committee”). See FDA Advisory Committee, Hearings on New Drug Application for the Use of Mifepristone for Interruption of Early Pregnancy, at 7 (July 19, 1996) (FDA Hearings Transcript) [FDA FOIA Release: MIF 005200-90, MIF 005209]. The Petitioners will, at times, cite to documents.
the proposal, however, reveals its inadequacy; the Advisory Committee stated that “[w]e agree in concept with the proposal but have serious reservations on how it is currently described in terms of assuring safe and adequate credentialing of providers.” The Sponsor also cited to its “comprehensive distribution plan” submitted in January 2000 and to its revised distribution plan submitted to FDA in March 2000. The Sponsor indicated in its January 2000 submission that it was providing the proposal only “in light of the unique situation surrounding abortion provision in the United States and not out of any medical safety concerns,” and the March 2000 submission was prefaced with a denial that mifepristone was “a highly toxic and risky drug.” However, as the Petition explained, the plans that the Sponsor submitted on both occasions were not designed with the safety of the patient in mind and when FDA proposed a set of restrictions that focused on patient safety, the Sponsor balked. Further, even if the Sponsor had participated willingly in drawing up restrictions that embodied key safeguards for patients, FDA could not necessarily expect similar cooperation from future generic producers of mifepristone.

Conclusion

As explained above, the Mifeprex approval cannot rest independently on Section 505(d) of the FD&C Act. The Sponsor refused to acknowledge that there are serious risks associated with the Mifeprex Regimen, let alone to propose restrictions designed to counteract those risks. FDA approved Mifeprex under Subpart H in order to impose mandatory safety restrictions on the distribution and use of the drug. That being said, the proper course would have been for FDA to have rejected the NDA because Mifeprex is unsafe and ineffective under Section 505 and fails to satisfy the Subpart H prerequisites that it treat a serious or life-threatening illness and provide a meaningful therapeutic benefit above existing treatments.
B. The Mifeprex Clinical Trials Were Legally and Clinically Insufficient.

The Petition describes numerous problems that plagued the clinical trials underlying the approval of Mifeprex. The Sponsor’s Opposition Comments, rather than demonstrating the sufficiency of the clinical trial data that formed the basis for the Mifeprex NDA, heightened the Petitioners’ concerns about the legal and clinical sufficiency of the French and U.S. Clinical Trials (collectively, “Mifeprex Trials”). First, a close reading of the Sponsor’s Opposition Comments reveals that the Mifeprex Trials were not historically controlled but, rather, were uncontrolled. Second, even if the Mifeprex trials were historically controlled, as the Sponsor maintains, the use of historically controlled trials to support this NDA violated clearly established FDA rules and agency policies. Finally, the Sponsor’s additional arguments in support of the scientific adequacy of the Mifeprex trials do not answer the objections presented in the Petition. Untested by adequate clinical trials, the Mifeprex Regimen cannot be deemed to be safe and effective; accordingly, the marketing of Mifeprex must be halted.

1. The Mifeprex Trials Were Uncontrolled.

A review of the record regarding the scope and methodology of the trials, prompted by the Sponsor’s defense of the Mifeprex Trials, reveals that the trials used to support the Mifeprex NDA were not historically controlled, but were uncontrolled. The Petition cited to the discussion between a member of FDA’s Advisory Committee and an FDA official in which the Mifeprex Trials were characterized as “historically” controlled. The Petitioners noted, however, that the Mifeprex Trials appeared to have been uncontrolled.

The French Clinical Trials consisted of two studies in which all participants were given a mifepristone-misoprostol regimen, and no concurrent control group underwent a different abortion treatment. The Sponsor did not describe any historical (or “external”) control group.

20 Because the Mifeprex Regimen was the first drug regimen that FDA approved to induce abortions, in order to scientifically demonstrate the safety and effectiveness of this drug regimen, the Sponsor should have compared this new drug regimen to surgical abortions performed during the first 49 days after a woman’s last menstrual period.

21 The Petitioners believe that a longitudinal analysis of all past occasions on which FDA accepted uncontrolled and historically controlled trials as an adequate basis for an NDA and all past occasions on which it has rejected the use of uncontrolled or historically controlled clinical trials would demonstrate the inadequacy of the clinical trials underlying this NDA. FDA is uniquely qualified to perform such an analysis.

22 See Opposition Comments at 6-9.

23 One consequence of the failure to conduct properly controlled trials is that a statistical evaluation of effectiveness could not be made. As FDA’s statistical reviewer noted, with reference to the French trials: “[i]n the absence of a concurrent control group in each of these studies, it is a matter of clinical judgment whether or not the sponsor’s proposed therapeutic regimen is a viable alternative to uterine aspiration for the termination of pregnancy.” See FDA, Statistical Review and Evaluation (May 21, 1996): at 7-8.

24 Petition at 36, n.168 (referring to statements by Dr. Cassandra Henderson, a member of the FDA Advisory Committee, and FDA’s Dr. Ridgely C. Bennett at the Advisory Committee Hearings).

25 Petition at 35.

26 Letter, C. Wayne Bardin, Population Council, to FDA/CDER (June 5, 1995) (Submission Serial Number: 131) at 3-4 (“Bardin Letter”).[FDA FOIA Release: MIF 004746-47]. The patients in the French Clinical Trials took 600 mg of mifepristone followed by 400 µg of misoprostol. In one of the French Clinical Trials, some patients received an
nor did the Sponsor indicate that any of the well-established scientific guidelines for selecting a proper control group before commencing a historically controlled study were used for the French Clinical Trials. The Sponsor, nevertheless, informed FDA that “[a]ll studies conducted with mifepristone in the induction of abortion can be regarded as having historical controls which consist of the body of information available on abortion using surgical procedures.”

This observation appears to be the only basis for the Sponsor’s claim that the French Clinical Trials were historically controlled, and it is inadequate.

The U.S. Clinical Trial mimicked the design of the French Clinical Trials. All participants were given a mifepristone-misoprostol regimen, and no concurrent control group underwent a different abortion treatment. Descriptions of the U.S. Clinical Trial do not mention a control group, historical or otherwise, or the procedures according to which a control group was selected. The absence of any reference to a control group suggests that the U.S. Clinical Trial was not historically (externally) controlled.

The Sponsor’s failure to precisely identify a historical control group is fatal to its claim that the Mifeprex Trials were historically controlled. Postulating the existence of some generic, extra 200 µg of misoprostol if the first 400 µg was not sufficient to complete the abortion. The approved Mifeprex Regimen consists of 600 mg of mifepristone followed by 400 µg of misoprostol.

A control group should be chosen for which there is detailed information, including, where pertinent, individual patient data regarding demographics, baseline status, concomitant therapy, and course on study. The control patients should be as similar as possible to the population expected to receive the test drug in the study and should have been treated in a similar setting and in a similar manner, except with respect to the study therapy. Study observations should use timing and methodology similar to those used in the control patients. To reduce selection bias, selection of the control group should be made before performing comparative analyses; this may not always be feasible, as outcomes from these control groups may have been published. Any matching on selection criteria or adjustments made to account for population differences should be specified prior to selection of the control group and performance of the study.”


30 See, e.g., Spitz Article.

31 The Spitz Article does compare two groups, patients who are differentiated by the age of their pregnancies, but a comparison of that type does not generate data about whether mifepristone-misoprostol abortions are safe and effective. To the extent the Sponsor believed that a correlation existed between the age of the pregnancy and the safety and efficacy of mifepristone-misoprostol abortions, any historical control group that the Sponsor used should have been classified by, among other characteristics, gestational age.
undefined comparison group based on the literature about surgical abortion does not suffice. In sum, the Mifeprex Trials were uncontrolled and cannot support the Mifeprex NDA.

2. **Mifeprex Is Not a Drug for Which Historically Controlled Trials Were Appropriate.**

Assuming arguendo, as the Sponsor maintains, that the Mifeprex Trials were historically controlled, they were nevertheless not *adequately* controlled and did not provide an adequate basis for approving the Mifeprex NDA. In its Opposition Comments, the Sponsor erroneously suggested that “historically controlled” trials yield data of the same quality as data generated in concurrently controlled trials. In fact, the scientific community (and FDA specifically) regard historically controlled studies to be little better than uncontrolled studies and, therefore, generally disfavor their use with a few well-defined exceptions.

Mifepristone-misoprostol abortions do not fall within any of those exceptions. The Rochester Glossary states that historical controls are “mainly used in the study of rare diseases” in which sample size would not be sufficient to support a randomized clinical trial. This exception is inapplicable because the number of pregnant women seeking to terminate their pregnancies is large enough to support randomized, concurrently controlled trials. Section 314.126(b)(2)(v) of FDA’s rules cautions that the use of historical controls is “usually reserved

---

33 In addition, the Sponsor, in its Opposition Comments, invented a historical control group *ex post facto* by comparing the rate of spontaneous abortions in the general population of pregnant women with the rate of abortions in patients who underwent a mifepristone-misoprostol regimen during the Mifeprex Trials. See Opposition Comments at 6-7 (“In these major studies, 92-95% of the 2508 women evaluated for efficacy had complete abortions … . By comparison, the rate of spontaneous abortion in the first trimester is assumed to be about 10%.”). Using the general population as a historical control group and retrospectively assuming a rate of spontaneous abortion in this group is not a scientifically acceptable approach to identifying a control group, particularly when, as here, an established surgical treatment group could have been used as the control group.

34 Section 314.126(e) of FDA’s rules states that “[u]ncontrolled studies or partially controlled studies are *not* acceptable as the sole basis for the approval of claims of effectiveness.” 21 C.F.R. § 314.126. A publicly available FDA staff presentation about clinical trials illustrates this point. The presentation explained, under the heading “Phase 3 – Comparative trial to evaluate drug,” “Comparator group important – Standard of care, placebo, never nothing in serious or life-threatening diseases (ICH E3, E9, E10).” See Peter A. Lachenbruch, “Some Things You Always Wanted to Know about Clinical Trials but Were Afraid to Ask,” Slide Presentation for CBER 101: An Introduction to the Center for Biologics Evaluation and Research (CBER) (March 24-26, 2003): at 5 (emphasis in original) (available at: http://www.fda.gov/cber/summaries/cber101032403pl.pdf).

35 See Opposition Comments at 6-8.

36 For example, the Research Subjects Review Board of the University of Rochester Medical Center authored a guidance document, which states that “[h]istorical controls are considered to be the least reliable because they compare results obtained in another time, in another place and by another investigator.” University of Rochester Medical Center, Research Subjects Review Board, “Glossary of Research Terms,” at 2 (“Rochester Glossary”) (available at: http://www.urmc.rochester.edu/rrsb/pdf/glossary.pdf). Similarly FDA has explained, “[t]he limitations of historical controls are well known (difficulty of assuring comparability of treated groups, inability to blind investigators to treatment, etc.) and deserve particular attention.” FDA/CDER, Guideline for the Format and Content of the Clinical and Statistical Sections of an Application (July 1988): at 54.

37 Rochester Glossary at 2 (“Historical controls are mainly used in the study of rare diseases where the *n* is not sufficient for a randomized clinical trial.”).
for special circumstances” and cites “studies of diseases with high and predictable mortality (for example, certain malignancies) and studies in which the effect of the drug is self-evident (general anesthetics, drug metabolism).” Mifepristone-misoprostol abortions do not fit within either of these categories. First, the Regimen does not treat a condition with “high and predictable mortality.” Second, the effects of the Regimen are not “self-evident” as in the case of general anesthetics. The Sponsor’s discussion of the adequacy of its trial data reflects the Sponsor’s fundamental misconception that there are only two possible outcomes of the Mifeprex Regimen, both of which are self-evident: regimen failure (failed abortion) and regimen success (death and complete expulsion of the fetus). The Sponsor’s focus on this dyadic set of possibilities (failure (0) or success (1)) obscures a whole range of less easily measurable, but critically important, outcomes. Such outcomes include tissue retention, life-threatening hemorrhaging, persistent bleeding, infection, teratogenicity, pain, continued fertility, and psychological effects.

The Sponsor’s reliance on FDA Guidance, ICH: E10, is also misplaced. Although ICH: E10 includes a discussion of situations in which externally controlled trials may be used, it also warns of their inherently problematic nature. The Sponsor’s reliance on the acknowledgement in ICH: E10 that historical controls are appropriate in some circumstances is misplaced. ICH: E10 explains:

An externally controlled trial should generally be considered only when prior belief in the superiority of the test therapy to all available alternatives is so strong that alternative designs appear unacceptable and the disease or condition to be treated has a well-documented, highly predictable course. It is often possible, even in these cases, to use alternative, randomized, concurrently controlled designs (see section 2.1.5).

38 21 C.F.R. § 314.126(b)(2)(v) provides:

Historical control. The results of treatment with the test drug are compared with experience historically derived from the adequately documented natural history of the disease or condition, or from the results of active treatment, in comparable patients or populations. Because historical control populations usually cannot be as well assessed with respect to pertinent variables as can concurrent control populations, historical control designs are usually reserved for special circumstances. Examples include studies of diseases with high and predictable mortality (for example, certain malignancies) and studies in which the effect of the drug is self-evident (general anesthetics, drug metabolism).

39 Opposition Comments at 7.

40 See ICH: E10 at 29 (§ 2.5.7) (“The externally controlled study cannot be blinded and is subject to patient, observer, and analyst bias; these are major disadvantages. It is possible to mitigate these problems to a degree, but even the steps suggested in section 2.5.2 cannot resolve such problems fully, as treatment assignment is not randomized and comparability of control and treatment groups at the start of treatment, and comparability of treatment of patients during the trial, cannot be ensured or well assessed. It is well documented that externally controlled trials tend to overestimate efficacy of test therapies. It should be recognized that tests of statistical significance carried out in such studies are less reliable than in randomized trials.”). See also Henry Sacks, Ph.D., M.D., Thomas C. Chalmers, M.D., Harry Smith, Jr., Ph.D., “Randomized Versus Historical Controls for Clinical Trials,” The American Journal of Medicine 72 (Feb. 1982): 233-240, 233 (“The data suggest that biases in patient selection may irretrievably weight the outcome of [historical controls] in favor of new therapies.”).

41 ICH: E10 at 28 (§ 2.5.4).
Even proponents of mifepristone-misoprostol abortions would not argue that such abortions are superior to alternative methods of abortion. In fact, the Mifeprex Regimen has been shown to be an inferior method of abortion. Absent a clear belief in the Regimen’s superiority, concurrently controlled trials should have been performed. Furthermore, pregnancies often do not follow a “well-documented, highly predictable course.” Mifepristone-misoprostol abortions do not satisfy either prong of the ICH: E10 prerequisite for the use of historically controlled studies.

3. The Mifeprex Clinical Trials Did Not Establish a “Meaningful and Therapeutic Benefit” As Required By Subpart H.

Drugs, like Mifeprex, approved pursuant to Section 314.520 (Subpart H) of the Agency’s rules, must provide a “meaningful therapeutic benefit to patients over existing treatments.” Subpart H drugs “will have had effectiveness demonstrated on the basis of adequate and well-controlled studies.” The Sponsor argued that “meaningful therapeutic benefit” does not impose design features for the clinical trials required to support an NDA approved pursuant to Subpart H. The Sponsor’s position is inconsistent with the plain meaning of the rule. Subpart H is reserved for drugs that have a higher risk profile than drugs approved through standard FDA processes. A meaningful therapeutic benefit over available therapies justifies the heightened risks, and only well-controlled clinical trials can demonstrate that such a benefit exists.

---

42 See, e.g., Richard Hausknecht, M.D., “Mifepristone and Misoprostol for Early Medical Abortion: 18 Months Experience in the United States,” Contraception 67 (2003): 463-65, 465 (“Hausknecht Article”) (“Which approach to early abortion, medical or surgical, is safer remains unknown but it does appear that medical abortion is as safe as early surgical abortion. There are no recent data on failed surgical abortions but the failure rate of mifepristone/misoprostol medical abortions is higher than that reported decades ago for suction curettage.”)


44 The Petitioners believe that trials comparing mifepristone-misoprostol abortion with the surgical alternative were not conducted for precisely this reason (i.e., such trials would have demonstrated that mifepristone-misoprostol abortions were inferior). Because of its inferiority, the Mifeprex Regimen is contraindicated.

45 Even though pregnancy occurs regularly, complications arise during pregnancy on a frequent basis (e.g., approximately 2% of pregnancies are ectopic and others involve such complications as high blood pressure, ruptured placenta, infection, cysts, abnormal pain, anemia, and fetal malposition).

46 Even if mifepristone-misoprostol abortion were deemed to be an acceptable candidate for historically-controlled testing, the Sponsor should have attempted to devise concurrently controlled trials anyway. ICH: E10 states that even when historically controlled testing may be appropriate, “[i]t is often possible … to use alternative, randomized, concurrently controlled designs.” ICH: E10 at 28 (§ 2.5.4).

47 21 C.F.R. § 314.520.


50 Opposition Comments at 8.

51 The Sponsor also argued that by the time FDA decided to approve Mifeprex using Subpart H, the Sponsor had completed the Mifeprex Trials and that FDA could not have required the Sponsor to modify the trial design and perform new trials for Subpart H purposes. See Opposition Comments at 9, n. 4. FDA is under no obligation to
The Sponsor argued that two of the examples of “meaningful therapeutic benefit” listed in Section 314.500 (“ability to treat patients unresponsive to, or intolerant of, available therapy”) present situations in which comparative trials with the existing therapy are not feasible. Yet, sponsors who intend their drugs to treat unresponsive or intolerant patients are not exempt from the requirement to conduct “well-controlled” trials. In fact, Subpart H trials are routinely designed to compare, in unresponsive or intolerant patients, the safety and effectiveness of the new therapy with either the standard of care or a placebo.

The Sponsor further claimed that FDA “routinely approves Subpart H drugs on the basis of study designs that do not compare the Subpart H drug directly to existing therapy.” In support of this claim, the Sponsor offered one example, the Subpart H approval of the leprosy drug, Thalomid (thalidomide). That example is inapposite because the Thalomid NDA was supported by three controlled trials despite the existence of factors that might have supported an exemption from the standard trial requirements. In one of the three underlying trials, thalidomide plus the standard treatment was compared against the standard treatment alone plus a placebo. This study design allowed for a meaningful statistical analysis of the effectiveness of this drug in comparison with the current available standard of care – in direct contrast to the faulty study designs and minimal statistical analysis associated with the Mifeprex NDA.

Conclusion

By statute and agency regulation, drug applications must be supported by adequate and well-controlled studies. The failure of the Sponsor to offer legally and scientifically sufficient trial data should have been fatal to its NDA and now requires withdrawal of that approval.
C. The Inclusion of Misoprostol in the Mifeprex Regimen Was Unlawful.

The Mifeprex Regimen combines the use of mifepristone and a second drug, misoprostol (Cytotec™). Although FDA never approved misoprostol as a stand-alone abortifacient, it approved misoprostol for use as an abortifacient in combination with mifepristone and mandated this use in the Mifeprex Package Insert. As explained in the Petition, FDA effectively sanctioned the use and promotion of misoprostol for an unapproved indication.69 The promotion of an unapproved use contradicts the FD&C Act, which takes the position that “a drug manufacturer may not promote [its] product for any use other than the ones for which the company received FDA approval.”60

In its Comment, the Sponsor defended the de facto approval of misoprostol for a new indication as an abortifacient and asserted that “FDA routinely approves drugs for use in combination with previously approved drugs without requiring any change in the labeling of the previously approved drug.”61 The Sponsor denied that this practice “puts either FDA or the sponsor of the later-approved drug in the position of ‘promoting’ off-label use of the previously approved drug.”62 The Sponsor offered four examples to support its position that this practice is not uncommon.63

In fact, the Sponsor’s four examples support the position set forth in the Petition that subsequently approved drugs (Drug Bs – like Mifeprex) may reference previously approved drugs (Drug As – like misoprostol) on Drug B’s labeling only for FDA-approved indications.64

59 See Petition at 41-48. The drug’s manufacturer, G.D. Searle & Co. (“Searle”), did not file a supplemental NDA to obtain approval for misoprostol’s use as an abortifacient. Searle has subsequently been purchased, most recently, by Pfizer. See Petition at 42, n.188.


61 Opposition Comments at 9.

62 Opposition Comments at 10.

63 Opposition Comments at 9-10.

64 The first example offered by the Sponsor is the approval by FDA on September 10, 2001 of the combination of Xeloda (capecitabine) and Taxotere (docetaxel) for treating patients with metastatic breast cancer that has progressed after treatment with an anthracycline-containing cancer therapy. FDA initially approved Xeloda, an oral therapy, for the treatment of breast cancer on April 30, 1998, and FDA approved Taxotere, an intravenous product, for the treatment of advanced breast cancer on May 15, 1998. See FDA Press Release, “FDA Approves Xeloda in Combination with Taxotere for Advanced Breast Cancer” (Sept. 10, 2001) (available at: <http://www.fda.gov/bbs/topics/ANSWERS/2001/ANS01101.html>). Thus, when Xeloda and Taxotere are used together, each is being used for an FDA-approved use.

The Sponsor’s second example is FDA’s approval on July 15, 1999 of Actos to improve glycemic control in patients with Type 2 diabetes. Actos is indicated as a monotherapy and for use in combination with a sulfonylurea, metformin, or insulin “when diet and the single agent does not result in adequate glycemic control.” Letter, FDA/CDER to Mikihiko Obayashi, President, Takeda America Research & Development Center, Inc. (July 15, 1999). When used alone or together to treat Type-2 diabetes, each drug is being used for one of its FDA-approved indications.
Each example describes drug products that are being used in combination to treat indications approved for the single drugs at issue.

Upon close examination, the Sponsor’s four examples underscore the fact that FDA’s approval of mifepristone for use in combination with misoprostol, a drug never approved as an abortifacient, constitutes a significant departure from FDA precedents. As Professor Richard Merrill explained, “[i]n FDA’s view, to promote any use of [its] new drug, the manufacturer must have agency approval – allowing that use to be included in the official labeling.”\(^65\) The approval in this instance struck at the heart of FDA’s long-held policy that in order for a new drug use to be promoted, the drug’s sponsor must submit an application seeking to demonstrate the safety and effectiveness of that new use.\(^66\) It defies logic to imagine that Danco could be allowed to do with misoprostol what Searle could not do with its own drug – that is, promote an unapproved use of misoprostol. Yet, that activity is exactly what FDA permitted in Mifeprex’s case. FDA’s regulatory framework would be rendered toothless if third parties were permitted to behave in this manner.

In fact, Searle, which held the patent for misoprostol,\(^67\) apparently objected to adding an indication for abortion to the Cytotec label. Searle’s objections were overridden because only the combined regimen was effective. As the Sponsor explained, “[t]he fact is that mifepristone used as contemplated in 1983 was a failed drug – it was not sufficiently efficacious to have ever been approved.”\(^68\) Perhaps to avoid having to obtain Searle’s cooperation, in an unprecedented

The Sponsor’s third example is FDA’s approval on October 26, 2001 of Viread (tenofovir disoproxil fumarate), a nucleotide reverse transcriptase inhibitor of HIV, for combined use with other antiretroviral agents for the treatment of HIV-1 infection in adults. The antiretroviral agents with which Viread is to be used have separately been approved for the treatment of HIV. Letter, FDA/CDER to Rebecca Coleman, Gilead Sciences, Inc. (Oct. 26, 2001) (NDA 21-356). The fact that Viread was not approved for use as a monotherapy in the treatment of HIV does not alter the analysis, but rather makes it a useful comparison for mifepristone, which has been approved as an abortifacient only in conjunction with misoprostol. Thus, when used together, each drug is being used for one of its FDA-approved indications.

The Sponsor offers as its fourth example FDA’s approval of Nexium (esomeprazole magnesium) on February 20, 2001 for the treatment of erosive esophagitis and other symptoms associated with GERD (Gastroesophageal Reflux Disease). Letter, FDA/CDER to Kathryn D. Kross, AstraZeneca, LP (Feb. 20, 2001) (NDA 21-153; NDA 21-154). For one of its approved indications, \(H. pylori\) eradication, Nexium is used in combination with amoxicillin and clarithromycin, both of which have been approved for treating \(H. pylori\). Thus, when they are used in combination with Nexium, each drug is simply being used for one of its approved indications.

\(^{65}\) Richard A. Merrill, “The Architecture of Government Regulation of Medical Products,” Univ. of Virginia Law Review 82 (1996): 1753-1866, at 1766, n.40. As noted in the Petition, former FDA general counsel, Peter Barton Hutt, observed that FDA’s actions with respect to misoprostol “set[] an extraordinary precedent” because FDA was “seemingly encouraging a drug’s unapproved use.” See Petition at 42-43 (Hutt’s quotation was reported in Rachel Zimmerman, “Clash Between Pharmacia and FDA May Hinder the Use of RU-486,” Wall Street Journal (Oct. 18, 2000): at B1).

\(^{66}\) A drug may be deemed “new” because of “[t]he newness of use of such drug in diagnosing, curing, mitigating, treating, or preventing a disease, or to affect a structure or function of the body, even though such drug is not a new drug when used in another disease or to affect another structure or function of the body.” 21 C.F.R. § 310.3(h)(4).

\(^{67}\) The patent for misoprostol has since expired, but at the time the Mifeprex Regimen was approved, Searle held exclusive rights to that patent.

\(^{68}\) Population Council Response to the Request for Revision of the Regulatory Review Period Determination for MIFEPREX® Submitted by Corcept Therapeutics Inc., Docket No. 01E-0363 (July 2, 2002): at 3 (“Sponsor’s
“joint decision” in July 1994, FDA and the Sponsor “determined that the NDA need not cover misoprostol as well as mifepristone.” The Sponsor subsequently explained, however, that “there can be no doubt that the approved human drug product contemplates both mifepristone and misoprostol, as shown in the approved labeling,” which “specifically states that administration of mifepristone must be followed by administration of misoprostol.” The Sponsor added that “FDA has made clear on numerous occasions, FDA review of an NDA is ‘inextricably intertwined’ with the proposed labeling for the product.” In so stating, the Sponsor speaks out of both sides of its mouth – acknowledging that combined use with misoprostol is necessary for Mifeprex’s effectiveness and labeling, but “agreeing” with FDA that a corresponding misoprostol approval is not necessary.

Conclusion

In summary, the inclusion of misoprostol in the Mifeprex Regimen, outside of the NDA approval process for misoprostol, was unlawful. In order to reverse the extraregulatory approval of misoprostol as an abortifacient, FDA must withdraw its approval of the Mifeprex NDA.

D. Mifeprex-Misoprostol Abortions Are Not Safe.

The Sponsor continued in its Opposition Comments to defend the safety of Mifeprex, but has not allayed the concerns set forth in the Petition. Rather than address the scientific and medical issues raised in the Petition, the Sponsor has mischaracterized them. As discussed above, the trials submitted by the Sponsor to support its NDA did not establish the safety of mifepristone-misoprostol abortions, and post-approval data on the Regimen have done no better - serving only to raise the Petitioners’ concerns about the safety of the Mifeprex Regimen.

1. FDA Determined that Mifeprex Would Be Unsafe without Restrictions.

FDA approved mifepristone under the restricted distribution prong of Subpart H, which FDA reserves for drugs that “can be used safely only if distribution or use is modified or restricted.” Accordingly, the Mifeprex Regimen includes a number of restrictions.

Response to Corcept”). In this document, the Sponsor responded to Corcept’s June 10, 2002 request that FDA consider 1983 rather than August, 4, 1994 as the starting date for the regulatory review of the Mifeprex investigational new drug application (“IND”). The Sponsor sought to convince FDA that the appropriate period for determining patent length began on August 4, 1994, the date of the IND that allowed for the investigation of mifepristone plus misoprostol to induce abortions. The Sponsor did not obtain the patent extension that it sought. The initial ruling in the Population Council’s favor was reversed by FDA. See Note, Determination of Regulatory Review Period for Purposes of Patent Extension; Mifeprex; Amendment, 67 Fed. Reg. 65358 (Oct. 24, 2002).

69 Sponsor’s Response to Corcept at 2.
70 Sponsor’s Response to Corcept at 3.
71 Sponsor’s Response to Corcept at 2.
72 Sponsor’s Response to Corcept at 2-3 (citation omitted).
73 See Opposition Comments at 10-14.
Petition explained, however, these restrictions were inadequate to make the drug safe.\textsuperscript{76} Moreover, the Sponsor never acknowledged the inherent dangers posed by the approved Mifeprex Regimen, balked at implementing distribution restrictions, and dismissed out of hand the challenges about the adequacy of the restrictions to reduce the dangers of the Mifeprex Regimen.\textsuperscript{77} Now that it has FDA’s imprimatur to market the drug, the Sponsor takes minimal, if any, actions to carry out the required restrictions.\textsuperscript{78}

Additionally, FDA’s final decision to omit key restrictions from the approved Regimen has subjected patients who use the Mifeprex Regimen to unnecessary risks. A pre-procedure ultrasound, for example, is necessary to evaluate the gestational age because the Mifeprex Regimen has been shown to be less effective and riskier to the patient as gestational age increases.\textsuperscript{79} Ultrasound is also necessary to identify women whose pregnancies are ectopic and who should not undergo the Mifeprex Regimen.\textsuperscript{80} Further, because complications and failures are common and predictable and can seriously endanger the health of the patient, FDA should

\textsuperscript{75} For a list of the restrictions, see Letter, FDA/CDER to Sandra P. Arnold, Population Council (Sept. 28, 2000): at 2 (“Mifeprex Approval Letter”). The Sponsor contends in its Opposition Comments that it cooperated with FDA by proposing restrictions. See Opposition Comments at 10-11. This contention reflects the Sponsor’s failure to distinguish between restrictions on the distribution of a drug to prescribing physicians and restrictions designed to ensure patient safety. Furthermore, contrary to the Sponsor’s suggestion that decisions about the restrictions in the Mifeprex Regimen were the product of “discussion, negotiation, give and take, debate, even on occasion disputes, between FDA and the Sponsors [that] is characteristic of the review process for many drugs” (Opposition Comments at 11), the Sponsor went to great lengths to avoid including safety restrictions in the Mifeprex Regimen. In fact, after the Sponsor failed to suggest appropriate restrictions to protect Mifeprex patients, FDA proposed its own set of restrictions. Then, the Sponsor complained publicly about the allegedly onerous restrictions. FDA relented and inappropriately eliminated a number of key restrictions. See Petition at 49-57 for a discussion of the development of and the Sponsor’s opposition to safety restrictions.

\textsuperscript{76} See Petition at 57-65.

\textsuperscript{77} See Opposition Comments at 10. The Petition did not assert that the approved regimen must exactly follow the regimen employed during the trials. Nevertheless, if trials include important safeguards that are omitted from the approved regimen, then the relevance of the data generated by those trials is undermined. For this reason, a trial should be designed to reflect the anticipated conditions under which a drug will be used. See Petition at 75-76. For example, had the Sponsor designed the trial to reflect anticipated conditions of use, misoprostol probably would have been administered vaginally during the trials, which appears to be the standard method of administration now that the Mifeprex Regimen is approved. Had the trial protocol called for vaginal administration, it would have drawn attention to the unlawful inclusion of misoprostol in the Regimen because misoprostol is approved only for oral use. As FDA has explained, “[i]n order to change or add a new dosing regimen to the labeling, the sponsor must submit data to FDA from clinical trials that show the new regimen is safe and effective.” See FDA, “Mifepristone Questions and Answers 4/17/2002” (“FDA Q & As”) at Question 9 (“Why are physicians using misoprostol ‘off-label,’ in other words, using misoprostol virginaly at different doses?”) (available at: <http://www.fda.gov/cder/drug/infopage/mifepristone/mifepristone-qa_4_17_02.htm>).

\textsuperscript{78} See Section I.D.3, herein.

\textsuperscript{79} See Spitz Article at 1241 (“Results”).

\textsuperscript{80} The Sponsor’s Opposition Comments addressed the use of ultrasound only for the purpose of dating pregnancies. As explained in the Petition, ectopic pregnancies cannot be treated by the Mifeprex Regimen and the symptoms of ectopic pregnancy are likely to be mistaken as the normal effects of undergoing a Mifeprex abortion. For a more complete discussion of the necessity of using ultrasound to identify ectopic pregnancies, see Petition at 60-61.
have required prescribing physicians to be trained in mifepristone-misoprostol administration and surgical abortions and to have admitting privileges at a nearby emergency facility.  

FDA determined that Subpart H restrictions were necessary because, without them, mifepristone-misoprostol abortions were not safe. Thus, the Petitioners’ concerns with the Regimen’s safety rest on the belief that the weakness of the Regimen’s restrictions is inconsistent with FDA’s decision to approve the drug under Subpart H.

2. Post-approval Evidence Confirms that the Approved Distribution Restrictions Were Insufficient to Adequately Protect Patients.

The Sponsor’s analysis inaccurately characterized the post-approval experience with the Mifeprex Regimen. A number of life-threatening adverse events experienced by Mifeprex patients caused FDA to work with the Sponsor to issue a letter to health care providers. The

81 In fact, FDA proposed to include such restrictions in the Mifeprex Regimen. The set of restrictions proposed by FDA on June 1, 2000, would have required physicians prescribing Mifeprex to be “trained and authorized by law” to perform surgical abortions, to be trained in administering the Mifeprex Regimen and handling resulting adverse events, and to have “continuing access (e.g., admitting privileges) to a medical facility equipped for instrumental pregnancy termination, resuscitation procedures, and blood transfusion at the facility or [one hour’s] drive from the treatment facility.” See FDA, “FDA Proposed Restricted Distribution System for NDA 20-687 on 6/1/00” (June 1, 2000) [FDA FOIA Release: MIF 000522]. See also American College of Obstetricians and Gynecologists, “Analysis of the Possible FDA Mifepristone Restrictions” (July 27, 2000): at 1 (setting forth FDA’s second proposed restriction, which is redacted in the publicly available copy of FDA’s proposal; also providing the redacted portion of the fifth restriction)[FDA FOIA Release: MIF 001366-69].

82 Opposition Comments at 10, 13-14. The Sponsor pointed to a recent article authored by the medical director of Danco, Dr. Richard Hausknecht, as evidence that Mifeprex is safe. See Opposition Comments at 10 (citing Hausknecht Article); regarding Dr. Hausknecht, see also Petition at 71, n.309. Unfortunately, the article, which reports on the drug’s use in the United States since approval, relies on data that are incomplete and of questionable quality. First, reliable data as to the number of patients who have undergone the Mifeprex Regimen is not available. Dr. Hausknecht used a figure of 80,000, which was derived from “sales figures [for Mifeprex] and known patterns of mifepristone utilization.” Hausknecht Article at 464. This number may be too high as it may not take into account drugs that were ordered but not used. Second, the number of adverse events reported is likely to be significantly underestimated. Abortion clinics, which (according to Dr. Hausknecht’s estimates) carried out approximately 90% of Mifeprex abortions, may have a disincentive to report adverse events from a procedure that they promote and may be less likely than physicians in private practice to report adverse events. In addition, it is likely that many patients were lost to follow up. In the U.S. Clinical Trial, 106 of the 2,121 patients (or nearly 5%) did not return for their third required visit. A higher “lost to follow up” number is to be expected outside of the clinical setting. Finally, the article’s descriptions of the adverse events that were reported generally appear to be incomplete and tend to downplay any possible connection with the Mifeprex Regimen. For example, the article explained that a twenty-one year old woman had suffered a coronary artery occlusion five days after she received misoprostol. See Hausknecht Article at 464, col. 2. The article provided few details about her Mifeprex abortion and pointed to her “strong family history of heart disease” without also mentioning that there are no data on the safety of the Mifeprex Regimen in women with cardiac problems and these women were excluded from the Clinical Trials. In sum, an objective assessment of the safety and efficacy of mifepristone-misoprostol abortions would require a concurrently-controlled, randomized comparison of a mifepristone-misoprostol regimen reflecting actual conditions of use with surgical abortion. The Sponsor did not conduct or provide data from such trials in support of its application and Dr. Hausknecht’s article – a very general overview without the first-hand, patient-level detail necessary to scientifically assess the safety of the Mifeprex Regimen – does not fill this void.

Petition discussed these life-threatening adverse events which included ruptured ectopic pregnancies, serious systemic bacterial infections, and a coronary event. The Sponsor, in its Opposition Comments, insisted that “FDA has not found any causal connection” between the Mifeprex Regimen and these adverse events. However, the clear implication of the issuance of the Dear Doctor Letter and FDA’s accompanying “Questions and Answers” is that such a causal link does exist.

The serious adverse events reported to date are consistent with concerns about the drug regimen that were expressed prior to the approval. The recent death of Holly Patterson, an eighteen year old from Livermore, California, unfortunately epitomizes the concerns of the Petitioners. According to Ms. Patterson’s father, at the time of his daughter’s death, she was terminating her pregnancy with a Mifeprex Regimen prescribed by the Planned Parenthood in Hayward, California. Apparently, Ms. Patterson started the abortion procedure on Wednesday, September 10, 2003, by taking mifepristone tablets. On Saturday, September 13, 2003, she apparently took the misoprostol that the clinic had given her. By Sunday she was having such severe cramping and bleeding that her boyfriend took her to the emergency room. Ms. Patterson received pain killers and was sent home, but she continued to bleed severely and experienced acute pain that prevented her from walking. Early Wednesday, September 17, 2003, Ms. Patterson’s boyfriend took her back to the emergency room, where she died that afternoon.

According to Mr. Patterson, the doctor told him that his daughter “hadn’t aborted all the fetus, and she had fragments left in her, and she had a massive systemic infection and went into septic shock.” The results of the coroner’s investigation are not expected to be released for several months, but Ms. Patterson’s apparent death of a serious systemic bacterial infection is not the first such death since FDA approved Mifeprex. As noted above, the Dear Doctor Letter

---

84 See Petition at 65-71. As the number of mifepristone-misoprostol abortions rises, the number of serious adverse events associated with these abortions is likely to increase as well. Because the normal progression of the Mifeprex Regimen is characterized by prolonged bleeding, the patient bears the responsibility for determining how much bleeding is excessive and whether she needs to seek medical assistance. Health care providers who are not experienced providers of abortion, generally, or mifepristone-misoprostol abortions, specifically, may be poorly equipped to assist the patient in determining whether medical intervention is necessary, let alone to provide the needed medical intervention.

85 See Opposition Comments at 13.

86 See Americans United for Life et al., Citizen Petition (Feb. 28 1995) (requesting FDA’s consideration of a number of potential hazards of mifepristone-misoprostol abortions) [FDA FOIA Release: MIF 006144-6248].


88 Id. See also Julian Guthrie, Sabin Russell, and Katherine Seligman, “After Daughter’s Death, Father Wants Close Look at RU-486; Abortion Pill’s Safety Defended by Doctors as Better than Surgery,” San Francisco Chronicle (Sept. 20, 2003): at A17 (available at: http://www.sfgate.com/cgi-bin/article.cgi?file=chronicle/archive/2003/09/20/BA310011.DTL) (‘Patterson said the attending physician at Pleasanton’s Valley Care Medical Center told him his daughter had died of septic shock – a severe bacterial infection. ‘The doctor told me she had fragments of the fetus still left in her uterus and that caused the infection.’”).
reported “[t]wo cases of serious systemic bacterial infection (one fatal).”\textsuperscript{89} The presence of retained products of conception can lead to the development of intrauterine or systemic infection, and it is possible that mifepristone could potentiate this possibility via negative effects on immune system function or normal protective mechanisms.\textsuperscript{90}

In addition to questions about Mifeprex causation in this case, questions also have been raised about the role that Ms. Patterson or her local hospital emergency room may have played in contributing to her death.\textsuperscript{91} These questions cannot be answered without recognizing that patients and emergency room physicians may be unable to distinguish the normal progress of the Regimen from a life-threatening situation. Consequently, it is not at all clear that emergency rooms will be able to rescue dangerously ill Mifeprex patients from the peril in which they have been placed by the Regimen. Consider the plausible scenario described in the footnote below.\textsuperscript{92} The severity of the reported adverse events requires FDA action to remove Mifeprex from the market.

\textsuperscript{89} Dear Doctor Letter at 1. The fatality apparently precipitated a halt in the Population Council’s clinical trials of mifepristone in Canada.

\textsuperscript{90} Given the nature of the Mifeprex Regimen, the embryo or other products of conception will not be expelled from the uterus in a number of cases. It is well known that the presence of retained necrotic products of conception can lead to intrauterine and systemic infection. Furthermore, it is possible that mifepristone itself may alter the local immune response at the level of the endometrium or the cervix. There are numerous alterations of the immune system during pregnancy, and progesterone can affect immune system function. Therefore, it is plausible that a progesterone receptor antagonist like mifepristone could negatively affect the normal immune system within the uterus, or compromise antibacterial mechanisms of the cervix, making a woman more susceptible to infection. \textit{See}, \textit{e.g.}, World Health Organization (WHO), “Pregnancy Termination with Mifepristone and Gemeprost: A Multicenter Comparison between Repeated Doses and a Single Dose of Mifepristone;” 56 \textit{Fertility & Sterility} 32-40 (1991) (29.4% of patients with incomplete abortion compared with 2.6% of those with complete abortion received antibiotics during a six week follow-up period for suspected genitourinary infection; both groups combined accounted for 3.9% of the total study population).

\textsuperscript{91} \textit{See}, \textit{e.g.}, Gina Kolata, “Death at 18 Spurs Debate Over a Pill for Abortion,” \textit{New York Times} (Sept. 24, 2003): at A24 (“But it is unclear what happened to Holly Patterson. Did she have enough medical supervision while taking the pills? When did she seek medical attention? Did she wait until it was too late? Did she tell the doctors in the emergency room that she had taken mifepristone? Why, in fact, did she die?”).

\textsuperscript{92} A patient comes to the emergency room complaining of significant pelvic pain and cramps. She reports that she has taken Mifeprex and misoprostol for a medical abortion. At this time, she has no significant change in vital signs (\textit{i.e.}, no fever or very low grade fever – which can be related to misoprostol – and no significant tachycardia, etc.). The emergency room physician, knowing that this drug combination normally causes cramping at this stage in the process, assumes she has a personal low pain tolerance threshold, and, therefore, gives her pain medications to try to alleviate her discomfort until the abortion completes. However, the patient may be in the early stage of an intrauterine infection even though she is not yet manifesting other signs of that condition aside from pain and bleeding which are both part of the Mifeprex abortion process. At this stage, the emergency room physician has no good way to detect that an infection has begun. Furthermore, even if the emergency room physician found evidence of retained tissue in the uterus, the physician would not be surprised or alarmed by that discovery given the nature of mifepristone-misoprostol abortions. Unless the patient had significant hemorrhaging or evidence of infection, no intervention would be necessary or even warranted since one would presume that the abortion was going according to plan at that juncture (recall that bleeding can last up to several weeks duration). So to continue this hypothetical scenario, the patient goes home, and the infection subsequently becomes systemic. The patient goes into septic shock and is not able to be saved by the time she re-presents to the emergency room. It would not be surprising if Ms. Patterson’s death followed such a course given statements made to the press by her father. In this credible scenario the Mifeprex Regimen, after having placed her in great danger, effectively camouflaged the seriousness of her condition from the emergency room physician.
Furthermore, FDA cannot rely on the “spotty” reporting of adverse events for the Mifeprex Regimen. The usual flow of post-approval adverse event information will not be forthcoming for this drug. It is questionable whether individual lawful distributors of Mifeprex, who tend to be outside the mainstream pharmaceutical wholesale distribution industry, will routinely report adverse events to FDA.93 Also, because the drug is intended to be administered in physicians’ offices, a pharmacist is unlikely to dispense the product or hear of drug-drug and drug-food interactions, or other adverse events. Moreover, the types of facilities that provide medical and surgical abortions are often staffed with social-work counselors and health care workers who are not medical doctors and have limited medical training. As such, they may be unfamiliar with the adverse event reporting procedure for medical professionals (i.e., MedWatch).

Even for properly-licensed physicians, FDA’s MedWatch reporting is voluntary.94 Since privacy issues are often the primary concern of women who seek abortions, a physician may not file a MedWatch report in order to protect patient confidentiality. Accordingly, the Petitioners are concerned about the possibility that medical complications are not being reported. Finally, it is possible that other women who have suffered adverse events during a mifepristone-misoprostol abortion have sought assistance from crisis pregnancy centers, counselors, and charitable organizations,95 which may not be familiar with the MedWatch reporting system. Given the foregoing, the Petitioners believe that FDA’s continuing review of the safety profile of Mifeprex relies improperly on an incomplete database of post-approval adverse events.

3. The Sponsor Has Failed to Require Adherence to the Restrictions.

The Sponsor insisted that it “will continue, as [it] always intended, to honor [its] commitments to carry out the program of restrictions imposed in the approval letter.”96 Yet, the Sponsor has broken its promise. The Sponsor apparently has not taken steps to ensure that Miféprax is used in accordance with the approved Regimen and has continued to distribute the drug to providers that depart from the Mifeprex Regimen. For instance, the Sponsor has asserted, in its Opposition Comments, the erroneous position that the guidelines in the Prescriber’s Agreement “do not state any specific dose or regimen for prescribing Mifeprex …”97 The Sponsor’s statement reflects only one example of its continuing refusal to accept even FDA’s minimal restrictions issued pursuant to Subpart H.

93 Obviously, distributors of mifepristone who are outside the lawful channels of distribution are even less likely to report adverse events.
95 Consider Estate of Brenda Vise vs. Volunteer Women's Medical Clinic, L.L.C., et al. (Circuit Court of Hamilton County, Tennessee, filed August 14, 2002); Danlin Tang, Albert Ng vs. Dr. Soon Chon Sohn, Family Planning Associates Medical Group, and Does 1 – 50 (Superior Court of the State of California for the County of Los Angeles, Central District, notice to file dated December 13, 2002).
96 Opposition Comments at 6.
97 Opposition Comments at 14.
In the face of this recalcitrance, FDA should exercise its enforcement authority, investigate the Sponsor’s failed commitments under its NDA approval, and take appropriate action, as it has in other cases where risk management programs were deemed insufficient to protect patients. We note that, contemporaneous with the issuance of the Sponsor’s Dear Doctor Letter, FDA underscored the possibility that if providers “do not follow the agreement, the distributor may discontinue distribution of the drug to them.” Shortly after approving Mifeprex, the Agency wrote to a member of Congress and stated, “If restrictions are not adhered to, FDA may withdraw approval.”

Even assuming that the Sponsor’s responsibilities extend only as far as ensuring that the prescriber is adhering to the Prescriber’s Agreement, the Sponsor is failing to meet its due diligence obligation. The Prescriber’s Agreement requires, *inter alia*, that the prescriber “must fully explain the procedure to each patient, provide her with a copy of the Medication Guide and PATIENT AGREEMENT, give her an opportunity to read and discuss them, obtain her signature on the PATIENT AGREEMENT, and sign it yourself.” The Patient Agreement, which both the patient and the prescriber sign, states that the patient “believe[s] I am no more than 49 days (7 weeks) pregnant.” Yet numerous prescriber websites advertise the Mifeprex Regimen as being available for patients whose pregnancies have progressed beyond 49 days. The Patient Agreement states that patients “believe[s] I am no more than 49 days (7 weeks) pregnant.”

---

98 For example, GlaxoSmithKline voluntarily withdrew its NDA for Lotronex (alostron hydrochloride) rather than accept restrictive risk management guidelines involving informing patients of risks, limiting access to closely monitored patients, and continued clinical research. See “FDA and Glaxo Still Working on Lotronex’s Return,” *Dickinson’s FDA Webview* (Jan. 24, 2002). Bayer voluntarily withdrew Baycol (cerivastatin) after reports of deaths due to severe rhabdomyolysis, when risk management efforts of labeling changes and “Dear Healthcare Provider” letters had little impact on physicians who continued to prescribe the drug at unrecommended higher doses. See “31 Baycol-related Deaths Cause the Drug’s Withdrawal,” *Dickinson’s FDA Webview* (Aug. 8, 2001). Warner Lambert withdrew Rezulin (troglitzone) at FDA’s urging after label restrictions and recommended monitoring of liver function failed to control inappropriate prescribing. See “Rezulin Withdrawal a Defeat for FDA ‘Labeling Can Do It’ Theory”, *Dickinson’s FDA Webview* (Mar. 21, 2000).

99 See FDA Q & As at Question 12.


101 See Opposition Comments at 14-15.

102 Mifeprex™ (Mifepristone) Tablets, 200 mg Prescriber’s Agreement (“Prescriber’s Agreement”).

103 See Item 4 of the Patient Agreement Mifeprex (mifepristone) Tablets (“Patient Agreement”). In addition, the Mifepristone Medication Guide (“Medication Guide”) states that you should not take Mifeprex if “[i]t has been more than 49 days (7 weeks) since your last menstrual period began.”

Agreement also states that the patient “will take misoprostol in [her] provider’s office two days after [she] take[s] Mifeprex (Day 3).” Yet many prescribers’ websites indicate that patients take misoprostol at home rather than at the provider’s office. The discrepancies between the marketplace regimen being prescribed and the approved Regimen that the patient agrees to follow indicate that many prescribers are allowing patients to make false statements. Under its NDA duties, the Sponsor has an obligation to conduct due diligence about the prescribers to whom it sells Mifeprex, and it must stop those sales if the approved Regimen is breached. Furthermore, the Sponsor has a duty to keep records of these stopped distributions.

Given that these discrepancies are freely published on prescriber websites, the Sponsor should be aware of them. Therefore, the Sponsor knowingly continues to supply prescribers who are not following the guidelines in the Prescriber’s Agreement. These prescribers are knowingly eviscerating the requirements to provide patients with the Medication Guide, to

---

105 See Patient Agreement, Item 6. In addition, the Medication Guide states that the patient “must return to [her] provider on Day 3 and about Day 14” (emphasis in original).

106 See, e.g., Family Planning Associates Medical Group, Phoenix and Tempe Arizona, (available at: <http://www.fpamg.com/medical.html>) (visited Sept. 5, 2003) (explaining that “[t]he patient inserts 4 tablets of Misoprostol into the vagina at home 2-3 days” after ingestion of Mifeprex); Little Rock Family Planning website < http://www.lrfps.com/RU486.html > (visited Sept. 5, 2003) (describing the regimen employed by the clinic, which is “one of these regimes [sic] which has been shown to be safe and is more convenient for women using the method”: “Step Two, at home (or motel) … Six to 8 hours after the mifepristone pills have been swallowed 8 Cytotec tablets are placed in the vagina. Step Three, this will depend on how far you live from our clinic: A) If you live within one hour of Little Rock … If you have not passed the pregnancy by 24 hours after you put the Cytotec tablets in your vagina, you will put a [sic] 4 tablets in your vagina and still plan to keep your appointment for the following week. B) If you live outside the Little Rock Area … You will return at 9AM the following morning to have an ultrasound to see if the abortion is complete. If the abortion is complete you will be discharged home and asked to take a urine pregnancy test in 3 weeks. … If you have not had a complete abortion you will be given 4 Cytotec [sic] to place in your vagina … “); Planned Parenthood Golden Gate (available at: <http://www.pppg.org/medical/abortion_medical.asp>) (visited Oct. 1, 2003) (“Medical abortion using Mifepristone involves three steps. First, the doctor will give you mifepristone pills, which block progesterone, a hormone needed to maintain pregnancy. Two days later, as directed by your clinician, you will insert another medication called misoprostol as a vaginal suppository. Misoprostol causes the uterus to contract and empty which completes the abortion. Finally, women must return to the clinic a few days after taking the misoprostol for a follow-up.”); Women’s Health Practice website (available at: <http://www.womenshealthpractice.com/abortion.htm>) (visited Sept. 5, 2003) (explaining, as part of the medical abortion regimen that the clinic describes as “most similar to the FDA-approved regimen,” that “[t]he misoprostol will be provided to you with medication instructions that carefully explain the timing and route of administration.”).

107 21 C.F.R. § 314.81(b)(2) (requiring NDA sponsors to submit an annual report describing distribution data). State or federal agencies may need these data if patient deaths continue and the public outcry (and/or the plaintiffs’ lawyers bar) demand investigations.

108 The Petition set forth a number of examples of Mifeprex provider websites that advertised noncompliance with the approved Mifeprex Regimen. See Petition at nn. 309, 313, 315, 317. Since the submission of the Petition, these websites have not been altered. (These websites were visited most recently on September 5-7, 2003. One of the website addresses changed and its content was updated, but it still states that “at home, the patient will insert four tablets [of misoprostol] into her vagina.” See <http://www.presidentialcenter.com/services_nonsurgical.html> (visited Sept. 7, 2003)). It appears, therefore, that the Sponsor, alerted by the Petition to these instances of noncompliance, has not taken any steps to require compliance with the approved regimen. Dr. Hausknecht, the medical director of Danco, operates one of the websites that continues to advertise a regimen that differs from the approved regimen. See <http://www.safeabortion.com/procedure.htm> (visited Sept. 7, 2003).
obtain their signatures on the Patient Agreement, and to give them the opportunity to read and discuss these documents. The Patient Agreement is intended by FDA to describe the Mifeprex Regimen as approved and to obtain the patient’s informed consent to adhere to the approved Regimen, all for the protection of the patient. Instead, some prescribers, with the Sponsor’s tacit approval, are permitting patients to sign the Patient Agreement while effectively directing them not to adhere to its requirements. In the face of such evidence, the Sponsor cannot be described as meeting its obligations with respect to the restrictions on Mifeprex.

Conclusion

Women are being told that Mifeprex is safe even if it is used in a manner different from the Regimen approved by FDA. This is a cavalier approach to distributing a drug that was deemed by FDA to be too dangerous to approve without restrictions. The Sponsor’s refusal to restrict distribution to physicians who adhere to the approved Regimen represents the continuation of a pattern of overlooking the risks to women’s health posed by Mifeprex. FDA should halt the marketing of this unsafe drug.

E. The Sponsor’s Revised Phase IV Commitments Are Inadequate.¹⁰⁹

The Sponsor’s Opposition Comments downplayed the significance of the changes prior to approval in the Sponsor’s Phase IV commitments.¹¹⁰ As noted in the Petition, those changes by the Sponsor relegated certain study objectives to secondary status, eliminated the commitment to study the long-term effects of multiple uses of the Regimen, and weakened the commitment to monitor the adequacy of the distribution and credentialing system.¹¹¹

The Sponsor’s insistence that the range of topics to be studied was not narrowed contradicts statements made by the Sponsor when it proposed modifications of its Phase IV commitments in September 2000.¹¹² The Sponsor, citing feasibility concerns, decided not to study the long-term effects of multiple uses of the Mifeprex Regimen.¹¹³ Moreover, combining multiple study objectives into one study reduced the value of the data that would be generated.

¹⁰⁹ The Petitioners requested, pursuant to FOIA, information about the Phase IV Mifeprex study protocols and any data arising from the Phase IV studies submitted by the Sponsor. See FOIA Request, filed by Wendy Wright, Director of Communications, CWA (Sept. 14, 2001). To date, the Petitioners have not received any responsive information.


¹¹¹ See Petition at 84-88.

¹¹² See Letter, Sandra Arnold to FDA/CDER, Office of Drug Evaluation III, Division of Reproductive and Urologic Products (Sept. 6, 2000): at 5 [FDA FOIA Release: MIF 001333-49] (“As new data have become available, some of the studies originally proposed have become unnecessary. Other studies, on reflection, seem unlikely to gather useful data at any reasonable cost or, in some cases, at any cost.”).

¹¹³ See Memorandum, FDA/CDER to “NDA 20-687 MIFEPRLEX (mifepristone) Population Council” (Sept. 28, 2000): at 7 (“Mifeprex Approval Memo”). As discussed in the Petition, the Sponsor, in asking for the elimination of this commitment, was motivated in part by concerns that conducting such a study would be burdensome for the Sponsor – a reason that is not generally persuasive with FDA. See Petition at 87.
with respect to the secondary study objectives. Given the importance of understanding the effect of a patient’s age, the effect of a patient’s smoking status, the rate of patient follow-up on Day 14, and the adequacy of the distribution and credentialing system, the Sponsor should not have been permitted to accord these study objectives secondary status.

The Sponsor defended the changes in the study requirements by citing FDA’s approval memorandum for the proposition that the changes in the Phase IV Study commitments reflected changes to the distribution system and labeling. The Sponsor’s argument is misleading. By allowing the distribution of mifepristone to physicians who could not provide surgical intervention, an immediate need arose to study the effect of that major change; accordingly, FDA added a primary study requirement. However, the September 2000 changes in distribution and labeling should not have reduced or eliminated other primary Phase IV study commitments that were not related to the distribution or labeling changes.

Conclusion

FDA inappropriately granted the Sponsor’s request to reduce its original Phase IV commitments. As a consequence, key questions about the safety of the Mifeprex Regimen will remain unanswered.

F. The Approval of Mifeprex Without Supporting Pediatric Data Was Both Unlawful And Imprudent.

In its Opposition Comments, the Sponsor admitted that it did not conduct clinical studies in the pediatric population, but relied instead on an FDA “waiver” of pediatric testing. Yet, the FD&C Act and FDA’s approval regulations for NDAs require safety and effectiveness testing to support a new drug’s indications for use. In a case where the Sponsor does not intend to restrict the drug’s use in the pediatric population, FDA has only limited authority to cede the requirement for pediatric testing. In the case of Mifeprex, FDA’s decision to approve the NDA without pediatric data was arbitrary, capricious and unlawful agency action.

114 Specifically, the effects of age and smoking status and the frequency with which patients return for follow-up on Day 14 were to be studied as part of “[a] cohort-based study of safety outcomes of patients having medical abortion under the care of physicians with surgical intervention skills compare to physicians who refer their patients for surgical intervention.” See Petition at 86 (citing Mifeprex Approval Letter at 3). Furthermore, this study would be the only Phase IV study of another objective originally slated to be the focus of a separate Phase IV study, namely the adequacy of the distribution and credentialing system. See generally Mifeprex Approval Memo at 7.

115 See Opposition Comments at 15-16 (citing Mifeprex Approval Memo at 7).

116 This change was deemed significant enough to require the addition of a “black box” warning to physicians who could not perform surgical abortions. The black box warning directed them to make arrangements for the provision of emergency surgical intervention.

117 FDA correctly noted the need for a new study objective when it approved this change: “To ensure that the quality of care is not different for patients who are treated by physicians who have the skill for surgical intervention (as in the clinical trials) compared to those treated by physicians who must refer patients for surgical intervention, FDA has proposed and the Population Council has agreed to structure a Phase 4 monitoring study.” Mifeprex Approval Memo at 5.
1. **FDA’s NDA Approval Regulations Required Pediatric Data.**

The law is clear that the clinical studies used to support an NDA must establish the drug’s safety and efficacy for the proposed conditions of use. Under the FD&C Act, a person may file an NDA requesting FDA approval of a new drug provided that the NDA contains, in relevant part, “full reports of investigations which have been made to show whether or not such drug is safe for use and such drug is effective in use . . .” Likewise, FDA’s NDA approval regulations require “a description and analysis of each controlled clinical study pertinent to a proposed use of the drug.” This testing requirement exists separately from the so-called “Pediatric Rule,” which also delineates pediatric testing requirements.

The Petitioners acknowledge that, as of October 17, 2002 and for the time being, FDA is enjoined from enforcing the Pediatric Rule. However, the Petitioners challenge the Sponsor’s contention that the issue of FDA’s proper administration of the Rule is moot, in light of the AAPS court’s decision to grant an appeal of the case, which is now pending. Rather, the Mifeprex NDA was subject to the Pediatric Rule, which was finalized and became effective while FDA was reviewing the NDA, and FDA should have administered it properly or waived it properly.

---

118 21 USC § 355(b)(1)(A) (emphasis added).

119 21 C.F.R. § 314.50(d)(5)(ii) (emphasis added).

120 See Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drugs and Biological Products in Pediatric Patients, Final Rule, 63 Fed. Reg. 66632 (Dec. 2, 1998) (testing requirements set forth in 21 C.F.R. § 314.55). See also Petition at 76-83 (discussing Pediatric Rule).


122 The Elizabeth Glaser Pediatric AIDS Foundation and the American Academy of Pediatrics filed a motion to appeal on December 16, 2002. See Docket for Case No. 00-CV-2898 (entry no. 73).

123 The Pediatric Rule was promulgated on December 2, 1998 and became effective on April 1, 1999. FDA reviewed the Mifeprex NDA from March 18, 1996 until September 28, 2000, when it was approved.

124 Under the Pediatric Rule, FDA’s treatment of the Mifeprex NDA was improper, in part, because the agency did not require the Sponsor to submit supporting pediatric data. The regulation stated that, “where the course of the disease and the effects of the drug are sufficiently similar in adults and pediatric patients, FDA may conclude that pediatric effectiveness can be extrapolated from adequate and well-controlled studies in adults usually supplemented with other information obtained in pediatric patients, such as pharmacokinetic studies.” 21 C.F.R. § 314.55(a) (emphasis added). This requirement also was articulated earlier by FDA in the Prescription Labeling regulation. See 59 Fed. Reg. 64240 (Dec.13, 1994); 21 C.F.R. § 201.57(f)(9)(iv). As noted elsewhere in this Response, the Petitioners also question whether the Sponsor’s adult data were derived “from adequate and well-controlled studies.”

125 It should be noted that even if FDA concluded that pediatric effectiveness of the Mifeprex Regimen could be extrapolated from adult studies, this would not be an appropriate ground for an actual waiver of the Pediatric Rule. The Pediatric Rule provides three grounds for waiver from the obligation imposed by the rule on drug sponsors to demonstrate that their drug is safe and effective for pediatric patients. 21 C.F.R. § 314.55(c). In some instances, drug sponsors are able to provide sufficient adult data, usually supplemented by pediatric-specific data, from which pediatric safety and efficacy can be extrapolated. 21 C.F.R. § 314.55(a). FDA stated that it was waiving the pediatric rule with respect to Mifeprex, yet did not cite to any of the bases for waiver provided in paragraph (c) of the Pediatric Rule. Mifeprex Approval Letter at 3. For a comprehensive discussion on the ineligibility of Mifeprex for a waiver from the Pediatric Rule, see the Petition at 78-82.
Irrespective of the current status of the AAPS case, at the time of the approval of the Mifeprex NDA the Agency was obligated to meet the requirements of its NDA approval regulations. FDA erred in its failure to require the Sponsor to submit pertinent pediatric data and to assess those data in its review of the NDA for Mifeprex. In so doing, the Agency abrogated its role of protecting and promoting the public health and safety. This constitutes the type of “arbitrary and capricious” action that is generally prohibited under the Administrative Procedures Act (“APA”).

2. The Drug’s Expected Conditions of Use Included the Pediatric Population.

Mifeprex is intended for use by menstruating females. The drug’s labeling states “Mifeprex is indicated for the medical termination of intrauterine pregnancy through 49 days’ pregnancy.” Nothing in the “Indication and Usage” section of the labeling limits the drug’s use to adults. Likewise, Danco’s marketing claims are not targeted to a particular age group, such as women “over age 18.” The patient population therefore logically includes all females who can become pregnant – that is, as of the age their first menstrual period begins (i.e., “menarche”) until they no longer have a menstrual period (i.e., “menopause”). According to FDA, the average age of menarche in the United States is 12 years, although menstruation may commence in healthy females as early as age 10.

Under the pediatric labeling regulations, the Agency defines “pediatric population(s)” and “pediatric patient(s)” as the age group “from birth to 16 years, including age groups often called … adolescents.” Therefore, the population of menstruating females (i.e., 10 or 12 and older) and the pediatric population (i.e., up to 16) overlap by up to 6 years. Based on Danco’s labeling and marketing to the menstruating female population without any age restriction, pediatric use of this product was clearly contemplated. Because Mifeprex will be used by some number of adolescent girls who become pregnant, FDA should have required the Sponsor to produce safety and effectiveness data for the pediatric population.

3. FDA Should Have Required the Submission of Pediatric Study Data Prior to Approving Mifeprex.

Under its broad authority granted by the FD&C Act, not only may FDA require the submission of pediatric data as part of a product’s NDA, but the Agency must require such data when the product’s conditions of use warrant pediatric testing. However, the Agency approved

---

126 5 USC § 706(2)(A).
127 Instead, the drug’s labeling contains one non-constructive statement in the “Precautions” section of the labeling: “Safety and effectiveness in pediatric patients have not been established.” Given the logical reading of the drug’s indication and the medical information on the age range of menstruation, this one sentence in a package insert of 15 pages is valueless.
129 21 C.F.R. § 201.57(f)(9).
Mifeprex without requiring the Sponsor to submit pediatric data or, apparently, any review of the pertinent scientific literature. When approving Mifeprex based solely on the data submitted in the NDA (i.e., studies conducted in an adult population), FDA made the unsupported assumption that younger females (i.e., children and adolescents) would have the same physiological response to this product as adult females.  Specifically, the Sponsor cited FDA’s conclusion that “the drug regimen is expected to be as safe and effective for pregnant women under the age of 18 years as it is for those of the age of 18 ...,” despite the Agency’s concession that most of the available data are from women 18 years and older. Further, the Sponsor noted that FDA has not found any “biological reason to expect that menstruating females under age 18 to have a different physiological outcome with the regimen.”

As stated in the Petition, however, FDA’s conclusion misreads the science. To assume, without specific data, that the effects of a potent antiprogesterone and a powerful prostaglandin analogue in pregnant adults will be the same for adolescents who are still developing in their physiologic, anatomic, and reproductive functions, is medically unsound. The relevant scientific evidence suggests that an assumption cannot be made that the effectiveness or safety of Mifeprex for adolescent girls is the same as for fully-developed adult women. Therefore, FDA’s decision to the contrary lacks a sound and justified scientific basis.

Moreover, the Agency decision disregards decades of its own medical judgment. In the past, FDA has said that drugs should be studied directly in the pediatric population because “the action and adverse actions of pharmaceutical agents will vary as absorption, distribution, metabolism, and excretion, and receptor sensitivity are altered by the changes associated with growth and development.” For Mifeprex, these factors were not directly studied in children.

Studying the subpopulation of adolescents is even more important, according to FDA. For example, “[t]he development of puberty and the known effects of sex hormones on drug metabolism warrant consideration in drug evaluation in the adolescent.” Other “special problems” arise from the intense concern with self-image, leading to increased use (both admitted and denied) of prescription and over-the-counter drugs, dietary supplements, and cosmetics for such purposes as altering physical growth and sexual development, regulating mood and behavior, and influencing physical appearance. FDA did not require a review of these adolescent-specific considerations with respect to the Mifeprex Regimen.

---

130 See Mifeprex Approval Memo at 7.
131 Opposition Comments at 15 (citing FDA, “Medical Officer’s Review of Amendments 024 and 033: Final Reports for the U.S. Clinical Trials Inducing Abortion up to 63 Days Gestational Age and Complete Responses Regarding Distribution System and Phase 4 Commitments,” at 28).
132 Opposition Comments at 15 (citing Mifeprex Approval Memo at 7).
134 Pediatric Study Guidance at 15.
135 See Pediatric Study Guidance at 16-17.
In addition, FDA has said previously that a drug’s safety profile may be different for adolescents because “medication may not be taken as prescribed. The adolescent frequently omits doses of medication, takes it at erratic intervals, and may take more than prescribed. Safety considerations should be addressed not only to the therapeutic dosage, but also to the consequences of suboptimal dosage and overdosage.”

Given the two-drug-regimen and three-doctor-visit administration of the Mifeprex Regimen, a study of patient compliance issues in adolescents was warranted.

Conclusion

In summary, it is logical to conclude that Mifeprex is intended for use by a female population that, under the pertinent definitions adopted by FDA, includes pediatric females. Therefore, FDA should have required the submission of pediatric data with the NDA. Without any consideration of pediatric data, FDA’s approval of Mifeprex is an abrogation of its fundamental duty to conduct the drug approval process in a way that protects and promotes the public health and safety. In so doing, the Agency acted in a way that was arbitrary, capricious, and contrary to law and its own regulations.

II. FDA Is Both Statutorily Empowered and Obligated to Grant an Administrative Stay of the Mifeprex NDA Approval.

The Sponsor’s Opposition Comments contain three technical objections to the request for an administrative stay of the Mifeprex NDA approval. First, the Sponsor alleges that an administrative stay is not the appropriate method by which FDA could withdraw the Mifeprex NDA. Second, the Sponsor alleges that the request is “untimely” because it was not filed within 30 days of the effective date for the Mifeprex NDA approval. Third, the Sponsor makes a general allegation that the Petitioners do not meet the criteria for an administrative stay under FDA’s regulations. As described below, these allegations stem from an incorrect and overly restrictive reading of the Petitioners’ request. Instead of answering the serious substantive issues raised in the Petition, the Sponsor has focused on the way in which the Petitioners framed their request for FDA action. Even more disconcerting, the Sponsor asks FDA to place administrative procedures above the Agency’s statutory obligation to protect the public health.

A. FDA Has the Statutory Authority to Suspend the Mifeprex NDA Pending the Outcome of a Decision to Withdraw the Application.

The Petitioners’ request for administrative stay of the Mifeprex NDA approval is equivalent to a request for FDA to use its authority under section 505(e) of the FD&C Act to “suspend the approval of [the] application immediately.” The FD&C Act states that an NDA may be “suspended” whenever FDA makes a finding of “imminent hazard to the public

136 Pediatric Study Guidance at 15.
137 See Opposition Comments at 16-24.
138 21 U.S.C. § 355(e); see also 21 C.F.R. § 314.150(a)(1).
health.” In the Petition and in this Response, the Petitioners have provided extensive evidence that Mifeprex poses, under FDA’s definition, “a significant threat of danger to health, [and] creates a public health situation . . . that should be corrected immediately to prevent injury.” Furthermore, an emergency or “crisis” situation is not required, but merely a “substantial likelihood that serious harm will be experienced during . . . any realistic projection of the administrative process.” In interpreting this definition, a court upheld an FDA decision similar to that which the Petitioners are requesting. Specifically, even though “respectable scientific authority [could] be found on both sides of this question”, and “much of the raw data used by the [Agency] in arriving at its conclusion had been available for some length of time,” these facts did not preclude FDA’s use of the data in finding an imminent hazard when “the magnitude of [the drug’s] risk was determined only after an extensive re-evaluation of the data.”

FDA’s authority is resolute and can be exercised immediately, notwithstanding any related issues regarding how the matter was initially raised (e.g., a Citizen Petition), who exercised the authority (e.g., HHS Secretary or FDA), and what actions follow it (e.g., notice and hearing). FDA should disregard the Sponsor’s attempt to redirect the Agency away from the substance of the Petition toward a focus on the administrative requirements of delegating authority, providing notice, and holding a hearing. Clearly, FDA’s suspension of the Mifeprex approval could occur during the pendency of any notice period or hearing which the Sponsor so forcefully claims to be entitled to under the FD&C Act, the APA and Constitutional due process provisions. Given the situation, the Petitioners are dismayed at the Sponsor’s insistence that its “property right to produce and market Mifeprex,” outweighs any concern for the safety of the patients that the Sponsor is seeking to “treat.”

Furthermore, even if FDA finds that an imminent hazard does not exist in this case, FDA may still summarily withdraw approval of an NDA in certain circumstances. During its four-page discussion on notice and hearings, the Sponsor fails to mention that the FD&C Act’s “due notice and hearing” provision does not guarantee an NDA Sponsor a hearing, and also leaves FDA with discretion regarding the type of notice that is provided. Rather, FDA may proceed by summary judgment to withdraw an NDA in certain circumstances – for example, when there

139 See id.
140 21 C.F.R. § 2.5.
143 Forsham v. Califano, 442 F. Supp. 203 (D.D.C. 1977) (on petition raised by a consumer health organization, the HHS Secretary referred the matter to FDA, which withdrew approval of a drug with notice but no formal hearing, based on a finding of imminent hazard to the public health).
144 Opposition Comments at 18. When the Sponsor included misoprostol as part of the Mifeprex Regimen, it did not demonstrate any concern for the property rights of Searle over misoprostol.
145 See John D. Copanos and Sons, Inc. v. FDA, 854 F.2d 510, 518, 520 (D.C. Cir. 1988) (“It is well settled that this [notice and hearing] provision does not guarantee the applicant a hearing in all circumstances.” and “The requirements of ‘due notice’ must depend upon the context of the agency’s action.”); Brandenfels v. Heckler, 716 F.2d 553, 555 (9th Cir. 1983) (“The FDA is authorized to satisfy its own notice requirements by providing holders of new drug applications with either general or specific notice of opportunity for hearing.”).
is no genuine and substantial issue of fact, when the applicant does not meet the minimum regulatory requirements, or when it appears conclusively from the applicant’s pleadings that the applicant cannot succeed.\textsuperscript{146}

The Petitioners’ request for administrative stay contains ample evidence to support a finding in this case of imminent hazard or the requisite basis for summary withdrawal. Millions of women are being misled to believe that the Mifeprex Regimen is safe, while in actuality neither the data submitted in the original NDA nor the subsequent marketing history can support a safety profile that justifies the continued marketing of the drug product. There is simply no legal basis to assert that FDA lacks the authority to grant the requested remedy of a “stay” (i.e., suspension) of the NDA pending resolution of a formal NDA withdrawal process.

\textbf{B. The Request for Administrative Stay Was Timely Filed.}

An NDA is not a “static” document. Rather, it is a “living” document that is constantly being supplemented, updated, and reviewed by FDA.\textsuperscript{147} Therefore, FDA is constantly making a “decision” to allow an NDA approval to stand in light of new information that is submitted to the Agency. Likewise, a drug’s safety and efficacy profile and risk/benefit profile also require constant re-analysis by FDA. For example, over time “newer” medical evidence comes to light and adverse reactions are recorded in the patient population. FDA’s approval decisions on NDAs are not “stuck in time.” Instead, “FDA has an obligation to judge a drug’s effectiveness by contemporary scientific standards. If those standards change to the extent that it is questionable whether a drug can be regarded as having been shown to be effective, FDA may under the act appropriately review the drug’s status.”\textsuperscript{148}

FDA’s regulations state that a stay of action must be filed within 30 days of the “date of the decision involved” unless FDA permits a later filing for “good cause.”\textsuperscript{149} In this instance, the “decision involved” is FDA’s decision to uphold the Mifeprex NDA and to not suspend the approval despite the influx of new information. This decision is ongoing. The Petitioners are requesting that FDA “stay” that decision and suspend the NDA approval immediately in response to the imminent hazard presented by the Mifeprex Regimen.

\textsuperscript{146} See Weinberger v. Hynson, Westcott & Dunning, Inc., 412 U.S. 609, 620-1 (1973) (withdrawing approval of NDA without a hearing based on lack of evidence negating “new drug” status); John D. Copanos and Sons, Inc. v. FDA, 854 F.2d 510, 518 (D.C. Cir. 1988) (withdrawing approval of NDA without a hearing based on failure to comply with current good manufacturing practices); Cooper Laboratories, Inc. v. FDA, 501 F.2d 772, 780 (D.C. Cir 1974) (withdrawing approval of NDA without a hearing based on insufficient evidence of efficacy).

\textsuperscript{147} See, e.g., 21 C.F.R. §§ 314.70, 314.72, 314.80, 314.81. At the very least, the Sponsor of the Mifeprex NDA is required to submit an annual report to FDA each year. 21 C.F.R. § 314.81(b)(2). The Sponsor’s misdirection on this matter is revealed by the fact that, under their interpretation of the “30 days” filing requirement, the Petitioners could “cure” the alleged timeliness defect by merely submitting the Petition within 30 days of any Mifeprex NDA Supplement or Annual Report.

\textsuperscript{148} 50 Fed. Reg. 7452, 7488 (Feb. 22, 1985) (FDA’s rejection of an industry suggestion, on withdrawal of approval of an application under 21 C.F.R. § 314.150, that FDA’s conclusion concerning a drug product “should remain unchanged even if FDA later adopted new standards”).

\textsuperscript{149} 21 C.F.R. § 10.35(b) (emphasis added).
Even if the request were considered to be “untimely” from a technical perspective, FDA should nevertheless still grant the requested stay pursuant to either (1) the Agency’s “imminent hazard” authority under section 505(e), which contains no time limitation; or (2) the “good cause” exception of 21 C.F.R. § 10.35(b). In fact, the “imminent hazard” authority and the “good cause” exception were included in the statute and regulations for the very reasons outlined in the Petitioners’ request. Namely, these provisions allow FDA to move quickly to protect the public from unsafe drug products without being slowed by overly technical readings of the regulations. Additionally, if FDA deemed the request to be untimely filed, the Agency still may stay its action on the NDA on its own initiative at any time. In other words, if FDA determines that the Petition’s underlying request has merit, FDA may suspend approval and/or initiate withdrawal proceedings independent of the Petitioners’ request.

C. The Petitioners Comply with the Spirit and Letter of the Requirements for an Administrative Stay.

As supported by the original submission, the Petitioners’ request for an administrative stay meets all of the requirements of 21 C.F.R. § 10.35(e). In particular, the Petitioners have demonstrated irreparable harm to American women and an overwhelming public policy reason for removing the Mifeprex drug product from the market. The Petitioners’ request is clearly not frivolous, and is being pursued in good faith. In response, the Sponsor has raised minor technical challenges that obfuscate and mischaracterize the issues raised by the Petitioners. Despite the evidence contained in the Petition concerning the harm that Mifeprex is inflicting on American women, and the Petitioners’ direct interest as their physicians in speaking for these women, the Sponsor has alleged that there is insufficient injury to justify an administrative stay. Specifically, the Sponsor argued that the Petitioners are not the actual injured party. Yet, that response is a mischaracterization of the Petitioners’ request. The Petition clearly stated that the Petitioners were seeking Agency action to prevent further injury to women seeking to terminate their pregnancies. The evidence submitted in the Petition and in this submission unequivocally demonstrates that women are being harmed by this drug product. In light of this fact, FDA is obliged to investigate whether the Mifeprex NDA approval should be suspended and ultimately withdrawn.

150 See Opposition Comments at 21-22.

151 Just as the Petitioners have with their Petition, patient advocacy groups routinely utilize the Citizen Petition process to request that FDA overturn its safety and effectiveness decision for drug products and, ultimately, withdraw them from the market. See Letter to FDA from AIDS Healthcare Foundation, August 19, 2003 (Docket number not assigned), requesting market removal of Trizivir (abacavir sulfate/lamivudine/zidovudine) due to poor efficacy results in post-approval clinical studies letter; Docket No. 02P-1778, Citizen Petition from Public Citizen and Arizona Arthritis Center, March 28, 2002, requesting market removal of Arava (leflunomide) due to patient deaths and severe liver failure; Docket No. 02P-0120, Citizen Petition from Public Citizen, March 19, 2002, requesting market removal of Meridia (sibutramine) due to patient deaths related to cardiovascular adverse effects. Many of these Citizen Petitions are ultimately successful. See e.g., Rezulin (troglitazone), banned March 2000 after a July 1998 Petition (Docket No. 98-0622); and Lotronex (alosetron HCl), banned November 2000 after an August 2000 Petition (Docket No. 00P-1499).
III. Conclusion.

For the foregoing reasons, the Petitioners respectfully request that FDA immediately suspend the approval of the NDA for Mifeprex and enter an administrative stay to halt any further distribution and marketing of Mifeprex until final Agency action is taken to withdraw the NDA approval for Mifeprex. For copies of any of the reference materials cited herein, please contact the undersigned.

Respectfully submitted,

Gary L. Yingling

Rebecca L. Dandeker
Exhibit 14

AAPLOG Statement on FDA removing Mifepristone safety protocols (REMS)
AAPLOG Statement on FDA removing Mifepristone safety protocols (REMS)

As women’s healthcare experts, we fight hard every day for the health of our patients. And when political agendas supersede the health of our patients, it is our responsibility to speak up. The FDA’s announcement yesterday that they plan to lift safety restrictions that govern the dispensing of medication abortions makes women’s health simply a pawn in the effort to push for more abortion. The American Association of Prolife Obstetricians and Gynecologists (AAPLOG) represents approximately 7,000 women’s healthcare practitioners who will not allow our patients’ lives to be put in jeopardy in order to appease the abortion industry and their allies.

When Mifepristone was first approved in 2000, it was only approved with safety regulations in place (known later as REMS) that would attempt to minimize the significant risk of hemorrhage, tissue not removed, and infection. These REMS were relaxed in 2016 by the FDA, without any further safety testing and despite evidence of significant adverse events, as well as maternal deaths. Inexplicably in 2016, the FDA stopped collecting data on non-fatal adverse events and has only collected data on maternal deaths related to Mifepristone. They have chosen to completely ignore the thousands of women who are showing up in their local emergency rooms due to heavy bleeding, retained tissue, infection, or other complications as a result of medication abortions. A recent analysis of the Adverse Events submitted to the FDA with the REMS in place shows over 3000 women suffering with complications, of which 24 of these women died, and another 500 would have died if they had not reached emergency medical care in time. These numbers will only increase if the current REMS, which require that a woman be seen and evaluated by a licensed healthcare practitioner prior to receiving the medications for an abortion, are removed. This requirement is not restrictive – it is protective.

It is critical that a woman be seen in person before being given Mifepristone for an abortion for numerous reasons, including:
1) Her doctor(s) will know her actual risks;
2) her doctor(s) will be able to rule out contraindications like ectopic pregnancies; and
3) her doctor(s) will be able to give her Rhogam if she is Rh negative.

Requiring that a woman be seen in person in order to undergo medication abortion ensures that she is able to give her fully informed consent – a basic tenet of medical ethics. Many women are pressured into abortions by their partner, a family member, or a trafficker. Oftentimes, their visit with a physician in early pregnancy is the only chance these women will have to expose this pressure they’re facing. As compassionate physicians, we should do everything we can to ensure that a woman is not being unduly pressured to have an abortion she does not want. Screening for abuse and trafficking is inadequate during a telemed visit because the physician cannot control
the environment of the woman on the other end of the screen, or know who is hovering behind the computer screen.

An in-person visit is medically necessary and sound medical practice because it ensures that every woman receives a full evaluation for any contraindications to a medication abortion. First, it ensures that the gestational age of her pregnancy can be confirmed. Mifepristone is only approved for use through 10 weeks gestation and the complication rates associated with it increase significantly after this gestational age. According to a Committee Opinion from the American College of OB/GYN’s (ACOG) on dating pregnancies, up to 50% of women will be wrong about their gestational age when relying only on recall of their last menstrual period. For this reason, a pregnancy that has not had a first trimester ultrasound is considered sub optimally dated. A woman’s risk of dying from an abortion increases by 38% for every week beyond 8 weeks gestation, and so confirmation of her gestational age is critical.

An ultrasound is also crucial to rule out an ectopic pregnancy, which can be life threatening if not detected. This cannot be diagnosed via a televisit or through symptom/risk factor screenings over the phone, as stated by ACOG – it requires an in person visit with an exam and ultrasound. This is particularly important since the symptoms of a life-threatening ruptured ectopic pregnancy mimic those of a medication abortion. Claims that allowing women to have Mifepristone delivered through the mail will put women who live hours from the closest medical care unit in danger – a woman experiencing hemorrhage related to her abortion or a ruptured ectopic pregnancy does not have hours and could die before she reaches a hospital.

Women who have an Rh negative blood type require an in person visit to receive a medication called Rhogam to prevent complications in future pregnancies. Even ACOG admits that it is standard medical care for women to receive Rhogam after a miscarriage or an abortion. Claims that this step can be skipped will potentially lead to the loss of future pregnancies from a disease known as rhesus isoimmunization.

These are not hypothetical scenarios. One of the largest studies to date analyzed high-quality registry data obtained from nearly 50,000 women in Finland who underwent abortions from 2000-2006 with a gestational duration of 9 weeks or less. This study found that the overall incidence of immediate adverse events is four-fold higher for medical abortions than for surgical abortions. In particular, this study indicated that hemorrhage and incomplete abortion are more common after medical abortions; the incidence of hemorrhage was 15.6 percent following medical abortions, compared to 2.1 percent for surgical abortions, and 6.7 percent of medical abortions resulted in incomplete abortion, compared with 1.6 percent of surgical abortions. This means that nearly 7% of women will need surgical intervention - a significant number when you consider how many abortions happen everyday in the U.S.

These figures do not tell the whole story, either. The true number of complications from use of a Mifepristone abortion regimen is much larger, since many studies show that on average 5-8% of women need emergency room visits for complications, and this does not even include the
number of surgeries done in the abortion clinics. 5% of the 3.7 million women who have used Mifepristone according to FDA estimates means at least 185,000 women have suffered and needed surgery and medical treatment as a result. The FDA Mifepristone Adverse Event Reports represent only 1.73% of these women. And no one is systematically collecting data on the women hurt or killed by Mifepristone complications. The FDA knows that there are widespread inadequacies in reporting and the FDA itself admits, for example, that it “does not receive reports for every adverse event… that occurs with a product.” This is in part because healthcare professionals are not required to report adverse events; rather, such reporting is voluntary.

It is impossible for a physician who is states away to safely, compassionately and fully care for a woman and ensure she has appropriate follow up. Abandoning our patients to the closest clinic or emergency room is not good medicine. We would like the FDA and ACOG to explain why women seeking abortions deserve substandard medical care that places their lives at risk. Mifepristone is a potentially dangerous medication for women, as evidenced by its black box warning label. Women deserve excellent healthcare – not the gross negligence that this decision by the FDA, at ACOG’s encouragement, provides.

Dr. Christina Francis
Chair of the Board, American Association of Pro-Life OB/GYNs (AAPLOG)
https://aaplog.org
Exhibit 15

Dear Drs. Harrison and Rudd and Ms. Nance:

This letter responds to your citizen petition submitted on August 20, 2002, to the Food and Drug Administration (FDA or Agency) on behalf of the American Association of Pro Life Obstetricians and Gynecologists (AAPLOG), the Christian Medical Association (CMA) (n/k/a the Christian Medical and Dental Associations), and Concerned Women for America (CWA) (Petition).1 Your Petition requests that the Agency stay FDA’s approval of Mifepristone (also known as RU-486), thereby halting the distribution and marketing of the drug pending final action on the Petition. The Petition also requests that the Agency revoke FDA’s approval of Mifepristone, requests a full audit of the French and U.S. clinical trials submitted in support of the new drug application (NDA) for Mifepristone.

We have carefully considered the information submitted in your Petition, comments on your Petition submitted to the docket, other submissions to the docket, and other relevant data available to the Agency. Based on our review of these materials and for the reasons described below, your Petition is denied.

1 The citizen petition was originally assigned docket number 2002P-0377/CP1. The number was changed to FDA-2002-P-0364 as a result of FDA’s transition to its new docketing system (Regulations.gov) in January 2008. This citizen petition was submitted by AAPLOG, CMA, and Sandy Rios, the then-President of CWA. We have addressed this response to CWA’s current CEO and President, Penny Young Nance.
I. BACKGROUND

On September 28, 2000, FDA approved Mifeprex for the medical termination of intrauterine pregnancy through 49 days’ pregnancy (NDA 20-687). The application was approved under 21 CFR part 314, subpart H, “Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses” (subpart H). This subpart applies to certain new drug products that have been studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit to patients over existing treatments. Specifically, § 314.520 of subpart H provides for approval with restrictions that are needed to assure the safe use of the drug product. In accordance with § 314.520, FDA restricted the distribution of Mifeprex as specified in the approval letter, including a requirement that Mifeprex be provided by or under the supervision of a physician who meets eight qualifications specified in the letter.

The September 28, 2000, approval letter also listed two Phase 4 commitments that the then-applicant of the Mifeprex NDA (i.e., the Population Council) agreed to meet. In addition, the letter stated that FDA was waiving the pediatric study requirement in 21 CFR 314.55.

II. DISCUSSION OF ISSUES RAISED

You maintain that good cause exists for granting an immediate stay of the Mifeprex approval and for the subsequent revocation of that approval under 21 CFR 314.530 (Petition at 3). You contend that:

- The approval of Mifeprex in 2000 violated the Administrative Procedure Act’s (APA’s) prohibition against agency action that is arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law (5 U.S.C. 706(2)(A));

- The 2000 approval violated section 505 of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 355) because Mifeprex does not satisfy the safety and labeling requirements of that section; and

- FDA approved Mifeprex in 2000 despite the presence of substantial risks to women’s health, including fatal hemorrhage and serious bacterial infections.

You make eight arguments for the stay and revocation of the 2000 Mifeprex approval, as follows (Petition at 4-7):

---

2 For purposes of this petition response, the term ‘Phase 4 commitments’ refers to the postmarketing studies that the Mifeprex sponsor agreed to perform as a condition of approval.

3 Effective October 31, 2002, the Population Council transferred ownership of the Mifeprex NDA to Danco Laboratories, LLC (Danco), which had been licensed to manufacture and market Mifeprex.
Docket No. FDA-2002-P-0364

- That the approval of Mifeprex in 2000 violated the legal requirements of the accelerated approval regulations under 21 CFR Subpart H.
- That Mifeprex was not proven safe and effective in 2000 as required by law.
- That the Mifeprex regimen requires that Mifeprex be used in conjunction with another drug, misoprostol, which has not been separately approved as an abortifacient.
- That the Mifeprex regimen was approved in 2000 without adequate safety restrictions.
- That the drug’s sponsor, following the approval in 2000, neglected to require Mifeprex providers to adhere to the restrictions contained in the regimen approved at that time.
- That the safeguards employed in one of the clinical trials that supported the 2000 approval were not mirrored in the regimen that FDA approved.
- That FDA improperly waived a requirement for pediatric studies in connection with the 2000 Mifeprex approval.
- That FDA did not require the sponsor of Mifeprex to honor its commitments for Phase 4 studies.

We respond to each of these arguments below.

We note your petition challenges the original approval of Mifeprex in 2000, and therefore this response is addressed to the 2000 approval and to the labeling that was approved at that time. Today, the Agency is approving a supplemental NDA submitted by Danco Laboratories, LLC (Danco), the holder of the Mifeprex NDA. This supplemental NDA proposed modified labeling for Mifeprex, including an updated dosing regimen, and included data to support the new labeling. After reviewing Danco’s supplemental NDA, FDA determined that it met the statutory standard for approval. The fact that the previously approved regimen is no longer included in the labeling does not reflect a decision that there were safety or effectiveness concerns with the previously approved regimen.

A. Approval of Mifeprex Was Consistent With Subpart H

You maintain that FDA’s 2000 approval of Mifeprex under the subpart H regulations was arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law, and thus violated the APA (Petition at 18-23). You state that pregnancy, without major complications, is not a serious or life-threatening illness; instead, you claim it is a normal physiological state experienced by most females one or more times and is rarely accompanied by life-threatening complications (Petition at 19). You contend that Mifeprex does not provide meaningful therapeutic benefit to patients over existing treatments because surgical abortion is a less dangerous, more effective alternative for the termination of pregnancy, and that Mifeprex does not treat any subset of the female population that is unresponsive to or intolerant of surgical abortion.
Docket No. FDA-2002-P-0364

(Petition at 21-23). Thus, you assert that the approval of Mifeprex did not meet the requirements for product approval under subpart H (Petition at 23).

We disagree with your conclusion that we inappropriately approved Mifeprex under subpart H. As stated in section I above, the accelerated approval regulations apply to new drug products that have been studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit to patients over existing treatments (§ 314.500). As FDA made clear in the preamble to the final rule for subpart H, the subpart H regulations are intended to apply to serious or life-threatening conditions, as well as to illnesses or diseases. The Agency also made clear that a condition need not be serious or life-threatening in all populations or in all phases to fall within the scope of these regulations.5 Unwanted pregnancy falls within the scope of subpart H under § 314.500 because unwanted pregnancy, like a number of illnesses or conditions, can be serious for certain populations or under certain circumstances.

Pregnancy can be a serious medical condition in some women.6 Pregnancy is the only condition associated with preeclampsia and eclampsia and causes an increased risk of thromboembolic complications, including deep vein thrombophlebitis and pulmonary embolus. Additionally, there is a significant risk of a major surgical procedure and anesthesia if a pregnancy is continued; for 2013 (the most recent data available), the Centers for Disease Control and Prevention reported an overall 32.7 percent rate of cesarean sections in the United States.7 Other medical concerns associated with pregnancy include the following: disseminated intravascular coagulopathy (a rare but serious complication); amniotic fluid embolism; life-threatening hemorrhage associated with placenta previa, placenta accreta, placental abruption, labor and delivery, or surgical delivery; postpartum depression; and exacerbation or more difficult management of preexisting medical conditions (e.g., diabetes, lupus, cardiac disease, hypertension). In addition, approximately 50 percent of all pregnancies in the United States each year are unintended.8 According to the

---

4 See, e.g., 57 FR 58942, 58946 (Dec. 11, 1992).

5 Id.

6 According to data from the Centers for Disease Control and Prevention (CDC), for 2012 (the most recent year for which data are available), the pregnancy-related mortality ratio in the United States was 15.9 maternal pregnancy-related deaths per 100,000 live births. See CDC, Pregnancy Mortality Surveillance System, available on the CDC Web page at http://www.cdc.gov/reproductivehealth/maternalinfanthealth/pmsss.html. A 2012 study by Raymond and Grimes provides a comparison for the mortality rate associated with legal abortion to live birth in the United States for the earlier period from 1998 through 2005. Investigators reported that over the study period, the pregnancy related mortality rate among women who delivered live neonates was 8.8 deaths per 100,000 live births. This lower rate excludes deaths from ectopic pregnancies, stillbirths, gestational trophoblastic disease, etc. During the same period, the rate of abortion related mortality was 0.6 per 100,000 abortions. The risk of childbirth related death was therefore approximately 14 times higher than the rate associated with legal abortion. Raymond, EG and DA Grimes, Feb. 2012, The Comparative Safety of Legal Induced Abortion and Childbirth in the United States, Obstet Gynecol, 119 (2, Part 1):215-219.


8 Guttmacher Institute, Feb. 2015, Unintended Pregnancy in the United States, at 1, available at http://www.guttmacher.org/pubs/FB-Unintended-Pregnancy-US.pdf. See also Institute of Medicine, 2011,
Institute of Medicine, women experiencing an unintended pregnancy may experience depression, anxiety, or other conditions.9

Furthermore, consistent with § 314.500, medical abortion through the use of Mifeprex provides a meaningful therapeutic benefit to some patients over surgical abortion.10 Although FDA provided several examples in the preamble to the final rule to illustrate how the term "meaningful therapeutic benefit" might be interpreted, the Agency did not suggest that the meaning of the term was limited to the examples provided.11 In the Phase 3 clinical trial of Mifeprex conducted in the United States, medical termination of pregnancy avoided an invasive surgical procedure and anesthesia in 92 percent of the 827 women with an estimated gestational age (EGA) of 49 days or less.12 Complications of general or local anesthesia, or of intravenous sedation ("twilight" anesthesia), can include a severe allergic reaction, a sudden drop in blood pressure with cardiorespiratory arrest, death, and a longer recovery time following the procedure. Medical (non-surgical) termination of pregnancy provides an alternative to surgical abortion; it is up to the patient and her provider to decide whether a medical or surgical abortion is preferable and safer in her particular situation.13

9 See Closing the Gaps, supra note 8, at 103.

10 For a discussion of how FDA interprets the phrase “meaningful therapeutic benefit to patients over existing treatments” in 21 CFR 314.500, see FDA guidance for industry, Expedited Programs for Serious Conditions—Drugs and Biologics, at 3-4, 16-17, available on the FDA Drugs guidance Web page at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.


13 CDC data indicate that for the 730,322 abortions reported in 2011, there were 2 deaths. The CDC’s calculated case fatality rate over the period from 2008 to 2011 (the most recent year for which data are available), the case fatality rate was 0.73 legal induced abortion-related deaths per 100,000 reported legal abortions. http://www.cdc.gov/mmwr/preview/mmwrhtml/ss6410a1.htm?s_cid=ss6410a1_e. Mortality rates identified by type of abortion (medical or surgical) were not available. However, the evidence suggests that the risk of mortality associated with medical abortion is quite low. Confirmation of the low risk of medical abortion is provided in a study by Trussell, et al., which recorded no deaths for 711,556 medical abortions performed by Planned Parenthood clinics under the buccal misoprostol administration protocol (Trussell J, D Nucatola, et al., Mar. 2014, Reduction in Infection-Related Mortality Since Modifications in the Regimen of Medical Abortion, Contraception, 89(3):193-6). We note that one study reported a comparatively high occurrence of fatality (1 death in a study of 11,155 early medical abortions); however, this apparent high occurrence of fatality is likely due to instability in the estimate as a result of the small sample size (Goldstone P, J Michelson, et al., Sept. 3, 2012, Early Medical Abortion Using Low-Dose Mifepristone Followed by
You cite a study by Jensen, et al., as support for your claim that surgical abortion is less dangerous and more effective than Mifeprex (Petition at 21-22 (citing Jensen, JT, et al., 1999, Outcomes of Suction Curettage and Mifepristone Abortion in the United States: A Prospective Comparison Study, Contraception, 59:153-159 (Jensen study)). This study was a prospective, nonconcurrent cohort analysis comparing the patients from one site in the U.S. phase 3 trial and a separate group of patients (who were not part of the U.S. phase 3 trial) who underwent surgical abortion at the same facility. The populations that were compared were not randomized to treatment (i.e., medical or surgical abortion) and the treatment periods did not overlap. In addition, the data on medical abortion cited in the Jensen study are based on the 178 subjects at a single site in the phase 3 U.S. Mifeprex trial that enrolled 2,121 women. This small subset of the U.S. trial included patients with pregnancies of up to 63 days’ gestation. Although you cite a surgical intervention rate of 18.3 percent in the Mifeprex patients, the surgical intervention rate for Mifeprex patients with an EGA ≤ 49 days was 12.7 percent (9 of 71), which, because of the small number of patients in the two groups, is not statistically significantly different from the 3.9 percent rate for re-intervention in the comparative surgical group (3 of 77). Furthermore, the 3.9 percent who first had a surgical abortion and then required surgical re-intervention ultimately required two surgical interventions, not one, thereby exposing them twice to the risks inherent in invasive surgical procedures and anesthesia. Finally, although you state that the medical abortion patients in the Jensen study reported significantly longer bleeding than did surgical patients, there was not a greater amount of bleeding in the medical abortion group, nor was there a significant difference between the two treatment groups in the incidence of anemia as determined by the overall change in hemoglobin concentrations.

You state that FDA “viewed [s]ubpart H as the only available regulatory vehicle that had the potential to make Mifeprex safe” (Petition at 23 (footnote omitted)). The question of whether subpart H was “the only available regulatory vehicle” is not relevant here. As described above, Mifeprex met the criteria for approval under subpart H. Additionally, as stated in the September 28, 2000, memorandum to NDA 20-687 (Mifeprex Approval Memorandum), “the Population Council proposed and FDA agreed that this drug will be directly distributed via an approved plan that ensures the physical security of the drug to physicians who meet specific qualifications” that were set out in the approval letter and the Prescriber’s Agreement.

Buccal Misoprostol: A Large Australian Observational Study, Med J Aust, 197(5):282-6. Much more accurate and meaningful data are provided by Trussell’s study covering >700,000 medical abortions.

We are not suggesting that in order to be adequate and well-controlled a trial must be concurrently controlled. As discussed below in section II.B.1, FDA’s regulations in § 314.126 recognize a number of different types of controls.

In addition, the mean surgical intervention rate for all Mifeprex patients with gestational ages ≤ 49 days in the Phase 3 U.S. trial was 7.9 percent (65 of 827 evaluable patients).

Furthermore, we approved a risk evaluation and mitigation strategy (REMS) for Mifeprex in June 2011, consisting of a Medication Guide, elements to assure safe use, an implementation system, and a timetable for submission of assessments of the REMS. Mifeprex was identified as one of the products that was deemed to have in effect an approved REMS under the Food and Drug Administration Amendments Act of 2007 (FDAAA) because on the effective date of Title IX, subtitle A of FDAAA (March 28, 2008), Mifeprex had in effect elements to assure safe use.\textsuperscript{17} The 2011 REMS for Mifeprex incorporated the restrictions under which the drug was approved. Indeed, there is substantial overlap between the requirements of subpart H and the statutory criteria for REMS set out in Title IX.

Given all of the above, the Mifeprex NDA was appropriately approved in 2000.

B. The French and U.S. Clinical Trials of Mifeprex Provided Substantial Evidence to Support Approval

You contend that the studies on which the Population Council relied in support of its NDA for Mifeprex do not meet the statutory and regulatory requirements for the quality and quantity of scientific evidence needed to support a finding that a new drug is safe and effective (Petition at 24).

Our review of Mifeprex was thorough and consistent with the FD&C Act and FDA regulations, including the requirements under section 505(d) of the FD&C Act that: (1) there be adequate tests to show that the drug is safe for use under the conditions prescribed, recommended, or suggested in the proposed labeling (section 505(d)(1)) and (2) there be substantial evidence that the drug will have the effect it purports or is recommended to have under the conditions of use prescribed, recommended, or suggested in the labeling (section 505(d)(5)). The Mifeprex NDA was thoroughly reviewed, and the drug product was found to be safe and effective for its approved indication. In addition, as noted in the Mifeprex Approval Memorandum (at 1), FDA’s Reproductive Health Drugs Advisory Committee (Advisory Committee) voted 6 to 0 (with 2 abstentions) on July 19, 1996, that the benefits of Mifeprex exceeded the risks. As set forth below, we disagree with your claims concerning the clinical trials that form the basis for the approval of Mifeprex.

1. The Clinical Trials Used to Support the Mifeprex NDA Were in Accordance With the FD&C Act and Applicable Regulations

You argue that because neither the French clinical trials nor the U.S. clinical trial of mifepristone were blinded, randomized, or concurrently controlled, these trials were inadequate to establish the safety and effectiveness of Mifeprex (Petition at 24-25 and 32-34). In addition, you assert in the response you submitted on October 10, 2003, to the comments in opposition to the Petition submitted by the Population Council and Danco (Response to Opposition) that the clinical trials of Mifeprex were not historically controlled but instead were uncontrolled.\textsuperscript{18} You state that the

\textsuperscript{17} 73 FR 16313 (Mar. 27, 2008).

\textsuperscript{18} Response to Opposition at 5. You also state that because the Mifeprex regimen was the first drug regimen that FDA approved to induce abortions, the applicant should have compared the new drug regimen to surgical abortions performed during the first 49 days after a woman’s last menstrual period (Response to Opposition at 6).
applicant did not describe any historical control group in the French clinical trials, and did not indicate that any of the scientific guidelines for selecting a proper control group before beginning a historically controlled study were used for these trials (id. at 5-6). You also reject the applicant’s claim that the available information on surgical abortion constitutes historically controlled data (id. at 6).

We disagree with your conclusion that the French and U.S. clinical trials of mifepristone were not clinically and legally adequate to support the approval of Mifeprex. The data from these three clinical trials (a large U.S. trial and two French trials) constitute substantial evidence that Mifeprex is safe and effective for its approved indication in accordance with section 505(d) of the FD&C Act. The labeling approved in 2000 for Mifeprex was based on data from these three clinical trials and from safety data from a postmarketing database of over 620,000 women in Europe who had had a medical termination of pregnancy (approximately 415,000 of whom had received mifepristone together with misoprostol).

The U.S. trial of Mifeprex involved 2,121 subjects enrolled at 17 sites. Of these, 827 had an EGA of \( \leq 49 \) days and were included in the efficacy evaluation. Medical termination of pregnancy was complete (without the need for surgical intervention) in 762 of these subjects (92 percent). Sixty-five of the subjects in the U.S. trial who were evaluable for efficacy were classified as having had a “treatment failure.” The reasons for treatment failure (and number of subjects experiencing each) were: incomplete pregnancy termination (n = 39), still pregnant (n = 8), subject request for surgical intervention (n = 5), and medical indication (bleeding, n = 13). The two French trials enrolled a total of 1,681 subjects providing effectiveness outcomes. Among the French subjects, the success rate for medical termination of pregnancy was 95.5 percent.

In the U.S. trial, 859 subjects with an EGA of \( \leq 49 \) days were evaluated for safety. Among these subjects, there were no deaths, one transfusion, and nine instances in which subjects received intravenous fluids. The safety profile of the patient group in the French trials with an EGA of \( \leq 49 \) days did not differ significantly from the safety profile of the same patient group in the U.S.

---

5, note 20). The fact that a drug might be the first one approved for a particular indication is not a factor in determining what type of control is adequate for a clinical trial of that drug for that indication. As discussed above, FDA’s regulations provide for a variety of different types of controls (see 21 CFR 314.126(b)), and do not require comparison of a proposed drug product to an active control group to establish the safety and effectiveness of the drug. Therefore, the clinical trials to support the approval of Mifeprex were not required to have a surgical comparator arm.


20 Mifeprex Approval Memorandum, supra note 16, at 1; Medical Officer’s Review, supra note 12, at 10.

21 Medical Officer’s Review, supra note 12, at 11 (Table 1) and 16.

22 Id. at 11 (Table 1).

23 Mifeprex Approval Memorandum, supra note 16, at 1.

trial, and the percentage of patients in the French and U.S. trials requiring hospitalization and blood transfusion and experiencing heavy bleeding was comparable. There were no deaths in the French trials.

Section 505(d) of the FD&C Act states, in part, that FDA must refuse to approve an application if the Agency finds that there is a lack of substantial evidence that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the drug's proposed labeling. Section 505(d) defines "substantial evidence" as "evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved."

As stated in 21 CFR 314.126(a), the purpose of conducting clinical investigations of a drug is to distinguish the effect of the drug from other influences, such as a spontaneous change in the course of the disease or condition, placebo effects, or biased observation. Reports of adequate and well-controlled investigations serve as the main basis for determining whether there is substantial evidence to support the claims of effectiveness for a drug.

We agree that randomization and the use of concurrent controls are two principal means of ensuring that clinical trial data are reliable and robust. However, that does not mean that in order to be adequate and well-controlled, a clinical trial must use a randomized concurrent control design. Section 314.126(b) lists the characteristics of an adequate and well-controlled study. Contrary to your assertion (Petition at 24), FDA regulations do not require that a study be blinded, randomized, and/or concurrently controlled. Among the characteristics of an adequate and well-controlled study is that it uses a design that permits a valid comparison with a control to provide a quantitative assessment of drug effect (§ 314.126(b)(2)). A historical control is one of the recognized types of control (§ 314.126(b)(2)(v)), and one in which the results of treatment with the test drug are compared with experience historically derived from the adequately documented natural history of the disease or condition, or from the results of active treatment in comparable patients or populations (id.). Unlike some other types of control (e.g., placebo concurrent control (§ 314.126(b)(2)(ii)) or dose-comparison concurrent control (§ 314.126(b)(2)(ii))), use of a historical control does not include randomization or blinding. Because historical control populations usually cannot be as well assessed with respect to pertinent variables as can concurrent control populations, historical control designs are usually reserved for special circumstances, including studies in which the effect of the drug is self-evident. Thus, in the proper setting,
Docket No. FDA-2002-P-0364

historically controlled trials can be considered adequate and well-controlled, and there is no need for the other types of control listed in § 314.126(b)(2). 28

The use of historical controls in the Mifeprex clinical trials was appropriate for two reasons. First, the natural history of a viable pregnancy is adequately documented (a pregnancy continues on average for 40 weeks' gestation). 29 Second, the effect of Mifeprex is dramatic, occurs rapidly following treatment, and has a low probability of having occurred spontaneously. 30 Furthermore, contrary to your assertion (Petition at 32-34), the use of a historical control in these circumstances is consistent with ICH's guidance for industry, **E10 Choice of Control Group and Related Issues in Clinical Trials** (E10 Guidance). 31 The E10 Guidance addresses external controls (including historical controls) that are used in externally controlled trials to compare a group of subjects receiving the test treatment with a group of patients external to the study, rather than with an internal control group consisting of patients from the same population assigned to a different treatment. 32 The guidance states that the "external control may be defined (a specific group of patients) or non-defined (a comparator group based on general medical knowledge of outcome)." 33

cite are complications that can be associated with all abortions (including surgical abortion, missed abortion (non-viable pregnancy that has not been expelled from the uterus), and spontaneous abortion.

28 You cite to a statement in the May 21, 1996, Statistical Review regarding the two French trials that "[i]n the absence of a concurrent control group in each of these studies, it is a matter of clinical judgement whether or not the sponsor’s proposed therapeutic regimen is a viable alternative to uterine aspiration for the termination of pregnancy" (Petition at 27). FDA’s finding that Mifeprex was safe and effective for its labeled indication occurred after 12 weeks" (Fritz, M and L Speroff, 2011, Clinical Gynecologic Endocrinology and Infertility (8th ed.), Williams and Wilkins, Philadelphia, at 535; see also Stenchever, MA, 2001, Comprehensive Gynecology (4th ed.), Mosby, at 414). According to the National Library of Medicine, “[a]mong women who know they are pregnant, the miscarriage rate is about 15-20%. Most miscarriages occur during the first 7 weeks of pregnancy,” (Miscarriage, available on the MedlinePlus Web site at http://www.nlm.nih.gov/medlineplus/ency/article/001488.htm).


30 Although sources and studies differ somewhat, the 92% success rate following mifepristone/misoprostol use far exceeds the rate of spontaneous abortion (spontaneous miscarriage). One source states: "No less than 30% and as much as 60% of all conceptions abort within the first 12 weeks of gestation, and at least half of all losses go unnoticed. Most recognized pregnancy losses occur before 8 weeks' gestation, and relatively few occur after 12 weeks" (Fritz, M and L Speroff, 2011, Clinical Gynecologic Endocrinology and Infertility (8th ed.), Lippincott Williams & Wilkins, Philadelphia, at 1193). Other sources indicate that 15% of all pregnancies between 4-20 weeks of gestation spontaneously abort (See Speroff, L, et al., 1989, Clinical Gynecologic Endocrinology and Infertility (4th ed.), Williams and Wilkins, Baltimore, at 535; see also Stenchever, MA, 2001, Comprehensive Gynecology (4th ed.), Mosby, at 414). According to the National Library of Medicine, “[a]mong women who know they are pregnant, the miscarriage rate is about 15-20%. Most miscarriages occur during the first 7 weeks of pregnancy.” (Miscarriage, available on the MedlinePlus Web site at http://www.nlm.nih.gov/medlineplus/ency/article/001488.htm).


32 Id.

33 Id.
Moreover, the E10 Guidance clearly states that, notwithstanding certain limitations of external controls, including the possibility of bias, external controls can be appropriate under circumstances where the effect of the treatment is dramatic and the usual course of the disease or condition is highly predictable. In other words, historical controls can be appropriate in circumstances such as medical termination of early pregnancy. The use of the expected rate of spontaneous abortion during early pregnancy as the control in the Mifeproxic clinical trials was appropriate and fully consistent with FDA regulations and guidance. The applicant could rely on the data from the three trials to support approval because they were adequate and well-controlled, using a historical control.

It is not uncommon for the drug product review divisions in FDA’s Center for Drug Evaluation and Research (CDER) to accept for filing and approve applications that rely on clinical trials employing historical controls to support approval for drug products in which the outcome of the condition is well known and the effect of the drug is anticipated to be markedly different from that of a placebo. Examples include FDA’s approval of numerous oncology drug products, including, for example, Xalkori (crizotinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test, and Adcetris (brentuximab vedotin) for the treatment of patients with Hodgkin lymphoma and a rare lymphoma known as systemic anaplastic large cell lymphoma. Other examples include iPlex (mecasermin rinfabate [rDNA origin] injection) for treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH; Myozyme (alglucosidase ALFA) for use in patients with Pompe disease (GAA deficiency); Ferriprox (deferiprone) for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate; Voraxae (glucarpidase) for treatment of toxic (>1 micromole per liter) plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function; and Elelyso (taliglucerase alfa) for injection for use as a long-term enzyme replacement therapy in patients with Type 1 Gaucher disease. Similarly, it is not unusual for the CDER review divisions to accept for filing applications relying on historically controlled clinical trials. Examples of reproductive drug products for which a historical control is often relied on in the drug approval process include contraceptive drug products (e.g., most birth control pills, Mirena intrauterine device, NuvaRing [an intravaginal hormonal contraceptive], and Implanon [an implanted hormonal contraceptive]) and menopausal hormonal therapy products with the addition of a progestin to prevent endometrial cancer secondary to unopposed estrogen stimulation.

34 Id. at 27.

35 We disagree with your statement that the sponsor’s failure to identify precisely a historical control group is fatal to its claim that the trials supporting the approval of Mifeproxic were historically controlled (Response to Opposition at 5-6). In situations where an investigational product is anticipated to have an effect that is readily discernible and greatly exceeds that which would be expected otherwise, the historical control may be relied upon without explicitly describing it as such. Examples of situations where this arises include, as here, the use of a drug for early medical abortion, given that the majority of pregnancies continue to term, and the use of a drug as a contraceptive, given that the pregnancy rate in sexually active women between 18 and 35 years old in the absence of contraception for one year is well documented at approximately 85% (Hatcher, RA, et al., 2012, Contraception Technology (20th ed.), Ardent Media, Inc., at 780.)
Docket No. FDA-2002-P-0364

You state that FDA did not conduct a statistical review of the results of the U.S. clinical trial (Petition at 29). The Agency, however, concluded that the clinical results of the supporting U.S. clinical trial were “similar enough to the results of the European studies” (the studies used to support the original approval of Mifeprex in Europe) that a statistical evaluation of the results of the U.S. trial was not required. 36

You maintain that the Mifeprex approval is not in accordance with Agency guidance 37 on when only one effectiveness trial may be necessary for approval because: (1) mifepristone had not been approved for any use in any population in the United States and (2) no one had ever presented to FDA any evidence from adequate and well-controlled trials regarding any use for mifepristone. 38

As stated above, our approval of Mifeprex was based on not one but three studies that met the requirements of § 314.126. Therefore, Agency guidance concerning reliance on only one effectiveness trial is not relevant to the approval of Mifeprex.

You argue that FDA’s acceptance of the French and U.S. clinical trial data violated § 314.126(e), which states that uncontrolled studies or partially controlled studies are not acceptable as the sole basis for approval of claims of effectiveness (Petition at 34-36). As explained above, the Mifeprex clinical trials were neither uncontrolled nor partially controlled. They were historically controlled, and the use of an historical control was appropriate under § 314.126(b)(2)(v). Consequently, § 314.126(e) is inapplicable.

Citing § 314.500, you contend that the approval of Mifeprex under subpart H was improper because FDA did not require the concurrent testing of mifepristone with surgical abortion to test the proposition that mifepristone provides a meaningful therapeutic benefit over the standard method for terminating pregnancies (Petition at 37-40). You maintain that Mifeprex is the only drug that we have approved under § 314.520 (approval with restrictions to assure safe use) without requiring “that safety and efficacy be scientifically demonstrated through blinded, comparator-controlled, and randomized clinical trials” (Petition at 37).

Nothing in subpart H requires that an applicant conduct comparative clinical trials in order to demonstrate that a drug product provides meaningful therapeutic benefit to patients over existing treatments. Furthermore, nothing in the concept of “meaningful therapeutic benefit” requires concurrent testing of a proposed drug with an existing treatment. 39 We have approved other drugs


38 Petition at 31-32 (citing Effectiveness Guidance at 5-17).

39 You state that “[c]onducting a concurrently-controlled randomized trial comparing surgical abortion with the mifepristone-misoprostol regimen is readily achievable” (Petition at 32, note 145). You add that “[t]here are study designs that would have also allowed for blinding” (Id.). Assuming, arguendo, that it may have been feasible to design a randomized, concurrently-controlled study, such study was not required under our regulations; as described previously in this response, the clinical trials supporting the approval of Mifeprex.
under subpart H based on clinical trials that do not directly compare the drug to an existing therapy, including Gleevec (imatinib mesylate), Tracleer (bosentan), and Xyrem (sodium oxybate). We also note that the latter two referenced drug products, Tracleer (bosentan) and Xyrem (sodium oxybate), were approved under the restricted distribution provisions at 21 CFR 314.520. As previously explained in this response, Mifeprex was deemed to have in effect an approved REMS under Title IX of FDAAA. The Mifeprex REMS, which was approved in June 2011 and is still in effect, incorporated the subpart H restrictions under which the drug was approved.

As evidenced by the foregoing, the studies supporting the 2000 approval of Mifeprex were consistent with the FD&C Act and FDA regulations, including § 314.126 and subpart H.

2. There Is No Need for an Audit of the French Clinical Data

You assert that FDA allowed “tainted data” to support the Mifeprex NDA by failing to require a comprehensive audit of the French clinical trial data after discovering violations of good clinical practices (Petition at 40–41). You maintain that we should therefore conduct a complete audit of all of the French clinical trial data to determine whether other trials must be conducted (Petition at 41 and 89).

We disagree with your characterization of both the French data and FDA’s reliance on that data. You reference the Form FDA 483 issued on June 28, 2006, to Dr. Elisabeth Aubeny, as well as the Summary of Findings related to that Form FDA 483. It is not uncommon to have trial sites receive a Form FDA 483, listing the FDA investigator’s observations regarding non-compliance with good clinical practice, at the conclusion of an inspection. The investigator will draft an Establishment Inspection Report (EIR) that reviews the violations noted and will recommend an action, taking into consideration the nature of the inspectional findings, any actions that occurred following the findings, and Agency policy. For products regulated by CDER, compliance reviewers in the Division of Clinical Compliance Evaluation in the Office of Scientific Investigations (previously, the Division of Scientific Investigations) review the EIR, the Form FDA 483, and the evidence collected during the inspection, as well as any written response submitted timely by the inspected party, to determine whether the recommended action is appropriate and is supported by adequate evidence. This review evaluates each violation’s effect on the timeliness, accuracy, and/or completeness of the data collected from the site to ascertain if the data are reliable. In this particular case, although there were violations cited on the Form FDA 483 and discussed in the EIR, the violations were determined not to affect the reliability of the data provided by that site. The statement you quote from the Summary of Findings reflects this conclusion. We note that, although the French studies were not performed under a U.S. investigational new drug application (IND), this is typical of many approved drugs that originally were developed or studied outside the United States, and is fully permissible under 21 CFR 312.120 (Foreign clinical studies not conducted under an IND) (including the version of the provision in effect at the time of the 2000
Docket No. FDA-2002-P-0364

It is worth noting that in 1996, when the Advisory Committee reviewed the French data without considering the U.S. data, the committee voted 6 to 2 that the French data alone demonstrated efficacy and 7 to 0 (with one abstention) that the French data supported safety.\textsuperscript{41} The subsequent approval of Mifeprex was based not only on the data from the two French trials but also on the data from the large Phase 3 U.S. trial. The Advisory Committee received a report on the U.S. trial (the article by Spitz, et al., referenced in note 12 above) and had no comments.

For the foregoing reasons, there is no scientific or regulatory need for us to further review the French clinical data on Mifeprex.

3. Your Request for an Audit of the U.S. Clinical Data

In addition to your request that FDA conduct a full audit of the data from the French trials, you request that FDA conduct a full audit of all data from the U.S. trial (Petition at 1-2 and 89). Other than one footnote referring to a letter from the NDA sponsor to FDA (Petition at 89, note 384), you have provided no information supporting this request. Accordingly, we do not address this request further, other than to note that we do not believe there is any scientific or regulatory need to further review the U.S. clinical trial data relied on for approval of the Mifeprex NDA.

C. FDA Lawfully Approved Labeling for Mifeprex for Use with Misoprostol

You contend that FDA’s “de facto” approval of misoprostol for use with Mifeprex as part of a medical abortion regimen was unlawful because the holder of the only approved NDA for misoprostol\textsuperscript{42} did not submit a supplemental NDA for this new use (Petition at 41-45). You further

\textsuperscript{40} The regulations in effect at the time of the Mifeprex approval in 2000 refer to FDA accepting such studies when they are “well designed, well conducted, performed by qualified investigators, and conducted in accordance with ethical principles acceptable to the world community” FDA has generally interpreted that language as incorporating the principles of “good clinical practice” (see, e.g., ICH guidance for industry, \textit{ICH E6 Good Clinical Practice: Consolidated Guidance} (E6 Guidance), available on the FDA Drugs Web page at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm), which is the term used in the current regulations. The E6 Guidance states that GCP:

is an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety, and well-being of trial subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and that clinical trial data are credible

(E6 Guidance at 1).

\textsuperscript{41} Mifeprex Approval Memorandum, supra note 16, at 1.

\textsuperscript{42} Two abbreviated new drug applications (ANDAs) for misoprostol have been approved since Mifeprex was approved: ANDA 076095 (IVAX Pharmaceuticals, Inc., approved July 10, 2002) and ANDA 091667 (Novel Laboratories Inc., approved July 25, 2012).
argue that FDA not only sanctioned, but participated in, the promotion of an off-label use of misoprostol by overseeing the creation of Mifeprex promotional materials that discuss the off-label use of misoprostol and by disseminating information about the off-label use in documents such as the press release announcing Mifeprex’s approval (Petition at 46-47).

The approval of Mifeprex was based on evidence from three adequate and well-controlled clinical trials using the treatment regimen of administration of mifepristone on day one, followed approximately 48 hours later (i.e., on day three) by the administration of misoprostol (unless a complete abortion has already been confirmed before that time). Neither the FD&C Act nor FDA regulations require the submission of a supplemental NDA by the sponsor of the misoprostol NDA for the use of misoprostol as part of the approved treatment regimen for Mifeprex. In this situation, the “drug product” subject to section 505(b) of the FD&C Act (21 U.S.C. 355(d)) was Mifeprex. The NDA for Mifeprex appropriately contained the full reports of investigations which have been conducted to show whether or not “such drug” is effective in use (§ 505(b)(1) of the FD&C Act), and FDA appropriately found that the Mifeprex NDA met the approval requirements in § 505(d) of the FD&C Act.

There are a number of drug products that FDA has approved as safe and effective in combination with another drug for a use that was not sought by the applicant of the second drug product, and for which the Agency did not require any change in the labeling of the second product (i.e., that the second product’s labeling include the indication for use with the newly approved drug product). Examples of approved drug labeling that refer to the concomitant use of another drug without there being a specific reference to the combined therapy in the previously approved labeling for the referenced drug include the following:

- Xeloda (capecitabine) for treatment of metastatic breast cancer in combination with Taxotere (docetaxel) after failure of prior anthracycline-containing therapy.

43 In the Response to Opposition, you reference a July 2, 2002, letter submitted by the Population Council to Docket 01E-0363 re: Determination of Regulatory Review Period for Purposes of Patent Extension; Mifeprex (Response to Opposition at 12-13). In its July 2, 2002, letter, the Population Council made several statements regarding what it believed should be considered “the approved human drug product” for purposes of 21 CFR 60.22(a)(1), for purposes of patent term restoration. In the Agency’s October 24, 2002, notice amending FDA’s previous determination of the regulatory review period for Mifeprex (67 FR 65558), we addressed — and rejected — the Population Council’s assertions. We stated that “[t]he applicant tries to characterize Mifeprex as mifepristone ‘in combination with another active ingredient’ in an attempt to take advantage of portions of the definition of ‘human drug product’ in 35 U.S.C. 156(f), that is, a human drug product means ‘the active ingredient of a new drug * * * as a single entity or in combination with another active ingredient.’ The applicant points to the definition of ‘combination product’ at 21 CFR 3.2(e) in this effort. A more useful description of a drug ‘in combination with another active ingredient’ is found at 21 CFR 300.50 (two or more drugs combined in a single dosage form). Mifeprex is not mifepristone ‘in combination with another active ingredient.’ Mifeprex is single entity mifepristone” (67 FR 65558, note 2).

44 We note your assertion that when Xeloda and Taxotere are used together, each is being used for an FDA-approved use (Response to Opposition at 11). Taxotere (docetaxel) was approved on May 14, 1996; its current labeling states that it is indicated as a single agent for treatment of locally advanced or metastatic breast cancer after failure of prior chemotherapy, and in combination with doxorubicin and cyclophosphamide as adjuvant treatment of patients with operable node-positive breast cancer. Xeloda (capecitabine), which
You maintain that the labeling for Mifepristone is misleading because it directs physicians to use misoprostol for a purpose that FDA never approved and because it creates the false expectation that misoprostol is approved for medical abortion (Petition at 47). We disagree that the labeling for Mifepristone is misleading by virtue of the fact that it includes instructions for the use of misoprostol as part of the approved treatment regimen for Mifepristone. The Mifepristone labeling appropriately describes the clinical trial treatment regimen in which Mifepristone was shown to be safe and effective. The labeling for Mifepristone makes clear that Mifepristone tablets contain mifepristone, not misoprostol, and although the Indication and Usage section in the 2000 labeling does address the use of misoprostol in a regimen with Mifepristone, the labeling is clearly addressed to Mifepristone.

You claim that Mifepristone is misbranded because, per 21 CFR 201.6(a), the references to misoprostol in the Mifepristone labeling constitute a false or misleading representation that misoprostol itself is approved for medical termination of pregnancy (Petition at 48). In addition, you contend that Mifepristone is misbranded under section 502(j) of the FD&C Act (21 U.S.C. 352(j)) because it is unsafe when used as directed in the 2000 approved labeling (id.).

The references to misoprostol in the Mifepristone labeling do not render Mifepristone misbranded as described in § 201.6(a) because the labeling does not make any false or misleading representations with regard to misoprostol. We determined, and the labeling reflects, that Mifepristone is safe and effective for the termination of early pregnancy when used in combination with misoprostol. The approval was based on evidence from adequate and well controlled clinical trials in which misoprostol was administered two days after mifepristone to help stimulate uterine contractions; accordingly, the approved labeling describes the use of Mifepristone in combination with misoprostol.
Additionally, the approved labeling in no way implies that misoprostol alone would be safe and effective for the termination of pregnancy. Thus, the statements in the labeling are neither false nor misleading with regard to the use of misoprostol.

With regard to section 502(j) of the FD&C Act, Mifeprex is not misbranded under that provision because, as discussed in the following section, the approved regimen for Mifeprex is not “dangerous to health when used in the dosage or manner, or with the frequency or duration prescribed, recommended, or suggested in the labeling thereof.”

D. Mifeprex Is Safe for Its Approved Use and the Conditions of Approval Do Not Lack Essential Safeguards

You contend that FDA “approved mifepristone for use in a deregulated regimen that lacks key safeguards” (Petition at 5). You claim that in 2000, the Population Council repudiated distribution restrictions that it had proposed in 1996, and that FDA subsequently approved a regimen that does not embody restrictions sufficient to address legitimate safety concerns (Petition at 49). You note that the February 18, 2000, Mifeprex approvable letter stated that restrictions (per § 314.520) on the distribution and use of Mifeprex were needed to ensure safe use of the drug but that in March 2000, the Population Council said such restrictions were unwarranted (Petition at 51-52). You claim that we later yielded to the applicant on several important issues (Petition at 54-55).

FDA has found that Mifeprex is safe and effective for its intended use. It is true that, before the 2000 approval of Mifeprex, FDA and the applicant were not always in full agreement about the distribution restrictions. It is not unusual for such differences to emerge during the course of the review process for a proposed drug product. We ultimately determined that the distribution restrictions stated in the approval letter were appropriate to ensure the safety of Mifeprex for its intended use.45 Three adequate and well-controlled clinical trials supported the safety of Mifeprex for its intended use, and over 15 years of postmarketing data and many comparative clinical trials in the United States and elsewhere continue to support the safety of this drug product.46 Further, we approved a risk evaluation and mitigation strategy (REMS) for Mifeprex in June 2011, consisting of a Medication Guide, elements to assure safe use, an implementation system, and a timetable for submission of assessments of the REMS.

Following is our response to the specific safety issues you raise in the Petition.

1. Ultrasound Dating

---

45 We note your reference in your Response to Opposition to the statement by the Reproductive Health Drugs Advisory Committee that it had concerns about the distribution proposal discussed at the July 19, 1996, meeting (Response to Opposition at 4 (referencing the minutes from the 1996 Reproductive Health Drugs Advisory Committee meeting)). In light of FDA's determination in 2000 that the distribution restrictions stated in the approval were appropriate to ensure that Mifeprex was safe for its intended use, as well as the 2011 approval of the Mifeprex REMS, the Committee's reservations in 1996 are not applicable.

46 See, e.g., Raymond, EG, et al., 2013, First-Trimester Medical Abortion With Mifepristone 200 mg and Misoprostol: A Systematic review, Contraception, 87:26-37. In this article, 87 trials were reviewed and 91 references were cited.
You maintain that the Mifeprex regimen is unsafe because it does not require ultrasound examination. Specifically, you maintain that the use of transvaginal ultrasound is necessary to accurately date pregnancies and to identify ectopic pregnancies, and you note both that Mifeprex was approved in 2000 only for women through 49 days' gestation and that it is contraindicated for women with a confirmed or suspected ectopic pregnancy (Petition at 57-61).

Although the protocol for the U.S. clinical trial required a transvaginal sonogram (TVS) for each patient at Visit 1 and stated that the test should be used “as indicated” at Visits 2 and 3, this does not mean that a TVS is essential to ensure the safe use of Mifeprex. As stated in the Mifeprex Approval Memorandum, during the review process, the Agency carefully considered the role of ultrasound. In the clinical trials, ultrasound was performed to ensure proper data collection on gestational age, but in clinical practice, pregnancies can also be (and frequently are) dated using other clinical methods. (As discussed in section II.F below, safeguards employed during clinical trials are not always essential for safe use of the approved drug product.) As part of the restricted distribution of Mifeprex put in place in 2000, each provider must have the ability to accurately assess the duration of pregnancy and to diagnose ectopic pregnancy. We determined that it was inappropriate for us to mandate how providers clinically assess women for duration of pregnancy and for ectopic pregnancy. These decisions should be left to the professional judgment of each provider, as no method (including TVS) provides complete accuracy. The approved labeling for Mifeprex recommended ultrasound evaluation as needed, leaving this decision to the judgment of the provider.

You claim that the only way to date a pregnancy accurately enough to exclude EGA > 49 days is by using TVS (Petition at 58). That is incorrect. As noted above, using TVS (or any other method) does not ensure complete accuracy in dating a pregnancy. In most cases, a provider can accurately make such a determination by performing a pelvic examination and obtaining a careful history, which would include the following: date of last menstrual period, regularity of menses, intercourse history, contraceptive history, and (if available) home pregnancy test results. If in doubt, the provider can order an ultrasound and/or a blood test measuring the quantitative beta-human chorionic gonadotropin (hCG) to further assist in dating the gestational age.

Furthermore, use of a TVS does not guarantee that an existing ectopic pregnancy will be identified. As of April 30, 2015, there were 89 unduplicated reports in FDA’s Adverse Event Reporting System (FAERS) database of ectopic pregnancy in women in the United States who had received mifepristone for termination of pregnancy since the approval of Mifeprex in the United States. In

\[\text{We note that the French clinical trials did not require an ultrasound examination; rather, the decision as to whether an ultrasound was needed was left to the discretion of the investigator.}\]

\[\text{Mifeprex Approval Memorandum, supra note 16, at 5.}\]

\[\text{See, e.g., Fielding, SL, et al., 2002, Clinicians’ Perception of Sonogram Indication for Mifepristone Abortion up to 63 Days, Contraception, 66:27-31 (discussing the results of a prospective study of 1,016 women in a medical abortion trial at 15 sites that concluded that “clinicians correctly assessed gestational age as no more than 63 days in 87% of women. In only 1% (14/1013) of their assessments did clinicians underestimate gestational age. We conclude that the clinicians felt confident in not using ultrasound in most cases”).}\]
Docket No. FDA-2002-P-0364

42.7% (38 of 89) of the reported cases, an ultrasound was completed. Of the 38 cases that had an ultrasound completed, 55.3% (21 of 38) showed no changes indicative of ectopic pregnancy. In light of the fact that Mifeprex is contraindicated for women with a confirmed or suspected ectopic pregnancy, we believe it is reasonable to expect that the women's providers would not have prescribed Mifeprex if a pelvic ultrasound examination had clearly indicated an ectopic pregnancy; this strongly suggests, therefore, that ultrasound examinations were falsely negative for ectopic pregnancy in these women. The currently approved labeling for Mifeprex reflects this, stating that the "presence of an ectopic pregnancy may have been missed even if the patient underwent ultrasonography prior to being prescribed Mifeprex."51

2. Physician Training and Admitting Privileges

You contend that the administration of Mifeprex should have been restricted to physicians who have formal training in both pharmaceutical and surgical abortion and who have admitting privileges to emergency facilities (Petition at 62-65).

Although we did not restrict the administration of Mifeprex to physicians with the specific requirements you list in your Petition, we did conclude in 2000 that Mifeprex had to be provided by a physician who, among other qualifications, either (1) has the ability to provide surgical intervention in cases of incomplete abortion or severe bleeding or (2) has made plans to provide such care through other qualified providers and facilities.

During the clinical trials for Mifeprex, the principal investigators were trained in surgical abortions and were able to conduct any necessary surgical interventions. The protocol for the U.S. trial was designed such that the studies were conducted at 17 centers where the principal investigators could perform abortions by either vacuum aspiration or dilatation and curettage and had access to facilities that provided blood transfusions and performed routine emergency resuscitation procedures.

During the NDA review process, the issue of physician qualifications and certification was thoroughly discussed within the Agency, with the applicant, and with an outside consultant with expertise in early pregnancy termination. Although the distribution of Mifeprex was not restricted to any particular medical specialist, the Agency did determine in 2000 that certain restrictions were

---

50 Seventeen cases were identified as having an ultrasound with a possible ectopic pregnancy. Fourteen of these 17 (82.3%) cases noted appropriate follow-up procedures, such as additional hCG monitoring, ultrasounds, appointments, or emergency room referral, while two cases did not include any additional follow-up information. In the remaining case, a diagnosis of a heterotopic gestation (simultaneous ectopic pregnancy and intrauterine pregnancy) was noted.


52 Additionally, it is common in drug development that the clinical investigators who conduct pivotal Phase 3 clinical trials have more specialized training than may be necessary to ensure the safe use of a drug post-approval. Examples are trials for male erectile dysfunction (typically conducted by urologists), hypertension (internists), depression (psychiatrists), and endometriosis (gynecologists).
necessary under § 314.520. In accordance with this determination, the Prescriber’s Agreement for Mifeprex stated the following: 53

Under Federal law, Mifeprex must be provided by or under the supervision of a physician who meets the following qualifications:

- Ability to assess the duration of pregnancy accurately.
- Ability to diagnose ectopic pregnancies.
- Ability to provide surgical intervention in cases of incomplete abortion or severe bleeding, or have [sic] made plans to provide such care through others, and are [sic] able to assure patient access to medical facilities equipped to provide blood transfusions and resuscitation, if necessary.
- Has read and understood the prescribing information of Mifeprex....

As noted in the Mifeprex Approval Memorandum, the requirement that a physician certify, by signing the Prescriber Agreement, that he or she has the qualifications described in that Agreement limited the physicians who would be eligible to receive Mifeprex from the sponsor to those who are familiar with managing early pregnancies. 54 Because only such qualified physicians would be using or would oversee the use of Mifeprex, we concluded that there was no need for special certification programs or additional restrictions. Additionally, as noted in the Mifeprex Approval Memorandum, in the U.S. clinical trial of Mifeprex, 11 out of roughly 850 patients needed surgical intervention to treat bleeding, and three of these patients were treated by non-principal investigators such as emergency room physicians and a non-study gynecologist. 55 These data suggested that patients would receive any needed surgical intervention from either their physician or another physician with the needed skills. 56 The Mifeprex Approval Memorandum also pointed out that the Mifeprex labeling and the Medication Guide approved at that time highlight that surgery may be needed and that patients must understand whether the provider will furnish any necessary medical intervention or whether they will be referred to another provider and/or facility. 57

In addition, one of the Phase 4 commitments accompanying the approval of Mifeprex was a cohort-based study of safety outcomes when Mifeprex is prescribed by physicians with the skills for surgical intervention compared to physicians who refer patients for surgical intervention. In a February 2008 submission, the applicant stated that so few medical abortions are prescribed by physicians who do not have surgical intervention skills that it was not feasible to do a meaningful

---


54 Mifeprex Approval Memorandum, supra note 16, at 5.

55 Id.

56 Id.

57 Id.
Docket No. FDA-2002-P-0364

study to assess this specific issue. After review of this submission, the Agency: (1) concurred with the applicant regarding the non-feasibility of conducting a meaningful study and (2) concluded that no differences between non-referrers or referrers in terms of clinical outcomes could be identified based on the data that had been submitted. Accordingly, on September 26, 2008, the Agency released the applicant from this commitment.

The provisions of the currently approved labeling (including the REMS) that relate to provider training and admitting privileges are substantially similar to the labeling provisions approved in 2000. Under current labeling, healthcare providers who administer Mifeprex must be licensed to prescribe, and must have the ability to date pregnancies accurately and to diagnose ectopic pregnancies. These healthcare providers must also (1) be able to provide any necessary surgical intervention, or (2) have made arrangements for others to provide for such care. Healthcare providers must be able to ensure that women have access to medical facilities for emergency care, and must agree to other responsibilities, including reviewing and signing the Patient Agreement Form with the patient and providing each patient with a copy of the signed Patient Agreement Form and the Medication Guide. 58

3. “Dear Health Care Provider” Letter and FDA “Mifepristone Questions and Answers”; Adverse Events Discussed in Response to Opposition

You maintain that your concerns about the safety of Mifeprex are validated by the April 19, 2002, “Dear Health Care Provider” letter issued by Danco and by statements in the “Mifepristone Questions and Answers” (Mifepristone Q&A) document (placed on FDA’s Web site on April 17, 2002) about reports of serious adverse events, including ruptured ectopic pregnancies and serious systemic bacterial infections (Petition at 65-71). You argue that FDA understated the possibility that the Mifeprex regimen caused the serious adverse events referred to in the letter and inappropriately attempted to link those events to the unapproved vaginal administration of misoprostol (Petition at 67-68).

The fact that Danco and FDA agreed that there was a need to issue a Dear Health Care Provider letter in April 2002 (or that a subsequent Dear Health Care Provider letter and a Dear Emergency Room Director letter were issued on September 30, 2004) does not imply that the approved Mifeprex regimen is unsafe. It is not uncommon for drug sponsors to issue “Dear Health Care Provider” letters, and, as noted in the Mifepristone Q&A document posted on our Web site in April 2002, “[w]hen FDA receives and reviews new information, the agency provides appropriate updates to doctors and their patients so that they have essential information on how to use a drug safely.” 59 The intent of the two “Dear Health Care Provider” letters and the “Dear Emergency Room Director” letter was to provide health care personnel with new safety information regarding the use of Mifeprex. Similarly, when these letters were issued, we posted Mifepristone Q&A documents to

Docket No. FDA-2002-P-0364

address questions that might arise as a result of the issuance of the letters. We disagree that we have in any way “inappropriately attempted to link” the adverse events to the intravaginal use of misoprostol. Rather, the April 2002 Mifepristone Q&A document accurately stated that in all of the adverse event cases at that time,\(^{60}\) the misoprostol was given vaginally not orally; that we did not know what role, if any, the use of Mifeprex and vaginal misoprostol may have in the development of serious infections; and that FDA had not reviewed data on the safety and effectiveness of vaginal administration of misoprostol.

You maintain that it is particularly important for FDA to respond to these adverse events because the clinical trials in support of Mifeprex allegedly did not adhere to the Agency’s scientific methodology for such trials (Petition at 70). As explained above, however, the clinical trials supporting the approval of Mifeprex were adequate and well-controlled, and they provided substantial evidence of the safety and effectiveness of the drug product in accordance with the FD&C Act and FDA regulations.

In your Response to Opposition, you state that the serious adverse events reported to date are consistent with concerns expressed before approval (Response to Opposition at 16). You refer to the death of Holly Patterson on September 17, 2003, after she had taken Mifeprex and misoprostol to terminate her pregnancy. You state that Ms. Patterson’s apparent death from a serious systemic bacterial infection after taking Mifeprex is “not the first such death since FDA approved Mifeprex,” referring to a fatality due to serious systemic bacterial infection mentioned in the April 2002 “Dear Health Care Provider Letter” (Response to Opposition at 16-17). You also question whether adverse events for Mifeprex will be adequately reported to FDA (Response to Opposition at 18).

As with all approved drug products, we continue to monitor the safety of Mifeprex. Since the approval of Mifeprex, the Agency has issued two public health advisories (one in July 2005\(^{61}\) and one in March 2006\(^{62}\)) and posted multiple MedWatch safety alerts (in November 2004\(^{63}\) and July 2005, the latter with updates in November 2005 and March 2006\(^{64}\)). As referenced above, Danco has issued two Dear Health Care Provider letters and one Dear Emergency Room Director letter. Furthermore, since you submitted your Response to Opposition, Danco has revised the labeling for

\(^{60}\) The April 2002 Mifepristone Q&A document refers to cases of ectopic pregnancy, sepsis, and heart attack.


\(^{64}\) Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111339.htm.
Docket No. FDA-2002-P-0364

Mifeprex (including the prescribing information, the Medication Guide, and the Patient Agreement), in November 2004, December 2004, July 2005, and April 200965 to provide prescribers and women with additional information about infection, vaginal bleeding, and ectopic pregnancy.

The boxed warning for Mifeprex currently states the following:

Serious and sometimes fatal infections and bleeding occur very rarely following spontaneous, surgical, and medical abortions, including following MIFEPREX use. No causal relationship between the use of MIFEPREX and misoprostol and these events has been established.

- Atypical Presentation of Infection. Patients with serious bacterial infections (e.g., Clostridium sordellii) and sepsis can present without fever, bacteremia, or significant findings on pelvic examination following an abortion. Very rarely, deaths have been reported in patients who presented without fever, with or without abdominal pain, but with leukocytosis with a marked left shift, tachycardia, hemoconcentration, and general malaise. A high index of suspicion is needed to rule out serious infection and sepsis.

- Bleeding. Prolonged heavy bleeding may be a sign of incomplete abortion or other complications and prompt medical or surgical intervention may be needed. Advise patients to seek immediate medical attention if they experience prolonged heavy vaginal bleeding.

Because of the risks of serious complications described above, MIFEPREX is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MIFEPREX REMS Program.

Before prescribing MIFEPREX, inform the patient about the risk of these serious events. Ensure that the patient knows whom to call and what to do, including going to an Emergency Room if none of the provided contacts are reachable, if she experiences sustained fever, severe abdominal pain, prolonged heavy bleeding, or syncope, or if she experiences abdominal pain or discomfort, or general malaise (including weakness, nausea, vomiting or diarrhea) for more than 24 hours after taking misoprostol.

Advise the patient to take the Medication Guide with her if she visits an emergency room or a healthcare provider who did not prescribe MIFEPREX, so that the provider knows that she is undergoing a medical abortion.

---

65 The Mifeprrex labeling also was revised in June 2011 when the REMS was approved. In addition, as described above, FDA is today approving a supplemental NDA submitted by Danco that proposed modified labeling for Mifeprrex. See Mifeprrex labeling (Mar. 29, 2016) available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist.
The WARNINGS section of the Mifeprex labeling states, in part, the following:

*With respect to infection and sepsis:*

As with other types of abortion, cases of serious bacterial infection, including very rare cases of fatal septic shock, have been reported following the use of MIFEPREx. Healthcare providers evaluating a patient who is undergoing a medical abortion should be alert to the possibility of this rare event. A sustained (> 4 hours) fever of 100.4°F or higher, severe abdominal pain, or pelvic tenderness in the days after a medical abortion may be an indication of infection.

A high index of suspicion is needed to rule out sepsis (e.g., from *Clostridium sordellii*) if a patient reports abdominal pain or discomfort or general malaise (including weakness, nausea, vomiting or diarrhea) more than 24 hours after taking misoprostol. Very rarely, deaths have been reported in patients who presented without fever, with or without abdominal pain, but with leukocytosis with a marked left shift, tachycardia, hemoconcentration, and general malaise. No causal relationship between MIFEPREx and misoprostol use and an increased risk of infection or death has been established. *Clostridium sordellii* infections have also been reported very rarely following childbirth (vaginal delivery and caesarian section), and in other gynecologic and non-gynecologic conditions.

*With respect to uterine bleeding:*

Uterine bleeding occurs in almost all patients during a medical abortion. Prolonged heavy bleeding (soaking through two thick full-size sanitary pads per hour for two consecutive hours) may be a sign of incomplete abortion or other complications and prompt medical or surgical intervention may be needed to prevent the development of hypovolemic shock. Counsel patients to seek immediate medical attention if they experience prolonged heavy vaginal bleeding following a medical abortion.

Women should expect to experience vaginal bleeding or spotting for an average of 9 to 16 days. Women report experiencing heavy bleeding for a median duration of 2 days. Up to 8% of all subjects may experience some type of bleeding for 30 days or more. In general, the duration of bleeding and spotting increased as the duration of the pregnancy increased.

Decreases in hemoglobin concentration, hematocrit, and red blood cell count may occur in women who bleed heavily.

Excessive uterine bleeding usually requires treatment by uterotonic, vasoconstrictor drugs, surgical uterine evacuation, administration of saline infusions, and/or blood transfusions. Based on data from several large clinical trials, vasoconstrictor drugs were used in 4.3% of all subjects, there was a decrease in hemoglobin of more than 2 g/dL in 5.5% of subjects, and blood transfusions were administered to ≤0.1% of subjects. Because heavy bleeding requiring surgical uterine evacuation occurs in about 1% of patients, special care should be given to patients with hemostatic disorders, hypocoagulability, or severe anemia.
MIFEPREX is contraindicated in patients with a confirmed or suspected ectopic pregnancy because MIFEPREX is not effective for terminating ectopic pregnancies. Healthcare providers should remain alert to the possibility that a patient who is undergoing a medical abortion could have an undiagnosed ectopic pregnancy because some of the expected symptoms experienced with a medical abortion (abdominal pain, uterine bleeding) may be similar to those of a ruptured ectopic pregnancy. The presence of an ectopic pregnancy may have been missed even if the patient underwent ultrasonography prior to being prescribed MIFEPREX.

Women who became pregnant with an IUD in place should be assessed for ectopic pregnancy.

The Agency has regularly completed a cumulative summary of U.S. postmarketing adverse events reported for the use of mifepristone for medical termination of pregnancy. From the approval date of Mifeprex (September 28, 2000) through October 31, 2012, we received 2,740 reports of adverse events associated with the use of mifepristone in the United States to terminate pregnancy, including 57 reports of severe infections and 416 incidences of blood loss requiring transfusion. From November 1, 2012, through April 30, 2015, we received 984 reports of adverse events associated with the use of mifepristone in the United States to terminate pregnancy, including 9 reports of severe bacterial infections and 134 incidences of blood loss requiring transfusion. As of April 30, 2015, 89 ectopic pregnancies associated with the use of mifepristone in the United States had been reported since the approval of Mifeprex. As of July 24, 2015, 17 U.S. deaths had been reported since the approval of Mifeprex. Deaths were associated with sepsis in 8 of the 17 reported fatalities (7 cases tested positive for *Clostridium sordellii*, and 1 case tested positive for *Clostridium perfringens*). Seven of the eight fatal sepsis case reported vaginal misoprostol use;
one case reported buccal misoprostol use. Seven of the nine remaining U.S. deaths involved two cases of ruptured ectopic pregnancy and one case each of the following: substance abuse/drug overdose; methadone overdose; suspected homicide; suicide; and a delayed onset of toxic shock-like syndrome. In the eighth case, the cause of death could not be established despite performance of an autopsy; tissue samples were negative for *C. sordellii*. In the ninth case, infection was ruled out and the final autopsy report listed pulmonary emphysema as the cause of death.

We disagree with your assertion that adverse event reporting for Mifeprex is "spotty" and that, as a result, the database for post-approval adverse events for Mifeprex is incomplete (Response to Opposition at 18). You are correct that reporting to the Agency's MedWatch program is voluntary, and we acknowledge that there is always a possibility with any drug that some adverse events are not being reported. We believe, however, that the potential for underreporting of serious adverse events associated with the use of Mifeprex for medical abortion has been very low because of the restricted distribution of the product and because healthcare providers have agreed in writing to report any hospitalizations, transfusions, or other serious adverse events associated with the drug to the sponsor, which is required under FDA's regulations to report all adverse events, including serious adverse events, to the Agency (see 21 CFR 314.80, 314.81). As with all drugs, we will continue to closely monitor the postmarketing safety data on Mifeprex.

Published experimental data from animal models suggest that this is a theoretical possibility, the overall event rate of serious infections does not support this. If Mifeprex were adversely affecting immune system function, we would expect to see a much higher rate of serious infections from more common organisms, as well as a higher number of deaths in Europe (where mifepristone has been approved for over 24 years) and in the United States. Contrary to your statements, data from the medical literature and findings by the CDC suggest that the critical risk factor in the reported cases of sepsis is pregnancy itself (see Miech, RF, 2005, Pathophysiology of Mifepristone-Induced Septic Shock Due to *Clostridium sordellii*, Ann Pharmacother, 39:1483-1488). In May 2006, FDA, along with the CDC and the National Institute of Allergy and Infectious Diseases at the National Institutes of Health held a workshop on emerging clostridial disease. The issue of immunosuppression also was discussed at length during this public workshop. It was clear from the presentations at the workshop that *C. sordellii* causes rapid and serious clinical illness in settings other than medical abortion, including among pregnant women who have recently undergone spontaneous abortion or term delivery. The fact that cases of *C. sordellii* have been identified both in pregnant women who have undergone medical abortion and those who have not supports the idea that the physiology of pregnancy may be a more plausible risk factor for *C. sordellii* illness than having undergone a medical abortion with Mifeprex.

FDA is aware of 11 additional deaths of women in foreign countries who used mifepristone for the termination of pregnancy. This included one death associated with sepsis (*Clostridium sordellii* identified in tissue samples) in a foreign clinical trial, and 10 deaths identified from post-marketing data. These 10 fatal cases were associated with the following: sepsis (Group A *Streptococcus pyogenes*); a ruptured gastric ulcer; severe hemorrhage; severe hemorrhage and possible sepsis; "multivisceral failure"; thrombotic thrombocytopenic purpura leading to intracranial hemorrhage; toxic shock syndrome (*Clostridium sordellii* was identified through uterine biopsy cultures); asthma attack with cardiac arrest; respiratory decompensation with secondary pulmonary infection 30 days after mifepristone in a patient on the lung transplant list with diabetes a jejunostomy feeding tube, and severe cystic fibrosis, *Clostridium septicum* sepsis (from a published literature report).

70 FDA is aware of 11 additional deaths of women in foreign countries who used mifepristone for the termination of pregnancy. This included one death associated with sepsis (*Clostridium sordellii* identified in tissue samples) in a foreign clinical trial, and 10 deaths identified from post-marketing data. These 10 fatal cases were associated with the following: sepsis (Group A *Streptococcus pyogenes*); a ruptured gastric ulcer; severe hemorrhage; severe hemorrhage and possible sepsis; "multivisceral failure"; thrombotic thrombocytopenic purpura leading to intracranial hemorrhage; toxic shock syndrome (*Clostridium sordellii* was identified through uterine biopsy cultures); asthma attack with cardiac arrest; respiratory decompensation with secondary pulmonary infection 30 days after mifepristone in a patient on the lung transplant list with diabetes a jejunostomy feeding tube, and severe cystic fibrosis, *Clostridium septicum* sepsis (from a published literature report).
E. Withdrawal of the Approval for Mifeprex Based on Current Use Is Not Appropriate

You claim that Mifeprex abortion providers have disregarded the restrictions in the approved regimen “without any reaction from FDA, the Population Council, or Danco” (Petition at 71). You also claim that “common departures from the approved regimen” have included (1) offering the regimen to women with pregnancies beyond 7 weeks and (2) eliminating the second of the three prescribed visits to the health care provider (Petition at 72-74). You argue that we should withdraw approval of Mifeprex under § 314.530(a)(4) due to the failure of the Population Council and Danco to adhere to the postmarketing restrictions in the approval letter (Petition at 71).

In the Response to Opposition, you suggest that some providers have not met their obligations because many prescriber Web sites (1) advertise the Mifeprex regimen as being available for patients whose pregnancies have progressed beyond 49 days and (2) indicate that patients take misoprostol at home rather than at the provider’s office (Response to Opposition at 19-20). Thus, you maintain that many prescribers have allowed patients to make false statements and that the applicant is obligated to stop sales to these prescribers (id. at 20). You claim that prescribers have disregarded the requirements imposed with the 2000 approval of Mifeprex to provide patients with the Medication Guide, obtain their signatures on the Patient Agreement, and give them the opportunity to read and discuss these documents (id. at 20-21). You state that because some prescribers, with the applicant’s tacit approval, have permitted patients to sign the Patient Agreement while effectively directing them not to adhere to its requirements, the applicant cannot be described as meeting its obligations (id. at 21).

FDA is aware that medical practitioners may use modified regimens for administering Mifeprex and misoprostol. However, FDA does not believe that it is appropriate to initiate proceedings under 21 CFR 314.530 or section 505(e) of the FD&C Act to withdraw the approval of Mifeprex based on available information regarding the distribution of Mifeprex.

The Mifeprex approval letter included nine items that the applicant and/or prescriber were obligated to follow. As stated earlier in this response, Mifeprex has been subject to a REMS which incorporated these restrictions, including by appending a Prescriber’s Agreement outlining required qualifications and guidelines prescribers must agree to follow. Specifically, the Prescriber’s Agreement required each physician to attest to possessing certain necessary skills and abilities related to managing early pregnancy to ensure safe use of the drug. The Prescriber’s Agreement also contained responsibilities that prescribers must carry out. The Prescriber’s Agreement stated that prescribers must have read and understood the prescribing materials.

---

71 Prescriber’s Agreement, supra note 53, at 1.
72 Id. at 1-2.
73 Id. at 1.
The 2000 Prescriber’s Agreement also required that the prescriber (1) provide each patient with a copy of the Medication Guide and the Patient Agreement, (2) fully explain the procedure to the patient, and (3) give the patient the opportunity to read and discuss the Medication Guide and Patient Agreement. FDA has no evidence, nor have you provided any evidence, that prescribers have not signed the Prescriber’s Agreement, or that women either have not been given the opportunity to read and discuss the Patient Agreement or have not signed the Patient Agreement.

As noted above, restrictions on the distribution and use of Mifeprex substantially similar to those approved in 2000 remain in place today.

F. Safeguards Employed in Clinical Trials Are Not Necessarily Essential Conditions for Approval

You maintain that we effectively approved a drug regimen that we had not tested because the Mifeprex regimen approved in 2000 does not include important safeguards employed in the U.S. clinical trial (e.g., governing physician training, use of ultrasound, 4-hour post-misoprostol monitoring, physician privileges at facilities that provide emergency care) (Petition at 75-76). You argue that we should not have extrapolated conclusions about the safety and effectiveness of the Mifeprex regimen from data generated under trial conditions that do not mirror the approved regimen (id.).

We disagree with your assertions. Furthermore, your implication that the approved conditions of use for a drug product must mirror those used in the clinical trials supporting its approval is incorrect. As discussed above with respect to ultrasound dating and physician qualifications, safeguards employed in clinical trials are often not reflected in approved drug product labeling nor are they necessarily needed for the safe and effective use of the drug product after approval. Many clinical trial designs are more restrictive (e.g., additional laboratory and clinical monitoring, stricter inclusion and exclusion criteria, more visits) than will be necessary or recommended in postapproval clinical use; this additional level of caution is exercised until the safety and efficacy of the product is demonstrated. For example, in menopause hormonal therapy trials, specialists perform periodic endometrial biopsies to establish the safety of long-term hormone use. Once the safety of the product has been established, these biopsies are not recommended in the approved product labeling, nor are they routinely performed in actual use with the approved product. During our review of the clinical data submitted in support of an NDA, we make an assessment of the procedures employed during the clinical trials and the conditions under which the drug was studied. This assessment is reflected in the approved labeling for the drug product.

Upon reviewing the data submitted in support of the Mifeprex NDA, we concluded in 2000 that restrictions requiring ultrasound dating of gestational age of the pregnancy and limiting access to Mifeprex to physicians trained in surgical abortions and capable of performing surgical intervention if complications arise subsequent to use of Mifeprex were not necessary to ensure its safe use (see discussion in section II.D above).
G. FDA Appropriately Concluded That Studies of Mifeprex in Pediatric Patients Were Unnecessary

You maintain that our 2000 approval of Mifeprex violated regulations requiring that new drugs be tested for safety and effectiveness in the pediatric population (Petition at 76). You state that although we stated in the September 28, 2000, approval letter that the application was subject to the Pediatric Rule (21 CFR 314.55), we waived the requirement without explanation (Petition at 78). You contend that the Mifeprex application was not in accordance with any of the three provisions under which an applicant may obtain a waiver under 21 CFR 314.55(c)(2) of the pediatric study requirement, for the following reasons:

- 21 CFR 314.55(c)(2)(i) does not apply because FDA maintained that Mifeprex represented a meaningful therapeutic benefit over existing treatments and because Mifeprex can be expected to be used in a substantial number of pediatric patients.
- 21 CFR 314.55(c)(2)(ii) does not apply because pediatric studies of Mifeprex would not have been either impossible or highly impractical because a large population of pediatric females becomes pregnant each year and the female population is evenly distributed throughout the country.
- 21 CFR 314.55(c)(2)(iii) does not apply because FDA stated that there was no reason to expect menstruating females under age 18 to have a different physiological outcome with the regimen than older females (Petition at 79-82).

As an initial matter, we reject your contention that the Population Council did not provide evidence from any adequate and well-controlled adult studies of Mifeprex, and that therefore it was inappropriate to rely on the submitted adult studies under § 314.55(a) with respect to the use of Mifeprex in the pediatric population (Petition at 82). As discussed above, the Mifeprex approval was based on three adequate and well-controlled clinical trials.

Our conclusion that studies of Mifeprex in pediatric patients were not needed for approval was consistent with FDA’s implementation of the regulations in effect at that time.\(^75\) We determined that there were sufficient data from studies of mifepristone. Therefore, the Mifeprex approval letter should have stated our conclusion that the pediatric study requirements were waived for premenarchal patients and that the pediatric study requirements were met for post-menarchal pediatric patients, rather than stating that we were waiving the requirements for all pediatric age groups.\(^76\)

---

\(^75\) FDA was enjoined from enforcing 21 CFR § 314.55 under Ass’n of Am. Physicians & Surgeons v. FDA, 226 F. Supp. 204 (D.D.C. 2002). However, on December 3, 2003, the President signed into law the Pediatric Research Equity Act of 2003 (PREA 2003), Public Law 108-155, which gave FDA the statutory authority to require pediatric studies of drugs when such studies are needed to ensure the safe and effective use of drugs in children. PREA 2003 stated that any waivers or deferrals that were granted under the Pediatric Rule were considered to be granted under PREA 2003 (see Section 4 of Public Law 108-155).

\(^76\) FDA’s implementation of the Pediatric Rule was still at a relatively early stage in September 2000 and the Agency was not always precise regarding the language used in approval letters to distinguish between situations where studies were waived and where studies were not needed because the requirements were met.
Docket No. FDA-2002-P-0364

It is still our scientific opinion, based on the medical literature and over 15 years of use in the United States, that there is no biological reason to expect menstruating females under age 18 — compared to women age 18 and older — to have a different physiological outcome with the Mifeprex regimen.²⁷

H. The Mifeprex Approval Letter Included Appropriate Phase 4 Commitments

You state that although the Population Council agreed in 1996 to perform Phase 4 studies with six different objectives, the Mifeprex approval letter included only two Phase 4 study obligations (Petition at 85-86). You allege that the changes in its Phase 4 commitments were largely in response to the Population Council’s unwillingness to explore the “ramifications” of the Mifeprex regimen (Petition at 87). You maintain that this alleged “curtailment” of Phase 4 study commitments was arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law (Petition at 88).²⁸

We disagree with your assertions. Our process for determining the appropriate Phase 4 studies for Mifeprex adequately addressed our concerns and reflected typical Agency-applicant interactions to reach consensus on appropriate postmarketing studies.²⁹ It is common for proposed Phase 4 commitments to evolve during the application review process. As you note (Petition at 85), in 1996, the Population Council committed to six postmarketing studies with the following objectives:

²⁷ In the Mifeprex Approval Memorandum, the Office Director stated, “FDA agrees there is no biological reason to expect menstruating females under age 18 to have a different physiological outcome with the regimen. The Spitz data actually suggests a trend towards increased success of medical abortion with younger patients” (Mifeprex Approval Memorandum, supra note 16, at 7).

²⁸ We note that post-marketing studies are not required for approvals under 21 CFR 314.520.

²⁹ You also state that, “[a]s a general rule, the clinical trials required by FDA to support an NDA are adequate to establish short-term drug safety and effectiveness. The standard pre-approval clinical trials, however, are typically incapable of providing either the amount or type of data necessary to assess a drug’s long-term effects” (Petition at 84). This argument is not relevant to Mifeprex, which is approved for medical termination of pregnancy. Mifeprex is not approved for long-term or chronic use, which is an important factor in assessing the need to study long-term effects of a drug. Long-term safety for a single-dose medication is generally not a concern. However, FDA routinely monitors postmarketing safety data for all approved drugs. Mifeprex is no exception. FDA’s Office of Surveillance and Epidemiology continuously monitors available safety data from use of mifepristone for termination of pregnancy both within and outside of the United States and has not identified any long-term safety signals. The Mifeprex adverse events reported are consistent with product labeling and with what can be expected with spontaneous and surgical abortions. Furthermore, as explained in this response, since Mifeprex’s approval, safety concerns and adverse events have been monitored through enhanced surveillance and reporting by certified prescribers, and we have required a REMS for Mifeprex including a Medication Guide, elements to assure safe use, an implementation system that requires the sponsor to assess the performance of certified distributors, and a timetable for submission of assessments of the REMS. We also continue to closely monitor the post-marketing safety of mifepristone for termination of pregnancy for any new or long-term signals.
Docket No. FDA-2002-P-0364

(1) Monitor the adequacy of the distribution and credentialing system.

(2) Follow-up on the outcome of a representative sample of Mifeprex-treated women who have surgical abortion because of method failure.

(3) Assess the long-term effects of multiple use of the regimen.

(4) Ascertain the frequency with which women follow the complete treatment regimen and the outcome of those who do not.

(5) Study the safety and efficacy of the regimen in women under age 18, women over age 35, and women who smoke.

(6) Ascertain the effect of the regimen on children born after treatment failure.

As stated in the Mifeprex Approval Memorandum (at 7), during the final review of the Mifeprex NDA in 2000, items 1, 2, 4, and 5 above were revised and integrated into a single Phase 4 study to assess whether, for providers who did not have surgical intervention skills and referred patients for surgery, clinical outcomes were similar to those of patients under the care of physicians (such as those in the clinical trials) who possessed surgical skills. Based on a revised protocol, this Phase 4 study would monitor the adequacy of provider qualifications (item 1) and collect data on safety outcomes and method failures (item 2) and return of patients for their follow-up visits (item 4). Because patients would not be restricted to a specific age range or smoking status, information to address item 5 also would be obtained. In a second Phase 4 study, the applicant would examine the outcomes of ongoing pregnancies (i.e., method failures) through a surveillance, reporting, and tracking system (item 6). Thus, although the approval letter listed only two Phase 4 studies, those two studies incorporated all but one element of the six studies listed in the September 18, 1996, approvable letter concerning the Mifeprex NDA. (As discussed below, the remaining study was not included for logistical and practical reasons.)

As mentioned in section II.D.2 above, for the first Phase 4 study, which addressed items 1, 2, 4, and 5 above, the applicant reported in a submission in February 2008 that so few medical abortions are prescribed by physicians who do not have surgical intervention skills that it was not feasible to do a meaningful study to assess this specific issue. We agreed with the applicant regarding the non-feasibility of conducting a meaningful study and concluded that no differences between non-referrers or referrers in terms of clinical outcomes could be identified based on the data that had been submitted. In September 2008, we released the applicant from this postmarketing commitment.

For the second Phase 4 study, which addressed item 6 above, based on the reporting of ongoing pregnancies during the first 5 years of Mifeprex distribution, the applicant provided updates in January 2006 and November 2007. Danco reported that only one to two pregnancies per year were followed for final outcomes, and explained that the small number was due, in part, to the requirement that the patients consent to participation after seeking a pregnancy termination. In January 2008, because of the lack of an adequate number of enrolled women, and based on subsequent reports, we released the applicant from this postmarketing commitment.
In addition, as noted in the Mifeprrox Approval Memorandum (at 7), we agreed with the Population Council both that it would not be feasible to identify and enroll sufficient numbers of repeat users of the drug and that the pharmacology of mifepristone does not suggest any carryover effect after one-time administration. Accordingly, we did not include item 3 as a Phase 4 commitment in the September 28, 2000, approval letter. However, we note that data from many other studies reported in the medical literature using mifepristone for, e.g., fibroids, uterine myoma, meningioma, psychiatric illnesses, and Cushing's disease, in much higher daily and lower daily doses for chronic use (months) have not raised any major safety issues.80

III. REQUEST FOR STAY AND REVOCATION OF APPROVAL

You request that we immediately stay the approval of Mifeprrox, thereby halting all distribution and marketing of the drug pending final action on your Petition (Petition at 2). You cite 21 CFR 10.35 as the basis for your request for a stay (Petition at 1). In addition, you urge us to revoke the approval of Mifeprrox because of the purported legal violations and safety concerns set forth in your Petition (Petition at 2).

As described above, we are denying your Petition. Therefore, your request for a stay pending final action on your Petition is moot.

For the reasons set forth in section II of this response, we conclude that you have not presented any evidence that the applicable grounds in 21 CFR 314.530 have been met with respect to Mifeprrox. Furthermore, you have not provided any evidence that any of the applicable grounds in section 505(e) of the FD&C Act have been met for Mifeprrox.81 Therefore, you have not provided any evidence that would serve as a basis for seeking to withdraw the approval of Mifeprrox.


81 You have not presented any clinical data or other information demonstrating that Mifeprrox is unsafe for use under its approved conditions for use, either on the basis of evidence available to the Agency at the time of approval or when also considering evidence obtained subsequent to approval. In addition, you have not provided any new evidence that, when evaluated with the evidence available at the time of Mifeprrox’s approval, shows that there is a lack of substantial evidence that the drug will have its intended effect.
Docket No. FDA-2002-P-0364

IV. CONCLUSION

We appreciate and share your concerns about the need to appropriately manage the risks associated with the use of Mifeprex. Our concerns about the potential complications associated with Mifeprex led to its approval in accordance with 21 CFR 314.520. It was deemed to have in effect a REMS in 2007, and it has had an approved REMS since 2011.82

For the reasons set forth above, your request that we immediately stay the approval of Mifeprex is moot, and we deny your request that we revoke approval of the Mifeprex NDA. In addition, we deny your request that we conduct an audit of all records of the French and U.S. clinical trials supporting the Mifeprex approval. As with all approved new drug products, we will continue to monitor the safety of Mifeprex and take any appropriate actions.

Sincerely,

Janet Woodcock, M.D.
Director
Center for Drug Evaluation and Research

82 As of today's approval of Danco's supplemental NDA, the Medication Guide is no longer part of the REMS. However, the Medication Guide will remain as part of approved patient labeling and will be required to be provided to the patient under current Medication Guide regulations.
Exhibit 16

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2008-N-0174]

Identification of Drug and Biological Products Deemed to Have Risk Evaluation and Mitigation Strategies for the Purposes of the Food and Drug Administration Amendments Act of 2007

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is issuing this notice to notify holders of certain prescription new drug and biological license applications that they will be deemed to have in effect an approved risk evaluation and mitigation strategy (REMS) under the Food and Drug Administration Amendments Act of 2007 (FDAAA). Holders of applications deemed to have in effect an approved REMS are required to submit a proposed REMS to FDA.

DATES: Submit proposed REMSs to FDA by September 21, 2008.

ADDRESSES: Written communications regarding the applicability of this notice to a specific product should be identified with Docket Number FDA–2008–N–0174 and submitted to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic communications to http://www.regulations.gov.

FOR FURTHER INFORMATION CONTACT:


SUPPLEMENTARY INFORMATION:

I. Introduction

On September 27, 2007, the President signed into law FDAAA (Public Law 110–85). Title IX, subtitle A, section 901 of FDAAA created new section 505–1 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355–1). Section 505–1(a) of the act authorizes FDA to require persons submitting certain applications to submit and implement a REMS if FDA determines that a REMS is necessary to ensure that the benefits of a drug outweigh the risks of the drug and informs the holder of the application for the drug of the determination. Section 909 of FDAAA provides that Title IX, subtitle A takes effect 180 days after its enactment, which is March 25, 2008.

FDAAA also contains REMS requirements for drug and biological products approved before the effective date of Title IX, subtitle A. Section 909(b)(1) of FDAAA specifies that a “drug that was approved before the effective date of this Act is * * * deemed to have in effect an approved risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act * * * if there are in effect on the effective date of this Act elements to assure safe use—(A) required under section 314.520 or section 601.42 of title 21, Code of Federal Regulations; or (B) otherwise agreed to by the applicant and the Secretary [of Health and Human Services] for such drug.”

Section 909(b)(3) of FDAAA states: “Not later than 180 days after the effective date of this Act, the holder of an approved application for which a risk evaluation and mitigation strategy is deemed to be in effect * * * shall submit to the Secretary a proposed risk evaluation and mitigation strategy. Such proposed strategy is subject to section 505–1 of the Act as if included in such application at the time of submission of the application to the Secretary.”

Section 909(b)(2) of FDAAA states that a REMS for a drug deemed to have a REMS consists of the timetable required under section 505–1(d) of the act and any additional elements under section 505–1(e) and (l) of the act in effect for the drug on the effective date of FDAAA.

The purpose of this notice is to identify those drugs that FDA has determined will be deemed to have in effect an approved REMS and to notify holders of applications for such drugs that they are required to submit a proposed REMS by September 21, 2008.

Ex. 16 pg. 001
App. 0323
### TABLE 1.—PRODUCTS DEEMED TO HAVE IN EFFECT AN APPROVED REMS

<table>
<thead>
<tr>
<th>Generic or Proper Name</th>
<th>Brand Name</th>
<th>Application Number</th>
<th>Date of Approval1</th>
<th>Date of Approval2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abarelix</td>
<td>Plenaxis3</td>
<td>NDA 21–320</td>
<td>11/25/2003</td>
<td></td>
</tr>
<tr>
<td>Alosetron</td>
<td>Lotronex</td>
<td>NDA 21–107</td>
<td>02/09/2000</td>
<td></td>
</tr>
<tr>
<td>Ambrisentan</td>
<td>Letairis</td>
<td>NDA 22–081</td>
<td>06/15/2007</td>
<td></td>
</tr>
<tr>
<td>Bosentan</td>
<td>Tracleer</td>
<td>NDA 21–290</td>
<td>11/20/2001</td>
<td></td>
</tr>
<tr>
<td>Clozapine</td>
<td>Clozaril</td>
<td>NDA 19–758</td>
<td>09/26/1989</td>
<td>11/26/97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ANDA 74–949</td>
<td>5/27/99</td>
<td>11/15/02</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ANDA 75–417</td>
<td>4/26/05</td>
<td>12/16/05</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ANDA 75–713</td>
<td></td>
<td>02/09/2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fazaclo ODT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dofetilide</td>
<td>Tikosyn</td>
<td>NDA 20–931</td>
<td>10/01/1999</td>
<td></td>
</tr>
<tr>
<td>Eculizumab</td>
<td>Soliris</td>
<td>BLA 125166</td>
<td>03/16/2007</td>
<td></td>
</tr>
<tr>
<td>Fentanyl PCA</td>
<td>Ionsys3</td>
<td>NDA 21–338</td>
<td>05/22/2006</td>
<td></td>
</tr>
<tr>
<td>Isotretinoin</td>
<td>Accutane</td>
<td>NDA 18–662</td>
<td>05/07/1982</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Amnesteem</td>
<td>ANDA 75–945</td>
<td>11/02/2002</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Claravis</td>
<td>ANDA 76–135</td>
<td>04/03/2003</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sotret</td>
<td>ANDA 76–356</td>
<td>04/03/2003</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ANDA 76–041</td>
<td>12/2002</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ANDA 76–503</td>
<td>06/2003</td>
<td></td>
</tr>
<tr>
<td>Lenalidomide</td>
<td>Revlimid</td>
<td>NDA 21–880</td>
<td>12/27/2005</td>
<td></td>
</tr>
<tr>
<td>Mifepristone</td>
<td>Mifeprex</td>
<td>NDA 20–687</td>
<td>09/28/2000</td>
<td></td>
</tr>
<tr>
<td>Natalizumab</td>
<td>Tysabri</td>
<td>BLA 125104</td>
<td>11/23/2004</td>
<td></td>
</tr>
<tr>
<td>Small pox (Vaccinia) Vaccine, Live</td>
<td>ACAM2000</td>
<td>BLA 125158</td>
<td>08/31/2007</td>
<td></td>
</tr>
<tr>
<td>Sodium oxybate</td>
<td>Xyrem</td>
<td>NDA 21–196</td>
<td>07/17/2002</td>
<td></td>
</tr>
<tr>
<td>Thalidomide</td>
<td>Thalomid</td>
<td>NDA 20–785</td>
<td>07/16/1998</td>
<td>NDA 21–430</td>
</tr>
</tbody>
</table>

1 New drug application (NDA), abbreviated new drug application (ANDA), biologics license application (BLA).

2 The original date of approval of the drug. FDA may have required elements to assure safe use at a later date.

3 Product is not currently marketed in the United States.

FDAs further asking members of the public to please notify the agency if they are aware of applications that have not been identified in this document and that they believe should be deemed to have in effect an approved REMS. Please provide the information to Mary Dempsey, Risk Management Coordinator (see the FOR FURTHER INFORMATION CONTACT section of this document).

Any application holder that believes its product identified in this notice should not be on the list of drug or biological products that will be deemed to have in effect an approved REMS should submit a letter identified with Docket Number FDA–2008–N–0174 to the Division of Dockets Management (see ADDRESSES) stating why the application holder believes its product was improperly identified in this notice. FDA will notify the application holder within 30 days of receipt of the letter of its determination.


Jeffrey Shuren, Associate Commissioner for Policy and Planning.

[FR Doc. E8–6201 Filed 3–26–08; 8:45 am] BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committees: Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee.

Ex. 16 pg. 002
App. 0324
Exhibit 17

Dear [redacted]

Please refer to your Supplemental New Drug Application (sNDA) dated September 16, 2008, received September 17, 2008, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for MIFEPREX® (mifepristone) Tablets. We note that NDA 020687 is approved under the provisions of 21 CFR 314.520 (Subpart H).

This supplemental application provides for a proposed risk evaluation and mitigation strategy (REMS) for MIFEPREX (mifepristone) and was submitted in accordance with section 909(b)(1) of the Food and Drug Administration Amendments Act of 2007 (FDAAA). Under section 909(b)(1) of FDAAA, we identified MIFEPREX (mifepristone) as a product deemed to have in effect an approved REMS because there were in effect on the effective date of FDAAA, March 25, 2008, elements to assure safe use required under 21 CFR 314.520.

We acknowledge receipt of your amendments dated December 9, 2008, November 8, 2010, and May 19 and 27, 2011.

In accordance with section 505-1 of the FDCA, we have determined that a REMS is necessary for MIFEPREX (mifepristone) to ensure the benefits of the drug outweigh the risks of serious complications by requiring prescribers to certify that they are qualified to prescribe MIFEPREX (mifepristone) and are able to assure patient access to appropriate medical facilities to manage any complications.

Your proposed REMS, as amended and appended to this letter, is approved. The REMS consists of a Medication Guide, elements to assure safe use, an implementation system, and a timetable for submission of assessments of the REMS.

We remind you that section 505-1(f)(8) of FDCA prohibits holders of an approved covered application with elements to assure safe use from using any element to block or delay approval of an application under section 505(b)(2) or (j). A violation of this provision in 505-1(f) could result in enforcement action.

Reference ID: 2957855
The REMS assessment plan will include the information submitted to FDA on May 27, 2011, and should include the following information:

a. Per section 505-1(g)(3)(A), an assessment of the extent to which the elements to assure safe use are meeting the goal or goals to mitigate a specific serious risk listed in the labeling of the drug, or whether the goal or goals or such elements should be modified.

b. Per section 505-1(g)(3)(B) and (C), information on the status of any postapproval study or clinical trial required under section 505(o) or otherwise undertaken to investigate a safety issue. With respect to any such postapproval study, you must include the status of such study, including whether any difficulties completing the study have been encountered. With respect to any such postapproval clinical trial, you must include the status of such clinical trial, including whether enrollment has begun, the number of participants enrolled, the expected completion date, whether any difficulties completing the clinical trial have been encountered, and registration information with respect to requirements under subsections (i) and (j) of section 402 of the Public Health Service Act. You can satisfy these requirements in your REMS assessments by referring to relevant information included in the most recent annual report required under section 506B and 21 CFR 314.81(b)(2)(vii) and including any updates to the status information since the annual report was prepared. Failure to comply with the REMS assessments provisions in section 505-1(g) could result in enforcement action.

We remind you that in addition to the assessments submitted according to the timetable included in the approved REMS, you must submit a REMS assessment and may propose a modification to the approved REMS when you submit a supplemental application for a new indication for use as described in Section 505-1(g)(2)(A) of FDCA.

Prominently identify future submissions containing the REMS assessments or proposed modifications with the following wording in bold capital letters at the top of the first page of the submission:

NDA 020687 REMS ASSESSMENT

NEW SUPPLEMENT FOR NDA 020687
PROPOSED REMS MODIFICATION
REMS ASSESSMENT

NEW SUPPLEMENT (NEW INDICATION FOR USE) FOR NDA 020687
REMS ASSESSMENT
PROPOSED REMS MODIFICATION (if included)

If you do not submit electronically, please send 5 copies of REMS-related submissions.

As part of the approval under Subpart H, as required by 21 CFR 314.550, you must submit all promotional materials, including promotional labeling as well as advertisements, at least 30 days
before the intended time of initial distribution of the labeling or initial publication of the advertisement. Send one copy to the and two copies of the promotional materials and the package insert directly to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
Food and Drug Administration  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, 

Sincerely,

{See appended electronic signature page}

ENCLOSURES:  
REMS Document  
REMS Materials
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

06/08/2011
Exhibit 18

2011 REMS for NDA 20-687 Mifeprex (mifepristone) Tablets, 200mg (June 8, 2011) (2011 REMS)
I. GOALS

A. To provide information to patients about the benefits and risks of MIFEPREX before they make a decision whether to take the drug.

B. To minimize the risk of serious complications by requiring prescribers to certify that they are qualified to prescribe MIFEPREX and are able to assure patient access to appropriate medical facilities to manage any complications.

II. REMS ELEMENTS

A. Medication Guide

1. A Medication Guide will be dispensed with each MIFEPREX prescription in accordance with 21 CFR 208.24.

2. Please see the appended Medication Guide.

B. Elements to Assure Safe Use

1. Healthcare providers who prescribe MIFEPREX will be specially certified.

   Danco will ensure that healthcare providers who prescribe MIFEPREX are specially certified.

   a. To become specially certified, each prescriber must complete and fax to the MIFEPREX distributor the one-time Prescriber’s Agreement, agreeing that they meet the qualifications and will follow the guidelines outlined in the Prescriber’s Agreement.

   b. The following materials are part of the REMS and are appended:

      i. Prescriber’s Agreement.

      ii. Patient Agreement.
2. MIFEPREX will be dispensed only in certain health care settings, specifically clinics, medical offices, and hospitals.

Danco will ensure that MIFEPREX will only be available to be dispensed in a clinic, medical office, or hospital, by or under the supervision of a specially certified prescriber. MIFEPREX will not be distributed to or dispensed through retail pharmacies.

3. MIFEPREX will only be dispensed to patients with documentation of safe use conditions.

Danco will ensure that MIFEPREX will only be dispensed to patients with documentation of the following safe use conditions:

a. The patient has completed and signed the Patient Agreement, and the Patient Agreement has been placed in the patient’s medical record.

b. The patient has been provided copies of the signed Patient Agreement and the Medication Guide.

C. Implementation System

The Implementation System will include the following:

1. Distributors who distribute MIFEPREX will be certified. To become certified, distributors must agree to:

   a. Ship drug only to site locations identified by specially certified prescribers in signed Prescriber’s Agreements, and maintain secure and confidential records of shipments.

   b. Follow all distribution guidelines, including those for storage, tracking package serial numbers, proof of delivery, and controlled returns.

2. Danco will assess the performance of the certified distributors with regard to the following:

   a. Whether a secure, confidential and controlled distribution system is being maintained with regard to storage, handling, shipping, and return of MIFEPREX.

   b. Whether MIFEPREX is being shipped only to site locations identified by specially certified prescribers in the signed Prescriber’s Agreement and only available to be dispensed to patients in a clinic, medical office, or hospital by or under the supervision of a specially certified prescriber.
3. If Danco determines the distributors are not complying with these requirements, Danco will take steps to improve their compliance.

D. Timetable for Submission of Assessments

Danco will submit REMS assessments to the FDA one year from the date of the approval of the REMS and every three years thereafter. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the assessment reporting interval covered by each assessment should conclude no earlier than 60 days before the submission date for that assessment. Danco will submit each assessment so that it will be received by the FDA on or before the due date.
MEDICATION GUIDE

Mifeprex® (MIF-eh-prex)
(mifepristone)

Read this information carefully before taking Mifeprex® and misoprostol. It will help you understand how the treatment works. This MEDICATION GUIDE does not take the place of talking with your health care provider (provider).

What is Mifeprex?

Mifeprex is used to end an early pregnancy. It blocks a hormone needed for your pregnancy to continue. It is not approved for ending later pregnancies. Early pregnancy means it is 49 days (7 weeks) or less since your last menstrual period began. When you use Mifeprex (Day 1), you also need to take another medicine misoprostol, 2 days after you take Mifeprex (Day 3), to end your pregnancy. But, about 5-8 out of 100 women taking Mifeprex will need a surgical procedure to end the pregnancy or to stop too much bleeding.

What is the most important information I should know about Mifeprex?

What symptoms should I be concerned with? Although cramping and bleeding are an expected part of ending a pregnancy, rarely, serious and potentially life-threatening bleeding, infections, or other problems can occur following a miscarriage, surgical abortion, medical abortion, or childbirth. Prompt medical attention is needed in these circumstances. Serious infection has resulted in death in a very small number of cases; in most of these cases misoprostol was used in the vagina. There is no information that use of Mifeprex and misoprostol caused these deaths. If you have any questions, concerns, or problems, or if you are worried about any side effects or symptoms, you should contact your provider. Your provider’s telephone number is ________________________.

Be sure to contact your provider promptly if you have any of the following:

**Heavy Bleeding.** Contact your provider right away if you bleed enough to soak through two thick full-size sanitary pads per hour for two consecutive hours or if you are concerned about heavy bleeding. In about 1 out of 100 women, bleeding can be so heavy that it requires a surgical procedure (surgical abortion/D&C) to stop it.

**Abdominal Pain or “Feeling Sick”**. If you have abdominal pain or discomfort, or you are “feeling sick”, including weakness, nausea, vomiting or diarrhea, with or without fever, more than 24 hours after taking misoprostol, you should contact your provider without delay. These symptoms may be a sign of a serious infection or another problem (including an ectopic pregnancy, a pregnancy outside the womb).

**Fever.** In the days after treatment, if you have a fever of 100.4°F or higher that lasts for more than 4 hours, you should contact your provider right away. Fever may be a symptom of a serious infection or another problem (including an ectopic pregnancy).

**Take this MEDICATION GUIDE with you.** When you visit an emergency room or a provider who did not give you your Mifeprex, you should give them your MEDICATION GUIDE so that
they understand that you are having a medical abortion with Mifeprex.

What to do if you are still pregnant after Mifeprex with misoprostol treatment. If you are still pregnant, your provider will talk with you about the other choices you have, including a surgical procedure to end your pregnancy. There is a chance that there may be birth defects if the pregnancy is not ended.

Talk with your provider. Before you take Mifeprex, you should read this MEDICATION GUIDE and sign a statement (PATIENT AGREEMENT). You and your provider should discuss the benefits and risks of your using Mifeprex.

Who should not take Mifeprex?

Some women should not take Mifeprex. Do not take it if:

- It has been more than 49 days (7 weeks) since your last menstrual period began.
- You have an IUD. It must be taken out before you take Mifeprex.
- Your provider has told you that you have a pregnancy outside the uterus (ectopic pregnancy).
- You have problems with your adrenal glands (chronic adrenal failure).
- You take a medicine to thin your blood.
- You have a bleeding problem.
- You take certain steroid medicines.
- You cannot return for the next 2 visits.
- You cannot easily get emergency medical help in the 2 weeks after you take Mifeprex.
- You are allergic to mifepristone, misoprostol, or medicines that contain misoprostol, such as Cytotec or Arthrotec.

Tell your provider about all your medical conditions to find out if you can take Mifeprex. Also, tell your provider if you smoke at least 10 cigarettes a day.

How should I take Mifeprex?

- **Day 1 at your provider’s office:**
  - Read this MEDICATION GUIDE.
  - Discuss the benefits and risks of using Mifeprex to end your pregnancy.
  - If you decide Mifeprex is right for you, sign the PATIENT AGREEMENT.
  - After getting a physical exam, swallow 3 tablets of Mifeprex.
- **Day 3 at your provider’s office:**
  - If you are still pregnant, take 2 misoprostol tablets.
  - Misoprostol may cause cramps, nausea, diarrhea, and other symptoms. Your provider may send you home with medicines for these symptoms.
- **About Day 14 at your provider’s office:**
  - This follow-up visit is very important. You must return to the provider about 14 days after you have taken Mifeprex to be sure you are well and that you are not pregnant.
  - Your provider will check whether your pregnancy has completely ended. If it has not ended, there is a chance that there may be birth defects. If you are still pregnant, your provider will talk with you about the other choices you have, including a surgical procedure to end your pregnancy.
What should I avoid while taking Mifeprex and misoprostol?

Do not take any other prescription or non-prescription medicines (including herbal medicines or supplements) at any time during the treatment period without first asking your provider about them because they may interfere with the treatment. Ask your provider about what medicines you can take for pain.

If you are breastfeeding at the time you take Mifeprex and misoprostol, discuss with your provider if you should stop breastfeeding for a few days.

What are the possible and reasonably likely side effects of Mifeprex?

Cramping and bleeding are expected with this treatment. Usually, these symptoms mean that the treatment is working. But sometimes you can get cramping and bleeding and still be pregnant. This is why you must return to your provider on Day 3 and about Day 14. See “How should I take Mifeprex?” for more information on when to return to your provider. If you are not already bleeding after taking Mifeprex, you probably will begin to bleed once you take misoprostol, the medicine you take on Day 3. Bleeding or spotting can be expected for an average of 9–16 days and may last for up to 30 days. Your bleeding may be similar to, or greater than, a normal heavy period. You may see blood clots and tissue. This is an expected part of ending the pregnancy.

Other common symptoms of treatment include diarrhea, nausea, vomiting, headache, dizziness, back pain, and tiredness. These side effects lessen after Day 3 and are usually gone by Day 14. Your provider will tell you how to manage any pain or other side effects.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

When should I begin birth control?

You can become pregnant again right after your pregnancy ends. If you do not want to become pregnant again, start using birth control as soon as your pregnancy ends or before you start having sexual intercourse again.

* * *

Medicines are sometimes prescribed for purposes other than those listed in a MEDICATION GUIDE. For more information, ask your provider for the information about Mifeprex that is written for health care professionals. Ask your provider if you have any questions.

This MEDICATION GUIDE has been approved by the U.S. Food and Drug Administration.

Rev 3: 4/22/09
*Mifeprex is a registered trademark of Danco Laboratories, LLC.
PRESCRIBER’S AGREEMENT

We are pleased that you wish to become a provider of Mifeprex* (Mifepristone) Tablets, 200 mg, which is indicated for the medical termination of intrauterine pregnancy through 49 days from the first day of the patient’s last menstrual period (see full prescribing information). Prescribing Information, Mifeprex Medication Guides and PATIENT AGREEMENT forms will be provided together with your order of Mifeprex.

Prior to establishing your account and receiving your first order, you must sign and return this letter to the distributor, indicating that you have met the qualifications outlined below and will observe the guidelines outlined below. If you oversee more than one office facility, you will need to list each facility on your order form prior to shipping the first order.

By signing the reverse side, you acknowledge receipt of the PRESCRIBER’S AGREEMENT and agree that you meet these qualifications and that you will follow these guidelines for use. You also understand that if you do not follow these guidelines, the distributor may discontinue distribution of the drug to you.

Under Federal law, Mifeprex must be provided by or under the supervision of a physician who meets the following qualifications:

• Ability to assess the duration of pregnancy accurately.

• Ability to diagnose ectopic pregnancies.

• Ability to provide surgical intervention in cases of incomplete abortion or severe bleeding, or have made plans to provide such care through others, and are able to assure patient access to medical facilities equipped to provide blood transfusions and resuscitation, if necessary.

• Has read and understood the prescribing information of Mifeprex. The prescribing information is attached to this letter, and is also available by calling our toll free number, 1-877-4 Early Option (1-877-432-7596), or logging on to our website, www.earlyoptionpill.com.

In addition to these qualifications, you must provide Mifeprex in a manner consistent with the following guidelines.

• Under Federal law, each patient must be provided with a Medication Guide. You must fully explain the procedure to each patient, provide her with a copy of the Medication Guide and PATIENT AGREEMENT, give her an opportunity to read and discuss them, obtain her signature on the PATIENT AGREEMENT, and sign it yourself.

• The patient’s follow-up visit at approximately 14 days is very important to confirm that a complete termination of pregnancy has occurred and that there have been no complications. You must notify Danco Laboratories in writing as discussed in the Package Insert under the heading DOSAGE AND ADMINISTRATION in the event of an on-going pregnancy which is not terminated subsequent to the conclusion of the treatment procedure.

• While serious adverse events associated with the use of Mifeprex are rare, you must report any hospitalization, transfusion or other serious event to Danco Laboratories, identifying the patient solely by package serial number to ensure patient confidentiality.

• Each package of Mifeprex has a serial number. As part of maintaining complete records for each patient, you must record this identification number in each patient’s record.

Danco Laboratories, LLC
P.O. Box 4816
New York, NY 10185
1-877-4 Early Option (1-877-432-7596)
www.earlyoptionpill.com
*MIFEPREX is a registered trademark of Danco Laboratories, LLC.

Reference ID: 2957855
ACCOUNT SETUP FORM  
MIFEPREX™ (Mifepristone) Tablets, 200 mg; NDC 64875-001-03

Billing information

Bill to Name ________________________________________________________________
Address ____________________________________________________________________
City ________________________________ State ________ ZIP ___________________
Phone ______________________________ Fax ________________________________
Attention ___________________________

Shipping information (❑ Check if same as above)

Ship to Name ________________________________________________________________
Address ____________________________________________________________________
City ________________________________ State ________ ZIP ___________________
Phone ______________________________ Fax ________________________________
Attention ___________________________

Additional site locations

I will also be prescribing Mifeprex® at these additional locations:

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>City</td>
<td>State ZIP</td>
</tr>
<tr>
<td>Phone</td>
<td>Fax</td>
</tr>
</tbody>
</table>

(Any additional sites may be listed on an attached sheet of paper.)

Request additional materials

❑ Medication Guides          ❑ Patient Agreements
❑ State Abortion Guidelines  ❑ Patient Brochures

Establishing your account (required only with first order)

Each facility purchasing Mifeprex must be included on this form (see additional site locations box above) before the
distributor can ship the product. Please read the Prescriber’s Agreement on the reverse of this form and sign below.

By signing below, you acknowledge receipt of the Prescriber’s Agreement and agree that
you meet these qualifications and that you will follow these guidelines for use.

Print Name _________________________________ Signature _________________________________
Medical License # ___________________________ Date ______________________________________

Fax this completed Account Setup Form to the authorized distributor. Fax: 1-866-227-3343

Please fax any questions to the above number or call 1-800-848-6142.

*Mifeprex is a trademark of Danco Laboratories, LLC.
Patient Agreement

Mifeprex® (mifepristone) Tablets
1. I have read the attached MEDICATION GUIDE for using Mifeprex and misoprostol to end my pregnancy.
2. I discussed the information with my health care provider (provider).
3. My provider answered all my questions and told me about the risks and benefits of using Mifeprex and misoprostol to end my pregnancy.
4. I believe I am no more than 49 days (7 weeks) pregnant.
5. I understand that I will take Mifeprex in my provider’s office (Day 1).
6. I understand that I will take misoprostol in my provider’s office two days after I take Mifeprex (Day 3).
7. My provider gave me advice on what to do if I develop heavy bleeding or need emergency care due to the treatment.
8. Bleeding and cramping do not mean that my pregnancy has ended. Therefore, I must return to my provider’s office in about 2 weeks (about Day 14) after I take Mifeprex to be sure that my pregnancy has ended and that I am well.
9. I know that, in some cases, the treatment will not work. This happens in about 5 to 8 women out of 100 who use this treatment.
10. I understand that if my pregnancy continues after any part of the treatment, there is a chance that there may be birth defects. If my pregnancy continues after treatment with Mifeprex and misoprostol, I will talk with my provider about my choices, which may include a surgical procedure to end my pregnancy.
11. I understand that if the medicines I take do not end my pregnancy and I decide to have a surgical procedure to end my pregnancy, or if I need a surgical procedure to stop bleeding, my provider will do the procedure or refer me to another provider who will. I have that provider’s name, address and phone number.
12. I have my provider's name, address and phone number and know that I can call if I have any questions or concerns.
13. I have decided to take Mifeprex and misoprostol to end my pregnancy and will follow my provider’s advice about when to take each drug and what to do in an emergency.
14. I will do the following:
   - contact my provider right away if in the days after treatment I have a fever of 100.4°F or higher that lasts for more than 4 hours or severe abdominal pain.
   - contact my provider right away if I have heavy bleeding (soaking through two thick full-size sanitary pads per hour for two consecutive hours).
   - contact my provider right away if I have abdominal pain or discomfort, or I am “feeling sick”, including weakness, nausea, vomiting or diarrhea, more than 24 hours after taking misoprostol.
   - take the MEDICATION GUIDE with me when I visit an emergency room or a provider who did not give me Mifeprex, so that they will understand that I am having a medical abortion with Mifeprex.
   - return to my provider’s office in 2 days (Day 3) to check if my pregnancy has ended. My provider will give me misoprostol if I am still pregnant.
   - return to my provider’s office about 14 days after beginning treatment to be sure that my pregnancy has ended and that I am well.

Patient Signature: ___________________________________________
Patient Name (print): ________________________________________
Date: _____________________________________________________

The patient signed the PATIENT AGREEMENT in my presence after I counseled her and answered all her questions. I have given her the MEDICATION GUIDE for mifepristone.

Provider’s Signature: ________________________________________
Name of Provider (print): ______________________________________
After the patient and the provider sign this PATIENT AGREEMENT, give 1 copy to the patient before she leaves the office and put 1 copy in her medical record. Give a copy of the MEDICATION GUIDE to the patient.

Rev 2: 7/19/05
*Mifeprex is a registered trademark of Danco Laboratories, LLC.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

06/08/2011
Exhibit 19

2016 FDA Letter to Danco Laboratories re: NDA 020687, Supp 20 (Mar. 29, 2016)
NDA 020687/S-020

Danco Laboratories, LLC
P.O. Box 4816
New York, NY 10185

Dear [Redacted]:

Please refer to your Supplemental New Drug Application (sNDA) dated May 28, 2015, received May 29, 2015, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Mifeprax (mifepristone) Tablets.

We acknowledge receipt of your risk evaluation and mitigation strategy (REMS) assessment dated July 17, 2015.

This “Prior Approval” supplemental new drug application proposes to provide for use through 70 days gestation, revise the labeled dose and dosing regimen and modify the REMS.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, Medication Guide), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf
The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

We request that the labeling approved today be available on your website within 10 days of receipt of this letter.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for pre-menarcheal patients because the use of this product before menarche is not indicated, and we have determined that you have fulfilled the pediatric study requirement for post-menarcheal patients.

RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS

The REMS for Mifeprex (mifepristone) Tablets was originally approved on June 8, 2011. The REMS consisted of a Medication Guide, elements to assure safe use, an implementation system, and a timetable for submission of assessments of the REMS. Your proposed modifications to the REMS included revisions to both the prescriber and patient agreement forms.

Other changes proposed in the efficacy supplement prompted additional revisions to the Mifeprex REMS materials. During review of this efficacy supplement, we also assessed the current REMS program to determine whether each Mifeprex REMS element remains necessary to ensure that the drug’s benefits outweigh the risks.

After consultations between the Office of New Drugs (OND) and the Office of Surveillance and Epidemiology (OSE), we have determined that the approved REMS for Mifeprex should be modified to continue to ensure that the benefits of Mifeprex outweigh its risks and to minimize the burden on the healthcare delivery system of complying with the REMS. The REMS modifications submitted by you on March 29, 2016 are approved.

We have determined that it is no longer necessary to include the Medication Guide as an element of the approved REMS to ensure that the benefits of Mifeprex outweigh its risks. The
Medication Guide will continue to be part of the approved labeling in accordance with 21 CFR 208. Like other labeling, Medication Guides are subject to the safety labeling change provisions of section 505(o)(4) of the FDCA.

Your proposed modified REMS, submitted on July 17, 2015, and appended to this letter, is approved as amended. The modified REMS consists of elements to assure safe use (A, C and D), an implementation system, and a timetable for submission of assessments of the REMS.

The timetable for submission of assessments of the REMS remains the same as that approved on June 8, 2011.

The REMS assessment plan will include the information submitted to FDA on March 29, 2016.

The revised REMS assessment plan must include, but is not limited to, the following:

**REMS Assessment Plan**

1. Number of prescribers enrolled (cumulative)
2. Number of new prescribers enrolled during reporting period
3. Number of prescribers ordering Mifeprex during reporting period
4. Number of healthcare providers who attempted to order Mifeprex who were not enrolled; describe actions taken (during reporting period and cumulative).
5. Number of women exposed to Mifeprex (during reporting period and cumulative)
6. Summary and analysis of any program deviations and corrective action taken
7. Based on the information reported, an assessment and analysis of whether the REMS is meeting its goals and whether modifications to the REMS are needed

The requirements for assessments of an approved REMS under section 505-1(g)(3) include with respect to each goal included in the strategy, an assessment of the extent to which the approved strategy, including each element of the strategy, is meeting the goal or whether 1 or more such goals or such elements should be modified.

We remind you that in addition to the REMS assessments submitted according to the timetable in the approved REMS, you must include an adequate rationale to support any proposed REMS modification for the addition, modification, or removal of any of goal or element of the REMS, as described in section 505-1(g)(4) of the FDCA.

We also remind you that you must submit a REMS assessment when you submit any future supplemental application for a new indication for use as described in section 505-1(g)(2)(A) of the FDCA. This assessment should include:

a) An evaluation of how the benefit-risk profile will or will not change with the new indication;

b) A determination of the implications of a change in the benefit-risk profile for the current REMS;
c) If the new indication for use introduces unexpected risks: A description of those risks and an evaluation of whether those risks can be appropriately managed with the currently approved REMS.

d) If a REMS assessment was submitted in the 18 months prior to submission of the supplemental application for a new indication for use: A statement about whether the REMS was meeting its goals at the time of the last assessment and if any modifications of the REMS have been proposed since that assessment.

e) If a REMS assessment has not been submitted in the 18 months prior to submission of the supplemental application for a new indication for use: Provision of as many of the currently listed assessment plan items as is feasible.

f) If you propose a REMS modification based on a change in the benefit-risk profile or because of the new indication of use, submit an adequate rationale to support the modification, including: Provision of the reason(s) why the proposed REMS modification is necessary, the potential effect on the serious risk(s) for which the REMS was required, on patient access to the drug, and/or on the burden on the health care delivery system; and other appropriate evidence or data to support the proposed change. Additionally, include any changes to the assessment plan necessary to assess the proposed modified REMS. If you are not proposing REMS modifications, provide a rationale for why the REMS does not need to be modified.

If the assessment instruments and methodology for your REMS assessments are not included in the REMS supporting document, or if you propose changes to the submitted assessment instruments or methodology, you should update the REMS supporting document to include specific assessment instrument and methodology information at least 90 days before the assessments will be conducted. Updates to the REMS supporting document may be included in a new document that references previous REMS supporting document submission(s) for unchanged portions. Alternatively, updates may be made by modifying the complete previous REMS supporting document, with all changes marked and highlighted. Prominently identify the submission containing the assessment instruments and methodology with the following wording in bold capital letters at the top of the first page of the submission:

NDA 020687 REMS CORRESPONDENCE
(insert concise description of content in bold capital letters, e.g.,)
UPDATE TO REMS SUPPORTING DOCUMENT - ASSESSMENT METHODOLOGY

An authorized generic drug under this NDA must have an approved REMS prior to marketing. Should you decide to market, sell, or distribute an authorized generic drug under this NDA, contact us to discuss what will be required in the authorized generic drug REMS submission.

We remind you that section 505-1(f)(8) of FDCA prohibits holders of an approved covered application with elements to assure safe use from using any element to block or delay approval of an application under section 505(b)(2) or (j). A violation of this provision in 505-1(f) could result in enforcement action.
Prominently identify any submission containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

**NDA 020687 REMS ASSESSMENT**

**NEW SUPPLEMENT FOR NDA 020687/S-000**
CHANGES BEING EFFECTED IN 30 DAYS
PROPOSED MINOR REMS MODIFICATION

*or*

**NEW SUPPLEMENT FOR NDA 020687/S-000**
PRIOR APPROVAL SUPPLEMENT
PROPOSED MAJOR REMS MODIFICATION

*or*

**NEW SUPPLEMENT FOR NDA 020687/S-000**
PRIOR APPROVAL SUPPLEMENT
PROPOSED REMS MODIFICATIONS DUE TO SAFETY LABEL CHANGES
SUBMITTED IN SUPPLEMENT XXX

*or*

**NEW SUPPLEMENT (NEW INDICATION FOR USE)**
FOR NDA 020687/S-000
REMS ASSESSMENT
PROPOSED REMS MODIFICATION (if included)

Should you choose to submit a REMS revision, prominently identify the submission containing the REMS revisions with the following wording in bold capital letters at the top of the first page of the submission:

**REMS REVISIONS FOR NDA 020687**

To facilitate review of your submission, we request that you submit your proposed modified REMS and other REMS-related materials in Microsoft Word format. If certain documents, such as enrollment forms, are only in PDF format, they may be submitted as such, but the preference is to include as many as possible in Word format.

If you do not submit electronically, please send 5 copies of REMS-related submissions.
PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate: (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf)).

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at [http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf](http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf). Information and Instructions for completing the form can be found at [http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf](http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf). For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see [http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm](http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call [Name]

Sincerely,

[See appended electronic signature page]

Center for Drug Evaluation and Research

Reference ID: 3909592
ENCLOSURES:
   Content of Labeling
   REMS
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

03/29/2016
Exhibit 20

FDA, Center for Drug Evaluation and Research, Summary Review of Application Number: 020687Orig1s020 (Mar. 29, 2016) (2016 Summary Review)
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

020687Orig1s020

SUMMARY REVIEW
### Summary Review for Regulatory Action

<table>
<thead>
<tr>
<th>Date</th>
<th>March 29, 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subject</td>
<td>Summary Review</td>
</tr>
<tr>
<td>NDA #/Supplement #</td>
<td>20687/S-020</td>
</tr>
<tr>
<td>Applicant name</td>
<td>Danco Laboratories, LLC</td>
</tr>
<tr>
<td>Date of submission</td>
<td>May 28, 2015</td>
</tr>
<tr>
<td>Date of submission receipt</td>
<td>May 29, 2015</td>
</tr>
<tr>
<td>PDUFA goal date</td>
<td>March 29, 2016</td>
</tr>
<tr>
<td>Proprietary name/established name</td>
<td>Mifeprex/mifepristone</td>
</tr>
<tr>
<td>Dosage form/strength</td>
<td>Oral tablet/200 mg</td>
</tr>
<tr>
<td>Dosage regimen</td>
<td>Mifeprex 200 mg tablet orally followed in 24-48 hours by 800 mcg buccal misoprostol</td>
</tr>
<tr>
<td>Proposed indication</td>
<td>Mifeprex is a progestin antagonist indicated, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation</td>
</tr>
<tr>
<td>Action</td>
<td>Approval</td>
</tr>
</tbody>
</table>
1. Introduction

Danco Laboratories, LLC, referred to hereafter as the Applicant, submitted an efficacy supplement (S-020) to NDA 20687 for Mifeprex (mifepristone). The Applicant sought the following changes to its approved application:

1. Decrease mifepristone dose from 600 to 200 mg, followed by misoprostol at a dose increased from 400 mcg to 800 mcg, administered buccally instead of orally; see below:
   - Day One: Mifeprex Administration (oral)
     One 200 mg tablet of Mifeprex is taken in a single oral dose
   - After a 24-48 hour interval: Misoprostol Administration (buccal)(minimum 24-hour interval between Mifeprex and misoprostol)
     Four 200 mcg tablets (total dose: 800 mcg) of misoprostol are taken by the buccal route

2. Removal of the instruction that administration of misoprostol must be done in-clinic, to allow for administration at home or other location convenient for the woman

3. Administration of misoprostol at 24-48 hours instead of 48 hours after Mifeprex

4. Follow-up, although still needed, not restricted to in clinic at 14 days after Mifeprex

5. Increase in the maximum gestational age from 49 days to 70 days

6. Change of the labeled time for expected expulsion of pregnancy from 4-24 hours to 2-24 hours post misoprostol administration

7. Addition that a repeat 800 mcg buccal dose of misoprostol may be used if needed

8. Change of “physician” to “healthcare provider” in the label and Risk Evaluation and Mitigation Strategies (REMS) document

9. Change in the indication statement to add reference to use of misoprostol:
   “Mifeprex is indicated, in a regimen with misoprostol, for the medical termination of pregnancy through 70 days gestation.”

10. Removal of references to “under Federal law” from the Prescriber’s Agreement under the REMS
11. Labeling changes addressing the pediatric requirements under the Pediatric Research Equity Act

This efficacy supplement submission includes information from published studies, review articles and additional information from the authors of some of the publications. These published studies evaluated reproductive age women in the U.S. and outside the U.S. who had early medical termination with mifepristone, in a regimen with misoprostol, including women up through 70 days of gestation.

This memorandum serves as the Division’s decisional memorandum for the efficacy supplement.

2. Background

The active ingredient of Mifeprex, mifepristone, is a progestin antagonist. Mifeprex, in a regimen with misoprostol, is approved for the medical termination of pregnancy up through 49 days’ gestation. The approved dosing regimen is currently labeled as follows:

- Day 1: The patient takes three 200 mg tablets of Mifeprex in a single oral dose in the clinic, medical office, or hospital.
- Day 3: The patient returns to the clinic, medical office, or hospital and takes two 200 mcg tablets of misoprostol orally.
- Day 14: The patient returns for a follow-up visit to confirm that a complete termination has occurred.

At the time of the September, 2000 approval, FDA restricted distribution of Mifeprex under 21 CFR 314.520, requiring that Mifeprex be dispensed only by or under the supervision of a physician who meets certain qualifications. With the passage of FDAAA in 2007, Mifeprex was deemed to have in effect an approved REMS. The Applicant submitted a formal REMS, which was approved on June 8, 2011 and consisted of the following: a Medication Guide, elements to assure safe use (ETASU A [special certification of healthcare providers who prescribe Mifeprex], ETASU C [dispensing only in certain healthcare settings], and ETASU D [safe use condition of a signed Patient Agreement]), an implementation system and a timetable for assessments. The goals of the REMS were 1) To provide information to patients about the benefits and risks of Mifeprex before they make a decision whether to take the drug and 2) To minimize the risk of serious complications by requiring prescribers to certify that they are qualified to prescribe Mifeprex and are able to assure patient access to appropriate medical facilities to manage any complications. The REMS for Mifeprex incorporated the restrictions under which the drug was originally approved.

Since 2011, the Applicant has submitted two REMS assessment reports. The Agency review of these reports determined that the REMS goals were being met and that no modifications were required to the REMS at that time.
FDA held a pre-NDA meeting with the Applicant on January 29, 2015, to discuss proposed labeling and REMS changes to be submitted in this efficacy supplement. These changes were submitted with the efficacy supplement.

The Applicant submitted published literature and supportive information to support changes to the dose, dosing regimen, gestational age, revisions to labeling, modifications to the REMS document, and to address PREA requirements. The Agency accepts the use of peer reviewed literature as primary data for an application under the framework of a 505(b)(2) application.

3. CMC

No new CMC information was submitted with this efficacy supplement. The CMC team determined no additional review or inspections were required. The CMC team completed a review of the labeling and found the CMC sections of labeling (sections 3, 11 and 16) acceptable (See review dated March 29, 2016). The CMC review team recommends approval of the efficacy supplement; refer also to the CMC review of the separate supplement proposing a single tablet blister pack for Mifeprex, dated January 11, 2016. There are no outstanding CMC issues or postmarketing commitments or requirements.

Comment: On March 10, 2016, a separate CMC supplement was approved that allowed the packaging of individual 200 mg tablets of mifepristone; previously packaging consisted of three 200 mg tablets per blister pack (a total of 600 mg Mifeprex as administered under the originally approved dosing regimen).

4. Nonclinical Pharmacology/Toxicology

No new nonclinical information was submitted in this supplement. The Pharmacology/Toxicology team revised labeling to conform to the Pregnancy and Lactation Labeling Rule. There are no outstanding nonclinical issues. The Pharmacology/Toxicology review team recommends approval of the efficacy supplement; refer to the Pharmacology/Toxicology review dated March 4, 2016.

5. Clinical Pharmacology

The Applicant did not conduct any new clinical pharmacology studies pertaining to the proposed regimen, but provided information on pharmacokinetics (PK) of misoprostol following various routes of administration. The PK of the 200 mg Mifeprex tablet has not been characterized in women, but data are available in men and were submitted in the original NDA. The Clinical Pharmacology review team determined that the PK data were appropriate for inclusion in labeling. Review of the labeling pertinent to the Clinical Pharmacology sections is complete and labeling relevant to pharmacokinetics and pharmacodynamics is acceptable. There are no outstanding Clinical Pharmacology issues or postmarketing commitments or requirements. The clinical pharmacology review team recommends approval of the efficacy supplement; refer to the Clinical Pharmacology review dated March 29, 2016.
6. **Clinical Microbiology**

Not applicable.

7. **Efficacy/Statistics**

The Applicant submitted published literature as the primary evidence to support the efficacy (and safety) of the proposed dosing regimen (refer to the Clinical Review dated March 29, 2016, Section 9.5 for a list of submitted references). Most published articles submitted by the Applicant and reviewed by the clinical review team reported the primary efficacy endpoint as complete termination of pregnancy without further medical or surgical intervention; the Division considers this to be a clinically relevant endpoint.

The majority of the publications included a statement that the study was conducted under institutional review board (IRB) or Ethical Review Committee approval and the women gave informed consent. The clinical review team concluded that the published literature was adequate as the primary information source to support the changes proposed in the efficacy supplement. During the course of the review, the team also requested and received more detailed information from select publications from their authors via communication with the Applicant.

Although there were slight demographic differences among the published studies from the database, these differences were not expected to alter the efficacy or safety of Mifeprex. Therefore, for the majority of the proposed efficacy changes, the clinical team assessed efficacy information from a subset of publications that evaluated a given proposed change. An independent statistical review was not needed for this review of published literature.

The clinical review team identified several major proposed clinical changes in the efficacy supplement. As these major changes are interrelated, in some cases data from a given study were relied on to provide evidence to support multiple changes. These major changes as considered by the clinical team included:

1. A proposed dosing regimen consisting of mifepristone 200 mg orally followed by the buccal administration of 800 mcg misoprostol including:
   a. Use of a revised interval between mifepristone and misoprostol from 48 hours to 24-48 hours
   b. Allowing home administration of misoprostol
   c. Use of an additional dose of misoprostol
2. Support for extending the gestation age through 70 days
3. Flexibility in follow-up visit: follow-up is needed in the range of 7-14 days after Mifeprex administration; the specific nature and exact timing of the follow-up to be agreed upon by the healthcare provider and patient.
4. Change in who can provide Mifeprex from physician to healthcare provider who prescribes
The following section summarizes the clinical review team’s evaluations that supported the above proposed changes:

1. **Support for the proposed dose and dosing regimen of 200 mg of Mifeprex orally and 800 mcg of misoprostol buccally 24-48 hours after Mifeprex administration:**
   The clinical review team reviewed the submission and identified studies and review articles that evaluated over 35,000 women who were treated with efficacy in the 91-98% range. For additional details on the efficacy from these studies, please refer to Section 6 of the Clinical Review.

2. **Support for extending the gestational age to 70 days:**
   The Applicant submitted a number of published articles and systematic reviews that supported the proposed dose and dosing regimen. Four studies and one systematic review evaluated the exact proposed dosing regimen through 70 days gestation. These include three prospective observational studies (Winikoff et al 2012, Boersma et al, Sanhueza Smith et al) and one randomized controlled trial (RCT) (Olavarrieta et al) that had a primary objective of evaluating medical abortion provision by non-physicians. The systematic review by Chen and Creinin covered 20 studies including over 30,000 women; all but one of the studies used the proposed regimen in gestations through 70 days (the remaining study used 400 mcg of buccal misoprostol). For those publications that provided overall success rates, these were in the range of 97-98%. Other relevant publications include the systematic review by Raymond of 87 studies, which covered a variety of misoprostol doses and routes of administration used with 200 mg of mifepristone. Assessing the efficacy by misoprostol dose, the paper noted that doses ≥ 800 mcg had a success rate of 96.8%, with an ongoing pregnancy rate of 0.7%.

---

1 Winikoff B, Dzuba IG, Chong E, et al. Extending outpatient medical abortion services through 70 days of gestational age. Obstet Gynecol 2012; 120: 1070-6
The original dosing regimen specifies taking misoprostol 2 days after Mifeprex. This efficacy supplement proposes a more flexible time frame of 24 to 48 hours between Mifeprex and misoprostol administration. Data from a review article by Wedisinghe et al\(^7\) evaluated different time intervals using administration of misoprostol after Mifeprex. A meta-analysis of all five studies found a non-significant odds ratio for failure for shorter vs. longer dosing intervals, but a trend for lower success if a dosing interval < 8 hours is used. Chen & Creinin’s systematic review\(^8\) of 20 studies including over 33,000 women, all but one using the proposed regimen, compared the success of dosing intervals of 24 hours with intervals ranging from 24-48 hours. The success rate in six studies that used a 24-hour interval through 63 days gestation was 94.2%, compared to the rate of 96.8% in 14 studies that used a 24-48 hour interval, and this difference was statistically significant. The clinical team concluded that the efficacy of the revised dosing regimen was not compromised by revising the dosing interval to 24-48 hours. In addition, they noted that the overall rate of ongoing pregnancies did not differ significantly by dosing interval.

3. **Administration of misoprostol after Mifeprex administration at home:** Currently, the dosing regimen specifies that misoprostol is taken in the clinic setting following Mifeprex administration. No specific publication evaluated treatment outcomes with use of misoprostol at home compared to in-clinic dosing. However, one large literature review (Raymond et al\(^9\)) evaluated a variety of mifepristone treatment regimens with different misoprostol doses, routes of administration and dosing intervals used in gestations through 63 days. Roughly half of the studies included in this review did not require women to take misoprostol in-clinic. Rates of treatment failure and of ongoing pregnancy were very similar regardless of whether misoprostol was taken in-clinic or at another location. The clinical review team concluded that the review provided sufficient data to support labeling that misoprostol does not need to be restricted to in-clinic administration.

4. **Use of a repeat misoprostol dose, if necessary:** The Applicant submitted several published studies that supported use of a repeat misoprostol dose, when complete uterine expulsion did not occur after the initial misoprostol dose following Mifeprex. In clinical practice, the usual treatment for incomplete expulsion (retained products of conception) may include either a repeat dose of misoprostol, expectant management or a surgical procedure (suction aspiration or a dilation and curettage). Studies that specifically report the success rate of a repeat dose of misoprostol are:

---


\(^8\) Creinin MD, Fox MC, Teal S, Chen A, Schaff EA, Meyn LA. MOD Study Trial Group: A randomized comparison of misoprostol 6-8 hours versus 24 hours after mifepristone for abortion. Obstet Gynecol 2004; 103: 851-859

Winikoff et al\textsuperscript{10} – studied the proposed regimen through 70 days gestation; of the few women who received a second dose for an incomplete abortion at follow-up, the success rate was 91% at 57-63 days and 67% at 64-70 days.

Chen and Creinin \textsuperscript{11} – a systematic review of 20 studies, all but one of which used the proposed regimen up through 70 days; success of a second dose ranged from 91-100%

Boersma et al\textsuperscript{12} – included pregnancies through 70 days treated with the proposed regimen; five of 330 women took a second dose due to absence of bleeding 48 hours after first dose; the success rate was 80%

Louie et al\textsuperscript{13} – studied the proposed regimen to 63 days; in 16 women (of 863) who took a second dose of misoprostol, the success rate was 100%

Chong et al\textsuperscript{14} – compared the proposed regimen to a lower dose of misoprostol; the success of a second dose of misoprostol was 92% overall, but the number of women in each dose arm getting a second dose was not specified.

Winikoff et al\textsuperscript{15} – 14 women in the proposed regimen took a second dose of misoprostol with a success rate of 92.9%.

Using the information from the above studies and other supportive data, the clinical team concluded that the available data support the efficacy of a repeat dose of misoprostol if complete expulsion has not occurred. The relatively high complete pregnancy termination rates indicate that this option is likely to reduce the need for a surgical intervention.

5. Requirements regarding follow-up care: Current labeling states that women will return to the clinic 14 days after Mifeprex administration for follow-up. This provision was based on the follow up regimen in the U.S. phase 3 trial that supported the initial approval in 2000. Although the Applicant submitted several studies that evaluated flexibility in the time of follow-up, the key publication identified by the review team that addressed this issue was a 2013 article by

\textsuperscript{10} Winikoff B, Dzuba IG, Chong E, et al. Extending outpatient medical abortion services through 70 days of gestational age. Obstet Gynecol 2012; 120: 1070-6


\textsuperscript{12} Boersma AA, Meyboom-de Jong B, Kleiverda G. Mifepristone followed by home administration of buccal misoprostol for medical abortion up to 70 days of amenorrhoea in a general practice in Curacao. Eur J Contracept Reprod Health Care 2011; 16: 61-6


\textsuperscript{14} Chong E, Tsereteli T, Nguyen NN, Winikoff B. A randomized controlled trial of different buccal misoprostol doses in mifepristone medical abortion. Contraception 2012; 86: 251-256

Raymond\textsuperscript{16}. The impact of the timing of follow-up was assessed in Raymond’s systematic review of studies using various treatment regimens. While some have posited that earlier follow-up may result in a higher rate of surgical intervention (for women who would have had complete expulsion had they been given a bit more time), Raymond’s analyses found no difference in failure rates for women followed less than one week after mifepristone as compared to a week or more after mifepristone. As follow-up was anticipated to not alter the efficacy of the proposing dosing regimen, this change is also discussed below in Section 7.

6. Allowing qualified healthcare providers to use Mifeprex.

The Applicant provided data on the efficacy of medical abortion provided by non-physician healthcare providers, including four studies with 3,200 women in randomized controlled clinical trials and 596 women in prospective cohorts. These studies included a study by Warriner et al\textsuperscript{17} that showed efficacy of 97.4\% with nurses versus 96.3\% by physicians.

Conclusions: I concur with the clinical review team’s assessments and conclusions and these conclusions will be reflected in labeling. The data and information reviewed constitute substantial evidence of efficacy to support the proposed dosing regimen for Mifeprex for pregnancy termination through 70 days gestation. Other proposed changes to the Mifeprex labeling, including the time interval between Mifeprex and misoprostol dosing, and use of a repeat dose, were also adequately supported by evidence. Finally, I concur with the clinical review team that the information from the published literature also supported efficacious use of Mifeprex by non-physician providers.

Comment: Discussion was held as to whether the original dosing regimen approved in 2000 (i.e., Mifeprex 600 mg and misoprostol 400 mcg up to 49 days gestation) should remain in labeling.\textsuperscript{8} [4]

\textsuperscript{8} I concur with their request to remove the current regimen from the labeling. Removal of the original dosing regimen simplifies labeling, and avoids any confusion regarding instructions. Therefore, the revised labeling, and REMS materials accompanying the approval of this efficacy supplement, will include only the proposed dosing regimen and instructions. It should be noted that there are no safety or efficacy concerns about the originally approved dosing regimen that led to removing it from the labeling.


8. Safety

The safety of the proposed dosing regimen for Mifeprex was supported by the evidence from submitted published literature and postmarketing experience. The focus of the safety analysis was on published studies that evaluated the proposed dosing regimen (Mifeprex 200 mg followed by 800 mcg misoprostol buccally 24-48 hours later), with comparison to the known safety profile of the currently approved dosing regimen.

Exposure: Per the Applicant’s submission, the clinical review concluded that there have been approximately 2.5 million uses of Mifeprex by U.S. women since the drug’s approval in 2000. The clinical review team estimated that exposure to the proposed dosing regimen for their safety analysis was based on approximately 30,000 patients (refer to Table 11 for a list of references used to evaluate safety). Such exposure volume is sufficient to characterize the safety profile of the proposed dosing regimen and other proposed changes in this efficacy supplement.

Deaths: Deaths with medical abortion rarely occur and causality can be difficult to determine. Most of the publications did not specifically report any deaths with medical abortion with Mifeprex. Among the seven U.S. studies submitted to support the safety profile of Mifeprex and misoprostol, only one (Grossman, et al18) explicitly addressed deaths and noted that there were no deaths among 578 subjects evaluated in the study. Only one observational study (Goldstone, et al19) from Australia contained a report of a death after a mifepristone and misoprostol dosing regimen. In this retrospective review of 13,345 pregnancy terminations, the authors identified one death from sepsis. The article stated that the death was in an individual who failed to follow-up with her healthcare provider despite showing signs of illness. Based on this information, deaths in association with abortion are extremely rare.

Deaths reported from the postmarketing experience of Mifeprex are summarized below in the Postmarketing Experience section.

Nonfatal serious adverse events: The clinical review team identified key nonfatal serious adverse events (SAEs) associated with the proposed dosing regimen for Mifeprex. These SAEs include: hospitalization, serious infection, bleeding requiring transfusion and ectopic pregnancy. Section 7 of the clinical review dated March 29, 2016, provides a detailed discussion of reported rates of hospitalization, serious infection, bleeding requiring transfusion and ectopic pregnancy. The latter is not an adverse reaction because an ectopic pregnancy would exist prior to the Mifeprex regimen; it represents instead a failure to diagnose an ectopic pregnancy. Overall rates identified by the clinical review team from the published literature are as follows:

- Hospitalization: 0.04-0.6% in U.S. studies of over 14,000 women; 0-0.7% in international studies of over 1,200 women

Serious infection/sepsis: 0-0.2% in U.S. and international studies of over 12,000 women

Transfusion: 0.03-0.5% in U.S. studies of over 17,000 women; 0-0.1% in international studies of over 12,000 women

A study by Upadhyay et al\textsuperscript{20} reported a 0.31% rate of major complications (including incomplete or failed abortion, hemorrhage, infection or uterine perforation that required hospitalization, surgery or transfusion) for medical abortions (dosing regimen unspecified) through 63 days; this was about double the rate reported for first trimester aspiration abortions and statistically significantly higher. However, these rates were driven by higher rates of incomplete/failed abortion; rates of hemorrhage (0.14%) and infection (0.23%) did not differ from those associated with aspirations.

Only one submitted study reported an ectopic pregnancy. This study (Winikoff et al\textsuperscript{21}) reported one ectopic among 847 women (0.12%).

Comment: The proposed dosing regimen has been studied extensively in the literature using U.S. and global sites. Serious adverse events including deaths, hospitalization, serious infections, bleeding requiring transfusion and ectopic pregnancy are rarely reported. The rates of these serious adverse events are well below 1% and do not suggest a safety profile different from the original approved Mifeprex dosing regimen. Although there is less serious adverse event data on women who received Mifeprex and misoprostol between 64-70 days of gestation, the data from a U.S. study of 379 women (Winikoff et al)\textsuperscript{22} in that gestational age is reassuring that the rates of these serious adverse events are not clinically different from that of other gestational age ranges.

In summary, based on the published literature, nonfatal serious adverse events occur with Mifeprex and misoprostol use with rates generally less than 1%. Increased gestational age (64-70 weeks) was not associated with an increased incidence of nonfatal SAEs. Other submission-specific safety issues that were evaluated including uterine rupture and angioedema/anaphylaxis are discussed in the Postmarketing Experience section below.

Loss to follow-up: The studies included in this safety review revealed a wide range of loss to follow-up, from 0.6% loss to follow-up in the study with telephone follow-up (Ngoc et al\textsuperscript{23}) to 22% in the Grossman et al\textsuperscript{24} study using telemedicine to deliver medical


abortion services.

**Comment:** Based on these data reviewed by the clinical review team, there is no literature that suggests that follow-up modality alters safety. Therefore, labeling will not be directive regarding follow-up; that will be a decision left to the patient and provider.

**Common adverse events:** The clinical review team evaluated common adverse reaction data and compared U.S. and global study locations. The comparison revealed that there were differences in the frequency of common adverse reactions, with the reporting rates considerably higher among the U.S. studies. There is no reason to anticipate regional differences in the safety profile for the same treatment regimen, so these differences likely reflect lower ascertainment or subject reporting of adverse reactions in non-U.S. studies. Regardless, inclusion of this non-U.S. data in labeling would not be appropriate, as it is unlikely to be informative to the U.S. population of users. The data to be reported in labeling is outlined in Table 1 below:

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th># U.S. studies</th>
<th>Number of Evaluable Women</th>
<th>Range of frequency (%)</th>
<th>Upper Gestational Age of Studies Reporting Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea</td>
<td>3</td>
<td>1,248</td>
<td>51-75%</td>
<td>70 days</td>
</tr>
<tr>
<td>Weakness</td>
<td>2</td>
<td>630</td>
<td>55-58%</td>
<td>63 days</td>
</tr>
<tr>
<td>Fever/chills</td>
<td>1</td>
<td>414</td>
<td>48%</td>
<td>63 days</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3</td>
<td>1,248</td>
<td>37-48%</td>
<td>70 days</td>
</tr>
<tr>
<td>Headache</td>
<td>2</td>
<td>630</td>
<td>41-44%</td>
<td>63 days</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3</td>
<td>1,248</td>
<td>18-43%</td>
<td>70 days</td>
</tr>
<tr>
<td>Dizziness</td>
<td>2</td>
<td>630</td>
<td>39-41%</td>
<td>63 days</td>
</tr>
</tbody>
</table>

Source: Data from Middleton, Winikoff, and Winikoff as outlined in Table 2 of the CDTL review dated March 29, 2016.

One concerning adverse event is severe vaginal bleeding. Severe vaginal bleeding can result in interventions such as hospitalization and transfusion and may be associated with infection. The overall rate of bleeding across publications varied between 0.5% and 4.2%. Two publications (Sanhueza Smith et al and Gatter et al) evaluated clinically significant bleeding by gestational age. Although the publications reported slightly different rates, there was no trend of increased bleeding requiring intervention with Mifepristone and misoprostol use with increasing gestational age.

---

25 Middleton T, et al. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. Contraception 2005; 72: 328-32
**Comment:** While not all of the studies reported common adverse events, those that reported did not have unexpected rates of common adverse events. These common adverse events are included in labeling in section 6.1 (Clinical Trial Experience) in the ADVERSE REACTIONS section.

**Postmarketing experience – Spontaneous reports:**

The safety profile for Mifepristone includes over 15 years of postmarketing safety data available on Mifepristone due to the reporting requirements under the REMS. The Year 3 REMS Assessment report was submitted by the Applicant in June, 2015. The (b)(6) provided a comprehensive review of adverse event reports submitted from 2000 through November 17, 2015. Findings include:

- No Clostridial septic deaths reported in the U.S. since 2009, and none worldwide since 2010.
- The postmarketing rates of hospitalization, severe infection, blood loss requiring transfusion and ectopic pregnancy reported from publications and remain stable and relatively low.

**Submission-specific safety issues:**

- **Anaphylaxis/angioedema:** The (b)(6) identified a safety signal of anaphylaxis and angioedema with mifepristone administration. This signal was based on a comprehensive review of adverse event reports submitted from 2000 through November 17, 2015. A FAERS search retrieved one case of anaphylaxis and six cases of angioedema with mifepristone administration. Six of the seven cases were seen in women using mifepristone for termination of pregnancy. Six of the seven cases noted some type of medical intervention, such as treatment with an antihistamine, a histamine H2 antagonist, a corticosteroid, or a combination of various medications. Hospitalization was noted in three of the seven total cases; all three hospitalization cases occurred in patients who experienced angioedema. There were no additional cases of anaphylaxis or angioedema identified in the literature.

  **Comment:** (b)(6) and the clinical review team recommended that anaphylaxis and angioedema be described in the Contraindications and Adverse Reactions sections of labeling. These labeling sections were discussed with the Applicant and labeling was revised for those sections to describe these serious adverse events.

- **Uterine rupture:** As discussed in the clinical review, the potential risk of uterine rupture was considered because the current labeling for misoprostol includes a Boxed Warning against the use of misoprostol for gestations more than 8 weeks due to the risk of uterine rupture. Although misoprostol is used alone for various obstetric indications, including induction of labor at term, it was important to consider whether labeling about this potential risk is warranted for Mifepristone. Both the clinical reviewer and the (b)(6) reviewed the literature and searched FAERS for adverse event reports.
Published literature reported three case reports of uterine rupture with mifepristone/misoprostol treatment in the first trimester. Of these three reports, two patients had a risk factor for uterine rupture (prior uterine surgery). The third case was in a patient who received more than two doses of misoprostol. After consideration, the clinical review team decided that labeling should include information about this event. The FAERS search did not identify any reports of uterine rupture with use of mifepristone alone. Of 80 reports, 77 cited use of misoprostol alone, and three of mifepristone and misoprostol. Only two reports of uterine rupture in the first trimester were identified, both using misoprostol alone; one entailed an unspecified dose and route of misoprostol at 5 weeks gestation, and one involved vaginal administration of 800 mcg misoprostol at 8 weeks gestation for cervical preparation prior to a surgical abortion in a woman with a prior uterine scar.

Based on the available safety reports of uterine rupture, the review team and clinical review team concluded that these data demonstrated that uterine rupture with Mifepristone and misoprostol in the first ten weeks (70 days) of gestation is exceedingly uncommon, and occurs most often in the face of a risk factor (previous uterine surgery).

Comment: I agree with the clinical review team and the team that the risk of uterine rupture with first trimester use of mifepristone and misoprostol appears to be extremely rare, and most often associated with a prior uterine scar, a known risk factor for uterine rupture. Labeling of these reports is included in section 2.3 of the DOSAGE AND ADMINISTRATION and section 6.2 of the ADVERSE REACTIONS of labeling to provide additional information to healthcare providers, but no restriction of use is needed based upon this extremely rare adverse reaction.

The clinical review team also evaluated the safety for each of the following major changes proposed in this efficacy supplement:

1. Changing the dosing interval between Mifepristone and misoprostol from 48 hours to 24-48 hours
2. Home administration of misoprostol
3. Use of a repeat dose of misoprostol
4. Change in the follow-up timeframe and method of follow-up
5. Allowing providers other than physicians to provide Mifepristone

---

To evaluate each of these changes, the reviewers evaluated the adverse event information regarding:

- **Changing the timing interval between Mifeprex and misoprostol and change in the gestational age to 70 days:** Support for the 24-48 hour interval and use up through 70 days was primarily based on a large systematic review by Shaw et al.\(^{33}\) This review evaluated studies looking at different follow-up modalities and demonstrated that there are a variety of acceptable alternatives to in-clinic follow-up that can identify cases in which there is need for additional intervention. In addition, the systematic review did not identify any significant difference in adverse events with different time intervals. Based on these findings, labeling will not be directive regarding specific details of how follow-up should be performed; this will be a decision between the patient and her healthcare provider.

- **Home administration of misoprostol:** The Applicant supplied several published studies that supported this change including Gatter et al.\(^{34}\) and Ireland et al.\(^{35}\). These studies reported on large numbers of women in the U.S. who took misoprostol at home. The authors showed that home administration of misoprostol, as part of the proposed regimen, is associated with exceedingly low rates of serious adverse events, and with rates of common adverse events comparable to those in the studies of clinic administration of misoprostol that supported the initial approval in 2000. Given that information is available on approximately 45,000 women from the published literature, half of which incorporated home use of misoprostol, there is no clinical reason to restrict the location in which misoprostol may be taken. Given the fact that the onset of cramping and bleeding occurs rapidly (i.e., generally within 2 hours) after misoprostol dosing, allowing dosing at home increases the chance that the woman will be in an appropriate and safe location when the process begins.

- **Use of a repeat dose of misoprostol:** Safety reporting from studies that evaluated a repeat dose of misoprostol did not specifically assess the subset of women who received a second dose, but no unexpected findings were identified. One randomized controlled trial (Coyaji et al.\(^{36}\)) conducted in 300 women seeking medical abortion in India looked at a single misoprostol dose as compared to two misoprostol doses. Although there was no difference in the complete pregnancy termination rate in women who received a second misoprostol dose compared to those who did not, the repeat misoprostol dose reduced the need for surgical intervention. This study was reassuring in that there was no significant difference in the adverse events observed—similar percentages of women experienced


\(^{34}\) Gatter M, Cleland K, Nucatola DL. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days. Contraception 2015; 91:269-273.


cramping (87% in the single dose group, 89% in the repeat dose group), nausea (both groups 1%), vomiting (both groups 0%), and diarrhea (0% in the single dose group versus 2% in the repeat dose group). A supportive systematic review by Gallo et al\textsuperscript{37} also provided safety information on subjects who received repeat misoprostol. In this review, the only side effects discussed in the trials were diarrhea, which was more common on those groups receiving misoprostol orally than in those receiving it exclusively vaginally (26-27% versus 9%). Rash was reported <1%. Based on these findings, labeling will be changed because the misoprostol dose does not need to be restricted to in clinic administration to assure safe pregnancy termination using the proposed dosing regimen. Given the onset of bleeding and cramping after misoprostol, allowing home administration increases the likelihood that a woman will be in an appropriate and safe location when the pregnancy termination process begins.

- **Change in the follow-up timeframe and method of follow-up:** The Applicant submitted several articles that described different methodologies in follow-up including phone calls and standardized instructions. The clinical reviewers evaluated a study in Scotland by Cameron et al\textsuperscript{38} that evaluated self-assessment as compared to standard follow-up methodologies (clinic visit or phone call). Most of the women chose self-assessment over an in-clinic visit or phone call, and there were no significant differences in adverse outcomes between women who underwent self-assessment of health compared to those who had a clinic visit or phone call. Among women with an ongoing pregnancy after Mifeprex and misoprostol, the majority self-identified and presented within two-weeks for care. Based on this information and the other data from the Raymond systematic article\textsuperscript{39} that did not identify a difference in failure rate for earlier (less than one week) as compared to one week or greater of follow-up, sufficient support was provided to use a broadened window of 7 to 14 days for follow-up. This revised follow-up time frame will be included in labeling.

- **Allowing providers other than physicians to provide Mifeprex:** The current Prescriber’s Agreement in the REMS specifies that “…Mifeprex must be provided by or under the supervision of a physician who meets the following qualifications…” In addition, current labeling states that Mifeprex will be supplied only to licensed physicians who sign and return a Prescriber’s Agreement. However, labeling states that other healthcare providers, acting under the supervision of a qualified physician, may also provide Mifeprex to patients. Several published studies submitted by the Applicant indicate that health care providers such as nurse practitioners, nurse midwives, and physician assistants are

\textsuperscript{37} Gallo MF, Cahill S, Castelman L, Mitchell EMH. A systematic review of more than one dose of misoprostol after mifepristone for abortion up to 10 weeks gestation. Contraception 2006;74:36-41.


currently providing abortion services. One of these studies (Kopp Kallner et al\textsuperscript{40}) was a randomized controlled trial of 1,068 women in Sweden who were randomized to receive medical abortion care from two nurse midwives experienced in medical terminations and trained in early pregnancy ultrasound versus a group of 34 physicians with varying training and experience. Success rates were $\geq 96\%$ regardless of gestational age. The nurse midwife group had few complications, though this was not statistically significant (4.1\% for nurse midwives, versus 6.1\% for doctors, $p=0.14$). No serious complications were reported and no blood transfusions were administered in the study. Based on this and other supportive studies, the information supports the efficacy and safety of allowing healthcare providers other than physicians can effectively and safely provide abortion services, provided that they meet the requirements for certification described in the REMS. The clinical team also felt that the term “healthcare provider who prescribes” would be the appropriate terminology as prescribing ability is a critical factor in dispensing Mifeproxic.

The clinical review team concluded that the evidence demonstrated acceptable safety for each of the above proposed changes, and I concur with their conclusion. The proposed dosing regimen has a similar safety profile as the original regimen approved in 2000. Adverse outcomes of interest, such as deaths, serious infection, transfusions, ectopic pregnancies and uterine rupture, remain rare, and are not necessarily attributable to Mifeproxic use. Overall, the rate of deaths and nonfatal serious adverse events are acceptably low, and data for the proposed regimen do not suggest a safety profile that deviates from that of the originally approved regimen. No association between adverse outcomes and increasing gestational age was identified. Finally, the available information supports the safety of the other proposed changes, including increasing the flexibility of the time interval between Mifeproxic and misoprostol, at home use of misoprostol, use of a repeat dose of misoprostol, change in the follow-up timeframe and allowing health care providers other than physicians to prescribe and dispense Mifeproxic were acceptable.

9. Advisory Committee Meeting

Mifeproxic is not a new molecular entity requiring discussion before an advisory committee. In addition, an advisory committee was not necessary as the application did not raise complex scientific or other issues that would warrant holding an AC before approval.

10. Pediatrics

This efficacy supplement triggered requirements under the Pediatric Research Equity Act (PREA). The Agency granted a partial PREA waiver for pre-menarcheal females ages birth to 12 years because it would be impossible to conduct studies in this pediatric population, as pregnancy does not exist in premenarcheal females.

\textsuperscript{40}Kopp Kallner H, Fiala C, Stephansson O, Gemzell-Danielsson K. Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days. Human Reprod 2010;25(5):1153-1157.
The Applicant fulfilled the remaining PREA requirement in postmenarcheal females by submitting published studies of Mifeprex for pregnancy termination in postmenarcheal females less than 17 years old. Efficacy and safety information in these adolescents was based on a U.S. study in 322 postmenarcheal adolescents (Gatter et al\textsuperscript{41}). Of the 322 adolescents, 106 of these adolescents were under 16; see Table 2 below:

**Table 2: Age and Number of Adolescents Undergoing Medical Abortion (Gatter et al\textsuperscript{42})**

<table>
<thead>
<tr>
<th>Age of Subject</th>
<th>Number of Subjects evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>1</td>
</tr>
<tr>
<td>12</td>
<td>1</td>
</tr>
<tr>
<td>13</td>
<td>2</td>
</tr>
<tr>
<td>14</td>
<td>20</td>
</tr>
<tr>
<td>15</td>
<td>82</td>
</tr>
<tr>
<td>16</td>
<td>216</td>
</tr>
</tbody>
</table>

Source: Refer to Table 17 of the Medical Officer’s review dated March 29, 2016

The Gatter et al\textsuperscript{43} study reported that postmenarchal females less than 18 years old had a 98.7% pregnancy termination rate as compared to females aged 18-24, who had a rate of 98.1%. This article reported that loss to follow-up was slightly higher in those less than 18 years old, however, age did not adversely impact efficacy outcomes.

One issue was whether adolescents would comply with at home use of misoprostol. The Gatter\textsuperscript{44} et al study incorporated at home use of misoprostol into the Mifeprex dose regimen given to all females, including postmenarchal females less than 18 years old. The overall efficacy in adolescents was similar to that of all older women. This information supports at home administration of misoprostol in postmenarcheal females under 17.

Two other published studies provided additional efficacy on Mifeprex use by adolescents for pregnancy termination:

- Phelps et al\textsuperscript{45} evaluated data from 28 adolescents aged 14 to 17, at \( \leq 56 \) days gestation, using Mifeprex 200 mg followed 48 hours later by misoprostol 800 mcg vaginally. In this study, 100% of subjects had a complete pregnancy termination, with five not requiring misoprostol.

\textsuperscript{41}Gatter M, Cleland K, Nucatola DL. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days. Contraception 2015; 91:269-273.

\textsuperscript{42}Ibid.

\textsuperscript{43}Gatter M, Cleland K, Nucatola DL. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days. Contraception 2015; 91:269-273.

\textsuperscript{44}Gatter M, Cleland K, Nucatola DL. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days. Contraception 2015; 91:269-273.

• Niinimaki et al\textsuperscript{46} used data from a Finnish Registry from 2000-2006. An analysis of efficacy between adolescents under age 18 compared to the women ≥ age 18 indicated that the adolescent group had a lower rate of incomplete abortions as compared to adults. And efficacy outcomes in adolescents were similar to those of adult women.

The safety of Mifepristone in postmenarcheal adolescents was primarily supported by adverse event information from the Gatter et al\textsuperscript{47} study.

Supportive data from a Finnish registry (Niinimaki et al\textsuperscript{48}) from 3024 adolescent females under 18 years of age reported that, compared to adult women, the risks of hemorrhage (adjusted odds ratio 0.87 [95% confidence interval: 0.77 to 0.99]), incomplete abortion (0.69, [95% confidence interval: 0.59 to 0.82]), and surgical evacuation (0.78, [95% confidence interval: 0.67 to 0.90]) were lower in the adolescent cohort. In the Finnish registry study, a majority of adolescents and adults received both Mifepristone and misoprostol. Safety findings from the Gatter et al and Niinimaki et al studies are reassuring and indicate that the safety profile of Mifepristone is similar between postmenarcheal adolescents and adult women.

Additional details from this article and other published data on Mifepristone use in adolescents (females under 17) are described in the clinical review (Refer to the Medical Officer’s review dated March 29, 2016).

\textit{(b)(5)} concurred that the efficacy and safety data in postmenarcheal adolescents less than 17 years old was sufficient to support the use of Mifepristone in this pediatric population and to fulfill the PREA pediatric study requirement. The revised Mifepristone labeling will state that efficacy and safety are similar to adult women in the Pediatric Use section (8.4).

11. Other Relevant Regulatory Issues

\textit{(b)(5)} reviewed the Medication Guide in conjunction with the \textit{(b)(5)} Both \textit{(b)(5)} and \textit{(b)(5)} found the Medication Guide to be acceptable with recommended changes (See review dated March 29, 2016). The Division considered all of the recommendations from \textit{(b)(5)} in revising and updating the text in


the Medication Guide and incorporated appropriate changes into the final agreed upon Medication Guide.

reviewed the Prescribing Information (PI) in addition to the joint review with of the Medication Guide in conjunction with . After review, provided recommended changes (See review dated March 29, 2016). The Division considered all of the recommendations from in revising and updating the text in the PI and incorporated appropriate changes into the final label.

) reviewed the proposed modifications to the REMS. The review reflected agreement with the Applicant’s proposed REMS changes which include:

• Removal of the term “under Federal law” from the Prescriber’s Agreement.

• Replacement of the word “physician” with a broader term to describe appropriate healthcare professionals who may order, prescribe and administer Mifepristone. believes that the Applicant’s proposed terminology of “prescriber,” which limits acceptable healthcare providers to those who are licensed in their state to prescribe medications.

• Removal of the Medication Guide from the REMS. The Medication Guide remains an important education tool for patients. It will still be dispensed to each patient in accordance with 21 CFR part 208. As described in the Medication Guide Guidance, a Medication Guide is not necessary to ensure that the benefits outweigh the risks of Mifepristone.

• Modification of Element to Assure Safe Use (ETASU) A, the Prescriber’s Agreement. recommends changing the name of the document to the Prescriber’s Agreement Form to be consistent with other REMS programs. References to “physician” should be changed to “healthcare provider who prescribes.”

• recommends removing the Patient Agreement from the REMS for a number of reasons:

  1. The established safety profile over 15 years of experience with Mifepristone is well-characterized, stable, and known serious risks occur rarely

  2. The Medication Guide contains the same risk information addressed in the Patient Agreement, and will still be provided to patients under 21 CFR part 208

  3. The Prescriber’s Agreement Form will continue to require providers to explain the treatment, its effects and risks associated with Mifepristone and to answer any questions that a patient may have

  4. Established clinical practice provides for counseling, informing the patient about follow-up, when to contact the provider/clinic, answering questions and obtaining signed informed consent before treatment. FDA has removed REMS
requirements in other programs based on the integration of the REMS safe use condition into clinical practice.

Other revisions to the REMS document will be made for consistency with changes described above and to reflect current FDA thinking and practice regarding format, language and flow in REMS documents. These changes include modification of the Mifeprex REMS goal, changes in requirements to certify prescribers (removal of the requirement to obtain a Patient Agreement) and other minor edits.

In summary, the overall recommendation for the REMS modification for this efficacy supplement was approval (Refer to review dated March 29, 2016).

12. Labeling

Carton and container labeling was reviewed by the and the Comments were conveyed to the Applicant as appropriate.

The label was submitted in the format prescribed by the PLR. Although the supplement was submitted prior to when it would otherwise have been required to comply with the PPLR requirements, the review team believed it would be of value to harmonize with this labeling standard to the extent possible.

Specific issues discussed during labeling negotiations included the selection of studies for inclusion in Section 6.1 (Clinical Trial Experience in the ADVERSE REACTIONS section) and 14 (CLINICAL STUDIES section). Only studies that evaluated the specific proposed regimen were included in these sections. For the Adverse Reactions section, examination of the common adverse reaction data by U.S. compared to non-U.S. study location revealed that there were large differences in the frequency of common adverse reactions, with the reporting rate considerably higher among the U.S. studies. This may reflect differences in ascertainment or subject reporting of adverse reactions in non-U.S. studies. Regardless, inclusion of this non-U.S. data would not be appropriate, as it is unlikely to be informative to the U.S. population of users. In the case of serious adverse reactions, the reported frequency was quite similar regardless of study location; for this reason, serious adverse reaction information from global studies is reported. Agreement on labeling was reached on March 29, 2016.
Post-Marketing Requirement/Commitment and Risk Evaluation and Mitigation Strategies (REMS):

Postmarketing Requirements/Postmarketing Commitments: None.

Risk Evaluation and Mitigation Strategies (REMS): The Applicant proposed a REMS modification for the Mifeprex REMS program with the submission of this efficacy supplement. The review teams from the [REDACTED] evaluated the current Mifeprex REMS program and the proposed REMS modifications to determine whether each Mifeprex REMS element remains necessary to ensure that the benefits of Mifeprex outweigh the risks. Factors that impacted the decision included findings from two REMS assessments (the more recent REMS assessment review was completed in October 2015), an unchanged safety profile, and published literature that documented adequate safeguards in clinical practice with the use of Mifeprex in a regimen with misoprostol.

The teams determined that the following REMS modifications were warranted:

1. Revisions to the Prescriber Agreement Form to reflect the new dosing regimen and to reflect current REMS formatting and language standards
2. Removal of the Medication Guide as a REMS element, as distribution of the Medication Guide is required under 21 CFR 208
3. Removal of the Patient Agreement as a Documentation of Safe Use Condition (ETASUD)
4. Updating of the REMS goals to reflect the above 3 changes.
5. Removal of the phrase “Under Federal law” from the Prescriber’s Agreement
6. Replacing the term “licensed physician” with “healthcare provider who prescribes”

The above modifications to the Mifeprex REMS program were discussed with the [REDACTED] on January 15, 2016, as per [REDACTED].

The [REDACTED] concurred with conforming changes to the Prescriber’s Agreement to reflect the new dosing regimen, and with removal of the Medication Guide from the REMS. The Medication Guide would remain a part of labeling to inform patients about the risks associated with Mifeprex use. The [REDACTED] also concurred with revisions to the REMS goals to reflect these changes.

The [REDACTED] concurred with the removal of the term “under Federal law”. A rationale for the original inclusion of the phrase “Under Federal law” cannot be discerned from available historical documents, nor is it consistent with REMS materials for other products. All the conditions of approval, including the REMS materials, are under Federal law; therefore, the phrase is unnecessary and it was decided that the phrase be removed from the Prescriber’s Agreement.
The [redacted] concurred with use of the term “healthcare providers who prescribe.” To support a change in the REMS that would allow qualified healthcare providers other than physicians to prescribe Mifeprex through the Mifeprex REMS program, the Applicant provided information from over 3,200 women in randomized controlled trials and 596 women in prospective cohort studies comparing medical abortion care by physicians versus other providers (nurses or nurse midwives). These studies were conducted in a variety of settings (international, urban, rural, and low-resource). No differences in serious adverse events, ongoing pregnancy or incomplete abortion were identified between the groups. Given that providers other than physicians are providing family planning and abortion care under supervision and that the approved labeling and REMS program stipulate that prescribers must be able to refer patients for additional care, including surgical management, allowing these prescribers to participate in the Mifeprex REMS program is acceptable.

The [redacted] also concurred with the teams’ recommendation to remove the Patient Agreement (ETASU D) from the REMS although some members commented that additional support for the review team’s rationale for this modification was needed. The review team’s rationale for this change was:
The safety profile of Mifeprex is well-characterized over 15 years of experience, with known risks occurring rarely; the safety profile has not changed over the period of surveillance.

Established clinical practice includes patient counseling and Informed Consent, and, more specifically with Mifeprex, includes counseling on all options for termination of pregnancy, access to pain management and emergency services if needed.

Medical abortion with Mifeprex is provided by a well-established group of organizations and their associated providers who are knowledgeable in this area of women’s health. Their documents and guidelines cover all the safety information that also appears in the Patient Agreement.

ETASUs A and C remain in place: The Prescriber’s Agreement under ETASU A requires that providers “explain the procedure, follow-up, and risks to each patient and give her an opportunity to discuss them.” The REMS will continue to require that Mifeprex be dispensed to patients only in certain healthcare settings, specifically, clinics, medical offices, and hospitals. This ensures that Mifeprex can only be dispensed under the direct supervision of a certified prescriber.

Labeling mitigates risk: The Medication Guide, which will remain a part of labeling, contains the same risk information covered under the Patient Agreement.

The Mifeprex REMS program will have a modified ETASU REMS that will continue to ensure that Mifeprex can only be prescribed by certified prescribers and be dispensed to patients in certain healthcare settings, specifically, clinics, medical offices and hospitals. The Medication Guide will continue to be distributed to patients required under 21 CFR part 208. As required for all ETASU REMS, ongoing assessments of the Mifeprex REMS program will continue to ensure that the modified Mifeprex REMS program is meeting its goals.

13. Decision/Action/Risk Benefit Assessment

Decision:

All regulatory and scientific requirements have been adequately addressed in this efficacy supplement. Review teams involved in this supplement have recommended approval of the supplement from their disciplines’ perspective. The submitted efficacy and safety information supported approval of the proposed dosing regimen through 70 days gestation, and other changes discussed in this summary memo. This supplement will receive an Approval action.

Benefit Risk Assessment:

This efficacy supplement provided substantial evidence of efficacy for the proposed dosing regimen through 70 days gestation. The efficacy findings were similar to those that led to the approval of the original dosing regimen in 2000. In addition, the submitted published literature supported other changes sought in this efficacy supplement that will
be reflected in labeling: 1) a more flexible time interval of 24 to 48 hours between Mifeprex and misoprostol administration, 2) the option of at home administration of misoprostol, 3) the option of repeat misoprostol dosing, if clinically indicated, 4) flexibility in the follow-up time frame of 7 to 14 days, and 5) permitting qualified healthcare providers other than physicians to prescribe Mifeprex.

The safety findings of the proposed dosing regimen were acceptable and were similar to those seen with the original dosing regimen approved in 2000.

After review of the REMS modifications proposed by the Sponsor, I concur with the clinical team and recommendations that:

1. The Medication Guide can be removed from the Mifeprex REMS program. The Medication Guide requirements under 21 CFR part 208 require the Medication Guide to be distributed to patients. Mifeprex will only be dispensed by a healthcare professional who will be knowledgeable and able to provide the patient instructions on appropriate use of the drug, including what potential side effects may occur or follow-up that may be required as appropriate, and who will answer any questions the patient may have. In that setting, the Medication Guide will already be a required available tool for counseling. Therefore, given the existing requirements under 21 CFR part 208, I concur that there is no reason for the Medication Guide to specifically be a part of the REMS.

2. The Prescriber Agreement Form (ETASU A) as revised reflects current FDA format and content to conform to current REMS programs and reflect the labeling changes that will be approved in this supplement. I concur that the changes are acceptable.

3. Revision of the Mifeprex REMS goals (ETASU C) will adequately mitigate the risk of serious complications by requiring certification of healthcare providers who prescribe and ensuring the Mifeprex is dispensed only in certain healthcare settings by or under the supervision of a certified prescriber.

4. Removal of the Patient Agreement Form (ETASU D): I concur with the clinical review team that the Patient Agreement Form, which requires a patient’s signature, does not add to safe use conditions for the patient for this REMS and is a burden for patients. It is standard of care for patients undergoing pregnancy termination to undergo extensive counseling and informed consent. The Patient Agreement Form contains duplicative information already provided by each healthcare provider or clinic. I believe that it is much more critical for the healthcare provider who orders or prescribes Mifeprex to provide and discuss informed consent derived from their own practice so that care can be individualized for the patient.
I support that the Mifeprex REMS with ETASUs A and C remain in place to support conditions critical to the use of the drug. Therefore, the implementation system and timetable for assessments should continue.

I also agree with the clinical review team that the reporting requirements should only be required for deaths. It is important that the Agency be informed of any deaths with Mifeprex to monitor new safety signals or trends. However, after 15 years of reporting serious adverse events, the safety profile for Mifeprex is essentially unchanged. Therefore, I agree that reporting of labeled serious adverse events other than deaths can be collected in the periodic safety update reports and annual reports to the Agency.

In summary, I believe that the benefit-risk profile for Mifeprex continues to be favorable and with the agreed-to labeling changes and REMS modifications, the Mifeprex REMS program will continue to assure safe use. Therefore, I support approval of this efficacy supplement and REMS modifications.

Addendum:

On March 28, 2016, Dr. Janet Woodcock, the Director, Center for Drug Evaluation and Research, asked [redacted] and the [redacted] to continue to include a Patient Agreement Form in the REMS for Mifeprex (see March 28, 2016 Memorandum from Janet Woodcock, MD, Director, Center for Drug Evaluation and Research, through the [redacted] Therefore, the Patient Agreement Form will be retained and other changes will be made in the REMS to reflect that it is being retained.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

03/29/2016
Exhibit 21

Beverly Winikoff et al., Extending Outpatient Medical Abortion Services Through 70 Days of Gestational Age, 120 Obstetrics & Gynecology 1070 (2012)
Extending Outpatient Medical Abortion Services Through 70 Days of Gestational Age


OBJECTIVE: To estimate the efficacy and acceptability of medical abortion at 64–70 days from last menstrual period (LMP) and to compare it with the already proven 57–63 days from LMP gestational age range.

METHODS: This prospective, comparative, open-label trial enrolled 729 women with pregnancies 57–70 days from LMP requesting abortion at six U.S. clinics. Medical abortions were managed with 200 mg mifepristone and 800 micrograms buccal misoprostol and sites' service delivery protocols. Follow-up visits occurred 7–14 days after mifepristone, with an abortion considered complete if surgical intervention was not performed. Success, ongoing pregnancy, and acceptability rates were compared.

RESULTS: A total of 629 cases were analyzable for efficacy. Success rates were similar in the two groups (57–63 days group: 93.5%, 95% confidence interval [CI] 90–96; 64–70 days group: 92.8%, 95% CI 89–95). Ongoing pregnancy rates also did not differ significantly (57–63 days: 3.1%, 95% CI 1.6–5.8; 64–70 days: 3.0%, 95% CI 1.5–5.7). Acceptability was high and similar in both arms, with most women (57–63 days: 87.4%; 64–70 days: 88.3%) reporting that their experience was either very satisfactory or satisfactory.

CONCLUSION: Medical abortion with mifepristone and misoprostol in current outpatient settings is an efficacious and acceptable method of ending pregnancies 64–70 days from LMP and can be offered without alteration of existing services.

DOI: http://10.1097/AOG.0b013e31826c315f
LEVEL OF EVIDENCE: II

When medical abortion with mifepristone and misoprostol was approved by the U.S. Food and Drug Administration (FDA) in 2000, the regimen was recommended for outpatient use through 49 days from the last menstrual period (LMP). Extensive research and more than 11 years of experience in the United States with approximately 1.75 million uses have established that medical abortion is safe and effective through 63 days from LMP when used by women at home (May 2011, Danco Laboratories, personal communication). Generally, women in the United States whose first-trimester pregnancies are beyond 63 days from LMP are not offered medical abortion with mifepristone and misoprostol. Medical abortion after 63 days from LMP is occasionally available outside the United States, but only on an inpatient basis using complex inpatient protocols. Extensive research and more than 11 years of experience in the United States with approximately 1.75 million uses have established that medical abortion is safe and effective through 63 days from LMP when used by women at home (May 2011, Danco Laboratories, personal communication).2–6

Financial Disclosure
The authors did not report any potential conflicts of interest.

© 2012 by The American College of Obstetricians and Gynecologists. Published by Lippincott Williams & Wilkins.
ISSN: 0029-7844/12
LMP in outpatient services are limited to one small trial, but results were not available when this study began. Our study sought to estimate the efficacy and acceptability of the most common outpatient medical abortion regimen in the United States (200 mg mifepristone and 800 micrograms buccal misoprostol) through 70 days from LMP and to compare outcomes between women with pregnancies of 64–70 days’ duration and women with pregnancies in the range of 57–63 days. The gestational age limit of 70 days extends the usual gestational age cutoff of 63 days by 1 week.

MATERIALS AND METHODS

The study was performed at six facilities: Family Planning Associates Medical Group (Chicago, IL), Planned Parenthood League of Massachusetts (Boston, MA), Planned Parenthood of New York City (New York, NY), Planned Parenthood of Waco (Waco, TX), Presidential Women’s Center (West Palm Beach, FL), and Planned Parenthood of Minnesota, North Dakota, South Dakota (St. Paul, MN). The Quorum Review Institutional Review Board approved the protocol.

Women seeking pregnancy termination were invited to participate in the study if they were eligible for medical abortion, were at least 18 years old, and had a confirmed intrauterine pregnancy 57 through 70 days from LMP, based on routine ultrasound practices of the respective study sites (crown-rump length + 42 was most commonly used). Participants had to be willing and able to provide informed consent, have access to a telephone and emergency transportation, be able to speak and read English or Spanish, and agree to follow study protocols. Screening and enrollment generally occurred during the same visit, except when a state-mandated 24-hour waiting period after informed consent required a second visit.

On day 1, participants swallowed mifepristone 200 mg (Mifeprex) in the clinic and then were provided with misoprostol 800 micrograms to take 24–48 hours later at home. Women were instructed to hold the misoprostol buccally for 30 minutes before swallowing any remains. Analgesics and anti-nausea medications were dispensed or prescribed according to local standards at each facility, and participants were counseled to call the clinic with questions or concerns. Participants maintained a diary for up to 15 days to record time of misoprostol administration, bleeding, expulsion time (if recognized), pain medications used, and days of missed work or school.

Participants returned to the study site 7 to 14 days after using mifepristone (according to clinic practice) for clinical assessment, which included ultrasonography. Uterine suction curettage was recommended for women with ongoing pregnancies. Women with non-viable pregnancies (eg, empty sac or static size with absent cardiac activity on ultrasonography) could opt for suction curettage, expectant management, or a second misoprostol dose. If either of the latter two options was chosen, then women were asked to return to the clinic in 1 week for further follow-up. If a persistent nonviable pregnancy was diagnosed at the extended follow-up visit, suction curettage was recommended. Providers also intervened surgically if they deemed it medically necessary or at the patient’s request. After expulsion of uterine contents was confirmed, women responded to a semi-structured interview about their experiences with the medical abortion overall, the incidence of side effects and their severity (based on their own definitions of mild, moderate, and severe), and the acceptability of the procedure. If a participant failed to return for a follow-up visit, then assessment of abortion status and the interview could be conducted by telephone. Study sites were required to document at least three attempts to contact women who were lost to follow-up.

The study’s primary objective was to assure that an outpatient medical abortion regimen could be used in gestations 64–70 days from LMP and achieve a success rate of at least 90%, which would characterize a clinically acceptable regimen. A cohort of women with gestations 57–63 days from LMP was also enrolled to serve as a comparison; 334 women per group were needed to detect a 5% or greater lower efficacy than the hypothesized 95% success rate in the 57–63 days group, based on previously published reports (α = 0.05, 1–β = 0.8, using a one-tailed test) and would allow us to estimate a success rate of 90% with a confidence interval (CI) of ±3.2%.

Data were analyzed using SPSS 15.0. An independent data and safety monitoring committee reviewed the interim results for safety and efficacy after 50% of the data were available.

The primary outcome of the trial was complete abortion without surgical intervention at any point, regardless of the number of misoprostol doses used. Secondary outcomes included side effects, patient satisfaction and acceptability, days of heavy bleeding, days of missed work or school, and number of calls and unscheduled visits to the clinic. One-tailed P < .05 was considered to indicate statistical significance. We chose to use one-tailed P values because our objective was to determine whether use of medical abortion in
the gestational age range of 64–70 days would result in worse outcomes than its current use in the 57- to 63-
day age range. Binomial proportion CIs for efficacy rates were calculated. We used Fisher’s exact test to
determine differences in proportions, and for continu-
ous variables we used the Student t test to determine
differences in means.

RESULTS

Between August 2009 and February 2011, the study
sites enrolled 729 women; 379 women in the 57–63
days group and 350 women in the 64–70 days group.
Fifty-three (14%) women in the earlier and 45 (13%) in
the later gestational age group were lost to follow-up,
and two women, one from each group, withdrew
before using mifepristone. Enrollment was continued
to 729 women to compensate for loss to follow-up.
Six-hundred twenty-nine cases had outcome data,
short of the estimated sample size of 668. Analysis of
the outcomes at that time were conducted to deter-
mine the utility of continuing the study and whether
a statistically significant difference in success would be
possible if the study were to continue and the remain-
ing 39 analyzable case records were available. We
analyzed the hypothetical scenario that maximized the
possible difference in efficacy between the two
groups by adding all 39 hypothetical additional cases
to the 57–63 days group (because it had the higher
efficacy rate) and assuming that every woman had
a successful abortion (to model the maximum mathe-
atical differences possible between the groups). This
model improved the efficacy rate in the 57–63 days
study group by 0.7 percentage points and doubled the
projection of possible difference in efficacy between the
two gestational age groups by adding all 39 hypothetical additional cases to the 57–63 days group.

Six-hundred twenty-nine cases had outcome data,
short of the estimated sample size of 668. Analysis of
the outcomes at that time were conducted to deter-
mine the utility of continuing the study and whether
a statistically significant difference in success would be
possible if the study were to continue and the remain-
ing 39 analyzable case records were available. We
analyzed the hypothetical scenario that maximized the
possible difference in efficacy between the two
groups by adding all 39 hypothetical additional cases
to the 57–63 days group (because it had the higher
efficacy rate) and assuming that every woman had
a successful abortion (to model the maximum mathe-
atical differences possible between the groups). This
model improved the efficacy rate in the 57–63 days
study group by 0.7 percentage points and doubled the
difference in efficacy between the two gestational age
groups from 0.7% to 1.4%. Comparing the projected
success rates of the two gestational age groups resulted in P=0.2. It was therefore determined that enrolling
all 688 women would not show a statistically signifi-
cant or a clinically meaningful difference in success
rates. The study would have required an additional
13,120 women with follow-up in each study group
(total 26,240 analyzable cases) to be able to find a sta-

tistically significant difference between the observed
success rates. Therefore, a total of 629 medical abor-
tions, 325 in the 57–63 days group and 304 in the 64–
70 days group, were analyzed for efficacy in the final
analysis. Baseline characteristics of women in the two
groups were similar for mean age, education level,
gravidity, and previous abortions (Table 1).

Efficacy of the outpatient medical abortion regi-
men in the 57–63 days group was 93.5% (95% CI
90.1–95.9) and 92.8% (95% CI 89.1–95.3; P=.41) in
the 64–70 days group (Table 2). Three percent of
women in both groups had a surgical intervention
because of ongoing pregnancy (57–63 days: 3.1%,
95% CI 1.6–5.8; 64–70 days: 3.0%, 95% CI 1.5–5.7;
P=.62). Rates of surgical intervention attributable to
persistent nonviable pregnancy or sac (P=.33), sub-
stantial uterine debris (P=.29), excessive prolonged
bleeding (P=.75), or woman’s request (P=.86) were
comparable between study groups. There was no sig-
nificant difference in efficacy by study site (P=.137).

Approximately 5.2% of women in the 57–63 days
group and 5.3% of women in the 64–70 days group
had incomplete abortion diagnosed (ie, persistent ges-
tational sac or substantial debris) at their first follow-
up visits (P=.56). The majority were treated with a sec-
ond dose of misoprostol, with those in the 57–63 days
group receiving a second dose at a higher rate than
those in the 64–70 days group (76.5% compared with
56.3%; P=.193). Of those who received a second dose
of misoprostol and underwent an extended follow-up
evaluation, 91% (10 of 11) in the earlier and 66.7%
(6 of 9) in the later gestational age group were deter-
mined to have a complete abortion (P=.974).

Almost 70% of participants in each group reported a time of expulsion at follow-up. Among
women who reported a time of expulsion, those in

Table 1. Participant Demographic Characteristics

<table>
<thead>
<tr>
<th></th>
<th>57–63 d (n=325)</th>
<th>64–70 d (n=304)</th>
<th>P (Two-Tailed)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>26 (18–42)</td>
<td>26 (18–42)</td>
<td>.66</td>
</tr>
<tr>
<td>Primigravid woman</td>
<td>32 (103)</td>
<td>31 (94)</td>
<td>.86</td>
</tr>
<tr>
<td>Previous abortion</td>
<td>47 (154)</td>
<td>48 (146)</td>
<td>.87</td>
</tr>
<tr>
<td>Previous medical abortion</td>
<td>21 (67)</td>
<td>24 (72)</td>
<td>.39</td>
</tr>
<tr>
<td>Education level</td>
<td>322</td>
<td>303</td>
<td>4 unknowns</td>
</tr>
<tr>
<td>Less than high school</td>
<td>8 (24)</td>
<td>9 (26)</td>
<td>.71</td>
</tr>
<tr>
<td>High school</td>
<td>59 (191)</td>
<td>60 (183)</td>
<td>.85</td>
</tr>
<tr>
<td>University</td>
<td>27 (87)</td>
<td>27 (83)</td>
<td>.99</td>
</tr>
<tr>
<td>Postgraduate</td>
<td>6 (20)</td>
<td>4 (11)</td>
<td>.19</td>
</tr>
</tbody>
</table>

Data are mean (range), n (%), or n unless otherwise specified.
the earlier gestational age group were significantly more likely than those in the later gestational age group to expel sooner (Fig. 1; log-rank test P = .005). This difference in reported expulsion time was most notably seen at 3 hours after using misoprostol (37.7% in week 9 compared with 22.5% in week 10; P = .001), but equal numbers (93.1% compared with 92.1%, respectively; P = .43) reported expulsion by 24 hours (Fig. 1).

Twenty-nine women made visits to an emergency department, primarily for pain and bleeding during the study period (3.7% from the earlier gestational age group and 4.6% from the later group (P = .35) (Table 2). Three women received blood transfusions, two in the 57–63 days group and one in the 64–70 days group (P = .52). One woman in the 57–63 days group was admitted to the hospital and was successfully treated for *Escherichia coli* sepsis, and one woman in the 57–63 days group with a history of chronic pancreatitis was admitted to the hospital for recurrence of her disease.

Eighty-five percent of participants completed and submitted the diaries they maintained for up to 15 days. Mean duration of heavy bleeding did not differ significantly by group (Table 3). There was no significant difference in mean days of work or school missed by women because of the abortion (1.85 in 57–63 days group compared with 1.80 in 64–70 days group; P = .81).

The side effect profiles of each study group were similar, with no significant differences except for vomiting (Table 3). A minority of women in each group experienced this side effect, but fewer in the earlier gestational age group (36% compared with 46%; P = .01). However, severe vomiting was no different in the two groups (10.7% for 57–63 days compared with 12.0% for 64–70 days; P = .35). Opiates were reportedly used more often for pain relief by women in the 64–70 days group (76% in the 57–63 days group compared with 84%; P = .003), but nonsteroidal anti-inflammatory drug use did not differ. Mean days of any analgesic use were the same in both groups. Fewer women in the 57–63 days group reported use of antiemetic medication (34% compared with 46%; P = .002).

The study participants requested relatively little clinic staff time beyond the scheduled study visits. Only 20%
of women in both groups made phone calls because of concerns related to their abortion, and 4% of women in the earlier and 3% of women in the later gestational age groups made unanticipated clinic visits.

The majority of women in both groups (57–63 days: 87.4%; 64–70 days: 88.3%) reported being either satisfied or very satisfied with the medical abortion method, and 78% and 79% of women in the two groups, respectively, reported that they would choose medical abortion again instead of surgery. Women in the earlier gestational age group were as likely to report seeing the pregnancy or some part of it as those in the later gestational age group (64% compared with 69.3%; P = .10). There were no significant differences in women’s reported reactions to what they saw, with the exception that women in the earlier gestational age group were more likely to report “nothing or no feeling” (13.9% compared with 8.2%; P = .04) and those in the later group were more likely to report that they were “relieved” (7.4% compared with 13.9%; P = .02).

DISCUSSION

The results show that medical abortion with an outpatient regimen of 200 mg mifepristone followed 24 to 48 hours later by 800 micrograms buccal misoprostol self-administered at home is efficacious and acceptable in women 64 to 70 days from LMP and is not statistically or clinically different from a current outpatient medical abortion protocol used with women 57–63 days from LMP. In 2000, the FDA approved mifepristone based on an efficacy of 92% for gestations up to 49 days from LMP.12 The success rate achieved in this study during week 10 of gestation (92.8%) is similar to that rate and clinically acceptable. Based on this evidence, medical abortion using the study protocol can be extended from 63 days from LMP to 70 days from LMP without reconfiguration of existing outpatient clinical services. Our findings are consistent with those of Boersma et al.,10 who offered the same outpatient medical abortion regimen as in the current study to 26 women with gestational ages 64–70 days from LMP, but with an interval of 24–36 hours between the mifepristone and misoprostol doses. That study found 96% success in those women but was too small to provide reliable point estimates of success rates.

The study cannot reject the null hypothesis that there is no difference between the success rates of medical abortion among women with pregnancies of 9 and 10 weeks of gestation. Although the inability to reject the null hypothesis theoretically could be attributable to early cessation of the study, the observed differences between study groups are much smaller than those originally hypothesized and are not clinically meaningful. The additional analyses conducted also suggest that continuing enrollment to include 668 analyzable cases would not have affected the study conclusions.

The overall high efficacy of the medical abortion regimen used in this study through 63 days from LMP is well-documented, and only a very minimal decline in efficacy as gestational age increases has been noted.2,13 The trend observed in the two point estimates for success in weeks 9 and 10 in this study is consistent with such a small decline (Fig. 2), alleviating concern of an abrupt decline in efficacy of the method beyond 63 days from LMP.

The study was not powered to detect a difference in safety outcomes because major adverse events attributable to medical abortion (eg, hospitalizations, emergency department visits, and blood transfusions) are rare. No medical abortion studies (including the pilot studies on which FDA approval was based) were powered to detect rates of rare occurrences such as transfusion or hospitalization. Similar to those studies, the occurrence of major adverse events in this study was very infrequent.

Many studies have explored women’s experiences with outpatient medical abortion in the first trimester,14

Table 3. Side Effect and Bleeding Profile

<table>
<thead>
<tr>
<th>Side Effects</th>
<th>57–63 d (n=318)</th>
<th>64–70 d (n=300)</th>
<th>P (One-Sided)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>22.6 (72)</td>
<td>17.0 (51)</td>
<td>.05</td>
</tr>
<tr>
<td>Chills</td>
<td>24.2 (77)</td>
<td>22.7 (68)</td>
<td>.36</td>
</tr>
<tr>
<td>Fever</td>
<td>11.9 (38)</td>
<td>10.3 (31)</td>
<td>.31</td>
</tr>
<tr>
<td>Vomiting</td>
<td>35.8 (114)</td>
<td>45.7 (137)</td>
<td>.008</td>
</tr>
<tr>
<td>Nausea</td>
<td>50.0 (159)</td>
<td>51.7 (155)</td>
<td>.37</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>17.9 (57)</td>
<td>17.3 (52)</td>
<td>.47</td>
</tr>
<tr>
<td>Heavy bleeding</td>
<td>319</td>
<td>298</td>
<td></td>
</tr>
<tr>
<td>Days of heavy bleeding</td>
<td>2.5±2.06 (0–14)</td>
<td>2.3±1.86 (0–11)</td>
<td>.09</td>
</tr>
<tr>
<td>Median days of heavy bleeding</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

Data are % (n), n, or mean±standard deviation (range) unless otherwise specified.
but often the information is not disaggregated by week. Although our findings do not show any differences between the two study groups in such aspects as bleeding profiles, days of school or work missed, and reports of seeing the expulsion, women’s experiences at these later weeks of gestational age may differ in some ways from women with earlier first-trimester pregnancies. The results from this study may help clinicians who provide medical abortion to women with pregnancies 57–70 days of gestational age to tailor counseling messages to prepare women for what to expect. For example, more than two-thirds of women reported witnessing uterine expulsion, so women should be counseled on that likelihood. Women with gestations in week 10 may expel their pregnancies less quickly after using misoprostol, but perhaps this is not surprising given the slightly larger size of the gestational sac at the later gestational age. The fact that more women in week 10 expressed relief after their medical abortions could be an artifact of participating in the test group of a research trial. Some women may have been misclassified into study groups based on usual variability in gestational age dating by ultrasonography. To be sure that such misclassification would not have affected study results, reanalysis of success among women with pregnancies at the opposite extremes of the gestational age spectrum considered in this study (i.e., a comparison of the earlier half of the early age range with the latter half of the later age range), as well as by standardizing gestational age assessment, did not affect our outcomes or our conclusions (data not shown).

The content of counseling was not dictated by the study protocol and was based on usual counseling provided. Possible assumptions that pain, bleeding, and the size of the expelled fetus in week 10 may be more than at earlier weeks of gestation could have had an effect on women’s perceptions. It is also possible that there were slight differences in counseling messages as a result of the counselors’ knowledge of gestational age in each woman. Similarly, observations and experience amassed during the course of the study may have resulted in adjustments in counseling messages to later enrollees, better-preparing women with pregnancies in week 10 for what they might experience.

The study sites already were highly experienced at providing medical abortion and were accustomed to administering the specific regimen used in this study. Therefore, the observed efficacy rates may not be generalizable to clinics that are less experienced. Results also are not generalizable to regimens other than the one studied, for either efficacy or the side effects of misoprostol, which are known to vary by route and dose. Last, because adverse events were so rare in our study, the sample size was not sufficient to characterize adequately the occurrence of adverse events for women who terminate their pregnancies medically during the ninth or tenth week other than to say that serious events are infrequent and side effects are tolerable.

In conclusion, the regimen of 200 mg mifepristone and 800 micrograms buccal misoprostol is efficacious and acceptable for women seeking medical abortion with pregnancies of 70 days or less. The findings of this research are important for expanding the availability of this nonsurgical option to women seeking termination of pregnancy in the first trimester.

### REFERENCES


Exhibit 22

Mary Gatter et al., Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days, 91
Contraception 269 (2015)
Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days

Mary Gattera, Kelly Clelandb, Deborah L. Nucatolaa,⁎

aPlanned Parenthood Los Angeles, 400 West 30th St., Los Angeles, CA 90007
b218 Wallace Hall, Office of Population Research, Princeton University, Princeton, NJ 08544

Received 24 June 2014; revised 7 January 2015; accepted 7 January 2015

Abstract

Objective: The aim of this study was to report on the safety and efficacy of an evidence-based medical abortion regimen utilizing 200 mg of mifepristone orally followed by home use of 800 mcg misoprostol buccally 24–48 h later through 63 days estimated gestational age.

Study design: We analyzed outcomes in women presenting for medical abortion between April 1, 2006, and May 31, 2011, using an evidence-based alternative to the United States Food and Drug Administration (FDA)-approved regimen. Cases were identified for this descriptive study from our electronic practice management (EPM) database, and our electronic database on adverse events was queried for information on efficacy and safety. The primary outcome was successful abortion. Logistic regression was used to identify predictors of successful abortion.

Results: Among the 13,373 women who completed follow-up, efficacy of the regimen was 97.7%. Efficacy was highest at 29 to 35 days (98.8%) and 36 to 42 days (98.8%) of gestation and lowest at 57 to 63 days (95.5%). The odds of needing aspiration for any reason were greatest at higher gestational ages. Rates of infection requiring hospitalization and rates of transfusion were 0.01 and 0.03%, respectively.

Conclusions: An evidence-based regimen of 200 mg of mifepristone orally followed by home use of 800 mcg of buccal misoprostol 24–48 h later is safe and effective through 63 days estimated gestational age. Further, the need for aspiration for any reason was low, and hospitalization was rare.

Implications: This study reinforces the safety and efficacy of the evidence-based regimen for medical abortion (200 mg mifepristone orally followed by home use of 800 mcg of misoprostol buccally 24–48 h later) through 63 days estimated gestational age, and contributes to the existing evidence against restrictions requiring use of the FDA-approved regimen.

© 2015 Elsevier Inc. All rights reserved.

Keywords: Medical abortion; Mifepristone; First-trimester abortion; Evidence-based regimen; Buccal misoprostol; Efficacy

1. Introduction

The United States Food and Drug Administration (FDA) approved the use of mifepristone and misoprostol for pregnancy termination in 2000. The regimen, labeled for use through 49 days estimated gestational age, required a minimum of three visits to the healthcare provider. Six hundred milligrams of mifepristone was taken orally at Visit 1, followed in 2 days by misoprostol 400 mcg, also taken orally. A third follow-up visit was required in 14 days to ensure that the abortion was complete. The efficacy of this regimen ranged from 92 to 97% [1–3]. Publications soon followed providing an evidence base for alterations to the regimen. Alterations included a lower dose of mifepristone, different routes of administration of misoprostol, variations in the timing of misoprostol administration, home use of misoprostol, and increasing the gestational age limit for the regimen [4–11]. A recent publication confirmed the low rate of significant adverse events with use of the evidence-based regimen [11].

In 2008, a prospective study was published describing the use of 200 mg of mifepristone followed in 24 to 36 h by 800 mcg of misoprostol for pregnancy termination to 63

☆ Funding source: Planned Parenthood Federation of America (MG and DN) and Eunice Kennedy Shriver National Institute of Child Health and Human Development, grant no. 2R24HD047879 (KC).
☆☆ Disclaimer: The findings and conclusions in this article are those of the authors and do not necessarily represent the views of Planned Parenthood Federation of America Inc.
⁎ Corresponding author at: 400 W. 30th Street, Los Angeles, CA 90007. Tel.: +1 212 261 4632; fax: +1 818 986 5035. E-mail address: deborah.nucatola@ppfa.org (D.L. Nucatola).
days of gestation with a success rate for the regimen of 96.2% [8]. Despite the growing literature supporting evidence-based provision of medical abortion, some providers are required by law to limit the provision of medical abortion to that regimen, which was FDA-approved more than a decade ago [12]. The goal of the current study was to assess, in a much larger cohort of patients, the safety and efficacy of an evidence-based medical abortion regimen utilizing 200 mg of mifepristone orally followed by home use of 800 mcg of misoprostol buccally 24–48 h later through 63 days estimated gestational age.

2. Materials and methods

2.1. Medical abortion protocols and monitoring

Our large network of urban healthcare centers includes 19 health centers providing approximately 15,000 abortions per year, of which about 30% are medical abortions. Demographic information, treatment dates, and diagnostic codes for all patients were retrieved using the electronic practice management (EPM) billing system. Some clinical information was retrieved from an electronic medical records (EMR) system, which was gradually implemented across all study sites between 2008 and 2010. All patients undergo an ultrasound examination for pregnancy dating prior to abortion. The clinician administering the medication abortion performed and interpreted the ultrasound. All clinicians had undergone the same standardized training and were monitored regularly to ensure accuracy and to maintain consistency. Ultrasound machines using a Hadlock scale calculated gestational age in days; herein, we analyze and report gestational age in 7-day increments (e.g., 22 to 28 days). Since April 2006, our medical abortion regimen has consisted of 200 mg of mifepristone taken orally at the health center followed by 800 mcg of buccal misoprostol used by the patient at home 24 to 48 h later. Medical protocols during the study period allowed for repeat doses of misoprostol for patients who had an incomplete medical abortion. Data on which patients received a repeat dose are not available from the EPM system, but only in the EMR system; therefore, for patients seen at sites that had not yet implemented EMR at the time of treatment, information on whether a repeat dose of misoprostol was given is not available. For the first 3 years of the study period, the upper gestational age limit for this regimen was 56 days. In February 2009, based on newly published data, the upper limit was increased to 63 days [8]. All patients were scheduled to return in 7 to 14 days for a postabortion evaluation. Beginning in 2007, all patients also received routine antibiotic coverage beginning on the day of the mifepristone administration. The standard antibiotic regimen was a 7-day course of doxycycline (100 mg twice a day), with an alternative regimen of one dose of azithromycin (1 g) for cases in which doxycycline was contraindicated.

Our EPM database contains information on all patients undergoing medical abortion, including patient demographics and the ultrasound-determined gestational age. We also maintain a separate electronic database of adverse events including ongoing pregnancy, aspiration for symptoms and/or retained products of conception, infection requiring hospitalization, and hemorrhage requiring transfusion.

2.2. Statistical methods

Bivariate and multivariate logistic regression were used to assess predictors of successful medical abortion. Covariates available in our data set were poverty level, race/ethnicity, gestational age, and patient age; other patient-level data were not available. Results were considered statistically significant at p < .05. Statistical analysis was performed using Stata/SE 11.2 (College Station, TX).

The primary outcome of interest was successful abortion. A successful abortion was defined as expulsion of the pregnancy without the need for aspiration. Patients who required aspiration for an ongoing pregnancy or symptoms such as pain or bleeding were considered to have had unsuccessful medical abortions. We queried our adverse events database to identify continuing pregnancies (those pregnancies with documented fetal growth or cardiac activity seen at the follow-up), all cases of aspiration, and hospitalization for either infection or transfusion. We cross-checked this against the list of postprocedure visits in our EPM system in order to ensure that all cases had been identified.

Institutional review board (IRB) approval was obtained from the Ethical and Independent Review Service of Independence, MO, and an exemption for analysis of the existing data was granted by the Princeton University IRB.

3. Results

3.1. Sample description

For this descriptive study, we queried our EPM database and identified 15,890 patients who had a medical abortion between April 1, 2006, and May 31, 2011. During the period under review, medical abortions were provided at 14 different clinic sites belonging to our network in one urban area, all using the same evidence-based protocol. There were 2470 (15.5%) patients who failed to return for a follow-up visit and were excluded from analysis. An additional 20 patients were excluded from the analysis due to missing data on gestational age, and a further 27 patients were excluded because they did not complete the medical abortion (these patients either changed their mind and chose a surgical abortion, were ineligible for a medical abortion because they were beyond the 63-day gestational limit, or began the regimen but did not take all of the medications). This left 13,373 patients for analysis.

Demographic characteristics of the 13,373 women who had a medical abortion between April 1, 2006, and May 31, 2011, and who returned for follow-up are shown in Table 1. Half of the women were between the ages of 18 and 24, and small proportions were under the age of 18 (4.5%) or 40 or
from 0.65 to 2.49%. The incidence of hospitalization for aspiration for symptoms, not ongoing pregnancy, ranged from 0.15% for those at 36 to 42 days of gestation to 1.8% for those at 50 to 56 days. The proportion with heavy bleeding, by gestational age. The proportion with ongoing pregnancy ranged from 0.15% for those at 36 to 42 days of gestation to 1.8% for those at 50 to 56 days.

Table 1: Demographic characteristics of women having a medical abortion with mifepristone 200 mg and misoprostol 800 mcg buccally (N=13,373) 

<table>
<thead>
<tr>
<th>Gestational age (days)</th>
<th>n</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>22–28</td>
<td>554</td>
<td>4.1</td>
</tr>
<tr>
<td>29–35</td>
<td>1080</td>
<td>8.1</td>
</tr>
<tr>
<td>36–42</td>
<td>2495</td>
<td>18.7</td>
</tr>
<tr>
<td>43–49</td>
<td>4816</td>
<td>36.0</td>
</tr>
<tr>
<td>50–56</td>
<td>3142</td>
<td>23.5</td>
</tr>
<tr>
<td>57–63</td>
<td>1286</td>
<td>9.6</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poverty level (% FPL)</th>
<th>n</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–100</td>
<td>9679</td>
<td>72.4</td>
</tr>
<tr>
<td>&gt;100</td>
<td>3694</td>
<td>27.6</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Race/ethnicity</th>
<th>n</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hispanic/Latino</td>
<td>6215</td>
<td>46.5</td>
</tr>
<tr>
<td>White</td>
<td>3235</td>
<td>24.2</td>
</tr>
<tr>
<td>African American</td>
<td>1263</td>
<td>9.5</td>
</tr>
<tr>
<td>Asian</td>
<td>1172</td>
<td>8.8</td>
</tr>
<tr>
<td>Other/declined</td>
<td>1487</td>
<td>11.1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient age (years)</th>
<th>n</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;18</td>
<td>605</td>
<td>4.5</td>
</tr>
<tr>
<td>18–24</td>
<td>6684</td>
<td>50.0</td>
</tr>
<tr>
<td>25–29</td>
<td>3317</td>
<td>24.8</td>
</tr>
<tr>
<td>30–34</td>
<td>1613</td>
<td>12.1</td>
</tr>
<tr>
<td>35–39</td>
<td>855</td>
<td>6.4</td>
</tr>
<tr>
<td>40+</td>
<td>299</td>
<td>2.2</td>
</tr>
</tbody>
</table>

Table 2 shows the proportion of patients requiring aspiration for ongoing pregnancy or for symptoms, such as heavy bleeding, by gestational age. The proportion with ongoing pregnancy ranged from 0.15% for those at 36 to 42 days of gestation to 1.63% at 57 to 63 days of gestation. Compared with the reference category (43 to 49 days), odds of ongoing pregnancy were greater for those at the highest gestational age. The proportion of women treated with aspiration for symptoms, not ongoing pregnancy, ranged from 0.65 to 2.49%. The incidence of hospitalization for infection or hemorrhage requiring transfusion was very low (Table 3). In total, six women required hospitalization for any reason (two women were hospitalized for infection, and four were hospitalized for transfusion), and incidence was at or below 0.1% among all gestational ages.

In a multivariate logistic regression model (Table 4), poverty level and race/ethnicity were not significant predictors of successful abortion. Certain categories of gestational age were significantly associated with success; compared with the reference category (43 to 49 days), those at 36 to 42 days of gestation had greater odds of success, whereas those at 50 to 56 days and 57 to 63 days had lower odds of success. Compared with the reference category (18 to 24), those in the middle three age groups had significantly lower odds of success, but differences for those in the youngest (17 and under) and highest (40 and older) age groups were not significant.

3.3. Loss to follow-up

A comparison of patients who completed follow-up and those who were lost to follow-up is presented in Table 5. Compared with patients at 43 to 49 days of gestation, patients at higher gestational ages were more likely to be lost to follow-up. For patients with incomes at or below the Federal Poverty Level (FPL), the odds of being lost to follow-up were greater than those above FPL. Odds of being lost to follow-up were greater for those younger than 18 (compared with those 18 to 24) and lower for those aged 40 and older.

4. Discussion

4.1. General implications

This study demonstrates that the evidence-based regimen for medical abortion (mifepristone 200 mg orally followed by home use of misoprostol 800 mcg buccally 24–48 h later) is highly effective through 63 days estimated gestational age, with an overall success rate of 97.7%. This is higher than the efficacy rates reported in two pivotal trials used in submission for FDA approval of mifepristone,[1,2] yet utilizes one-third the dose of mifepristone (200 mg rather than 600 mg) and buccal administration and home use of misoprostol rather than oral administration in the clinic. Repeat dosing of misoprostol was administered in only 1.2% of patients for whom this information is available, and given the way in which the EMR system was implemented across study sites, we can assume that this rate would be representative of the entire sample. Although efficacy is lower at later gestational ages, even in the 57- to 63-day range, this evidence-based regimen was still more effective than rates reported in the FDA-approved regimen, which sets the upper gestational age limit at 49 days. Furthermore, the rates of unsuccessful abortion in this study are lower than the rates reported in the two trials that were initially submitted to the FDA for approval of mifepristone.
loss of follow-up of 18 to 45% [14–17]. We found that loss to follow-up was significantly more common among those at higher gestational ages; given that odds of success are lower among those with more advanced pregnancies, it is possible that this study underestimates the true odds of unsuccessful abortion. Loss to follow-up was significantly higher among the youngest age group and lower among the oldest age group, but as these age categories were unrelated to whether the abortion was successful, we do not believe that these differences would systematically bias our results.

4.3. Conclusion

In summary, an evidence-based regimen of mifepristone 200 mg orally followed by misoprostol 800 mcg buccally...

### Table 4

Factors associated with successful medical abortion in women using mifepristone 200 mg and misoprostol 800 mcg bucally (N=13,373)

<table>
<thead>
<tr>
<th>Gestational age (days)</th>
<th>Successful n (%)</th>
<th>Unsuccessful n (%)</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>22–28</td>
<td>539 (97.3)</td>
<td>15 (2.7)</td>
<td>0.72 (0.41–1.25)</td>
</tr>
<tr>
<td>29–35</td>
<td>1067 (98.8)</td>
<td>13 (1.2)</td>
<td>1.68 (0.94–3.01)</td>
</tr>
<tr>
<td>35–42</td>
<td>2465 (98.8)</td>
<td>30 (1.2)</td>
<td>1.65 (1.09–2.50)</td>
</tr>
<tr>
<td>42–49</td>
<td>4722 (98.1)</td>
<td>94 (2.0)</td>
<td>Ref</td>
</tr>
<tr>
<td>50–56</td>
<td>3045 (96.9)</td>
<td>97 (3.1)</td>
<td>0.62 (0.47–0.83)</td>
</tr>
<tr>
<td>56–63</td>
<td>1228 (95.5)</td>
<td>58 (4.5)</td>
<td>0.42 (0.30–0.58)</td>
</tr>
<tr>
<td>Total</td>
<td>13,066 (97.7)</td>
<td>307 (2.3)</td>
<td></td>
</tr>
</tbody>
</table>

### Table 3

Hospitalizations for infection or transfusion in women having a medical abortion with mifepristone 200 mg and misoprostol 800 mcg bucally (N=13,373)

<table>
<thead>
<tr>
<th>Gestational age</th>
<th>Patients n</th>
<th>Infections n (%)</th>
<th>Transfusions n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>22–28 days</td>
<td>554</td>
<td>0 (0.00)</td>
<td>1 (0.18)</td>
</tr>
<tr>
<td>29–35 days</td>
<td>1080</td>
<td>1 (0.09)</td>
<td>0 (0.00)</td>
</tr>
<tr>
<td>36–42 days</td>
<td>2495</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
</tr>
<tr>
<td>43–49 days</td>
<td>4816</td>
<td>1 (0.02)</td>
<td>0 (0.00)</td>
</tr>
<tr>
<td>50–56 days</td>
<td>3142</td>
<td>0 (0.00)</td>
<td>3 (0.10)</td>
</tr>
<tr>
<td>57–63 days</td>
<td>1286</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
</tr>
<tr>
<td>Total</td>
<td>13,373</td>
<td>2 (0.01)</td>
<td>4 (0.03)</td>
</tr>
</tbody>
</table>

This study adds to the growing literature supporting provision of medical abortion using evidence-based regimens, and supports the conclusion that legislative efforts to restrict medical abortion to the FDA regimen are based on political goals to restrict abortion services, not efficacy or patient safety.

4.2. Limitations

Our study has some limitations. It is retrospective in nature and relies on the accuracy of our EPM database. However, review of our EPM system has shown a high degree of accuracy when compared with patient records [13]. In addition, we are not a closed system, and it is possible and even likely that some patients who experienced complications did not return to us for care. However, since many patients need to pay for aftercare obtained outside our system, but not within our system, it is more likely than not that the patients who did not return for follow-up did so because they did not feel that they needed follow-up, rather than that they were experiencing a complication. In that case, excluding them from our analysis would have tended to overestimate, rather than underestimate, the need for abortion in our population. We based our analysis of efficacy only on those patients who did return for a follow-up visit, so we cannot exclude the possibility of additional visits or treatment elsewhere.

Loss to follow-up is common in studies of medical abortion, as many patients may determine on their own that their abortion is complete and that follow-up is not needed. The rate of loss to follow-up in this study (15.5%) is lower than loss to follow-up found in other clinical medical abortion studies, which report...
48–72 h later is safe and effective through 63 days estimated gestational age. Further, need for aspiration for any reason was low, the chance of needing aspiration increased with gestational age at the time of medical abortion, and the frequency of hospitalization was rare. This study reinforces the safety and efficacy of the evidence-based regimen for medical abortion, and contributes to the evidence against restrictions that require use of the FDA-approved regimen.

References


Table 5
Loss to follow-up analysis among women having a medical abortion with mifepristone 200 mg and misoprostol 800 mcg buccally (N=13,373)

<table>
<thead>
<tr>
<th>Gestational age (days)</th>
<th>Completed follow-up n (%)</th>
<th>Lost to follow-up n (%)</th>
<th>OR* 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>22–28</td>
<td>554 (85.1)</td>
<td>97 (14.9)</td>
<td>1.00 0.79–1.25</td>
</tr>
<tr>
<td>29–35</td>
<td>1080 (86.3)</td>
<td>172 (13.7)</td>
<td>0.91 0.76–1.08</td>
</tr>
<tr>
<td>36–42</td>
<td>2495 (85.6)</td>
<td>419 (14.4)</td>
<td>0.96 0.84–1.09</td>
</tr>
<tr>
<td>43–49</td>
<td>4816 (85.1)</td>
<td>845 (14.9)</td>
<td>1.07 0.90–1.26</td>
</tr>
<tr>
<td>50–56</td>
<td>3142 (83.0)</td>
<td>645 (17.0)</td>
<td>1.17 1.05–1.31</td>
</tr>
<tr>
<td>57–63</td>
<td>1286 (81.7)</td>
<td>288 (18.3)</td>
<td>1.28 1.10–1.48</td>
</tr>
<tr>
<td>Poverty level (% FPL)</td>
<td>Completed follow-up n (%)</td>
<td>Lost to follow-up n (%)</td>
<td>OR* 95% CI</td>
</tr>
<tr>
<td>0–100</td>
<td>9679 (83.7)</td>
<td>1887 (16.3)</td>
<td>1.24 1.12–1.38</td>
</tr>
<tr>
<td>&gt;100</td>
<td>3694 (86.5)</td>
<td>579 (13.6)</td>
<td>0.97 0.84–1.12</td>
</tr>
<tr>
<td>Race/ethnicity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic/Latino</td>
<td>6215 (84.1)</td>
<td>1173 (15.9)</td>
<td>1.05 0.95–1.17</td>
</tr>
<tr>
<td>White</td>
<td>3235 (83.4)</td>
<td>463 (16.6)</td>
<td>1.05 0.95–1.17</td>
</tr>
<tr>
<td>African American</td>
<td>1263 (82.8)</td>
<td>262 (17.2)</td>
<td>1.10 0.95–1.27</td>
</tr>
<tr>
<td>Asian</td>
<td>1172 (91.1)</td>
<td>115 (8.9)</td>
<td>0.52 0.43–0.64</td>
</tr>
<tr>
<td>Other/declined</td>
<td>1487 (84.5)</td>
<td>273 (15.5)</td>
<td>0.97 0.84–1.12</td>
</tr>
</tbody>
</table>

OR, odds ratio; CI, confidence interval.
* OR represents odds of being lost to follow-up.
Exhibit 23

2019 Citizen Petition of AAPLOG to FDA
(Mar. 29, 2019)
Citizen Petition

March 29, 2019

The undersigned submit this petition to request the Commissioner of Food and Drugs to: (I) restore and strengthen elements of the Mifeprex regimen and prescriber requirements approved in 2000, and (II) retain the Mifeprex Risk Evaluation and Mitigation Strategy (REMS), and continue limiting the dispensing of Mifeprex to patients in clinics, medical offices, and hospitals, by or under the supervision of a certified prescriber.

A. Action Requested

I. RESTORE AND STRENGTHEN ELEMENTS OF THE MIFEPREx REGIMEN AND PRESCRIBER REQUIREMENTS APPROVED IN 2000.

Current language and requested language for the Mifeprex Label and the Mifeprex Risk Evaluation and Mitigation Strategy (REMS) are included in Exhibit A.1 Requests include:

A. Indications and Usage. Mifeprex, in a regimen with misoprostol, for the termination of intrauterine pregnancy, should be limited to 49 days’ gestation.

B. Dosage and Administration.

1. Mifeprex should be administered by or under the supervision of a physically present and certified physician who has ruled out ectopic pregnancy.

2. The use of Mifeprex and misoprostol for the termination of pregnancy should require three office visits by the patient.

C. Contraindications. Mifeprex use is contraindicated for patients who do not have convenient access to emergency medical care.

D. Adverse Event Reporting. Certified prescribers, emergency medical personnel, physicians treating complications, and Danco Laboratories should report to FDA’s MedWatch Reporting system any deaths, hospitalizations, blood transfusions, emergency room visits, failures requiring surgical completion, ongoing pregnancy, or other major complications following the use of Mifeprex and misoprostol.

1 Other documents will require corresponding modifications, including the Mifeprex Medication Guide, Prescriber Agreement Form, and Patient Agreement Form.
E. **Additional studies.** The Mifeprex REMS should require a formal study of outcomes for at-risk populations, including: patients under the age of 18; patients with repeat Mifeprex abortions; patients who have limited access to emergency room services; and patients who self-administer misoprostol.

II. **RETAINTHE MIFEPREX RISK EVALUATION AND MITIGATION STRATEGY (REMS), AND CONTINUE LIMITING THE DISPENSING OF MIFEPREX TO PATIENTS IN CLINICS, MEDICAL OFFICES, AND HOSPITALS, BY OR UNDER THE SUPERVISION OF A CERTIFIED PRESCRIBER.**

A. **Retain the Mifeprex REMS.**

B. **Continue limiting the dispensing of Mifeprex to patients in clinics, medical offices, and hospitals, by or under the supervision of a certified prescriber.**

1. Mifeprex should be dispensed only in clinics, medical offices, and hospitals.
   a. The “TelAbortion” Direct-to-Consumer Mifeprex Study
   b. The Mifeprex through Pharmacy Dispensing Study
   c. Beyond the Current Studies

2. Mifeprex Prescribers Should be Certified.
B. Statement of Grounds


A. Indications and Usage. Mifeprlex, in a regimen with misoprostol, for the termination of intrauterine pregnancy, should be limited to 49 days’ gestation.

In 2016, FDA increased the maximum gestational age for Mifeprlex use for abortion from 49 days (7 weeks) to 70 days (10 weeks), and changed the method of administration of misoprostol from oral to buccal (i.e., in the cheek pouch). However drug-induced abortion regimens demonstrate an increase in complications and failures after 49 days’ gestation.

In a 2011 study of thousands of patients, the majority of whom had a drug-induced abortion using what is now the Mifeprlex regimen, the rate of infection and the rate of failure requiring surgical intervention increased with gestational age. The American College of Obstetricians and Gynecologists (ACOG) has stated: “the risk of clinically significant bleeding and transfusion may be lower in women who undergo medical abortion of gestations up to 49 days compared with those who undergo medical abortion of gestations of more than 49 days.”

Further, a 2015 meta-analysis examined all the existing publications on buccal administration of misoprostol, 20 studies in all, from November 2005 through January 2015. The failure rate of the buccal misoprostol regimen increased as the gestational age

---

2 The FDA approved Mifeprlex for use in the United States on September 28, 2000, with safeguards considered necessary to ensure patient safety. The drug’s initial approval was for termination of pregnancy, in a regimen with misoprostol, through 49 days of pregnancy. FDA significantly modified the drug’s label at the application of the manufacturer, Danco Laboratories, in 2016, extending approved use to 70 days of pregnancy. Additional changes included: a new dosage of both Mifeprlex and misoprostol; permitting home administration of Mifeprlex and misoprostol; a new route of administration for the misoprostol (buccal, in the cheek pouch); permitting non-physicians to become certified prescribers; a decrease from 3 to 1 mandatory office visits by the patient; and reduced reporting requirements. U.S. Gov’t Accountability Office, GAO-18-292, Food and Drug Administration: Information on Mifeprlex Labeling Changes and Ongoing Monitoring Efforts 4-7 (2018); Mifeprlex Risk Evaluation and Mitigation Strategy (REMS), https://www.accessdata.fda.gov/drugsatfda_docs/rems/Mifeprlex_2016-03-29_REMS_full.pdf; Mifeprlex Medication Guide, https://www.fda.gov/downloads/Drugs/DrugSafety/ucm088643.pdf.

3 The terms “Medication abortion,” “medical abortion,” “chemical abortion,” and “drug-induced abortion” [or termination of pregnancy] share the same meaning and refer to the use of abortion-inducing drugs, rather than surgery, to induce abortion. The current FDA-approved regimen uses two drugs, mifepristone (a.k.a. Mifeprlex or RU-486) and misoprostol.


increased, especially at gestational ages greater than 49 days. The current FDA label also acknowledges this fact.6

Given the serious risks of failure, hemorrhage, infection, and ongoing pregnancy that increase as pregnancy advances, the gestational limit for the Mifeprex regimen should have never been increased.

B. Dosage and Administration.

1. Mifeprex should be administered by or under the supervision of a physically present and certified physician who has ruled out ectopic pregnancy.

The 2000 Mifeprex regimen required Mifeprex to be “provided by or under the supervision of a physician” who meets qualifications discussed in this section below.8 However, the 2016 regimen replaced “physician” with “healthcare provider,” thus permitting non-physicians to apply to be certified prescribers.9 Given the regimen’s serious risks, the FDA should limit the ability to prescribe and dispense Mifeprex to qualified, licensed physicians. Physicians are better trained to diagnose patients who have contraindications to Mifeprex and to verify gestational age.

The current Mifeprex Risk Evaluation and Mitigation Strategy (REMS), discussed in Section II below, continues to provide that “Mifeprex must be dispensed to patients only in certain healthcare settings, specifically clinics, medical offices, and hospitals, by or under the supervision of a certified prescriber.”10 Yet, abortion providers today are promoting and performing “telemedicine abortions,” where the certified prescriber’s “supervision” of the dispensing of Mifeprex is limited to a videoconference.11 This practice demonstrates a flagrant disregard for FDA safeguards.

To ensure true supervision, the FDA should require certified prescribers to be physically present when Mifeprex is dispensed so that they can appropriately examine patients and rule out contraindications to the use of Mifeprex. This requirement would be consistent with other requirements in the Mifeprex Label and REMS.

---

8 Mifeprex 2000 label, Dosage and Administration, emphasis added.
In the Mifeprex Label, the FDA emphasizes that “Mifeprex is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS)” because of the drug’s “risks of serious complications.” In a bold-print box, the FDA states that before prescribing Mifeprex, a provider must inform a patient: about the risks of serious events; whom to call and what to do if certain symptoms occur; and to take the Medication Guide with her if she visits an emergency room or healthcare provider who did not prescribe Mifeprex, so that she receives appropriate, informed care.\(^\text{12}\)

Further, a provider must sign a Provider Agreement Form, attesting that he or she can:

- **Assess the duration of pregnancy accurately.**\(^\text{13}\) Failures and complications of Mifeprex abortion increase with increasing gestational age. Mifeprex use is approved through 70 days’ gestation.\(^\text{14}\) FDA should strengthen this requirement by mandating that gestational age be accurately assessed by ultrasound in order to both ensure compliance with FDA restrictions and adequately inform the patient of gestational age-specific risks, which rise with increasing gestational age.

- **Diagnose ectopic pregnancies**\(^\text{15}\) (i.e., extrauterine pregnancy; pregnancy outside the uterus), which Mifeprex cannot end. When an ectopic pregnancy progresses, it can rupture the fallopian tube, causing bleeding, severe pain, or death. If a woman with an extrauterine pregnancy is given Mifeprex, she may believe the symptoms for ectopic pregnancy are simply the side effects of drug-induced abortion, which are similar. As of December 31, 2017, at least 97 women with ectopic pregnancies in the United States had been given Mifeprex.\(^\text{16}\) Of these women, at least two bled to death from an undiagnosed ectopic pregnancy.\(^\text{17}\) They likely did not recognize that their cramps, abdominal pain, and perhaps vaginal bleeding were dangerous—not side effects expected in a Mifeprex abortion.\(^\text{18}\)


\(^{13}\) *Mifeprex Prescriber Agreement Form,* https://www.accessdata.fda.gov/drugsatfda_docs/rems/Mifeprex_2016-03-29_Prescriber_Agreement_Form.pdf.

\(^{14}\) See Section I.A, *supra.*

\(^{15}\) *Mifeprex Prescriber Agreement Form,* https://www.accessdata.fda.gov/drugsatfda_docs/rems/Mifeprex_2016-03-29_Prescriber_Agreement_Form.pdf.


\(^{17}\) *Id.*

\(^{18}\) Donna Harrison, M.D. & Michael J. Norton Testimony before the Iowa Board of Medicine, p. 3 (Aug. 21, 2013), *citing* Postmarket Drug Safety Information for Patients and Providers, Questions and Answers on Mifeprex.
• **Provide surgical intervention if needed, or has made plans to provide such care through others.**\(^{19}\) He or she must assure patient access to medical facilities equipped to provide blood transfusions and resuscitation, if necessary.\(^{20}\)

Clearly, a provider who does not physically meet with and examine a patient, but simply consults with the patient over the Internet, is not capable of fulfilling these requirements, or of ruling out additional contraindications (i.e., circumstances that make a treatment or medication *unadvisable*) to Mifeprex use. These physical contraindications include pelvic infections, ovarian masses, cardiac arrhythmias, and liver abnormalities.\(^{21}\) A physician bears responsibility to diagnose and rule out contraindications prior to Mifeprex use. It is inadequate to entrust this critical care to another healthcare provider who is not trained in diagnosis. Further, a healthcare provider who is not physically accessible to a patient cannot provide adequate follow-up care to patients, as required by the FDA Mifeprex regimen.

Thirty-four states permit only physicians to prescribe Mifeprex,\(^{22}\) with nineteen states requiring the provider to be physically present with the patient.\(^{23}\) For example, the law in Alabama states that the physical presence and care of a physician are necessary because “the failure and complications from medical abortion increase with advancing gestational age, because the physical symptoms of medical abortion can be identical to the symptoms of ectopic pregnancy, and because abortion-inducing drugs do not treat ectopic pregnancies but rather are contraindicated in ectopic pregnancies.”\(^{24}\)

Lawmakers in these states recognize that abortion providers cannot diagnose contraindications and cannot adequately care for their patients through a videoconference. Fundamentally, telemedicine “may be legitimate when it comes to discrete, document-based tasks such as reading X-rays,” but it “is not the standard of care when it comes to abortion or the management of miscarriage.”\(^{25}\)

---

\(^{19}\) Mifeprex Prescriber Agreement Form, [https://www.accessdata.fda.gov/drugsatfda_docs/label/2016-03-29_Prescriber_Agreement_Form.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016-03-29_Prescriber_Agreement_Form.pdf).

\(^{20}\) Id.

\(^{21}\) Harrison & Norton Testimony, p. 3.


\(^{23}\) Id.


\(^{25}\) Harrison & Morton Testimony, p. 19.
2. The use of Mifeprex and misoprostol for the termination of pregnancy should require three office visits by the patient.

The 2016 regimen significantly diminished doctor-patient interaction. While the 2000 Mifeprex label required three patient visits with the abortion provider, women may now obtain Mifeprex at a clinic and self-administer it at home. They are no longer required to return to the clinic for the administration of misoprostol, which prevents abortion providers from ensuring that they take the drugs at the correct times. Further, providers may now “confirm” that a patient’s drug-induced abortion was successful without a clinic visit, increasing the threat that Rh-negative patients will not receive administration of Rhogam, which is necessary to prevent serious risks in subsequent pregnancies.

The 2016 regimen directs that patients be given or prescribed misoprostol to take 24 to 48 hours after taking Mifeprex. However, without monitoring, a patient may take misoprostol before 24 hours have passed since she consumed Mifeprex, rendering the regimen ineffective and increasing the likelihood that she will experience a failed drug-induced abortion and require surgery.

Using buccal misoprostol sooner than 24 hours after administering mifepristone leads to a significantly increased failure rate. In one study investigating the timing of buccal misoprostol after mifepristone, nearly one out of every three to four women who took buccal misoprostol shortly after mifepristone failed to abort. The failure rate ranged from 27% to 31%, depending on the pregnancy gestation. Given these results, the authors of this study strongly recommended that buccal misoprostol not be taken immediately after mifepristone because of the very high abortion failure rate. However, with home administration of misoprostol, healthcare providers have no control over when their patients consume the drug.

A woman may also choose to swallow misoprostol rather than keep the pill between her cheek and gum for 30 minutes, converting a “buccal” administration into an “oral” administration. An oral administration of misoprostol following the lower dose of mifepristone in the current regimen is not as effective in ending the pregnancy.

Further, waiting until 24 hours after Mifeprex to administer misoprostol does not guarantee success, and the failure rate of buccal misoprostol is higher than that under the 2000 regimen. A comprehensive systematic review and meta-analysis of the existing

28 Id.
29 Id.
studies of the 2016 regimen found that women who take misoprostol earlier than 48 hours after mifepristone are more likely to fail the regimen.30

Under the 2000 regimen, doctors were also able to provide care to patients during the most challenging and painful time in the drug-induced abortion. According to the World Health Organization, up to 90% of women will abort within 4-6 hours after taking misoprostol.31 The 2000 regimen permitted a patient to be in a clinic for this period of time, during which she would be under the observation and care of medical personnel. This observation period is for “both patient safety and compassion. . . . This is the time when women should be in a place where their bleeding can be monitored, their vital signs can be observed by trained medical personnel, and they can receive sufficient pain medication during the most difficult part of the expulsion.”32

Abortion complications are also more frequent when women abort at home, without the oversight of a healthcare provider. A 2018 combined retrospective and longitudinal follow-up study of complications related to induced abortion in Sweden determined that “[t]he complication frequency [of drug-induced abortion] was significantly higher among women <7 gestational weeks who had their abortions at home.”33

In-person contact with a healthcare provider is critical to post-abortion care as well. Abortion providers should perform a “follow-up [physical exam] after the use of mifepristone in order to confirm abortion and rule out life-threatening infection.”34 Before FDA approved the 2016 regimen, the follow-up visit was considered “very important to confirm by clinical examination or ultrasonographic scan that a complete termination of pregnancy has occurred.”35 In fact, the 2000 label provided that “[e]ach patient must understand the necessity of completing the treatment schedule, including a follow-up visit approximately 14 days after taking Mifeprex.”36 ACOG’s current policy explains that:

Women are not good candidates for medical abortion if they … desire quick completion of the abortion process [or] are not available for follow-up contact or evaluation….37

34 Harrison & Norton Testimony, p. 18.
35 Mifeprex 2000 label, Day 14: Post-Treatment Examination.
36 Mifeprex 2000 label, Information for Patients.
37 ACOG Practice Bulletin 143, p. 6.
In addition to ensuring for all drug-induced abortion patients that the uterus has been emptied of retained tissue and that they are not suffering from infection, the follow-up examination is particularly critical for Rh-negative patients. These patients must be administered Rhogam in order to prevent Rh isoimmunization in subsequent pregnancies. Without follow-up, women will not receive the Rhogam after the abortion, greatly increasing their risk of subsequent Rh isoimmunization, which can endanger future pregnancies.38

Nonetheless, abortion advocates strongly supported the reduction in required visits, and continue to advocate for the elimination of direct provider-patient contact. Gynuity Health Projects (an organization that “has been at the forefront of efforts to increase women’s access to medical abortion in settings throughout the world”)39 has conducted at least three domestic and five international studies40 on eliminating pelvic ultrasound or exam after drug-induced abortion. Following one study, researchers determined that “[s]emi-quantitative pregnancy tests … could be used in lieu of transvaginal ultrasound and/or serum hCG at clinic-based follow-up or by women themselves for home-based follow-up.”41

In a more recent study, researchers asserted that the “common practice of scheduling a clinical contact after every medical abortion may not be necessary to ensure safety; enabling patients to determine for themselves whether or not a contact is needed can be a

39 See Gynuity Health Projects, Medical Abortion, https://gynuity.org/programs/medical-abortion. Founded by Beverly Winikoff, M.D, M.P.H., in 2003, Gynuity outlines on its “Medical Abortion” page the organization’s research projects, including efforts to: “Develop innovative service delivery systems through telemedicine; Simplify and de-medicalize medical abortion services; Expand access to medical abortion in the 1st and 2nd trimesters of pregnancy; Conduct clinical research to develop new abortion medications; Develop a ‘missed menses pill’/menstrual regulation method; Develop additional clinical indications for mifepristone.” Gynuity has launched “coalition to expand access to mifepristone in the United States,” co-created a “medical abortion commodities database,” “introduce[d] medical abortion in new settings,” “incorporate[ed] new clinical evidence into service guidelines,” and “expanded medical abortion access through education and local champions.”
reasonable approach.” They reached this conclusion even with 26% of participants failing to provide sufficient follow-up information.\footnote{Raymond EG, et al., \textit{Self-assessment of Medical Abortion Outcome Using Symptoms and Home Pregnancy Tests}, Contraception 97 (2018) 324-28.} Gynuity researchers also conducted a recent systematic review of existing studies on “the accuracy and acceptability of a strategy for identifying ongoing pregnancy after medical abortion treatment using a low-sensitivity pregnancy test (LSPT).” While the researchers acknowledged that “the LSPT strategy had \textit{moderate} sensitivity for identifying ongoing pregnancy” and “the LSPT itself had a limited role in the detection of treatment failures \textit{[i.e., ongoing pregnancy]} in the studies,” they stated that the “LSPT strategy shows promise for reducing the need for in-person follow-up after medical abortion. A range of home-based options should be validated to meet the varied needs of women and abortion providers in diverse settings.”\footnote{Raymond EG, et al., \textit{Low-sensitivity Urine Pregnancy Testing to Assess Medical Abortion Outcome: A Systematic Review}, Contraception (2018), https://doi.org/10.1016/j.contraception.2018.03.013 (emphasis added).}

In reality, a de-emphasis on follow-up care increases risks of post-abortion complications. As discussed above, the 2000 regimen’s requirement that women return approximately 14 days after ingesting mifepristone was considered necessary to ensure that all pregnancy tissue had been passed.\footnote{\textit{Mifeprex} 2000 label, Day 14: Post-Treatment Examination.} This determination is crucial, because retained pregnancy tissue can lead to continued bleeding and serious intrauterine infections. The return visit permits healthcare providers to ensure that a patient is not experiencing these or other complications from the abortion procedure, and that Rh negative patients are administered Rhogam to protect future pregnancies.

Abortion advocates argue that three clinic visits make accessing abortion-inducing drugs more difficult for patients with transportation challenges; however, as noted above, ACOG acknowledges that drug-induced abortion is \textit{contraindicated} for patients who “are not available for follow-up contact or evaluation.”\footnote{ACOG Practice Bulletin 143, p. 6.} Surgical abortion is a better choice for these patients, because it “[d]oes not require follow-up in most cases.”\footnote{\textit{Id}.}

Drug-induced abortion is a longer process that requires more attention and care from healthcare providers. Three visits to a physician in the interest of patient safety should not be sacrificed for the convenience of healthcare providers or even their patients.

\footnote{\textit{Id}.}
\footnote{\textit{Mifeprex} 2000 label, Day 14: Post-Treatment Examination.}
\footnote{ACOG Practice Bulletin 143, p. 6.}
\footnote{\textit{Id}.}
C. Contraindications. Mifeprex use is contraindicated for patients who do not have convenient access to emergency medical care.

The 2000 Mifeprex Label stated:

Because it is important to have access to appropriate medical care if an emergency develops, the treatment procedure is contraindicated if a patient does not have adequate access to medical facilities equipped to provide emergency treatment of incomplete abortion, blood transfusions, and emergency resuscitation during the period from the first visit until discharged by the administering physician.\(^{48}\)

This critical language was excluded from the 2016 Mifeprex Label. Yet, studies comparing the outcome of surgical versus drug-induced abortion “have clearly demonstrated that Mifeprex abortions have a greater risk of hemorrhage, infection, continued pregnancies, retained tissue and need for emergency reoperation than surgical abortions.”\(^{49}\) ACOG acknowledges that “[c]ompared with surgical abortion, medical abortion takes longer to complete, requires more active patient participation, and is associated with higher reported rates of bleeding and cramping,” and has lower success rates.\(^{50}\)

Drug-induced abortion is optional. If a woman does not meet the criteria necessary to use abortion-inducing drugs, then surgical abortion is still an option. For women with transportation difficulties, an abortion provider can complete surgical abortion “in a predictable period of time,” and the procedure “[d]oes not require follow-up in most cases.”\(^{51}\)

Efforts to promote abortion-inducing drugs to women in rural areas where access to emergency medical care is scarce are detrimental to women’s health. It is better for a patient in a remote region to have a surgical abortion, “which requires a single visit, and is less likely to result in serious or life-threatening complications.”\(^{52}\)

\(^{48}\) Mifeprex 2000 label, Contraindications.
\(^{49}\) Harrison Aff. ¶ 115.
\(^{50}\) ACOG Practice Bulletin 143, p. 3 & Box 1.
\(^{51}\) Id.
\(^{52}\) Harrison & Norton p. 9.
D. Adverse Event Reporting. Certified prescribers, emergency medical personnel, physicians treating complications, and Danco Laboratories should report to FDA’s MedWatch Reporting system any deaths, hospitalizations, blood transfusions, emergency room visits, failures requiring surgical completion, ongoing pregnancy, or other major complications following the use of Mifeprex and misoprostol.

The 2016 regimen dramatically reduced accountability for Mifeprex providers by limiting adverse event reporting (AER) requirements, a critical safety mechanism. While prescribers were required to report any serious adverse event associated with Mifeprex under the 2000 label, they are now required to report only deaths associated with Mifeprex.

Even with the 2000 regimen requirements, collecting accurate and complete adverse event information was highly difficult. Adverse events were often not reported or were interpreted by emergency health care providers as the results of spontaneous abortion. The Mifeprex label instructs prescribers to “[a]dvise the patient to take the Medication Guide with her if she visits an emergency room or a healthcare provider who did not prescribe Mifeprex, so that the provider knows that she is undergoing a medical abortion.” Yet, many Mifeprex prescribers violate FDA protocol, instructing their patients to lie to emergency medical personnel. The organization Aid Access instructs patients that if they need to go to an emergency room:

You do not have to tell the medical staff that you tried to induce an abortion; you can tell them that you had a spontaneous miscarriage. Doctors have the obligation to help in all cases and know how to handle a miscarriage. The symptoms of a miscarriage and an abortion with pills are exactly the same and the doctor will not be able to see or test for any evidence of an abortion, as long as the pills have completely dissolved.

Such deception prevents emergency healthcare providers from appropriately caring for their patients, and further decreases the likelihood that adverse events will be reported.

With reduced AER reporting requirements under the 2016 label, what was previously difficult is now virtually impossible. The FDA cannot adequately assess the safety of the current Mifeprex regimen without comprehensive information on adverse events. AERs are the only objective means by which FDA has any data whatsoever on the effects of the

53 Mifeprex 2016 label.
54 See GAO-18-292, pp 24-25.
Mifeprex regimen on women, and the voluntary and minimal nature of the current AERs means that FDA has no accurate information about the actual number of women injured by drug-induced abortion, or the nature of complications caused by this drug.

After prescribing Mifeprex and misoprostol, certified prescribers should at minimum be required to report the following directly to the FDA Medwatch reporting system, copying Danco Laboratories: deaths, hospitalizations, blood transfusions, emergency room visits, failures requiring surgical completion, ongoing pregnancy, or other major complications. Detailed information must also be included, such as pulse, blood pressure, temperature, pre- and post-transfusion hemoglobin/hematocrit, white blood count, number of units of blood transfused, surgeries, and any other pertinent laboratory or hospital course information, as well as emergency room and hospital discharge diagnoses.

Further, FDA should provide guidance to emergency healthcare providers and physicians responsible for treating complications so that they know how to distinguish complications following drug-induced abortion from complications following spontaneous miscarriage. The guidance should also instruct these providers on how to report adverse events.57

The abysmal quality of the current AERs received from Danco Laboratories shows the lack of concern that Danco has demonstrated for the safety of the women who have undergone drug-induced abortion. Responsible reporting is a fundamental safety mechanism that should not be sacrificed in the interest of convenience for abortion providers.

E. Additional Studies. The Mifeprex REMS should require a formal study of outcomes for at-risk populations, including: patients under the age of 18; patients with repeat Mifeprex abortions; patients who have limited access to emergency room services; and patients who self-administer misoprostol.

Mifeprex was approved for use in the pediatric population in 2000 after the FDA waived, without explanation, the requirement for studies in the pediatric population. The developmental stage of puberty involves a complex interplay of both progesterone and estrogen effects on the developing female reproductive system. The use, and especially the potential multiple use, of Mifeprex, which is a powerful progesterone blocker, is

57 The Self-Induced Abortion Legal Team has created a document titled “Self-Induced Abortion and the Law: What Emergency Room Staff Need to Know.” This document heavily emphasizes patient privacy requirements, including the penalties that healthcare providers may face if they disclose patient information. While these concerns are valid, emergency healthcare providers should also have training on public health reporting requirements and how such reporting does not violate HIPAA or other laws regarding patient privacy. See, https://www.sialegalteam.org.
likely to significantly impact the developing reproductive system of the adolescent female.\textsuperscript{58} It is irresponsible to allow the continued uninvestigated use of Mifeprex in the pediatric female population\textsuperscript{59} without requiring long-term studies on the impact of Mifeprex use on pubertal development.

More than one out of every three abortions in the U.S. is a repeat abortion.\textsuperscript{60} The repeat use of Mifeprex has been associated in some studies with adverse reproductive health outcomes in future wanted pregnancies.\textsuperscript{61} This concern requires further study.

The adverse events of hemorrhage, retained tissue, and infection are common after Mifeprex use. The hemorrhage is often significant enough to warrant transfusion. When patients lack access to emergency medical facilities, such complications could easily translate to deaths. Thus a study of deaths and of severe hemorrhages requiring transfusion should be done to compare outcomes in women with and without access to emergency medical facilities.

II. RETAIN THE MIFEPREx RISK EVALUATION AND MITIGATION STRATEGY (REMS), AND CONTINUE LIMITING THE DISPENSING OF MIFEPREx TO PATIENTS IN CLINICS, MEDICAL OFFICES, AND HOSPITALS, BY OR UNDER THE SUPERVISION OF A CERTIFIED PRESCRIBER.

A. Retain the Mifeprax REMS.

Mifeprax, when used for abortion, is subject to a Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU). FDA determined that the Mifeprax REMS is necessary to ensure the safety and efficacy of the drug, because it carries risks of life-threatening hemorrhage, infection, continued pregnancy, retained tissue, need for emergency surgery, and death. The approved Mifeprax regimen includes the use of another potent drug, misoprostol, which carries its own risks.

Under the Mifeprax REMS with ETASU, a healthcare provider must be certified to prescribe Mifeprax by reviewing the prescribing information and completing a

\textsuperscript{58} Arain M, et al., Maturation of the adolescent brain, Neuropsychiatric Disease and Treatment, 2013:9 449-461.
\textsuperscript{59} Because of their immaturity, minors are also less likely to understand the importance of following prescriber instruction or of recognizing when they need to seek emergency medical treatment.
“Prescriber Agreement Form,” attesting that they can: assess the duration of pregnancy accurately; diagnose ectopic pregnancies; and provide surgical intervention in cases of incomplete abortion or severe bleeding, or designate someone else to provide that care. Further, they must agree to follow the guidelines for use of Mifeprex.

The REMS also requires Mifeprex to “be dispensed to patients only in certain healthcare settings, specifically clinics, medical offices, and hospitals, by or under the supervision of a certified prescriber.” Mifeprex may not be distributed or dispensed through retail pharmacies. Also, a patient must sign a “Patient Agreement Form” and be fully informed of the risks by a certified prescriber. She must receive the Mifeprex Medication Guide, informing her that she needs a “follow-up assessment” 7 to 14 days after she has taken Mifeprex to ensure that she is well and has terminated her pregnancy.62

The REMS remains the lone safeguard to monitor and mitigate the risks of death and adverse events from the Mifeprex regimen. Gynuity Health Projects and researchers from the University of California, San Francisco (UCSF) obtained approval from FDA through Investigational New Drug Applications (INDs) to conduct studies that do not comply with the Mifeprex REMS. They intend to use the results of these studies to press for the elimination of the Mifeprex REMS.63 [See Section II.B, below.]

The Mifeprex Medication Guide acknowledges that serious risks accompany FDA’s approved regimen for drug-induced abortion, which includes the use of Mifeprex and another potent drug, misoprostol. The document improperly downplays the risks, however, stating that “rarely, serious and potentially life-threatening bleeding, infections, or other problems can occur following . . . medical abortion.” Specifically, “in about 1 out of 100 women [administered Mifeprex and misoprostol] bleeding can be so heavy that it requires a surgical procedure.”64

In fact, the internationally used criteria for reporting complications from drugs demonstrate that complications from drug-induced abortions are common, not rare. The Council for International Organizations of Medical Sciences (CIOMS)65 defines the word

65 The Council for International Organizations of Medical Sciences (CIOMS) is an international, non-governmental, nonprofit organization established jointly by WHO and UNESCO in 1949. Through its membership, CIOMS is representative of a substantial proportion of the biomedical scientific community. In 2013, the membership of CIOMS included 49 international, national, and associate member organizations, representing many of the biomedical disciplines, national academies of sciences, and medical research councils.
“rare” in adverse event reporting as an event that happens in between “1 out of 1,000” to “1 out of 10,000” uses. “Common” is the uniform term used for events that happen in between “1 out of 10” to “1 out of 100” uses. Given that “about 1 out of 100 women” using Mifeprex/misoprostol require surgery, serious complications are common, not rare.

Also, as discussed in Section I.C above, Mifeprex abortions carry greater risks than surgical abortions. A study of over 42,000 women in Finland who had abortions from 2000 to 2006 found that “overall, medical abortion had roughly four times the rate of adverse events than surgical abortion, and hemorrhaging was experienced by 16 percent of medical abortion patients compared with 2 percent of surgical abortion patients.”

A combined retrospective and longitudinal follow-up study of complications related to induced abortion in Sweden published in 2018 determined that the share of complications related to drug-induced abortions at less than 12 weeks increased significantly during 2008-2015 without an evident cause. The increase was from 4.2% in 2008 to 8.2% in 2015, with incomplete abortion as the most common complication related to drug-induced abortions at less than 12 weeks.

Abortion advocates are also attacking the REMS by advocating for mifepristone use in spontaneous miscarriage management. In a small recent study, researchers compared the efficacy and safety of using mifepristone with misoprostol for the management of early miscarriages to using misoprostol alone. Notably, 6-10% of study participants had a gestational age of “4-5 weeks gestation.” It is not clear from the authors how participants of that gestational age could meet the published guidelines for diagnosis of non-viable pregnancy recently published by the Society of Radiologists in Ultrasound multispecialty consensus panel. The panel requires the crown-rump length cutoff to 7 mm for embryos without a heartbeat and the mean sac diameter cutoff to 25 mm for

67 See Mifeprex Medication Guide; CIOMS training manual on medicine safety, supra.
68 See Harrison Aff. ¶ 115; ACOG Practice Bulletin 143, p. 3 & Box 1.
72 Id. Table 1.
“empty” sacs, in order to minimize interventions that “interrupt a pregnancy that otherwise would have had a normal outcome.”

The authors admit that the study “was not powered to show differences between groups in the proportions of serious adverse events,” an important consideration prior to recommending a change in spontaneous abortion management protocols. Yet, the authors incorrectly stated “such events were rare.” Table 3 gives a total number of serious adverse events as 3.4% for the mifepristone pretreatment group, and 2.0% for the misoprostol alone group. Under the CIOMS criteria for reporting complications from drugs, discussed above, the rate of 2%-3.4% of adverse events in each study arm demonstrates clearly that adverse events are common, not rare, in both misoprostol alone and mifepristone + misoprostol miscarriage management.

Further, the Mifeprex + misoprostol arm raises a concern about the need for further study of adverse events, especially hemorrhage. Mifepristone is known to inhibit endometrial hemostasis (i.e., arrest of bleeding), as demonstrated by many reports of hemorrhage with transfusions reported to the FDA after use of mifepristone and misoprostol for elective abortions.

Of additional concern is the vaginal route of administration of misoprostol. After reports of overwhelming sepsis following vaginal administration of misoprostol, Planned Parenthood changed the route of administration of misoprostol from vaginal to buccal, with subsequent decrease in reported infections. Animal studies have demonstrated that both mifepristone and misoprostol can profoundly suppress innate immunity and the ability to fight infections.

---

75 Schreiber, supra p. 2168.
76 Id.
77 Id. p. 2169.
Despite the clear methodological errors, including a failure to accurately diagnose fetal death according to accepted criteria as well as lack of adherence to the stated inclusion criteria, and despite the absence of power to evaluate safety, abortion advocates are calling for the routine use of mifepristone to manage spontaneous miscarriages.\(^{83}\) Any change in spontaneous miscarriage management with mifepristone should require an FDA New Drug Application (NDA) with two randomized controlled trials (RCTs) comparing the arms of mifepristone and misoprostol, misoprostol alone, surgical management, and expectant management. Without blinded RCTs to evaluate not only efficacy but also safety, it is premature to remove the REMS for Mifeprex to facilitate mifepristone access for spontaneous miscarriage management.

Despite the presence of serious risks and contraindications to the Mifeprex regimen, Gynuity, the University of California, San Francisco (UCSF), and other abortion advocates want the FDA to eliminate the remaining safeguards that were enacted to ensure the safety and efficacy of Mifeprex. They are pursuing their goals through publication, advocacy, litigation,\(^{84}\) and/or controversial research enabled by FDA.\(^{85}\)

Further, as Section II.B below explains, lifting the REMS is only the starting point for abortion advocates.

**B. Continue limiting the dispensing of Mifeprex to patients in clinics, medical offices, and hospitals, by or under the supervision of a certified prescriber.**

1. **Mifeprex should be dispensed only in clinics, medical offices, and hospitals.**

The Mifeprex REMS requires that Mifeprex “be dispensed to patients only in clinics, medical offices and hospitals, by or under the supervision of a certified prescriber.” That prescriber must be capable of assessing the duration of a pregnancy accurately, diagnosing ectopic pregnancies, and providing or referring for surgical intervention in cases of incomplete abortion or hemorrhaging.\(^{86}\)

Abortion advocates, however, want the FDA to permit healthcare providers to prescribe Mifeprex to pregnant patients over the Internet or phone, with the drug available at pharmacies or through the mail, and through advance provision (i.e., before a patient is pregnant). Eliminating or relaxing the REMS to facilitate Internet or telephone prescriptions would be dangerous to women and adolescent girls. Healthcare providers

---


\(^{85}\) See Section II.B, below.

prescribing abortion-inducing drugs over the Internet or phone or before a patient is even pregnant cannot adequately evaluate patients for contraindications to the drugs.\textsuperscript{87} Further, as discussed above, Rh-negative patients must be administered Rhogam in order to prevent Rh isoimmunization in subsequent pregnancies. Without direct patient contact, women will not receive the Rhogam after the abortion, greatly increasing their risk of subsequent Rh isoimmunization, which can endanger future pregnancies.\textsuperscript{88} [See Section I.B.2, supra.]

Telemedicine abortion further distances women from the practitioners responsible for caring for them, and approval by FDA would further absolve abortion providers of responsibility for the well-being of their patients. Promoting telemedicine abortion to women and adolescent girls in rural areas with limited access to healthcare is extremely dangerous—they will have little recourse if they face known and predictable emergency complications such as severe hemorrhage.\textsuperscript{89}

Nonetheless, Gynuity Health Projects and researchers from UCSF obtained approval from FDA through Investigational New Drug Applications (INDs) to conduct studies that do not comply with the Mifeprex REMS. They will use the results of these studies to press for the elimination of the Mifeprex REMS.

a. The “TelAbortion” Direct-to-Consumer Mifeprex Study

Gynuity Health Projects is the sponsor of the study “Feasibility of Medical Abortion by Direct-to-Consumer Telemedicine.”\textsuperscript{90} Gynuity filed an IND with the FDA.\textsuperscript{91} The status is listed as “recruiting,” with age eligibility that includes 11-year-old children and an estimated enrollment of 1,000 participants at five locations.\textsuperscript{92} The start date is listed as March 22, 2016, and the estimated completion date was extended from June 2018 to June 2019.

The study’s brief summary states: “This pilot study is designed to obtain preliminary data on the safety, acceptability, and feasibility of direct-to-consumer telemedicine

\textsuperscript{87} Harrison & Norton Testimony, p. 2.
\textsuperscript{89} Harrison & Norton Testimony, p. 9.
\textsuperscript{92} Hawaii – University of Hawaii Women’s Options Center; Maine – Maine Family Planning; New York – Choices Women’s Medical Center (active, but not recruiting according to ClinicalTrials.gov, and not listed on TelAbortion.org); Oregon and Washington – Planned Parenthood Columbia Willamette; Oregon Health and Sciences University Women’s Health Research Unit. Washington State patients may also participate because an Oregon abortion provider is also licensed in Washington State. Claire Lampen, Webcam Abortion Services Offer Crucial Access—So What’s Stopping them? Gizmodo (Apr. 17, 2018).
abortion.” The study’s website states that “[a] TelAbortion involves all the same steps and procedures as a regular medical abortion, but you do them without going into an abortion clinic.”

Women who participate in the study have a video “evaluation” with the study abortion provider over the Internet, during which they can ask questions, provide medical history, and learn about the pre-abortion tests that they need. They also electronically sign consent forms for the study. Afterwards, they are required to obtain the tests and direct the reports to be sent to the study provider.

Once a patient is determined eligible, the study provider will send her a package containing Mifeprex and misoprostol, with instructions that she must follow on her own. She is also instructed to have additional tests to verify that the abortion is complete, and later have another consultation with the study provider to review the results.

Obviously, a woman may not take the abortion drugs in the manner prescribed, nor obtain the follow-up care that is recommended. With a doctor-patient relationship limited to online chats, she has virtually no accountability or support as she navigates a complicated procedure. The responsibility of the provider of the drugs to follow up with the patient is obviated as well.

b. The Mifeprex through Pharmacy Dispensing Study

The University of California, San Francisco (UCSF) is the sponsor of the “Alternative Provision of Medication Abortion via Pharmacy Dispensing” study. Daniel Grossman, M.D., with UCSF is listed as the study’s “responsible party.” Like Gynuity, UCSF filed an IND with the FDA to obtain authorization for this study. The status is listed as “recruiting,” with July 2019 as the estimated completion date. The sponsors plan to recruit 300 patients at four study clinic sites and survey 50 pharmacists at associated study pharmacy sites.

---

95 Id.
97 Id.
98 In a May 2018 phone conversation with a contact for the UCSF study, she stated that the study was approved through an IND application with FDA.
99 Grossman, pp. 5-7; 16-17.
The stated aim of the study is to “investigate the feasibility, acceptability, and effectiveness of pharmacy dispensing of Mifeprex; safety data will also be collected. . . . The results of this study eventually could lead to changes in the Mifeprex REMS. . . .”

The sponsors intend to measure “pharmacist satisfaction with dispensing Mifeprex and the proportion of pharmacists who refuse to dispense the medication to patients.” They secondarily intend to assess patient satisfaction, describe clinical outcomes, including effectiveness and adverse events, and compare pharmacists’ knowledge about medication abortion before and after.

Patients enroll at one of the study clinic sites on Day 1, where they choose medication abortion, have an ultrasound if one has not been done, and obtain pre-abortion counseling. They then are prescribed Mifeprex, misoprostol, and anything else necessary to be filled at the associated study pharmacy site. Some patients have serum hCG measured on the day of Mifeprex administration and again around eight days later “to assess for completion of the abortion.” The “follow-up” for patients “may include a follow-up visit or a phone call from clinic staff approximately 7-14 days after the initial visit.” However, as discussed extensively above, a clinician needs to perform an exam to rule out retained tissue—even if the patient has a negative serum hCG. A phone call that “may” be placed, or fail to connect, is not enough.

Notably, “[a]ll except one of [the participating] pharmacies is [sic] located within the same building as the clinic…. While UCSF is using a community pharmacy not affiliated with the University, the other three study clinic sites are using affiliated pharmacies.

---

100 Grossman, p.14 (emphasis added). The sponsors dubiously assert that “pharmacy dispensing could [] help increase the number of clinicians willing and able to provide medication abortion by enabling them to avoid the associated costs and logistical challenges of stocking and dispensing the medication at their facilities.” They reference a survey of Fellows of the American College of Obstetricians and Gynecologists that sought to determine if doctors not presently practicing abortion would prescribe Mifeprex if their patients could obtain the drug at a pharmacy. Fifty-four percent responded to the survey. Seventy-seven percent of respondents do not perform abortions and nine percent perform surgical abortions only—of those, 19% said they would prescribe Mifeprex if it could be obtained at a pharmacy, and an additional 18% said they were unsure. Based on this, the sponsors claim “the proportion of obstetrician-gynecologists providing [Mifeprex] would at least double (from 14% to 29%) “if the dispensing restriction in the REMS were removed and physicians could write a prescription for Mifeprex that could be dispensed at a pharmacy.” The fact that 46 percent of the fellows surveyed did not take the time to respond, however, places this conclusion in doubt. See Grossman, pp. 12-14.

101 Grossman, pp. 15-16.
102 Grossman, p. 23.
103 Grossman, p. 23.
105 Grossman, p. 20.
While the rationale for the study states that pharmacy dispensing of Mifeprex could “help facilitate provision of medication abortion through telemedicine,” the sponsors emphasize that the only difference between this study and FDA protocol “is that the patient would obtain the mifepristone directly from the pharmacist, rather than in a clinic facility.” In fact, the schedules for the participating pharmacists are “mapped” to “ensure that trained pharmacists are available to dispense to study participants during business hours.”

The following demonstrates the extensive assistance that the sponsors offer patients in obtaining the drugs from the participating pharmacies:

[The patient] will be told that only a limited number of pharmacies are able to dispense Mifeprex and given information about how to get to the participating pharmacy (as well as the hours during which a participating pharmacist will be working, if needed). If there are any gaps in staffing at the pharmacy, the patient will be notified of the timing of those gaps in coverage before leaving the clinic via the pharmacy directions/handout. If this will be an issue for the patient, a solution will be found at the clinic before the patient leaves or she will not be enrolled in the study. Patients will be told that if they have any problems accessing the medications at the clinic, they should come back to the clinic [where they can obtain Mifeprex].

While this assistance may ensure that the study does not deviate dramatically from FDA protocol, the study certainly does not model the experience a patient would have outside of this controlled environment—particularly a patient who obtains Mifeprex through telemedicine and has no physical contact with her prescriber.

The physical proximity of the study pharmacy sites to the study clinic sites, the probable professional associations between participating doctors and pharmacists, and the extensive assistance offered by the clinics to ensure that patients access abortion-inducing drugs at participating pharmacies, raise questions as to whether the study is fundamentally biased and will inaccurately forecast widespread behavior and experiences if the REMS is removed. Therefore, any results of the study cannot provide a justification for permitting pharmacy distribution of Mifeprex, much less abortion through telemedicine.

Further, as discussed below, eliminating the REMS to enable pharmacy dispensing of Mifeprex is only the beginning of a long-term strategy to achieve over-the-counter status for Mifeprex, further diminishing patient care and abortion provider accountability.

c. Beyond the Current Studies

A recent article by Dr. Grossman and colleagues reveals that they want Mifeprex access extended even beyond the parameters contained in their Pharmacy Dispensing study. They used an online survey to gauge women’s “personal interest in and general support for three alternative methods for accessing abortion pills: (1) in advance from a doctor for future use, (2) over-the-counter (OTC) from a drugstore and (3) online without a prescription.”111

None of the options in the survey require a healthcare provider to provide patient care comparable to even the inadequate care provided in the two studies discussed above. Only the first option requires a prescription from a doctor; however, the doctor would not know in advance when his patient actually becomes pregnant and chooses to use the drugs. The survey disingenuously stated that “[m]edication abortion, or the abortion pill, is a safe and effective way to terminate a pregnancy up to 10 weeks,” without informing participants of a single risk associated with the regimen.112

Further, in a November, 21, 2018 op-ed, Dr. Grossman advocated for providing abortion pills before women are pregnant. He stated:

The idea is simple: Give women abortion pills before they need them – “advance provision,” as it’s known – so that they can take them as soon as they discover a pregnancy. Women could get the pills from their gynecologist at the time of their annual exam, say, or the pills could be made available online.113

Incredibly, Dr. Grossman stated that he has “few medical concerns about handing out abortion pills in advance.”114 He asserts that evidence from advance provision research “could strengthen the case for making [abortion-inducing drugs] available without a prescription.”115

112 See id.
113 Daniel Grossman, American women should have access to abortion pills before they need them, Los Angeles Times (Nov. 21, 2018).
114 Id.
115 Id.
In addition to his failure to address all of the dangers posed by abortion-inducing drugs, Dr. Grossman does not acknowledge the risk that women will share their abortion-inducing pills with other women. While an abortion provider may screen his patient for contraindications to Mifeprex, nothing will stop his patient from giving her stored Mifeprex to a friend who is unaware that she is Rh negative, for instance, which poses health risks for future pregnancies (See section I.B.2, supra).

In fact, Dr. Grossman’s research program has listed a study titled “Alternative Provision of Medication Abortion Via Advance Provision” on ClinicalTrials.gov, with May 2019 listed as the estimated study start date. In the study, patients who are “at risk of unintended pregnancy and with a desire to avoid pregnancy will be assessed by a clinician and provided counseling on pregnancy recognition and testing, as well as how to administer [drug-induced abortion] at home.” They will then receive Mifeprex and misoprostol while not pregnant. If/when the patient becomes pregnant and wants to take the drugs, she is instructed to contact a study clinician for an “over-the-phone assessment of eligibility” for drug-induced abortion, “including evaluation of contraindications and gestational age” before taking the drugs, and “then attend a follow-up visit with the clinician.” However, it is impossible for the study sponsors to truly assess the patient for contraindications, verify gestational age, prevent patients from sharing the drugs with others, or ensure that patients attend a follow-up visit.

In a 2018 Policy Review, the Guttmacher Institute also advocated for lifting the Mifeprex REMS. However, the article did not stop there. The author argues:

[w]hile lifting the REMS on mifepristone would open new possibilities for medication abortion access, stopping there would fall short of realizing the full potential of this method, particularly when it comes to self-managed abortion care. In a self-management model, anyone who needs to terminate a pregnancy would be able to legally access mifepristone and misoprostol without a requirement to see a health care provider or pharmacist first. . . . To fully integrate self-managed medication abortion with existing abortion practices in the United States, misoprostol and mifepristone must first become available without a prescription.

These recent publications demonstrate how abortion advocates will continue to pressure FDA to eliminate the REMS and move towards over-the-counter access for Mifeprex. In spite of the serious risks and contraindications to the Mifeprex regimen, abortion advocates will not rest until Mifeprex is available to all, without a prescription.

117 Id.
or mandatory medical management of any kind. The FDA’s vigilance in protecting women from such negligence is critically important.

2. Mifeprex Prescribers Should be Certified.

The 2016 regimen requires Mifeprex prescribers to be certified as qualified. This is simply common sense—only healthcare providers qualified to prescribe an abortion-inducing drug should do so. The prescriber form attests that the healthcare provider must be able to assess pregnancy duration, diagnose ectopic pregnancy, and provide or refer for surgical intervention if necessary.

Given that drug-induced abortion is contraindicated beyond 10 weeks’ gestation and when the pregnancy is not in the uterus, and that at least 1 out of 100 women using Mifeprex need surgery, these qualifications are entirely logical. Yet, abortion advocates, ignoring the best interests of their patients, claim such restrictions are onerous.

CONCLUSION

The Mifeprex REMS with ETASU remains critical for patient safety. Mifeprex carries risks of life-threatening hemorrhage, infection, continued pregnancy, retained tissue, need for emergency surgery, and death. The 2000 regimen provided significantly more protections for patients than the 2016 regimen. FDA should restore and strengthen elements of the Mifeprex regimen and provider requirements, including: limiting Mifeprex use to 49 days’ gestation; requiring that Mifeprex be administered only by or under the supervision of a physically present physician; requiring three office visits by a patient who has been prescribed Mifeprex; clarifying that Mifeprex use is contraindicated for patients who do not have convenient access to emergency medical care; expanding mandatory adverse event reporting; and requiring additional studies of Mifeprex use in at-risk populations.

At the very least, FDA should not further erode patient protections. The agency should retain the Mifeprex REMS, and continue limiting the dispensing of Mifeprex to patients in clinics, medical offices, and hospitals, by or under the supervision of a certified prescriber.

C. Environmental Impact

This petition is categorically excluded under 21 C.F.R. § 25.30.

D. Economic Impact

Available upon Commissioner’s request, pursuant to 21 C.F.R. §10.30(3).

E. Certification

The undersigned certify, that, to the best knowledge and belief of the undersigned, this petition includes all information and views on which the petition relies, and that it includes representative data and information known to the petitioners, which are unfavorable to the petition.

Signature: /s/ Donna J. Harrison M.D., Executive Director

Name of petitioner: American Association of Pro-Life Obstetricians and Gynecologists

Mailing address: PO Box 395, Eau Claire, MI 49111-0395

Telephone number: (202) 230-0997

Signature: /s/ Quentin L. Van Meter, M.D., FCP, President

Name of petitioner: American College of Pediatricians

Mailing address: PO Box 357190, Gainesville, FL 32635-7190

Telephone number: (352) 376-1877
Exhibit 24

2019 FDA ANDA Approval Letter to GenBioPro, Inc. (Apr. 11, 2019)
ANDA APPROVAL

GenBioPro, Inc.

Attention:

Dear Sir:

This letter is in reference to your abbreviated new drug application (ANDA) received for review on February 3, 2009, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Mifepristone Tablets, 200 mg.

Reference is also made to the complete response letter issued by this office on February 23, 2018, and to any amendments thereafter.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the ANDA is approved, effective on the date of this letter.

The has determined your Mifepristone Tablets, 200 mg, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug (RLD), Mifeprex Tablets, 200 mg, of Danco Laboratories, LLC.

Under section 506A of the FD&C Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

RISK EVALUATION AND MITIGATION STRATEGY (REMS) REQUIREMENTS

Section 505-1 of the FD&C Act authorizes FDA to require the submission of a risk evaluation and mitigation strategy (REMS), if FDA determines that such a strategy is necessary to ensure that the benefits of the drug outweigh the risks [section 505-1(a)]. In accordance with section 505-1(i) of the FD&C Act, a drug that is the subject of an ANDA under section 505(j) is subject to certain elements of the REMS required for the applicable listed drug.

The details of the REMS requirements were outlined in our letter dated June 15, 2011. In that letter, you were also notified that pursuant to section 505-1(i) of the FD&C Act, a drug that is the subject of an ANDA and the listed drug it references must use a single, shared system for elements to assure safe use (ETASU), unless FDA waives that requirement.

Your REMS, known as the Mifepristone REMS Program, submitted on May 30, 2017; is approved, and will be posted on the FDA REMS website: http://www.fda.gov/REMS

The REMS consists of ETASU and an implementation system.
Your REMS must be fully operational before you introduce Mifepristone Tablets, 200 mg, into interstate commerce.

The Mifepristone REMS uses a single, shared system for the ETASU. This single, shared system REMS Program currently includes the products listed on the FDA REMS website, available at [http://www.fda.gov/rem](http://www.fda.gov/rem). Other products may be added in the future if additional NDAs or ANDAs are approved.

Under section 505-1(g)(2)(C) of the FD&C Act, FDA can require the submission of a REMS assessment if FDA determines an assessment is needed to evaluate whether the REMS should be modified to ensure the benefits of the drug outweigh the risks or to minimize the burden on the healthcare delivery system of complying with the REMS.

We remind you that you must include an adequate rationale to support a proposed REMS modification for the addition, modification, or removal of any goal or element of the REMS, as described in section 505-1(g)(4) of the FD&C Act.

We also remind you that section 505-1(f)(8) of the FD&C Act prohibits holders of an approved covered application from using any element to assure safe use to block or delay approval of an application under section 505(b)(2) or (j). A violation of this provision in 505-1(f) could result in enforcement action.

Prominently identify any submission containing a REMS assessment or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

**ANDA 091178 REMS ASSESSMENT**

NEW SUPPLEMENT FOR ANDA 091178/S-000
CHANGES BEING EFFECTED IN 30 DAYS
PROPOSED MINOR REMS MODIFICATION

or

NEW SUPPLEMENT FOR ANDA 091178/S-000
PRIOR APPROVAL SUPPLEMENT
PROPOSED MAJOR REMS MODIFICATION

or

NEW SUPPLEMENT FOR ANDA 091178/S-000
PRIOR APPROVAL SUPPLEMENT
PROPOSED REMS MODIFICATIONS DUE TO SAFETY LABELING CHANGES
SUBMITTED IN SUPPLEMENT XXX

Should you choose to submit a REMS revision, prominently identify the submission containing the REMS revisions with the following wording in bold capital letters at the top of the first page of the submission:
REMS REVISION FOR ANDA 091178

To facilitate review of your submission, we request that you submit your proposed modified REMS and other REMS-related materials in Microsoft Word format. If certain documents, such as enrollment forms, are only in PDF format, they may be submitted as such, but the preference is to include as many as possible in Word format.

SUBMISSION OF REMS DOCUMENT IN SPL FORMAT

In addition to submitting the proposed REMS as described above, you can also submit the REMS document in Structured Product Labeling (SPL) format. If you intend to submit the REMS document in SPL format, include the SPL file with your proposed REMS submission.

For more information on submitting REMS in SPL format, please email REMSWebsite@fda.hhs.gov

REPORTING REQUIREMENTS

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98 and at section 506I of the FD&C Act. The Agency should be advised of any change in the marketing status of this drug or if this drug will not be available for sale after approval. In particular, under section 506I(b) of the FD&C Act, you are required to notify the Agency in writing within 180 days from the date of this letter if this drug will not be available for sale within 180 days from the date of approval. As part of such written notification, you must include (1) the identity of the drug by established name and proprietary name (if any); (2) the ANDA number; (3) the strength of the drug; (4) the date on which the drug will be available for sale, if known; and (5) the reason for not marketing the drug after approval.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling materials prior to publication or dissemination. Please note that these submissions are voluntary. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert (PI), Medication Guide, and patient PI (as applicable) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov
You must also submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

ANNUAL FACILITY FEES

The Generic Drug User Fee Amendments of 2012 (GDUFA) (Public Law 112-144, Title III) established certain provisions with respect to self-identification of facilities and payment of annual facility fees. Your ANDA identifies at least one facility that is subject to the self-identification requirement and payment of an annual facility fee. Self-identification must occur by June 1st of each year for the next fiscal year. Facility fees must be paid each year by the date specified in the Federal Register notice announcing facility fee amounts.

All finished dosage forms (FDFs) or active pharmaceutical ingredients (APIs) manufactured in a facility that has not met its obligations to self-identify or to pay fees when they are due will be deemed misbranded. This means that it will be a violation of federal law to ship these products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those responsible, injunctions, or seizures of misbranded products. Products misbranded because of failure to self-identify or pay facility fees are subject to being denied entry into the United States.
CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical in content to the approved labeling (including the package insert, and any patient package insert and/or Medication Guide that may be required). Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf. The SPL will be accessible via publicly available labeling repositories.

Sincerely yours,

[See appended electronic signature page]

Center for Drug Evaluation and Research

1 Some of these provisions were amended by the Generic Drug User Fee Amendments of 2017 (GDUFA II) (Public Law 115-52, Title III).
Exhibit 25

FDA Supplemental Approval Letter to Danco Laboratories, LLC (Apr. 11, 2019)
SUPPLEMENT APPROVAL

Danco Laboratories, LLC
P.O. Box 4816
New York, NY 10185

Dear [Name],

Please refer to your Supplemental New Drug Application (sNDA) dated November 4, 2015, received November 5, 2015, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Mifeprex (mifepristone) Tablets.

This Prior Approval supplemental new drug application proposes modifications to the approved risk evaluation and mitigation strategy (REMS) for Mifeprex to establish a single, shared system (SSS) REMS for mifepristone products for the medical termination of intrauterine pregnancy and updates to the approved Prescribing Information, Medication Guide, and REMS materials including the Prescriber Agreement and Patient Agreement Forms to incorporate language reflecting the proposed SSS REMS.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(b)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at:

Reference ID: 4418041

EX. 25 pg. 001
The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS**

The REMS for Mifeprex (mifepristone) Tablets was originally approved on June 8, 2011. The most recent modification was approved on March 29, 2016. The REMS consists of elements to assure safe use, an implementation system, and a timetable for submission of assessments of the REMS. Your proposed modifications to the REMS establish a SSS REMS for the elements to assure safe use and the implementation system required for the reference listed drug (RLD) Mifeprex and ANDAs referencing Mifeprex, called the Mifepristone REMS Program.

Your proposed modified REMS, submitted on January 25, 2018, and appended to this letter, is approved.

The timetable for submission of assessments of the REMS must be revised to one year from the date of the initial approval of the SSS REMS (04/11/19) and every three years thereafter.

The revised REMS assessment plan must include, but is not limited to, the following:

Both cumulative data from the date of the initial approval of the SSS REMS (04/11/19) and data from the reporting period (i.e., from the preceding Mifeprex REMS assessment cut-off date to the cut-off date for the Mifepristone REMS Program.)

**REMS Assessment Plan**

Provide each metric for the current reporting period and cumulative for the RLD and ANDA(s):

1. Number of prescribers enrolled
2. Number of prescribers ordering mifepristone
3. Number of healthcare providers who attempted to order mifepristone who were not enrolled; describe actions taken
4. Number of women exposed to mifepristone
5. Summary and analysis of any program deviations and corrective action taken
6. Based on the information reported, an assessment and analysis of whether the REMS is meeting its goals and whether modifications to the REMS are needed
The requirements for assessments of an approved REMS under section 505-1(g)(3) include with respect to each goal included in the strategy, an assessment of the extent to which the approved strategy, including each element of the strategy, is meeting the goal or whether 1 or more such goals or such elements should be modified.

We remind you that in addition to the REMS assessments submitted according to the timetable in the approved REMS, you must include an adequate rationale to support any proposed REMS modification for the addition, modification, or removal of any of goal or element of the REMS, as described in section 505-1(g)(4) of the FDCA.

We also remind you that you must submit a REMS assessment when you submit any future supplemental application for a new indication for use as described in section 505-1(g)(2)(A) of the FDCA. This assessment should include:

a) An evaluation of how the benefit-risk profile will or will not change with the new indication;
b) A determination of the implications of a change in the benefit-risk profile for the current REMS;
c) If the new indication for use introduces unexpected risks: A description of those risks and an evaluation of whether those risks can be appropriately managed with the currently approved REMS.
d) If a REMS assessment was submitted in the 18 months prior to submission of the supplemental application for a new indication for use: A statement about whether the REMS was meeting its goals at the time of that the last assessment and if any modifications of the REMS have been proposed since that assessment.
e) If a REMS assessment has not been submitted in the 18 months prior to submission of the supplemental application for a new indication for use: Provision of as many of the currently listed assessment plan items as is feasible.
f) If you propose a REMS modification based on a change in the benefit-risk profile or because of the new indication of use, submit an adequate rationale to support the modification, including: Provision of the reason(s) why the proposed REMS modification is necessary, the potential effect on the serious risk(s) for which the REMS was required, on patient access to the drug, and/or on the burden on the health care delivery system; and other appropriate evidence or data to support the proposed change. Additionally, include any changes to the assessment plan necessary to assess the proposed modified REMS. If you are not proposing REMS modifications, provide a rationale for why the REMS does not need to be modified.

If the assessment instruments and methodology for your REMS assessments are not included in the REMS supporting document, or if you propose changes to the submitted assessment instruments or methodology, you should update the REMS supporting document to include specific assessment instrument and methodology information at least 90 days before the assessments will be conducted. Updates to the REMS supporting document may be included in a new document that references previous REMS supporting document submission(s) for unchanged portions. Alternatively, updates may be made by modifying the complete previous
REMS supporting document, with all changes marked and highlighted. Prominently identify the submission containing the assessment instruments and methodology with the following wording in bold capital letters at the top of the first page of the submission:

**NDA 020687 REMS CORRESPONDENCE**

(insert concise description of content in bold capital letters, e.g.,

**UPDATE TO REMS SUPPORTING DOCUMENT - ASSESSMENT METHODOLOGY**

An authorized generic drug under this NDA must have an approved REMS prior to marketing. Should you decide to market, sell, or distribute an authorized generic drug under this NDA, contact us to discuss what will be required in the authorized generic drug REMS submission.

We remind you that section 505-1(f)(8) of FDCA prohibits holders of an approved covered application with elements to assure safe use from using any element to block or delay approval of an application under section 505(b)(2) or (j). A violation of this provision in 505-1(f) could result in enforcement action.

Prominently identify any submission containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

**NDA 020687 REMS ASSESSMENT**

**NEW SUPPLEMENT FOR NDA 020687/S-000/ SECONDARY TRACKING NUMBER**

**CHANGES BEING EFFECTED IN 30 DAYS**

**PROPOSED MINOR REMS MODIFICATION**

*Or*

**NEW SUPPLEMENT FOR NDA 020687/S-000/ SECONDARY TRACKING NUMBER**

**PRIOR APPROVAL SUPPLEMENT**

**PROPOSED REMS MODIFICATIONS DUE TO SAFETY LABEL CHANGES SUBMITTED IN SUPPLEMENT XXX**

*Or*

**NEW SUPPLEMENT (NEW INDICATION FOR USE)**

**FOR NDA 020687/S-000**

**REMS ASSESSMENT**

**PROPOSED REMS MODIFICATION (if included)**

Should you choose to submit a REMS revision, prominently identify the submission containing the REMS revisions with the following wording in bold capital letters at the top of the first page of the submission:
of the submission:

REMS REVISIONS FOR NDA 020687

To facilitate review of your submission, we request that you submit your proposed modified REMS and other REMS-related materials in Microsoft Word format. If certain documents, such as enrollment forms, are only in PDF format, they may be submitted as such, but the preference is to include as many as possible in Word format.

SUBMISSION OF REMS DOCUMENT IN SPL FORMAT

FDA can accept the REMS document in Structured Product Labeling (SPL) format. If you intend to submit the REMS document in SPL format, as soon as possible, but no later than 14 days from the date of this letter, submit the REMS document in SPL format using the FDA automated drug registration and listing system (eLIST).

For more information on submitting REMS in SPL format, please email REMS_Website@fda.hhs.gov.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call

Sincerely,

{See appended electronic signature page}

Center for Drug Evaluation and Research

EX. 25 pg. 005
ENCLOSURES:
	Content of Labeling
	Prescribing Information
	Medication Guide
	REMS
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

04/11/2019 02:13:59 PM
Exhibit 26

2020 Letter from ACOG and SMFM, to FDA about Mifepristone REMS (Apr. 20, 2020)  
(2020 ACOG-SMFM Letter)
April 20, 2020

Stephen M. Hahn, M.D.
Commissioner
U.S. Food and Drug Administration
10903 New Hampshire Avenue NW
Silver Spring, MD 20993

Re: Docket Number: FDA-2020-D-1106; Policy for Certain REMS Requirements During the COVID-19 Public Health Emergency Guidance for Industry and Health Care Professionals

Dear Commissioner Hahn:

On behalf of more than 60,000 of the nation’s primary care obstetrician-gynecologists and subspecialty and high-risk obstetric practitioners dedicated to advancing women’s health, thank you for your recent action to suspend enforcement of Risk Evaluation and Mitigation Strategy (REMS) requirements for certain drugs with laboratory testing or imaging requirements for the duration of the COVID-19 public health emergency. The American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine urge the U.S. Food and Drug Administration (FDA) to immediately expand this policy to REMS and Elements to Assure Safe Use (ETASU) requirements for certain prescription drugs requiring in-person health care professional administration, where treatment could safely occur through telehealth or self-administration. In addition, physicians who provide such services in accordance with current clinical guidelines during this pandemic should not be held liable.

Obstetrician-gynecologists are serving on the front lines responding to the COVID-19 crisis. In order to provide the safest care for their patients and themselves, in-person visits are limited to emergency and essential physically necessary visits. We support the FDA’s acknowledgment that REMS-required health care professional in-person dispensation is difficult because patients may need to avoid public places and patients suspected of having COVID-19 may be self-isolating and/or subject to quarantine. Under these circumstances, undergoing in-person clinic administration in order to obtain a drug subject to a REMS can put patients and others, including health care professionals and their families, at risk for COVID-19 transmission. As referenced in ACOG Committee Opinion #798, Implementing Telehealth in Practice, evidence suggests that telehealth provides comparable health outcomes when compared with traditional methods of health care delivery without compromising the patient–physician relationship. Telehealth has quickly become integrated into nearly every aspect of obstetrics and gynecology. During this pandemic, it is essential to use telehealth services to limit COVID-19 transmission.

It is critical that the FDA promptly expand its recent policy to apply to the REMS and ETASU requirements for certain drugs requiring in-person dispensation, especially mifepristone. The current REMS and ETASU requirements for mifepristone are outdated and serve as a barrier to accessing this safe, effective medication. Further, they cause unnecessary delays in obtaining time-sensitive health care, without supporting improvements to patient safety or outcomes. During this federally declared public health emergency, these antiquated and superfluous requirements put patients and their physicians at risk, with no demonstrated benefit. As noted in the ACOG Position Statement, Improving Access to
Mifepristone for Reproductive Health Indications, mifepristone has been used by over 3 million women in the United States since FDA approval in 2000 and strong evidence exists regarding the safety of mifepristone for medication-induced abortion and medical management of early pregnancy loss.\textsuperscript{2,3,4,5}

Restricting access to mifepristone interferes with the ability of obstetrician–gynecologists and other women’s health clinicians to deliver the highest quality care for their patients, especially during the COVID-19 pandemic. Abortion is an essential component of comprehensive health care and is a time-sensitive service for which a delay of several weeks, or in some cases days, may increase the risks or potentially make it completely inaccessible.\textsuperscript{6} Temporarily waiving REMS and ETASU requirements that certain drugs be dispensed in-person by certain medical professionals is particularly important for patients who suffer from other medical conditions and are at higher risk of serious complications from COVID-19, as well as those in rural areas for whom hours of travel for in-person administration would disallow social distancing recommendations and travel advisories.

In addition, we urge you to consider waiving the requirement for health care professional administration of subcutaneous depot medroxyprogesterone acetate (DMPA). Several studies have shown patient interest in self-administration and increased continuation of DMPA via subcutaneous at-home delivery.\textsuperscript{7,8,9} In a period when limiting patient interactions with the health care system is essential to prevent COVID-19 transmission, it is in our patients’ best interest to have unencumbered access to the contraceptive method of their choice, including DMPA.

Ensuring the safety of patients and physicians during the COVID-19 pandemic requires policy changes such as those already enacted by FDA to waive the REMS requirements for certain drugs with laboratory testing or imaging requirements. We strongly urge FDA to further protect patients and their health care professionals from the risk of transmission by promptly expanding the existing policy to waive REMS and ETASU requirements that certain drugs be dispensed in-person by certain medical professionals.

Thank you for your consideration. We are available to answer any questions you may have regarding these issues.

Sincerely,

Maureen G. Phipps, MD, MPH, FACOG
Chief Executive Officer
American College of Obstetricians and Gynecologists

Judette Louis, MD, MPH
President
Society for Maternal-Fetal Medicine

Matt J. Granato, LL.M., MBA
Chief Executive Officer
Society for Maternal-Fetal Medicine


Exhibit 27

April 12, 2021

Maureen G. Phipps, MD, MPH, FACOG
Chief Executive Officer
American College of Obstetricians and Gynecologists
c/o Rachel Tetlow, Federal Affairs Director
rtetlow@acog.org

Skye Perryman, General Counsel
sperryman@acog.org

William Grobman, MD, MBA
President
Society for Maternal-Fetal Medicine
w-grobman@northwestern.edu

Dear Drs. Phipps and Grobman,

In your letter of April 20, 2020, to former Commissioner Stephen Hahn, you expressed concerns about the in-person dispensing requirements for certain prescription drugs during the current public health emergency. In my letter to you of March 19, 2021, I indicated that staff in the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) were evaluating the issues you raised.

Following up on my March 19, 2021, letter I am writing to report the results of CDER’s review and analysis.

CDER conducted a literature search for studies pertinent to the in-person dispensing requirement in the Mifepristone REMS Program during the COVID-19 pandemic. Based on this literature search, CDER identified four publications that included relevant clinical outcome data.1

found that although there are limitations to the study designs, the overall findings from these studies do not appear to show increases in serious safety concerns (such as hemorrhage, ectopic pregnancy, or surgical interventions) occurring with medical abortion as a result of modifying the in-person dispensing requirement during the COVID-19 pandemic.

CDER also reviewed postmarketing adverse events that reportedly occurred from January 27, 2020 - January 12, 2021, with mifepristone use for medical termination of early pregnancy, along with available information about deviations or noncompliance events associated with the Mifepristone REMS Program. CDER found that the small number of adverse events reported to FDA during the COVID-19 public health emergency (PHE) provide no indication that any program deviation or noncompliance with the Mifepristone REMS Program contributed to the reported adverse events.

In summary, provided the other requirements of the Mifepristone REMS Program are met, and given that the in-person dispensing of mifepristone for medical termination of early pregnancy may present additional COVID-related risks to patients and healthcare personnel because it may involve a clinic visit solely for this purpose, CDER intends to exercise enforcement discretion during the COVID-19 PHE with respect to the in-person dispensing requirement of the Mifepristone REMS Program, including any in-person requirements that may be related to the Patient Agreement Form. Further, to the extent all of the other requirements of the Mifepristone REMS Program are met, CDER intends to exercise enforcement discretion during the COVID-19 PHE with respect to the dispensing of mifepristone through the mail either by or under the supervision of a certified prescriber, or through a mail-order pharmacy when such dispensing is done under the supervision of a certified prescriber.

CDER is communicating this decision to the approved application holders subject to the Mifepristone REMS Program.

Sincerely yours,

Janet Woodcock, M.D.
Acting Commissioner of Food and Drugs

---

2 See Mifepristone REMS Program at https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=RemsDetails.page&REMS=390. CDER’s analysis covers both products that are subject to the Mifepristone REMS Program (Mifeprex and the approved generic, Mifepristone Tablets, 200 mg).
Exhibit 28

FDA Supplemental Approval Letter to Danco Laboratories, LLC
(May 14, 2021)
Dear [Redacted]:

Please refer to your supplemental new drug application (sNDA) dated and received March 15, 2021, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Mifeprex (mifepristone) Tablets.

This Changes Being Effected sNDA provides for changes to the single, shared system risk evaluation and mitigation strategy (REMS) for mifepristone products for the medical termination of intrauterine pregnancy, known as the Mifepristone REMS Program, to include gender neutral language in the Patient Agreement Form. This sNDA also provides for minor changes to the REMS document to be consistent with the changes made to the Patient Agreement Form.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

RISK EVALUATION AND MITIGATION STRATEGY (REMS) REQUIREMENTS

The REMS for Mifeprex was originally approved on August 7, 2012, and the most recent REMS modification, establishing the Mifepristone REMS Program, was approved on April 11, 2019. The Mifepristone REMS Program consists of elements to assure safe use, an implementation system, and a timetable for submission of assessments of the REMS. Your proposed modification to the Mifepristone REMS Program consists of a
revised Patient Agreement Form to include gender neutral language and minor revisions to the REMS document to be consistent with the revisions to the Patient Agreement Form.

The timetable for submission of assessments of the REMS remains the same as that approved on April 11, 2019.

There are no changes to the REMS assessment plan described in our April 11, 2019 letter.

We remind you that in addition to the REMS assessments submitted according to the timetable in the approved Mifepristone REMS Program, you must include an adequate rationale to support a proposed REMS modification for the addition, modification, or removal of any goal or element of the Mifepristone REMS Program, as described in section 505-1(g)(4) of the FDCA.

We also remind you that you must submit a REMS assessment when you submit a supplemental application for a new indication for use, as described in section 505-1(g)(2)(A) of the FDCA. This assessment should include:

a) An evaluation of how the benefit-risk profile will or will not change with the new indication;

b) A determination of the implications of a change in the benefit-risk profile for the current REMS;

c) If the new indication for use introduces unexpected risks: A description of those risks and an evaluation of whether those risks can be appropriately managed with the currently approved REMS.

d) If a REMS assessment was submitted in the 18 months prior to submission of the supplemental application for a new indication for use: A statement about whether the REMS was meeting its goals at the time of that last assessment and if any modifications of the REMS have been proposed since that assessment.

e) If a REMS assessment has not been submitted in the 18 months prior to submission of the supplemental application for a new indication for use: Provision of as many of the currently listed assessment plan items as is feasible.

f) If you propose a REMS modification based on a change in the benefit-risk profile or because of the new indication of use, submit an adequate rationale to support the modification, including: Provision of the reason(s) why the proposed REMS modification is necessary, the potential effect on the serious risk(s) for which the REMS was required, on patient access to the drug, and/or on the burden on the

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
health care delivery system; and other appropriate evidence or data to support the proposed change. Additionally, include any changes to the assessment plan necessary to assess the proposed modified REMS. If you are not proposing REMS modifications, provide a rationale for why the REMS does not need to be modified.

If the assessment instruments and methodology for your REMS assessments are not included in the REMS supporting document, or if you propose changes to the submitted assessment instruments or methodology, you should update the REMS supporting document to include specific assessment instrument and methodology information at least 90 days before the assessments will be conducted. Updates to the REMS supporting document may be included in a new document that references previous REMS supporting document submission(s) for unchanged portions. Alternatively, updates may be made by modifying the complete previous REMS supporting document, with all changes marked and highlighted. Prominently identify the submission containing the assessment instruments and methodology with the following wording in bold capital letters at the top of the first page of the submission:

NDA 020687 REMS ASSESSMENT METHODOLOGY
(insert concise description of content in bold capital letters, e.g., ASSESSMENT METHODOLOGY, PROTOCOL, SURVEY METHODOLOGIES, AUDIT PLAN, DRUG USE STUDY)

An authorized generic drug under this NDA must have an approved REMS prior to marketing. Should you decide to market, sell, or distribute an authorized generic drug under this NDA, contact us to discuss what will be required in the authorized generic drug REMS submission.

We remind you that section 505-1(f)(8) of FDCA prohibits holders of an approved covered application with elements to assure safe use from using any element to block or delay approval of an application under section 505(b)(2) or (j). A violation of this provision in 505-1(f) could result in enforcement action.

Prominently identify any submission containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

NDA 020687 REMS ASSESSMENT

or

NEW SUPPLEMENT FOR NDA 020687/S-000
CHANGES BEING EFFECTED IN 30 DAYS
PROPOSED MINOR REMS MODIFICATION

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
Should you choose to submit a REMS revision, prominently identify the submission containing the REMS revisions with the following wording in bold capital letters at the top of the first page of the submission:

REMS REVISIONS FOR NDA 020687

To facilitate review of your submission, we request that you submit your proposed modified REMS and other REMS-related materials in Microsoft Word format. If certain documents, such as enrollment forms, or website screenshots are only in PDF format, they may be submitted as such, but Word format is preferred.

SUBMISSION OF REMS DOCUMENT IN SPL FORMAT

FDA can accept the REMS document in Structured Product Labeling (SPL) format. If you intend to submit the REMS document in SPL format, as soon as possible, but no later than 14 days from the date of this letter, submit the REMS document in SPL format using the FDA automated drug registration and listing system (eLIST).

For more information on submitting REMS in SPL format, please email FDAREMSwebsite@fda.hhs.gov.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
If you have any questions, call [redacted].

Sincerely,

{See appended electronic signature page}

Center for Drug Evaluation and Research

ENCLOSURE:
- REMS
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

05/14/2021 02:14:29 PM
Exhibit 29

2021 FDA Center for Drug Evaluation & Research Director Patrizia Cavazzoni Letter to Dr. Graham Chelius (Dec. 16, 2021)
December 16, 2021

Graham Chelius, M.D.
The Society of Family Planning
The California Academy of Family Physicians

Dear Dr. Chelius:

This letter is to inform you that FDA has completed its review of the Mifepristone Risk Evaluation and Mitigation System (REMS) Program. The agency has determined that the Mifepristone REMS Program continues to be necessary to ensure that the benefits of the drug outweigh the risks. However, we have determined that it must be modified to minimize the burden on the health care delivery system of complying with the REMS and to ensure that the benefits of the drug outweigh the risks. See 21 USC 355-1(g)(4)(B). The modifications to the REMS will consist of: (1) removing the requirement that mifepristone be dispensed only in certain healthcare settings, specifically clinics, medical offices, and hospitals (i.e., the “in-person dispensing requirement”); and (2) adding a requirement that pharmacies that dispense the drug be specially certified.

A REMS Modification Notification letter has been sent to both Applicants subject to the Mifepristone REMS Program. The letter describes the modifications and directs the Applicants to submit prior approval supplements within 120 days. We have also answered a related citizen petition from the American Association of Pro-Life Obstetricians and Gynecologists and the American College of Pediatricians. That response will be posted in the public docket (Docket No. FDA-2019-P-1534; available at www.regulations.gov).

Sincerely,

Patrizia Cavazzoni, M.D.
Director
Center for Drug Evaluation and Research

1 We also note your letter of September 29, 2021 to us on this subject.
Exhibit 30

Donna J. Harrison, M.D.
Executive Director
American Association of Pro-Life Obstetricians and Gynecologists
P.O. Box 395
Eau Claire, MI 49111-0395

Quentin L. Van Meter, M.D., FCP
President
American College of Pediatricians
P.O. Box 357190
Gainesville, FL 32635-7190

December 16, 2021

Re: Docket No. FDA-2019-P-1534

Dear Drs. Harrison and Van Meter:

This letter responds to your citizen petition submitted to the Food and Drug Administration (FDA or Agency) on March 29, 2019, on behalf of the American Association of Pro-Life Obstetricians and Gynecologists and the American College of Pediatricians (Petition). In the Petition, you request that FDA: (1) restore and strengthen elements of the Mifeprex regimen and prescriber requirements approved in 2000, and (2) retain the Mifeprex Risk Evaluation and Mitigation Strategy (REMS) and continue limiting the dispensing of Mifeprex to patients in clinics, medical offices, and hospitals, by or under the supervision of a certified prescriber.

Specifically, in your Petition you request that the Agency:

(1) Restore and strengthen elements of the Mifeprex regimen and prescriber requirements approved in 2000, to include the following:

- Indications and Usage - Mifeprex, in a regimen with misoprostol, for the termination of intrauterine pregnancy, should be limited to 49 days gestation.

- Dosage and Administration:
  - Mifeprex should be administered by or under the supervision of a physically present and certified physician who has ruled out ectopic pregnancy.
  - The use of Mifeprex and misoprostol for the termination of pregnancy should require three office visits by the patient.
Contraindications - Mifeprex use is contraindicated for patients who do not have convenient access to emergency medical care.

Adverse Event Reporting - Certified prescribers, emergency medical personnel, physicians treating complications, and Danco Laboratories should report to FDA’s MedWatch Reporting system any deaths, hospitalizations, blood transfusions, emergency room visits, failures requiring surgical completion, ongoing pregnancy, or other major complications following the use of Mifeprex and misoprostol.

Additional studies - The Mifeprex REMS should require a formal study of outcomes for at-risk populations, including: patients under the age of 18; patients with repeat Mifeprex abortions; patients who have limited access to emergency room services; and patients who self-administer misoprostol.

(2) Retain the Mifeprex REMS and continue limiting the dispensing of Mifeprex to patients in clinics, medical offices, and hospitals, by or under the supervision of a certified prescriber.

We have carefully considered the information submitted in your Petition and other relevant data available to the Agency. Based on our review of this information, your Petition is granted in part and denied in part.

I. BACKGROUND

A. Mifeprex

On September 28, 2000, FDA approved Mifeprex for the medical termination of intrauterine pregnancy through 49 days’ pregnancy (new drug application (NDA) 020687). The application was approved under part 314, subpart H (21 CFR part 314, subpart H), “Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses” (subpart H). Specifically, § 314.520 of subpart H provides for approval with restrictions that are needed to assure the safe use of the drug product. In accordance with § 314.520, FDA restricted the distribution of Mifeprex as specified in the September 2000 approval letter.¹

Subsequently, Mifeprex was identified as one of the products that was deemed to have in effect an approved REMS under the Food and Drug Administration Amendments Act of 2007 (FDAAA) because on the effective date of Title IX, subtitle A of FDAAA (March 28, 2008), Mifeprex had in effect elements to assure safe use.² Accordingly, in June 2011, we approved a REMS for Mifeprex, consisting of a Medication Guide, elements to assure safe use (ETASU), an implementation system, and a timetable for submission of assessments of the REMS.

Elements to assure safe use included: (1) prescriber certification (ETASU A); (2) that Mifeprex is dispensed only in certain healthcare settings by or under the supervision of a certified prescriber

² 73 FR 16313 (Mar. 27, 2008).
(ETASU C); and (3) that Mifepristone is dispensed only with documentation of safe use conditions (ETASU D). Documentation of safe use conditions consists of a Patient Agreement Form between the prescriber and the patient indicating that the patient has received counseling from the prescriber regarding the risk of serious complications associated with Mifepristone.

On March 29, 2016, we approved an efficacy supplement (S-020) to NDA 020687 for Mifepristone submitted by the applicant Danco Laboratories, LLC (S-020 efficacy supplement). The approval included changes in the dose of Mifepristone and the dosing regimen for taking Mifepristone and misoprostol (including the dose of misoprostol and a change in the route of misoprostol administration from oral to buccal (in the cheek pouch); the interval between taking Mifepristone and misoprostol; and the location at which the patient may take misoprostol). The approval also modified the gestational age up to which Mifepristone has been shown to be safe and effective, as well as the process for follow-up after administration of the drug.

Specifically, the following changes, among others, were made as part of the 2016 approval:

- Revised the dosing regimen to consist of 200 mg of Mifepristone taken by mouth, followed in 24-48 hours by 800 mcg of misoprostol taken buccally (in the cheek pouch). This differs from the originally approved dosing regimen of 600 mg of oral Mifepristone followed 48 hours later by 400 mcg of oral misoprostol.

- Revised the indication for use of Mifepristone, in a regimen with misoprostol, to extend the maximum gestational age for the medical termination of intrauterine pregnancy from 49 days to 70 days.

- Reduced the number of office visits by the patient under the approved regimen from three to one.

- Replaced the term “physician” with the term “healthcare provider.”

In addition, after reviewing the data and information submitted by the applicant in the S-020 efficacy supplement, and after taking into consideration the safety data that had become available since the initial approval of Mifepristone in 2000, we determined the Mifepristone REMS continued to be necessary to ensure the benefits of the product outweigh the risks. However, we approved modifications to the Mifepristone REMS that reflected the changes approved in the efficacy supplement. These changes to the REMS included, among others:

- Updating the Prescriber Agreement Form to reflect the revised indication and dosing regimen.

- Removing the Medication Guide as a REMS element (but retaining the Medication Guide as labeling).

---


4 See https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/020687Orig1s020RemsR.pdf.
• Removing the requirement that certified prescribers report certain enumerated adverse
events to the applicant (specifically, any hospitalization, transfusion or other serious
adverse events), but retaining the requirement that certified prescribers report all deaths to
the sponsor.

Under the March 2016 approval, the Mifeprex REMS also continued to require that Mifeprex be
dispensed to patients only in certain healthcare settings, specifically, clinics, medical offices, and
hospitals, by or under the supervision of a certified prescriber.5

B. Generic Version of Mifeprex

On April 11, 2019, we approved GenBioPro, Inc.’s generic version of Mifeprex, Mifepristone
Tablets, 200 mg (abbreviated new drug application (ANDA) 091178). This action took place after
this Petition was submitted to the Agency. As required by 21 CFR 314.94(a)(8), GenBioPro’s
approved generic version of Mifeprex, Mifepristone Tablets, 200 mg, has the same labeling (with
certain permissible differences) as the brand product it references, Mifeprex. Accordingly,
although we refer to the Mifeprex labeling in several sections of this response, our discussions in
this response apply equally to both the NDA and the generic product labeling, unless otherwise
specifically noted.6

GenBioPro’s generic version of Mifeprex is subject to the same ETASU as its listed drug (21
U.S.C. -1(i)). At the time we approved GenBioPro’s generic version of Mifeprex, that ANDA
product was required to use a single, shared system for the ETASU with the brand drug product,
Mifeprex, unless the requirement was waived by FDA (21 U.S.C. 355-1(i)). FDA did not waive
this requirement. Accordingly, at the same time that FDA approved GenBioPro’s generic version
of Mifeprex in 2019, FDA approved a supplemental new drug application (sNDA) for Mifeprex,
approving modifications to the existing, approved REMS for Mifeprex to establish a single, shared
system REMS for mifepristone products for the medical termination of intrauterine pregnancy
through 70 days gestation (referred to as the Mifepristone REMS Program). In establishing the
single, shared system REMS in 2019, no substantive changes were made to the ETASU in the
March 2016 Mifeprex REMS. References to the REMS in this response refer to the Mifepristone
REMS Program established in 2019, unless otherwise noted.

C. In-Person Dispensing Requirement During the COVID-19 PHE

5 See https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/020687Orig1s020ltr.pdf.
6 We note that Korlym and the generic version of Korlym (Mifepristone Tablets, 300 mg) contain the same
active ingredient – mifepristone - as Mifeprex and the generic version of Mifeprex (Mifepristone Tablets, 200
mg). Although these drug products contain the same active ingredient, their intended uses target different
receptors, and the products have different strengths and use different dosing regimens. Korlym and the
generic version of Korlym are approved for the control of hyperglycemia (high blood sugar levels) due to
hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes or glucose
intolerance, and have failed surgery or are not candidates for surgery. References to mifepristone in this
response refer to the use of mifepristone for the medical termination of intrauterine pregnancy through 70
days gestation, unless otherwise noted.
FDA has recognized that during the COVID-19\(^7\) public health emergency (PHE),\(^8\) certain REMS requirements for various products may be difficult to comply with because patients may need to avoid public places and patients suspected of having COVID-19 may be self-isolating and/or subject to quarantine. The Agency has also received queries concerning products with REMS that have ETASUs, including REMS with ETASUs that restrict distribution, and the impact of such ETASUs on patient access when patients self-isolate or are subject to quarantine.

In April 2021, FDA communicated its intent to exercise enforcement discretion during the COVID-19 PHE regarding the requirement in the Mifepristone REMS Program that mifepristone used for medical termination of intrauterine pregnancy through 70 days gestation be dispensed to patients by or under the supervision of a certified prescriber only in certain healthcare settings, specifically clinics, medical offices, and hospitals (referred to as the “in-person dispensing requirement”).

Specifically, FDA communicated that provided all other requirements of the Mifepristone REMS Program are met, the Agency intends to exercise enforcement discretion with respect to the in-person dispensing requirement of the Mifepristone REMS Program, including any in-person requirements that may be related to the Patient Agreement Form, during the COVID-19 PHE. This determination, which FDA made on April 12, 2021, was effective immediately. We also note that from July 13, 2020 to January 12, 2021, per a court order, FDA was enjoined from enforcing the in-person dispensing requirement of the Mifepristone REMS Program.\(^9\)

Further, and as we also communicated on April 12, 2021, to the extent all of the other requirements of the Mifepristone REMS Program are met, the Agency intends to exercise enforcement discretion during the COVID-19 PHE with respect to the dispensing of Mifeprex or the approved generic version of Mifeprex, Mifepristone Tablets, 200 mg, through the mail, either by or under the supervision of a certified prescriber, or through a mail-order pharmacy when such dispensing is done under the supervision of a certified prescriber.

FDA’s intent to exercise enforcement discretion with respect to these requirements during the COVID-19 PHE was the result of a thorough scientific review by experts within FDA’s Center for Drug Evaluation and Research (CDER), who evaluated relevant information, including available clinical outcomes data and adverse event reports.

**D. Minor Modification**

---

\(^7\) The virus has been named “SARS-CoV-2” and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19).


In response to a request submitted by the applicants, FDA approved a minor modification to the Mifepristone REMS Program on May 14, 2021. This minor modification revised the Patient Agreement Form to use gender neutral language. Specifically, the pronouns “she” and “her” in the Patient Agreement Form were replaced with “the patient.” The minor modification also included revisions to the REMS document to be consistent with the revisions to the Patient Agreement Form. These changes did not affect the substance of the Patient Agreement Form, the REMS document, or the Mifepristone REMS Program.

E. Review of the Mifepristone REMS Program

In 2021, FDA also undertook a full review of the Mifepristone REMS Program. In conducting this review, FDA reviewed multiple different sources of information, including published literature, safety information submitted to the Agency during the COVID-19 PHE, FDA Adverse Event Reporting System (FAERS) reports, the first REMS assessment report for the Mifepristone REMS Program, and information provided by advocacy groups, individuals, and the Plaintiffs in ongoing litigation, as well as information submitted by the sponsors of the NDA and the ANDA (together, the Applicants). As discussed in more detail below, based on our review of this information, FDA has determined that certain elements of the Mifepristone REMS Program remain necessary to assure the safe use of mifepristone for medical termination of intrauterine pregnancy through 70 days gestation; and therefore, the Mifepristone REMS Program continues to be necessary to ensure the benefits outweigh the risk. Specifically, we find that the healthcare provider certification and dispensing of mifepristone to patients with evidence or other documentation of safe use conditions continue to be necessary components of the REMS to ensure the benefits of mifepristone outweigh the risks for this indication.

We also find that the in-person dispensing requirement is no longer necessary to assure the safe use of mifepristone for medical termination of intrauterine pregnancy through 70 days gestation. We have concluded that mifepristone will remain safe and effective for medical abortion if the in-person dispensing requirement is removed, provided all the other requirements of the REMS are met and pharmacy certification is added. Removing the in-person dispensing requirement will render the REMS less burdensome to healthcare providers and patients, and provided all other requirements of the REMS are met, including the additional requirement for pharmacy certification, the REMS will continue to ensure that the benefits of mifepristone for medical abortion outweigh the risks. Accordingly, today we are sending a REMS Modification Notification letter to both Applicants in the Mifepristone REMS Program. As stated in that letter, FDA has concluded that a modification is necessary and must include the following changes:

- Removing the requirement that mifepristone be dispensed only in certain healthcare settings, specifically clinics, medical offices, and hospitals.

---

10 We note that the Agency is in litigation regarding the Mifepristone REMS Program and committed to conducting a full review of the Mifepristone REMS Program, including reviewing any relevant data and evidence submitted to the Agency by the Plaintiffs in that litigation (Chelius et al v. Becerra, Joint Mot. to Stay Case Pending Agency Review, ECF No. 148, May 7, 2021, Civ. No. 1:17-00493 (D. Haw.)).

11 Although we have determined that the Mifepristone REMS Program must be modified to add a requirement for pharmacy certification, this was not raised in your Petition and therefore is not discussed further in this response.
• Adding a requirement that pharmacies that dispense the drug be specially certified.

II. DISCUSSION OF ISSUES RAISED

A. Mifeprex Regimen

1. Indications and Usage

In the Petition, you ask FDA to restore and strengthen elements of the Mifeprex regimen and prescriber requirements approved in 2000, to limit Mifeprex, in a regimen with misoprostol, for the termination of intrauterine pregnancy, to 49 days gestation (Petition at 1 and 3). For the reasons explained below, we deny this request.

Citing to a 2011 study and a practice bulletin issued by the American College of Obstetricians and Gynecologists (ACOG), you state that medical abortion regimens demonstrate an increase in complications and failures, including serious risks of hemorrhage, infection, and ongoing pregnancy, after 49 days gestation (Petition at 3-4).

Our review of the S-020 efficacy supplement in 2016 concluded that Mifeprex, in a regimen with misoprostol, is safe and effective for medical termination of intrauterine pregnancy through 70 days gestation. Complete medical abortion rates from the pivotal clinical trials relied on for the initial approval of Mifeprex (with an indication for medical termination of intrauterine pregnancy through 49 days gestation) were 92.1 percent and 95.5 percent in the United States and French trials, respectively. The studies reviewed in support of the 2016 approval for Mifeprex (with an indication for medical termination of intrauterine pregnancy through 70 days gestation) showed comparable efficacy. The 2016 Clinical Review of the S-020 efficacy supplement summarized clinical outcomes and adverse effects from 22 studies (7 in the United States and 15 from outside the United States) through 70 days gestation, using the currently approved regimen of 200 mg oral mifepristone with 800 mcg buccal misoprostol. The ranges of complete medical abortion rates calculated by the clinical reviewer were 93.2 percent to 98.7 percent in the United States studies, and 92 percent to 98 percent in the non-United States studies.

Serious adverse events associated with the use of mifepristone through 70 days gestational age are rare. Per the current mifepristone labeling, the rates of serious adverse events are low: transfusions are 0-0.1 percent, sepsis is less than 0.01 percent, hospitalization related to medical abortion is 0-0.7 percent, and hemorrhage is 0.1 percent. As discussed

---

12 In this response, the terms “medical abortion” and “medication abortion” both refer to the use of mifepristone, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy.


16 See https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020687s022lbl.pdf.
throughout this response, the benefit/risk assessment supported our 2016 conclusion that the product is safe and effective through 70 days gestation.

In support of your assertion that medical abortion demonstrates an increase in complications after 49 days gestation, you cite to Mentula, et al., a register-based, retrospective cohort study that included 18,248 women in Finland who underwent medical abortion between January 1, 2003, and December 31, 2006 (Petition at 3). As an initial matter, we note that the Mentula study was primarily designed to assess the immediate adverse events following medical abortion in the second trimester (13 to 24 gestational weeks as defined by the authors) and then compare those events to those identified with medical abortion in the first trimester (up to 12 gestational weeks as defined by the authors). The study was not designed to compare rates of complications across gestational weeks within the first trimester. It is true that the Mentula publication includes information on the percentages of women who had surgical evacuation following medical abortion and the percentages of women who had infection following medical abortion, based on weekly gestational age, from 5 weeks to 20 weeks gestation. However, the data in the Mentula study are relatively old (2003-2006); in our 2016 review of the S-020 efficacy supplement, we conducted an extensive review of more recent data and concluded that Mifeprex, in a regimen with misoprostol, is safe and effective for medical termination of intrauterine pregnancy through 70 days gestation.

You also cite to ACOG Practice Bulletin No. 143, which states: “the risk of clinically significant bleeding and transfusion may be lower in women who undergo medical abortion of gestations up to 49 days compared with those who undergo medical abortion of gestations of more than 49 days.” This statement is based on a 1998 publication which evaluated patients undergoing medical abortion with mifepristone 600 mg and then oral misoprostol 400 mcg two days later. The regimen studied in this 1998 publication is not the currently approved regimen for mifepristone in the United States. Further, ACOG Practice Bulletin No. 143 has been withdrawn and replaced by Practice Bulletin No. 225, which was published in October 2020 and no longer contains this statement.

You also state that the failure rate of the approved regimen (which you refer to as the “buccal misoprostol regimen”) increases as the gestational age increases, especially at

18 Id. at Fig. 2 and Fig. 3. Surgical intervention after medical abortion and infection after medical abortion are two distinct adverse events. The calculation of abortion completion rates accounts for the need for surgical intervention. In clinical studies we reviewed, success of medical abortion was defined as the complete expulsion of the products of conception without the need for surgical intervention.
19 See 2016 Cross-Discipline Team Leader Review, available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/020687Orig1s020CrossR.pdf, at 37 (Table 4).
22 See ACOG Practice Bulletin No. 225. Medication Abortion Up to 70 Days of Gestation. Obstetrics and Gynecology 2020; 136(4); e31 to e47.
gestational ages greater than 49 days, relying on a 2015 meta-analysis, and that the gestational limit should not have been increased (Petition at 3-4). We agree that the failure rate of medical abortion regimens, including the currently approved regimen, generally increases with increasing gestational age. However, the increase in failure rate with each incremental week of gestation, as described in approved mifepristone labeling and in this 2015 meta-analysis, is small, and we believe that the benefit/risk profile for medical termination of intrauterine pregnancy between 49 and 70 days gestation remains acceptable.

For these reasons, we deny your request that FDA limit mifepristone, in a regimen with misoprostol for the termination of intrauterine pregnancy, to 49 days gestation.

2. Dosage and Administration

a. Prescriber Qualifications

You state that FDA should limit the “ability” to prescribe and dispense Mifeprex to qualified, licensed physicians, rather than permitting non-physicians to apply to be certified prescribers, because of the regimen’s serious risks and because physicians are better trained to diagnose patients who have contraindications to Mifeprex and to verify gestational age (Petition at 4). We do not agree.

Healthcare providers who are licensed to prescribe can become certified in REMS programs if they are able to meet the applicable REMS requirements. To become certified to prescribe mifepristone under the Mifepristone REMS Program, the prescriber must review the prescribing information for mifepristone and complete a Prescriber Agreement Form. By signing the form, the prescriber agrees that they meet certain qualifications, including the ability to date pregnancies accurately and to diagnose ectopic pregnancies. These healthcare providers must also: (1) be able to provide any necessary surgical intervention or have made arrangements for others to provide for such care; or (2) be able to assure patient access to medical facilities equipped to provide blood transfusions and resuscitation, if necessary.

In our review of the S-020 efficacy supplement in 2016, we determined that available data support that Mifeprex is safe and effective when prescribed by midlevel providers, such as physician assistants and nurse practitioners, as well as by physicians. Our 2016 review included four studies that evaluated the safety and efficacy of medical abortion when performed by non-physician healthcare providers. Two trials evaluated the currently

23 Petition at 4, fn. 6 (citing Chen MJ, Creinin MD, Mifepristone with Buccal Misoprostol for Medical Abortion, Obstet. Gynecol 126 (1) July 2015 12-21).
25 See 2016 Clinical Review, supra n. 13, at 79; see also 2016 Cross-Discipline Team Leader Review, supra n. 19, at 17-18. We also note that in most states, midlevel clinicians, such as physician assistants and nurse practitioners, are licensed to prescribe medications.
approved Mifepristone and buccal misoprostol regimen (Olavarrieta and Kopp Kallner);\textsuperscript{26,27} one trial studied a regimen using vaginal misoprostol (Warringer);\textsuperscript{28} a fourth study did not specify the route of misoprostol administered (Puri).\textsuperscript{29} Olavarrieta reported a completion rate of 97.9 percent when medical abortion was provided by nurses as compared with 98.4 percent with physicians. Kopp Kallner reported a completion rate of 99 percent with certified nurse midwives versus 97.4 percent with physicians. Warriner reported an abortion completion rate of 97.4 percent with nurses as compared with 96.3 percent with physicians. Puri reported an abortion completion rate of 96.8 percent when the service was provided by nurse-midwives as compared with 97.4 percent in the “standard care” group.\textsuperscript{30} Our 2016 review also included a systematic review of six controlled clinical studies by Renner;\textsuperscript{31} the authors concluded that the evidence “indicates that trained mid-level providers may effectively and safely provide first trimester surgical and medical termination of pregnancy services.” Additionally, Barnard et al., in a Cochrane systematic review, assessed the safety and effectiveness of abortion procedures administered by mid-level providers (nurse practitioners, midwives, other non-physician healthcare providers) compared to doctors.\textsuperscript{32} The authors concluded, based in part on two of the studies that we had reviewed in 2016,\textsuperscript{33} that there was no statistically significant difference in the risk of failure for medical abortions performed by mid-level providers compared with doctors.

We also believe that the identification of patients for whom the use of mifepristone is contraindicated can be done by mid-level healthcare providers, as well as physicians. Mifepristone in a regimen with misoprostol for medical termination of intrauterine pregnancy through 70 days gestation is contraindicated in patients with any of the following conditions:\textsuperscript{34}

- Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass

\textsuperscript{27} Kopp Kallner H, Gomperts R, Salomonsson E, et al. The efficacy, safety and acceptability of medical termination of pregnancy provided by standard care by doctors or by nurse-midwives: a randomised controlled equivalence trial. BJOG. 2015; 122: 510-517.
\textsuperscript{30} 2016 Clinical Review, supra n. 13, at 43.
\textsuperscript{31} Renner RM, Brahmi D, Kapp N. Who can provide effective and safe termination of pregnancy care? A systematic review. BJOG 2013 Jan;120(1):23-31.
\textsuperscript{32} Barnard S, Kim C, Park MN, Ngo TD. Doctors or mid-level providers for abortion (Review). Cochrane Database of Systematic Reviews. 2015, Issue 7.
\textsuperscript{33} Of the medical abortion studies reviewed by Barnard et al (Id.), two were reviewed by the Agency as part of the review of the S-020 supplement in 2016. See Warriner et al (supra n. 28) and Kopp Kallner et al (supra n. 27). The third used a different dose of misoprostol than the currently approved regimen. See Jejeebhoy SJ, Kalyanwala S, Zaviera AJF, Kumara R, Mundle S, Tanke J, et al. Feasibility of expanding the medication abortion provider based in India to include avurvedic physicians and nurses. International Perspectives on Sexual and Reproductive Health 2012;38(3)133-42)
\textsuperscript{34} See https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020687s022lbl.pdf.
- An intrauterine device in place
- Chronic adrenal failure
- Concurrent long-term corticosteroid therapy
- History of allergy to mifepristone, misoprostol, or other prostaglandins
- Hemorrhagic disorder or concurrent anticoagulant therapy
- Inherited porphyrias

These contraindications can be assessed by trained healthcare providers who prescribe mifepristone by obtaining a medical history, from medical records, and/or from physical examination or ultrasound if appropriate. We continue to believe that available data support the conclusion that mid-level healthcare providers, as well as physicians, possess the clinical and counseling skills necessary to provide medical abortion. We note this is consistent with ACOG’s statement in its current practice bulletin that “[i]n addition to physicians, advanced practice clinicians, such as nurse-midwives, physician assistants, and nurse practitioners, possess the clinical and counseling skills necessary to provide first-trimester medical abortion.” Further, if necessary, ultrasound training and certification is available to nurse practitioners and physician assistants, as well as physicians. In sum, available information supports that mid-level healthcare providers as well as physicians can determine whether mifepristone is an appropriate treatment for a particular patient and dispense it.

You also assert that FDA should strengthen the requirement that providers accurately assess the duration of the pregnancy by mandating that gestational age be assessed by ultrasound (Petition at 5). We refer you to FDA’s 2016 Response to the citizen petition submitted to Docket No. FDA-2002-P-0364 (the “2016 CP Response”), where FDA stated that the determination of gestational age does not always require an ultrasound. In the 2016 CP Response, FDA stated it had “determined that it was inappropriate for us to mandate how providers clinically assess women for duration of pregnancy and for ectopic pregnancy. These decisions should be left to the professional judgment of each provider, as no method (including TVS [transvaginal ultrasound]) provides complete accuracy. The approved labeling for Mifeprex recommended ultrasound evaluation as needed, leaving this decision to the judgment of the provider.”

In the Petition, you reference the Prescriber Agreement Form, in which the provider must attest they have the ability to: (1) accurately assess the duration of the pregnancy; (2) diagnose ectopic pregnancies; and (3) provide surgical intervention if needed (or have made plans to provide such care through others), and you state that a provider who does not physically meet with and examine a patient, but simply consults with the patient over the Internet, is not capable of fulfilling these requirements, or of ruling out additional

35 ACOG Practice Bulletin No. 225, supra n. 22.
contraindications (Petition at 5-6). You state that FDA should require certified prescribers to be physically present when Mifeprex is dispensed so that they can appropriately examine patients and rule out contraindications to the use of Mifeprex (Petition at 4).

Certified prescribers do not have to be physically present with the patient as long as they have confirmed the patient’s gestational age and intrauterine pregnancy. As noted above, in the 2016 CP response, FDA “determined that it was inappropriate for us to mandate how providers clinically assess women for duration of pregnancy and for ectopic pregnancy.”

Moreover, the evaluation of patients for contraindications to medical abortion does not necessarily require direct physical contact with the certified prescriber and can be done in different types of healthcare settings. A certified prescriber can also review the Patient Agreement Form with the patient, fully explain the risks of the mifepristone treatment regimen, and answer any questions, as in any consent process, without physical proximity. See also section II.B.1.c (ETASU C – In-person Dispensing).

With respect to providing surgical intervention in cases of incomplete abortion or severe bleeding and assuring patient access to medical facilities equipped to provide blood transfusions and resuscitation (if necessary), the Prescriber Agreement Form does not reflect a requirement that the certified prescriber must provide such care personally; rather, the prescriber must agree that they have the ability to provide such care or that they have made plans to provide such care through others, and that they have the ability to assure the patient has access to appropriate medical facilities. It is common practice for healthcare providers to provide emergency care coverage for other healthcare providers’ patients, and in many places, hospitals employ “hospitalists” to provide care to all hospitalized patients. We also note ACOG’s statement that “[i]n rare cases, a patient who undergoes a medication abortion may need to obtain an additional intervention, such as uterine aspiration. If the prescribing clinician does not perform the intervention, it is medically appropriate to provide a referral.”

For these reasons, we deny your request that FDA limit the “ability” to prescribe and dispense mifepristone to licensed physicians, and we deny your request that FDA require certified providers to physically meet with and examine the patient.

b. Office Visits and Administration of Mifepristone/Misoprostol

In the Petition, you state that the use of mifepristone and misoprostol should require three office visits by the patient (Petition at 7). In support of this position, you state the following:

- Drug-induced abortion is contraindicated for patients who are not available for follow-up contact or evaluation (Petition at 10).

---

38 Id.
40 ACOG Practice Bulletin Number 225 supra n. 22.
• Abortion complications are more frequent when women abort at home and more healthcare oversight is needed (Petition at 8).

• Home administration of misoprostol does not permit healthcare providers to control when their patients take misoprostol and without monitoring:
  o a patient may take buccal misoprostol before the minimum 24-hour period after taking Mifeprex, which leads to a significantly increased failure rate (Petition at 7).
  o a patient may swallow misoprostol rather than administer it buccally, and oral administration is not as effective as buccal administration in ending the pregnancy (Petition at 7).

• Because providers may now “confirm” that a patient’s drug-induced abortion was successful without a clinic visit, this increases the threat that Rh-negative patients will not receive Rhogam, which is necessary to prevent serious risks in subsequent pregnancies (Petition at 7 and 9).

We address each of these points below.

i. Follow-up Care

The safe use of mifepristone when used in the approved regimen with misoprostol is not contingent on a specific number of office visits being made by the patient undergoing a medical termination of pregnancy. The 2016 labeling change for Mifeprex regarding post-treatment assessment, including the change to the approved regimen to reduce the number of offices visits from three to one, was based on evidence reviewed in the S-020 efficacy supplement. We concluded, upon reviewing the data, that three office visits were not necessary to assure the safe use of Mifeprex.41

In your Petition, you point to statements by ACOG that medical abortion is contraindicated for patients who are not available for follow-up contact or evaluation (Petition at 8, 10). The ACOG statements you point to are from ACOG Practice Bulletin No. 143, which has been withdrawn and replaced by Practice Bulletin No. 225.42 Neither of the statements from the withdrawn Practice Bulletin nor Practice Bulletin No. 225 contraindicate medical abortion in women who are not available for an in-clinic follow-up visit. The current ACOG recommendations indicate that for medical abortion, “[f]ollow-up can be performed by telephone at 1 week, with subsequent at-home urine pregnancy testing at 4 weeks after treatment, which avoids the need for the patient to go to a facility.”43 The patient and their healthcare provider should determine the best option for follow-up as part of the consultation and consent process.44 As reflected in ACOG’s guidance, appropriate follow-

---

41 See 2016 Clinical Review, supra n. 13, at 44 and 64-67.
42 ACOG Practice Bulletin Number 225, supra n. 22.
43 Id.
44 Id.
up after medical termination of a pregnancy may be accomplished in multiple ways and not all require an in-clinic visit.

You also question findings in multiple studies that evaluated the effectiveness of semiquantitative urine pregnancy tests (multi-level pregnancy tests, or MLPT) and low sensitivity urine pregnancy tests (LSPT) to rule out on-going pregnancies and assessed the ability of patients to self-administer these tests and interpret the test results (Petition at 9-10). Overall, these studies concluded that in the majority of women, it is feasible to use a simplified test to determine if further follow-up is necessary. A recent systematic review and meta-analysis by Baiju assessed the effectiveness and safety of self-assessment of the outcome of medical abortion completed at home versus routine clinic follow-up after medical abortion, concluding self-assessment was not inferior to routine clinic follow-up. We note that this is consistent with current ACOG recommendations, which state that “follow-up can be performed by telephone at 1 week, with subsequent at-home urine pregnancy testing at 4 weeks after treatment, which avoids the need for the patient to go to a facility.”

You also assert that it is important for a patient to be under observation after taking misoprostol to ensure that they are appropriately monitored and provided sufficient pain medication (Petition at 8). You cite the World Health Organization (WHO)’s statement in guidance that up to 90 percent of women will abort within 4-6 hours after taking misoprostol; you further state that the 2000 regimen permitted patients to be in the clinic during this time period (Petition at 8). Your reference to the WHO guidance document appears to be out of context. The WHO guidance takes no position on whether women should return to and remain in the clinic during a follow-up visit for purposes of taking misoprostol; in fact, it explicitly recognizes that post-abortion care may not require a follow-up visit if the patient is adequately counseled. In the United States, and as reflected in the approved labeling, medical termination of pregnancy usually involves patients terminating the pregnancy at home, with appropriate follow-up that may not include a return visit.

ii. At Home Medical Abortion and Healthcare Oversight

In addition, you cite a 2018 study to support your statement that abortion complications are more frequent when women abort at home (Petition at 8). The study evaluated complications following medical abortion (both less than 12 weeks and more than 12 weeks gestation) as well as following surgical abortion, at one hospital in Sweden between 2008 and 2015. For the years 2008 to 2010, data were collected retrospectively; for the years

---

46 ACOG Practice Bulletin Number 225, supra n. 22.
48 Id. at Section 2.3 Post-abortion care and follow-up, at 52.
2011 to 2015, data were collected prospectively. In this study, medical abortions after 12 gestational weeks all occurred at the hospital. The authors report that, among medical abortions less than 12 weeks, the complication frequency increased from 5.4 percent (2008 to 2010) to 8.2 percent (2015). However, the authors also compared the complications related to medical abortions that occurred at less than 12 gestational weeks between “at home” abortions (managed as an outpatient) and “at the hospital” abortions, in 2015 and found no statistically significant difference (8.2 percent “at home” versus 8.0 percent at the hospital). For pregnancies less than or equal to 9 gestational weeks, the rates are similar for the “at home” group (10.0 percent) and the “at the hospital” group (9.3 percent). Notably, as part of our review and approval of the S-020 efficacy supplement in 2016, we assessed serious adverse events by gestational age, including hospitalizations, serious infection requiring hospitalization or intravenous antibiotics, bleeding requiring transfusion, and ectopic pregnancy, as reported in the literature submitted by the Applicant. We concluded that these serious adverse events are rarely reported in the literature and that the regimen of mifepristone 200 mg followed by buccal misoprostol 800 mcg in 24-48 hours is safe to approve for use through 70 days gestation.50

You also state that medical abortion is a longer process than surgical abortion and that it requires more attention and care from healthcare providers (Petition at 10). We agree that medical abortion can be a longer process than surgical abortion,51 but we disagree that medical abortion always requires in-person follow-up with a healthcare provider. Not all of the complications associated with medical abortion necessarily require more intensive management from healthcare providers during a follow-up visit. The question of whether to include an in-person follow-up visit should be discussed by the healthcare provider and the patient. We have concluded that medical abortions are safe and effective for patients who are appropriate candidates and reducing the number of clinic visits does not compromise patient safety.

The current approved labeling for mifepristone for medical termination of pregnancy states that complete pregnancy termination “can be confirmed by medical history, clinical examination, human Chorionic Gonadotropin (hCG) testing, or ultrasonographic scan.” Not all these modalities require an in-clinic assessment during a follow-up visit. Our review of the S-020 efficacy supplement concluded that “available data support … that there are a variety of follow-up modalities that can adequately identify the need for additional intervention.”52 We note that these findings are also consistent with ACOG guidelines, which state that “[r]outine in-person follow-up is not necessary after uncomplicated medication abortion” and recommend several methods for post-treatment follow-up, as appropriate, including serial serum hCG testing alone or telephone follow-up at one week after treatment followed by urine pregnancy testing at four weeks after treatment.53 Because there is more than one effective method to detect an on-going pregnancy, we conclude that the way in which post-treatment follow-up is performed may be determined by the healthcare provider and the patient.

51 See ACOG Practice Bulletin Number 225, supra note 22.
52 2016 Cross Discipline Team Leader Review, supra n. 19, at 17.
53 ACOG Practice Bulletin Number 225, supra note 22.
iii. Misoprostol

In the Petition, you make a number of assertions regarding the use of misoprostol. We address each in turn.

First, you assert that a patient may take misoprostol before the prescribed minimum 24-hour period after taking Mifeprex, thereby rendering the regimen ineffective, and that home administration of misoprostol does not permit health providers to control when their patients take misoprostol (Petition at 7). You similarly assert that the use of buccal misoprostol sooner than 24 hours after administering mifepristone leads to significantly increased failure rates (Petition at 7).

As an initial matter, our review of the S-020 efficacy supplement in 2016 included data that evaluated the home use of misoprostol in over 30,000 women. The data showed that Mifeprex was safe and effective in a regimen with misoprostol when misoprostol was self-administered at home.54 Therefore, any incorrect administration resulting in a failed abortion was infrequent and did not significantly affect the safety and efficacy of medical abortion. Furthermore, because the process of expelling the pregnancy may begin as soon as 2 hours after taking misoprostol, there is a benefit in allowing patients to choose when and where to start this process, to maximize the possibility of their being at a safe place at a convenient time to experience cramping and bleeding.55

In support of your assertion of significantly increased failure rates, you cite a pilot study by Lohr et al.56 Lohr et al. assessed the complete abortion rate using simultaneous oral mifepristone and buccal misoprostol in three gestational age groupings (less than or equal to 49 days, 50-56 days, 57-63 days) and compared the rates with those published in previous pilot investigations57 using simultaneous oral mifepristone and vaginal misoprostol in the same three gestational age groupings. The complete abortion rates reported by Lohr at 24 hours for oral mifepristone and buccal misoprostol were 72.5 percent, 69.2 percent, and 72.5 percent, respectively; the complete abortion rates at two weeks, however, were 97.5 percent, 100 percent, and 94.9 percent, respectively (and are consistent with the completion rates as described in the approved labeling).58 The published complete abortion rates at 24 hours for simultaneous oral mifepristone and vaginal misoprostol administration were 90 percent, 88 percent, and 83 percent, respectively, for the gestational age groupings and the complete abortion rates at 2 weeks were 98 percent, 93 percent, 90 percent, respectively. Based on the data presented in Lohr,

---

55 Id. at 38.
58 See https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020687s022lbl.pdf.
the use of buccal misoprostol at the same time as oral mifepristone does not adversely affect efficacy, although expulsion may be delayed. As recommended in Section 2.3 of the approved labeling, follow-up at 7-14 days after administration of mifepristone is more appropriate to evaluate efficacy. It is misleading to only reference the abortion completion rates observed at the 24-hour timepoint from Lohr. Therefore, we do not agree that data from Lohr indicate higher failure rate with misoprostol taken before the prescribed minimum 24-hour period after taking mifepristone.

Although we disagree that Lohr demonstrates a higher failure rate with misoprostol taken before 24-hours after taking mifepristone, we note that our 2016 review of the S-020 efficacy supplement referenced a 2013 systematic review by Raymond, which concluded that if the interval between mifepristone and misoprostol interval is less than or equal to 24 hours, the procedure is less effective compared to an interval of 24-48 hours. As explained above, the data reviewed in 2016 showed that Mifeprex, in a regimen with misoprostol administered at home, was safe and effective. Therefore, incorrect administration, if it occurred, was infrequent and did not significantly affect the safety and efficacy of medical abortion. However, in light of the data reviewed, section 2.1 of the labeling approved in 2016 (as well as the currently approved labeling and Medication Guide) states that there should be a “minimum 24-hour interval between” mifepristone and misoprostol (emphasis included in the labeling). The approved dosing regimen also states that misoprostol is taken within 24 to 48 hours after taking mifepristone and acknowledges that the effectiveness of the regimen may be lower if misoprostol is administered less than 24 hours after mifepristone administration.

In addition to your concerns that a woman may take misoprostol too soon after administering mifepristone, you also state that waiting until 24 hours after administering mifepristone does not guarantee success (Petition at 7-8). In support of this concern, you cite a 2015 review by Chen and Creinin. You state that this review found “women taking misoprostol earlier than 48 hours after Mifeprex are more likely to fail the regimen” (Petition at 8). Chen and Creinin included studies in which the intervals between mifepristone and buccal misoprostol were 24 hours or 24-48 hours and stated that “based on the available literature, the overall efficacy of regimens with a 24-hour interval between mifepristone and buccal misoprostol is significantly lower than those with a 24- to 48-hour interval (94.2 percent compared with 96.8 percent).” The rate differences were statistically significant, but both regimens were more effective than the 92 percent efficacy rate of the original regimen approved in 2000 (administering misoprostol 48 hours after taking mifepristone).

Finally, you also express concern that if misoprostol is self-administered, a woman may swallow it rather than keep the pill between her cheek and gum, and oral administration of

59 See https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020687s022lbl.pdf.
61 See https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020687s022lbl.pdf.
misoprostol (i.e., swallowing the pill) following the lower dose of mifepristone in the current regimen is not as effective in ending the pregnancy (Petition at 7). Winikoff et al. specifically studied the use of oral compared to buccal misoprostol 24-36 hours after mifepristone 200 mg with overall success rates of 91.3 percent and 96.2 percent, respectively. 63 Both regimens resulted in a greater than 91 percent successful medical abortion. Although the study showed decreased efficacy with oral versus buccal administration in 57-63 days gestational age, there were no statistical differences in other gestational age groupings. Even assuming there is a small proportion of women who are 57-63 days gestational age and use oral administration of misoprostol (rather than buccal as labeled), a small decrease in the reported efficacy in that population would not justify requiring a clinic visit for all women undergoing medical abortion.

Overall, studies support the efficacy of the mifepristone, in a regimen with misoprostol when taken by the patient at home, Therefore, we do not agree that an in-person visit is necessary to manage administration of misoprostol.

iii. Rh-Negative Patients

In the Petition, you state that a follow-up examination is particularly critical for Rh-negative patients and that without that follow-up examination, women will not receive Rhogam after the abortion, increasing their risk of subsequent Rh isoimmunization, which can endanger future pregnancies (Petition at 9). You suggest that a clinic visit after the administration of Mifeprex is important for Rh-negative women to receive Rhogam and that removing the required follow-up visit puts Rh-negative women at risk for isoimmunization. We do not agree.

Rh testing is standard of care in the United States and RhD immunoglobulin (such as Rhogam) should be administered if indicated. Further, administration of RhD immunoglobulin should be given within 72 hours of a sensitizing event (e.g., medical abortion). 64 However, the facility where the RhD immunoglobulin injection occurs (clinic, hospital or laboratory) is not critical. A shift from medical clinics to hospitals for administration of injections has occurred over the years due to shortages of RhD immunoglobulin and poor reimbursement for RhD immunoglobulin injection from third-party payers. 65 This has resulted in pregnant women frequently obtaining routine 28-week RhD immunoglobulin injections at hospitals/laboratories with a prescription provided by their healthcare providers. This same process of obtaining RhD immunoglobulin via prescription is available to patients after medical termination of pregnancy and does not require a follow-up clinic visit.

In summary, the totality of data on the efficacy and safety of medical abortion at less than 70 days gestation, derived from numerous studies, has characterized the complications and rates of complications for completing medical abortion at home, and the findings show medical abortion at home is both safe and effective without three office visits. We therefore deny your request that the use of mifepristone in a regimen with misoprostol require three office visits by the patient.

c. Contraindications

In the Petition, you assert that critical language contraindicating Mifeprex for patients without access to appropriate emergency medical care was excluded from the 2016 Mifeprex labeling. You cite to a study and ACOG statements as evidence that medical abortions have greater risks and more need for emergency “operation” than a surgical abortion, particularly for patients in rural areas with limited access to emergency medical care (Petition at 11).

Although inadequate access to medical facilities for appropriate care was removed from the list of contraindications in section 4 of the approved labeling when we approved the S-020 efficacy supplement, the 2016 Mifeprex labeling and the currently approved mifepristone labeling, as well as the Mifepristone REMS Program, continue to include appropriate instructions for providers regarding patient access to appropriate medical care. For example, the Boxed Warning includes language directing healthcare providers to ensure that the patient knows whom to call and what to do, including potentially going to an emergency room, if the patient experiences serious events associated with the use of mifepristone. The labeling also directs healthcare providers, as part of the dosing regimen, to give the patient the name and phone number of a healthcare provider who will be handling emergencies. In addition, one of the required qualifications listed in the Prescriber Agreement Form is the “[a]bility to provide surgical intervention in cases of incomplete abortion or severe bleeding, or to have made plans to provide such care through others, and ability to assure patient access to medical facilities equipped to provide blood transfusions and resuscitation, if necessary.” Therefore, although certain language about access to medical facilities was removed from the approved labeling in 2016, we disagree that critical language about access to appropriate emergency medical care is lacking from the approved labeling.

---

67 See Mifeprex labeling, approved 2016.
68 Id.
69 Mifepristone REMS Program,
You also cite information in Box 1, Features of Medical and Surgical Abortion (page 3) in the ACOG Practice Bulletin No. 143.\textsuperscript{70} As mentioned above, the ACOG Practice Bulletin No. 143 has been withdrawn and the language you cite is not included in the current Practice Bulletin No. 225.

d. Adverse Event Reporting

In the Petition, you assert that even under the regimen approved in 2000, it was difficult to collect accurate and complete adverse event information for Mifepristone, and that collecting such information is virtually impossible under the regimen approved in 2016 because prescribers only are required to report deaths associated with Mifepristone (Petition at 12). You also assert that FDA cannot adequately assess the safety of the current Mifepristone regimen without comprehensive information on adverse events (Petition at 12). You state that certified prescribers should at a minimum be required to report the following to FDA’s MedWatch reporting system and to the sponsor: deaths, hospitalizations, blood transfusions, emergency room visits, failures requiring surgical completion, ongoing pregnancy, or other major complications, including detailed information on these events (Petition at 13).

We acknowledge that there is always a possibility with any drug that some adverse events are not being reported, because reporting to the Agency’s MedWatch program by health care professionals and patients is voluntary. We do not agree, however, that the 2016 changes to the prescriber reporting requirements limit our ability to adequately monitor the safety of mifepristone for medical termination of pregnancy. Prior to the 2016 approval of the S-20 efficacy supplement, we assessed approximately 15 years of adverse event reports both from the Applicant and through the MedWatch program and determined that certain ongoing additional reporting requirements under the Mifepristone REMS, such as hospitalization and blood transfusions, were not warranted. This assessment was based on the well-characterized safety profile of Mifepristone, with known risks occurring rarely, along with the essentially unchanged safety profile of Mifepristone during this 15-year period of surveillance. Accordingly, the Prescriber Agreement Form was amended as part of our 2016 approval of the S-20 efficacy supplement to require, with respect to adverse event reporting, only that prescribers report any cases of death to the Applicant.

We also note that the reporting changes to the Prescriber Agreement Form as part of our 2016 approval do not change the adverse event reporting requirements for the Applicants. Like all other holders of approved NDAs and ANDAs, the Applicants are required to report all adverse events, including serious adverse events, to FDA in accordance with the requirements set forth in FDA’s regulations (see 21 CFR 314.98, 21 CFR 314.80, and 21 CFR 314.81). FDA also routinely reviews the safety information provided by the Applicants in the Annual Reports. As with all drugs, FDA continues to closely monitor the postmarketing safety data on mifepristone for the medical termination of pregnancy.

You state that FDA should provide guidance to emergency healthcare providers and physicians so that they know how to distinguish complications following drug-induced abortion from complications following spontaneous miscarriage (Petition at 13). We disagree that specific guidance is needed at this time. In the past, when appropriate, FDA has worked with the NDA Applicant to issue communications to healthcare providers and emergency department providers concerning certain serious adverse events.71 Furthermore, the approved Medication Guide advises patients to take the Medication Guide with them if they need to go to the emergency room or seek care from a healthcare provider other than the one who dispensed the medication to them, so the emergency room or healthcare provider understands the patient is having a medical abortion. We have not identified a change in the safety profile of mifepristone that would warrant additional communications to healthcare providers and emergency department providers concerning complications following medical abortion. If we become aware of safety information that merits further communications with emergency department providers or healthcare providers, or that warrants revisions to the approved labeling, we will act as appropriate.

You also assert that many Mifeprex prescribers “violate FDA protocol,” instructing their patients to lie to emergency medical personnel, and that this prevents emergency healthcare providers from appropriately caring for their patients and further decreases the likelihood that adverse events will be reported (Petition at 12). Your only support for this claim is a reference to instructions from the organization Aid Access72 to patients that they can tell emergency room staff that they had a miscarriage and do not need to tell medical staff that they had a medical abortion. The Petition does not provide any data or additional information establishing “many Mifeprex prescribers violate FDA protocol, instructing their patients to lie,” or that these providers thereby prevented appropriate care and decreased the number of adverse events reported.

**B. REMS**

**1. Request to Retain Mifeprex REMS**

In your Petition, you request that FDA retain the Mifeprex REMS (Petition at 14). We agree that a REMS is necessary to ensure that the benefits of mifepristone in a regimen with misoprostol outweigh the risks. FDA’s determination as to whether a REMS is necessary

71 See Historical Information on Mifepristone (Marketed as Mifeprex), available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111334.htm. For example, the NDA applicant and FDA agreed that there was a need to issue a Dear Health Care Provider letter in April 2002 and a Dear Emergency Room Director letter in September 2004. The fact that these letters were issued does not imply that the approved mifepristone regimen is unsafe; it is not uncommon for drug sponsors to issue “Dear Health Care Provider” letters, and, as noted in the Mifepristone Q&A document posted on our Web site in April 2002, “[w]hen FDA receives and reviews new information, the agency provides appropriate updates to doctors and their patients so that they have essential information on how to use a drug safely.”

to ensure that the benefits of a drug outweigh its risks is a complex, drug-specific inquiry, reflecting an analysis of multiple, interrelated factors and of how those factors apply in a particular case. In conducting this analysis, FDA considers whether (based on premarketing or postmarketing risk assessments) there is a particular risk or risks associated with the use of the drug that, on balance, outweigh its benefits and whether additional interventions beyond FDA-approved labeling are necessary to ensure that the drug’s benefits outweigh its risks.

As described in the background section of this response (see section I.A.), FDA determined that interventions in addition to the FDA-approved labeling were necessary to ensure that the benefits of Mifepristone outweighed its risks when the drug was initially approved in 2000, and periodic re-evaluations of the REMS since that time have reached the same conclusion. As further described in the background section of this response (see section I.E.), FDA recently undertook a review of the Mifepristone REMS Program. As explained below, the Mifepristone REMS Program continues to be necessary to ensure the benefits outweigh the risks.

After review of multiple different sources of information, including published literature, safety information submitted to the Agency during the COVID-19 PHE, FAERS reports, the first REMS assessment report for the Mifepristone REMS Program, and information provided by advocacy groups, individuals, and the Plaintiffs in ongoing litigation, as well as information submitted by the Applicants, we have concluded that the REMS can be modified to reduce the burden on the health care delivery system without compromising patient safety. As explained below, we agree that the healthcare provider certification (ETASU A) and dispensing of mifepristone to patients with evidence or other documentation of safe use conditions (ETASU D) continue to be necessary components of the REMS to ensure the benefits outweigh the risks. However, we have concluded that the Mifepristone REMS Program must be modified to remove the requirement under ETASU C that mifepristone be dispensed only in certain healthcare settings, specifically clinics, medical offices, and hospitals.

Below, we discuss each of these elements of the Mifepristone REMS Program.

a. **ETASU A – Prescriber Certification/Qualifications**

ETASU A under the Mifepristone REMS Program requires healthcare providers who prescribe mifepristone to be certified. In order to become certified, prescribers must: 1) review the prescribing information for mifepristone and 2) complete the Prescriber Agreement Form. In signing the Prescriber Agreement Form, prescribers agree they meet the qualifications listed below:

---

74 Id.
75 See supra n. 10.
• Ability to assess the duration of pregnancy accurately
• Ability to diagnose ectopic pregnancies
• Ability to provide surgical intervention in cases of incomplete abortion or severe bleeding, or to have made plans to provide such care through others, and ability to assure patient access to medical facilities equipped to provide blood transfusions and resuscitation, if necessary.
• Has read and understood the Prescribing Information of mifepristone (which the provider can access by phone or online).

In addition to meeting these qualifications, as a condition of certification the healthcare provider also agrees to follow the guidelines for use below:

• Review the Patient Agreement Form with the patient and fully explain the risks of the mifepristone treatment regimen. Answer any questions the patient may have prior to receiving mifepristone.
• Sign and obtain the patient’s signature on the Patient Agreement Form.
• Provide the patient with a copy of the Patient Agreement Form and the Medication Guide.
• Place the signed Patient Agreement Form in the patient’s medical record.
• Record the serial number from each package of mifepristone in each patient’s record.
• Report deaths to the Applicant, identifying the patient by a non-identifiable patient reference and the serial number from each package of mifepristone.

Our review of the published literature did not identify any studies comparing healthcare providers who met these qualifications with healthcare providers who did not. In the absence of such studies, there is no evidence to contradict our previous finding that prescribers’ ability to accurately date pregnancies, diagnose ectopic pregnancies, and provide surgical intervention either personally or through others, is necessary to mitigate the serious risks associated with the use of mifepristone in a regimen with misoprostol. Therefore, our conclusion continues to be that a healthcare provider who prescribes mifepristone in a regimen with misoprostol should meet the above qualifications. Absent these provider qualifications, we are concerned that serious and potentially fatal complications associated with medical abortion, including missed ectopic pregnancy and heavy bleeding from incomplete abortion, may not be detected or appropriately managed.

Accordingly, we have determined that ETASU A must remain an element of the Mifepristone REMS Program to ensure the benefits outweigh the risks. Maintaining the requirement for prescriber certification ensures that providers meet the necessary qualifications and adhere to the guidelines for use listed above. The burden of prescriber certification has been minimized to the extent possible by requiring prescribers to certify only one-time for each applicant.
Although we agree with your request to retain the REMS for mifepristone (now the Mifepristone REMS Program) insofar as it pertains to ETASU A, as discussed in section II.A.2.a of this response, we do not agree with your request that the healthcare provider needs to be a licensed physician to meet this requirement.

b. ETASU D – Requirement For The Drug To Be Dispensed With Evidence Or Other Documentation Of Safe-Use Conditions

ETASU D under the Mifepristone REMS Program requires mifepristone to be dispensed with evidence or other documentation of safe-use conditions. To receive mifepristone for medical termination of intrauterine pregnancy through 70 days gestation, the patient must sign a Patient Agreement Form indicating that the patient has received, read, and been provided a copy of the Patient Agreement Form and received counseling from the prescriber regarding the risk of serious complications associated with mifepristone for this indication. The Patient Agreement Form ensures that patients are informed of the risks of serious complications associated with mifepristone for this indication. In a number of approved REMS, Patient Agreement Forms or Patient Enrollment Forms ensure that patients are counseled about the risks of the product and/or informed of appropriate safe use conditions.76

As a condition of certification under the Mifepristone REMS Program, healthcare providers must follow the guidelines for use of mifepristone, including reviewing the Patient Agreement Form with the patient, fully explaining the risks of the treatment regimen and answering any questions the patient may have before receiving the medication. With this form, the patient acknowledges that they have received and read the form, and that they have received the counseling regarding when to take mifepristone, the risk of serious complications associated with mifepristone and what to do if they experience adverse events (e.g., fever, heavy bleeding). Both the healthcare provider and patient must sign the document and the patient must receive a copy of the signed form. In addition to the counseling described in the Patient Agreement Form, patients also receive a copy of the Medication Guide for mifepristone. Ultimately, the Patient Agreement Form serves as an important counseling component, and documentation that the safe use conditions of the Mifepristone REMS Program have been satisfied, as the prescriber is required to place the signed Patient Agreement Form in the patient’s medical record.

In addition, we conducted an updated review of published literature since 2016 to assess the utility of maintaining the Patient Agreement Form as part of the Mifepristone REMS Program, and these studies do not provide evidence that would support removing ETASU D. For these reasons, we have determined that ETASU D must remain an element of the Mifepristone REMS Program to ensure the benefits outweigh the risks.

c. ETASU C – In-Person Dispensing

ETASU C under the Mifepristone REMS Program currently requires mifepristone to be dispensed to patients only in certain healthcare settings, specifically clinics, medical offices, and hospitals, by or under the supervision of a certified prescriber. This creates what we refer to in this response as an in-person dispensing requirement under the REMS; i.e., the patient must be present in person in the clinic, medical office, or hospital when the drug is dispensed. The mifepristone REMS document currently states that mifepristone may not be distributed to or dispensed through retail pharmacies or settings other than a clinic, medical office, or hospital. As explained below, based on a recent review of the REMS, we believe that the Mifepristone REMS Program must be modified to remove the requirement that mifepristone be dispensed only in certain healthcare settings, specifically clinics, medical offices, and hospitals, because this requirement is no longer necessary to ensure that the benefits of the drug outweigh the risks. This conclusion is based on our review of information from the Mifepristone REMS Program one-year (1st) REMS77 assessment data and postmarketing safety information, and supported by our review of the published literature.

i. Assessment Data

As part of our review of the REMS, we evaluated information included in the 1st REMS assessment report for the Mifepristone REMS Program, which included healthcare provider certification data, program utilization data, and non-compliance data. This 1st REMS assessment report covers a reporting period between April 11, 2019 through February 29, 2020. During this reporting period, a small number of non-compliance events were reported.

As described in section I.C. of this response, during the timeframe from January 27, 2020 through September 30, 2021, there were periods when the in-person dispensing requirement was not enforced. To better understand whether there was any impact on safety or non-compliance during the periods when the in-person dispensing requirement was not enforced, we requested additional information from the Applicants to provide for more comprehensive assessment of the REMS for the time period from January 27, 2020 (the effective date of the COVID-19 PHE) to September 30, 2021. We requested the Applicants provide a summary and analysis of any program deviation or non-compliance events from the REMS requirements and any adverse events that occurred during this time period that had not already been submitted to FDA. The NDA and the ANDA Applicants reported a total of eight cases reporting adverse events between January 27, 2020 and September 30, 2021. These eight cases were also identified in the FAERS database and are described below.

The number of adverse events reported to FDA during the COVID-19 PHE with mifepristone use for medical termination of pregnancy is small, and the data provide no

---

77 This REMS assessment report was the first submitted following the approval of the single, shared system REMS for mifepristone.
indication that any program deviation or noncompliance with the Mifepristone REMS Program contributed to these reported adverse events.

ii. FAERS/Postmarketing Safety Data

FDA routinely monitors postmarketing safety data for approved drugs through adverse events reported to our FAERS database, through our review of published medical literature, and when appropriate, by requesting applicants submit summarized postmarketing data. For our recent review of the REMS, we searched our FAERS database, reviewed the published medical literature for postmarketing adverse event reports for mifepristone for medical termination of pregnancy, and requested that the Applicants submit a summary and analysis of certain adverse events. Our review of this postmarketing data indicates there have not been any new safety concerns with the use of mifepristone for medical termination of pregnancy through 70 days gestation, including during the time when in-person dispensing was not enforced.

In order to evaluate the periods when in-person dispensing was and was not enforced, we conducted a search of the FAERS database and the published medical literature to identify U.S. postmarketing adverse events that reportedly occurred from January 27, 2020 through September 30, 2021 with mifepristone use for medical termination of pregnancy. The data for this time period were then further divided into the date ranges when in-person dispensing was enforced per the REMS (January 27, 2020 - July 12, 2020 and January 13, 2021 - April 12, 2021) versus when in-person dispensing was not enforced: July 13, 2020 - January 12, 2021 (in-person dispensing enforcement was temporarily enjoined) and April 13, 2021 - September 30, 2021 (enforcement discretion for in-person dispensing because of the COVID-19 PHE).

Based on the above search, a total of eight cases were identified in FAERS and no additional case reports were identified in the medical literature. Two of the eight cases reported adverse events that occurred when in-person dispensing was being enforced (i.e., January 27, 2020-July 12, 2020 and January 13, 2021-April 12, 2021). These two cases reported the occurrence of uterine/vaginal bleeding (case 1) and uterine/vaginal bleeding and sepsis (case 2). Of note, uterine/vaginal bleeding and sepsis are labeled adverse events. Five of the eight cases reported adverse events that occurred when in-person dispensing was not enforced (i.e., July 13, 2020-January 12, 2021 and April 13, 2021-September 30, 2021); however, the narratives provided in the FAERS reports for three of the five cases explicitly stated that mifepristone was dispensed in-person. These five cases reported the occurrence of ongoing pregnancy (case 3), drug intoxication and death approximately 5 months after ingestion of mifepristone (case 4), death [cause of death is currently unknown] (case 5), sepsis and death (case 6), and pulmonary embolism (case 7). Of note, ongoing pregnancy and sepsis, including the possibility of fatal septic shock, are labeled adverse events. The remaining case reported the occurrence of oral pain/soreness (case 8) in July

---

78 FAERS is a database that contains adverse event reports, medication error reports and product quality complaints resulting in adverse events that were submitted to FDA. The database is designed to support FDA’s post-marketing safety surveillance program for drug and therapeutic biologic products.
2021, but did not provide sufficient information to determine the exact date of the adverse event.

As discussed in section II.A.2.d., the Applicants report adverse events, including serious adverse events, to FDA in accordance with applicable regulations.\(^{79}\) To enable additional review of adverse events, Applicants were requested to provide a summary and analysis for adverse events reported with incomplete medical abortion requiring surgical intervention to complete abortion, blood transfusion following heavy bleeding or hemorrhage, ectopic pregnancies, sepsis, infection without sepsis, hospitalization related to medical abortion, and emergency department/urgent care encounter related to medical abortion. The Applicant for Mifeprex provided the requested summary of postmarketing safety information from March 29, 2016, when S-020 was approved, through September 30, 2021. The Applicant for the generic provided the requested summary of postmarketing safety information from April 11, 2019 (date of initial approval) through September 30, 2021. The information provided by the Applicants included the same cases identified in FAERS, as discussed above.

We analyzed the FAERS data referenced above to determine if there was a difference in adverse events when in-person dispensing was and was not enforced. Based on FDA’s review of this data, we concluded that there does not appear to be a difference in adverse events when in-person dispensing was and was not enforced and that mifepristone may be safely used without in-person dispensing. FDA’s review of the summary and analysis data submitted by the Applicants (which, as noted above, included the same cases identified from FAERS) did not change this conclusion.

iii. Published Literature

As noted above, we also conducted an extensive review of the published literature since March 29, 2016 (the date the S-020 efficacy supplement for Mifeprex was approved) through September 30, 2021.\(^{80}\) Published studies have described alternatives in location and method for dispensing mifepristone by a certified prescriber (or equivalent healthcare provider in countries other than the United States). Some studies have examined replacing in-person dispensing in certain healthcare settings with dispensing at retail pharmacies.\(^{81}\)

\(^{79}\) See 21 CFR 314.98, 21 CFR 314.80, and 21 CFR 314.81.

\(^{80}\) In support of your request that we retain the REMS and continue limiting the dispensing of Mifeprex to patients in clinics, medical offices, and hospitals by or under the supervision of a certified prescriber, you reference two studies that you assert do not comply with the REMS (Petition at 19-22). Outcomes from both of the studies you reference have been reported in the published literature and are addressed in the discussion that follows. We note that as a general matter, a clinical investigation of an approved drug that is subject to a REMS can take place in healthcare settings outside those provided for in the REMS. When an approved drug that is subject to a REMS is studied in a clinical trial, the REMS does not apply to the use of the drug in that clinical trial. However, FDA reviews the protocol to ensure that it will be conducted in a manner that adequately addresses the risks that the REMS is intended to mitigate, such that the trial participants will not be exposed to an unreasonable and significant risk of illness or injury. See 21 CFR 312.42(b)(1)(i) and (b)(2)(i).

and dispensing mifepristone from pharmacies by mail. Other studies have evaluated two modes of dispensing by prescribers: (1) prescribers mailing the medications to patients, and (2) prescribers using couriered delivery of medications. Different studies have evaluated dispensing mifepristone by mail by an entity described as “a partner organization.”

We note that the ability to generalize the results of these studies to the United States population is hampered by differences between the studies with regard to pre-abortion care (e.g., telemedicine versus in-person). In addition, the usefulness of the studies is limited in some instances by small sample sizes and lack of follow-up information on outcomes with regard to both safety and efficacy. There are also factors which complicate the analysis of the dispensing element alone. Some of these factors are: (1) only a few studies have evaluated alternatives for in-person dispensing of mifepristone in isolation (for example, most studies on mail dispensing of mifepristone also include telemedicine consultation); and (2) because most serious adverse events with medical abortion are infrequent, further evaluation of changes in dispensing would require studies with larger numbers of participants. We did not find any large clinical studies that were designed to collect safety outcomes in healthcare systems similar to the United States. Despite the limitations of the studies we reviewed, we have concluded that overall the outcomes of these studies are not inconsistent with our conclusion that, based on the 1st year REMS assessment report and postmarketing safety data, mifepristone will remain safe and efficacy will be maintained if the in-person dispensing requirement is removed from the Mifepristone REMS Program.
Below is a summary of our review of the literature, organized by the methods of dispensing mifepristone that were studied.

(a) Retail pharmacy dispensing

Three studies reported medical abortion outcomes for retail pharmacy dispensing of mifepristone after clinical evaluation (Grossman, Rocca, Wiebe). Grossman conducted a US-based study in which mifepristone and misoprostol were dispensed from a pharmacy partnered with the clinic. Complete abortion without additional procedures occurred in 93.5 percent of participants with known outcomes. The reported proportion of complete abortion is within the range described in the approved mifepristone labeling. No participants experienced a serious adverse event, were hospitalized or required transfusion. Three participants had emergency department (ED) visits with treatment (intravenous hydration, pain medication, pelvic infection after uterine aspiration for incomplete abortion). The study safety and efficacy outcomes are consistent with labeled outcome frequencies. The study has limited generalizability because it was conducted in two US states and involved partnered pharmacies, some of which were in the same building as the clinic. Additionally, all participating pharmacies in this study were required to have a pharmacist on duty during clinic hours who had been trained in the study protocol and was willing to dispense mifepristone. The study conditions may not be generalizable to United States retail pharmacies; there is insufficient information to assess this.

Rocca conducted an observational study evaluating participants who obtained medical abortions in Nepal by comparing the provision of medical abortion service by newly trained nurse midwives in pharmacies to medical abortion provided in government-certified clinics. The authors reported that, with respect to complete abortion (greater than 97 percent) and complications (no hospitalizations or transfusions), evaluation and dispensing in pharmacy was non-inferior to in-clinic evaluation and dispensing.

Wiebe, in a retrospective, chart review study conducted in Canada, compared abortion outcomes of women who underwent medical abortion with telemedicine consult, and either received medications by courier or picked them up at a local pharmacy, with outcomes of a matched control cohort of women who received the medications at a pharmacy after an in-clinic visit. The groups had similar documented complete medical abortion outcomes (equal to or greater than 95 percent participants with known outcomes). The telemedicine group had one case of hemorrhage (0.5 percent) and one case of infection requiring antibiotics (0.5 percent) compared with no cases of hemorrhage or infection requiring antibiotics in the in-clinic cohort. The telemedicine group had more ED visits (3.3 percent compared to 1.5 percent in-clinic cohort). Both models of dispensing mifepristone resulted in efficacy and safety outcomes within labeled frequency.

---

86 Grossman et al., supra n. 81.
87 Rocca et al., supra n. 81.
88 Wiebe et al., supra n. 81.
89 Rocca et al., supra n. 81.
90 Wiebe et al., supra n. 81.
None of the three studies allow a determination regarding differences in safety between in-person dispensing by a certified prescriber in a health care setting and dispensing through a retail pharmacy, due to limitations on the generalizability of the results of the studies to the current retail pharmacy environment in the United States. The outcome findings from the one United States study (Grossman)\(^9\), in which the pharmacies were partnered with prescribers, are unlikely to be broadly generalizable to the current retail pharmacy environment and do not reflect typical prescription medication availability with use of retail pharmacy dispensing. For the retail pharmacy dispensing study in Canada (Wiebe),\(^9\) timely provision of medication from the retail pharmacy was accomplished by either courier to the woman or faxed prescription to the woman’s pharmacy. It is unknown whether conditions that would allow timely access to medications for medical abortion would occur in retail pharmacies throughout the United States, suggesting the findings from that study may not be broadly generalizable. The third study (Rocca)\(^9\) evaluated medical abortion provided in Nepali pharmacies and essentially moved the abortion provider and clinical examination into the pharmacy, a scenario that is not, at this time, applicable to the United States retail setting.

**(b) Mail order pharmacy**

Three studies evaluated mail order pharmacy dispensing (Grossman,\(^9\) Upadhyay,\(^9\) Hyland\(^9\)). Grossman published an interim analysis of an ongoing prospective cohort study evaluating medical abortion with mifepristone and misoprostol dispensed by mail-order pharmacy after in-person clinical assessment. Complete abortion without additional procedures occurred in 96.9 percent of participants with known outcomes. Two (0.9 percent) participants experienced serious adverse events; one received a blood transfusion and one was hospitalized overnight. Nine (4 percent) participants attended 10 ED visits. In this interim analysis, the outcomes are consistent with labeled frequencies.

Upadhyay\(^9\) reports findings from a retrospective cohort study of women undergoing medical abortion in the United States without a consultation or visit. Eligibility was assessed based on a participant-completed online form collecting pregnancy and medical history. Participants who were considered eligible received medication delivered by a mail-order pharmacy. Abortion outcome was determined by either an assessment on day 3 or a 4-week pregnancy test. The investigators reported a complete abortion rate without additional procedures of 95 percent for participants with known outcomes and stated that no participants had any major adverse events. The proportion of abortion outcomes assessed at 3 days versus 4 weeks is not reported. Regardless, determining outcomes at 3 days is insufficient to determine outcome rates or safety findings because a 3-day follow-up period is too short. As recommended in Section 2.3 of the approved labeling, follow-up at

---

\(^9\) Grossman et al., supra n. 81.
\(^9\) Wiebe et al., supra n. 81.
\(^9\) Rocca et al., supra n. 81.
\(^9\) Grossman et al, supra n. 82.
\(^9\) Upadhyay et al., supra n. 82.
\(^9\) Hyland et al., supra n. 82.
\(^9\) Upadhyay et al., supra n. 82.
7-14 days after administration of mifepristone is more appropriate to evaluate safety and efficacy. This study used a model with numerous deviations from standard provision of medical abortion in the United States, such as no synchronous interaction with the prescriber during informed consent or prior to prescribing medication and no confirmation of self-reported medical, surgical, and menstrual history. These deviations, limited follow-up information, and small sample size limit the usefulness of this study.

Hyland\textsuperscript{98} describes findings from a cohort study in Australia evaluating medical abortion outcomes utilizing telemedicine and a central mail order pharmacy. Complete abortions without additional procedures occurred in 96 percent of participants with documented outcomes and is consistent with labeled efficacy. Of the participants included in the analysis, 95 percent had no face-to-face clinical encounters after medications were mailed while 3 percent were admitted to the hospital and 2 percent had an outpatient encounter. One participant who was hospitalized and underwent a surgical uterine evacuation received a transfusion. Not included in the findings are 7 hospitalizations occurring in 7 participants who did not have “full follow up.” The authors do not report any other adverse events and conclude use of the telemedicine medical abortion service is safe. However, the reasons for hospitalization are not discussed by the authors; therefore, it is unknown why the patients were hospitalized. Although the reported frequency of hospitalizations (3 percent) is higher than the less than 1 percent in the FDA-approved mifepristone labeling, conclusions on the safety findings cannot be made in the absence of information about the reasons for hospitalization. Other limitations of this study include incomplete information about outcomes with face-to-face encounters.

Overall, the three studies evaluating mail order pharmacy dispensing suggest that efficacy of medical abortion is maintained with mail order pharmacy dispensing. With respect to safety, in the Grossman study\textsuperscript{99} the interim analysis, although small, does not raise serious safety concerns. Safety findings from the Hyland\textsuperscript{100} study are difficult to interpret. Although only one transfusion is reported and the authors state the findings demonstrate safety, a higher hospitalization rate and lack of information on the reasons for hospitalization preclude reaching any conclusions about the safety findings. Lastly, the Upadhyay\textsuperscript{101} study had no reported adverse events, but the findings are less useful because of the limited follow-up, and because medical abortions were provided using a model with numerous deviations from standard provision of medical abortion in the United States.

(c) Clinic dispensing by mail

A total of five studies evaluated clinic dispensing by mail. Gynuity Health Projects conducted a prospective cohort study (the “TelAbortion” study) evaluating use of telemedicine for remote visits and mifepristone being dispensed from clinics via overnight or regular tracked mail. Three publications reviewed have reported outcomes for the Gynuity population exclusively: Raymond (outcomes from May 2016 to December

\textsuperscript{98} Hyland et al., supra n. 82.
\textsuperscript{99} Grossman et al., supra n. 82.
\textsuperscript{100} Upadhyay et al., supra n. 82.
\textsuperscript{101} Hyland et al., supra n. 82.
Chong (outcomes from May 2016 to September 2020)\textsuperscript{102} and Anger (outcomes from March 2020 to September 2020).\textsuperscript{104} A fourth study, Kerestes,\textsuperscript{105} reports outcomes of medical abortion at the University of Hawai‘i from April 2020 to November 2020 and a fifth study, Aiken (2021)\textsuperscript{106} reports outcomes of medical abortion up to 70 days gestational age in the United Kingdom before and during the COVID-19 PHE in a retrospective cohort study.

In Raymond,\textsuperscript{107} complete abortion without additional procedures occurred in 93 percent of participants with known outcomes. There were two hospitalizations (one participant received a transfusion for severe anemia despite having had a complete abortion) and 7 percent of participants had clinical encounters in ED/urgent care centers. The reported outcomes are similar to outcomes described in approved labeling except the combined ED/urgent care center encounters (7 percent) exceeded the ED visits in approved labeling (2.9-4.6 percent).\textsuperscript{108} Of note, the authors state that half of the ED/urgent care visits did not entail any medical treatment. In Chong,\textsuperscript{109} approximately 50 percent of the medical abortions occurred during the period of the COVID-19 PHE. Complete abortion without an additional procedure occurred in 95 percent of those with known outcomes. Transfusions were 0.4 percent and hospitalizations were 0.7 percent; 6 percent of participants had unplanned clinical encounters in ED/urgent care. Surgical interventions were required in 4.1 percent to complete abortion. The reported outcomes in Chong (which updated the findings described in Raymond) are similar to outcomes described in approved labeling except that (as with the Raymond study it updated) the combined ED/urgent care center encounters (6 percent) exceeded the ED visits in approved labeling (2.9-4.6 percent).

Anger,\textsuperscript{110} which compared outcomes among participants enrolled in the Gynuity study who did ("test medical abortion cohort") versus did not ("no-test medical abortion cohort")\textsuperscript{111}

\begin{footnotesize}
\begin{enumerate}
\item Raymoed et al., supra n. 83.
\item Anger et al., supra n. 83.
\item Raymond, supra n. 83.
\item The authors reported the combined frequency of emergency department/urgent care visits, whereas the approved labeling includes the frequency for emergency department (emergency room) visits. Therefore it is unknown whether the frequency of emergency department visits in the trial, as distinct from the combined frequency of emergency department/urgent care visits, is comparable to the frequency of emergency department visits reflected in approved labeling.
\item Chong et al., supra n. 103.
\item Anger et al., supra n. 83.
\item "No-test medication abortion” refers to medical abortion provided without a pretreatment ultrasound, pelvic examination or laboratory tests when, in the judgment of the provider, doing so is medically appropriate (appropriateness based on history and symptoms); “no-test medication abortion” does include post-abortion follow up. A sample protocol is described by Raymond et al.” (Raymond EG, Grossman D, Mark A, et.al. Commentary: No-test medication abortion: A sample protocol for increasing access during a pandemic and beyond. Contraception 2020;101:361-366)
\end{enumerate}
\end{footnotesize}
have confirmation of gestational age/intruterine location with an examination or ultrasound, found that those without an examination or ultrasound prior to medical abortion were more likely to require procedural interventions and had more unplanned clinical encounters.\textsuperscript{112} There were no reported ectopic pregnancies in either group. The number of ED/urgent care visits and the proportion of unplanned clinical encounters that led to medical treatment were not reported. In the “test” group, complete medical abortion was confirmed in 98 percent of participants with known outcomes; one participant was “hospitalized and/or blood transfusion” and 8 percent had an unplanned clinic encounter (participant sought in-person medical care related to abortion and the visit was not planned prior to abortion). In the “no-test” group, complete medical abortion was confirmed in 94 percent of participants with known outcomes; two participants were “hospitalized and/or blood transfusion” and 12.5 percent had an unplanned clinical encounter.

Kerestes\textsuperscript{113} included three different delivery models: traditional in-person visits, telemedicine consultation with in-person pick-up of medications, and telemedicine consultation with delivery of medications by mail (most of the latter were enrolled through Gynuity’s TelAbortion study). Among participants with follow-up data, the rates of successful medical abortion without surgery were consistent with outcomes in approved labeling. Blood transfusion was given to two participants (both in the telemedicine plus in-person pickup group). Although ED visits occurred the most frequently in the telemedicine plus mail group (four participants or 5.8 percent) and the least in the in-person group (two participants or 2.1 percent), the study reported no increases in other serious adverse events. Aiken (2021)\textsuperscript{114} reported outcomes before and during the pandemic in a retrospective cohort study in the United Kingdom. The study compared the two cohorts: one before the pandemic with in-person visits and dispensing (traditional model) and one during the pandemic with either an in-person visit and in-person dispensing or a telemedicine visit and dispensing by mail or picked up from the clinic (hybrid model). Complete abortion occurred in greater than 98 percent in both cohorts; the rate was slightly higher in the telemedicine group than in the in-person group. There were no significant differences in the rates of reported serious adverse events. The investigators’ analysis determined that the efficacy and safety were comparable between both cohorts and concluded the hybrid model for medical abortion is effective and safe.

Taken together, data from the three Gynuity study reports (Raymond, Chong, and Anger), Kerestes, and Aiken (2021) support that efficacy of medical abortion was maintained when mifepristone was dispensed by mail from the clinic. Study reports of Raymond, Chong, and Kerestes all suggest there may be an increase in ED/urgent care visits with telemedicine visits and dispensing by mail from the clinic, but without increases in other serious adverse events. Anger’s comparative analysis suggests a pre-abortion examination may decrease the occurrence of procedural intervention and decrease the number of unplanned visits for postabortion care. The Aiken (2021) study appears to be of sufficient

\textsuperscript{112} We note that the two cohorts were not randomized in the Anger study; they had different baseline characteristics. Consequently, findings based on the comparisons between the two cohorts should be interpreted carefully.

\textsuperscript{113} Kerestes et al., supra n. 105.

\textsuperscript{114} Aiken et al., supra n. 106.
sample size to determine whether safety outcomes with mail dispensing differ from in-
person dispensing; however, significant limitations include that the analysis was based on
deidentified information and the investigators were unable to verify the outcomes extracted.
Further, the study’s design did not capture all serious safety outcomes, thus limiting the
certainty of the findings.

Notwithstanding the limitations discussed above, these studies overall support that
dispersing by mail from the clinic is safe and effective. Although the literature suggests
there may be more frequent ED/urgent care visits related to the use of mifepristone when
dispensed by mail from the clinic, there are no apparent increases in other serious adverse
events related to mifepristone use.

(d) Clinic dispensing by courier

Reynolds-Wright\textsuperscript{115} reported findings from a prospective cohort study of participants at less
than 12 weeks gestational age in Scotland undergoing medical abortion at home that
provided mifepristone for pick up at the service or by couriered delivery to woman’s home.
The outcomes from this study in Scotland are consistent with the outcomes in the approved
mifepristone labeling. However, the number of couriered deliveries was not reported. Thus
this study does not provide abortion outcomes separately for couriered delivery of
mifepristone and misoprostol. The study shares the same limitations as the Aiken (2021)
study; the study's design did not capture all serious safety outcomes, thus limiting the
certainty of the findings.

(e) Partner organization dispensing by mail

Women on Web (WoW), an internet group, connects patients and providers outside of the
US and provides medical abortion globally, dispensing mifepristone through “a partner
organization” by mail. WoW uses a model with numerous deviations from the standard
provision of medical abortion in the United States. For example, this model has no
synchronous interaction with the prescriber during informed consent or prior to prescribing
medication and no confirmation of self-reported medical, surgical, and menstrual history or
confirmed pregnancy testing. Three studies (Endler, Norten, and Aiken (2017))\textsuperscript{116} reported
outcomes based on dispensing through this model. Endler and Norten reported outcomes
from WoW cohorts but do not provide relevant information on mifepristone dispensing by
mail because neither provide meaningful outcomes data for consideration. Although Aiken
(2017) is a large cohort study, the outcomes are self-reported and an unusually high rate of
outcomes are unaccounted for; these limitations result in the data being insufficient to
determine the safety of dispensing mifepristone by mail though a partner organization.

In sum, there are insufficient data from the literature we have reviewed to determine the
safety and efficacy of dispensing from a retail pharmacy, by courier, or by a partner
organization. With respect to dispensing mifepristone by mail, our review of the literature
indicates that dispensing mifepristone by mail from the clinic or from a mail order

\textsuperscript{116} Endler et al., Norten et al., and Aiken et al., supra n. 85.
pharmacy does not appear to jeopardize the efficacy of mifepristone for medical abortion. While the studies we reviewed are not adequate on their own to establish the safety of the model of dispensing mifepristone by mail, the safety and efficacy outcomes reported in these studies remain within the ranges labeled for the approved mifepristone products. Although the literature suggests there may be more frequent ED/urgent care visits related to the use of mifepristone when dispensed by mail from the clinic, there are no apparent increases in other significant adverse events related to mifepristone use.

Based on the REMS assessment data, FAERS data from the time period when the in-person dispensing requirement was not being enforced, and our review of the literature, we conclude that mifepristone will remain safe and effective if the in-person dispensing requirement is removed, provided all the other requirements of the REMS are met and pharmacy certification is added. Removing the in-person dispensing requirement will render the REMS less burdensome to healthcare providers and patients, and provided all other requirements of the REMS are met, including the additional requirement for pharmacy certification, the REMS will continue to ensure that the benefits of mifepristone for medical abortion outweigh the risks. Therefore, to reduce the burden imposed by the Mifepristone REMS Program, the REMS must be modified to remove the in-person dispensing requirement, which would allow, for example, dispensing of mifepristone by mail via certified prescribers or pharmacies, in addition to in-person dispensing in clinics, medical offices and hospitals as currently outlined in ETASU C.

In your Petition, you state that “[e]liminating or relaxing the REMS to facilitate Internet or telephone prescriptions would be dangerous to women and adolescent girls” and that “health care providers prescribing abortion-inducing drugs over the Internet or phone or before a patient is even pregnant cannot adequately evaluate patients for contraindications to the drugs” (Petition at 18-19).

We do not agree that eliminating the REMS requirement for the dispensing of Mifeprex in certain healthcare settings will be dangerous to patients, nor do we agree that doing so will affect the ability of healthcare providers to evaluate women for contraindications to mifepristone in a regimen with misoprostol for medical termination of intrauterine pregnancy through 70 days gestation. There are many factors that contribute to patient safety, including evaluation of a patient, informed consent, development of a follow-up plan, and provision of a contact for emergency care. All of these can occur in many types of healthcare settings. The evaluation of patients for contraindications to medical abortion does not necessarily require direct physical contact with the certified prescriber.

You also assert that telemedicine abortion absolves abortion providers of responsibility for the well-being of their patients (Petition at 19). We do not agree. Healthcare providers who prescribe mifepristone are responsible for the well-being of their patients regardless of mode of evaluation or dispensing of medication. The Agency agrees with the American Medical Association that a healthcare provider-patient relationship is entered when the “physician serves a patient’s medical needs;”[117] in the context of medical abortion, this

healthcare provider-patient relationship continues until resolution of the pregnancy or transfer of care to another healthcare provider.\textsuperscript{118}

We also note that patients who are not pregnant at the time of evaluation would not be appropriate candidates for being prescribed mifepristone for medical termination of pregnancy because they do not fulfill the approved indication of having an intrauterine pregnancy of up to 70 days gestation.

2. Other Safety Issues and Additional Studies

In support of your request that we retain the Mifeprex REMS, you cite the Council for International Organizations of Medical Sciences’ (CIOMS) definition of “rare” to assert that because “about 1 out of 100 women” using Mifeprex and misoprostol require surgery, serious complications are common, not rare (Petition at 15-16).\textsuperscript{119} Although we agree that certain elements of the Mifepristone REMS Program are necessary to assure the safe use of mifepristone, we do not agree with your assertion.

In the Petition, you state that the Medication Guide improperly downplays the risks of the use of Mifeprex in a regimen with misoprostol and you cite the Medication Guide as stating “rarely, serious and potentially life-threatening bleeding, infections, and other problems can occur following medical abortion.” Specifically, ‘in about 1 out of 100 women [administered Mifeprex and misoprostol] bleeding can be so heavy that it requires a surgical procedure.” (Petition at 15). Using these two separate statements in the Medication Guide, you argue that the CIOMS’s definition of rare (“1 out of 1000”) means that if 1 out of 100 women using Mifeprex in a regimen with misoprostol require surgery, serious complications are common, not rare. (Petition at 16). However, your reference to the two sentences in the Medication Guide conflates two different clinical scenarios: (1) the adverse event of serious and potentially life-threatening bleeding, and (2) treatment failure.

The first sentence you reference states: “Although cramping and bleeding are an expected part of ending a pregnancy, rarely, serious and potentially life-threatening bleeding, infections, or other problems can occur following a miscarriage, surgical abortion, medical abortion, or childbirth.” This statement refers to life-threatening adverse events that can occur during termination regardless of gestational age or during miscarriage or childbirth regardless of the mode of delivery (e.g., vaginal delivery or cesarean section). At the time of our review of the clinical studies submitted to support the S-020 efficacy supplement, the reported rate of death in the studies reviewed, based on one death, was 0.007 percent (very rare under the CIOMS definition).\textsuperscript{120} The rate of infections requiring hospitalization or

\textsuperscript{118} See \url{https://www.ama-assn.org/delivering-care/ethics/ethical-practice-telemedicine}.


\textsuperscript{120} Id. at 36 (defining the “very rare” standard category of frequency as less than 0.01 percent).
intravenous antibiotics was less than 0.1 percent (rare under the CIOMS definition), and rates of transfusion were 0.03-0.7 percent (rare to uncommon under the CIOMS definition). Therefore, “rarely” accurately refers to the frequency of the adverse events referenced in this statement.

The second sentence you reference from the Medication Guide states: “In about 1 out of 100 women, bleeding can be so heavy that it requires a surgical procedure (surgical aspiration or D&C).” This statement refers to the rate of surgical procedures for bleeding following treatment with mifepristone. Heavy bleeding or hemorrhage after medical abortion is a small subset of bleeding and can require a surgical procedure due to ongoing pregnancy or incomplete expulsion; these are considered failed treatment rather than adverse events and are not characterized using the CIOMS definitions. Even if heavy, bleeding after medical abortion may not be considered a serious adverse event unless clinically diagnosed as hemorrhage or requiring a transfusion. Furthermore, in the vast majority of medical abortions, surgical intervention is not necessary.

You also cite a 2009 study and a 2018 study to assert that medical abortions carry greater risks than surgical abortions (Petition at 16). The 2009 Niinimaki, et al. study reported overall incidences of immediate adverse events (up to 42 days) in medical and surgical abortions performed in women undergoing induced abortion from 2000-2006 based on data from the Finnish national registries. We agree that the overall incidence of adverse events for medical abortion was fourfold higher when compared with surgical abortion (20.0 percent versus 5.6 percent). Specifically, the incidence of hemorrhage, incomplete abortion, and surgical (re)evacuation were higher for medical abortion. However, the authors specifically noted that because medical abortion is associated with longer uterine bleeding, the high rate of events, which were pulled from a national registry reflecting both inpatient and outpatient visits, is not surprising. They opined that uterine bleeding requiring surgical evacuation probably better reflects the severity of bleeding after termination of pregnancy; the incidence of such bleeding was relatively low, although it was more common with medical abortion. In addition, the authors acknowledged there are inherent weaknesses in registry-based studies; there is variable reliability both of diagnoses and of severity of diagnoses. Nevertheless, the authors concluded that both methods are generally safe and recommended discussing the adverse event profiles of different methods when counseling women seeking pregnancy termination.

We note that Ireland, et al. reported findings from a more recent retrospective cohort study of 30,146 United States women undergoing pregnancy termination before 64 days of gestation from November 2010 to August 2013. Efficacy of pregnancy termination was 99.6 percent and 99.8 percent for medical and surgical abortion, respectively.

121 Id. at 36 (defining the “rare” standard category of frequency as greater than or equal to 0.01 percent and less than 0.1 percent).
122 Id. at 36 (defining the “uncommon” standard category of frequency as greater than or equal to 0.1 percent and less than 1 percent); see also 2016 Clinical Review, supra n. 13, at 47 and 51.
Unanticipated aspiration for persistent pain, bleeding or both were 1.8 percent and 0.4 percent for medical and surgical abortion respectively. These findings are compatible with the Niinimaki study findings. There was no difference in major adverse events as defined by the authors (emergency department visit, hospitalization, uterine perforation, infection, hemorrhage requiring transfusion) between the groups. The authors conclude medical and surgical abortion before 64 days of gestation are both highly effective with low complication rates.

The 2018 Carlsson study is addressed above in section II.A.2.b.ii. of this response; as discussed above, that study showed no statistically significant difference between the overall complication rates between an “at home” and “at the hospital” abortion.125

We acknowledge that medical abortion is known to have more days of bleeding and increased rates of incomplete abortion compared to surgical abortion. However, as noted above, in the vast majority of medical abortions, surgical intervention is not necessary. Thus, medical abortion and surgical abortion are two options; both have benefits, side effects, and potential complications. Patients and their healthcare providers should discuss which method is preferable and safer according to each woman’s unique situation.

You state that the Mifeprex REMS should require a formal study for at-risk populations, including: patients under the age of 18; patients with repeat Mifeprex abortions; patients with limited access to emergency room services; and patients who self-administer misoprostol (Petition at 13-14). As we explain below, additional studies are not needed at this time.

In justifying your assertion that a formal study is required in patients under the age of 18, you state that Mifeprex was approved for use in the pediatric population in 2000 after the requirement for studies in the pediatric population was waived (Petition at 13-14). The approved indication for mifepristone does not limit its use by age. Although patients age 17 and under were not included in the clinical trials supporting the initial approval of Mifeprex in 2000, we stated at the time that the safety and efficacy were expected to be the same for postpubertal (i.e., post-menarchal) adolescents. Our conclusion in 2000 that pediatric studies of Mifeprex were not needed for approval was consistent with FDA’s implementation of the regulations in effect at that time. Because we determined that there were sufficient data from studies of mifepristone, the original Mifeprex approval should have reflected the Agency’s conclusion that the pediatric study requirements were waived for pre-menarchal females and that the pediatric study requirements were met for post-menarchal adolescents, rather than stating that the Agency was waiving the requirements for all pediatric age groups.

As currently required by the Pediatric Research Equity Act (PREA),126 certain applications or supplemental applications must include pediatric assessments of the safety and effectiveness of the drug for the claimed indication(s) in all relevant pediatric

---

125 Carlsson et al., supra n. 49.
subpopulations, unless that requirement is waived or deferred.\textsuperscript{127} In accordance with PREA, when FDA reviewed the S-020 efficacy supplement, a partial waiver was granted for pediatric studies in pre-menarchal females because pregnancy does not occur in premenarchal females. We also determined that the applicant had fulfilled the pediatric study requirement in post-menarchal adolescents. This determination was based on data extrapolated from adults and information in literature. Review of these findings found the safety and efficacy in this population to be similar to the safety and efficacy in the adult population.\textsuperscript{128} Therefore, we do not agree that a formal study is required in patients under 18.

With regard to your concerns about repeat abortions and your assertion that a study is necessary in this population, we acknowledge that published data concerning adverse reproductive health outcomes in U.S. women who undergo repeat medical abortions are limited. We concluded in our 2016 review of the S-020 efficacy supplement that there is no evidence that repeated medical or surgical abortion is unsafe or that there is a tolerance effect. We also noted that return to fertility after the use of mifepristone is well documented.\textsuperscript{129} This is reflected both in Section 17 of the approved labeling, Patient Counseling Information, which states that the provider should “inform the patient that another pregnancy can occur following medical abortion and before resumption of normal menses,” and in the Medication Guide, which states “You can become pregnant again right after your pregnancy ends.” Although you state that more than one out of every three abortions in the United Sates is a repeat abortion (Petition at 14),\textsuperscript{130} we are not aware of reports suggesting greater safety concerns in repeat abortions than a first-time abortion. Therefore, we do not agree that a study is necessary in this population. You also cite a published study, using a mouse model, of repeated medical termination of pregnancy that showed repeat medical abortion impaired the reproductive function of female mice (Petition at 14).\textsuperscript{131} Per our 2016 review, there is no evidence in available clinical data that repeated medical or surgical abortion is unsafe, or that fertility is impaired by the use of mifepristone; therefore, data from a single non-clinical study in mice are not persuasive.\textsuperscript{132}

With respect to your request for a formal study of mifepristone for medical abortion in women without access to emergency care, we disagree that such a study is necessary. In order to become a certified prescriber, a healthcare provider must agree that they have the ability to provide surgical intervention in cases of incomplete abortion or severe bleeding or have made plans to provide such care through others, and that they have the ability to assure patient access to medical facilities equipped to provide blood transfusions and resuscitation, if necessary. These prescriber qualifications ensure that mifepristone is prescribed to women for whom emergency care is available.

\textsuperscript{127} Section 505B(a)(2) of the FD&C Act (21 U.S.C. 355c(a)(2)).
\textsuperscript{128} 2016 Clinical Review, supra n. 13, at 74-76.
\textsuperscript{129} Id. at 47.
\textsuperscript{130} In support of this assertion, you cite Jones R, Jerman J, Ingerick M. Which abortion patients have had a prior abortion? Findings from the 2014 U.S. Abortion Patient Survey. J Womens Health.
\textsuperscript{132} 2016 Clinical Review, supra n. 13, at 47.
Finally, you assert that FDA should require a formal study in patients who self-administer misoprostol. As explained in section II.A.2.b.ii of this response, FDA conducted a literature review of self-administration of misoprostol at home as part of its review of the S-020 efficacy supplement and found no safety or efficacy concerns with home self-administration of misoprostol. Therefore, we disagree that a formal study is required in this population.

With regard to safety generally, in addition to the FAERS data provided above (see section II.B.1.c.ii. in this response), FDA routinely monitors adverse events reported to FAERS and published in the medical literature for mifepristone for medical termination of pregnancy through 70 days gestation. We have not identified any new safety concerns with the use of mifepristone for this indication.

3. Other Articles

In your Petition, you reference several documents that discuss alternative models of providing abortion medications and advocate for the lifting of the REMS on mifepristone (Petition at 23–24). You assert that these recent publications demonstrate how abortion advocates will continue to pressure FDA to eliminate the REMS and move towards over-the-counter access for Mifeprex.\textsuperscript{133} We agree that the overarching message in the publications you reference appears to be advocating self-management of medical abortion. Nonetheless, as discussed in this response, we have determined that the Mifepristone REMS Program continues to be necessary for the safe use of this drug product, with some modifications.

III. CONCLUSION

For the reasons set forth above, we deny your request that FDA restore and strengthen elements of the Mifeprex regimen and prescriber requirements approved in 2000; and we grant in part and deny in part your request to retain the Mifepristone REMS Program. As with all approved drug products, we will continue to monitor the safety of mifepristone for the approved indication and take any appropriate actions.

Sincerely,

Patrizia A. Cavazzoni, M.D.
Director
Center for Drug Evaluation and Research

\textsuperscript{133} You also reference clinical trials relating to the use of mifepristone for spontaneous miscarriage management and question the results of studies related to this use (Petition at 16-18). The use of mifepristone for the management of early miscarriage is not an approved indication for this drug product and is outside the scope of the Mifepristone REMS Program. Therefore, we do not address it in this response.
Exhibit 31

Questions and Answers on FDA’s Adverse Event Reporting System (FAERS)
Questions and Answers on FDA’s Adverse Event Reporting System (FAERS)

What is FAERS?

The FDA Adverse Event Reporting System (FAERS) is a database that contains adverse event reports, medication error reports and product quality complaints resulting in adverse events that were submitted to FDA. The database is designed to support the FDA’s post-marketing safety surveillance program for drug and therapeutic biologic products. The informatic structure of the FAERS database adheres to the international safety reporting guidance issued by the International Conference on Harmonisation (ICH E2B (/drugs/guidances-drugs/international-council-harmonisation-efficacy)). Adverse events and medication errors are coded using terms in the Medical Dictionary for Regulatory Activities (MedDRA) ([http://www.meddra.org/](http://www.meddra.org/)) terminology.

How does FDA use the information in FAERS?

FAERS is a useful tool for FDA for activities such as looking for new safety concerns that might be related to a marketed product, evaluating a manufacturer’s compliance to reporting regulations and responding to outside requests for information. The reports in FAERS are evaluated by clinical reviewers, in the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER), to monitor the safety of products after they are approved by FDA.

If a potential safety concern is identified in FAERS, further evaluation is performed. Further evaluation might include conducting studies using other large databases, such as those available in the Sentinel System. Based on an evaluation of the potential safety concern, FDA may take regulatory action(s) to improve product safety and protect the public health, such as updating a product’s labeling information, restricting the use of the drug, communicating new safety information to the public, or, in rare cases, removing a product from the market.

Who sends reports to FAERS?

Healthcare professionals, consumers, and manufacturers submit reports to FAERS. FDA receives voluntary reports directly from healthcare professionals (such as physicians, pharmacists, nurses and others) and consumers (such as patients, family members, lawyers and others). Healthcare professionals and consumers may also report to the products’ manufacturers. If a manufacturer receives a report from a healthcare professional or consumer, it is required to send the report to FDA as specified by regulations.

How can I report an adverse event or medication error to FDA?


Can mandatory reporters submit adverse events electronically?

Yes, the FDA Adverse Events Reporting System (FAERS) Electronic Submissions ([/drugs/fda-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-electronic-submissions](/drugs/fda-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-electronic-submissions)) website provides drug and therapeutic biological product manufacturers, distributors, packers, and other interested parties with information about FDA Adverse Event Reporting System (FAERS) electronic submissions and instructions on how to electronically submit post-marketing individual case safety reports (ICSRs), with and without attachments.
Does FAERS data have limitations?

Yes, FAERS data does have limitations. First, there is no certainty that the reported event (adverse event or medication error) was due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. Furthermore, FDA does not receive reports for every adverse event or medication error that occurs with a product. Many factors can influence whether an event will be reported, such as the time a product has been marketed and publicity about an event. There are also duplicate reports where the same report was submitted by a consumer and by the sponsor. Therefore, FAERS data cannot be used to calculate the incidence of an adverse event or medication error in the U.S. population. For more information, please refer to the question “What points should I consider while viewing the dashboard content? (https://fis.fda.gov/extensions/fpdwidgets/2e01da82-13fe-40e0-8c38-4da505737e36.html#_Toc493751926)”

Is FAERS data available to the public?

FAERS data is available to the public in the following ways:


- **FAERS data files (https://drugs.fda-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files):** provides raw data consisting of individual case safety reports extracted from the FAERS database. A simple search of FAERS data cannot be performed with these files by persons who are not familiar with the creation of relational databases.

- Individual case safety reports from the FAERS database can also be obtained by sending a Freedom of Information (FOI) request to FDA (https://how-make-foia-request).

How do I find or confirm my report is in FAERS?

To confirm that your report is in FAERS, please send a Freedom of Information (FOI) request to FDA (https://how-make-foia-request).

What are the benefits of the FAERS public dashboard?

This tool makes the data easier to query and produces user-friendly information and charts. For example, users can view a summary of adverse event reports received from 1968 to the present or for a specific timeframe. In addition, users can search on a product of interest within a specific timeframe.

Will there be a tutorial so I can learn how to use this database?

Yes, a recorded webinar (https://about-fda/pharmacy-student-experiential-program/fda-drug-topics-fda-adverse-events-reporting-system-faers-public-dashboard-january-30-2018) is available which reviews the capabilities, and limitations, of the FAERS public dashboard.

Is the FAERS public dashboard accessible on an Android™ or iPhone®?

Yes, but the user interface layout may not be very user friendly. FDA will continue to work on the dashboard to make the user interface Android and iPhone friendly.
Can I download my search results from the dashboard?

Yes, you will be able to export a limited set of search data to an Excel® spreadsheet and then download it. FDA will still continue to provide the FAERS Latest Quarterly Data Files (/drugs/fda-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files) online.

Note: The data fields listed on the FAERS Dashboard currently is a subset of the data fields available in the FAERS Quarterly Data files. Future release of the FAERS Dashboard plans to make the other data fields available. Also the data displayed in the FAERS Dashboard may not be identical to the data in the FAERS Quarterly Data files due to different data extraction dates.

Where else can I find safety information?

- Potential Signals of Serious Risks/New Safety Information Identified from the FDA Adverse Event Reporting System (FAERS): quarterly reports on potential serious side effects identified by FAERS. (/drugs/fda-adverse-event-reporting-system-faers/potential-signals-serious-risks-new-safety-information-identified-fda-adverse-event-reporting-system)

- Post-marketing Drug and Biologic Safety Evaluations (/drugs/surveillance/postmarket-drug-and-biologic-safety-evaluations): provides summary information about ongoing and completed post-marketing safety evaluations of adverse experience reports made to FDA for New Drug Applications (NDAs) and Biologic License Applications (BLAs) approved since September 27, 2007.


- MedWatch: The FDA Safety Information and Adverse Event Reporting Program (https://www.fda.gov/Safety/MedWatch/default.htm)

How are versions of a case in FAERS handled?

Each unique submission of a case received is assigned a version number (for example, Case #1234567, version 1). The initial version received will be version 1. If a follow up is received on a previously submitted case, then that version of the case will be version 2, and so on. The latest version of a case represents the most current information about that case.

The data is updated quarterly.

What points should I consider while viewing the dashboard content?

When you view the website output of reported reactions (side effects or adverse drug reactions) for a drug product, it is important to consider the following points:

- **Data Quality:** There are many instances of duplicative reports and some reports do not contain all the necessary information. Duplicate reporting occurs when the same report is submitted by the consumer and the sponsor. The information in FAERS evolves daily and the number of individual cases may increase or decrease. It is therefore possible that the information on this website may change over time.

- **Existence of a report does not establish causation:** For any given report, there is no certainty that a suspected drug caused the reaction. While consumers and healthcare professionals are encouraged to report adverse events, the reaction may have been related to the underlying disease being treated, or caused by some
other drug being taken concurrently, or occurred for other reasons. The information in these reports reflects only the reporter's observations and opinions.

- **Information in reports has not been verified:** Submission of a report does not mean that the information included in it has been medically confirmed nor it is an admission from the reporter that the drug caused or contributed the event.

- **Rates of occurrence cannot be established with reports:** The number of suspected reactions in FAERS should not be used to determine the likelihood of a side effect occurring. The FDA does not receive reports for every adverse event or medication error that occurs with a product. Many factors can influence whether an event will be reported, such as the time a product has been marketed and publicity about an event. Therefore, information in these reports cannot be used to estimate the incidence (occurrence rates) of the reactions reported.

- **Patients should talk to their doctor** before stopping or changing how they take their medications.

- **Patient Outcomes received in FAERS:** These data describe the outcome of the patient as defined in U.S. reporting regulations (21 CFR 310.305, 314.80, 314.98, 600.80). Serious means that one or more of the following outcomes were documented in the report: death, hospitalization, life-threatening, disability, congenital anomaly, and/or other serious outcome. Documenting one or more of these outcomes in a report does not necessarily mean that the suspect product(s) named in the report was the cause of the outcomes.

Importantly, the FAERS data by themselves are not an indicator of the safety profile of the drug.
Exhibit 32

Kathi A. Aultman et al., Deaths and Severe Adverse Events after the use of Mifepristone as an Abortifacient from September 2000 to February 2019, 26 Law & Medicine 3, 25–26 (2021)
Deaths and Severe Adverse Events after the use of Mifepristone as an Abortifacient from September 2000 to February 2019

Kathi A. Aultman M.D.,* Christina A. Cirucci M.D.,
Donna J. Harrison M.D.,** Benjamin D. Beran M.D.,***
Michael D. Lockwood D.O.,**** Sigmund Seiler M.D.*****

ABSTRACT: Objectives: Primary: Analyze the Adverse Events (AEs) reported to the Food and Drug Administration (FDA) after use of mifepristone as an abortifacient. Secondary: Analyze maternal intent after ongoing pregnancy and investigate hemorrhage after mifepristone alone.

Methods: Adverse Event Reports (AERs) for mifepristone used as an abortifacient, submitted to the FDA from September 2000 to February 2019, were analyzed using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAEv3).

Results: The FDA provided 6158 pages of AERs. Duplicates, non-US, or AERs previously published (Gary, 2006) were excluded. Of the remaining, there were 3197 unique, US-only AERs of which there were 537 (16.80%) with insufficient information to determine clinical severity, leaving 2660 (83.20%) Codable US AERs (Figure 1). Of these, 20 were Deaths, 529 were Life-threatening, 1957 were Severe, 151 were Moderate, and 3 were Mild.

* Associate Scholar with the Charlotte Lozier Institute.
** Executive Director, American Association of Pro-Life Obstetricians and Gynecologists, PO Box 395 Eau Claire, Michigan 49111-0395. Ph 202 230-0997. donna@aaplog.org.
*** Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI.
**** Department of Osteopathic Manipulative Medicine, Liberty University College of Osteopathic Medicine.
***** Associate Professor of Family Medicine, Liberty University College of Osteopathic Medicine.
The deaths included: 9 (45.00%) sepsis, 4 (20.00%) drug toxicity/overdose, 1 (5.00%) ruptured ectopic pregnancy, 1 (5.00%) hemorrhage, 3 (15.00%) possible homicides, 1 (5.00%) suicide, 1 (5.00%) unknown (Table 1).

Retained products of conception and hemorrhage caused most morbidity. There were 75 ectopic pregnancies, including 26 ruptured ectopics (includes one death).

There were 2243 surgeries including 2146 (95.68%) D&Cs of which only 853 (39.75%) were performed by abortion providers.

Of 452 patients with ongoing pregnancies, 102 (22.57%) chose to keep their baby, 148 (32.74%) had terminations, 1 (0.22%) miscarried, and 201 (44.47%) had unknown outcomes.

Hemorrhage occurred more often in those who took mifepristone and misoprostol (51.44%) than in those who took mifepristone alone (22.41%).

**Conclusions:** Significant morbidity and mortality have occurred following the use of mifepristone as an abortifacient. A pre-abortion ultrasound should be required to rule out ectopic pregnancy and confirm gestational age. The FDA AER system is inadequate and significantly underestimates the adverse events from mifepristone.

A mandatory registry of ongoing pregnancies is essential considering the number of ongoing pregnancies especially considering the known teratogenicity of misoprostol.

At the very least, the FDA should reinstate the original 2011 REMS and strengthen the reporting requirements.

**Conflict of Interest Statement:** The authors did not report any potential conflicts of interest. Authors note that although Dr. Harrison is an associate editor for Issues in Law and Medicine, she recused herself from any involvement in the peer review process for this manuscript.

**Keywords:** Mifepristone, Mifeprex, RU-486, Misoprostol, Abortifacient, Medical Abortion, Abortion Pill, Medical Abortion Complications, No touch abortion, DIY Abortion, Self-Administered Abortion, Adverse Events, Adverse Event Reports, Post-marketing Surveillance, FAERS, Drug Safety, Emergency Medicine, FDA, REMS, Risk Evaluation Mitigation Strategy.
**Introduction**

The application for mifepristone (RU-486, RU-38486, Mifeprex) as an abortifacient was submitted to the Food and Drug Administration (FDA) in 1996 by the Population Council, which was given the manufacturing and distribution rights from Roussel Uclaf. The Population Council partnered with Danco Laboratories, newly created in 1995, and gave them the manufacturing, marketing, and distribution rights. The FDA approved mifepristone in September 2000 under restricted distribution regulations (Subpart H) due to the FDA’s conclusion that restrictions "on the distribution and use of mifepristone are needed to ensure safe use of this product."2

Included in these restrictions was the requirement that all serious Adverse Events (AEs), after the use of mifepristone as an abortifacient, be reported to the FDA by Danco as part of post-marketing surveillance. According to the FDA,3 the purpose of such post-marketing surveillance includes identification of potential risks recognized after the time of approval, identification of unexpected deaths, causal attribution of AEs based on the product’s known pharmacological action, and AEs for which a Risk Evaluation Mitigation Strategy (REMS) is intended to mitigate the risk.

In 2006, in response to the deaths of 4 women from a rare bacterial sepsis from *Clostridium sordellii* (*C. sordellii*), the FDA and CDC convened a workshop, during which mifepristone alteration of the immune system was detailed, and they concluded that such alteration could lead to impaired ability to respond to *C. sordellii* toxin.4

---


There is evidence that both mifepristone⁵, ⁶, ⁷ and misoprostol⁸ can suppress immune response to *C. sordellii* in animal models.

In response to the septic deaths, Planned Parenthood changed their off-label protocol from vaginal administration of misoprostol to buccal in 2006.⁹,¹⁰ Yet, as we found in our analysis, sepsis deaths from *C. sordellii* and other bacteria continued to occur after 2007. All sepsis deaths occurred with either vaginal or buccal misoprostol, which were both off label routes of administration until the buccal route was authorized in 2016.¹¹

In 2011, the FDA approved a Risk Evaluation and Mitigation Strategy (REMS) for Mifepristone incorporating the original restrictions.¹² In May 2015, Mifepristone’s sponsor submitted a supplemental new drug application to the FDA to obtain approval to revise the drug’s labeling, which the FDA approved in 2016.¹³,¹⁴ The 2016 changes in the Regimen and Prescriber Agreement extended the original gestational age limit from 49 days to 70 days, changed the mifepristone dose from 600 mg to 200 mg orally, changed the misoprostol dose from 400 mcg orally on Day 3 to 800 mcg buccally on Day 2 or 3, allowed non-physicians to become prescribers, reduced the number of required office visits from 3 to just one initial office visit, and allowed a repeat dose of misoprostol if complete expulsion did not occur.¹⁵ The prescriber agreement was changed so

---


that instead of being required to “report any hospitalization, transfusion or other serious event to Danco Laboratories,” providers were only required to report deaths. The requirement to report ongoing pregnancies that are not terminated was also eliminated. “The FDA approved GenBioPro, Inc.’s abbreviated new drug application (ANDA) for generic Mifeprex on April 11, 2019” and “established a single, shared system REMS for mifepristone products” without substantially changing the REMS.

During the COVID-19 pandemic the Maryland District Court issued a preliminary injunction prohibiting the FDA from enforcing the in-person dispensing and signature requirements contained in the mifepristone REMS. This decision eliminated the need for an initial office visit for dispensing the medication and opened the door for dispensing of the drug via telehealth with no actual clinician contact. On January 12, 2021, the Supreme Court enabled the FDA to enforce the mifepristone REMS. These requirements are essential for the safety of women and must be kept in place.

The first systematic analysis of these Adverse Event Reports (AERs) obtained by the Freedom of Information Act (FOIA), was published by Gary and Harrison in 2006. This paper extends that analysis to AERs not previously published and augments the scant published literature on mifepristone safety.

**Objectives**

Primary: To analyze and codify the significant adverse events and their treatment after the use of mifepristone as an abortifacient, extending the previously published analysis by Gary in 2006. Secondary: To examine maternal decisions in the case of ongoing pregnancy after attempted mifepristone termination, and to determine if failing to take misoprostol after mifepristone increased the risk of hemorrhage.

---


Materials and Methods

FDA AERs related to the use of mifepristone from September 2000 to February 2019 were obtained through the Freedom of Information Act (FOIA) from the FDA, and a comparison was made with FDA reports available online on the FDA Adverse Events Reporting System (FAERS) Dashboard. Duplicate AERs were identified by comparing FDA case identification numbers, manufacturer identification numbers, dates of treatment, patient age, and descriptions of case scenarios to ensure that each case was included only once in this analysis. The authors excluded duplicates, cases originating outside of the United States, and cases previously published in the Gary analysis (Figure 1).

One of the concerns in looking at AEs is the risk of falsely assigning causality. The FDA does not give guidance for determining causality for AEs in the AERs but does give guidance for selecting AEs for inclusion in the Adverse Reaction section of the Drug Label. They recommend that, “Decisions on whether there is some basis to believe there is a causal relationship are a matter of judgment and are based on factors such as” the “frequency of reporting,” “the extent to which the adverse event is consistent with the pharmacology of the drug,” “the timing of the event relative to the time of drug exposure,” and other factors. Although a causal relationship cannot be attributed with certainty to all reported AEs for a drug, a causal relationship seems probable for each of the categories of AEs we chose to analyze based on these factors, except for ectopic pregnancies and some of the deaths. Ectopic pregnancies were included in our analysis not because there is a causal relationship, but because ectopic pregnancy is a contraindication to the use of mifepristone and the diagnosis was missed, putting women’s lives at risk. The deaths must be evaluated individually to determine causality.

Because reporting is often voluntary and sporadic, there is no denominator for how many mifepristone abortions are performed in the U.S. It was therefore impossible to calculate complication rates for mifepristone and misoprostol abortions based on AER data. For clarity, we specified the denominator used in each case. Coding for severity was done using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAEv3), since this was

the methodology used in the original analysis of the first 607 Adverse Events. The five levels of coding are: Mild, Moderate, Severe, Life-threatening, and Death.

Overall severity (Figure 1) for each unique AER was determined independently by two board-certified physicians (Obstetrics and Gynecology or Family Medicine). Since within each AER, a patient may have experienced several Adverse Events (AEs), the overall severity of the AER was based on the highest severity of its AEs. For the diagnoses we analyzed (Table 1), each AE was coded in the same manner and stratified according to type, severity, and treatment. Disagreements were resolved by discussion or review by a third board-certified Obstetrician-Gynecologist who also reviewed coding for uniformity. Surgeries, transfusions, providers, and location of treatment were analyzed and tabulated.

Ruptured ectopic pregnancies were coded as Life-threatening and unruptured ectopic pregnancies as Severe.

Infections were coded as Life-threatening when evidence of sepsis was present, or ICU-level treatment was required. They were coded as Severe if parenteral/IV antibiotics were given and Moderate if oral antibiotics were prescribed.

Life-threatening hemorrhage was defined, as in the previous analysis, to be transfusion of two or more units of packed red blood cells (PRBCs), hemoglobin less than 7, or documented large volume, rapid blood loss with clinical symptomatology of acute blood loss anemia (e.g., syncope, tachycardia, hypotension). Severe hemorrhage was defined as requiring surgical intervention and/or less than 2 U PRBCs. Moderate hemorrhage was defined as management with fluids/medication alone.

Retained Products of Conception (RPOC) was coded as Severe if a dilatation and curettage/evacuation (D&C) was performed. Ongoing viable intrauterine pregnancy was considered equivalent in severity to RPOC requiring curettage and thus Severe. When the ultimate outcome was unknown, the pregnancy was considered ongoing if “ongoing pregnancy” was noted or ultrasound showed cardiac motion or significant growth.

AEs which did not contain sufficient information to assign an accurate severity code were deemed “Uncodable.” AERs lacking any codable information were deemed overall Uncodable.

The percent of women with significant hemorrhage after mifepristone alone was compared to those who took both mifepristone and misoprostol, to investigate the validity of the assertion that lack of subsequent misoprostol administration was a causative factor in hemorrhage after mifepristone use.

---


Results

Adverse Event Report Overall Severity

Figure 1 summarizes the handling of the AERs provided by the FDA and their severity coding. The FDA provided 6158 pages of AERs. Of these, any duplicates, non-US, or AERs previously published in the Gary paper were excluded from the analysis. There were 3197 unique, US-only AERs of which 537 had insufficient information to determine clinical severity, leaving 2660 Codable US-only AERs. Of these, 20 were Deaths, 529 were Life-threatening, 1957 were Severe, 151 were Moderate, and 3 were Mild.

Deaths (Table 1)

Our analysis identified 23 of the 24 deaths reported by the FDA as of 2018.\(^29\) Three of those deaths were previously published in the Gary paper\(^30\) leaving 20 deaths (Table 1). Our analysis yielded a total of 7 sepsis deaths. These included five cases of \textit{C. sordellii} and one case of \textit{Clostridium perfringens}, all consistent with those reported by the FDA. There was an additional death which we categorized as a sepsis death whereas the FDA labeled this case as “delayed onset toxic shock-like syndrome” but did not include it as a sepsis death. The patient had an exploratory laparotomy revealing green pus, which was culture positive for \textit{prevotella} and \textit{peptostreptococcus}, and she died intraoperatively.\(^31\)

Deaths and Severe Adverse Events after the use of Mifepristone as an Abortifacient

Figure 1. AER Distribution

- Total Pages from FDA: 6158
- Duplicates, non-US or previously published in Gary analysis
- Uncodable due to lack of critical information n= 537
  16.80% of US only

Unique US-only AERs: 3197
Unique US-only Codable AERs
n=2660
83.20% of US only

Deaths n= 20
0.75%
Life-threatening n= 529
19.89%
Severe n= 1957
73.57%
Moderate n= 151
5.68%
Mild n= 3
0.11%

Note: From 2000 to 2016 FDA only required the manufacturer to report AEs which were severe, life-threatening or had fatal outcomes. Since 2016, FDA only requires the manufacturer to report fatal outcomes.

We categorized two deaths as suspicious for infectious death. One case was labeled by the FDA as “undetermined natural causes,” however, the AER reported the cause of death as “acute visceral and pulmonary (1420 grams) congestion and edema,” which is consistent with the clinical findings for sepsis/Acute Respiratory Distress Syndrome (ARDS). This patient had autopsy-proven retained products of conception and blood cultures which grew *Strep viridans* isolated at less than 24 hours incubation. One additional case which the FDA labeled “methadone overdose” we considered suspicious for sepsis. Prior to her death, this patient had fever and chills and was treated by an outside physician with cephalexin, which would have been ineffective against infections from *C. sordellii* or anaerobic gram-negative bacilli. There was no autopsy report or toxicology report in the AER.

Non-infectious deaths include one death that the FDA listed as “natural,” caused by “pulmonary emphysema.” This patient was a 40-year-old chronic smoker who died within hours of misoprostol ingestion and had a contusion on her head consistent with a fall, a scenario possibly related to a cardiac event or acute respiratory reaction to misoprostol. She had an intact fetus at the time of death.

---


EX. 32 pg. 009
App. 0507
autopsy. Other non-infectious deaths included one death from a ruptured ectopic pregnancy, one from hemorrhage, 3 possible homicides, one suicide, and 4 deaths from drug toxicity/overdose. It is unknown whether the 8 women who died by homicide, suicide, or drug toxicity/overdose were screened for domestic violence, drug addiction, or depression prior to the abortion.

**Infection (Table 1)**

Infection was the leading cause of mortality. There were 502 cases of infection, which included 9 Deaths, 39 had Life-threatening sepsis, 249 were Severe infections, 132 Moderate infections, and 73 infections which were Uncodable.

**Ectopic Pregnancy (Table 1)**

There were 75 ectopic pregnancies. Of these, 26 were ruptured, including 1 death. Twenty-four were unruptured, and there were 25 for which the rupture status was not given. Fifty-six ectopic pregnancies were treated surgically and 11 were treated with methotrexate. The management was not documented in 7 cases. The patient who died received no treatment as she died on the way to the hospital.

**Retained Products of Conception (RPOC) (Tables 1 and 2)**

RPOC was the leading cause of morbidity. There were 977 confirmed cases of RPOC, including 2 molar pregnancies, and 1506 likely cases of RPOC (documentation was inadequate for confirmation). Of the 2146 total D&Cs, most were for RPOC, including 897 for confirmed RPOC, 1058 for bleeding or presumed RPOC, but no pathology was provided, and 2 for molar pregnancy. A small percentage of RPOC had medical treatment or no treatment.

**Hemorrhage/Bleeding (Table 1)**

There were 1639 bleeding events including one death. These included 466 Life-threatening and 642 Severe events. There were also 106 events coded as Moderate, while 424 reports of bleeding were Uncodable given the information in the database.

**Ongoing Pregnancy (Table 1)**

There were 452 ongoing pregnancies. Of these 102 chose to keep their baby, 148 chose termination, 1 miscarried, and 201 had an unknown outcome. Of those with an unknown outcome, there were 44 patients referred or scheduled for termination, who did not follow through (39 no-showed, 3 canceled, 2 did not schedule).
**Surgeries (Table 2)**

There were 2243 surgeries including 2146 D&Cs, 76 laparoscopies/laparotomies without hysterectomy, 7 hysterectomies, and 14 other surgeries. Of the hysterectomies, 3 were performed for sepsis, 2 for hemorrhage, 1 for a cervical ectopic, and 1 for placenta accreta. There were 1291 surgeries performed in the hospital or ER and 952 in an outpatient setting. Of the 2146 D&Cs, 1194 were performed in the hospital or ER, and 952 in an outpatient setting. Of the 2146 D&Cs, 1194 were provided by the Hospital or ER, 853 by the abortion provider, and 99 by another outpatient provider.

**Transfusions (Table 2)**

Four hundred and eighty-one patients required blood transfusion following medical abortions. Of these, 365 received 1 to 10 units packed red blood cells (PRBCs) alone, 1 received fresh frozen plasma (FFP) alone, 8 received a combination of PRBCs and FFP, and 107 received an unknown amount of blood product.

**Relationship of Misoprostol Use to Hemorrhage (Table 3)**

The use of mifepristone with misoprostol was associated with a higher incidence of hemorrhage than the use of mifepristone alone. Of the 3056 women who took both mifepristone and misoprostol, 1572 (51.44%) hemorrhaged, whereas, among the 58 women who did not take misoprostol, only 13 (22.41%) hemorrhaged. It was unclear whether 84 patients took misoprostol or not. Fifty-four (64.29%) of them hemorrhaged. The hemorrhage rate was higher for the mifepristone with misoprostol group as compared to the mifepristone alone group even if all the unknowns were assigned to the mifepristone alone group or vice versa.
### Table 1 - Diagnoses

<table>
<thead>
<tr>
<th>Deaths</th>
<th>Deaths (n)</th>
<th>Deaths (%)</th>
<th>Deaths: % of (3197) Unique US AERs (%)</th>
<th>Organism (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sepsis</td>
<td>9</td>
<td>45.00%</td>
<td>0.28%</td>
<td>100%</td>
</tr>
<tr>
<td>Sepsis confirmed</td>
<td>7</td>
<td>35.00%</td>
<td>0.22%</td>
<td>100%</td>
</tr>
<tr>
<td><em>Clostridium sordellii</em></td>
<td>5</td>
<td>25.00%</td>
<td>0.16%</td>
<td>71.43%</td>
</tr>
<tr>
<td><em>Clostridium perfringens / Peptostreptococcus</em></td>
<td>1</td>
<td>5.00%</td>
<td>0.03%</td>
<td>14.29%</td>
</tr>
<tr>
<td><em>Peptostreptococcus</em></td>
<td>1</td>
<td>5.00%</td>
<td>0.03%</td>
<td>14.29%</td>
</tr>
<tr>
<td>Sepsis Likely, Unknown Organism</td>
<td>2</td>
<td>10.00%</td>
<td>0.06%</td>
<td></td>
</tr>
<tr>
<td>Visceral and Pulmonary Congestion consistent with ARDS / sepsis</td>
<td>1</td>
<td>5.00%</td>
<td>0.03%</td>
<td></td>
</tr>
<tr>
<td>Fever / chills treated with cephalexin, found dead(^a)</td>
<td>1</td>
<td>5.00%</td>
<td>0.03%</td>
<td></td>
</tr>
<tr>
<td>Ruptured Ectopic Pregnancy</td>
<td>1</td>
<td>5.00%</td>
<td>0.03%</td>
<td></td>
</tr>
<tr>
<td>Hemorrhage</td>
<td>1</td>
<td>5.00%</td>
<td>0.03%</td>
<td></td>
</tr>
<tr>
<td>Possible Homicide</td>
<td>3</td>
<td>15.00%</td>
<td>0.09%</td>
<td></td>
</tr>
<tr>
<td>Suicide</td>
<td>1</td>
<td>5.00%</td>
<td>0.03%</td>
<td></td>
</tr>
<tr>
<td>Drug Toxicity/Overdose</td>
<td>4</td>
<td>20.00%</td>
<td>0.13%</td>
<td></td>
</tr>
<tr>
<td>Unknown(^f)</td>
<td>1</td>
<td>5.00%</td>
<td>0.03%</td>
<td></td>
</tr>
<tr>
<td><strong>Total Deaths</strong></td>
<td><strong>20</strong></td>
<td><strong>100%</strong></td>
<td><strong>0.63%</strong></td>
<td></td>
</tr>
</tbody>
</table>

### Infections, Level of Severity

<table>
<thead>
<tr>
<th>Infections, Level of Severity</th>
<th>Infections (n)</th>
<th>Infections (%)</th>
<th>Infections: % of (3197) Unique US AERs (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Death</td>
<td>9</td>
<td>1.79%</td>
<td>0.28%</td>
</tr>
<tr>
<td>Life threatening infection/sepsis</td>
<td>30</td>
<td>7.77%</td>
<td>1.22%</td>
</tr>
<tr>
<td>Severe infection (IV antibiotics)</td>
<td>249</td>
<td>49.60%</td>
<td>7.79%</td>
</tr>
<tr>
<td>Moderate infection (oral antibiotics)</td>
<td>132</td>
<td>26.29%</td>
<td>4.13%</td>
</tr>
<tr>
<td>Uncodable(^b)</td>
<td>73</td>
<td>14.54%</td>
<td>2.28%</td>
</tr>
<tr>
<td><strong>Total Infections</strong></td>
<td><strong>502</strong></td>
<td><strong>100%</strong></td>
<td><strong>15.70%</strong></td>
</tr>
</tbody>
</table>
### Table 1 – Diagnoses (Continued)

<table>
<thead>
<tr>
<th>Ectopic Pregnancies, Rupture Status</th>
<th>Ectopic Pregnancies (n)</th>
<th>Ectopic Pregnancies (%)</th>
<th>Ectopic Pregnancies: % of (3197) Unique US AERs (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ruptured(^a)</td>
<td>26</td>
<td>34.67%</td>
<td>0.81%</td>
</tr>
<tr>
<td>Unruptured(^b)</td>
<td>24</td>
<td>32.00%</td>
<td>0.75%</td>
</tr>
<tr>
<td>Surgical Treatment</td>
<td>13</td>
<td>17.33%</td>
<td>0.41%</td>
</tr>
<tr>
<td>Methotrexate Treatment</td>
<td>11</td>
<td>14.67%</td>
<td>0.34%</td>
</tr>
<tr>
<td>Unknown Rupture Status(^c)</td>
<td>25</td>
<td>33.33%</td>
<td>0.78%</td>
</tr>
<tr>
<td>Surgical Treatment</td>
<td>18</td>
<td>24.00%</td>
<td>0.56%</td>
</tr>
<tr>
<td>Unknown Treatment</td>
<td>7</td>
<td>9.33%</td>
<td>0.22%</td>
</tr>
<tr>
<td><strong>Total Ectopic Pregnancies</strong></td>
<td><strong>75</strong></td>
<td><strong>100%</strong></td>
<td><strong>2.35%</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ectopic Pregnancies, Level of Severity</th>
<th>Ectopic Pregnancies (n)</th>
<th>Ectopic Pregnancies (%)</th>
<th>Ectopic Pregnancies: % of (3197) Unique US AERs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Death</td>
<td>1</td>
<td>1.33%</td>
<td>0.03%</td>
</tr>
<tr>
<td>Life Threatening (Ruptured, survived)</td>
<td>25</td>
<td>33.33%</td>
<td>0.78%</td>
</tr>
<tr>
<td>Severe (Not Ruptured)</td>
<td>24</td>
<td>32.00%</td>
<td>0.75%</td>
</tr>
<tr>
<td>Uncodable</td>
<td>25</td>
<td>33.33%</td>
<td>0.78%</td>
</tr>
<tr>
<td><strong>Total Ectopic Pregnancies</strong></td>
<td><strong>75</strong></td>
<td><strong>100%</strong></td>
<td><strong>2.35%</strong></td>
</tr>
</tbody>
</table>
Table 1 – Diagnoses (Continued)

<table>
<thead>
<tr>
<th>Retained Products of Conception (RPOC)</th>
<th>RPOC (n)</th>
<th>RPOC (%)</th>
<th>RPOC: % of (3197) Unique US AERs (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RPOC confirmed</td>
<td>977</td>
<td>39.35%</td>
<td>30.56%</td>
</tr>
<tr>
<td>RPOC confirmed (by pathology or ultrasound); Had D&amp;C</td>
<td>891</td>
<td>35.88%</td>
<td>27.87%</td>
</tr>
<tr>
<td>RPOC confirmed by U/S but D&amp;C not documented</td>
<td>29</td>
<td>1.17%</td>
<td>0.91%</td>
</tr>
<tr>
<td>RPOC treated medically</td>
<td>27</td>
<td>1.09%</td>
<td>0.84%</td>
</tr>
<tr>
<td>Tissue at os (no D&amp;C)h</td>
<td>27</td>
<td>1.09%</td>
<td>0.84%</td>
</tr>
<tr>
<td>Molar Pregnancy</td>
<td>2</td>
<td>0.08%</td>
<td>0.06%</td>
</tr>
<tr>
<td>No Treatment, RPOC on autopsy</td>
<td>1</td>
<td>0.04%</td>
<td>0.03%</td>
</tr>
<tr>
<td>RPOC Likely</td>
<td>1506</td>
<td>60.65%</td>
<td>47.11%</td>
</tr>
<tr>
<td>Had D&amp;C, no pathology provided</td>
<td>1056</td>
<td>42.53%</td>
<td>33.03%</td>
</tr>
<tr>
<td>Unknown(^1)</td>
<td>450</td>
<td>18.12%</td>
<td>14.08%</td>
</tr>
<tr>
<td><strong>Total RPOCs</strong></td>
<td><strong>2483</strong></td>
<td><strong>100%</strong></td>
<td><strong>77.67%</strong></td>
</tr>
</tbody>
</table>

Bleeding Events, Level of Severity

<table>
<thead>
<tr>
<th>Bleeding Events, Level of Severity</th>
<th>Bleeding Events (n)</th>
<th>Bleeding Events (%)</th>
<th>Bleeding Events: % of (3197) Unique US AERs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Death</td>
<td>1</td>
<td>0.06%</td>
<td>0.03%</td>
</tr>
<tr>
<td>Life threatening or Disabling: 2U or more transfusion or Hgb&lt;7 or witnessed massive blood loss</td>
<td>466</td>
<td>28.43%</td>
<td>14.58%</td>
</tr>
<tr>
<td>Severe: surgical intervention and/or 1 U transfusion</td>
<td>642</td>
<td>39.17%</td>
<td>20.08%</td>
</tr>
<tr>
<td>Moderate: medical intervention</td>
<td>106</td>
<td>6.47%</td>
<td>3.32%</td>
</tr>
<tr>
<td>Uncodable(^1)</td>
<td>424</td>
<td>25.87%</td>
<td>13.26%</td>
</tr>
<tr>
<td><strong>Total Bleeding Events</strong></td>
<td><strong>1639</strong></td>
<td><strong>100%</strong></td>
<td><strong>51.27%</strong></td>
</tr>
</tbody>
</table>
Table 1 – Diagnoses (Continued)

<table>
<thead>
<tr>
<th>Ongoing Pregnancies, Outcome</th>
<th>Ongoing Pregnancies (n)</th>
<th>Ongoing Pregnancies</th>
<th>Ongoing Pregnancies: % of (3197) Unique US AERs (%)</th>
<th>Ongoing Pregnancies with Unknown Outcome (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Desired to Keep Pregnancy</td>
<td>102</td>
<td>22.57%</td>
<td>3.19%</td>
<td></td>
</tr>
<tr>
<td>Kept Pregnancy</td>
<td>101</td>
<td>22.35%</td>
<td>3.16%</td>
<td></td>
</tr>
<tr>
<td>Kept Pregnancy but baby died in-utero</td>
<td>1</td>
<td>0.22%</td>
<td>0.03%</td>
<td></td>
</tr>
<tr>
<td>Terminated Pregnancy</td>
<td>148</td>
<td>32.74%</td>
<td>4.63%</td>
<td></td>
</tr>
<tr>
<td>Surgical Termination(^{4})</td>
<td>139</td>
<td>30.75%</td>
<td>4.35%</td>
<td></td>
</tr>
<tr>
<td>Medical Termination</td>
<td>9</td>
<td>1.99%</td>
<td>0.28%</td>
<td></td>
</tr>
<tr>
<td>Unknown Intent, miscarried</td>
<td>1</td>
<td>0.22%</td>
<td>0.03%</td>
<td></td>
</tr>
<tr>
<td>Unknown Outcome</td>
<td>201</td>
<td>44.47%</td>
<td>6.29%</td>
<td>100%</td>
</tr>
<tr>
<td>Referred D&amp;C but did not show</td>
<td>39</td>
<td>8.63%</td>
<td>1.22%</td>
<td>19.40%</td>
</tr>
<tr>
<td>Referred D&amp;C but cancelled</td>
<td>3</td>
<td>0.66%</td>
<td>0.09%</td>
<td>1.49%</td>
</tr>
<tr>
<td>Told to schedule/referred D&amp;C did not go</td>
<td>2</td>
<td>0.44%</td>
<td>0.06%</td>
<td>1.00%</td>
</tr>
<tr>
<td>Unknown outcome, no other information(^{5})</td>
<td>157</td>
<td>34.73%</td>
<td>4.91%</td>
<td>78.11%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>452</strong></td>
<td><strong>100%</strong></td>
<td><strong>14.14%</strong></td>
<td><strong>78.11%</strong></td>
</tr>
</tbody>
</table>

\(^{a}\) Because of rounding, percentages may not appear to add up exactly.

\(^{b}\) FDA attributed to methadone overdose.

\(^{c}\) 40 year old smoker died within hours of misoprostol ingestion. Per FDA, “natural causes due to severe pulmonary emphysema.”

\(^{d}\) Patients with documented infection but inadequate information to determine severity.

\(^{e}\) One of the ruptured ectopics died on the way to the hospital. The other 25 were treated surgically.

\(^{f}\) The unruptured ectopics include two cornual ectopics, one treated surgically and one treated medically.

\(^{g}\) Includes two cervical ectopics, one treated with D&C/Hysterectomy/massive transfusion and one with unknown treatment.

\(^{h}\) Either with path provided, or described as RPOC, placental fragments, fetus, or tissue.

\(^{i}\) Suspected RPOC indicating D&C needed, but not documented as being done.

\(^{j}\) Patients with documented bleeding but inadequate information to determine severity.

\(^{k}\) Includes one hysterotomy for pregnancy in non-communicating horn.

\(^{l}\) After no show for surgical termination.

\(^{m}\) Includes 10 with known gestational age 20-29 weeks.
Table 2 – Treatment\textsuperscript{a}

<table>
<thead>
<tr>
<th>Type of Surgery</th>
<th>Type of surgery (n)</th>
<th>Type of surgery (%)</th>
<th>Surgery: % of (3197) Unique US AERs (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>D&amp;C\textsuperscript{c}</td>
<td>2146</td>
<td>95.68%</td>
<td>67.13%</td>
</tr>
<tr>
<td>Hysterectomy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sepsis (includes 2 deaths)</td>
<td>7</td>
<td>0.31%</td>
<td>0.22%</td>
</tr>
<tr>
<td>Hemorrhage after uterine perforation</td>
<td>2</td>
<td>0.09%</td>
<td>0.06%</td>
</tr>
<tr>
<td>Hemorrhage - Cervical Ectopic</td>
<td>1</td>
<td>0.04%</td>
<td>0.03%</td>
</tr>
<tr>
<td>Placenta accreta</td>
<td>1</td>
<td>0.04%</td>
<td>0.03%</td>
</tr>
<tr>
<td>Laparoscopy/Laparotomy without hysterectomy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ectopic (Actual or Suspected)</td>
<td>66</td>
<td>3.39%</td>
<td>2.38%</td>
</tr>
<tr>
<td>Infection</td>
<td>7</td>
<td>0.31%</td>
<td>0.22%</td>
</tr>
<tr>
<td>Uterine Perforation</td>
<td>1</td>
<td>0.04%</td>
<td>0.03%</td>
</tr>
<tr>
<td>Salpingo oophorectomy for Torsion</td>
<td>1</td>
<td>0.04%</td>
<td>0.03%</td>
</tr>
<tr>
<td>Hysterotomy for pregnancy in non-communicating horn</td>
<td>1</td>
<td>0.04%</td>
<td>0.03%</td>
</tr>
<tr>
<td>Other Surgeries</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uterine Artery Embolization</td>
<td>1</td>
<td>0.04%</td>
<td>0.03%</td>
</tr>
<tr>
<td>Vaginal sutures (after 15 week surgical termination for ongoing pregnancy)</td>
<td>1</td>
<td>0.04%</td>
<td>0.03%</td>
</tr>
<tr>
<td>Peritonitis (multiple, same patient, death)</td>
<td>1</td>
<td>0.04%</td>
<td>0.03%</td>
</tr>
<tr>
<td>Necrotozing fascitis debridement and below knee amputation</td>
<td>1</td>
<td>0.04%</td>
<td>0.03%</td>
</tr>
<tr>
<td>Upper and lower endoscopy for bright red bleeding</td>
<td>1</td>
<td>0.04%</td>
<td>0.03%</td>
</tr>
<tr>
<td>Unknown surgery for deep venous thrombosis</td>
<td>1</td>
<td>0.04%</td>
<td>0.03%</td>
</tr>
<tr>
<td>Angioplasty</td>
<td>1</td>
<td>0.04%</td>
<td>0.03%</td>
</tr>
<tr>
<td>Cholecystectomy</td>
<td>2</td>
<td>0.09%</td>
<td>0.06%</td>
</tr>
<tr>
<td>Appendectomy</td>
<td>1</td>
<td>0.04%</td>
<td>0.03%</td>
</tr>
<tr>
<td>Laceration repair (scalp, chin)</td>
<td>2</td>
<td>0.09%</td>
<td>0.06%</td>
</tr>
<tr>
<td>Unknown Surgery</td>
<td>2</td>
<td>0.09%</td>
<td>0.06%</td>
</tr>
<tr>
<td>Total</td>
<td>2243</td>
<td>100%</td>
<td>70.16%</td>
</tr>
</tbody>
</table>
Table 2 – Treatment (Continued)

<table>
<thead>
<tr>
<th>Location of Surgery</th>
<th>Location of Surgery (n)</th>
<th>Location of Surgery (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All Surgeries</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospital or ER</td>
<td>1291</td>
<td>57.56%</td>
</tr>
<tr>
<td>Outpatient</td>
<td>952</td>
<td>42.44%</td>
</tr>
<tr>
<td><strong>D&amp;C</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospital or ER</td>
<td>1194</td>
<td>55.64%</td>
</tr>
<tr>
<td>Outpatient</td>
<td>952</td>
<td>44.36%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Surgical Provider for D&amp;C</th>
<th>Surgical Provider (n)</th>
<th>Surgical Provider (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital/ER</td>
<td>1194</td>
<td>55.64%</td>
</tr>
<tr>
<td>Abortion Provider</td>
<td>853</td>
<td>39.75%</td>
</tr>
<tr>
<td>Other Provider</td>
<td>99</td>
<td>4.61%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>2146</td>
<td>100%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Indication for D&amp;Cs</th>
<th>Indication for D&amp;C (n)</th>
<th>Indication for D&amp;C (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Confirmed D&amp;C</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RPOC (confirmed by pathology or ultrasound)</td>
<td>897</td>
<td>41.80%</td>
</tr>
<tr>
<td>RPOC/Bleeding (no pathology provided)</td>
<td>1058</td>
<td>49.30%</td>
</tr>
<tr>
<td>Ongoing pregnancy, surgical termination by D&amp;C</td>
<td>139</td>
<td>6.48%</td>
</tr>
<tr>
<td>RPOC ruled out</td>
<td>34</td>
<td>1.58%</td>
</tr>
<tr>
<td>Ectopic evaluation</td>
<td>12</td>
<td>0.56%</td>
</tr>
<tr>
<td>Molar pregnancy</td>
<td>2</td>
<td>0.09%</td>
</tr>
<tr>
<td>Not able to take misoprostol</td>
<td>4</td>
<td>0.19%</td>
</tr>
<tr>
<td><strong>Possible D&amp;C</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Possible RPOC, unknown treatment, possible D&amp;C</td>
<td>450</td>
<td></td>
</tr>
<tr>
<td>RPOC confirmed by U/S but D&amp;C not documented</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>Ongoing pregnancy Unknown outcome, possible D&amp;C</td>
<td>201</td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL (Confirmed and Possible)</strong></td>
<td><strong>2826</strong></td>
<td></td>
</tr>
</tbody>
</table>
Table 2 – Treatment (Continued)

<table>
<thead>
<tr>
<th>Transfusions</th>
<th>Transfusions (n)</th>
<th>Transfusions (%)</th>
<th>Transfusion: % of (3197) Unique US AERs (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRBC alone</td>
<td>365</td>
<td>75.88%</td>
<td>11.42%</td>
</tr>
<tr>
<td>1U</td>
<td>32</td>
<td>6.65%</td>
<td>1.00%</td>
</tr>
<tr>
<td>1-2U</td>
<td>1</td>
<td>0.21%</td>
<td>0.03%</td>
</tr>
<tr>
<td>2U</td>
<td>246</td>
<td>51.14%</td>
<td>7.69%</td>
</tr>
<tr>
<td>2.5U</td>
<td>1</td>
<td>0.21%</td>
<td>0.03%</td>
</tr>
<tr>
<td>3U</td>
<td>45</td>
<td>9.36%</td>
<td>1.41%</td>
</tr>
<tr>
<td>4U</td>
<td>27</td>
<td>5.61%</td>
<td>0.84%</td>
</tr>
<tr>
<td>5U</td>
<td>5</td>
<td>1.04%</td>
<td>0.16%</td>
</tr>
<tr>
<td>6U</td>
<td>5</td>
<td>1.04%</td>
<td>0.16%</td>
</tr>
<tr>
<td>7U</td>
<td>2</td>
<td>0.42%</td>
<td>0.06%</td>
</tr>
<tr>
<td>10U</td>
<td>1</td>
<td>0.21%</td>
<td>0.03%</td>
</tr>
<tr>
<td>Other Blood products</td>
<td>9</td>
<td>1.87%</td>
<td>0.28%</td>
</tr>
<tr>
<td>1 U FFP</td>
<td>1</td>
<td>0.21%</td>
<td>0.03%</td>
</tr>
<tr>
<td>2 U PRBC/1 U FFP</td>
<td>1</td>
<td>0.21%</td>
<td>0.03%</td>
</tr>
<tr>
<td>2 U PRBC/ 4 U FFP</td>
<td>1</td>
<td>0.21%</td>
<td>0.03%</td>
</tr>
<tr>
<td>3 U PRBC/ 1 U FFP</td>
<td>1</td>
<td>0.21%</td>
<td>0.03%</td>
</tr>
<tr>
<td>4 U PRBC/ 1 U FFP</td>
<td>1</td>
<td>0.21%</td>
<td>0.03%</td>
</tr>
<tr>
<td>4 U PRBC/ 2 U FFP</td>
<td>1</td>
<td>0.21%</td>
<td>0.03%</td>
</tr>
<tr>
<td>5 U PRBC/ 4 U FFP</td>
<td>1</td>
<td>0.21%</td>
<td>0.03%</td>
</tr>
<tr>
<td>6 U PRBC/ 2 U FFP</td>
<td>1</td>
<td>0.21%</td>
<td>0.03%</td>
</tr>
<tr>
<td>7 U PRBC/ FFP and Platelets unknown amount</td>
<td>1</td>
<td>0.21%</td>
<td>0.03%</td>
</tr>
<tr>
<td>Unknown amount (documented as given, units not recorded)</td>
<td>107</td>
<td>22.25%</td>
<td>3.35%</td>
</tr>
<tr>
<td>Total</td>
<td>481</td>
<td>100%</td>
<td>15.05%</td>
</tr>
</tbody>
</table>

a Because of rounding, percentages may not appear to add up exactly.
b With or without suction, one with hysteroscopy.
c There were 8 patients who had 2 D&Cs and one who required uterine artery embolization. There were 4 perforations: two had resultant hysterectomies, one had a laparoscopy, and one received 2 U PRBCs but no documented surgery.
d Additionally there were 7 patients who likely received transfusion, but was not recorded, 3 patients who refused transfusion, and 1 patient for whom transfusion was considered but not given.
Deaths and Severe Adverse Events after the use of Mifepristone as an Abortifacient

Table 3 – Relationship of Misoprostol to Hemorrhage

<table>
<thead>
<tr>
<th></th>
<th>Mifepristone + Misoprostol</th>
<th>Mifepristone alone</th>
<th>Unknown</th>
<th>Mifepristone + Misoprostol + unknown</th>
<th>Mifepristone alone + unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>%</td>
<td>n</td>
<td>%</td>
<td>n</td>
</tr>
<tr>
<td>No Hemorrhage</td>
<td>1484</td>
<td>48.56%</td>
<td>45</td>
<td>77.59%</td>
<td>30</td>
</tr>
<tr>
<td>Hemorrhage</td>
<td>1572</td>
<td>51.44%</td>
<td>13</td>
<td>22.41%</td>
<td>54</td>
</tr>
<tr>
<td>Death</td>
<td>1</td>
<td>0.03%</td>
<td>0</td>
<td>0.00%</td>
<td>0</td>
</tr>
<tr>
<td>Life threatening</td>
<td>441</td>
<td>14.43%</td>
<td>5</td>
<td>8.62%</td>
<td>20</td>
</tr>
<tr>
<td>Severe</td>
<td>633</td>
<td>20.71%</td>
<td>3</td>
<td>5.17%</td>
<td>6</td>
</tr>
<tr>
<td>Moderate</td>
<td>101</td>
<td>3.30%</td>
<td>1</td>
<td>1.72%</td>
<td>4</td>
</tr>
<tr>
<td>Uncodable</td>
<td>396</td>
<td>12.96%</td>
<td>4</td>
<td>6.90%</td>
<td>24</td>
</tr>
<tr>
<td>Total US AERs</td>
<td>3056</td>
<td>100%</td>
<td>58</td>
<td>100%</td>
<td>84</td>
</tr>
</tbody>
</table>

a Because of rounding, percentages may not appear to add up exactly.
b Assumes all unknowns took both mifepristone and misoprostol.
c Assumes all unknowns took mifepristone, but not misoprostol.

Discussion

This article is critically important considering the paucity of published literature on mifepristone safety and the minimal analysis done on the AERs by the FDA.

Ectopic Pregnancies

Although reported as AEs, ectopic pregnancies are not a direct adverse event from the medication, but rather a contraindication to its administration. They were reported as adverse events because the ectopic pregnancies were missed.

The American College of Obstetricians and Gynecologists (ACOG) notes that “According to the Centers for Disease Control and Prevention, ectopic pregnancy accounts for approximately 2% of all reported pregnancies. However, the true current incidence of ectopic pregnancy is difficult to estimate because many patients are treated in an outpatient setting where events are not tracked, and national surveillance data on ectopic pregnancy have not been updated since 1992. Despite improvements in diagnosis and management, ruptured ectopic pregnancy continues to be a significant cause of pregnancy-related mortality and morbidity. In 2011–2013, ruptured ectopic pregnancy accounted for 2.7% of all pregnancy-related deaths and was the leading cause of hemorrhage-related mortality.”

---

doi:10.1097/AOG.0000000000002560
Confirmed/suspected ectopic pregnancy and undiagnosed adnexal mass are contraindications to mifepristone use under current prescribing requirements. The label warnings state: “Ectopic pregnancy: exclude before treatment.” Unfortunately, it is difficult to rule out ectopic pregnancy by history alone because, “half of all women who receive a diagnosis of an ectopic pregnancy do not have any known risk factors.” According to ACOG Practice Bulletin No. 193, “The minimum diagnostic evaluation of a suspected ectopic pregnancy is a transvaginal ultrasound evaluation and confirmation of pregnancy.” Of the 75 reported ectopic pregnancies in the FDA AERs we analyzed, over a third were known to be ruptured including one death. Clearly, an ultrasound should be required prior to the administration of mifepristone to document that the pregnancy is located within the uterus. Although not 100% effective, this will screen for ectopic pregnancy, confirm gestational age, which can be inaccurate based on menstrual history alone, and screen for adnexal masses, another contraindication to mifepristone use.

**Ongoing pregnancies**

Of the women with an ongoing pregnancy, less than a third were known to have proceeded with termination of the pregnancy, and almost a quarter were known to have kept their pregnancy; in almost half, the outcome was unknown. The significant percentage of women with ongoing pregnancy who changed their mind and chose to keep their pregnancy, after initially choosing termination, raises concerns regarding the pre-abortion counseling and informed consent they received. Women undergoing abortion should receive the same quality of informed consent and pre-procedural counseling that is standard of care prior to other medical treatment or surgery. It is imperative that women considering abortion be provided adequate and complete information and counseling on risks, advantages, disadvantages, and alternative options.

Additionally, the high percentage of women with ongoing pregnancies for whom there is no follow up or known outcome is concerning. As health care providers we are to continue to care for our patients and manage any complications, yet in the AERs we reviewed this was not typically the case for the abortion provider. Furthermore, a federal registry of known outcomes and birth defects is imperative. One of the initial FDA post-marketing requirements for

---

Danco was a surveillance study of outcomes of ongoing pregnancies.\textsuperscript{41} The FDA released them from this post-marketing commitment in January 2008 because Danco reported that only one or two ongoing pregnancies per year were followed for final outcomes in part because of consent requirements.\textsuperscript{42} This is disturbing in light of the percentage of women in our analysis who kept their pregnancies, as well as those with ongoing pregnancy and unknown outcomes, all of whom could have been followed for final outcomes. The significant lack of follow-up of ongoing pregnancies (44.47\% with unknown outcomes) and the very minimal information on those who chose to keep the pregnancy, highlights the need for a national registry especially considering the teratogenicity of misoprostol.\textsuperscript{43}

\textbf{Relationship of Misoprostol to Hemorrhage}

The Creinin study of abortion pill reversal was stopped for safety concerns due to hemorrhage in 3 of the 12 study participants.\textsuperscript{44} One of the conclusions of that study was that “Patients who use mifepristone for a medical abortion should be advised that not using misoprostol could result in severe hemorrhage, even with progesterone treatment.”\textsuperscript{45} The authors hypothesized that the absence of misoprostol caused these women to hemorrhage. The women who had documented use of misoprostol in our database hemorrhaged at a higher rate than those documented not to have taken misoprostol.

\textbf{Reporting of Adverse Events}

Although not the initial goal of this study, the analysis of the AERs revealed glaring deficiencies in the AE reporting system making it difficult to properly evaluate adverse events. When mifepristone was approved in 2000, FDA required that providers “must report any hospitalization, transfusion or other serious event to Danco Laboratories.”\textsuperscript{46} This created an inherent conflict of interest as it is not in the best interest of the entities or providers to report adverse events to those regulating them. Because only severe events were reportable, this requirement likely resulted in an underestimation of moderate and mild AEs. It

\begin{footnotesize}
\begin{itemize}
  \item \textsuperscript{44} Creinin MD, Hou MY, Dalton L, Steward R, Chen MJ. Mifepristone Antagonization With Progesterone to Prevent Medical Abortion: A Randomized Controlled Trial. Obstet Gynecol. 2020;135(1):158-165. doi:10.1097/AOG.0000000000003620
  \item \textsuperscript{45} Creinin MD, Hou MY, Dalton L, Steward R, Chen MJ. Mifepristone Antagonization With Progesterone to Prevent Medical Abortion: A Randomized Controlled Trial. Obstet Gynecol. 2020;135(1):5. doi:10.1097/AOG.0000000000003620
\end{itemize}
\end{footnotesize}
is also likely that some of the AEs that we coded as Mild or Moderate were actually Severe but there was not enough information in the AER for us to justify coding them as Severe. In March 2016, the FDA substantially reduced the prescribing requirements and changed the drug protocol \(^{47}\) and yet at the same time eliminated reporting requirements except for deaths.\(^{48}\) With the relaxation of reporting requirements, the ability to perform any relevant post-marketing evaluation of mifepristone was lost. It is imperative for the safety of women that the FDA restore and strengthen the 2011 REMS requirements.

The information in the AERs is almost exclusively obtained from abortion providers, rather than the physician treating the complication, yet in this analysis, abortion providers managed only 39.75% of surgical complications (a number which is likely much lower since these are only the cases which are known to the abortion provider). Throughout the reports, there was also a lack of detail and many patients who were simply “lost to follow-up.” This resulted in 16.80% of the AERs being Uncodable as to severity and likely under-coding of many AERs and AEs, as coding could only be assigned based on the scant information provided. Many of the AEs experienced by women were unknown to the abortion provider until the follow-up examination, which is troubling considering the poor follow-up rate and elimination of the requirement for an in-office follow up visit. Some of the patient deaths were not known to the abortion provider until they saw the death in an obituary or were contacted by an outside source. Because of this, in addition to abortion providers, hospitals, emergency departments, and private practitioners should be required to report AEs.

Complications occur in the best of hands in all areas of medicine, but as physicians, we are responsible to manage those complications and follow our patients through to resolution. The findings that: 1. the most common outcome of ongoing pregnancy was unknown outcome, 2. abortion providers performed less than half the D&Cs done for complications, and 3. a third of ectopic pregnancies (missed prior to administering the abortifacient) had unknown rupture status, leave us deeply concerned regarding the care these women received. A post-marketing requirement was that there be a “cohort-based study of safety outcomes of patients having medical abortion under the care of physicians with surgical intervention skills compared to physicians who refer their patients for surgical intervention.”\(^{49}\) The applicant was released from this requirement because they stated that because there were so few providers

---


Deaths and Severe Adverse Events after the use of Mifepristone as an Abortifacient

without surgical intervention skills, no meaningful study could be done. Yet, that same year the FDA changed the provider agreement to allow non-physicians to become prescribers. These findings highlight the importance of follow-up and management of complications by the abortion provider. Allowing any further relaxation of mifepristone prescribing requirements will put women at an even higher risk of adverse events

**Limitations and Strengths**

It was not possible to calculate complication rates for mifepristone and misoprostol abortions based on AER data because there is no denominator for how many mifepristone abortions are performed in the U.S. since reporting is often voluntary and sporadic. For clarity, we specified the denominators we used.

Our analysis was limited by the fact that the number of AEs for which we received reports is likely a gross underestimation of the actual number of AEs that occurred. In our analysis, the surgical management of over half the complications was performed by someone other than the abortion provider, yet treating physicians are not required to report complications. Few reports were generated by those in Emergency Departments and hospitals who treated the complications.

Our analysis was also limited by the lack of information in the AERs, including redaction of critical dates, a paucity of diagnosis and treatment information, and lack of follow up.

Our study has several strengths. Our data comes from information provided to the FDA and is the largest analysis of AERs for mifepristone abortions. This data is publicly available under the Freedom of Information Act so that anyone can verify the data for themselves. This analysis reviews all AERs not reported in the first study by Gary. Although heavily redacted, there was sufficient information in over 80% of the AERs to evaluate severity. An objective standardized system, CTCAEv3, was used to code for severity, and each AER was coded by at least two board-certified obstetrician-gynecologists or family medicine physicians.

**Conclusions and Relevance**

This article is important because it augments the scant published literature on mifepristone safety.

Due to the lack of adequate reporting of adverse events, especially by those treating them, these unique AERs represent a fraction of the actual adverse events occurring in American women.

---


Significant morbidity and mortality have occurred with the use of mifepristone as an abortifacient, including at least 24 US deaths reported by the FDA from September 2000 to December 2018. Because of this and the significant morbidity associated with this drug, the FDA should consider at a minimum reinstating the original 2011 REMS and strengthening the reporting requirements. The reporting of transfusions, hospitalizations, and other serious adverse events are essential.

Given the morbidity and mortality of undiagnosed ectopic pregnancy, a clear contraindication to the use of mifepristone, an ultrasound to confirm pregnancy location is essential before mifepristone is dispensed.

Considering the significant percentage of women with ongoing pregnancies who chose to continue their pregnancy, there must be reasonable waiting periods, parental involvement, and adequate pre-abortion counseling on all pregnancy options. It is also critical that a pregnancy registry be established.

In our analysis, the patients who used mifepristone alone had a lower rate of hemorrhage than those using mifepristone followed by misoprostol.

The FDA Adverse Event Reporting System is woefully inadequate to determine the post-marketing safety of mifepristone due to its inability to adequately assess the frequency or severity of adverse events. The reliance solely on interested parties to report, the large percentage of uncodable events, the redaction of critical clinical information unrelated to personally identifiable information, and the inadequacy of the reports highlight the need to overhaul the current AER System.

This analysis evaluated 3197 adverse events resulting from the use of mifepristone as an abortifacient and brought to light serious concerns about the safety requirements and care of women undergoing mifepristone abortion. Although complications may occur in the best of hands, and no medical procedure is without risks, safety measures must be employed to minimize these adverse outcomes. Women undergoing abortion should receive the same quality of informed consent and pre-procedural counseling that is standard of care prior to other medical treatment or surgery. It is imperative that women considering abortion be provided adequate and complete information and counseling on risks, advantages, disadvantages, and alternative options. Although there may be disagreements about the ethics of abortion, there must be total agreement that our patients—whether undergoing a medical abortion or otherwise—deserve the highest standard of medical care.

Acknowledgments:

Authors would like to acknowledge the other members of the American Association of Pro-Life Obstetricians and Gynecologists (AAPLOG) Mifeprex Adverse Events Coding Team: Jennifer J. Barr M.D., Brent Boles M.D., Watson A. Bowes, Jr. M.D., Steven Braatz M.D., Byron Calhoun M.D., Myles Dotto M.D., Steve Foley M.D., R. Scott French M.D., Victoria Gerthe OMSIV, Mary Jo Heinrichs M.D., Maureen Kennedy M.D., Sarah Kennedy M.D., Paul LaRose M.D., Daniel Lickness
Deaths and Severe Adverse Events after the use of Mifepristone as an Abortifacient

M.D., Jenny Mao D.O., Patrick Marmion M.D., Richard Moutvic M.D., Mary O'Sullivan M.D., Catherine Reese M.D., AnnaLisa Schmitz M.D., Ingrid Skop M.D., Barbara Talamo M.D., Michael T. Valley M.D., Marilyn J. Vanover M.D., Elizabeth Wehlage M.D., Belinda Williams M.D, Jerry Wittingen M.D.

Authors would also like to acknowledge Christopher Gacek of the Family Research Council for assistance with FOIA requests to the FDA over 2 decades.

Authors would also like to acknowledge William Marshall of Judicial Watch for assistance with FOIA requests to the FDA.

Authors would also like to acknowledge The Charlotte Lozier Institute, especially Genevieve Plaster and Dr. John Fisher, for support for data processing.
Exhibit 33

Christiana A. Cirucci et al., Mifepristone Adverse Events Identified by Planned Parenthood in 2009 and 2010 Compared to Those in the FDA Adverse Event Reporting System and Those Obtained Through the Freedom of Information Act, 8 Health Servs. Rsch & managerial Epidemiology 1 (2021)
Mifepristone Adverse Events Identified by Planned Parenthood in 2009 and 2010 Compared to Those in the FDA Adverse Event Reporting System and Those Obtained Through the Freedom of Information Act

Christina A. Cirucci, Kathi A. Aultman, and Donna J. Harrison

Abstract

Background: As part of the accelerated approval of mifepristone as an abortifacient in 2000, the Food and Drug Administration (FDA) required prescribers to report all serious adverse events (AEs) to the manufacturer who was required to report them to the FDA. This information is included in the FDA Adverse Event Reporting System (FAERS) and is available to the public online. The actual Adverse Event Reports (AERs) can be obtained through the Freedom of Information Act (FOIA).

Methods: We compared the number of specific AEs and total AERs for mifepristone abortions from January 1, 2009 to December 31, 2010 from 1. Planned Parenthood abortion data published by Cleland et al. 2. FAERS online dashboard, and 3. AERs provided through FOIA and analyzed by Aultman et al.

Results: Cleland identified 1530 Planned Parenthood mifepristone cases with specific AEs for 2009 and 2010. For this period, FAERS online dashboard includes a total (from all providers) of only 664, and the FDA released only 330 AERs through FOIA. Cleland identified 1158 ongoing pregnancies in 2009 and 2010. FAERS dashboard contains only 95, and only 39 were released via FOIA.

Conclusions: There are significant discrepancies in the total number of AERs and specific AEs for 2009 and 2010 mifepristone abortions reported in 1. Cleland's documentation of Planned Parenthood AEs, 2. FAERS dashboard, and 3. AERs provided through FOIA. These discrepancies render the FAERS inadequate to evaluate the safety of mifepristone abortions.

Keywords
mifepristone, misoprostol, adverse drug reaction reporting systems, drug-related side effects and adverse reactions, postmarketing product surveillance, induced abortion, steroidal abortifacient agents, United States food and drug administration

Introduction

The accelerated approval of mifepristone in the United States (US) in 2000 included post-marketing restrictions to monitor safety. Prescribers were required to report any ongoing pregnancies, hospitalizations, transfusions, and other serious events to the manufacturer, who was required to submit them to the Food and Drug Administration (FDA). Adverse events (AEs) are documented in the FDA Adverse Event Reporting System (FAERS), available online. Copies of the actual Adverse Event Reports (AERs) can be obtained via the Freedom of Information Act (FOIA).

A paper published by Cleland et al. analyzed eight adverse events/outcomes (AEs) from mifepristone abortions at 63 days and less performed by Planned Parenthood in 2009 and 2010. They analyzed hospital admissions, blood transfusions, emergency department (ED) treatments, intravenous (IV)

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
antibiotics, infections requiring IV antibiotics or hospitalization, deaths, ongoing pregnancies, and ectopic pregnancies. Cleland explained that Planned Parenthood reports all significant AEs to Danco Laboratories, which submits them to the FDA, per the mifepristone prescribing information. Their analysis for these specific AEs led them to conclude that, “Among the 233,805 medical abortions provided at Planned Parenthood health centers in 2009 and 2010, significant adverse events or outcomes were reported in 1530 (0.65%) cases.” Unless associated with another AE, they did not include data on incomplete abortion managed at Planned Parenthood or hemorrhage without transfusion, two of the most common AEs resulting from mifepristone abortion. They also admit that “we cannot exclude the possibility that some clinically significant adverse events or outcomes were not included. Some patients may have experienced a significant adverse event or outcome but did not follow up after their medical abortion.” Cleland did not provide the loss to follow-up rate.

In 2021, Aultman et al. published an analysis of the AERs for mifepristone abortion from September 2000 to February 2019 (excluding those published by Gary in 2006) utilizing AERs obtained through FOIA.

The objective of this paper was to compare the total number of AERs/cases (which may include more than one AE) and the individual AEs identified by Cleland for 2009 and 2010 mifepristone abortions from three sources: those identified by Planned Parenthood as published by Cleland, those currently posted on the FAERS dashboard, and those provided by the FDA in response to FOIA and analyzed by Aultman.

### Methods

We searched the FAERS dashboard for any US AERs related to mifepristone abortion occurring from January 1, 2009 through December 31, 2010 and tabulated the total number of AERs, hospital admissions, deaths, ongoing pregnancies, and ectopic pregnancies. The FAERS did not have enough information to evaluate for transfusion, ED visits, IV antibiotics, or infections requiring IV antibiotics or hospital admission. Since FAERS does not provide the “abortion date,” we used the “event date”; in cases where there was no “event date,” we used the “latest manufacturer received date.” We evaluated Aultman’s AERs for the events in Cleland and confirmed any missing reports by searching the 6158 pages of AERs related to mifepristone abortion obtained by FOIA. In analyzing FOIA data, Aultman accounted for duplicates. In the FAERS data, we accounted for duplicates for deaths and ectopic pregnancies, but FAERS did not provide sufficient detail to do so for hospital admissions and ongoing pregnancies. We then compared the total number of reports, as well as hospitalizations, ongoing pregnancies, ectopic pregnancies, and deaths from Cleland, FAERS, and FOIA AERs for 2009 and 2010. Adverse events not reported by Cleland were not evaluated. The FAERS and FOIA total AERs include reports from all sources, not just from Planned Parenthood, and include all reports for those years, not just those with the eight AEs evaluated by Cleland.

### Results

Our analysis shows significant discrepancies between the number of AERs identified by Planned Parenthood as reported in Cleland, the number in the FAERS database, and the number received under FOIA. There are also discrepancies in the number of hospitalizations, ectopic pregnancies, and ongoing pregnancies.

### Total Reports (Figure 1)

Cleland identified 1530 cases involving eight specific AEs after Planned Parenthood mifepristone abortion in 2009 and 2010. The FAERS dashboard contains only 664 AERs for this period, and only 330 were provided through FOIA. Both include AERS with other types of adverse events not included by Cleland and include reports from all sources, not just Planned Parenthood.

### Specific Adverse Events/Outcomes (Table 1)

Cleland identified 548 ongoing pregnancies after mifepristone abortion in 2009, the FAERS dashboard includes just 56, and only seven were received via FOIA. For 2010, Cleland identified 610 ongoing pregnancies, FAERS contains just 39, and only 32 were obtained via FOIA. Cleland identified 70 hospital admissions in 2009 and 65 in 2010. FAERS includes 87 and 125, respectively, but the FDA only provided 14 and 94 via FOIA. Ectopic pregnancy, although not caused by mifepristone, is a contraindication to its use. Cleland reported eight ectopic pregnancies in 2009 and eight in 2010. FAERS includes eight for 2009 and nine for 2010. The FOIA AERs have only one ectopic for 2009 and eight for 2010. Cleland reported no deaths in 2009 and one in 2010. FAERS and FOIA were consistent with one death in 2009 and two in 2010.

### Discussion

The total number of AEs published in Cleland is significantly higher than the number in the FAERS database, even though Cleland did not evaluate all AEs, including...
failed abortions treated at Planned Parenthood.\(^4\) The discrepancy is particularly concerning because the total number of AEs and AERs in the FAERS should be significantly higher than Cleland since Planned Parenthood performs only 37% of US abortions.\(^7\) It is unclear why so many cases identified by Planned Parenthood in Cleland do not appear in FAERS. Cleland states, “In accordance with the mifepristone prescribing information, Planned Parenthood Federation of America reports all significant adverse events and outcomes to Danco Laboratories, the US distributor of mifepristone, which in turn reports them to the FDA.” If this claim is true, then either Danco did not report a significant number of adverse events to the FDA, or the FDA did not include them in FAERS. It also raises the question of whether FAERS includes all complications reported by the other 63% of abortion providers.

We are concerned that FDA and others will continue to rely on Cleland’s statement, “significant adverse events or outcomes were reported in 1530 (0.65%) cases”\(^14\) to claim that the complication rate for the abortion pill regimen is low. Although Cleland’s paper is a study of over 200,000 abortions and is cited extensively in support of the safety of medical abortion\(^8\)–\(^11\), the analysis excludes the most common adverse events (retained products of conception and hemorrhage not requiring transfusion). Additionally, Cleland’s reported complication rate of 0.65% is only a report of the complications known to Planned Parenthood. Cleland does not report the percent of patients lost to follow-up.\(^4\)

There is also concern that the FDA will continue to rely on the FAERS to make decisions about removing mifepristone REMS, despite the findings herein that FAERS does not include all the events even known to the abortion provider. To compound this problem, in 2016, the FDA eliminated the requirement to report adverse events resulting from mifepristone other than death.\(^12\) Nevertheless, in her April 12, 2021 letter to the American College of Obstetricians and Gynecologists, FDA Commissioner Janet Woodcock stated that, based on a review of post-marketing AEs from January 27, 2020, to January 12, 2021, the in-person dispensing requirements in the mifepristone REMS would not be enforced.\(^13\) It is alarming that policy decisions that affect women’s safety are based on a lack of information in the FAERS. Whether the inaccuracy of FAERS extends to required reporting for other medications is unknown to us, but the findings in this paper have significant implications for drug safety evaluation in general.

The ability of the FAERS to accurately identify complications from mifepristone abortion depends on 1. the abortion provider being aware of the adverse event, 2. the provider reporting the adverse event to the manufacturer, 3. the manufacturer reporting to the FDA, and 4. the FDA including the event in the FAERS. One problem inherent in this system is that adverse events unknown to the abortion provider or occurring in patients lost to follow-up will be missed. In addition, ED physicians or treating physicians other than the abortion provider were never obligated to report and may not even be aware of the system. For those events known to Planned Parenthood, it is unclear whether the error occurred in the abortion provider reporting to the manufacturer, the manufacturer reporting to the FDA, or the FDA uploading to the database.

FDA compliance in response to FOIA requests is required by law.\(^3\) The number of AERs supplied under FOIA is much lower than the number in the FAERS database and known to the FDA at the time. Although there may be extenuating circumstances requiring that some information be withheld, withholding information, especially to this extent, interferes with independent, scientific analysis necessary to validate claims of safety and efficacy.

### Strengths and Limitations

One of the limitations of this study is that Cleland only reported on a limited number of possible AEs. Because of the scant information included in the FAERS, we could not even compare all AEs reported by Cleland. Since we do not have

---

**Table I. Comparison of Number of Specific Adverse Events\(^a\) from Three Sources.**

<table>
<thead>
<tr>
<th></th>
<th>2009 Cleland</th>
<th>FAERS(^b)</th>
<th>FOIA</th>
<th>2010 Cleland</th>
<th>FAERS(^b)</th>
<th>FOIA</th>
<th>Total 2009 to 2010 Cleland</th>
<th>FAERS(^b)</th>
<th>FOIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital Admission</td>
<td>70</td>
<td>87</td>
<td>14</td>
<td>65</td>
<td>125</td>
<td>94</td>
<td>135</td>
<td>212</td>
<td>108</td>
</tr>
<tr>
<td>Transfusion</td>
<td>42</td>
<td>10</td>
<td>72</td>
<td>72</td>
<td>59</td>
<td>114</td>
<td>238</td>
<td>132</td>
<td></td>
</tr>
<tr>
<td>ED Treatment</td>
<td>87</td>
<td>27</td>
<td>151</td>
<td>105</td>
<td>57</td>
<td>32</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV Antibiotics</td>
<td>23</td>
<td>5</td>
<td>34</td>
<td>27</td>
<td>57</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infection requiring IV Antibiotics or Admission</td>
<td>14</td>
<td>4</td>
<td>23</td>
<td>21</td>
<td>37</td>
<td>25</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td></td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Ongoing Pregnancy</td>
<td>548</td>
<td>56</td>
<td>7</td>
<td>610</td>
<td>32</td>
<td>95</td>
<td>1158</td>
<td>95</td>
<td>39</td>
</tr>
<tr>
<td>Ectopic Pregnancy</td>
<td>8</td>
<td>8</td>
<td>1</td>
<td>8</td>
<td>9</td>
<td>8</td>
<td>16</td>
<td>17</td>
<td>9</td>
</tr>
</tbody>
</table>

\(^a\)Events are not mutually exclusive.

\(^b\)If blank, FAERS dashboard does not provide this detail.
access to the Planned Parenthood records, reports cannot be evaluated on a patient-by-patient basis but only as a composite.

One of the strengths of this study is that it is the first known study comparing FAERS data with an outside report of mifepristone complications.

**Conclusions**

There are significant discrepancies in the number of AEs and total AERs reported for 2009 and 2010 mifepristone abortions identified by Planned Parenthood as reported by Cleland, those in FAERS, and those provided by FOIA, impugning the reliability of FAERS to evaluate the safety or efficacy of mifepristone abortions at a time when the FDA is under pressure to eliminate REMS on mifepristone. The FDA used their review of post-marketing adverse events that occurred in 2020 and 2021 as a rationale for removing the in-person dispensing requirements for mifepristone during COVID, even though reporting requirements (other than death) were eliminated in 2016. Whether Planned Parenthood did not submit all the AEs to Danco, Danco did not submit all to the FDA, or the FDA did not include all is unknown. By withholding a significant number of AERs, the FDA did not adequately comply with the FOIA request by the authors of the Aultman paper, hampering their ability to analyze the data. These discrepancies, and the fact that since 2016, reporting AEs other than deaths is no longer required, demonstrate that the FAERS is inadequate to evaluate the safety of mifepristone.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship and/or publication of this article.

**ORCID iDs**

Christina A. Cirucci [https://orcid.org/0000-0002-4681-6529](https://orcid.org/0000-0002-4681-6529)
Kathi A. Aultman [https://orcid.org/0000-0002-9235-5049](https://orcid.org/0000-0002-9235-5049)

**References**

11. Gatter M, Cleland K, Nucatola DL. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days. Contraception. 2015;91(4):269-273. [https://doi.org/10.1016/j.contraception.2015.01.005](https://doi.org/10.1016/j.contraception.2015.01.005)
Author biographies

Christina A. Cirucci, MD received her Bachelor of Science in Mechanical Engineering from Virginia Tech in Blacksburg, VA and her MD from Thomas Jefferson University, Philadelphia, PA. She completed her residency in obstetrics and gynecology at the Medical College of Virginia in Richmond, VA. She is a diplomate of the American Board of Obstetrics and Gynecology and a life Fellow of the American College of Obstetricians and Gynecologists. She is a member of the Christian Medical and Dental Associations, the North American Menopause Society, the Pennsylvania Medical Society, and the Allegheny County Medical Society. She is a board member of the American Association of Pro-Life Obstetricians and Gynecologists. She worked in private practice for twenty years in Pittsburgh, PA.

Kathi A. Aultman, MD received her B.A. from Drew University in 1972, earned her MD at the University of Florida College of Medicine in 1977, and completed her OB/GYN Residency at the University of Florida affiliated Jacksonville Health Education Program in 1981. She is a diplomate of the American Board of Obstetrics and Gynecology and is currently an Associate Scholar with the Charlotte Lozier Institute. She is a member of the American Association of Pro-Life Obstetricians and Gynecologists, the Christian Medical and Dental Associations, the Florida Medical Association, and is a Life Fellow of the American College of Obstetricians and Gynecologists. She practiced medicine from 1981-2014 in Orange Park, Florida. Dr. Aultman was the co-founder and co-director of the first Rape Treatment Center in Jacksonville, Florida and performed sexual assault exams on women and children as a medical examiner for Duval and Clay Counties. She performed 1st trimester D&C with suction abortions and 2nd trimester D&Es. She also served as the Medical Director for Planned Parenthood of Northeast Florida, Inc. from 1981 to 1983.

Donna J. Harrison, MD received her MD from the University of Michigan and completed her OB/GYN residency at a University of Michigan affiliate hospital (St. Joseph Mercy Hospital). She is a diplomate of the American Board of Obstetrics and Gynecology. She is currently CEO of the American Association of Pro-Life Obstetricians and Gynecologists.
Exhibit 34

FDA Adverse Event Reporting System (FAERS)
Electronic Submissions
FDA Adverse Event Reporting System (FAERS) Electronic Submissions

Updates for Electronic Submission of Individual Case Safety Reports (ICSRs) to FAERS


Premarketing Safety Reporting

In preparation for the electronic transmission of premarketing safety reports in the International Council for Harmonisation (ICH) E2B(R3) format, FDA has posted the following documents regarding the electronic submission of ICSRs for certain investigational new drug application (IND) safety reports for drug and biological products and IND-exempt bioavailability/bioequivalence (BA/BE) safety reports to FAERS. These documents are posted to help sponsors prepare their systems for electronic submission of IND safety reports in the E2B(R3) format.


Postmarketing Safety Reporting

In preparation for the receipt of postmarketing safety reports in the E2B(R3) format, FDA has posted the following documents regarding the electronic submission of safety reports for drug and biological products to FAERS. These documents are posted to help prepare systems for electronic submissions of postmarketing safety reports.


2. FDA E2B(R3) Core and Regional Data Elements and Business Rules (/media/157982/download?attachment) (Excel file June 2023)

3. FDA E2B(R3) Forward Compatible Rules (https://www.fda.gov/media/157993/download) (Excel file April 2022)

4. FDA ICSR XML Instances (/media/157983/download?attachment) (zip file September 2023)


Please note, FDA is not currently accepting the submission of postmarketing ICSRs in the E2B(R3) format. FDA will update this web page when postmarketing ICSRs will be accepted in the E2B(R3) format. In the meantime, please continue to submit postmarketing ICSRs in the E2B(R2) format.

For questions related to this update, please contact the FAERS electronic submission coordinator at faersesub@fda.hhs.gov.
This page provides drug and nonvaccine biological product manufacturers, distributors, packers, outsourcing facilities, and other interested parties with information about FDA Adverse Event Reporting System (FAERS) electronic submissions and instructions on how to electronically submit postmarketing individual case safety reports (ICSRs) with and without attachments.

Since 2000, FDA has accepted electronic submissions of both expedited and non-expedited Individual Case Safety Reports (ICSRs) for human drug and nonvaccine biologic products. To date, FDA has only accepted electronic submissions of ISCRs in the XML format, prepared in accordance with International Conference on Harmonisation-E2B (ICH E2B) (/media/76278/download) (PDF - 266KB) to transmit information directly from database-to-database using standardized (ICH E2B(M)) data elements.

Starting June 10, 2015,* FDA is requiring that applicants electronically submit all ICSRs, ICSR attachments, and periodic safety reports. There are two options for submitting ICSRs electronically:

- Database-to-database transmission (“E2B”)
- The Safety Reporting Portal (SRP) by manually entering the data via our SRP portal.
- Attachments: for both methods, we will only accept attachments in the PDF format.


Submitting Individual Case Safety Reports (ICSRs), ICSR Attachments, & Periodic Safety Reports (PSRs)

1. **Electronic submission of ICSRs**
   You have the 2 options for submitting ICSRs electronically.

   **ICSR Option A: Database-to-Database Transmission (“E2B”)**
   - ICSRs must be submitted in the XML format.
   - Attachments must be in the pdf format.
   - See document “Specifications for Preparing and Submitting Electronic ICSRs and ICSR Attachments (/media/132096/download?attachment)” (PDF - 204KB). XML files are submitted to the FDA via the Electronic Submissions Gateway (ESG).
   - For additional instruction on how to begin submitting ICSRs in the XML format, go to our document titled, "Steps to Submitting ICSRs Electronically in the XML".
ICSR Option B: Safety Reporting Portal (SRP)

Applicants and non-applicants who do not have database-to-database capability may submit electronic ICSRs using the SRP. To submit via SRP, you must have an account to access the portal site. Those who are Gateway partners cannot use the SRP. Gateway partners are those companies that submit electronically via the Electronic Submission Gateway.

Steps for requesting an SRP account

- Contact FAERSESUB@fda.hhs.gov to advise FDA of your intent to begin submitting via the SRP.

SRP account activation

- Your account will be activated in about 7 to 10 business days.
- You will be notified via email with the subject line “SRP Account Activation” that will include the web link to the SRP portal along with account information.
- After receiving this email, your account will be considered active and you may begin submitting reports.

2. Submitting ICSR Attachments

Attachments to ICSRs include supporting information for ICSRs such as relevant hospital discharge summaries and autopsy reports, death certificate, and published articles for ICSRs based on scientific literature.

- Database-to-Database Transmission (“E2B”).
  - Submit attachments to ICSRs through the electronic submission gateway (ESG). See page 32 of the document “Specifications for Preparing and Submitting Electronic ICSRs and ICSR Attachments” (PDF - 204KB).

- Safety Reporting Portal (SRP).
  - To submit ICSR attachments via the SRP, use the features within the portal that allows you to browse, select, and attach documents to an ICSR.

3. Submitting Periodic Safety Reports (PSR)

Periodic safety reports are comprised of a descriptive portion and non-expedited ICSRs (21 CFR 314.80 and 600.80), regardless of the format.

1. Descriptive Portion:
- Use Electronic Common Technical Document (eCTD) specifications to submit the descriptive portion electronically.

- Indicate in the descriptive portion that the ICSRs have been submitted electronically as XML files to the FDA Electronic Submissions Gateway (ESG) or via the Safety Reporting Portal (SRP).

2. **Non-expedited ICSRs:** must be submitted as described above and on or before the periodic safety report due date. Do NOT submit expedited ICSRs previously submitted.

**Resources For You**

- FAQ: Combination Products
- FAERS Submissions Frequently Asked Questions
- Public Meeting: Electronic Submission of Adverse Event Reports to FDA Adverse Event Reporting System (FAERS) using International Council for Harmonisation (ICH) E2B(R3) Standards
- FAQs: Safety Reporting Portal
Exhibit 35

Specifications for Preparing and Submitting Electronic ICSRs and ICSR Attachments

(April 2021),

https://www.fda.gov/media/132096/download
Specifications for Preparing and Submitting Electronic ICSRs and ICSR Attachments

Technical Specifications Document

Associated Guidance Documents and Conformance Guide:

Draft Guidance for Industry: Providing Submissions in Electronic Format – Postmarketing Safety Reports (June 2014)

Guidance for Industry and FDA Staff: Postmarketing Safety Reporting for Combination Products (July 2019)


Electronic Submissions of IND Safety Reports Technical Conformance Guide (October 2019)

For questions regarding this technical specifications document, contact the Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, at FAERSESUB@fda.hhs.gov; or Office of Communication, Outreach and Development, Center for Biologics Evaluation and Research, Food and Drug Administration, at CBERICSRSUBMISSIONS@fda.hhs.gov.

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)

April 2021
## Specifications for Preparing and Submitting Electronic ICSRs and ICSR Attachments

### Revision History Table

<table>
<thead>
<tr>
<th>Date</th>
<th>Version</th>
<th>Summary of Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008-06-11</td>
<td>1.0</td>
<td>Initial Version</td>
</tr>
<tr>
<td>2008-08-06</td>
<td>1.1</td>
<td>Added Filename format information</td>
</tr>
<tr>
<td>2008-10-10</td>
<td>1.2</td>
<td>Updated UTF-8 to ISO-8859-1 encoding; indicated simultaneous acceptance of ICSR and ICSR attachments; provided another acceptable file extension for SGML files; and clarified use of abbreviations (NDA, ANDA, and STN)</td>
</tr>
<tr>
<td>2008-10-22</td>
<td>1.3</td>
<td>Provided clarification in Section II; updated footnote 3; and added new paragraph to Section V.C.</td>
</tr>
<tr>
<td>2013-07-05</td>
<td>1.4</td>
<td>Updated AERS to FAERS migration changes, removed references to SGML file formatting, incorporated updates from CBER</td>
</tr>
<tr>
<td>2018-02-06</td>
<td>1.5</td>
<td>Added a new section to highlight data fields for reporting ICSRs on Combination Products</td>
</tr>
<tr>
<td>2019-09-30</td>
<td>1.6</td>
<td>Added two new sections to provide regional data elements for electronic submissions of certain IND safety reports (section I) and IND-exempt Bioavailability (BA)/Bioequivalence (BE) studies (section J). Added an appendix (II) highlighting various case scenarios for electronic submissions of IND safety reports to FAERS.</td>
</tr>
<tr>
<td>Date</td>
<td>Version</td>
<td>Changes</td>
</tr>
<tr>
<td>------------</td>
<td>---------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 2020-02-11 | 1.7     | Added a new value to the data element B.4.k.1 for drug characterization to accommodate a similar device.  
Updated the data element B.4.k.18.2 to specify values.  
Updated the data element B.4.k.18.3 to use default value. |
| 2020-12-18 | 1.8     | Added a new regional data element A.1.FDA.16 (FDA Safety Report Type) in Table 2 Detailed Description of Administrative Tags  
Added section Submission Rules  
Added a new value to the data element B.4.k.1 and B.4.k.19 in section J. IND-exempt BA/BE Studies |
| 2021-03-26 | 1.9     | Updated section XML Header to include DTD 3.0 for premarketing reporting  
Updated the reference description to data element A.1.FDA.16 in Table 2 Detailed Description of Administrative Tags  
Updated section ICSR Message Header Information to include information in premarketing reporting  
Updated section AS2 Headers and Routing IDs for Premarketng Safety Report Submissions  
Updated section Submission Rules |
Specifications for Preparing and Submitting
Electronic ICSRs and ICSR Attachments

Table of Contents

I. ELECTRONIC SUBMISSIONS OF ICSRS AND ICSR ATTACHMENTS.................. 6

II. SUBMISSION FILE NAME .......................................................................................... 7

III. ICSR ACKNOWLEDGEMENTS.......................................................................................... 7

A. ESG ACKNOWLEDGEMENT............................................................................................. 7
B. FAERS ACKNOWLEDGMENT........................................................................................... 7

IV. ELECTRONIC TRANSPORT FORMAT: XML FILES.............................................. 7

A. AS2 HEADERS AND ROUTING IDS FOR POSTMARKETING SAFETY REPORT SUBMISSIONS ... 8
B. AS2 HEADERS AND ROUTING IDS FOR PREMARKETING SAFETY REPORT SUBMISSIONS...... 8
C. XML HEADER ............................................................................................................... 9
D. ICSR MESSAGE HEADER INFORMATION........................................................................ 10
E. ICSR FILE EXTENSION ................................................................................................. 10

V. DATA ELEMENTS FOR ELECTRONIC SUBMISSIONS........................................ 10

A. MINIMUM DATA ELEMENTS REQUIREMENTS.......................................................... 10
B. ADMINISTRATIVE AND IDENTIFICATION ELEMENTS...................................................... 11
C. AUTHORIZATION/ APPLICATION NUMBER FORMAT...................................................... 12
D. UNIQUE CASE IDENTIFICATION NUMBERS FOR INITIAL AND FOLLOW-UP ICSRs.............. 13
E. MEDDRA SPECIFIC ELEMENTS..................................................................................... 13
  1. Reaction/Event ........................................................................................................ 14
  2. Other E2B Elements ................................................................................................. 14
F. DRUG DESCRIPTION AND CASE NARRATIVE ELEMENTS....................................... 15
  1. Recording Multiple Drugs....................................................................................... 15
  2. Medicinal Product Name and Active Drug Substance Name..................................... 15
  3. Case Narrative ........................................................................................................ 16
G. OTHER DATA ELEMENTS............................................................................................ 16
  1. Dosage Information Field........................................................................................ 16
  2. Pharmaceutical Form Field..................................................................................... 16
  3. Route of Administration Field................................................................................ 16
  4. Receiver Field (A.3.2)............................................................................................. 16
  5. Message Receiver Field (M.I.6)............................................................................... 17
H. DATA ELEMENTS FOR ELECTRONIC SUBMISSIONS OF SAFETY REPORTS FOR
  POSTMARKETING COMBINATION PRODUCTS........................................................... 17
I. DATA ELEMENTS FOR ELECTRONIC SUBMISSIONS OF IND SAFETY REPORTS ....................... 28
J. DATA ELEMENTS FOR ELECTRONIC SUBMISSIONS OF ICSRs FROM IND-EXEMPT BIOAVAILABILITY (BA)/ BIOEQUIVALENCE (BE) STUDIES ................................................................. 35

VI. ELECTRONIC FORMAT FOR ICSR ATTACHMENTS ...................................................... 38
A. CONVERTING THE ICSR ATTACHMENT TO PDF .......................................................... 38
B. IDENTIFICATION INFORMATION IN THE PDF DOCUMENT INFORMATION FIELDS .... 38

VII. SUBMISSION RULES ...................................................................................................... 39

APPENDIX I. EXAMPLES OF CORRECT AND INCORRECT APPLICATION NUMBER AND DRUG ELEMENT FORMATS ......................................................................................... 41

APPENDIX II. CASE SCENARIOS FOR IND SAFETY REPORTS SUBMITTED TO FAERS ................................................................................................................................. 43

APPENDIX III. CASE SCENARIOS FOR SAFETY REPORTS FROM IND-EXEMPT BA/BE STUDIES TO FAERS ......................................................................................... 47

List of Tables
Table 1. Minimum Data Elements ...................................................................................... 11
Table 2. Detailed Description of Administrative Tags* ........................................................ 12
Table 3. Detailed Description of Application Number Formats ......................................... 13
Table 4. Additional E2B Elements for Preferred MedDRA Coding .................................... 14
Table 5. Detailed Description of Drug(s) and Narrative Elements*† ................................... 15
Table 6. Receiver Information ............................................................................................ 17
Table 7. Combination Product Data Elements .................................................................... 18
Table 8. Investigational New Drug Clinical Data Elements ................................................. 28
Table 9. Data Elements for IND-Exempt BA/BE Studies .................................................... 35
Table 10. Document Information Fields in ICSR Attachments ............................................. 39
Table 11. Submission Rules and Acknowledgement Status .................................................. 40
Table 12. Examples of Application Number Formats and Drug Element Formats ............. 41
Table 13. Case Scenario 1. For IND Safety Reports Submitted to FAERS ......................... 43
Table 14. Case Scenario 2. For IND Safety Reports Submitted to FAERS ......................... 45
Table 15. ICH E2B Data Element & Value Selections for IND-Exempt BA/BE Study Exposures .......................................................................................................................... 48

Draft Version 1.9
Specifications for Preparing and Submitting
Electronic ICSRs and ICSR Attachments

This document provides current specifications for submitting individual case safety reports (ICSRs) and ICSR attachments in electronic form. The specifications apply to electronic submission of ICSRs for drug and biological products studied under an investigational new drug application (IND) (including bioequivalence studies conducted under IND), ICSRs from IND-exempt bioavailability (BA)/bioequivalence (BE) studies, and ICSRs for marketed drug and biological products and combination products to the FDA Adverse Event Reporting System (FAERS). The specifications do not apply to the following marketed biological products: prophylactic vaccines, whole blood or components of whole blood, human cells, tissues, and cellular and tissue-based products (HCT/Ps) regulated by FDA.

This document discusses the technical specifications for electronic submission of ICSRs and ICSR attachments through the FDA Electronic Submissions Gateway (ESG). ICSRs (and any ICSR attachments) are to be prepared in accordance with the International Council for Harmonisation (ICH) E2B(R2) data elements in extensible markup language (XML) file format for compatibility with the FAERS database. ICSRs for marketed products should not be submitted to the electronic Common Technical Document (eCTD).

If you have not previously submitted an ICSR in electronic format to FAERS, you should contact the FAERS electronic submission coordinator at faersesub@fda.hhs.gov and they will assist you with submission of a test file.

I. ELECTRONIC SUBMISSIONS OF ICSRS AND ICSR ATTACHMENTS

Each initial ICSR or follow-up ICSR may consist of structured information and non-structured information, such as ICSR attachments.

For the FDA to process, review, and archive the ICSRs, prepare your ICSRs for electronic submission by following these steps:

- Provide a unique filename for the submission; see section II of this document.
- Add a file header and file extension; see section IV of this document.
- Populate the elements of the ICSR file; see section V of this document.

---

1 For information on providing submissions using the ESG, refer to https://www.fda.gov/ForIndustry/ElectronicSubmissionsGateway/default.htm.

II. SUBMISSION FILE NAME

Each electronic submission of ICSRs or attachments to ICSRs must have a unique filename (e.g., your named file + date and time stamp down to the second: filenameYYYYMMDDHHMMSS). You may choose your own format to maintain uniqueness.

III. ICSR ACKNOWLEDGEMENTS

A. ESG Acknowledgement

After submitting an ICSR or ICSR attachment, you should receive an ESG message delivery notice (MDN) notifying the sender of the receipt of their submission, but not acknowledging the acceptance of the submission. If the MDN is not received within 2 hours, go to the ESG System Status web page. If the ESG web page is non-operational, go to the ESG Home Page for further information.

B. FAERS Acknowledgment

The MDN is then followed by a FAERS acknowledgment within 2 hours of the ESG acknowledgement. The FAERS acknowledgement notifies the sender whether their submission has been processed. If you do not receive the FAERS acknowledgement, resubmit the ICSRs without changing the filename.

If you receive a report acknowledgement code 02, indicating that your submission did not process due to file error/s that are specified in the acknowledgment, then proceed as follows:

- For submission with a single ICSR, resubmit the corrected ICSR with a new unique filename.
- For a submission consisting of multiple ICSRs, if one or more ICSRs in the submission failed to process, separate those ICSRs from the processed ICSRs, correct them and resubmit only the corrected ICSRs as a new submission with a unique filename. For example, if there were 50 ICSRs in an original submission and 15 of them failed to process, then only those 15 ICSRs must be separated, corrected appropriately, and resubmitted with a new unique filename. The resubmission should not contain any of the previously processed ICSRs.

IV. ELECTRONIC TRANSPORT FORMAT: XML FILES

FDA accepts the data elements defined in the “Guidance for Industry E2BM Data Elements for
Transmission of Individual Case Safety Reports (April 2002)."\(^3\) The ICH E2B(R2) guidance provides additional information and clarification of the previously issued guidances.\(^4\)

The electronic transport format also known as the Document Type Definition (DTD) for XML files is described in the associated document “XML Formatted DTD” (DTD Version 2.1, DTD Version 2.2 and DTD Version 3.0) (see links to the documents below in section C).

**A. AS2 Headers and Routing IDs for Postmarketing Safety Report Submissions**

For postmarketing safety report submissions, the sponsors should include the unique AS2 headers or routing IDs for safety reports and attachments in one of the two ways listed below.

- AS2 Headers
  - Destination: “CDER”
  - XML files: AERS
  - PDF’s: AERS_ATTACHMENTS

  or

- Routing IDs
  - XML files: FDA_AERS
  - PDF’s: FDA_AERS_ATTACHMENTS

**B. AS2 Headers and Routing IDs for Premarketing\(^5\) Safety Report Submissions**

For premarketing safety report submissions, the sponsors should include the unique AS2 headers or routing IDs for premarketing safety reports and attachments, as listed below, to differentiate these reports between CDER and CBER, and from postmarketing ICSRs.

---

\(^3\) For information on Guidance for Industry on E2BM Data Elements for Transmission of Individual Case Safety Reports, please refer to the following: [https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073092.pdf](https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073092.pdf)

\(^4\) See the guidance for industry entitled *E2B Data Elements for Transmission of Individual Case Safety Reports* (January 1998) (E2B). FDA currently supports use of E2B data elements in addition to the E2BM data elements. However, it is preferred that ICSRs be submitted with E2BM data elements to allow for the most efficient processing of the submissions. For those who wish to use E2B data elements and the corresponding electronic transport format (ICH M2 Electronic Transmission of Individual Case Safety Reports Message Specification Final Version 2.3 Document Revision February 1, 2001 (ICH ICSR DTD Version 2.1)), please refer to documentation provided at [https://www.fda.gov/downloads/drugs/ucm149932.pdf](https://www.fda.gov/downloads/drugs/ucm149932.pdf)

\(^5\) The term premarketing safety report refers to IND safety reports and IND-exempt BA/BE studies safety reports.
1. Submitting premarketing safety reports for CDER IND and IND-Exempt BA/BE
   - AS2 Headers
     - Destination: “CDER”
     - XML files: AERS_PREMKT_CDER
     - PDF’s: AERS_ATTACHMENTs_PREMKT_CDER
     or
   - Routing IDs
     - XML files: FDA_AERS_PREMKT_CDER
     - PDF’s: FDA_AERS_ATTACHMENTs_PREMKT_CDER

2. Submitting premarketing safety reports for CBER IND
   - AS2 Headers
     - Destination: “CBER”
     - XML files: AERS_PREMKT_CBER
     - PDF’s: AERS_ATTACHMENTs_PREMKT_CBER
     or
   - Routing IDs
     - XML files: FDA_AERS_PREMKT_CBER
     - PDF’s: FDA_AERS_ATTACHMENTs_PREMKT_CBER

C. XML Header
The addition of an XML header enables FDA to process ICSRs in an XML format successfully. FDA supports only the ISO-8859-1 character set for encoding the submissions.

   1. For submissions of postmarketing safety reports for drug and biological products, add the following XML header to the ICSR file:
      <?xml version="1.0" encoding="ISO-8859-1”?>
      <!DOCTYPE ichicsr SYSTEM "https://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd”>

   2. For submissions of postmarketing safety reports for combination products, add the following XML header to the ICSR file:
      <?xml version="1.0" encoding="ISO-8859-1”?>
      <!DOCTYPE ichicsr SYSTEM "https://www.accessdata.fda.gov/xml/icsr-xml-
3. **For submissions of premarketing safety reports, add the following XML header to the ICSR file:**

```xml
<?xml version="1.0" encoding="ISO-8859-1"?>
<!DOCTYPE ichicsr SYSTEM "https://www.accessdata.fda.gov/xml/icsr-xml-v3.0.dtd">
```

### D. ICSR Message Header Information

1. **For submissions of postmarketing drug and biological product safety reports, use the value “2.1” for the DTD Descriptor **`<messageformatversion>`**:  

```xml
<messageformatversion>2.1</messageformatversion>
```

2. **For submissions of postmarketing combination product safety reports, use the value “2.2” for the DTD Descriptor **`<messageformatversion>`**:  

```xml
<messageformatversion>2.2</messageformatversion>
```

3. **For submissions of premarketing safety reports, use the value “3.0” for the DTD Descriptor **`<messageformatversion>`**:  

```xml
<messageformatversion>3.0</messageformatversion>
```

### E. ICSR File Extension

Use “xml” as the file extension for ICSRs in XML format. The name of the file should be 200 characters or less, excluding the three-digit extension. FDA does not support file names with multiple periods “.” or the use of any special or foreign characters except underscore “_” and dash “-”.

### V. DATA ELEMENTS FOR ELECTRONIC SUBMISSIONS

#### A. Minimum Data Elements Requirements

For a submission to be successfully processed, submit an ICSR with the minimum data elements for reporting that are appropriate for the product type. If a sponsor submits an ICSR without the minimum data elements, they will receive a FAERS acknowledgement code 02 stating that the submission was not processed (see section III.B above). The minimum data elements for reporting are provided in Table 1 and the bullets that follow list the data elements to include in an ICSR by product type.
Table 1. **Minimum Data Elements**

<table>
<thead>
<tr>
<th>Element</th>
<th>Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>B.1</td>
<td>Identifiable Patient</td>
</tr>
<tr>
<td>A.2</td>
<td>Identifiable Reporter</td>
</tr>
<tr>
<td>B.2</td>
<td>Reaction or Event</td>
</tr>
<tr>
<td>B.4</td>
<td>Suspect Drug Product</td>
</tr>
</tbody>
</table>

- Adverse event reports submitted for unapproved prescription drug products, unapproved nonprescription drug products and products approved for marketing under an abbreviated new drug application (ANDA), biologics license application (BLA), or new drug application (NDA), including combination products should have, at a minimum, the four data elements listed in Table 1.

- Adverse event reports for compounded drugs submitted by registered outsourcing facilities should have at a minimum, a suspect product and an adverse event.

- IND safety reports should include, at a minimum, the four data elements listed in Table 1 and the IND number under which the clinical trial where the event occurred is conducted.

- Serious adverse event reports from IND-exempt BA/BE studies should include, at a minimum, the four data elements listed in Table 1 and the pre-assigned ANDA number (hereafter referred as, Pre-ANDA number).

**B. Administrative and Identification Elements**

For FDA to successfully process your electronic ICSR submissions, populate the administrative and identification elements as indicated in Table 2.
### Table 2. Detailed Description of Administrative Tags*

<table>
<thead>
<tr>
<th>Element</th>
<th>DTD Descriptor 2.1</th>
<th>Length</th>
<th>Element Values for DTD 2.1</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.1.9</td>
<td>&lt;fulfillexpeditecriteria&gt;</td>
<td>1N</td>
<td>1= Yes (15-Day expedited) 2= No (non-expedited) 4= 5-Day 5= 30-Day 6= 7-Day expedited</td>
</tr>
<tr>
<td>A.1.0.1</td>
<td>&lt;safetyreportid&gt;</td>
<td>100AN</td>
<td>Sender’s (Case) Safety Report Unique Identifier†</td>
</tr>
<tr>
<td>A.1.10.1</td>
<td>&lt;authoritynumb&gt;</td>
<td>100AN</td>
<td>Regulatory authority’s case report number</td>
</tr>
<tr>
<td>A.1.10.2</td>
<td>&lt;companynumb&gt;</td>
<td>100AN</td>
<td>Other sender’s case report number</td>
</tr>
<tr>
<td>A.3.1.2</td>
<td>&lt;senderorganization&gt;</td>
<td>60AN</td>
<td>Sender identifier</td>
</tr>
<tr>
<td>A.2.3.2†</td>
<td>&lt;sponsorstudynumb&gt;</td>
<td>35AN</td>
<td>IND or Pre-ANDA number under which the clinical trial where the event occurred is conducted</td>
</tr>
<tr>
<td>A.1.FDA.16††</td>
<td>&lt;fdasafetyreporttype&gt;</td>
<td>1N</td>
<td>1=IND Safety Report 2=IND-Exempt BA/BE Safety Report 3=Postmarketing Safety Report</td>
</tr>
</tbody>
</table>

* Include either &lt;companynumb&gt; or &lt;authoritynumb&gt; values. FDA cannot process the ICSR without one of these element values.
† The Sender’s Safety Report Unique Identifier is comparable to the Manufacturer Report Number (also referred to as the Manufacturer Control Number (MCN)) provided on paper in FDA Form 3500A. This number is the company’s unique case identification number, which is used for the life of the case. †† For IND and IND-exempt BA/BE study safety reports only. An IND-exempt BA/BE study refers to a BA/BE study not conducted under IND.

C. Authorization/ Application Number Format

In the section designated for drug and biological products information, use the following format for the “Authorization/ Application Number” element (B.4.k.4.1) &lt;drugauthorizationnumb&gt; as indicated in Table 3 and described below.

- For approved drug and biological products marketed under an approved application, include the acronym “NDA” or “ANDA,” followed by a space and then the number for the application (e.g., NDA 012345, ANDA 012345). For prescription drug products marketed without an approved application (Rx No Application), use “000000.” For a nonprescription drug product marketed without an approved application (Non-Rx No
Application), use “999999.” For adverse event reports for compounded drug products submitted by registered outsourcing facilities, use “COMP99.”

- For marketed biological products, include the appropriate acronym “BLA,” “STN,” or “PLA” followed by a space and the primary six-digit number (e.g., STN 123456).

<table>
<thead>
<tr>
<th>Table 3. Detailed Description of Application Number Formats</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type of Application</strong></td>
</tr>
<tr>
<td>NDA/ANDA</td>
</tr>
<tr>
<td>STN/BLA/PLA</td>
</tr>
<tr>
<td>Rx No Application</td>
</tr>
<tr>
<td>Non-Rx No Application</td>
</tr>
<tr>
<td>Compounded Products</td>
</tr>
</tbody>
</table>

D. **Unique Case Identification Numbers for Initial and Follow-Up ICSRs**

For the follow-up ICSR safety reports to be correctly linked to your initial ICSR report, follow these steps:

- Use the same `<safetyreportid>` for the E2BM elements in section A.1.0.1 for the initial ICSR and any of its follow-up ICSRs; this allows the follow-up report to be linked to the initial report in the FAERS database.

- If the initial ICSR was submitted on paper but its follow-up ICSR is submitted electronically, include the Manufacturer Control Number (MCN) listed in Box G9 of the FDA paper Form 3500A from the initial report in both A.1.0.1 `<safetyreportid>` and in A.1.10.2 `<companynumb>` field in the follow-up electronic submission.

- Always use the `<safetyreportid>` that was assigned to the initial ICSR when submitting follow-up reports. If you need to change the `<safetyreportid>` internally, note the internally reassigned `<safetyreportid>` in the narrative section of the follow-up report (i.e., element B.5.1) (e.g., “This ICSR has been reassigned to the Company ID number COA12345”). Do not use the internally reassigned `<safetyreportid>` for any follow-up reports.

- In the event that an incorrect `<safetyreportid>` has been used in a follow-up report, contact the FAERS electronic submission coordinator at faersesub@fda.hhs.gov so that the follow-up ICSR can be matched to the initial ICSR.

E. **MedDRA Specific Elements**

Use the ICH Medical Dictionary for Regulatory Activities (MedDRA) to code medical
terminology. When possible, use the Lowest Level Term (LLT), and record the LLT as the MedDRA numeric code rather than the LLT name (e.g., the LLT name is Rash; the MedDRA numeric code for LLT Rash is 10378444).

1. **Reaction/Event**
   
a) **Reaction/Event as reported by the primary source field**

   Record the original reporter’s words verbatim and/or use short phrases to describe the reaction/event in element (B.2.i.0).

   b) **Reaction/Event MedDRA Term LLT numeric code or text field**

   Record the MedDRA LLT that most closely corresponds to the term reported by the original reporter in element (B.2.i.1).

   c) **Reaction/Event MedDRA Preferred Term (PT) numeric code or text field**

   Record the MedDRA PT that most closely corresponds to the term reported by the original reporter in element (B.2.i.2).

2. **Other E2B Elements**

   For the E2B elements listed in Table 4, use either MedDRA text or, preferably, the corresponding numeric code.

Table 4. **Additional E2B Elements for Preferred MedDRA Coding**

<table>
<thead>
<tr>
<th>Element</th>
<th>DTD Descriptor 2.1</th>
<th>Length</th>
</tr>
</thead>
<tbody>
<tr>
<td>B.1.7.1a.2</td>
<td>&lt;patientepisodename&gt;</td>
<td>250 AN</td>
</tr>
<tr>
<td>B.1.8f.2</td>
<td>&lt;patientdrugindication&gt;</td>
<td>250 AN</td>
</tr>
<tr>
<td>B.1.8g.2</td>
<td>&lt;patientdrugreaction&gt;</td>
<td>250 AN</td>
</tr>
<tr>
<td>B.1.9.2b</td>
<td>&lt;patientdeathreport&gt;</td>
<td>250 AN</td>
</tr>
<tr>
<td>B.1.9.4b</td>
<td>&lt;patientdeterminemultipleautopsy&gt;</td>
<td>250 AN</td>
</tr>
<tr>
<td>B.1.10.7.1a.2</td>
<td>&lt;parentmedicalepisodename&gt;</td>
<td>250 AN</td>
</tr>
<tr>
<td>B.1.10.8f.2</td>
<td>&lt;parentdrugindication&gt;</td>
<td>250 AN</td>
</tr>
<tr>
<td>B.1.10.8g.2</td>
<td>&lt;parentdrugreaction&gt;</td>
<td>250 AN</td>
</tr>
<tr>
<td>B.3.1c</td>
<td>&lt;testname&gt;</td>
<td>100 AN</td>
</tr>
<tr>
<td>B.4.k.11b</td>
<td>&lt;drugindication&gt;</td>
<td>250 AN</td>
</tr>
<tr>
<td>B.4.k.17.2b</td>
<td>&lt;drugreaction&gt;</td>
<td>250 AN</td>
</tr>
<tr>
<td>B.4.k.18.1b</td>
<td>&lt;drugreactionasses&gt;</td>
<td>250 AN</td>
</tr>
<tr>
<td>B.5.3b</td>
<td>&lt;senderdiagnosis&gt;</td>
<td>250 AN</td>
</tr>
</tbody>
</table>

---

6 Companies can license MedDRA from an international maintenance and support services organization (MSSO) (toll free number 877-258-8280; Direct 571-313-2574; fax 571-313-2345; e-mail MSSOhelp@mssotools.com).
F. Drug Description and Case Narrative Elements

To ensure the successful processing of your electronic ICSR submission, applicants are advised to populate the drug description and narrative elements as indicated in Table 5.

Table 5. Detailed Description of Drug(s) and Narrative Elements

<table>
<thead>
<tr>
<th>Element</th>
<th>DTD Descriptor 2.1</th>
<th>Length</th>
<th>Element Values for DTD 2.1</th>
</tr>
</thead>
<tbody>
<tr>
<td>B.4.k.1</td>
<td>&lt;drugcharacterization&gt;</td>
<td>1N</td>
<td>1=Suspect 2=Concomitant 3=Interacting 4=Drug not administered</td>
</tr>
<tr>
<td>B.4.k.2.1</td>
<td>&lt;medicinalproduct&gt;</td>
<td>70AN</td>
<td>Proprietary Medicinal Product Name</td>
</tr>
<tr>
<td>B.4.k.2.2</td>
<td>&lt;activesubstancename&gt;</td>
<td>100AN</td>
<td>Drug Substance Name</td>
</tr>
<tr>
<td>B.5.1</td>
<td>&lt;narrativeincludeclinical&gt;</td>
<td>20000AN</td>
<td>Case Narrative</td>
</tr>
</tbody>
</table>

*Include <medicinalproduct> and/or <activesubstancename>. FDA cannot process the ICSR without at least one of these elements.
†Appendix I lists various examples of correct drug element formats.

1. Recording Multiple Drugs

If you are submitting safety reports for products containing multiple drugs, you should follow these steps:

- List the proprietary drug product name in element (B.4.k.2.1) and/or list the drug substance name in element (B.4.k.2.2).
- List the characterization of each reported drug’s role, such as suspect, concomitant, interacting, drug not administered, or similar device in element (B.4.k.1).

2. Medicinal Product Name and Active Drug Substance Name

FDA validates medicinal product names to the available Structured Product Labeling (SPL), the submitted label (as ICSR attachment), and the Substance Registration System (SRS). These are further described below:

- When the product has an SPL, use the same naming convention as it appears in the SPL when submitting the ICSR.

---

7 The SPL is a document markup standard approved by Health Level Seven (HL7) and adopted by FDA as a mechanism for exchanging product and facility information. See [https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm).
• When submitting a product label as an attachment to an ICSR, use the name as it appears on the submitted product label.

• If no medicinal product is named and only the active substance is named, use the name of the active substance as it appears in the SRS.8

3. Case Narrative
   a) Initial ICSR
   Record all case narrative information including clinical course, therapeutic measures, outcome, and all additional relevant information in element (B.5.1). If the information exceeds the field length, consider describing the information using fewer words. Although the use of only the most widely used medical abbreviations is permissible if necessary, their use should be limited when possible.

   b) Follow-up ICSR
   Record both new information and corrections to previously submitted ICSRs in element (B.5.1).

G. Other Data Elements

1. Dosage Information Field
   If dosage information cannot be captured in the structured fields in B.4.k.5, then use the element (B.4.k.6) <drugdosagetext>.

2. Pharmaceutical Form Field
   Record the pharmaceutical form in element (B.4.k.7) <drugdosageform>. FDA accepts the European Medicines Agency (EMA) dosage codes or text.9

3. Route of Administration Field
   Code the route of administration in element (B.4.k.8) <drugadministrationroute> as described in the ICH E2B(R2) guidance.

4. Receiver Field (A.3.2)
   Complete the receiver using the code or text listed in Table 6.

8 https://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSystem-UniqueIngredientIdentifierUNII/default.htm.

9 For a complete list of EMA dosage form codes and text, please refer to https://www.ema.europa.eu/documents/other/list-pharmaceutical-dosage-forms_en.xls
### Table 6. Receiver Information

<table>
<thead>
<tr>
<th>Element</th>
<th>DTD Descriptor 2.1</th>
<th>Code or Text</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.3.2.1</td>
<td>&lt;receivertype&gt;</td>
<td>2</td>
</tr>
<tr>
<td>A.3.2.2a</td>
<td>&lt;receiverorganization&gt;</td>
<td>FDA</td>
</tr>
<tr>
<td>A.3.2.2b</td>
<td>&lt;receiverdepartment&gt;</td>
<td>Office of Surveillance and Epidemiology</td>
</tr>
<tr>
<td>A.3.2.2d</td>
<td>&lt;receivergivenname&gt;</td>
<td>FAERS</td>
</tr>
<tr>
<td>A.3.2.3a</td>
<td>&lt;receiverstreetaddress&gt;</td>
<td>10903 New Hampshire Avenue</td>
</tr>
<tr>
<td>A.3.2.3b</td>
<td>&lt;receivercity&gt;</td>
<td>Silver Spring</td>
</tr>
<tr>
<td>A.3.2.3c</td>
<td>&lt;receiverstate&gt;</td>
<td>MD</td>
</tr>
<tr>
<td>A.3.2.3d</td>
<td>&lt;receiverpostcode&gt;</td>
<td>20993</td>
</tr>
<tr>
<td>A.3.2.3e</td>
<td>&lt;receivercountrycode&gt;</td>
<td>US</td>
</tr>
<tr>
<td>A.3.2.3l</td>
<td>&lt;receiveremailaddress&gt;</td>
<td><a href="mailto:faersesub@fda.hhs.gov">faersesub@fda.hhs.gov</a></td>
</tr>
</tbody>
</table>

5. **Message Receiver Field (M.1.6)**

The following two message receiver identifiers are used by FDA to distinguish between test and production submissions:

- Test ICSRs: `<messagereceiveridentifier>ZZFDATST</messagereceiveridentifier>
- Production ICSRs: `<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>

H. **Data Elements for Electronic Submissions of Safety Reports for Postmarketing Combination Products**

To ensure the successful processing of your electronic ICSR submission for a marketed drug- or therapeutic biologic led- combination product (e.g., a combination product containing a drug/biologic and device and marketed under an NDA or a BLA), you should populate the data elements indicated in Table 7.

Note: Some of the DTD descriptors listed in Table 7 are under existing E2B(R2) header elements, and some DTD descriptors are under new data elements. Those data element numbers that are new, have the word “FDA” incorporated into the number and are U.S.-specific regional elements related to reporting on combination products.
Table 7. Combination Product Data Elements

<table>
<thead>
<tr>
<th>Data Element</th>
<th>DTD Descriptor 2.2</th>
<th>Title</th>
<th>Description</th>
<th>Length</th>
<th>Element Values for DTD 2.2</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>M.1.2</td>
<td>&lt;messageformatversion&gt;</td>
<td>Message Format Version</td>
<td>Version number of Message Format</td>
<td>3AN</td>
<td>2.2</td>
<td>Use value 2.2 if using icsr-xml-v2.2.dtd</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Use value 2.1 if using icsr-xml-v2.1.dtd</td>
</tr>
<tr>
<td>A.1</td>
<td>&lt;safetyreport&gt;</td>
<td>Header/Entity</td>
<td>Identification of the case safety report</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A.1.9</td>
<td>&lt;fulfillexpeditecriteria&gt;</td>
<td>Does this case fulfill the local criteria for an expedited report</td>
<td></td>
<td>1N</td>
<td>1=Yes 2=No 4=5-Day 5=30-Day</td>
<td>Element values= 1 for 15-Day Expedited* and 2 for periodic non-expedited†</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Element value= 4 for remedial action to prevent an unreasonable risk of substantial harm to the public health</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Element value= 5 for malfunction with no associated adverse event</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Do not use element value of 3.</td>
</tr>
<tr>
<td>A.1.FDA.15</td>
<td>&lt;combinationproductreport&gt;</td>
<td>Combination Product Report Flag</td>
<td>Combination Product Report Flag</td>
<td>1N</td>
<td>1=Yes 2=No</td>
<td></td>
</tr>
<tr>
<td>A.2</td>
<td>&lt;primarysource&gt;</td>
<td>Primary source(s) of information</td>
<td>Header/Entity</td>
<td></td>
<td>Area below should be a repeatable block</td>
<td></td>
</tr>
<tr>
<td>Data Element</td>
<td>DTD Descriptor 2.2</td>
<td>Title</td>
<td>Description</td>
<td>Length</td>
<td>Element Values for DTD 2.2</td>
<td>Notes</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------</td>
<td>-------</td>
<td>-------------</td>
<td>--------</td>
<td>--------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>A.2.1</td>
<td></td>
<td>Primary source(s)</td>
<td>Header</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A.2.1.3.FDA.4</td>
<td>&lt;reporteremailaddress&gt;</td>
<td>Reporter’s Email Address</td>
<td></td>
<td>100AN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.1.1</td>
<td>&lt;patientinitial&gt;</td>
<td>Patient</td>
<td>Patient Identifier</td>
<td>10AN</td>
<td></td>
<td>If a single report is reported for a malfunction with no adverse event, the element value should be “NONE.” If there are multiple malfunction reports with no adverse event, then the element value should be “SUMMARY.”</td>
</tr>
<tr>
<td>B.4</td>
<td>&lt;drug&gt;</td>
<td>Drug(s) Information</td>
<td>Header/ Entity</td>
<td>Area below should be a repeatable block</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.4.k.1</td>
<td>&lt;drugcharacterization&gt;</td>
<td>Characterization of drug role</td>
<td>1N</td>
<td>1=Suspect 2=Concomitant 3=Interacting 5=Similar Device</td>
<td>If the product in the report is about a similar device, the element value should be 5=Similar Device.</td>
<td></td>
</tr>
<tr>
<td>B.4.k.2</td>
<td></td>
<td>Drug Identification</td>
<td>Header</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.4.k.2.4.FDA.1a</td>
<td>&lt;expirationdateformat&gt;</td>
<td>Expiration date format</td>
<td>Product Expiration date</td>
<td>3N</td>
<td>102=CCYYMM DD 610=CCYYMM 602=CCYY</td>
<td></td>
</tr>
<tr>
<td>B.4.k.2.4.FDA.1b</td>
<td>&lt;expirationdate&gt;</td>
<td>Expiration date</td>
<td>Product Expiration date</td>
<td>8N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data Element</td>
<td>DTD Descriptor 2.2</td>
<td>Title</td>
<td>Description</td>
<td>Length</td>
<td>Element Values for DTD 2.2</td>
<td>Notes</td>
</tr>
<tr>
<td>-----------------------</td>
<td>--------------------</td>
<td>----------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>--------</td>
<td>---------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>B.4.k.2.FDA.5</td>
<td>&lt;productavailableforevaluation&gt;</td>
<td>Product available for evaluation</td>
<td>Indicate whether product is available for evaluation</td>
<td>1N</td>
<td>1=Yes 2=No 3=Return</td>
<td></td>
</tr>
<tr>
<td>B.4.k.2.6.FDA.1a</td>
<td>&lt;productreturndateformat&gt;</td>
<td>Product return date format</td>
<td>Date Format</td>
<td>3N</td>
<td>102=CCYYMM DD 610=CCYYMM 602=CCYY</td>
<td></td>
</tr>
<tr>
<td>B.4.k.2.6.FDA.1b</td>
<td>&lt;productreturndate&gt;</td>
<td>Product return date</td>
<td>Date when Product was returned</td>
<td>8N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.1</td>
<td>&lt;brandname&gt;</td>
<td>Brand Name</td>
<td>The trade or proprietary name of the device constituent part of the suspect combination product as used in product labeling or in the catalog</td>
<td>80AN</td>
<td>At least one of the 3 must be reported &lt;brandname&gt; or &lt;commondevicename&gt; or &lt;productcode&gt; for the device constituent part</td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.2</td>
<td>&lt;commondevicename&gt;</td>
<td>Common Device Name</td>
<td>Generic or common name of the device constituent part of the suspect combination product or a generally descriptive name</td>
<td>80AN</td>
<td>At least one of the 3 must be reported &lt;brandname&gt; or &lt;commondevicename&gt; or &lt;productcode&gt; for device constituent part</td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.3</td>
<td>&lt;productcode&gt;</td>
<td>Product Code</td>
<td>Product code</td>
<td>3AN</td>
<td><a href="http://www.acce">http://www.acce</a></td>
<td>At least one of the 3 must be</td>
</tr>
<tr>
<td>Data Element</td>
<td>DTD Descriptor 2.2</td>
<td>Title</td>
<td>Description</td>
<td>Length</td>
<td>Element Values for DTD 2.2</td>
<td>Notes</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------</td>
<td>------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>--------</td>
<td>---------------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>B.4.k.20.FDA.4</td>
<td>&lt;manufacturer&gt;</td>
<td>Manufacturer</td>
<td>Header/ Entity</td>
<td></td>
<td></td>
<td>reported <code>&lt;brandname&gt;</code> or <code>&lt;commondevicename&gt;</code> or <code>&lt;productcode&gt;</code> for device constituent part</td>
</tr>
<tr>
<td>B.4.k.20.FDA.4a</td>
<td>&lt;manufacturername&gt;</td>
<td>Device Manufacturer Name</td>
<td>Manufacturer name of the device constituent part of the suspect combination product</td>
<td>100AN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.4b</td>
<td>&lt;manufactureraddress&gt;</td>
<td>Manufacturer Address</td>
<td>Manufacturer address of the device constituent part of the suspect combination product</td>
<td>100AN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.4c</td>
<td>&lt;manufacturercity&gt;</td>
<td>Manufacturer City</td>
<td>Manufacturer city of the device constituent part of the suspect combination product</td>
<td>35AN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.4d</td>
<td>&lt;manufacturerstate&gt;</td>
<td>Manufacturer State</td>
<td>Manufacturer state of the device</td>
<td>40AN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data Element</td>
<td>DTD Descriptor 2.2</td>
<td>Title</td>
<td>Description</td>
<td>Length</td>
<td>Element Values for DTD 2.2</td>
<td>Notes</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------</td>
<td>-------</td>
<td>-------------</td>
<td>--------</td>
<td>---------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>B.4.k.20.FDA.4e</td>
<td>&lt;manufacturercountry&gt;</td>
<td>Manufacturer Country</td>
<td>Manufacturer country of the device constituent part of the suspect combination product</td>
<td>2AN</td>
<td>ISO3166</td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.5</td>
<td>&lt;modelnumber&gt;</td>
<td>Model Number</td>
<td>Model number of the device constituent part</td>
<td>30AN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.6</td>
<td>&lt;catalognumber&gt;</td>
<td>Catalog Number</td>
<td>Catalog number of the device constituent part</td>
<td>30AN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.7</td>
<td>&lt;serialnumber&gt;</td>
<td>Serial Number</td>
<td>Serial number of the device constituent part</td>
<td>30AN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.8</td>
<td>&lt;udinumber&gt;</td>
<td>Unique Identifier UDI#</td>
<td>Unique identifier of the device constituent part</td>
<td>50AN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.9a</td>
<td>&lt;dateimplantedformat&gt;</td>
<td>Device Implant Date Format</td>
<td>Date format of device implant in the patient</td>
<td>3N</td>
<td>102=CCYYMM DD 610=CCYYMM 602=CCYY</td>
<td>For medical devices that are implanted in the patient, provide the implant date or best estimate. If day is unknown, month and year are acceptable. If month and day are unknown, year is acceptable.</td>
</tr>
<tr>
<td>Data Element</td>
<td>DTD Descriptor 2.2</td>
<td>Title</td>
<td>Description</td>
<td>Length</td>
<td>Element Values for DTD 2.2</td>
<td>Notes</td>
</tr>
<tr>
<td>----------------------</td>
<td>-----------------------------</td>
<td>-------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>--------</td>
<td>---------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>B.4.k.20.FDA.9b</td>
<td>&lt;dateimplanted&gt;</td>
<td>Device Implant Date</td>
<td>Date of device implant in the patient</td>
<td>8N</td>
<td></td>
<td>For medical devices that are implanted in the patient, provide the implant date or best estimate. If day is unknown, month and year are acceptable. If month and day are unknown, year is acceptable</td>
</tr>
<tr>
<td>B.4.k.20.FDA.10a</td>
<td>&lt;dateexplantedformat&gt;</td>
<td>Device Explant Date Format</td>
<td>Date format of device explant from the patient</td>
<td>3N</td>
<td>102=CCYYMM DD 610=CCYYMM 602=CCYY</td>
<td>If an implanted device was removed from the patient, provide the explant date or best estimate. If day is unknown, month and year are acceptable. If month and day are unknown, year is acceptable</td>
</tr>
<tr>
<td>B.4.k.20.FDA.10b</td>
<td>&lt;dateexplanted&gt;</td>
<td>Device Explant Date</td>
<td>Date of device explant from the patient</td>
<td>8N</td>
<td></td>
<td>If an implanted device was removed from the patient, provide the explant date or best estimate. If day is unknown, month and year are acceptable. If month and day are unknown, year is acceptable</td>
</tr>
<tr>
<td>B.4.k.20.FDA.11a</td>
<td>&lt;deviceage&gt;</td>
<td>Approximate age of device/ product</td>
<td>Age of device constituent part</td>
<td>5N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.11b</td>
<td>&lt;deviceageunit&gt;</td>
<td>Approximate age unit of device/</td>
<td>Age unit of device constituent part</td>
<td>3N</td>
<td>800=Decade 801=Year 802=Month</td>
<td></td>
</tr>
<tr>
<td>Data Element</td>
<td>DTD Descriptor 2.2</td>
<td>Title</td>
<td>Description</td>
<td>Length</td>
<td>Element Values for DTD 2.2</td>
<td>Notes</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------</td>
<td>-------</td>
<td>-------------</td>
<td>--------</td>
<td>--------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>product</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.12</td>
<td>&lt;labeledsingleusedevice&gt;</td>
<td>Single Use Device</td>
<td>Indicate whether the device constituent part was labeled for single use or not</td>
<td>1N</td>
<td>1=Yes 2=No</td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.13a</td>
<td>&lt;devicemanufacturedateformat&gt;</td>
<td>Device Manufacture Date Format</td>
<td>Device Manufacture Date format</td>
<td>3N</td>
<td>102=CCYYMMDD 610=CCYYMM 602=CCYY</td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.13b</td>
<td>&lt;devicemanufacturedate&gt;</td>
<td>Device Manufacture Date</td>
<td>Device Manufacture Date</td>
<td>8N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.14</td>
<td></td>
<td></td>
<td>Remedial action initiated/ Remedial action taken for the product</td>
<td></td>
<td>Header</td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.14.1</td>
<td>&lt;remedialactionrecall&gt;</td>
<td>Recall</td>
<td>Recall initiated</td>
<td>1N</td>
<td>1=Yes 2=No</td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.14.1</td>
<td>&lt;remedialactionrepair&gt;</td>
<td>Repair</td>
<td>Repair initiated</td>
<td>1N</td>
<td>1=Yes 2=No</td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.14.1</td>
<td>&lt;remedialactionreplace&gt;</td>
<td>Replace</td>
<td>Replace initiated</td>
<td>1N</td>
<td>1=Yes 2=No</td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.14.1</td>
<td>&lt;remedialactionrelabel&gt;</td>
<td>Relabeling</td>
<td>Relabeling initiated</td>
<td>1N</td>
<td>1=Yes 2=No</td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.14.1</td>
<td>&lt;remedialactionnotify&gt;</td>
<td>Notification</td>
<td>Notification</td>
<td>1N</td>
<td>1=Yes</td>
<td></td>
</tr>
<tr>
<td>Data Element</td>
<td>DTD Descriptor 2.2</td>
<td>Title</td>
<td>Description</td>
<td>Length</td>
<td>Element Values for DTD 2.2</td>
<td>Notes</td>
</tr>
<tr>
<td>-----------------------------------------------------------------------------</td>
<td>--------------------</td>
<td>---------------------------</td>
<td>--------------------------------------------------</td>
<td>--------</td>
<td>---------------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>B.4.k.20.FDA.14.1f</td>
<td>&lt;remedialactioninspection&gt;</td>
<td>Inspection</td>
<td>Inspection initiated</td>
<td>1N</td>
<td>1=Yes 2=No</td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.14.1g</td>
<td>&lt;remedialactionpatientmonitor&gt;</td>
<td>Patient monitoring</td>
<td>Patient monitoring</td>
<td>1N</td>
<td>1=Yes 2=No</td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.14.1h</td>
<td>&lt;remedialactionmodifyadjust&gt;</td>
<td>Modification/Adjustment</td>
<td>Modification/Adjustment initiated</td>
<td>1N</td>
<td>1=Yes 2=No</td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.14.li</td>
<td>&lt;remedialactionother&gt;</td>
<td>Other</td>
<td>Other Remedial Action initiated</td>
<td></td>
<td></td>
<td>75AN</td>
</tr>
<tr>
<td>B.4.k.20.FDA.15</td>
<td>&lt;deviceusage&gt;</td>
<td>Device Usage</td>
<td>Indicate the use of the device constituent part of the suspect combination product</td>
<td>1N</td>
<td>1=Initial Use of Device 2=Reuse 3=Unknown</td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.16</td>
<td>&lt;devicelotnumber&gt;</td>
<td>Device Lot Number</td>
<td>Lot number of the device constituent part of the suspect combination product</td>
<td>35AN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.17</td>
<td>&lt;malfunction&gt;</td>
<td>Malfunction</td>
<td>Malfunction of product</td>
<td>1N</td>
<td>1=Yes 2=No</td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.18</td>
<td>&lt;followuptype&gt;</td>
<td>Follow-up type</td>
<td>Header</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.18.1a</td>
<td>&lt;followupcorrection&gt;</td>
<td>Correction</td>
<td>Correction</td>
<td>1N</td>
<td>1=Yes 2=No</td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.18.1b</td>
<td>&lt;followupadditionalinfo&gt;</td>
<td>Additional information</td>
<td>Additional information</td>
<td>1N</td>
<td>1=Yes 2=No</td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.18.1c</td>
<td>&lt;followupresponsetoFDA&gt;</td>
<td>Response to</td>
<td>Response to FDA</td>
<td>1N</td>
<td>1=Yes</td>
<td></td>
</tr>
<tr>
<td>Data Element</td>
<td>DTD Descriptor 2.2</td>
<td>Title</td>
<td>Description</td>
<td>Length</td>
<td>Element Values for DTD 2.2</td>
<td>Notes</td>
</tr>
<tr>
<td>--------------------------</td>
<td>---------------------------------------</td>
<td>--------------------------------------</td>
<td>-----------------------------------</td>
<td>--------</td>
<td>---------------------------</td>
<td>--------------------------------------------</td>
</tr>
<tr>
<td>c</td>
<td>FDA request</td>
<td>request</td>
<td></td>
<td>2=No</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.18.1d</td>
<td>&lt;followupdeviceevaluation&gt;</td>
<td>Device Evaluation</td>
<td>Device Evaluation</td>
<td>1N</td>
<td>1=Yes</td>
<td>Area Below Should be a Repeatable Block</td>
</tr>
<tr>
<td>B.4.k.20.FDA.19</td>
<td>&lt;deviceproblemandevaluation&gt;</td>
<td>Device Problem and evaluation codes</td>
<td>Header/ Entity</td>
<td></td>
<td>2=No</td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.19.1a</td>
<td>&lt;evaluationtype&gt;</td>
<td>Evaluation Type</td>
<td>Type of problem and/or the evaluation</td>
<td>2N</td>
<td>01=Device Problem</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>02=Method</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>03=Result</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>04=Conclusion</td>
<td></td>
</tr>
<tr>
<td>B.4.k.20.FDA.19.1b</td>
<td>&lt;evaluationvalue&gt;</td>
<td>Evaluation Value</td>
<td>The FDA code value based on the respective evaluation type</td>
<td>6N</td>
<td></td>
<td>The value depends on the respective &lt;evaluationtype&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>If &lt;evaluationtype&gt; = 01 --&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="https://www.fda.gov/media/146825/download">https://www.fda.gov/media/146825/download</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>If &lt;evaluationtype&gt; = 02 --&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="https://www.fda.gov/media/146827/download">https://www.fda.gov/media/146827/download</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>If &lt;evaluationtype&gt; = 03 --&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="https://www.fda.gov/media/146828/download">https://www.fda.gov/media/146828/download</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>If &lt;evaluationtype&gt; = 04 --&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="https://www.fda.gov/media/146829/download">https://www.fda.gov/media/146829/download</a></td>
</tr>
<tr>
<td>B.4.k.20.FDA.20</td>
<td>&lt;operatorofdevice&gt;</td>
<td>Operator of</td>
<td>Operator of the</td>
<td>100AN</td>
<td></td>
<td>Use the value “Health”</td>
</tr>
<tr>
<td>Data Element</td>
<td>DTD Descriptor 2.2</td>
<td>Title</td>
<td>Description</td>
<td>Length</td>
<td>Element Values for DTD 2.2</td>
<td>Notes</td>
</tr>
<tr>
<td>-------------</td>
<td>--------------------</td>
<td>-------------</td>
<td>-------------</td>
<td>--------</td>
<td>---------------------------</td>
<td>--------------------------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>the Device</td>
<td>Device</td>
<td></td>
<td></td>
<td>Professional” or “Lay User/Patient.” If none applicable, then specify the “Other” value</td>
</tr>
</tbody>
</table>

*21 CFR 314.80(c)(1) and 600.80(c)(1) use the term “15-day Alert reports.” In the combination product PMSR final rule (21 CFR 4.101), these reports are defined as “Fifteen-day reports.”

† Periodic non-expedited ICSRs are the reports required under 21 CFR 314.80(c)(2)(ii)(B) and 21 CFR 600.80(c)(2)(ii)(B) for serious, expected and nonserious adverse drug experiences.
I. Data Elements for Electronic Submissions of IND Safety Reports

To ensure the successful processing of your electronic IND ICSR submission, you should populate the following data elements as described in Table 8.

Table 8. Investigational New Drug Clinical Data Elements

<table>
<thead>
<tr>
<th>Data Element</th>
<th>DTD Descriptor 3.0</th>
<th>Title</th>
<th>Description</th>
<th>Field Length</th>
<th>Element Values for DTD 3.0</th>
<th>Notes</th>
</tr>
</thead>
</table>
| A.1.4        | <reporttype>       | Type of Report | 1N          | 1=Spontaneous  
2=Report from Study  
3=Other  
4=Not Available to Sender (unknown) | Element value= 2 for Report from Study |
| A.1.9        | <fulfillexpeditecriteria> | Does this case fulfill the local criteria for an expedited report? | 1N          | 1=Yes  
2=No  
4=5-Day  
5=30-Day  
6=7-Day | Element value=1 for 15-Day Expedited  
Element value= 6 for 7-Day Expedited |
<p>| A.1.12       | &lt;linkreportnumb&gt;  | Identification Number of the report which is linked to this report | 100AN        | Used to link all individual cases (safetyreportid) that make up an IND Safety Report submitted as a result of an Aggregate Analysis as per 312.32(c)(1)(i)(C) or for several events |</p>
<table>
<thead>
<tr>
<th>Data Element</th>
<th>DTD Descriptor 3.0</th>
<th>Title</th>
<th>Description</th>
<th>Field Length</th>
<th>Element Values for DTD 3.0</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>submitted as per (312.32(c)(1)(i)(B)) when a Narrative Summary Report is provided, this field should be populated in the IND Safety Report that contains the Narrative Summary Report.</td>
</tr>
<tr>
<td>A.2.3.1</td>
<td>&lt;studyname&gt;</td>
<td>Study Name</td>
<td></td>
<td>100AN</td>
<td>Study ID $Abbreviated Trial Name</td>
<td>The Study ID should be the same value used in the study tagging file format of the eCTD submission.</td>
</tr>
<tr>
<td>A.2.3.2</td>
<td>&lt;sponsorstudynumb&gt;</td>
<td>Sponsor Study Number</td>
<td>IND number under which the clinical trial where the event occurred is conducted</td>
<td>35AN</td>
<td>Populate this field with the Primary IND in the first block and repeat block A.2 with elements A.2.3.2 and A.2.3.3 as noted below with element value = 5 for sponsor’s other INDs evaluating suspect product (where applicable)</td>
<td></td>
</tr>
</tbody>
</table>

Include the acronym "IND" followed by a space and then the IND
<table>
<thead>
<tr>
<th>Data Element</th>
<th>DTD Descriptor 3.0</th>
<th>Title</th>
<th>Description</th>
<th>Field Length</th>
<th>Element Values for DTD 3.0</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.2.3.3</td>
<td>&lt;observestudytype&gt;</td>
<td>Study type in which the Reaction(s)/Event(s) were observed</td>
<td></td>
<td>1N</td>
<td>submitted as per (312.32(c)(1)(i)(B)), from trials conducted under more than one IND</td>
<td>number for the application (e.g. IND 123456) See Appendix II (Case Scenarios) for additional information on how to submit reports from sponsor’s other INDS (Cross-reporting).</td>
</tr>
</tbody>
</table>

Repeat this field as needed with element value=5 for each Cross-reported IND.

The first block of this element in the report must not be 5.

If element value 4 is chosen, then A.1.9=1.

See Appendix II (Case Scenarios) for additional information on how to submit reports from sponsor’s other INDS (Cross-reporting).
<table>
<thead>
<tr>
<th>Data Element</th>
<th>DTD Descriptor 3.0</th>
<th>Title</th>
<th>Description</th>
<th>Field Length</th>
<th>Element Values for DTD 3.0</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>B.1.1</td>
<td>&lt;patientinitial&gt;</td>
<td>Patient Identifier</td>
<td>10AN</td>
<td>Aggregate Analysis as per 312.32(c)(1)(i)(C) or for several events submitted as per 312.32(c)(1)(i)(B) if a Narrative Summary Report is provided 5= Cross-reported IND Safety Report</td>
<td>Scenarios) for additional information on how to submit reports from an Aggregate Analysis.</td>
<td></td>
</tr>
<tr>
<td>B.4.k.2.1</td>
<td>&lt;medicinalproduct&gt;</td>
<td>Proprietary Medicinal Product Name</td>
<td>70AN</td>
<td>For a report from an Aggregate Analysis as per 312.32(c)(1)(i)(C) or for several events submitted as per 312.32(c)(1)(i)(B) if a Narrative Summary Report is provided, the element value should be “AGGREGATE”</td>
<td>For investigational drug and biological products without an established name (i.e. INN or USAN)</td>
<td></td>
</tr>
<tr>
<td>Data Element</td>
<td>DTD Descriptor 3.0</td>
<td>Title</td>
<td>Description</td>
<td>Field Length</td>
<td>Element Values for DTD 3.0</td>
<td>Notes</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------</td>
<td>-------</td>
<td>-------------</td>
<td>--------------</td>
<td>---------------------------</td>
<td>-------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>name), prior to submitting IND safety reports to FAERS, the sponsor should submit a clinical information amendment to the IND, listing the names of the active drug substance/s and the medicinal product as they will be reported in E2B file submissions. The names should fit within the established E2B character length limits. Use company product code if no established name, for multi-ingredient products, or if name exceeds character length</td>
</tr>
<tr>
<td>B.4.k.2.2</td>
<td>&lt;activesubstancename&gt;</td>
<td>Active Drug Substance Names</td>
<td>100AN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.4.k.18</td>
<td>&lt;drugreactionrelatedness&gt;</td>
<td>Relatedness of Drug to</td>
<td></td>
<td>For IND Safety Reports, at least one suspect</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data Element</td>
<td>DTD Descriptor 3.0</td>
<td>Title</td>
<td>Description</td>
<td>Field Length</td>
<td>Element Values for DTD 3.0</td>
<td>Notes</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------</td>
<td>-------</td>
<td>-------------</td>
<td>--------------</td>
<td>----------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>B.4.k.18.1a</td>
<td>&lt;drugreactionassesmeddraversion&gt;</td>
<td>Reaction/Event</td>
<td>MedDRA Version for Reaction Assessed</td>
<td>8AN</td>
<td></td>
<td>product should have relatedness of drug to reaction/event</td>
</tr>
<tr>
<td>B.4.k.18.1b</td>
<td>&lt;drugreactionasses&gt;</td>
<td>Reaction Assessed</td>
<td></td>
<td>250AN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.4.k.18.2</td>
<td>&lt;drugassessmentsource&gt;</td>
<td>Source of Assessment</td>
<td></td>
<td>60AN</td>
<td></td>
<td>Use the value “Sponsor” or “Investigator”. Include sponsor and investigator assessment when reporting both in separate blocks</td>
</tr>
<tr>
<td>B.4.k.18.3</td>
<td>&lt;drugassessmentmethod&gt;</td>
<td>Method of Assessment</td>
<td></td>
<td>35AN</td>
<td></td>
<td>Use the value “FDA”.</td>
</tr>
<tr>
<td>B.4.k.18.4</td>
<td>&lt;drugresult&gt;</td>
<td>Result</td>
<td></td>
<td>35AN</td>
<td>1=Suspected 2=Not suspected</td>
<td>For IND Safety Reports, at least one suspect product should have relatedness of drug to reaction/event</td>
</tr>
<tr>
<td>B.5.1</td>
<td>&lt;narrativeincludeclinical&gt;</td>
<td>Case Narrative Including Clinical</td>
<td></td>
<td>20,000 AN</td>
<td></td>
<td>FDA strongly encourages sponsors to construct narratives that fit within the ICH E2B character</td>
</tr>
<tr>
<td>Data Element</td>
<td>DTD Descriptor 3.0</td>
<td>Title</td>
<td>Description</td>
<td>Field Length</td>
<td>Element Values for DTD 3.0</td>
<td>Notes</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------</td>
<td>--------------</td>
<td>---------------------------</td>
<td>-------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Course, Therapeutic Measures, Outcome, and Additional Relevant Information</td>
<td></td>
<td></td>
<td></td>
<td>limit of 20,000 AN. If your narrative exceeds this limit, sponsors should include as much of the narrative as possible in this field and submit an ICSR attachment for any text that exceeds the character limit. Sponsors should not submit an ICSR attachment containing the entire narrative and leave the case narrative field empty. For reports from Aggregate Analysis as per 312.32(c)(1)(i)(C) or for several events submitted as per 312.32(c)(1)(i)(B) where PDF is attached, put “see attached Narrative Summary Report” in this field.</td>
</tr>
</tbody>
</table>
### Data Elements for IND-Exempt BA/BE Studies

For successful processing of your electronic ICSRs submissions for a BA/BE study not conducted under an IND, you should populate the following data elements as described in Table 9.

#### Table 9. Data Elements for IND-Exempt BA/BE Studies

<table>
<thead>
<tr>
<th>Data Element</th>
<th>DTD Descriptor 3.0</th>
<th>Title</th>
<th>Description</th>
<th>Field Length</th>
<th>Element Values for DTD 3.0</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.1.4</td>
<td>&lt;reporttype&gt;</td>
<td>Type of Report</td>
<td></td>
<td>1N</td>
<td>1=Spontaneous</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2=Report from Study</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3=Other</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4=Not Available to Sender (unknown)</td>
<td></td>
</tr>
</tbody>
</table>

---

*The “parent IND” is the IND under which clinical investigations were initiated in the United States. (If the drug is being evaluated in multiple INDs, this is generally the IND with the lowest number.) NOTE: This may not be the same as the first A.2.3.2 block if the drug is being evaluated under multiple INDs.*

NOTE: See [FAERS Webpage](#) for case scenario examples for reporting IND safety reports (e.g., IND safety reports where the sponsor is evaluating suspect product under more than one IND, IND safety reports that are a result of an aggregate analysis, and IND safety reports with unapproved and approved drugs listed as suspect products).

---

_J. Data Elements for Electronic Submissions of ICSRs from IND-Exempt Bioavailability (BA)/ Bioequivalence (BE) Studies_

For successful processing of your electronic ICSRs submissions for a BA/BE study not conducted under an IND, you should populate the following data elements as described in Table 9.

**Table 9. Data Elements for IND-Exempt BA/BE Studies**

<table>
<thead>
<tr>
<th>Data Element</th>
<th>DTD Descriptor 3.0</th>
<th>Title</th>
<th>Description</th>
<th>Field Length</th>
<th>Element Values for DTD 3.0</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.1.4</td>
<td>&lt;reporttype&gt;</td>
<td>Type of Report</td>
<td></td>
<td>1N</td>
<td>1=Spontaneous</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2=Report from Study</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3=Other</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4=Not Available to Sender (unknown)</td>
<td></td>
</tr>
</tbody>
</table>

---

**Draft Version 1.9**  

EX. 35 pg. 035  

App. 0571
<table>
<thead>
<tr>
<th>Data Element</th>
<th>DTD Descriptor 3.0</th>
<th>Title</th>
<th>Description</th>
<th>Field Length</th>
<th>Element Values for DTD 3.0</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.1.9</td>
<td>&lt;fulfillexpeditecriteria&gt;</td>
<td>Does this Case Fulfill the Local Criteria for an Expedited Report?</td>
<td>1N</td>
<td></td>
<td>1=Yes 2=No 4=5-Day 5=30-Day 6=7-Day</td>
<td>Element value=1 for 15-Day Expedited Or Element value= 6 for 7-Day Expedited</td>
</tr>
<tr>
<td>A.2.3.1</td>
<td>&lt;studyname&gt;</td>
<td>Study Name</td>
<td></td>
<td>100AN</td>
<td>Abbreviated Trial Name</td>
<td></td>
</tr>
<tr>
<td>A.2.3.2</td>
<td>&lt;sponsorstudynumb&gt;</td>
<td>Sponsor Study Number</td>
<td></td>
<td>35AN</td>
<td>Pre-ANDA number for the IND-Exempt BA/BE Studies</td>
<td>Include the acronym &quot;Pre-ANDA&quot; followed by a space and then the Pre-ANDA number for the application (e.g. Pre-ANDA 123456)</td>
</tr>
<tr>
<td>A.2.3.3</td>
<td>&lt;observestudytype&gt;</td>
<td>Study Type in Which the Reaction(s)/Event(s) were Observed</td>
<td></td>
<td>1N</td>
<td>1= Clinical Trials 2= Individual Patient Use (e.g., 'Compassionate Use' or 'Named Patient Basis') 3= Other Studies (e.g., Pharmacoepidemiology, Pharmacoeconomics, Intensive Monitoring) 4= Report from Aggregate Analysis as per 312.32(c)(1)(i)(C) or for</td>
<td>Element value=“1” for Clinical Trials.</td>
</tr>
<tr>
<td>Data Element</td>
<td>DTD Descriptor 3.0</td>
<td>Title</td>
<td>Description</td>
<td>Field Length</td>
<td>Element Values for DTD 3.0</td>
<td>Notes</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------</td>
<td>-------</td>
<td>-------------</td>
<td>--------------</td>
<td>---------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>B.4.k.2.1</td>
<td>&lt;medicinalproduct&gt; Proprietary Medicinal Product Name</td>
<td></td>
<td></td>
<td>70AN</td>
<td>Several Events Submitted as per 312.32(c)(1)(i)(B) if a Narrative Summary Report is Provided 5= Cross-Reported IND Safety Report</td>
<td></td>
</tr>
<tr>
<td>B.4.k.1</td>
<td>&lt;drugcharacterization&gt; Characterization of drug role</td>
<td></td>
<td></td>
<td>1N</td>
<td>1 = Suspect 2 = Concomitant 3 = Interacting 4 = Drug not administered</td>
<td>For no exposure to a study drug use 4=Drug not administered</td>
</tr>
<tr>
<td>B.4.k.2.2</td>
<td>&lt;activesubstancename&gt; Active Drug Substance Name</td>
<td></td>
<td></td>
<td>100AN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.4.k.19</td>
<td>&lt;drugadditional&gt; Additional Information on Drug</td>
<td></td>
<td></td>
<td>100AN</td>
<td>1 = Test drug 2 = Reference drug 3 = Placebo/Vehicle 4 = Control (negative or positive) 5 = Other drug</td>
<td>Specify whether the product exposed is the Test drug, Reference drug, Placebo, Vehicle, Control or Other drug</td>
</tr>
</tbody>
</table>
VI. ELECTRONIC FORMAT FOR ICSR ATTACHMENTS

FDA can accept and archive ICSR attachments in PDF format. Currently approved formats for the non-structured component of an ICSR, such as ICSR attachments, are PDF versions 1.4 (current ICH standard) or 1.6 (current version in use at FDA). An ICSR attachment should be electronically submitted to FAERS after the associated ICSR has been submitted and accepted by FAERS.

A. Converting the ICSR Attachment to PDF

Applicants should provide an individual PDF file for each ICSR attachment. If you are submitting multiple ICSR attachments for a particular ICSR, include each attachment in the same PDF file and provide a PDF bookmark to distinguish each attachment. For example, if you are submitting a hospital discharge summary and an autopsy report for a single ICSR, include both in a single PDF file with a bookmark to the hospital discharge summary and a bookmark to the autopsy report.

B. Identification Information in the PDF Document Information Fields

Each PDF file contains fields to be completed by the author of the document. FAERS uses these fields to locate and retrieve the attachments to specific ICSRs. To enable FDA to match the attachment(s) to the correct ICSR, applicants should fill in the PDF document information fields with the appropriate E2B(R2) data elements for the ICSR as indicated in Table 10.
Table 10. Document Information Fields in ICSR Attachments

<table>
<thead>
<tr>
<th>PDF Document Information Field</th>
<th>Include/Optional</th>
<th>Document Information*</th>
<th>Length</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title</td>
<td>Include</td>
<td>A.1.0.1 &lt;safetyreportid&gt; Sender’s (Case) Safety Report Unique Identifier</td>
<td>100AN</td>
</tr>
<tr>
<td>Subject</td>
<td>Include</td>
<td>A.1.10.1 &lt;authoritynumb&gt; Regulatory Authority’s Case Report Number OR A.1.10.2 &lt;companynumb&gt; Other Sender’s Case Report Number</td>
<td>100AN</td>
</tr>
<tr>
<td>Author</td>
<td>Optional</td>
<td>A.1.11.2 &lt;duplicatenumb&gt; Other Identification Number</td>
<td>100AN</td>
</tr>
<tr>
<td>Keywords</td>
<td>Optional</td>
<td>A.1.7b &lt;receiptdate&gt; Date of Receipt of the Most Recent Information for this ICSR</td>
<td>8N</td>
</tr>
</tbody>
</table>

* The information refers to the data elements in E2B(R2)

In addition:

- Use the ISO-8859-1 character set for the information fields.
- Do not exceed the character length indicated above for each information field.
- Avoid creating any custom fields with names identical to the information fields listed in Table 10.

If you need assistance, you can contact the FAERS electronic submission coordinator at faersesub@fda.hhs.gov.

VII. SUBMISSION RULES

The submission rules define the condition that shall result in a negative acknowledgement and not be accepted by FAERS.
Table 111. Submission Rules and Acknowledgement Status

<table>
<thead>
<tr>
<th>Data Element</th>
<th>DTD Descriptor 2.1/2.2/3.0</th>
<th>Rejection Rule Description</th>
<th>Acknowledgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>NA</td>
<td>NA</td>
<td>ICSR submitted via AS2 Header where XML file: AERS or Routing ID where XML file: FDA_AERS and using DTD 3.0</td>
<td>reportacknowledgmentcode (B.1.8) = 02</td>
</tr>
<tr>
<td>NA</td>
<td>NA</td>
<td>ICSR submitted via AS2 Header where XML file: AERS_PREMKT or Routing ID where XML file: FDA_AERS_PREMKT and using DTD 2.1 or 2.2</td>
<td>reportacknowledgmentcode (B.1.8) = 02</td>
</tr>
<tr>
<td>A.1.FDA.16</td>
<td>&lt;fdasafetyreporttype&gt;</td>
<td>ICSR submitted via AS2 Header where XML file: AERS_PREMKT or Routing ID where XML file: FDA_AERS_PREMKT using DTD 3.0 and data value is empty</td>
<td>reportacknowledgmentcode (B.1.8) = 02</td>
</tr>
<tr>
<td>A.2.3.2</td>
<td>&lt;sponsorstudynumb&gt;</td>
<td>ICSR submitted via AS2 Header where XML file: AERS_PREMKT or Routing ID where XML file: FDA_AERS_PREMKT using DTD 3.0 and data value is empty or not prefixed with ‘IND’ or ‘Pre-ANDA’</td>
<td>reportacknowledgmentcode (B.1.8) = 02</td>
</tr>
</tbody>
</table>
## APPENDIX I. EXAMPLES OF CORRECT AND INCORRECT APPLICATION NUMBER AND DRUG ELEMENT FORMATS

### Table 122. Examples of Application Number Formats and Drug Element Formats

<table>
<thead>
<tr>
<th>Examples of Application Number Format</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Correct</td>
<td></td>
</tr>
<tr>
<td><code>&lt;drugauthorizationnumb&gt;NDA 012345&lt;/drugauthorizationnumb&gt;</code></td>
<td></td>
</tr>
<tr>
<td>Correct</td>
<td></td>
</tr>
<tr>
<td><code>&lt;drugauthorizationnumb&gt;BLA 123456&lt;/drugauthorizationnumb&gt;</code></td>
<td></td>
</tr>
<tr>
<td>Correct</td>
<td></td>
</tr>
<tr>
<td><code>&lt;drugauthorizationnumb&gt;NDA 012345&lt;/drugauthorizationnumb&gt;</code></td>
<td></td>
</tr>
<tr>
<td><code>&lt;drugauthorizationholder&gt;COMPANYX&lt;/drugauthorizationholder&gt;</code></td>
<td>Use the appropriate prefix for the NDA/ ANDA/ STN/ BLA/ PLA. Do not include additional data after the application number</td>
</tr>
<tr>
<td>Incorrect</td>
<td></td>
</tr>
<tr>
<td><code>&lt;drugauthorizationnumb&gt;123456/10300&lt;/drugauthorizationnumb&gt;</code></td>
<td>Use the appropriate prefix for the NDA/ ANDA/ STN/ BLA/ PLA. Do not include additional data after the application number</td>
</tr>
<tr>
<td>Incorrect</td>
<td></td>
</tr>
<tr>
<td><code>&lt;drugauthorizationnumb&gt;NDA 12-345;IND12,345&lt;/drugauthorizationnumb&gt;</code></td>
<td>Omit hyphens and commas in the application number. Do not populate the tag with two application numbers</td>
</tr>
<tr>
<td>Incorrect</td>
<td></td>
</tr>
<tr>
<td><code>&lt;drugauthorizationnumb&gt;OTC Product&lt;/drugauthorizationnumb&gt;</code></td>
<td>For a non-prescription drug product marketed without an approved application (Non-Rx No Application), use “999999”</td>
</tr>
<tr>
<td>Incorrect</td>
<td></td>
</tr>
<tr>
<td><code>&lt;drugauthorizationnumb&gt;NDA 012345(COMPANYX)&lt;/drugauthorizationnumb&gt;</code></td>
<td>Do not populate the company name in the <code>&lt;drugauthorizationnumb&gt;</code> tag</td>
</tr>
<tr>
<td><code>&lt;drugauthorizationholder&gt;&lt;/drugauthorizationholder&gt;</code></td>
<td></td>
</tr>
</tbody>
</table>
## Examples of Application Number Format

<table>
<thead>
<tr>
<th>Correct</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;medicinalproduct&gt;TYLENOL&lt;/medicinalproduct&gt;</td>
<td></td>
</tr>
<tr>
<td>&lt;activesubstancename&gt;ACETAMINOPHEN&lt;/activesubstancename&gt;</td>
<td></td>
</tr>
<tr>
<td>Correct</td>
<td></td>
</tr>
<tr>
<td>&lt;medicinalproduct&gt;MIRACLE WONDER DRUG&lt;/medicinalproduct&gt;</td>
<td></td>
</tr>
<tr>
<td>&lt;activesubstancename&gt;ACETAMINOPHEN&lt;/activesubstancename&gt;</td>
<td></td>
</tr>
<tr>
<td>Incorrect</td>
<td></td>
</tr>
<tr>
<td>&lt;medicinalproduct&gt;AMAZING DRUG OTC®&lt;/medicinalproduct&gt;</td>
<td></td>
</tr>
<tr>
<td>&lt;activesubstancename&gt;ACETAMINOPHEN 500 mg&lt;/activesubstancename&gt;</td>
<td></td>
</tr>
<tr>
<td>Incorrect</td>
<td></td>
</tr>
<tr>
<td>&lt;medicinalproduct&gt;NEW DRUG 40 mg/mL&lt;/medicinalproduct&gt;</td>
<td></td>
</tr>
<tr>
<td>&lt;activesubstancename&gt;NEWSUBSTANCE Inj&lt;/activesubstancename&gt;</td>
<td></td>
</tr>
<tr>
<td>Incorrect</td>
<td></td>
</tr>
<tr>
<td>&lt;medicinalproduct&gt;MWD&lt;/medicinalproduct&gt;</td>
<td>Do not use abbreviations for the brand</td>
</tr>
<tr>
<td>&lt;activesubstancename&gt;APAP&lt;/activesubstancename&gt;</td>
<td>name or active substance in the</td>
</tr>
<tr>
<td></td>
<td>&lt;medicinalproduct&gt; and</td>
</tr>
<tr>
<td></td>
<td>&lt;activesubstancename&gt; tags</td>
</tr>
</tbody>
</table>
APPENDIX II. CASE SCENARIOS FOR IND SAFETY REPORTS SUBMITTED TO FAERS

The following case scenarios are intended to provide examples to sponsors on the use of ICH E2B data standard elements for submission of IND safety reports to FAERS that may differ from postmarketing safety reports.

1. For any IND safety report where the sponsor is evaluating the suspect product under more than one IND (i.e. “Cross-reporting”)
   a. Repeat block A.2 for each IND
      i. Use first block A.2 to designate IND where the event occurred = “primary IND”
         1. A.2.3.2 = primary IND
         2. A.2.3.3 = data value could either be 1, 2, 3, or 4
         3. Other relevant information for the report to be populated in block A.2
      ii. Repeat block A.2 as many times as needed with only the following data elements for each IND that the sponsor holds where that suspect product is being evaluated:
          1. A.2.3.2 = IND number for each cross-reported IND
          and
          2. A.2.3.3 = 5

Table 133. Case Scenario 1. For IND Safety Reports Submitted to FAERS

<table>
<thead>
<tr>
<th>Data Element</th>
<th>DTD Descriptor 3.0</th>
<th>Title</th>
<th>Element Values for DTD</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.2.3.2</td>
<td>&lt;sponsorstudynumb&gt;</td>
<td>Sponsor Study Number</td>
<td>IND number under which the Clinical Trial where the event occurred is conducted</td>
</tr>
</tbody>
</table>
### Data Element

<table>
<thead>
<tr>
<th>Data Element</th>
<th>DTD Descriptor 3.0</th>
<th>Title</th>
<th>Element Values for DTD</th>
</tr>
</thead>
</table>
| A.2.3.3      | <observestudytype> | Study Type in Which the Reaction(s) were observed | 1= Clinical Trial  
2= Individual Patient Use (e.g. ‘Compassionate Use’ or ‘Named Patient Basis’)  
3= Other Studies (e.g. Pharmacoepidemiology, Pharmacoeconomics, Intensive Monitoring)  
4= Report from Aggregate Analysis  
312.32(c)(1)(i)(C) or for several events submitted as per  
312.32(c)(1)(i)(B) if a Narrative Summary report is provided.  
5= Cross-reported IND safety report |

2. For an IND safety report that is a result of an aggregate analysis as per 312.32(c)(1)(i)(C) or for several events submitted as per 312.32(c)(1)(i)(B) if a narrative summary report is provided:

   a. Submit one IND safety report with the IND where the event occurred in A.2.3.2 <sponsorstudynumb> (or the “parent” IND if the events occurred in multiple INDs).

      For this IND safety report, populate the data elements below in addition to other relevant information regarding the event and suspect product.

      i. Use data element = 4 in A.2.3.3<observestudytype>

      ii. Use the term “AGGREGATE” in B.1.1 <patientinitial>

   b. Section VII.A.2. of the *FDA Guidance for Industry – “Safety Reporting Requirements for INDs and BA/BE Studies” (December 2012)* discusses several submission requirements for IND safety reports that are a result of an aggregate analysis. The following two sections describe these submission elements and how they are accomplished with electronic submission to FAERS.

      1. The guidance states that IND safety reports that are a result of an aggregate analysis should contain a narrative description of the event and the results of the analysis (hereafter referred to as a “narrative
summary report”). For IND reports submitted to FAERS, attach the narrative summary report to the IND safety report as a PDF attachment (do not put the narrative summary report in the E2B narrative field).

   a. These instructions also apply to several events submitted as per 312.32(c)(1)(i)(B) if a narrative summary report is provided.

2. The guidance states that all the individual cases that were analyzed in the aggregate analysis should be submitted. Use the repeatable block A.1.12 to link all the safety report numbers for the individual supportive ICSRs (i.e. the numbers in A.1.0.1 for all the individual cases that are summarized in the narrative summary report).

   a. These instructions also apply to several events submitted as per 312.32(c)(1)(i)(B) if a narrative summary report is provided.

   b. IND safety reports previously submitted as ICSRs to FAERS do not have to be resubmitted (place the safety report numbers for these previously submitted reports in A.1.12).

   c. For IND safety reports previously submitted in eCTD format, the sponsor should list the eCTD sequence number and date of submission in the narrative summary report. (The eCTD sequence number is the unique four-digit number for each IND submission the sponsor submits in the us-regional.xml file for the eCTD submission.)

   d. IND safety reports previously submitted on paper should be attached to the IND safety report as PDF attachments.

Table 144. Case Scenario 2. For IND Safety Reports Submitted to FAERS

<table>
<thead>
<tr>
<th>Data Element</th>
<th>DTD Descriptor 3.0</th>
<th>Title</th>
<th>Element Values for DTD</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.1.12</td>
<td>&lt;linkreportnumb&gt;</td>
<td>Identification number of the report(s) which are linked to this report</td>
<td>Used to link all individual cases (safetyreportid) that make up an IND Safety Report submitted as a result of an Aggregate Analysis as per 312.32(c)(1)(i)(C) or for several events submitted as per 312.32(c)(1)(i)(B) if a narrative summary report is provided</td>
</tr>
<tr>
<td>A.2.3.2</td>
<td>&lt;sponsorstudynumb&gt;</td>
<td>Sponsor Study Number</td>
<td>IND number under which the Clinical Trial where the event occurred is conducted</td>
</tr>
<tr>
<td>Data Element</td>
<td>DTD Descriptor 3.0</td>
<td>Title</td>
<td>Element Values for DTD</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------</td>
<td>-------</td>
<td>------------------------</td>
</tr>
</tbody>
</table>
| A.2.3.3      | &lt;observestudytype&gt; | Study Type in Which the Reaction(s) were Observed | 1= Clinical Trials  
2= Individual Patient Use (*e.g.* ‘Compassionate Use’ or ‘Named Patient Basis’)  
3= Other Studies (*e.g.* Pharmacoeconomics, Intensive Monitoring)  
4= Report from Aggregate Analysis 312.32(c)(1)(i)(C)  
5= Cross-reported IND safety report |
| B.1.1        | &lt;patientinitial&gt; | Patient Identifier | For a Report from an Aggregate Analysis, the element value should be “AGGREGATE” |

3. For adverse events that occur with a marketed drug being evaluated under an IND that meets both IND and post-marketing safety reporting requirements (21 CFR 312.32 and 314.80, 600.80, or 310.305), sponsors must submit two separate ICSRs:
   a. for the marketed drug for the NDA/BLA
      and
   b. for the study drug for the IND (IND number in A.2.3.2)
APPENDIX III. CASE SCENARIOS FOR SAFETY REPORTS FROM IND-EXEMPT BA/BE STUDIES TO FAERS

Table 15 illustrates the ICH E2B data elements and element values for each IND-exempt BA/BE study exposure scenario described below:

Scenario 1: Exposure to a study drug:
This scenario applies to all drugs specified in the study protocol. For example, if a BA/BE study protocol for a generic opiate includes administration of naltrexone to each study subject prior to administration of a test or reference drug, naltrexone is a study drug, although it is not the test or reference drug. Similarly, a selective 5-HT3 receptor antagonist to prevent nausea and vomiting is considered a study drug if the BA/BE study protocol states that the drug is administered to each study subject prior to administration of a test or reference drug.

Scenario 2: Exposure to an other drug:
Other drugs are drugs taken by or administered to a subject that are not part of study conduct per protocol. For example, a subject with a diagnosis of hypertension has normal blood pressure while treated with a beta blocker. The subject meets study enrollment criteria and continues to take his beta blocker during study participation. In this situation, the beta blocker is an other drug. Similarly, if a subject develops symptoms of heartburn during participation in a BA/BE study and is permitted, by the investigator, to use a nonprescription antacid or H2 blocker for symptomatic relief, the nonprescription drug taken by the subject is an other drug.

Scenario 3: No exposure to a study drug:
A serious adverse event a subject experiences after enrollment to the study, but prior to exposure to a study drug, is subject to the expedited safety reporting requirement. To report a serious adverse event with no study drug exposure, the submitter should select values as shown in the Table 15, Scenario 3.
### Table 155. ICH E2B Data Element & Value Selections for IND-Exempt BA/BE Study Exposures

<table>
<thead>
<tr>
<th>Drug Exposure Scenario</th>
<th>Data Element</th>
<th>Element Values</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Scenario 1:</strong></td>
<td>B.4.k.1</td>
<td>Select one element value</td>
</tr>
<tr>
<td>Exposure to a <em>study</em> drug</td>
<td>B.4.k.2.1</td>
<td>Proprietary medicinal product name</td>
</tr>
<tr>
<td></td>
<td>B.4.k.2.2</td>
<td>Drug substance name</td>
</tr>
<tr>
<td></td>
<td>B.4.k.19</td>
<td>Select one from the following: 1 = Test drug, 2 = Reference drug, 3 = Placebo/Vehicle, 4 = Control (negative or positive)</td>
</tr>
<tr>
<td><strong>Scenario 2:</strong></td>
<td>B.4.k.1</td>
<td>Select one element value</td>
</tr>
<tr>
<td>Exposure to an <em>other</em> drug</td>
<td>B.4.k.2.1</td>
<td>Proprietary medicinal product name</td>
</tr>
<tr>
<td></td>
<td>B.4.k.2.2</td>
<td>Drug substance name</td>
</tr>
<tr>
<td></td>
<td>B.4.k.19</td>
<td>5 = Other drug</td>
</tr>
<tr>
<td><strong>Scenario 3:</strong></td>
<td>B.4.k.1</td>
<td>4 = Drug not administered</td>
</tr>
<tr>
<td>No exposure to a <em>study</em> drug</td>
<td>B.4.k.2.1</td>
<td>Proprietary medicinal product name</td>
</tr>
<tr>
<td></td>
<td>B.4.k.2.2</td>
<td>Drug substance name</td>
</tr>
<tr>
<td></td>
<td>B.4.k.19</td>
<td>1 = Test drug</td>
</tr>
</tbody>
</table>
Exhibit 36

Declaration of James Studnicki
DECLARATION OF JAMES STUDNICKI, SC.D., MPH, MBA

1. I, James Studnicki, state under oath that I am of at least 18 years of age, and that I am competent to testify as follows.

BACKGROUND AND QUALIFICATIONS

2. I am Vice President and Director of Data Analytics for the Charlotte Lozier Institute. From 2006 to 2016, I was the Irwin Belk Endowed Chair in Health Services Research, and Professor of Public Health Sciences, at the University of North Carolina, Charlotte, College of Health and Human Services. I was the first Director of the Master of Health Science (M.H.S.) Program in Health Finance and Management at the Johns Hopkins School of Hygiene and Public Health, where I served as a faculty member for 13 years. Subsequently, I was Chairman, Department of Health Policy and Management, and Director, Center for Health Outcomes Research, at the University of South Florida Health Sciences Center. I have also been a senior hospital executive and President of a technology company, which was started in a University incubator.

3. My research has focused on health services research, in particular the use of large-scale databases, and associated information technology, in analyzing outcomes at the patient, hospital, and community levels. I have been a frequent contributor to the health services research and public health systems and services research literatures. My publications have appeared in some of the most influential journals in public health, medical care and information technology/sciences. I have been a winner of the Article of the Year award given annually by the Public Health Systems Research (PHSR) interest group of Academy Health.

4. My work has contributed to many important research domains: quality comparisons between U.S.-trained and foreign-trained physicians; the regionalization of complex surgical procedures; data pattern recognition strategies; sub-population analytics; racial disparity in effects
of abortion; community health status and priority determination; hospital admissions from the
emergency room; career phase, workload composition, and outcomes for general surgeons;
community networks, websites, and report cards; complex adaptive systems and surgery; data
warehousing in bioterrorism surveillance; rating the health status of American communities;
malpractice claims against hospital defendants; intensive care, survival, and treatment of
terminally ill cancer patients; excessive clinical laboratory testing; state high-risk health insurance
pools; cybernetic systems and inappropriate hospital utilization; multi-hospital systems;
correlation, scaling, and sensitivity of medical audits; and state Certification of Need programs.

5. I hold both Doctor of Science (Sc.D.) and Master of Public Health (M.P.H.) degrees
from Johns Hopkins University and a Master of Business Administration (M.B.A.) degree from
the George Washington University. A copy of my curriculum vitae is attached as Exhibit “A”.

EMERGENCY ROOM UTILIZATION FOLLOWING
MIFEPRISTONE ABORTION AND SURGICAL ABORTIONS

6. In 2021, I published a peer-reviewed study with seven other coauthors in Health
Services Research and Managerial Epidemiology entitled “A Longitudinal Cohort Study of
Emergency Room Utilization Following Mifepristone Chemical and Surgical Abortions, 1999–
2015.”

7. In this research, we completed the first (and, to our best knowledge, only)
population-based longitudinal cohort study of post abortion emergency room utilization following
chemical mifepristone abortions and surgical abortions.

8. A previous study “categorized whether visits were abortion related based only on
information taken from the ER visit record. There was no independent confirmation from a
different source that an abortion had occurred.” Id. at 2.
9. The 2021 study, in contrast, relied on cases in states where Medicaid paid for abortion, so there was a confirmed “code payment for mifepristone abortion, thus eliminating the need for the treating physician to recognize a complication from a chemical abortion.” Id. at 7. The study looked at “every emergency room visit occurring within thirty days” of the abortion and “disaggregated ER visits into 3 categories: all-cause, abortion-related codes (ICD-9, 630-639) and spontaneous abortion code (ICD-9, 634).” Id. at 3.

10. We identified 423,000 confirmed induced abortions and 121,283 subsequent ER visits that occurred within 30 days of the procedure, in the years 1999-2015 to Medicaid-eligible women over 13 years of age with at least one pregnancy outcome, in the 17 states that provide public funding for abortion.

11. The study made two important findings. First, “Regression analysis definitively supports the hypothesis that chemical abortion is associated with more frequent emergency room visits of all kinds.” Id. at 6. We concluded that the actual number and per-abortion rate of ER visits following any induced abortion were increasing, but chemical abortion was consistently associated with more post abortion ER visit morbidity than surgical abortion. While surgical abortions led to ER visits 4% to 5% of the time, the percentage for chemical abortions leading to ER visits was 8% to 9% between 2002 and 2013, increasing to a peak of 14.6% from 2014 to 2015. Thus, “an ER visit is significantly more likely to occur following a prior chemical abortion than following a prior surgical abortion.” Id. at 5.

12. This increased ER rate may be because “adverse events following a mifepristone abortion are more likely to be experienced at home in the absence of a physician,” id. at 2, and because chemical abortions are sometimes provided by clinicians who lack surgical knowledge “to handle complications after chemical abortions,” id. at 7.
13. Second, “Treatment in the ER miscoded as for spontaneous abortion is consistently and progressively more likely following a chemical abortion than following a surgical abortion.” *Id.* at 4. “Spontaneous abortion” is another term for natural miscarriage. Because the study sample included women who were already confirmed by medical records to have received an abortion within the previous 30 days, the study was able to ascertain whether follow-up emergency room care was correctly coded as a complication from abortion or incorrectly coded as a complication from a miscarriage. The study determined, “As a percent of abortion-related visits (ICD-9, 630-639), visits miscoded for spontaneous abortion treatments (ICD-9, 634) following a confirmed mifepristone abortion averaged approximately 30% between 2003 and 2012 and increased between 2013 and 2015, reaching 60.9%.” *Id.* at 4. This was “2 to 4 times as likely” as miscoding after a surgical abortion. *Id.* at 3.

14. This may help explain why “[a]bortion studies in the United States consistently report lower postabortion complication rates than are documented in the international scientific literature.” *Id.* at 7. Due to miscoding, up to 60.9% of abortion complications from chemical abortions “would have been invisible to previous researchers, resulting in a large underestimation of actual mifepristone abortion complications.” *Id.* “There are likely multiple reasons for this discrepancy, but among them are the miscoding of abortion-related complications by the provider and the nondisclosure of prior abortion history by the patient.” *Id.* Also, “some abortion advocates encourage women to withhold information if seeking treatment for an adverse event.” *Id.*

15. “These findings are especially consequential because they are derived directly from all paid medical claims records, unlike most other studies of abortion complications which involve voluntary survey reporting and/or a more limited query of a select set of treatment codes.” *Id.*
16. The 2021 study made several other findings:
   a. Chemical abortions as a percentage of total abortions among the study population
grew from 4.4% in 2002 to 34.1% in 2015;
   b. For the entire 17-year study period (1999-2015), all three types of emergency room
visits are significantly more likely to occur within 30 days of the chemical abortion
procedure. Any type of visit (i.e. all-cause ER visit) is 1.22 times more likely to
occur following chemical rather than surgical abortion. An abortion-related ER
visit is 1.53 times as likely; and, a miscoded spontaneous abortion ER visit is 1.88
times more likely following a chemical abortion.
   c. Between 2002 and 2015, abortion related ER visits as a percentage of total ER visits
was consistently about twice as high for chemical abortions as surgical abortions,
reaching 14.6% versus 6.2% in 2015.
   d. ER visits miscoded as spontaneous abortion as a percentage of all ER visits, from
2005 to 2015, went from 2 to nearly 4 times as likely following a chemical rather
than a surgical abortion, reaching 8.9% of total visits versus 2.4% in 2015.
   e. Visits miscoded as spontaneous abortion as a percentage of abortion-related visits
following chemical abortion reached 60.9% in 2015, compared to 39% following
surgical abortion.
   f. The surgical abortion rate of ER visits per 1,000 abortions increased from 5.3 in
2002 to 22.0 in 2015, an increase of 315%. The chemical abortion rate of ER visits
per 1,000 abortions increased from 8.5 to 51.7 during the same time period, an
increase of 507%.
By the final observation year, 2015, more than 35% of women having any type of induced abortion were having an ER visit for some reason within 30 days of the procedure.

**HIGHER HOSPITALIZATION RATES FROM MISCODING**

17. In 2022, I published a peer-review study with eight other coauthors, also in *Health Services Research and Managerial Epidemiology*, entitled “A Post Hoc Exploratory Analysis: Induced Abortion Complications Mistaken for Miscarriage in the Emergency Room are a Risk Factor for Hospitalization.” This paper analyzed the same data as the 2021 paper.

18. Out of 423,000 confirmed induced abortions, 121,283 abortion recipients, or 28.7%, had an ER visit within 30 days.

19. A subset of those patients were admitted to the hospital, and patients who had received chemical abortions were admitted at higher rates. “Chemical abortions are significantly more likely (OR 1.80, CL 1.38-2.35) than surgical abortions to result in an RPOC [retained products of conception] admission and chemical abortions miscoded in the ER are more likely (OR 2.18, CL 1.65-2.88) than abortions without miscoding to have a subsequent RPOC admission.” *Id.* at 2.

20. In particular, chemical abortions concealed by miscoding were 2.18 times more likely to result in a subsequent hospital admission for the removal of retained products of conception (RPOC) than chemical abortions without miscoding. Chemical abortion patients also “did exhibit a striking pattern of multiple admissions (3.2 per patient) for those women who were subsequently admitted compared to 1.8 admissions per woman whose abortion was not miscoded.” *Id.*
21. The paper concluded, “It is important for emergency room personnel to obtain an accurate history when faced with an incomplete induced abortion,” and “A patient’s concealment of a chemical abortion, and/or the ER staffs’ failure to identify the failed abortion attempt, are risk factors for multiple hospital admissions and delayed provision of necessary surgical treatment, compared with care for those whose abortion is not miscoded.” *Id.* at 3.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on 9/8/23.

James Studnicki
BIBLIOGRAPHY

doi:10.1177/23333928211053965

Exhibit 37

Declaration of Priscilla K. Coleman, Ph.D.
DECLARATION OF PRISCILLA K. COLEMAN, PH.D

1. I am over 18 years of age, have personal knowledge of the matters set forth here, and am competent to make this declaration. The opinions here are mine alone, and they do not represent those of any group.

2. I was retained by the Missouri Attorney General’s Office to address topics that are within my areas of expertise and have relevance to this case.

I. BACKGROUND AND QUALIFICATIONS

3. I am a developmental psychologist and retired Professor of Human Development and Family Studies (HDFS) at Bowling Green State University (BGSU) in Ohio. I was a full-time employee at BGSU for 20 years. I received promotion to Associate Professor with tenure in 2005, and promotion to Full Professor in 2010. As a faculty member in HDFS, I was responsible for teaching the following undergraduate courses: Adolescent Development, Child Development, Life-Span Development, Parenting Processes, and Research Methods. I also advised approximately 30-60 students enrolled in the HDFS major each year, and I served on various committees at the Program, School, College, and University levels at BGSU. I have a B.A. in Psychology, an M.A. in General Psychology, and a Ph.D. in Life-Span Developmental Psychology. A current copy of my CV may be found at the very end of this declaration, entitled Exhibit A.

4. I have published over 60 peer-reviewed journal articles, with the majority related to the psychology of abortion (reproductive decision-making, psychological outcomes associated with abortion, and risk factors that increase the probability of women experiencing post-abortion mental-health declines). Based on my expertise, I often serve as an expert in civil cases involving abortion. I have given invited presentations in parliament houses in Great Britain, Northern Ireland, New South Wales, and Queensland, and I have testified before state legislative bodies and
before a U.S. congressional committee.

5. My training as a developmental research psychologist equips me to evaluate the methodological strengths and weaknesses of studies across various disciplines. I have numerous professional experiences relevant to my expertise as a methodologist. Among the most significant are doctoral-level methodology training, extensive editorial board and reviewer experience for academic journals, a reviewer for two professional organizations’ literature reviews on abortion and mental health (American Psychological Association and the National Collaborating Centre for Mental Health (NCCMH) Royal College of Psychiatrists), and teaching undergraduate and graduate research methods for 30 years.

6. The statements in this declaration are based on my education, professional experience, the research I have conducted, and my extensive and ongoing review of abortion decision-making and complications literature. The references to peer-reviewed publications in this report have been formative in shaping my opinions on the issues I address, as have other publications too numerous to mention in my ongoing review of scientific literature. I hold the opinions expressed in this report to be true to a reasonable degree of scientific certainty.

7. My career spans three decades, with publications in highly reputable academic journals. An “Impact Factor” is an index of the reputation of a journal within a discipline, and the measure incorporates the frequency an average article in a journal is cited. The majority of my publications have been in journals with Impact Factors exceeding the average for psychology (1.39) and medicine (2.90).¹ Eleven of the journals I have published in are in the top 20% of journals across all disciplines according to Journal Citation Reports (impact factor at or above 3.0). On Google Scholar, there are 7,686 peer-reviewed citations to my scholarship. Google Scholar

¹ Althouse et al., 2009.
also reports the h-index, or Hirsch index, which measures the impact of a scientist based on the total number of publications and citations to publications. Hirsch (2005) estimated that after 20 years a “successful scientist” would have a score of 20; my current h-index is 35. There is evidence that scores tend to be lower in the social and behavioral sciences, even in top ranking programs. For example, Barner et al. (2015) reported the average h-index of faculty affiliated with 25 highly ranked psychology programs was 15.67; my score is over twice as high. Finally, I am a member of Research Gate, a global community of scholars. According to Research Gate, my journal articles have been read 80,253 times, and my “Research Interest” score is 2,563—higher than 97% of affiliated scholars.

8. As outlined in my CV, I have been invited to share my research and analysis of peer-reviewed studies conducted by others in numerous countries (Australia, Canada, Chili, Ecuador, England, Germany, Ireland, Northern Ireland, Poland, Portugal, and Scotland) to wide ranging audiences, most notably in Parliament Houses as medical and government personnel evaluated current and/or future laws regulating abortion.

9. My research has been deemed reliable and utilized in courts across the U.S. as a basis for informed consent, waiting period, and mandatory counseling laws. Particularly noteworthy, my research factored heavily into the decision in Planned Parenthood Minn., N.D., S.D. v. Rounds, 686 F.3d 889, 895 (8th Cir. 2012). The First District Court of Appeals for the State of Florida also cited favorably my declaration as an expert witness assisting the State in defending a 24-hour waiting period bill. State v. Gainesville Woman Care, LLC, 278 So. 3d 216, 221 (Fla. App. 2019).

II. General Mental Health Risks Associated with Abortion

10. A number of studies affirm abortion generally as a risk factor for adverse emotional
and psychological outcomes that may require medical or psychological treatment.

11. Abortion evokes powerful negative emotions in a significant percentage of women.² This is reflected in “A Clinician’s Guide to Medical and Surgical Abortion,”³ a textbook for training abortion providers. The chapter on counseling outlines adverse reactions that women may experience after abortion, including depression, severe guilt, shame, and unresolved grief.⁴

12. Depression may include crying, suicidal ideation, poor performance in school or work, loss of interest in activities, and feelings of worthlessness. Symptoms of severe guilt might entail self-punishing behaviors, such as substance abuse or indiscriminate sexual activity, nightmares about killing or saving babies, blocking out the experience, avoiding anything that triggers memories of the event, fearing God’s punishment, and interpreting misfortune, illness, or accident as signs of God’s punishment. Symptoms of shame include relentless thoughts of being a bad person, engaging in self-destructive behaviors, and fear of anyone finding out about the abortion.

13. The number of negative emotional responses to abortion a woman experiences is a significant predictor of subsequent mental health disorders.⁵

14. Hundreds of peer-reviewed studies identify adverse mental health outcomes directly associated with abortion generally. This literature base reveals that women who choose abortion—compared to those who carry their pregnancies to term—experience an increased risk of mental health problems, including substance abuse, anxiety, depression, suicidal ideation, and

---

³ Paul, et al., 199.
⁵ 2009 longitudinal study by Fergusson and colleagues.
suicide, among other conditions and symptoms.⁶

a. For instance, in a U.S. sample, after extensive controls for other pregnancy outcomes and sociodemographic variables, abortion was associated with increased overall risk of mental health disorders (OR: 1.45). A Population Attributable Risk analysis showed 8.7% of the prevalence of mental disorders was attributable to abortion.⁷

b. A large Chinese study determined that abortion was related to increased risk of depression (OR: 1.381) and anxiety (OR: 1.211) in the first trimester of a later pregnancy, after controlling for age, education, pre-pregnancy MBI, income, and residence.⁸

c. A study of German women determined that induced abortion was positively associated with the elevated risk of psychiatric disorders.⁹

d. An Italian study found that women were more than two times more likely to commit suicide after an abortion (compared to after a birth).¹⁰

e. A study of Finnish women found a similar twofold increased risk of suicide,

---

⁶ Bradshaw & Slade, 2003; Coleman et al., 2002a, 2002b; Coleman, 2005, 2006; Cougle et al., 2003, 2005; Dingle, 2008; Fergusson et al., 2006, 2008; Gissler et al., 2005; 2015; Mccarthy, 2015; Pedersen, 2007, 2008; Reardon et al., 2003; Rees & Sabia, 2007; Sullins, 2016.
⁹ Jacob, L., Gerhard, C., Kostev, K., & Kalder, M. (2019) (finding ORs ranging from 1.75 to 2.01, including induced-abortion-predicted depression (HR=1.34), adjustment disorder (HR=1.45), and somatoform disorder (HR=1.56)).
even after implementation of new guidelines requiring post-abortion follow-up sessions at 2-3 weeks to monitor women’s mental health.\textsuperscript{11}

f. A Chinese study found the odds of suicide was nearly two times as likely in unmarried women who had an abortion compared to those who gave birth.\textsuperscript{12}

15. The above findings are also supported by a meta-analysis I published, entitled “Abortion and Mental Health: A Quantitative Synthesis and Analysis of Research Published from 1995-2009” in the British Journal of Psychiatry in 2011.

16. My review offers the largest quantitative estimate of mental health risks associated with abortion available in the world. After applying methodological selection criteria and extraction rules to minimize bias, the sample consisted of 22 studies, 36 measures of effect, and 877,297 participants (163,880 of whom experienced an abortion).\textsuperscript{13}

17. My review revealed that women who aborted (compared to women who did not) experienced an 81% increased risk for mental health problems. Following an unintended pregnancy, women who aborted had a 55% increased risk of mental health problems.\textsuperscript{14}

III. \textbf{Chemically Induced Abortions are Associated with Greater Risk for Negative Mental Health Outcomes Compared to Surgical Abortions}

18. Research indicates that women who choose chemical abortion over surgical abortion tend to exhibit greater psychological instability compared to their counterparts who choose surgical abortion.

\textsuperscript{14} Id.
19. Compared to women choosing surgical abortion, those choosing chemical abortion are more psychologically at risk, as they exhibit significantly higher rates of obsessive-compulsive symptoms, guilt, interpersonal sensitivity scores, paranoid ideation, and general psychiatric symptoms.\textsuperscript{15}

20. This fact underscores the necessity of chemical abortion patients spending time in person with a trained counselor.

21. Elimination of on-site visits for chemical abortions may put an already vulnerable segment of the abortion-seeking population at serious risk for psychological harm.

22. Some of the negative mental health impacts from chemical abortion are associated with its painfulness and disruptiveness.

   a. For instance, one study found that, compared to those who had surgical abortions, those who had chemical abortions rated their experience as more painful and as resulting in more life disruption.\textsuperscript{16}

   b. The same study found that seeing the fetus was associated with more intrusive events (nightmares, flashbacks, unwanted thoughts related to the experience).\textsuperscript{17}

23. Other researchers noted that one of the main differences between the two methods of termination is the consciousness and participation of the patient in the chemical abortion, a “process that involves blood, pain, and death.”\textsuperscript{18} As a participant in one study explained, “You really take your child’s life. I think if you see it then you see that you really do take the life of your

\textsuperscript{15} Lowenstein and colleagues (2006).
\textsuperscript{16} Slade and colleagues (1998).
\textsuperscript{17} Id.
\textsuperscript{18} Slade and colleagues (1998).
child.\textsuperscript{19}

24. Along these lines, women’s chemical-abortion experiences reveal that negative and difficult emotions following chemical abortion are common, with 38% explicitly stating problems with anxiety, depression, drug abuse, and suicidal thoughts.\textsuperscript{20}

a. For example, one woman said, “I am haunted by the image of my tiny baby. I always will be. I cut myself and even wanted to die.” Another woman recounted “[l]ooking at [her] kids thinking of another beautiful child. [She] couldn’t live with [her]self. [She was] wishing God would take [her] life.”\textsuperscript{21}

b. Many women in this chemical-abortion sample also felt regret, with 77% explicitly stating that they regretted their decision to have an abortion. One woman stated, “Had I known how badly I would feel now, I would have kept the baby, even if I had to go through it alone.”\textsuperscript{22}

25. Women who experience chemical abortion have a higher incidence of certain mental health challenges. For instance, a study of women randomized to a chemical or surgical abortion group demonstrated that, women who had chemical abortions had higher PTSD intrusion scores indicative of nightmares, unwanted thoughts, and images.\textsuperscript{23}

26. The most salient mechanisms potentially underlying the empirically documented enhanced risk for chemical abortions include the following:

a. The participatory role of the woman. In a chemical abortion, women are

---

\textsuperscript{19} Hallden and colleagues (2009).
\textsuperscript{20} Rafferty and Longbons (2020).
\textsuperscript{21} Id.
\textsuperscript{22} Id.
\textsuperscript{23} Kelly and colleagues (2010).
directly responsible for their abortions (because they take the pills themselves), which may exacerbate guilt and other negative self-directed thoughts and feelings.

b. Chemical abortion requires the woman to be more alert and involved during the process than she would be while under sedation or anesthesia during a surgical abortion. This makes it difficult for her to psychologically distance herself from what is happening.

c. The woman may (and often does) see the expelled fetus.

d. The woman is more likely to be alone and without emotional support at the time of the abortion.

e. After the chemical abortion, the woman may continue associating her home, or the bathroom, with abortion. Her home may become a trigger for uncomfortable emotions rather than a refuge.

IV. Chemically Induced Abortions are Associated with More Negative Mental Health Outcomes When Performed at Later Gestational Ages

27. In 2016, the FDA expanded the approved window of time for the use of chemical abortions from 49 days to 70 days, which potentially increases the psychological trauma from chemical abortions because the fetus—likely to be seen by the woman undergoing the chemical abortion—looks much more like a person.

28. Pre-natal development advances rapidly in the first few months of gestation.

29. At 7-weeks the developing human being is in the embryonic stage and is 0.37 inches long; whereas at 10-weeks, he or she is in the fetal stage and is much more recognizably human
with the length more than tripling to approximately 1.22 inches.\(^{24}\)

30. For instance, at 6 to 7 weeks, arm and leg buds start to grow. Some cranial nerves are visible. Eyes and ears begin to form. Tissue grows that will become the spine and other bones.\(^{25}\)

31. In week 8, arms and legs have grown longer. Hands and feet begin to form and look like little paddles. The brain continues to grow. The lungs start to form.\(^{26}\)

32. In week 9, nipples and hair follicles form. Arms grow and elbows develop. Toes can be seen. All essential organs have begun to grow.\(^{27}\)

33. In week 10, eyelids are more developed and begin to close. The outer ears begin to take shape. Facial features become more distinct.\(^{28}\)

V. Chemical Abortions are Associated with Increased Medical Complications Compared to Surgical Abortions

34. The main complications associated with chemical abortion are retaining a nonviable gestational sac or failing to expel all pregnancy tissue (aka. “incomplete abortion”), persistent bleeding, continuing pregnancy, hemorrhage, infection, and undiagnosed ectopic pregnancy.\(^{29}\)

35. A number of studies show the complication rate for chemical abortions is higher than the rate for surgical abortions.

a. For instance, one study found that 29% of women who had a chemical abortion during the second trimester experienced complications versus 4%

\(^{24}\) https://perinatology.com/Reference/Fetal%20development.htm


\(^{26}\) Id.

\(^{27}\) Id.

\(^{28}\) Id.

\(^{29}\) London, S. (2003); Macnaughton et al. (2021); Niinimäki et al. (2009); Sonalkar et al. (2017).
of women who had a surgical abortion during the same trimester.\textsuperscript{30} Another study demonstrated similar results on abortions between 14 and 24 weeks.\textsuperscript{31} Those women who received chemical abortions experienced complications at a rate of 23\% and serious complications (unplanned hospital admission, removal or injury to organ, uterine rupture, readmission within 14 days, blood transfusion, ICU admission, cardiopulmonary arrest, or death) at a rate of 3.3\%. Women who received surgical abortions had a 7\% rate of complications and a 1.5\% rate of serious complications.\textsuperscript{32}

b. Another study revealed that women undergoing a surgical abortion at 63 days’ gestation or less had four times fewer complications than women undergoing a chemical abortion during the same timeframe. Of women undergoing a chemical abortion in this timeframe, 20\% experienced adverse chemical events, 15.6\% experienced hemorrhage, 6.7\% experienced incomplete abortion, and 5.9\% experienced surgical evacuation. Comparatively, women who had a surgical abortion in this gestational timeframe, 5.6\% experienced adverse medical events, 2.1\% experienced hemorrhage, 1.6\% experienced incomplete abortion, and 1.8\% experienced surgical re-evacuation.\textsuperscript{33}

c. Another study found that, of women receiving first-trimester abortions,

\textsuperscript{31} Sonalkar, S. and colleagues (2017).
\textsuperscript{32} Id.
those who received chemical abortions experienced a 5.2% rate of abortion-related complications resulting in emergency-room visits while those who had surgical abortions experienced only a 1.3% rate of abortion-related complications resulting in emergency-room visits.34

d. Incomplete abortion is more common after chemical abortion than after surgical abortion.35

36. In fact, studies show that 33% of women who had a chemical abortion sought care during or after the self-managed chemical-abortion process.36 Another study demonstrated that self-managed chemical abortion using misoprostol provided by an online-telemedicine service resulted in 12% of patients requiring instrumentation to complete their abortions and 2% of patients experiencing one or more serious medical events.37

37. This follow-up care often occurs at hospitals rather than abortion clinics. Several factors play into this. The woman may never have received the medication for the chemical abortion at an abortion clinic in the first instance; some abortion clinics to not have after-hours support; and women often forego after-abortion care at abortion clinics generally.38

38. When continuing pregnancy occurs after an abortion, women must undergo surgical aspiration to complete the abortion, and they often seek treatment for this and other complications at hospitals rather than with abortion providers.

34 Upadhyay and colleagues (2015).
36 Moseson and colleagues (2020). This study was funded by the David and Lucile Packard Foundation, which actively advocates for and funds reproductive rights initiatives.
37 Johnson and colleagues (2023). This study was sponsored by the highly political, pro-choice organization, the Society of Family Planning (https://societyfp.org/).
38 Picker Institute, 1999 (finding that more than two-thirds of women do not return for follow-up appointments at abortion clinics).
39. In a recent study analyzing the adverse effects reported to the Food and Drug Administration (FDA) after mifepristone was used as an abortifacient, the researchers found 3,197 unique adverse effects. This included 20 deaths, 529 life-threatening complications, 1,957 severe complications, 151 moderate complications, and 3 mild complications. Certain of the 20 total deaths resulted from sepsis (9), drug toxicity/overdoses (4), ruptured ectopic pregnancy (1), hemorrhage (1), possible homicides (3), and suicide (1).39

VI. Complications From Chemical Abortions Increase When They Occur at a Later Gestational Age.

40. The risks of medical complications requiring hospital follow up after chemical abortions increase as the baby’s gestational age increases. For instance, one study showed that women who had a chemical abortion at nine or fewer weeks’ gestation went to the hospital at a rate of 3.3% and experienced heavy bleeding at a rate of 6.8%. Women who had an abortion at more than nine weeks went to the hospital at a rate of 11.7% and experienced heavy bleeding at a rate of 10.1%.40

41. Another study also found that complication rates for first-trimester chemical abortions were much lower than for complication rates for second-trimester chemical abortions.41 That study found that the medical complications associated with first trimester chemical abortions included 3.3% of patients visiting the emergency room, 5.7% of patients being admitted to the hospital, and 5.6% of patients having follow-up dilation & curettage surgery. Comparatively, the medical complications associated with second-trimester chemical abortions included 14% of patients visiting the emergency room, 12% of patients being readmitted to the hospital, 2% of

40 Endler and colleagues (2019).
patients being admitted to intensive care, and 33% having surgical intervention.

VII. Undertaking Chemical Abortion Without Meeting a Provider in Person Further Increases the Risk of Adverse Mental Health Outcomes.

42. It is important for women to meet in-person with a medical provider or other professionals prior to having an abortion—which they often do not do if they have a chemical abortion—for a number of reasons.

43. First, available scientific data has revealed high rates of abortion related stress, decisional conflict/ambivalence, uncertainty, and pressure or coercion from others among women seeking an abortion. Under such circumstances, women are likely to undergo procedures that do not meet the basic elements of informed consent.

44. For an abortion decision to meet the requirements of informed consent, the decision must be voluntary and completely free from pressure or coercion.

   a. Extensive research reveals that women who have abortions often do not freely choose them. Instead, they have an abortion because they feel varying degrees of pressure from close family members, friends, and/or abortion clinic personnel. One study reported that 31% of women made their childbirth-or-abortion decision based on persuasive messages from others.43

   b. A qualitative study with nearly 1000 participants revealed that 73% of American women who had abortions felt subtle to substantial unwanted pressure to abort. Approximately 70% were age 21 or under when they had

42 Husfeldt and colleagues (1995); Kero, Hogberg, and Lalos (2004); Ralph and colleagues (2017); Rocca and colleagues (2015); Tornbom and colleagues (1999); Kjelsvik and Gjengedal (2011); Kimport (2012); Ralph and colleagues (2018); Kjelsvik and colleagues (2018); Røseth et al (2022).

43 Harvey-Knowles (2012).
their first abortion, indirectly suggesting that a majority were low income and that their pregnancies were unintended. More than half of the women reported that the perceived pressure was great enough to influence their decision to abort, with 58.3% reporting that they decided to abort to make others happy. Many women (67.5%) said that the decision to terminate their pregnancies was one of the hardest decisions of their lives.44

c. In a quantitative analysis using the same sample of about 1,000 women from across the U.S., results revealed that situational pressure predicted anxiety, depression, substance abuse, and PTSD, after controlling for prior psychological history and demographic variables.45

d. In fact, the majority of chemical abortions are not voluntary and free from pressure or coercion. One study revealed that 53% of women did not make their decisions to have a chemical abortion independently.46 Often, the child’s father or the mother’s other family members (e.g., parents) overrode her own desire to continue the pregnancy.47

44 Coleman et al., 2017.
45 Coleman, 2018.
46 Rafferty and Longbons (2020).
47 Rafferty and Longbons (2020). For example, one woman said, “I remember my husband telling me, ‘well, don’t expect me to be too happy with the idea of having it if you decide to keep it. I won’t be too loving.’ That was a knife through my heart, and I made the tough decision to go through with the abortion.” Another woman’s father coerced her into the chemical abortion, “[M]y father…is an old school Puerto Rican who told me that I had to leave if I kept the baby. I had 2 weeks to get an abortion or else he would disown me forever.” The authors reported that, in many of the narratives, women did not feel that they had alternatives to abortion until after it was completed. One woman said: “They all tell you ‘it’s your choice’ in the moment, but you don’t feel that it is. Being unable to afford it, unable to tell your loved ones, not having the help or feeling unable to support a child. When your partner doesn’t want it like you do. All these things push you, blind you to a decision that you don’t realize will destroy you.”
e. In-person abortion counseling is also particularly important for women who are in abusive relationships,\textsuperscript{48} which they are unlikely to receive with a chemical abortion—particularly one obtained over-the-counter or through the mail.

f. Women in abusive relationships who have an abortion also have an increased risk for mental health problems, including depression, stress, and suicidal ideation.\textsuperscript{49}

45. Second, many women who seek abortions have other mental health issues that make decision-making difficult.

a. One study revealed that 17.6\% of women with a pre-existing psychiatric history experienced pressure to abort.\textsuperscript{50}

b. Women seeking an abortion also have higher-than-average rates of pre-existing mental illness,\textsuperscript{51} which can interfere with effective decision-making.\textsuperscript{52}

46. Given the number of persons who potentially affect a woman’s abortion decision and the rates of mental illness in women determining whether to abort, a woman needs an in-person meeting with a medical provider or trained professional before an abortion to ensure that her choice is a voluntary one and that she is choosing the most appropriate reproductive outcome for her unique situation.

\textsuperscript{48} Pallitto et al. (2013) (finding that that 30\% of abortions were directly related to intimate-partner violence).

\textsuperscript{49} Ely, Nugent, Cerel, & Vimba, 2011; Ely, Nugent, & Flaherty, 2009; Ely & Otis, 2011.

\textsuperscript{50} van Ditzhuijzen and colleagues (2015).

\textsuperscript{51} Van Ditzhuijzen and colleagues (2013).

\textsuperscript{52} C\'aceda, Nemeroff, and Harvey (2014, p. 208); Martin-Soelch, 2009; Cisler & Koster, 2010.
47. When women are unable to meet in-person with a provider—as is the case with chemical abortions procured through the mail or over the counter—women are more likely to suffer from significant psychological distress.

48. Women are more likely to be satisfied with and feel that their abortion procedure was acceptable (and thus, less likely to experience mental health challenges) if they were adequately counseled about what to expect and had support during the procedure.  

49. Women who have chemical abortions commonly report that they did not receive enough information about what to expect during their chemical abortions.

a. In one study, one-third (34%) of women who had chemical abortions stated that they received insufficient information about what to expect. Another study revealed that 53% of women who experienced chemical abortion felt the procedure was worse than expected. A third study demonstrated that that number was 14% and participants described their experiences. The narratives contained an explicit theme about needing more detailed

---

54 Hedqvist et al., 2016.
55 Kelly and colleagues (2010).
56 Rafferty and Longbons (2020). For instance, one woman said, “I knew to expect blood clotting, but nothing could’ve prepared me for seeing her body. It was the color of my own skin and was actually starting to look like a person.” Another woman shared, “They lied to me and said they would give me some pills that would make it just like a late period with a little cramping … The pain of the contractions was so intense I felt like my intestines were pulled out slowly. I collapsed screaming on my bathroom floor…” A third woman recounted, “They told me, if you by chance are in pain you can take these pain relievers. … That sounded like the process would be easy and not so painful. Well NO that was not the case, within 30 minutes I felt really bad cramping. It just kept getting worse and worse. I was crying and moaning from the pain. I literally thought I was dying.” A woman who felt betrayed said, “They told me it wouldn’t hurt and I wouldn’t feel a thing. THAT WAS SUCH A LIE. I felt everything, I heard everything, I seen everything. I ended up blacking out from the pain and puking all over myself.” Finally, a woman wrote, “We were told we would go back to normal and it won’t affect us but they were wrong!!! All I feel is emptiness and hatred. I used to be the happiest most positive girl. All I want is to take it back.”
information related to potential side effects, the intensity of cramping and bleeding, what to do after passing the baby, and potential negative emotions (e.g., fear, uncertainty, sadness, pain) they might experience following the abortion.\textsuperscript{57}

b. Another study determined that when women requesting abortion were counseled on the topics they were interested in (82% procedural information; 40% their decisions and doubts; 31% their emotions; 36% reasons for the abortion request; 76% the consequences of abortion; and 31% alternatives to abortion), they were very satisfied with the experience, felt less distress and greater decisiveness, and found the counseling to be more helpful than they anticipated it would be.\textsuperscript{58}

50. Women who reported severe pain from a chemical abortion had higher baseline anxiety levels than those who did not.\textsuperscript{59}

51. Three studies separately demonstrated that women who experienced chemical abortion were about two times less likely to say that they would choose the same procedure again, compared to those who experienced surgical abortion.\textsuperscript{60}

52. There is simply no guarantee that a woman who mail-orders mifepristone, obtains

\textsuperscript{57} Id.

\textsuperscript{58} Vandamme and colleagues (2013).

\textsuperscript{59} Arena and colleagues (2023).

\textsuperscript{60} Kelly et al. (2010) (100% of women who experienced a surgical abortion reported they would opt for the same procedure again versus 53% who experienced a chemical abortion said the same). Further, a much higher percentage of chemical-abortion patients compared to surgical abortion patients found the experience to be worse than expected (53% versus 0%). Slade and colleagues (1998) (that 47% of a chemical-abortion group would not choose the same procedure again compared with 23% of a surgical group); Ashok and colleagues (2002) (30% of women who underwent chemical abortion and 21% who underwent surgical abortion would not opt for the same method in future).
it over the counter, or receives it from an abortion clinic is ever privy to counseling.

53. Additionally, telemedicine is also unlikely to serve as an adequate substitute for an in-person counseling session because of the quality or availability of technology, obtaining accurate medical information, and developing a new patient relationship.\(^\text{61}\)

VIII. **Women Living in Poverty are Particularly Vulnerable to Post-Abortion Mental Health Problems and Have Great Need for Substantive In-Person Counseling.**

54. Economically disadvantaged women, such as those on Medicaid, are particularly likely to benefit from in-person counseling before undergoing an abortion.

55. Poverty has long been identified as a predictor of poor mental health and substance abuse, including heavy alcohol use and depression.\(^\text{62}\) Poverty is also associated with higher risk of compromised mental health outcomes following abortion compared to birth.\(^\text{63}\)

56. Women living in poverty are over-represented among abortion-seeking women, are more likely to be pressured by others and life circumstances to abort and are more inclined to report being personally “pro-life.”\(^\text{64}\) Impoverished women comprise half of all U.S. women undergoing abortions. A full 76% of all abortions in the U.S. occur among women at or below 200% of the Federal poverty level.\(^\text{65}\)

57. Poor women are the natural recipients of more pressure and coercion to abort, as

---

\(^{61}\) Mills and colleagues (2020); Wilhite and colleagues (2021).

\(^{62}\) Patel, 2017; Lund et al., 2011; Whiteford et al., 2013.

\(^{63}\) Coleman et al., 2009.

\(^{64}\) Gallop poll data presented in a document titled “‘Pro-Choice’ or ‘Pro-Life’ Demographic Table” (https://news.gallup.com/poll/244709/pro-choice-pro-life-2018-demographictables.aspx) reveals the percentage of Americans in 2023 with annual incomes below $40,000 who self-identified as “pro-life” was 54% compared to “40%” who identified as “pro-choice.” In 2019, among Americans with incomes below $40,000, those who self-identified as “pro-life” comprised 59% of the sample compared to only 34% who voiced “pro-choice” beliefs. Finally, in 2018, the percentage of Americans with incomes below $30,000, who self-identified as “pro-life,” was likewise 59% compared to “36%” who held “pro-choice” personal positions.

\(^{65}\) Jones & Jerman, 2017.
they are likely to believe they cannot afford to raise a child, and other people are inclined to view them as financially unable to provide adequate care for a child.66

58. Thus, women living in poverty are a psychologically vulnerable segment of the population of women with respect to abortion. Sensitive counseling and the time to process the counseling session is essential for low-income women to make abortion decisions with which they are truly comfortable.

59. Abortion decisions are often wrought with ambivalence and pressure from others, and published data indicates women generally desire more time and information before consenting to the procedure, not less. Chemical abortion can be a frightening and isolating experience. Based on the data presented in this declaration, in-person dispensing of abortion pills wherein chemical abortion patients must meet face-to-face with an abortion provider before receiving a prescription is necessary and beneficial to women’s physical and psychological health. The pre-abortion counseling and opportunity for the provider to answer women’s questions will help promote informed decision-making. Finally, evidence demonstrates that chemical abortion carries the potential to be more psychologically traumatizing than surgical abortion, a well-established risk factor for mental health problems.

66 Finer, et al., 2005 (finding that when asked why they chose abortion, the majority of women (73%) pointed to the high cost of motherhood, saying that they could not afford to have a baby); Biggs, Gould, & Foster 2013 (confirming the influential role of financial instability in a woman’s decision to abort a pregnancy); Faria, Barrett and Goodman 1985 (same); Torres and Forrest 1988 (same).
I declare under penalty of perjury that the foregoing is true and correct.

Executed on _10-09-2023____________.

Dr. Priscilla K. Coleman

BIBLIOGRAPHY

Works Cited

REFERENCES


60. National Collaborating Centre for Mental Health at the Royal College of Psychiatrists (2011). Induced abortion and mental health: A systematic review of the mental health outcomes of induced abortion, including their prevalence and associated factors. London: Royal College of Psychiatrists.


Exhibit A – Curriculum Vitae
PRISCILLA K. COLEMAN

Academic Degrees

<table>
<thead>
<tr>
<th>Date</th>
<th>Degree</th>
<th>University</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>Ph.D. Lifespan Developmental Psychology</td>
<td>West Virginia University, Morgantown, WV</td>
</tr>
<tr>
<td>1992</td>
<td>M.A. General Psychology</td>
<td>James Madison University, Harrisonburg, VA</td>
</tr>
<tr>
<td>1986</td>
<td>B.A. Psychology Minor: Studio Art</td>
<td>Southern Connecticut State University, New Haven, CT</td>
</tr>
</tbody>
</table>

Academic Positions

2010-2022 Professor of Human Development and Family Studies, School of Family and Consumer Sciences, Bowling Green State University, Bowling Green, OH

2005-2010 Associate Professor of Human Development and Family Studies, School of Family and Consumer Sciences, Bowling Green State University, Bowling Green, OH

2002-2005 Assistant Professor of Human Development and Family Studies, School of Family and Consumer Sciences, Bowling Green State University, Bowling Green, OH

1998-2002 Assistant Professor of Psychology, Department of Psychology, University of the South, Sewanee, TN

1995-1997 Teaching Assistant, Department of Psychology, West Virginia University, Morgantown, WV

1993-1995 Instructor of Psychology, Department of Psychology, James Madison University, Harrisonburg, VA

1991-1992 Research Assistant, Department of Psychology, James Madison University, Harrisonburg, VA

Administrative Positions

2003-2004 Program Coordinator, Human Development and Family Studies, School of Family and Consumer Sciences, Bowling Green State University, Bowling Green

1997-1998 Research Specialist, Center for Assessment and Research Studies, James Madison University, Harrisonburg, VA
Non-academic Positions

1988-1989 Residential Counselor, Homestead, Ellsworth ME

Teaching Experiences

Bowling Green State University (Campus and Web-based Delivery)
Human Development across the Life-Span
Parenting Processes
Research Methods
Child Development
Research Methods (Graduate)
Family Studies (Graduate)

University of the South
Child Development
Introduction to Personality and Development
Social Psychology
Social Psychology Research Seminar
Educational Psychology: Introduction to Educational Assessment
Exceptionality in the Classroom

West Virginia University
Life-Span Development
Child Behavior and Development
Exceptional Child
Applying to Graduate School Seminar

James Madison University
Psychological Statistics
Experimental Psychology with lab

Research Interests

The development, expression, and effects of individual differences in parenting
Socio-emotional development in early childhood
Parent-child interaction and family dynamics
Abortion decision-making
Post-abortion mental health
Abortion and intimate relationship quality
Perinatal loss and parenting

Research Projects and Grants

EDHD Research Grant, April 2004 entitled “The Choice to Abort Among Mothers Living Under Ecologically Deprived Conditions: Predictors and Consequences” to the Research
Development Committee, College of Education and Human Development, Bowling Green State University, $12,058. funded.

Faculty Research Committee Research Incentive Grant for AY 2003, entitled “The Choice to Abort vs. Deliver During Adolescence: Personal and Social Predictors and Consequences”, $5,976.


duPont Faculty-Student Research Grant from the University of the South Spring 2002 “Development of Maternal Self-Efficacy and its Relation to Early Maternal Behavior”, $1,428 Funded.


Publications

Chapters of Books


Encyclopedia Entries


Refereed Journal Articles


Coleman, P. K. (2020). The psychology of abortion decision-making & the necessity of pre-abortion waiting periods. Bioethics in Law and Culture Quarterly, 3 (2).


Coleman, P. K., Reardon, D. C., Rue, V., & Cougle, J. (2003). Reply to letter to the editor by Darroch, Finer, Henshaw, and Jones pertaining to our article entitled “History of induced abortion in relation to substance use during subsequent pregnancies carried to term”, American Journal of Obstetrics and Gynecology, 189 (2), 617.


Coleman, P. K., Reardon, D. C., Rue, V., & Cougle, J. (2002). State-funded abortions vs. deliveries: A comparison of outpatient mental health claims over four years. The American Journal of Orthopsychiatry, 72, 141-152.


Abstracts


Papers Read to Professional Societies

Invited Papers


Life Foundation, Louisville, KY


Coleman, P. K. (February, 2013). Reaching Women Before the Decision to Abort: Mental Health Research Priorities Presentation for the American Association of Pro-Life Obstetricians and Gynecologists (a special interest group of the American College of Obstetricians and Gynecologists), Annual CME meeting, Washington, DC.


Coleman, P. K. (May, 2012). Abortion and Women’s Mental Health: Research to Practice. Emily’s Voice, Toowoomba, Queensland, Australia.


Coleman, P. K. (March, 2012). Abortion and Women’s Mental Health: Knowledge to Practice. The McAuley Education Center, Mater Hospital, Dublin, Ireland.


Coleman, P. K. (September, 2011). Abortion and Women’s Mental Health: Helping through Knowledge. Care Net Annual Conference, Orland FL.

Coleman, P. K. (October, 2011). Abortion and Women’s Mental Health: Knowledge to Practice. Healing Vision International Conference, Milwaukee, WI.


Coleman, P. K. (January, 2011). Abortion and Women’s Mental Health: Research to Practice: Presentation for the American Association of Pro-Life Obstetricians and Gynecologists (a special interest group of the American College of Obstetricians and Gynecologists), Annual CME meeting.

Coleman, P. K. (January, 2011). Abortion and Women’s Mental Health: Model Research: Presentation for the American Association of Pro-Life Obstetricians and Gynecologists (a special interest group of the American College of Obstetricians and Gynecologists), Annual CME meeting.

Coleman, P. K. (January, 2010). Evidence-Based Practice in Informed Consent for Abortion: Toward More Systematic Qualitative and Quantitative Reviews of the Literature Presentation for the American Association of Pro-Life Obstetricians and Gynecologists Annual CME meeting.


**Refereed Papers**


Coleman, P. K. (March, 2007). Development of Parenting Self-Efficacy during the First Six Months (Troutman, B.R., Chair). Serving as Discussant for symposium accepted for presentation at the Biennial Meeting of SRCD.


Coleman, P. K., & Karraker, K. H. (April, 2004). Parenting self-efficacy, competence in Parenting, and possible links to children’s social and academic outcomes. 12th International Roundtable on School, Family, and Community Partnerships.

Coleman, P. K., Reardon, D. C., & Cougle, J. (June, 2003). Substance use associated with prior history of abortion and unintended birth: A national cross sectional cohort study. Presented at the 15th annual meeting of the American Psychological Society, Atlanta, GA.


Coleman, P. K., Reardon, D. C., Rue, V., & Cougle, J. (June, 2002). Prior history of induced abortion and substance use during pregnancy. Poster presented at the American Psychological Society, 14th Annual Convention, New Orleans, LA.


Coleman, P. K. (April, 2002). Self-efficacy beliefs, parenting, and toddler behavior and development. In M. Stern (Chair), Maternal expectations, caregiving and infant outcomes. Symposium paper presented at the 13th Biennial International Conference on Infant Studies, Toronto, Canada.

Coleman, P. K., & Neilsen, A. (April, 2002). Length of institutionalization, contact with relatives, and previous hospitalizations as predictors of social and emotional behavior in young Ugandan Orphans. Poster presented at the 13th Biennial International Conference on Infant Studies, Toronto, Canada.


Coleman, P. K., Reardon, D. C., & Cougle, J. (March, 2001). Child developmental outcomes associated with maternal history of abortion using the NLSY data. Poster presented at the 1st World Congress on Women’s Mental Health, Berlin, Germany.

Coleman, P. K., Reardon, D. C., Rue, V. & Cougle, J. (March, 2001). State-funded abortions vs. deliveries: A Comparison of outpatient mental health claims over six years. Poster presented at the 1st World Congress on Women’s Mental Health, Berlin, Germany.


Cougle, J., Reardon, D. C., Rue, V., Shuping, M., Coleman, P. K., & Ney, P. (March, 2001). Psychiatric admissions following abortion and childbirth: A record-based study of low-income women. Poster presented at the 1st World Congress on Women’s Mental Health, Berlin, Germany.


Coleman, P. K., & Nelson, E. S. (April, 1997). The quality of abortion decisions and college students' reports of post-abortion emotional sequelae and abortion attitudes. Poster presented at the meeting of the Society for Research in Child Development,

Professional Service

Founder and Director of the World Expert Consortium for Abortion Research and Education (WECARE). The website for this 501 c(s), June, 2011-present. is www.wecareexperts.org

Served as an external reviewer for Stacy Thompson’s promotion to Full Professor, Southern Illinois University (Sept, 2016).

Served as an external reviewer for Dr. Alice Hall’s promotion to Full Professor, Georgia Southern University (Aug, 2016).
Served as an external reviewer for Dr. Shannon Zentall, applicant for tenure and promotion to Associate Professor in Child and Family Development in the School of Family and Consumer Sciences, University of Akron (Aug, 2015)

Served as an external reviewer for M. Angela Nievar’s application for tenure. Development and Family Studies Program, Educational Psychology Department, University of North Texas. (Fall, 2009)


Served on the Scientific Committee for an international conference entitled “Abortion: Causes, Ramifications, Therapy” sponsored by the Demographic Committee of the Polish Academy of Science, The Ombudsman for Children in Poland, and the Institute of Psychiatry and Neurology (June, 2004).

Serving on the Council of Healthcare Advisors, Gerson Lehrman Group. The Council of Healthcare Advisors provides investment analysts access to a highly structured network of industry and academic experts to conduct surveys, phone consultations, and arrange in-person events (Fall, 2003-present).

**Editorships of Journals**

Editorial Board Member for Current Women’s Health Reviews. (June 04 – present)

Editorial Board Member Open General/Internal Medicine Journal (2007-present)

Editorial Board Member Open Women’s Health Journal (2008-present) Editorial

Member for the World Journal of Psychiatry (2011-present) Editorial Board Member,

**Reviewer for Submissions**

*Addiction*

*Annales Academiae Medicae Bialostocensis*

*BMC Pregnancy and Childbirth*

*British Journal of Medicine and Medical*

*British Journal of Psychiatry*

*Current Women’s Health Reviews*

*Depression and Anxiety*

*Developmental Psychology*

*European Journal of Clinical Nutrition*
European Journal of Psychology of Educations
Family Relations
General Hospital Psychiatry Infant Behavior and Development
International Internet Journal of Mental Health
Issues in Law and Medicine Journal of Adolescence
Journal of Applied Developmental Psychology
Journal of Child Psychology and Psychiatry and Allied Disciplines
Journal of Clinical and Social Psychology
Developmental Processes
Journal of Family Psychology
Journal of Medical Ethics
Journal of Pediatrics
Journal of Personality and Social Psychology
Journal of Psychiatric Research
Journal of Reproductive and Infant Psychology
Journal of Women’s Health and Gender-Based Medicine
Journal of Youth and Adolescence
New England Journal of Medicine
Obstetrics and Gynecology International
Open Family Studies Journal
Open Women’s Health Reviews
Parenting: Science and Practice
Psychology, Health, and Medicine
Psychology in the Public Interest
Research to Practice Journal for the Intervention Field
Social Problems
Social Sciences and Medicine
The Lancet
Women’s Health Issues

Honors and Awards

Phi Kappa Phi, West Virginia University, 1997- present
Recipient of College of Education and Human Development Faculty Scholarship Award, $1,000, August, 2004
Expert Testimony

Serving as an expert witness for the Defendant, SISTERSONG WOMEN OF COLOR REPRODUCTIVE JUSTICE COLLECTIVE, on behalf of itself and its members; FEMINIST WOMEN’S HEALTH CENTER, PLANNED PARENTHOOD SOUTHEAST, INC., ATLANTA COMPREHENSIVE WELLNESS CLINIC, ATLANTA WOMEN’S MEDICAL CENTER, FEMHEALTH USA d/b/a CARAFEM, and SUMMIT MEDICAL ASSOCIATES, P.C., on behalf of themselves, their physicians and other staff, and their patients; CARRIE CWIAK, M.D., M.P.H., LISA HADDAD, M.D., M.S., M.P.H., and EVA LATHROP, M.D., M.P.H., on behalf of themselves and their patients; and MEDICAL STUDENTS FOR CHOICE, on behalf of itself, its members, and their patients, Plaintiffs, v. STATE OF GEORGIA, Defendant, August 2022-present.


Serving as a rebuttal expert witness in JANE DOE NO. 1; JANE DOE NO. 2; JANE DOE NO. 3; WILLIAM MUDD MARTIN HASKELL, M.D.; CASSIE HERR, N.P.; KELLY MCKINNEY, N.P.; and WOMEN’S MED GROUP PROFESSIONAL CORPORATION, Plaintiffs, v. ATTORNEY GENERAL OF INDIANA; COM-MISSIONER OF THE INDIANA STATE DE-PARTMENT OF HEALTH; MEDICAL LI-CENSING BOARD OF INDIANA; INDIANA STATE BOARD OF NURSING; and MARION COUNTY PROSECUTOR, September, 2021–present.

Serving as an expert witness in JANE SMITH, JILL PARK, MARY DOE, ANN JONES, and DR. AMY MOE, Plaintiffs, v. ANDREW CUOMO, as Governor of the State of New York in his official capacity et al. Defendants. In the UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF NEW YORK, December 2020-present.

Served as an expert witness in American College of Obstetricians and Gynecologists, et al., Plaintiffs, vs. United States Food and Drug Administration, et al., Defendants (Case No. 8:20-cv-1320-TDC).


Served as an expert witness in PLANNED PARENTHOOD ASSOCIATION OH UTAH, Plaintiffs v. JOSEPH MINER, et al, in the UNITED STATES DISTRICT COURT FOR THE DISTRICT of UTAH (Case No. 2:19-cv-00238).

Served as an expert witness in REPRODUCTIVE HEALTH SERVICES OF PLANNED PARENTHOOD OF THE ST. LOUIS REGION, INC., on behalf of itself, its physicians, its staff, and its patients, and COLLEEN P. MCNICHOLAS, D.O., M.S.C.I., F.A.C.O.G., on behalf of herself and her patients, Plaintiffs, v. MICHAEL L. PARSON, in his official capacity as Governor of the State of Missouri; ERIC S. SCHMITT, in his official capacity as Attorney
General of the State of Missouri, et al., Defendants, in THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF MISSOURI CENTRAL DIVISION (Case No. 2:19-cv-4155).

Served as an expert witness in WHOLE WOMAN’S HEALTH ALLIANCE; ALL-OPTIONS, INC.; and JEFFREY GLAZER, MD, Plaintiffs v. CURTIS HILL, Attorney General of Indiana, in his official capacity et al., Defendants, in the UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF INDIANA INDIANAPOLIS DIVISION (Case no. 1:18-cv-1904).

Served as an expert witness in AMERICAN CIVIL LIBERTIES UNION OF MISSOURI and SARA E. BAKER, Plaintiffs v. JOHN R. ASHCROFT, et al., Defendants, in the CIRCUIT COURT OF COLE COUNTY, STATE OF MISSOURI (Case No. 19AC-CC00246).


Served as an expert witness in Campagne Québec-Vie et al vs. Attorney-General of Québec in the Superior Court of Quebec.

Served as an expert witness in Hughes v. Hughes, Supreme Court of British Columbia, Canada.

Served as an expert witness in ADAMS & BOYLE, P.C., on behalf of itself and its patients; et al., Plaintiffs, v. HERBERT H. SLATERY III, Attorney General of Tennessee, in his official capacity; et al. In the United States District Court for the MIDDLE DISTRICT OF TENNESSEE NASHVILLE DIVISION (Case no. 3:15-cv-00705).

Served as an expert witness in COMPREHENSIVE HEALTH OF PLANNED PARENTHOOD GREAT PLAINS, et al., Plaintiffs, RANDALL WILLIAMS, M.D., in his Official capacity as Director of the Missouri Department of Health and Senior Services, et al., Defendants. In the United States District Court for the Western District of Missouri Case No. 2:16-cv-04313-HFS).

Served as an expert witness in COMPREHENSIVE HEALTH PLANNED PARENTHOOD GREAT PLAINS, et. al., Plaintiffs, v. JOSHUA D. HAWLEY, in his official capacity as Attorney General of Missouri, et. al., Defendants. In the Circuit Court of Jackson County, Missouri at Kansas City (Case No. 1716-CV24109).

Served as an expert witness in GAINESVILLE WOMAN CARE LLC d/b/a BREAD AND ROSES WOMEN’S HEALTH CENTER, on behalf of itself, its doctor, and its patients; and MEDICAL STUDENTS FOR CHOICE, on behalf of its members and their patients, Plaintiffs, v. STATE OF FLORIDA; FLORIDA DEPARTMENT OF HEALTH; JOHN H. ARMSTRONG, M.D., in his official capacity as Secretary of Health for the State of Florida et al. In the Circuit Court of the Second Judicial Circuit in and for Leon County, Florida (Case No. 2015-CA-001323).

Served as an expert witness in COMPREHENSIVE HEALTH OF PLANNED PARENTHOOD GREAT PLAINS, et al. v. PETER LYSKOWSKI, in his official capacity as Director of the Missouri Department of Health and Senior Services, et al. In the United States District Court for the Western District of Missouri Central Division (Case No. 2:16-cv-04313).

Served as an expert witness in Planned Parenthood Minnesota, North, Dakota, South Dakota, and Carol E. Ball, MD, Plaintiffs, vs. Dennis Daugaard, Governor SD, Marty J. Jackley, Attorney General SD, ALPHA CENTER, Sioux Falls, SD, Intervenors. House Bill 1217. In the United States District Court for the District of South Dakota Southern Division (Civ. 11-4071-KES).

Served as an expert witness for the Office of the Attorney General, Civil Litigation Division as an expert witness on behalf of the State of North Dakota in defense of House Bill 1456. In the United States District Court for the District of North Dakota Southwestern Division (Case No. 1:13-CV-071).


Provided expert testimony for Ohio House Bill 78, Post-Viability Ban, March, 2011.

Affidavit submitted in the case of PLANNED PARENTHOOD OF THE HEARTLAND vs. DAVE HEINEMAN, Governor of Nebraska: JON BRUNING, Attorney General of Nebraska; KERRY WINTERER, Chief Executive Officer, and DR. JOANN SCHAEFER, Director of the Division of Public Health, Nebraska Department of Health and Services; and CRYSTAL HIGGINS, President, Nebraska Board of Nursing, and BRENDRA BERGMAN-EVANS, President, Nebraska Board of Advanced Practice Registered Nurses, In the United States District Court for the District of Nebraska (Case No: 4:10-cv-3122), July 1010.

Affidavit submitted to the Supreme Court of the United States in support of Amicus Brief of Sandra Cano, the former “Mary Doe” of Doe v. Bolton and the American Association of Pro-Life Obstetricians and Gynecologists (AAPLOG) in Rosa Acunav. Sheldon C. Turkish, M.D., May, 2008.

Served as an Expert witness, Zallie v. Brigham, Camden, NJ, Superior Court of New Jersey Law Division, Camden County (Docket No: CAM-L-5528-04).

Served as an expert witness, ROE ET AL. v. PLANNED PARENTHOOD, Hamilton County Court of Common Pleas (Case No: A0502691) Cincinnati, OH.

Served as an expert witness for the defense in PLANNED PARENTHOOD MINNESOTA, NORTH DAKOTA, SOUTH DAKOTA, and CAROL E. BALL, M.D., Plaintiffs, v. MIKE ROUNDS, Governor, and LARRY LONG, Attorney General, Defendants, HB 1166, United States District Court for the District of South Dakota (Civil Case No.: 05-4077). December 2005-2012.

Assisted legislation consultant, Vincent Rue, Ph.D. hired by Attorney General Phil Kline of Kansas in the defense of a mandatory underage sexual activity reporting statute (S.A.38-1522), AID FOR WOMEN v FOULSON, Federal District Court, October, 2005 February 2006.

Provided expert testimony for Ohio House Bill 239 pertaining to studies comparing the psychological effects of abortion versus childbirth, October 12, 2005.

Provided expert testimony to the South Dakota Task Force to Study Abortion on post- abortion mental health literature accumulated since 1973. The task force consists of eight legislators and nine medical and legal professionals and interested lay persons charged with studying the application of medical, psychological, technological, societal, economic, and sociological developments and research to legislative and public policy formulations on abortion issues. South Dakota, September 21, 2005.
Exhibit 38

Declaration of Tumulesh K.S. Solanky
DECLARATION OF TUMULESH K. S. SOLANKY

1. I, Tumulesh K. S. Solanky, state under oath that I am of at least 18 years of age, and that I am competent to testify as follows.

2. I am a professor and chair of the mathematics department at the University of New Orleans (UNO). I am also the University of Louisiana System Foundation and Michael and Judith Russell Professor in Data/Computational Sciences. I have a PhD degree in Statistics from the University of Connecticut. I have been teaching statistics and mathematics at the University of New Orleans since August of 1990. I have taught a number of graduate classes in statistics, such as Sampling Theory, Applied Statistics, Regression Analysis, Linear Models, Design of Experiments, Biostatistics, Statistical Consulting, Nonparametric Statistics, Data Analytics, Multivariate Analysis, and Time Series Analysis.

3. At present, I serve as an associate editor of four scholarly journals including the American Journal of Mathematical and Management Sciences. My primary research interest is in the area of data collection/sampling strategies and deriving new sampling designs to collect and analyze data.

4. I have authored/coauthored a research level book in Statistics, two book chapters, and over twenty research articles in scholarly peer-reviewed journals. I have also served as the guest editor of a special issue of AJMMS in my research area. I have presented my research at over 50 national and international conferences/meetings of peers. I have provided my statistical expertise to the National Aeronautics and Space Administration (NASA), the United States Department of Agriculture (USDA), banks, hospitals, school boards, polling firms, Attorneys General Offices, District Attorney’s Offices, and others. As a statistical consultant, I have designed a number of surveys and authored over 150 internal/expert reports.

6. A number of researchers and federal agencies have studied the impact of generic drugs on the availability of the drugs in US and the cost of generic drugs relative to the cost of non-generic drugs.

7. Based on the Office of Generic Drugs (OGD) 2022 Annual Report¹, the generic drug competition lowers drug prices and improves access to needed drugs in United States. The OGD report concludes that approval of generics often means that there are multiple manufacturers for a drug product, which stabilizes the supply of medicines and reduces the risk of drug shortages. The OGD Annual Report states:

   Competition from generic drug makers helped make drugs more widely available and generally less expensive, allowing millions of patients to access the medicines they need more easily.

¹ The Office of Generic Drugs, 2022 Annual Report is available for download at the website (last accessed on September 28, 2023) https://www.fda.gov/media/165435/download#page=9
8. The OGD report further notes that for certain pharmaceutical products, known as complex products, which are harder to develop as generics there are few or no generics. And, in the absence of market competition, these medicines can be so expensive that patients who need them may not be able to afford them.

9. In a recent article, Gupta et al. (2019)\textsuperscript{2}, studied the cost of prescription drugs in the U.S. and found that the drug prices typically decline rapidly once generic drugs receive U.S. Food and Drug Administration (FDA) approval and enter the market. The researchers concluded that the greater the number of generic manufacturers’ versions in a market, the steeper the price decline, with prices decreasing to less than 20\% of the original drug’s price. The researchers have reported that a 2005 FDA analysis found that after patent and exclusivity expiration, the introduction of one generic manufacturer into the market reduced the price of the drug by only 6\%, whereas, with two generic manufacturers, the price reached 52\% of the brand-name drug’s price. Figure 1 below summarizes the relationship between the number of generic manufacturers and the average relative price per dose.

\textbf{Figure 1: Generic Competition and Drug Prices}
\textit{(Reproduced Figure 1 in Gupta et al. (2019))}

10. For the trend presented in Figure 1, there is statistically significant negative correlation between the number of generic manufacturers and the average relative price per dose (correlation is -0.827, \( P < 0.0001 \)). As reported in Gupta et al. (2019), the biggest drop is observed with two generic manufacturers and the price reached 52% of the brand-name drug’s price in that case. Additionally, the price drop continues in general as the number of generic manufacturers increases from 2 to 19 (a drop of 2.18 percent relative to the brand-name drug’s price for each additional generic manufacturer; R-Square for a regression model is 0.8554 and the model \( P < 0.0000001 \)).

11. Other researchers have also studied this relationship between the number of generic manufacturers and the average relative price per dose and have arrived at similar conclusions as in Gupta et al. (2019), For example, Hartzema, et al. (2017)\(^3\) reported that the number of manufacturers of the generic drug was strongly associated with drop in the relative price (\( P < 0.001 \) for trend).

12. Assuming the abortion demand stays the same and the cost of surgical abortion stays the same or significantly higher than with mifepristone, approval of the generic version of mifepristone will lead to drop in the price of mifepristone and that will lead to the quantity of mifepristone sold to increase.

13. Assuming that the generic version of the drug mifepristone is chemically the same as the already approved drug mifepristone, the following is expected:

1. Approval of a generic drug, like generic mifepristone, would increase the supply of that drug due to competition from generic drug makers and would make the drug more widely available and generally less expensive

2. The approval of the generic version of mifepristone is statistically likely to lead to an increase in use of mifepristone for abortion.

14. I declare under penalty of perjury that the foregoing is true and correct.

Executed on October 23, 2023.

Tumulesh K. S. Solanky, PhD
Exhibit “A”
(CV OF TUMULESH K. S. SOLANKY)

ADDRESS:
Home: 4717 Rue Laurent, Metairie, LA 70002.
Cell Phone: (504) 427-0188
Email: tsolanky@gmail.com
Citizenship: USA

EDUCATION:
Ph.D. in Statistics University of Connecticut, 1990
M.Sc. in Mathematics Indian Institute Of Technology, New Delhi, India, 1987
B.Sc. in Mathematics (Honors) University of Delhi, India, 1985

EMPLOYMENT AND POSITIONS:
August 2008-present Professor and Chair of the Mathematics Department
2021- present The University of Louisiana System Foundation and
Michael and Judith Russell Professor in Data/Computational Sciences
2001-2008 Professor of Mathematics, University of New Orleans
1995-2001 Associate Professor of Mathematics, University of New Orleans
1996-1997 Visiting Associate Professor, University of Toronto (On Sabbatical Leave)
1990-1995 Assistant Professor of Mathematics, University of New Orleans
1989-1990 Lecturer of Statistics, University of Connecticut

MAJOR AWARDS
(i). Seraphia D. Leyda University Teaching Fellow, Awarded in year 2009.
(ii). Cooper R. Macklin Medallion, Awarded in year 2018. Cooper R. Macklin Medallion is awarded to a faculty or staff member who has made outstanding contributions in support of the University’s mission. The recipient is an individual who has demonstrated excellent, sustained, and selfless service to the university.

MAJOR STATISTICAL CONSULTING EXPERIENCE:

42. DR. DOROTHY NAIRNE, et al., v. KYLE ARDOIN, in his official capacity as Secretary of State for Louisiana, consolidated with EDWARD GALMON, SR., et al.; CIVIL ACTION NO. 3:22-cv-00178 SDD-SDJ.
Duration: May 2022—present.
Extent of Involvement: Submitted two expert reports; Deposed.

41. Louisiana Organ Procurement Agency (LOPA) and Mid-America Transplant Services (MOMA), St Louis, MO; Assisted LOPA and MOMA with statistical analysis related to organ procurement data in Louisiana and Missouri.
Duration: August 2021—present.
Extent of Involvement: Submitted several internal reports.

Duration: May 2022—June 2022.
Extent of Involvement: Submitted two expert reports; Testified in Court.

Duration: May 2021—October 2021.
Extent of Involvement: Submitted expert report; Deposed.


32. PLANNED PARENTHOOD OF ARKANSAS & EASTERN OKLAHOMA, d/b/a PLANNED PARENTHOOD GREAT PLAINS and STEPHANIE HO, M.D., on behalf of themselves and their patients, v LARRY JEGLEY, Prosecuting Attorney for Pulaski County, in his official capacity, his agents and successors; MATT DURRETT, Prosecuting Attorney for Washington County, in his official capacity, his agents and successors; Duration: June 2018- December 2018. Extent of Involvement: Submitted one expert report; Testified in Court.


30. UNITED STATES DISTRICT COURT, SOUTHERN DISTRICT OF TEXAS, HOUSTON DIVISION, REBA CARTER, et. al., v. HOUSTON INDEPENDENT SCHOOL DISTRICT; Duration: June 2017- April 2018. Extent of Involvement: Submitted expert report.

28. UNITED STATES DISTRICT COURT, EASTERN DISTRICT OF LOUISIANA, UNITED STATES of AMERICA v. HENRY EVANS, M.D., MICHAEL JONES, M.D., SHELTON BARNES, M.D., GREGORY MOLDEN, M.D., PAULA JONES, JONATHON NOR; Duration: September 2016- May 2017. Extent of Involvement: Testified in Court.


25. UNITED STATES DISTRICT COURT, EASTERN DISTRICT OF ARKANSAS WESTERN DIVISION PLANNED PARENTHOOD ARKANSAS & EASTERN OKLAHOMA, d/b/a PLANNED PARENTHOOD OF THE HEARTLAND; and STEPHANIE HO, M.D. v. LARRY JEGLEY, Prosecuting Attorney for Pulaski County, in his official capacity and MATT DURRETT, Prosecuting Attorney for Washington County; Duration: December 2015- February 2016. Extent of Involvement: Submitted expert report.

24. UNITED STATES DISTRICT COURT, MIDDLE DISTRICT OF LOUISIANA, JUNE MEDICAL SERVICES, LLC, ET AL., KATHY KLIEBERT, ET AL.; Duration: October 2014- August 2016. Extent of Involvement: Submitted expert report; Deposed; Testified in Court.


19. United States District Court, St. Tammany Parish Hospital. vs. Ace American Ins. Co. and Trinity Marine Products, Inc. (and several other related cases); Civil Action; Duration: March 2010- March 2012. Extent of Involvement: Submitted over ten expert reports; Deposed.


13. United States District Court, St. Bernard Parish, Mumphrey v. Chalmette Medical Center; Civil Action; Duration: October 2008- November 2008. Extent of Involvement: Submitted an expert report; Deposed; Testified in Court.

12. GCR, New Orleans; Statistical Consultant; Provided statistical expertise to GCR in designing polls & analyzing the poll results for the state elections in 2007; Duration: May 2007- October 2007.

11. United States District Court, 19th Judicial District, Parish of East Baton Rouge, Patrick J. Cunningham, et al. vs. IBM Corp.; Civil Action; Duration: December 2006- August 2007; Extent of Involvement: Assisted the attorneys and other experts; wrote over 25 internal reports related to statistical computations and interpretation of results.

10. UNITED STATES DISTRICT COURT, EASTERN DISTRICT OF LOUISIANA; Provided statistical expertise in a jury selection matter; Wrote an expert report/Affidavit; Attorney, Eastern District of Louisiana. Duration: May 2006- August 2006;


8. United States District Court, Down South Entertainment versus SMG; Civil Action; Statistical estimation of crowd for Easter Jam; Wrote three expert reports on statistical projections and the reliability of projections; Duration: December 2003- May 2005; Extent of Involvement: Deposed twice and testified in court.

7. Naval Oceanographic Center (US Navy), Mississippi; statistical guidance to update their methods of data collection and data storage, statistical algorithms to discard the noise and save only the relevant data. Duration: May 1998- March 2002.
6. United States District Court, Bank of Louisiana versus Kenwin Shops Inc.; Civil Action; *Wrote two expert reports on statistical analysis related to Bankruptcy of a BOL’s client*; Duration: May 1999- December 1999; Extent of Involvement: Deposed.

5. Jefferson Parish Public Schools; *As the statistician for the court appointed expert witness*: designed a survey of schools under Jefferson Parish Public Schools, assisted in statistical projections reported to the court. Duration: August 1998- January 1999.

4. Lifemark Hospitals of Louisiana (Kenner Regional Medical Center); *Statistical sampling of patient charts*; Wrote three expert reports on statistical analysis/sampling of the patient charts; Duration: August 1996 – August 1997; Extent of Involvement: Deposed.

3. KPMG New Orleans; *Sample size determination, Designed and Analyzed samples of patient charts/drug usage to estimate total drug cost for the Tenet group of Hospitals/Lifemark Hospitals*; Wrote two expert reports on statistical analysis; Duration: August 1994 – December 1995.

2. USDA, Department of Forestry, Louisiana: *Statistical assistance to USDA in data collection, designing and modeling, Models used: Time-Series Models (for forecasting; Both Time Domain--ARIMA MODELS-- and Frequency Domain models).* Duration: August 1991- December 1994.


**CURRENT EDITORIAL SERVICE:**
- **Associate Editor**: AJMMS (American Journal of Mathematical and Management Sciences), 2012-present.
- **Associate Editor**: Sequential Analysis, 2003-present.
- **Associate Editor**: Journal of Combinatorics, Information and System Sciences, 2003-present.
- **Associate Editor**: Journal of the Indian Society of Agricultural Statistics, 2009-present.

**SCHOLARLY/PROFESSIONAL ACTIVITIES:**
- **Reviewer**: Journal of Statistical Planning and Inference, Sequential Analysis, Metrika, Communications in statistics, Statistics and Decisions, and others.
- **Member**: American Statistical Association (ASA), Life member of the Forum for Interdisciplinary Mathematics.
- **Selection Committee Chair**: Abraham Wald Prize in Sequential Analysis for Best Paper: Sequential Analysis Journal. The first prize was awarded at JSM, 2005. Chaired the international selection committee from 2006-2023.
- **Guest Editor**: Special Volume of *AJMMS* (American Journal of Mathematical and Management Sciences). Co-edited a special volume of *AJMMS* related to my research area of Selection and Ranking/MCP.
- **Symposium Organizer**: Co-organized “Symposium on Ranking and Selection Methodologies – Multiple Comparison Procedures”. The symposium was held during the *Pre-ICM International Convention on Mathematical Sciences*, University of Delhi, December, 2008.
- **Symposium Organizer**: Co-organized a symposium at the Auburn University (December 2005) in my research area of Selection and Ranking/MCP. I also chaired the symposium. The symposium was held during the SCMA 2005/FIM XII Conference.
• **Editor (Statistical Science):** AJMMS (American Journal of Mathematical and Management Sciences), 2009-2012.

• **Associate Editor:** Statistical Methodology, 2010-2015.

**RESEARCH PUBLICATIONS**

**Scholarly books:**

**Refereed Scholarly book chapters:**


**As Guest Editor of a Journal’s Special Issue:**
Co-edited a Special Volume of AJMMS (American Journal of Mathematical and Management Sciences) in my research area: RANKING AND SELECTION AND MULTIPLE COMPARISON PROCEDURES. American Journal of Mathematical and Management Sciences, Volume 29 (2009), Nos. 1 & 2, 294 pages.

**As Associate Editor of Conference Proceedings:**

**REFEREED JOURNAL PUBLICATIONS**


18. A two-stage procedure with elimination for partitioning a set of normal populations with respect to a control, Sequential Analysis, 25, 297-310, 2006.


**OTHER PUBLICATIONS**


- Presented at the Joint Statistical Meetings, San Francisco, August 1993.

- Presented at the Joint Statistical Meetings, Boston, August 1992.
- Article appears as a separate section in Multistage Selection and Ranking Procedures: Second-Order Asymptotics, Marcel Dekker, Inc., 1994, Section 4.9, page 198-208.

- Presented at the Joint Statistical Meetings, Atlanta, August 1991.
- Article appears as a separate section in Multistage Selection and Ranking Procedures: Second-Order Asymptotics, Marcel Dekker, Inc., 1994, Section 3.9, page 117-141.

GRANTS AND CONTRACTS FUNDED AS PI/Co-PI

{21.} L.E.Q.S.F. Enhancement Grant, $54,112.00, 2017-2018, Redesigning Freshman Mathematics Instruction at UNO Using Technology Based Interactive Teaching Format [The proposal was ranked first among all the proposals in the category. With Lisa Crespo and Lori Hodges].
{20.} Howard Hughes Medical Institute (HHMI), $1,500,000.00, 2014-2019, Increasing recruitment and retention of STEM students at UNO, an urban university [as Co-PI, Dr. Wendy Schluchter is the PI].
{19.} L.E.Q.S.F. Enhancement Grant, $15,000.00, 2011-2013, Continuation of Statistical Consulting Education at UNO [Linxiong Li].
{18.} UNO SCoRE award, $15,000, 2011.
{17.} L.E.Q.S.F. Enhancement Grant, $20,000.00, 2008-2010, Enhancement of Industry Oriented Statistical Education at UNO: Post Katrina Years [Linxiong Li].
{16.} L.E.Q.S.F. Enhancement Grant, $27,500.00, 2005-2007, Continuation of: Enhancement of Industry Oriented Statistical Education at UNO [with Terry Watkins and Linxiong Li].
{15.} L.E.Q.S.F. Enhancement Grant, $35,874.00, 2002-2004, Enhancement of Industry Oriented Statistical Education at UNO. [The proposal was ranked first among all the proposals in the category. With Terry Watkins, Linxiong Li, and Zhide Fang].
{14.} AFCEA Silicon Bayou Chapter Award, $300, 2002-2003, for purchasing classroom supplies for the mathematics department.
{13.} National Science Foundation (NSF), $219,900, 2000-2002, UNOMACSS: A Scholarship Program in the Mathematical and Computer Sciences [with A. DePano of Computer Science Department]. It provided scholarship to 20 mathematics and 20 computer science students for two years.
{10.} NASA, Graduate Student Research Program, $64,000, 1994-1996, Statistical Analysis of Rocket Seal Tester.
[8.] Institute of Mathematical Statistics, $400, 1994, \textit{Travel Award to present a paper at the annual meeting in Chapel Hill, North Carolina}.
[7.] UNO Research Support Award, $2,000, 1994-1995.
[4.] Institute of Mathematical Statistics, $800, 1990, \textit{Travel Award to present a paper at the annual meeting in Uppsala, Sweden}.
[1.] UNO Faculty Development Award, $1,600, June-December 1993.

\textbf{Professional Service as Referee:}
I have refereed several hundred papers as a referee for scholarly journals and over 20 books in the field of statistics/Data Science. The books reviewed in the academic year 2020-21 are:

\textbf{PROFESSIONAL PRESENTATIONS}
[57.] Some issues related to implementation of the partition problem formulations for normal population, \textit{invited talk}, 34th NESS (New England Statistics Symposium), University of Rhode Island, September 30- October 2, 2021.
[53.] Designing Experiments for Multiple Comparisons, \textit{plenary talk}, The Sixth International Workshop in Sequential Methodologies (IWSM 2017), University of Rouen Normandy, France, June, 2017.
[50.] A Generalization of the Partition Problem, Poster Session, FRONTIERS OF HIERARCHICAL MODELING IN OBSERVATIONAL STUDIES, COMPLEX SURVEYS AND BIG DATA, University of Maryland, July, 2014 (With Jie Jhou).
[48.] Nonparametric sequential procedure for partitioning a set of populations with respect to a standard or control \textit{invited talk}, International Conference On Statistics and Informatics in Agricultural Research, New Delhi, India, December, 2012.
[45.] On a generalization of the Partition Problem, \textit{invited talk}, International Workshop on Sequential Methods, Stanford University, June, 2011 (with Jie Zhou).

SQA Editor’s Round Table, **Plenary Session**, IWSM 2009, Troyes, France, June, 2009(with Marie Hušková, N. Mukhopadhyay, Alexander Tartakovsky, and S. Zacks).

Multistage Methodologies for Partitioning a Set of Several Populations With Respect to a Standard or a Control, **SQA Editors Special Invited Talk**, Joint Statistical Meeting, Denver, Colorado, August, 2008.


The role of Statistics in Clinical Trials, Invited talk for the students in the Honors Program, **University of New Orleans, invited talk**, April, 2008.

On Optimality of the Sample Size for the Partition Problem, **ISI 2007 Conference**, Lisbon, Portugal, August, 2007 (with Y. Wu).


The problem of selection and Ranking: An introduction and some current research, **invited talk**, Department of mathematics, IIT Delhi, January, 2007.

An Efficient Design For Partitioning a set of Populations With Respect to a Control, **International Conference on Statistics and Informatics, invited talk**, Delhi, India, December, 2006.

Efficient Designs for the Partition Problem, Department of Mathematics, Department of Mathematics, **University of Louisiana, Lafayette, invited talk**, September, 2005.


Implementation and other issues related to the partition problem, **Punjab University, Chandigarh, invited talk**, India, December, 2004.


A two stage procedure with elimination, **Department of Electrical Engineering, UNO, invited talk**, September, 2003.


A sequential procedure with elimination, **International conference on statistical inference and reliability, invited talk**, Chandigarh, India, December, 2001.

On generalizing the partition problem for the normal population, **Joint Statistical Meeting of IISA, etc., New Delhi, India, invited talk**, December, 2000.


Few generalizations to the selection and Ranking Problem, **Department of Statistics, University of Toronto, invited talk**, November, 1996 (with N. Mukhopadhyay).

16
Multistage methodologies for fixed-width simultaneous confidence intervals for all pairwise comparisons, Indian Science Congress Meeting, Patiala, India, January, 1996 (with N. Mukhopadhyay).

On estimating the reliability after sequentially estimating the mean: the exponential case, Annual Joint Statistical Meetings of ASA, IMS etc., Orlando, August, 1995 (with N. Mukhopadhyay and A. Padmanabhan).

Multistage methodologies for fixed-width simultaneous confidence intervals for all pairwise comparisons, Bose Memorial Conference, Colorado State University, Colorado, June, 1995 (with N. Mukhopadhyay).

On an Improved Accelerated Sequential Methodology With Applications in Selection and Ranking, Annual Joint Statistical Meetings of ASA, IMS etc., Toronto, August, 1994 (with N. Mukhopadhyay).


Accelerated Sequential Procedure for Selecting the Largest Mean, Department of Statistics, University of Southwestern Louisiana, April, 1991 (with N. Mukhopadhyay).


A note on Sequential Selection and Ranking Procedures, Department of Statistics, University of Connecticut, April, 1990 (with N. Mukhopadhyay).


UNIVERSITY SERVICE (University of New Orleans)

Selected University Service:
President’s Executive Committee: Member, 2008-09.
Policy Committee: Chair, 2008-09.
Strategic Planning Committee (The Strategic Plan 2009-2012): Committee Member.
Policy Committee: Represented the College of Sciences, 2006-2009.
Provost Search Committee: Member, 2008-2009.
Dean Search Committee: Member, 2009-2010.
First Year Initiatives (FYI): Committee member, 2009-2013.
University Committee: Committee on University Admissions, member 2003-2006, Committee Chair 2005-2006, member 2006-2009.
Strategic Planning Committee (2013-2014): Committee Member.
Provost Search Committee: Member, 2014-2015.
Faculty Governance Committee: Member, 2013-2016.
Strategic Enrollment Management Committee (SEMC): Faculty Co-Chair, 2015-present.
Retention Steering Committee, Chair, 2015- Fall 2019.
Provost Search Committee: Member, 2016.
Charges Committee: Fall 2020—present.

College Service:
Chair, College of Sciences Retention Committee, 2013-14.
College of Sciences, Dean Search Committee, 2009-10.
Member, College of Sciences Teaching Award Committee, 2002-2008.

Department Service:
Department Chair: Fall 2008—present.
Member of Several Departmental Committees such as Computer Committee; Graduate Advisory;
Courses and Curricula, etc: 1990-present.

**Mathematical Service:**
- Math Bootcamp for 9th and 10th Graders [Funded by *College Track*], Summer 2013.
- Math Bootcamp for 11th and 12th Graders [Funded by *College Track*], Summer 2013.
- ACING THE ACT: Organized ACT preparation workshop [Funded by *College Track*], Summer & Fall 2013
- Dual Enrollment ACT Preparation: Tutoring program for about 25 Lake Area High School students to improve their ACT Math score to make them eligible for DE class at UNO [Funded by *Urban League*]

**DOCTORAL THESIS SUPERVISION AS MAJOR PROFESSOR**

**Other Activities Related to Teaching and MS/PhD Committee Memberships**
- (i). Master’s thesis supervision for 2 students.
- (ii). Major Professor for over 40 Masters Students with non-thesis Master’s Degree program.

**Major Areas of Research Interest**
Statistical Consulting, Statistical Sampling, Statistical Modeling, Sequential Analysis, Selection and Ranking, Change point Problem, Statistical Computing, Biostatistics, and Biomedical applications.
Exhibit 39

DHSS Abortion Data Affidavit
THE STATE OF MISSOURI

COUNTY OF COLE

AFFIDAVIT

Before me, the undersigned authority, personally appeared Christy Higgins, who being by me duly sworn, deposed as follows:

1. My name is Christy Higgins, I am of sound mind, capable of making this affidavit, and personally acquainted with the facts stated herein:

2. I am the custodian of records of the Missouri Department of Health and Senior Services.

3. Attached hereto are eight (8) pages of records from the Missouri Department of Health and Senior Services, consisting of:
   - Missouri Abortion Complication Reports, April 28, 2018 – Aug. 23, 2023 (1 page)
   - Graph D. Resident Abortion Ratios per 1,000 Live Births: Missouri, 1971-2021 (1 page)
   - Table 11. Resident Teen-Age Pregnancies and Abortions by Selected Ages by County of Residence: Missouri, 2021 (2 pages)
   - Table 12A. Resident Abortions by Race, Age, and Type of Procedure by Weeks of Gestation: Missouri, 2021 (1 page)
   - Table 12B: Recorded Abortions by Race, Age, and Type of Procedure by Weeks of Gestation: Missouri, 2021 (1 page)
   - Table 12C. Post-Abortion Complication Report: Missouri, 2021 (1 page)
   - Table 13: Resident Abortions by Age, Marital Status, and Education by Race and Hispanic Origin: Missouri, 2021 (1 page)

4. These eight (8) pages of records are kept by the Missouri Department of Health and Senior Services in the regular course of business, and it was the regular course of business of the Missouri Department of Health and Senior Services for an employee or representative of the Missouri Department of Health and Senior Services with knowledge of the act, event, condition, opinion, or diagnosis recorded to make the record or to transmit information thereof to be included in such record; and the record was made at or near the time of the act, event, opinion, or diagnosis. The records attached hereto are the original or exact duplicates of the original.

I declare under penalty of perjury that the foregoing is true and correct.

[Signature]
Affiant, Christy Higgins, Custodian of Records

In witness whereof I have hereunto subscribed by name and affixed by official seal this.
Subscribed and affirmed before me this 1st day of November, 2023.

[Seal]
Notary Public

My commission expires: February 7, 2024
<table>
<thead>
<tr>
<th>Year</th>
<th>Missouri Abortion Complication Reports: April 28, 2018 - Aug. 23, 2023</th>
<th>Total Complication Reports</th>
<th>Total Complication Reports for Medical Abortions</th>
<th>Total Complications Reports for Public Hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td>2023</td>
<td>34</td>
<td>60</td>
<td>50</td>
<td>5</td>
</tr>
<tr>
<td>2022</td>
<td>34</td>
<td>66</td>
<td>50</td>
<td>5</td>
</tr>
<tr>
<td>2021</td>
<td>66</td>
<td>66</td>
<td>50</td>
<td>5</td>
</tr>
<tr>
<td>2020</td>
<td>66</td>
<td>66</td>
<td>50</td>
<td>5</td>
</tr>
<tr>
<td>2019</td>
<td>45</td>
<td>66</td>
<td>50</td>
<td>5</td>
</tr>
<tr>
<td>2018</td>
<td>103</td>
<td>66</td>
<td>50</td>
<td>5</td>
</tr>
</tbody>
</table>

App. 0667
### Table: Estimated Resident Abortion Rates

<table>
<thead>
<tr>
<th>Year</th>
<th>Resident Rate</th>
<th>Resident Rate</th>
<th>Resident Rate</th>
<th>Resident Rate</th>
<th>Estimate Rate</th>
<th>Estimate Rate</th>
<th>Estimate Rate</th>
<th>Estimate Rate</th>
<th>Estimate Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>1.2</td>
<td>1.3</td>
<td>0.9</td>
<td>0.8</td>
<td>1.4</td>
<td>1.5</td>
<td>1.6</td>
<td>1.7</td>
<td>1.8</td>
</tr>
<tr>
<td>2020</td>
<td>1.1</td>
<td>1.2</td>
<td>0.9</td>
<td>0.8</td>
<td>1.3</td>
<td>1.4</td>
<td>1.5</td>
<td>1.6</td>
<td>1.7</td>
</tr>
<tr>
<td>2019</td>
<td>1.0</td>
<td>1.1</td>
<td>0.9</td>
<td>0.8</td>
<td>1.2</td>
<td>1.3</td>
<td>1.4</td>
<td>1.5</td>
<td>1.6</td>
</tr>
<tr>
<td>2018</td>
<td>0.9</td>
<td>1.0</td>
<td>0.9</td>
<td>0.8</td>
<td>1.1</td>
<td>1.2</td>
<td>1.3</td>
<td>1.4</td>
<td>1.5</td>
</tr>
<tr>
<td>2017</td>
<td>0.8</td>
<td>0.9</td>
<td>0.8</td>
<td>0.7</td>
<td>1.0</td>
<td>1.1</td>
<td>1.2</td>
<td>1.3</td>
<td>1.4</td>
</tr>
</tbody>
</table>


### Graph: D. Resident Abortion Rates per 1,000 Live Births, Missouri, 1971-2021

The graph illustrates the trend of resident abortion rates per 1,000 live births in Missouri from 1971 to 2021, showing a significant decrease over the years.
Case 2:22-cv-00223-Z Document 176-1 Filed 01/12/24

Page 673 of 684 PageID 6431

App. 0669


### Table 11: Resident Teen-Age Pregnancies and Abortions by Selected Ages by County of Residence: Missouri 2021

<table>
<thead>
<tr>
<th>County</th>
<th>Under 16 - 18-19</th>
<th>Total Pregnancies</th>
<th>Abortions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randolph</td>
<td>9</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Rolla</td>
<td>18</td>
<td>7</td>
<td>1</td>
</tr>
<tr>
<td>Pemiscott</td>
<td>11</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Pike</td>
<td>29</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Pottawatom</td>
<td>32</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Polk</td>
<td>34</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Platte</td>
<td>17</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Pike</td>
<td>20</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Putnam</td>
<td>34</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Randolph</td>
<td>9</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Rolla</td>
<td>18</td>
<td>7</td>
<td>1</td>
</tr>
<tr>
<td>Pemiscott</td>
<td>11</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Pike</td>
<td>29</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Pottawatom</td>
<td>32</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Pike</td>
<td>20</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Pottawatom</td>
<td>34</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Pemiscott</td>
<td>11</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Pike</td>
<td>29</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Pottawatom</td>
<td>32</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Pike</td>
<td>34</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Pemiscott</td>
<td>11</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Pike</td>
<td>29</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Pottawatom</td>
<td>32</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Pike</td>
<td>34</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Pemiscott</td>
<td>11</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Pike</td>
<td>29</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Pottawatom</td>
<td>32</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Pike</td>
<td>34</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Pemiscott</td>
<td>11</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Pike</td>
<td>29</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Pottawatom</td>
<td>32</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Pike</td>
<td>34</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Pemiscott</td>
<td>11</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Pike</td>
<td>29</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Pottawatom</td>
<td>32</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Pike</td>
<td>34</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>Weeks of Gestation</td>
<td>Under 0</td>
<td>0-10</td>
<td>11-19</td>
</tr>
<tr>
<td>-------------------</td>
<td>---------</td>
<td>------</td>
<td>-------</td>
</tr>
<tr>
<td>Male</td>
<td>284</td>
<td>340</td>
<td>299</td>
</tr>
<tr>
<td>Female</td>
<td>313</td>
<td>322</td>
<td>271</td>
</tr>
</tbody>
</table>

Table 12A. Resident Abortions by Race, Age, and Type of Procedure by Weeks of Gestation: Missouri, 2021.
<table>
<thead>
<tr>
<th>State</th>
<th>Other Patient's Race and Hispanicity</th>
<th>0-9</th>
<th>10-19</th>
<th>20-29</th>
<th>30-39</th>
<th>40 and Over</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>White, Non-Hispanic</td>
<td>23</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Hispanic, Any Race</td>
<td>21</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Black, Non-Hispanic</td>
<td>16</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Other, Non-Hispanic</td>
<td>13</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Unknown</td>
<td>58</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Medical/Non-surgical Procedure</td>
<td>45</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Laminitis D &amp; E</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Intrauterine Instillation</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Curceltage</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Weeks of Gestation</th>
<th>State Total</th>
<th>Other</th>
<th>0-9</th>
<th>10-19</th>
<th>20-29</th>
<th>30-39</th>
<th>40 and Over</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-9</td>
<td>190</td>
<td>23</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>10-19</td>
<td>13</td>
<td>6</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>20-29</td>
<td>12</td>
<td>13</td>
<td>5</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>30-39</td>
<td>13</td>
<td>13</td>
<td>5</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>40 and Over</td>
<td>11</td>
<td>7</td>
<td>7</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Unknown</td>
<td>35</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
Table 1: Post-Abortion Complication Report Missouri, 2021

<table>
<thead>
<tr>
<th>Procedure Type</th>
<th>Total</th>
<th>Surgical</th>
<th>Medical</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safe Abortion</td>
<td>13</td>
<td>0</td>
<td>13</td>
<td>0</td>
</tr>
<tr>
<td>Incomplete Abortion</td>
<td>18</td>
<td>0</td>
<td>18</td>
<td>0</td>
</tr>
<tr>
<td>Hemorrhage</td>
<td>8</td>
<td>0</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>Embolizations</td>
<td>6</td>
<td>0</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>Prematurity</td>
<td>5</td>
<td>0</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>4</td>
<td>0</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Pelvic Infection</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Pelvic Access</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Bladder Perforation</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Miscarriage</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Abortion</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Other</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>43</td>
<td>0</td>
<td>43</td>
<td>0</td>
</tr>
<tr>
<td>Patient's Age</td>
<td>Hispanic/Non-Hispanic</td>
<td>Total</td>
<td>Non-Hispanic</td>
<td>Hispanic</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------------</td>
<td>-------</td>
<td>--------------</td>
<td>----------</td>
</tr>
<tr>
<td>Under 15</td>
<td>13</td>
<td>14</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>15-17</td>
<td>15</td>
<td>18</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>18-30</td>
<td>24</td>
<td>26</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>31-35</td>
<td>33</td>
<td>36</td>
<td>10</td>
<td>4</td>
</tr>
<tr>
<td>36-40</td>
<td>41</td>
<td>45</td>
<td>14</td>
<td>5</td>
</tr>
<tr>
<td>41-45</td>
<td>49</td>
<td>53</td>
<td>16</td>
<td>6</td>
</tr>
<tr>
<td>46-50</td>
<td>57</td>
<td>61</td>
<td>18</td>
<td>7</td>
</tr>
<tr>
<td>51-55</td>
<td>65</td>
<td>69</td>
<td>20</td>
<td>8</td>
</tr>
<tr>
<td>56-60</td>
<td>73</td>
<td>77</td>
<td>22</td>
<td>9</td>
</tr>
<tr>
<td>61-65</td>
<td>81</td>
<td>85</td>
<td>24</td>
<td>10</td>
</tr>
<tr>
<td>66-70</td>
<td>89</td>
<td>93</td>
<td>26</td>
<td>11</td>
</tr>
<tr>
<td>71-75</td>
<td>97</td>
<td>101</td>
<td>28</td>
<td>12</td>
</tr>
<tr>
<td>76-80</td>
<td>105</td>
<td>109</td>
<td>30</td>
<td>13</td>
</tr>
<tr>
<td>81-85</td>
<td>113</td>
<td>117</td>
<td>32</td>
<td>14</td>
</tr>
<tr>
<td>86-90</td>
<td>121</td>
<td>125</td>
<td>34</td>
<td>15</td>
</tr>
<tr>
<td>91-95</td>
<td>129</td>
<td>133</td>
<td>36</td>
<td>16</td>
</tr>
<tr>
<td>96-100</td>
<td>137</td>
<td>141</td>
<td>38</td>
<td>17</td>
</tr>
</tbody>
</table>

Table 13. Resident Abortions by Age, Marital Status, and Education by Race and Hispanic Origin: Missouri, 2021.
Exhibit 40

Declaration of Juliet Charron
DECLARATION OF JULIET CHARRON

I, Juliet Charron, hereby declare and swear as follows:

1. I am over 18 years of age, have personal knowledge of the matters set forth here, and am competent to make this declaration.

2. I currently work in the Idaho Department of Health and Welfare (DHW) as the Division of Medicaid Administrator.

3. In my role with DHW, I am familiar with the administration of the Idaho Medicaid program.

4. The statements in this declaration are based on my professional knowledge and experience.

Idaho Medicaid & Health claims data.

5. When a provider seeks coverage for medical services, it submits a claim to Idaho Medicaid.

6. The claims typically include information regarding services rendered, diagnosis.
codes, and payment amounts.

7. In my role with DHW, I am familiar with Idaho Medicaid claim records, and in preparing this declaration, I’ve reviewed a subset of paid claim amounts for Calendar Years 2019 and 2022.

**Idaho Medicaid covers abortion complications.**

8. Idaho Medicaid provides coverage for treatment and follow-up care at hospitals following abortion complications.

9. In Calendar Year 2022, Idaho Medicaid expended $12,658.05 in total funds ($3,797.42 state funds and $8,860.64 federal funds) covering treatment and follow-up care for abortion medical complications.

10. In Calendar Year 2019, Idaho Medicaid expended at least $10,086.47 total funds ($3,025.94 state funds and $7,060.53 federal funds) covering treatment and follow-up care for abortion medical complications.

**Idaho Medicaid covers medical intervention needed following use of mifepristone.**

11. Idaho Medicaid provides coverage for medical intervention needed resulting from a medication abortion, including mifepristone’s use.

12. For example, in Calendar Year 2022, Idaho Medicaid provided coverage for a woman presenting with bleeding following a failed medication abortion. The medical intervention that was required and that Idaho Medicaid covered was dilation & curettage.

**Idaho and the Federal Government both spend money on Idaho Medicaid.**

13. Idaho Medicaid is a federal/state partnership. Both Idaho and the federal government pay money to cover Idaho Medicaid claims. For instance, from July 2020 to June 2021 Idaho Medicaid expended $3.24 billion on services for Medicaid participants. Of this amount, approximately $2.27 billion was federal money.
Number of Idahoans on Idaho Medicaid

14. From July 2020 and June 2021 Idaho Medicaid average monthly enrollment was 379,954 participants.

15. During that time, Idaho Medicaid average monthly enrollment was 97,055 women between the ages of 14 and 45.

* * * * *

I declare that the foregoing is true and correct to the best of my knowledge, information and belief.

Executed on November 2, 2023. /s/ Juliet Charron

Juliet Charron

3

App. 0678
Exhibit 41

Declaration of Lora Brown
DECLARATION OF LORA BROWN

1. I am over 18 years of age, have personal knowledge of the matters set forth here, and am competent to make this declaration.

2. I work for the Missouri Department of Social Services (DSS) as the Research Data Analysis Manager. I have worked for DSS for over thirty years.

3. As part of my position with DSS, I am familiar with the DSS’s data for purposes of producing data reports for DSS, for federal agencies, and for external requesters.

4. The statements in this declaration are based on my professional knowledge and experience.

5. Some data reports are made available publically through the Department of Social Services website at https://dss.mo.gov/mis/cqfacts/. The information contained on DSS’s website is normally pulled by me or a member of the DSS Research Data team. Per data published at https://dss.mo.gov/mis/cqfacts/, between July 2020 and June 2021, an average of 1,030,053 Missourians were enrolled for MO HealthNet Services at the end of each month.\(^\text{1}\)

6. Per data reported as of October 31, 2023, 398,945 women between the ages of 14 and 45 were eligible\(^\text{2}\) for MO HealthNet services.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on November 3, 2023

/s/ Lora K. Brown

---

\(^\text{1}\) https://dss.mo.gov/mis/cqfacts/

\(^\text{2}\) Eligibility for Medicaid services indicates that an individual meets eligibility criteria for a Medicaid program. Enrollment in Medicaid is contingent upon payment of a premium or spend down for certain eligibility categories.